16715435|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PATIENTS AND METHODS</title>
16715435|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">Retrospective review of a prospectively collected melanoma database of our institution identified 1014 CHNMs. Two-hundred twenty-three patients underwent SLNB, and 73 (33%) had preoperative lymphoscintigraphy (PLSG) and intraoperative lymphatic mapping to the region of the parotid gland between May 1995 and June 2003. One patient underwent SLNB at an outside institution, and that patient was excluded from this analysis. We excluded patients with clinically palpable lymph nodes and patients who had already undergone wide local excision associated with a reconstructive procedure, such as a skin graft, rotational skin flap, or other surgical procedure that could interfere with the lymphatic drainage from the primary tumor. Clinical data, surgical details, histopathologic characteristics, and outcome were prospectively entered into a melanoma database, and patients with SLN mapping to the parotid region (n = 72) formed the basis of this analysis.</p>
16715435|Preoperative Lymphoscintigraphy|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Preoperative Lymphoscintigraphy</title><p id="P8">PLSG was used in all 72 patients to identify nodal basins at risk and to identify other sites of nonanatomical uptake. Briefly, .05 mCi (1.9 MBq) of radiation <sup>99m</sup>Tc sulfur colloid (CIS-US, Inc., Belford, MA) filtered through a .22-<italic>μ</italic>m filter in a volume of .4 mL was injected into four quadrants of the primary lesion or around the previous biopsy site or primary tumor. Injections were performed the morning of the planned surgical procedure, and dynamic scans of all nodal basins at risk were obtained beginning immediately after injection at a rate of one frame per minute for approximately 10 minutes. Anterior and lateral static images were obtained at 5-minute intervals for 20 minutes to 2 hours. A radioactive lead marker was placed in selected patients in the external auditory canal to provide orientation in interpretation of the images. The PLSG was reviewed and discussed with the nuclear medicine physician who performed the study. Basins outside the parotid gland or on the contralateral side were considered separately.</p></sec>
16715435|Intraoperative Lymphatic Mapping and SLNB|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Intraoperative Lymphatic Mapping and SLNB</title><p id="P9">The SLNB was performed within 4 hours of injection of the radiocolloid, and images were used to guide the procedure in the operating room. Our standardized approach for SLNB includes equipment for injection of 1% isosulfan blue dye (Lymphazurin; Hirsh Industries, Inc., Richmond, VA) and localization of the radioactive colloid. A tuberculin syringe was used to inject the blue dye in an intradermal plane on the side of the lesion nearest to the relevant draining nodes identified by PLSG. Most commonly, a volume of ≤.5 mL was used, because larger volumes tend to dissipate into the subcutaneous tissue and cause artifacts, thus complicating the procedure. A handheld gamma probe (Neoprobe 1000 [Neoprobe Corp, Dublin, OH] or C-Track [Case Wide Medical Products Corp., Morgan Hill, CA]) was used to measure radioactivity counts over the SLNs and to record the background and correlated with the PLSG findings. The gamma probe was used to measure the ex vivo radioactivity of the SLN. Reduction of the background activity of the basin to &lt; 10% of the hottest SLN was considered as indicative of excision of all SLNs. While the SLN was undergoing frozen-section analysis, the primary melanoma or surgical scar was excised by using margins according to the depth of invasion and the site of the lesion. If histopathologic examination revealed metastatic disease, parotidectomy with preservation of the facial nerve and ipsilateral modified radical neck dissection was performed as an immediate completion lymph node dissection.</p></sec>
16715435|Histopathologic Examination of SLNs|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Histopathologic Examination of SLNs</title><p id="P10">Frozen-section analysis was performed in all patients. Each SLN sent to pathology was bisected from the hilum to its periphery. Half of the node was immediately processed for frozen-section analysis by using routine hematoxylin and eosin staining, and the other half was processed for immunohistochemical staining by using antibodies to S-100 protein and HMB-45. All lymphatic and parotid tissues were embedded in paraffin and sectioned according to routine departmental protocol.</p></sec>
16715435|Statistical Methods|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Statistical Methods</title><p id="P11">Data were analyzed with a statistical package (SPSS 12; SPSS Inc., Chicago, IL). Follow-up was calculated in months from the date of SLNB to the date of last follow-up or death, and the disease-free interval was calculated from the date of SLNB to the date of first recurrence.</p></sec>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I. Measuring the Causal Effect of Health Insurance</title>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P5">We work with a simple reduced form model of the causal effects of health insurance status: <disp-formula id="FD1"><label>(1)</label><mml:math display="block" id="M1" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">y</mml:mi><mml:mi>ija</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">X</mml:mi><mml:mi>ija</mml:mi></mml:msub><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">f</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo>;</mml:mo><mml:mi>β</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="normal">k</mml:mi></mml:munder><mml:msub><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:msup><mml:mi>ija</mml:mi></mml:msub><mml:msup><mml:mi>δ</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:msup><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mi>ija</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where y<sub>ija</sub> is a measure of health care use for individual i in socioeconomic group j at age a, u<sub>ija</sub> is an unobserved error component, X<sub>ija</sub> is a set of covariates (e.g., gender and region), f<sub>j</sub>(a; β) is a smooth function representing the age profile of outcome y for group j, and C<sup>k</sup><sub>ija</sub> (k=1,2,...,K) are characteristics of the insurance coverage held by the individual. These can include a simple coverage indicator as well as variables summarizing other features such as copayment rates or the presence of gatekeeper restrictions.</p>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">A fundamental problem for the estimation of <xref ref-type="disp-formula" rid="FD1">equation (1)</xref> is that insurance coverage is endogenous. The age threshold for Medicare eligibility at 65 provides a credible source of exogenous variation in insurance status. To illustrate this claim, <xref ref-type="fig" rid="F1">Figure 1</xref> shows the age profiles of health insurance coverage estimated with data from the pooled 1999−2003 NHIS, where age is measured in quarters (the sample is described below and in more detail in the online <xref ref-type="supplementary-material" rid="SD1">appendix</xref>). Overall coverage rates (plotted with open diamonds) rise from 85 to 96 percent at age 65. Even more striking is the impact of Medicare eligibility on differences across socioeconomic groups. Prior to age 65 less-educated minorities (blacks, Asians, and Hispanics with under 12 years of education) have 25 percentage points lower coverage rates than highly-educated whites. After 65 the gap falls to 10 points or less.</p>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7"><xref ref-type="fig" rid="F1">Figure 1</xref> also shows the fractions of individuals with two or more insurance policies. Before age 65, multiple coverage is relatively rare. The incidence rises at 65, with a bigger gain for highly educated whites, reflecting a greater likelihood of enrollment in supplemental “Medigap” policies (see Section II, below). Thus, Medicare eligibility is associated with a narrowing of disparities in the probability of any coverage, but a widening of disparities in at least one indicator of the generosity of coverage.</p>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">To proceed, suppose that a person's health insurance coverage can be summarized by two indicator variables: C<sup>1</sup><sub>ija</sub> indicating any coverage, and C<sup>2</sup><sub>ija</sub> indicating a relatively generous insurance package (i.e., low copayments and few gatekeeper restrictions). Consider linear probability models for the events of any coverage and generous coverage of the form: <disp-formula id="FD2"><label>(2a)</label><mml:math display="block" id="M2" overflow="scroll"><mml:mrow><mml:msub><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mi>ija</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">X</mml:mi><mml:mi>ija</mml:mi></mml:msub><mml:mspace width="thickmathspace"/><mml:msub><mml:msup><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi mathvariant="normal">g</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:msub><mml:msub><mml:msup><mml:mi>π</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi mathvariant="normal">v</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mi>ija</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="FD3"><label>(2b)</label><mml:math display="block" id="M3" overflow="scroll"><mml:mrow><mml:msub><mml:msup><mml:mi mathvariant="normal">C</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>ija</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">X</mml:mi><mml:mi>ija</mml:mi></mml:msub><mml:mspace width="thickmathspace"/><mml:msub><mml:msup><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi mathvariant="normal">g</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:msub><mml:msub><mml:msup><mml:mi>π</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi mathvariant="normal">v</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>ija</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where β<sup>1</sup><sub>j</sub> and β<sup>2</sup><sub>j</sub> are group-specific coefficients, g<sup>1</sup><sub>j</sub>(a) and g<sup>2</sup><sub>j</sub>(a) are smooth age profiles for group j, and D<sub>a</sub> denotes an indicator for being age 65 or older. Combining <xref ref-type="disp-formula" rid="FD2">equations (2a)</xref> and <xref ref-type="disp-formula" rid="FD3">(2b)</xref> with <xref ref-type="disp-formula" rid="FD1">equation (1)</xref>, the reduced form model for outcome y is: <disp-formula id="FD4"><label>(3)</label><mml:math display="block" id="M4" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="normal">y</mml:mi><mml:mi>ija</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">X</mml:mi><mml:mi>ija</mml:mi></mml:msub><mml:mspace width="thickmathspace"/><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mspace width="thickmathspace"/><mml:msub><mml:msup><mml:mi>δ</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mspace width="thickmathspace"/><mml:msub><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">h</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi mathvariant="normal">a</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">D</mml:mi><mml:mi mathvariant="normal">a</mml:mi></mml:msub><mml:mspace width="thickmathspace"/><mml:msub><mml:msup><mml:mi>π</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi mathvariant="normal">v</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:msup><mml:mi>ija</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where h<sub>j</sub>(a) = f<sub>j</sub>(a)+δ<sup>1</sup><sub>j</sub>g<sup>1</sup><sub>j</sub>(a)+δ<sup>2</sup><sub>j</sub>g<sup>2</sup><sub>j</sub>(a) represents the reduced form age profile for group j, π<sup>y</sup><sub>j</sub> = π<sup>1</sup><sub>j</sub>δ<sup>1</sup> + π<sup>2</sup><sub>j</sub>δ<sup>2</sup>, and v<sup>y</sup><sub>ija</sub> = u<sub>ija</sub>+v<sup>1</sup><sub>ija</sub>δ<sup>1</sup><sub>j</sub>+v<sup>2</sup><sub>ija</sub>δ<sup>2</sup><sub>j</sub> is an error term. Assuming that the profiles f<sub>j</sub>(a), g<sup>1</sup><sub>j</sub>(a), and g<sup>2</sup><sub>j</sub>(a) are all continuous at age 65, any discontinuity in y can be attributed to discontinuities in insurance. The magnitude depends on the size of the insurance changes at 65 (π<sup>1</sup><sub>j</sub> and π<sup>2</sup><sub>j</sub>), and on the associated causal effects (δ<sup>1</sup> and δ<sup>2</sup>).</p>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">For some basic health care services – for example, routine doctor visits – it is arguable that only the presence of insurance matters. In this case, the implied discontinuity in y at age 65 for group j will be proportional to the change in insurance coverage experienced by the group. For more expensive or elective services the generosity of coverage may also matter, if patients are unwilling to cover the required copayment or if managed care programs will not cover the service. This creates a potential identification problem in interpreting the discontinuity in y for any one group. Since π<sup>y</sup><sub>j</sub> is a linear combination of the discontinuities in coverage and generosity, δ<sup>1</sup> and δ<sup>2</sup> can be estimated by a regression across groups: <disp-formula id="FD5"><label>(4)</label><mml:math display="block" id="M5" overflow="scroll"><mml:mrow><mml:msub><mml:msup><mml:mi>π</mml:mi><mml:mi mathvariant="normal">y</mml:mi></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>0</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:msub><mml:msup><mml:mi>π</mml:mi><mml:mn>1</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:msup><mml:mi>π</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">e</mml:mi><mml:mi mathvariant="normal">j</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula> where e<sub>j</sub> is an error term reflecting a combination of the sampling errors in π<sup>y</sup><sub>j</sub> , π<sup>1</sup><sub>j</sub>, and π<sup>2</sup><sub>j</sub>.</p>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P10">This framework can be extended to include additional dimensions of insurance coverage. In practice, however, a key limitation is the lack of information on the insurance packages held by different individuals. In the absence of more complete data, we use the presence of at least two forms of coverage as an indicator of “generous” coverage. We also explore a simple measure of gatekeeper limitations, based on whether an individual's primary insurer is a managed care provider.</p>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">In our empirical analysis, we fit regression discontinuity (RD) models like (2a), (2b) and (3) by demographic subgroup to individual data using OLS estimators. We then combine the estimates across groups in the final section of the paper to estimate models like (4). For our main results we follow <xref ref-type="bibr" rid="R9">DiNardo and Lee (2004)</xref> and assume the age profiles in <xref ref-type="disp-formula" rid="FD1">equations (1)</xref>, <xref ref-type="disp-formula" rid="FD2">(2a)</xref> and <xref ref-type="disp-formula" rid="FD3">(2b)</xref> are continuous polynomials with potential discontinuities in the derivatives at age 65. We have also fit many of the models using local linear regression (as suggested by <xref ref-type="bibr" rid="R12">Hahn, Todd and van der Klaauw, 2001</xref>). As discussed below, the estimated discontinuities are generally quite robust, reflecting the relative smoothness of the age profiles in insurance features and health outcomes.</p>
19079738|None|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P12">We use data from two main sources: the 1992−2003 National Health Interview Surveys, and 1992−2003 hospital discharge records for California, Florida and New York. The NHIS reports respondents’ birth year and birth month, and the calendar quarter of the interview. We use these data to construct an estimate of age in quarters. We adopt the convention that a person who reaches their 65<sup>th</sup> birthday in the interview quarter is age 65 and 0 quarters. Assuming a uniform distribution of interview dates, about one-half of these people will be 0−6 weeks younger than 65, and one-half will be 0−6 weeks older. We limit our analysis to people who are over 55 and under 75: the final sample size is 160,821, although some outcomes (e.g., detailed insurance characteristics) are only available in later years. Sample counts and descriptive statistics by age are reported in the online <xref ref-type="supplementary-material" rid="SD1">appendix</xref>. The discharge files represent a complete census of discharges from all hospitals in the three states (except federally-regulated institutions). The data files include information on age in months at the time of admission. For our analysis we drop records for people admitted as transfers from other institutions, and limit attention to people between 60 and 70 years of age at admission. The sample sizes are 4,017,325 for California; 2,793,547 for Florida; and 3,121,721 for New York.</p>
19079738|II. Changes in Insurance Coverage at Age 65|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S2"><title>II. Changes in Insurance Coverage at Age 65</title><p id="P13">Medicare is available to people who are at least 65 and have worked 40 quarters or more in covered employment (or have a spouse who did).<xref ref-type="fn" rid="FN1">1</xref> Coverage is also available to younger people with severe kidney disease and recipients of Social Security Disability Insurance (DI). Eligible individuals can obtain Medicare hospital insurance (Part A) free of charge, and medical insurance (Part B) for a modest monthly premium. Individuals receive notice of their impending eligibility for Medicare shortly before their 65<sup>th</sup> birthday, and are informed that they have to enroll in the program and choose whether or not to accept Part B coverage. Coverage begins on the 1<sup>st</sup> day of the month in which they turn 65.</p><p id="P14"><xref ref-type="table" rid="T1">Table 1</xref> shows the effects of reaching age 65 on five insurance-related variables: the probability of Medicare coverage, the probability of any health insurance coverage, the probability of private coverage, the probability of two or more forms of coverage, and the probability that an individual's primary health insurance is a managed care program. As in <xref ref-type="fig" rid="F1">Figure 1</xref>, the data are drawn from the 1999−2003 NHIS surveys. For each characteristic we show the incidence rate at age 63−64, and the change at age 65, based on a version of <xref ref-type="disp-formula" rid="FD2">equations (2a</xref>/<xref ref-type="disp-formula" rid="FD3">2b)</xref> that includes a quadratic in age, fully interacted with a post-65 dummy.<xref ref-type="fn" rid="FN2">2</xref> Alternative  specifications – including a parametric model fit to a narrower age window (ages 63−67) and a local linear regression specification using a rule-of-thumb bandwidth selection procedure – are shown in the online <xref ref-type="supplementary-material" rid="SD1">appendix</xref> (see <xref ref-type="supplementary-material" rid="SD1">Appendix Table 1a</xref>), and yield very similar estimates of the change at age 65.</p><p id="P15">Medicare coverage rises by 60 percentage points at age 65, from a base level of 12 percent among 63−64 year olds. Consistent with DI enrollment patterns (<xref ref-type="bibr" rid="R1">Autor and Duggan, 2003</xref>), Medicare enrollment prior to 65 is higher for minorities and people with below-average schooling and these groups experience relatively smaller gains at age 65 (see rows 2−7). The pattern is reversed for the probability of any insurance coverage (cols. 3 and 4): groups with lower insurance coverage rates prior to 65 experience larger gains at age 65. There is still some disparity in insurance coverage after 65, but the 28 point gap between more-educated whites and less-educated minorities narrows to about 10 points. Similarly, as shown in rows 8−10, the 21 point gap in coverage between whites and Hispanics before age 65 closes to only 12 points after. Thus, the onset of Medicare eligibility dramatically reduces disparities in insurance coverage.</p><p id="P16">Columns 5 and 6 present information on the prevalence of private insurance coverage (i.e., employer-provided or purchased coverage). Prior to age 65 private coverage rates range from 33 percent for less educated minorities to 86 percent for better-educated whites. The RD estimates in column 6 show that these differences are hardly affected by the onset of Medicare eligibility. This stability reflects the fact that most people who hold private coverage before 65 transition to a combination of Medicare and supplemental coverage, either through an employer-provided plan or an individually purchased Medigap policy.<xref ref-type="fn" rid="FN3">3</xref> Columns 7 and 8 of <xref ref-type="table" rid="T1">Table 1</xref> analyze the age patterns of multiple coverage (i.e., reporting two or more policies). Prior to age 65, the rate of multiple coverage is quite low (around 11 percent) and similar across groups. As shown in column 8, the overall rate of dual coverage rises by about 44 percentage points at age 65, with gains close to 60 percentage points for better-educated whites, but only on the order of 20 percentage points for less educated minorities. Thus, significant disparities in dual coverage arise after age 65 (see also <xref ref-type="fig" rid="F1">Figure 1</xref>).</p><p id="P17">Another important dimension of coverage is managed care versus indemnity coverage. The entries in column 9 of <xref ref-type="table" rid="T1">Table 1</xref> show that among 63−64 year olds with insurance coverage, nearly 60 percent have managed care, with higher rates for whites and better educated groups. At age 65, the overall fraction of people with managed care for their primary insurance drops sharply, with larger declines for groups with higher rates prior to 65, leading to rough convergence in managed care rates across groups. This decline reflects the relatively low enrollment in Medicare managed care: about 85 percent of 65−66 year old Medicare recipients are enrolled in fee-for-service Medicare, which offers patients and providers substantial leeway over the use of services.</p><p id="P18">Overall, there are major changes in health insurance at age 65. Many of those who lacked insurance prior to 65 obtain coverage, equalizing coverage rates across groups. There is also a sharp rise in multiple coverage, particularly among whites and the better-educated. Coupled with the shift from managed care to fee-for-service coverage, it appears that the relative “generosity” of insurance coverage among more advantaged groups actually increases with the onset of Medicare eligibility.</p><sec id="S3"><title>Other Changes at Age 65</title><p id="P19">Formal identification of an RD model that relates an outcome y (e.g., insurance coverage) to a treatment (Medicare age-eligibility) that depends on age (a) relies on an assumption about the expectation of y conditional on age and treatment status. Let y(0) and y(1) denote the potential outcomes for a given person if he or she was or was not “treated.” Note that y(0) is only observed for people under 65, while y(1) is only observed for people 65 or over. The key assumption is that E[y(0)|a] and E[y(1)|a] are both continuous at a=65 (<xref ref-type="bibr" rid="R13">Imbens and Lemieux, 2008</xref>, Assumption 2.1). In this case the average treatment effect at age 65 is identified as lim<sub>a↓65</sub> E[y(1)|a] – lim<sub>a↑65</sub> E[y(0)|a]. Continuity requires that all other factors that might affect the outcome of interest trend smoothly at age 65.</p><p id="P20">An obvious concern in our context is employment, since 65 is a traditional age of retirement, and any abrupt change in the fraction of people working at 65 could lead to differences in health care utilization if non-workers have more time to visit doctors.<xref ref-type="fn" rid="FN4">4</xref> As noted by <xref ref-type="bibr" rid="R14">Lee (2008)</xref>, a simple test for the potential impact of discontinuities in confounding variables like employment is fitting a model like (3) for the confounding variable and testing for jumps at age 65.</p><p id="P21"><xref ref-type="table" rid="T2">Table 2</xref> presents estimation results for a set of models that test for discontinuities in the age profiles of employment, using data from the 1992−2003 NHIS (with age measured in quarters) and the 1996−2004 March Current Population Surveys (with age measured in years).<xref ref-type="fn" rid="FN5">5</xref>  Using either data source, the estimated jumps in employment-related outcomes are small in magnitude and statistically insignificant. <xref ref-type="fig" rid="F3">Figure 3</xref> displays the actual and fitted age profiles of employment for the overall NHIS sample and for highly educated whites and less educated minorities. These profiles all trend relatively smoothly through age 65, though there is some evidence of a discrete drop at age 62, reflecting the large fraction of people who retire as soon as Social Security benefits are available (e.g., <xref ref-type="bibr" rid="R20">Rust and Phelan, 1997</xref>). When we estimate the discontinuity at 65 using a local linear regression procedure or a narrow sample window (see <xref ref-type="supplementary-material" rid="SD1">Appendix Table 1a in online appendix</xref>) the estimated changes are slightly larger (−2.3 percent for the overall sample) and statistically significant, but still small in comparison to the changes in insurance.</p><p id="P22">One concern is that the smoothness in overall employment trends at 65 may be masking differences between men and women. The bottom two rows of <xref ref-type="table" rid="T2">Table 2</xref> present results by gender, and show no large discontinuities for either men or women.<xref ref-type="fn" rid="FN6">6</xref> As an additional check, we used longitudinal data from the 2001 Survey of Income and Program Participation to estimate month-to-month changes in individual employment (see the online <xref ref-type="supplementary-material" rid="SD1">appendix</xref>). Consistent with the results here, we found no evidence of a discontinuity in employment at age 65. We also investigated the age profiles of marriage, being classified as poor, and of receiving food stamps in the NHIS, as well as residential mobility, marital status, and the incidence of low income in the CPS. As summarized in the online <xref ref-type="supplementary-material" rid="SD1">appendix</xref> to this paper, none of these outcomes show significant discontinuities at age 65 for the overall sample or the subgroups used in <xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T2">2</xref>. Taken as a whole, we conclude that employment, family structure, family income, and location all trend relatively smoothly at age 65, and are unlikely to confound our analysis of the impact of Medicare eligibility.</p></sec></sec>
19079738|III. Changes in Health Care Access and Utilization at Age 65|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>III. Changes in Health Care Access and Utilization at Age 65</title><p id="P23">We now turn to an analysis of the effects of reaching age 65 on access to care and utilization of health care services. Since 1997 the NHIS has asked two questions: (1) “During the past 12 months has medical care been delayed for this person because of worry about the cost?” (2) “During the past 12 months was there any time when this person needed medical care but did not get it because (this person) could not afford it?” Columns 1 and 3 of <xref ref-type="table" rid="T2">Table 2</xref> show the fractions of people age 63−64 in the pooled 1997−2003 NHIS samples who responded positively to these two questions. Overall, about 7 percent of the near-elderly reported delaying care, and 5 percent reported not getting care, with relatively higher rates for less educated minorities, and for Hispanics. Our RD estimates in columns 2 and 4 imply significant declines at age 65 in both measures of access problems, especially for less educated minorities and Hispanics. The onset of Medicare eligibility leads to a fall in cost-related access problems and a narrowing of inter-group disparities in access.<xref ref-type="fn" rid="FN7">7</xref></p><p id="P24">The right-hand columns of <xref ref-type="table" rid="T3">Table 3</xref> present results for two key measures of health care utilization: (1) “Did the individual have at least one doctor visit in the past year?” and (2) “Did the individual have one or more overnight hospital stays in the past year?” based on pooled samples of the 1992−2003 NHIS. Inspection of the utilization rates among 63−64 year olds shows a well-known fact: less educated and minority groups are <italic>less</italic> likely to have a routine doctor visit than better-educated and non-minority groups, but <italic>more</italic> likely to have had a hospital spell. The RD estimates in column 6 suggest that the age 65 threshold is associated with a (modest) increase in routine doctor visits, with relatively larger gains for the groups with lower rates before 65.<xref ref-type="fn" rid="FN8">8</xref> For example, among the near-elderly there is a 7.4 percentage point gap in the probability of a routine doctor visit in the previous year for better educated whites (87.6 percent) versus less-educated minorities (80.2 percent). The relatively large 5.0 percentage point gain for the latter group at 65 closes 5.0/7.4=68 percent of the pre-65 disparity.</p><p id="P25">The RD estimates in column 8 are harder to interpret. Overall, there is a rather large rise in hospitalization rates at 65 (on the order of 10 percent), but the gains are larger for better-educated whites than other groups. Indeed, the 2.1 percentage point RD at 65 represents a 20 percent increase in hospitalization for this group. The gains for other groups are smaller, and for blacks in particular are quite small, though somewhat imprecise. In the next section we use 100 percent samples of hospital discharge records from California, Florida, and New York to refine these estimates. These data have the advantages of very large sample sizes, and the ability to compare reasons for hospitalization, which turn out to be helpful in understanding the changes at age 65.</p></sec>
19079738|IV. Changes in Hospitalization - Evidence from Discharge Data|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>IV. Changes in Hospitalization - Evidence from Discharge Data</title><p id="P26">In this section we use hospital discharge records from 1992−2002 for people between the ages of 60 and 70 in California, Florida, and New York to examine changes in the number and characteristics of hospital admissions at 65. For some of our analyses we convert the numbers of hospital admissions into rates, using population estimates derived from Census Bureau data as denominators. The advantage of hospitalization <italic>rates</italic> is that they can be compared across groups to evaluate disparities in the pre-65 population. The disadvantage is that the denominators must be interpolated from Census Bureau population estimates, introducing some noise in the age profiles of the hospitalization rates. For our RD models we therefore estimate discontinuities in the log of the number of admissions at age 65. Under the assumption that the underlying population counts trend smoothly, the estimated discontinuities in log admission counts can be interpreted as estimates of the percentage discontinuities in admission rates (see <xref ref-type="bibr" rid="R3">Card, Dobkin, and Maestas (2004)</xref> for a formal justification of this approach).<xref ref-type="fn" rid="FN9">9</xref></p><p id="P27"><xref ref-type="fig" rid="F3">Figure 3</xref> shows the actual and fitted age profiles of hospital admission rates based on our pooled data. The markers in the figure represent actual averages (by month of age) of the number of admissions divided by the estimated population of that age. The lines represent fitted regressions from models that assume a quadratic age profile with a full set of post-65 interactions. Overall admission rates rise steadily prior to age 65, then jump sharply at age 65. The increase appears to be “permanent,” with no tendency after age 65 to revert to the previous level, as might occur if the jump in admissions represented only catch-up for deferred care.</p><p id="P28"><xref ref-type="table" rid="T4">Table 4</xref> shows estimated hospital admission rates among 60−64 year olds in the three states, and the percentage changes in the numbers of admissions at age 65. The entry in row 1 shows that the jump in overall admissions in <xref ref-type="fig" rid="F3">Figure 3</xref> corresponds to a 7.6 percent increase, comparable to the national estimate of about 10 percent in <xref ref-type="table" rid="T3">Table 3</xref>.<xref ref-type="fn" rid="FN10">10</xref> As shown in <xref ref-type="supplementary-material" rid="SD1">Appendix Table 1b in the online appendix</xref>, the corresponding estimate from a local linear regression procedure is 8.0 percent (standard error 0.3 percent). Entries in the other columns show the average admission rates at age 60−64 (per 10,000 person-years) by race and ethnicity, and the increases in these rates at age 65. Hispanics have the lowest admission rates prior to age 65 but experience a slightly larger gain than whites (9.5 percent). Blacks, in contrast, have much higher admission rates prior to 65 but experience a much smaller gain (4.5 percent). On net, these estimates suggest that both the black-white and the Hispanic-white differences in admission rates narrow at age 65, as whites gain relative to blacks and Hispanics gain relative to whites.</p><p id="P29">For reference, the bottom row of <xref ref-type="table" rid="T4">Table 4</xref> shows insurance coverage rates among 60−64 year olds in the three states, along with estimated jumps in insurance coverage at 65.<xref ref-type="fn" rid="FN11">11</xref> Coverage rates in the three states are below the national average prior to 65, but rise by more (15 percent versus a national average of about 10 percent). Consistent with the national data in <xref ref-type="table" rid="T1">Table 1</xref>, the gains in insurance coverage in the three states are largest for Hispanics (20.3 vs. 17.3 percent nationally), a little smaller for blacks (17.6 vs. 11.9 percent nationally) and smallest for whites (12.7 vs. 7.3 percent nationally).</p><p id="P30">A key advantage of our hospital data is that we can break down admissions by route into the hospital, and by admission diagnosis and primary procedure. A comparison of rows 2 and 3  in <xref ref-type="table" rid="T4">Table 4</xref> show that most of the jump in admissions at age 65 is driven by non-emergency room admissions, although for each race/ethnic group there is also some increase in ER admissions.<xref ref-type="fn" rid="FN12">12</xref> Further insights can be gleaned from the admissions patterns across diagnoses. The most common admission diagnosis for near-elderly patients is chronic ischemic heart disease (IHD), which is often treated by coronary artery bypass surgery. There are substantial disparities in IHD admission rates prior to age 65, with a black-white relative admission rate of only 72 percent (see row 4). Overall admissions for this diagnosis rise by 12 percent at age 65, with the largest proportional rise for Hispanics (who have the lowest base rate), and the smallest gain for blacks. The onset of Medicare eligibility therefore leads to a surprising <italic>widening</italic> of the black-white disparity in admission rates for IHD, but a slight narrowing of the Hispanic-white disparity.</p><p id="P31">The second most common admission diagnosis is acute myocardial infarction (AMI or heart attack). AMI admission rates among 60−64 year olds are fairly similar for whites and blacks, but lower for Hispanics. There is a small rise in total AMI admissions at age 65 (4.6 percent), although estimates for the different race/ethnic groups are not precise enough to rule out equality across the groups.</p><p id="P32">The third most common admission diagnosis is heart failure (HF), a progressive disorder caused by deterioration of the functional capacity of the heart. Unlike IHD, there is no surgical treatment for HF: the main treatment is medication. HF is particularly prevalent among African Americans, and consistent with this fact, the data show that 60−64 year old blacks have a 280 percent higher admission rate for HF than whites. Interestingly, there is no evidence of a jump at age 65 for HF admissions for any group.</p><p id="P33">We can also classify admissions by the primary procedure (rows 11−16). The leading primary procedure is diagnostic procedures on the heart (such as cardiac catheterization, often performed for people admitted with AMI). Admissions for this group of procedures rise by about 9 percent at age 65, with the largest rise for Hispanics (16.6 percent), leading to a narrowing in Hispanic-white disparities. Blacks have somewhat higher admission rates for this procedure than whites prior to 65, but show a similar proportional increase at 65.</p><p id="P34">Admission rates for the second most common group of procedures – removal of a coronary artery obstruction (including angioplasty and related procedures) – rise by around 11 percent. Again, the rise is larger for Hispanics than for whites, leading to a narrowing of the Hispanic-white disparity. The gains for blacks, by comparison, are small and statistically insignificant. Black admission rates for these interventions prior to 65 are notably below those for whites, so the changes associated with Medicare eligibility further increase an already large disparity. A similar pattern emerges for admissions for bypass surgeries, which rise by 19.4 percent for Hispanics, 16.2 percent for whites, but by only a statistically insignificant 5 percent for blacks, again leading to a widening of the black-white disparity in admission rates.</p><p id="P35">The fourth most common group of admission diagnoses is osteoarthrosis (degenerative joint disease), which has substantial overlap with admissions for hip and knee replacement surgery. The impact of Medicare on the age profile of hip/knee surgery admissions is revealing because on the one hand these procedures are readily deferred, and on the other, they are relatively expensive but “routine” interventions that are thought to have a beneficial effect on quality of life. Prior to 65 whites have a much higher admission rate for hip and knee replacements than blacks or Hispanics.<xref ref-type="fn" rid="FN13">13</xref> At 65, whites experience a large (23 percent) increase in admissions for these procedures. The proportional gain for Hispanics is about the same, but given their much lower base rate, the Hispanic-white disparity actually increases at age 65. Blacks show a much smaller gain than whites or Hispanics, and coupled with their lower rates pre-65, the net effect is a substantial widening in the black-white disparity in hip/knee replacement surgeries.</p><p id="P36">These conclusions are visually confirmed in <xref ref-type="fig" rid="F3">Figure 3</xref>. Close inspection of the age profile for whites in <xref ref-type="fig" rid="F3">Figure 3</xref> also reveals a drop-off in procedure rates just prior to 65, coupled with a temporary surge shortly after 65. This pattern suggest that some people who are close to 65 delay knee and hip replacements until they become eligible for Medicare. A recent panel convened by the National Institutes of Health concluded that hip and knee replacement surgeries are under-performed in the U.S. If true, this implies that the rise in admissions for these procedures at age 65 may be due to stringent limitations in the insurance coverage available prior to age 65, rather than to excessive generosity of Medicare.</p><p id="P37">Looking across the patterns in <xref ref-type="table" rid="T4">Table 4</xref> by diagnosis and procedure, an interesting contrast emerges between conditions that typically are treated with medication or bed rest (HF, bronchitis and pneumonia), and those that are treated with specific procedures (IHD, osteoarthrosis, gall bladder removal). The first group of admissions tend to increase only slightly at age 65, with similar gains across groups. The second group rises by more, with a pattern that often widens existing racial/ethnic disparities -- especially between blacks and whites. This contrast suggests there is an interaction between the availability and generosity of insurance, on one hand, and the  existence of specific surgical procedures, on the other, that lead to differences in rises in hospital admissions once Medicare becomes available. In this light, it is interesting to note that the increase in admissions for people who receive no procedures is below the overall growth in admissions (5.8 percent versus an overall average of 7.6 percent).</p><p id="P38">Further evidence that supply-side reactions to the changes in insurance status at age 65 play a role is presented in <xref ref-type="fig" rid="F4">Figure 4</xref>, which plots the age profiles of hospital admissions by hospital ownership type in California.<xref ref-type="fn" rid="FN14">14</xref> Private non-profit hospitals (the largest category) and private for-profits (the second largest category) experience relatively large increases in admissions at age 65. By comparison, hospitals owned by Kaiser Permanente (a large and long-established HMO) show little change in admissions at age 65, and county hospitals experience a sharp decline. These patterns point to two important conclusions. First, the jump at age 65 in overall hospital admissions masks a significant redistribution of caseloads across hospitals. Once Medicare is available some patients no longer have to use county hospitals and choose a private alternative. Second, the lack of any discontinuity at the Kaiser hospitals suggests that changes in managed care status may have some role in explaining the rises in admissions in the hospital system as a whole. In particular, Kaiser patients remain under a very similar managed care regime before and after 65, and these patients show no rise in hospitalization at 65, whereas other patients appear to be entering the hospital more frequently after 65 and at the same time switching between hospitals. Moreover, physicians at Kaiser are paid on a salary basis and face no particular incentives to seek out Medicare patients for high-cost procedures.</p></sec>
19079738|VI. Summary of Patterns across Groups|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>VI. Summary of Patterns across Groups</title><p id="P39">To summarize our findings, we use the framework of <xref ref-type="disp-formula" rid="FD5">equation (4)</xref> to relate changes in insurance characteristics at 65 to the changes in health related outcomes. The entries in column 1 of <xref ref-type="table" rid="T5">Table 5</xref> represent estimates of the coefficients δ<sup>1</sup> or δ<sup>2</sup>, obtained by regressing the estimated discontinuities in the outcome variable indicated in the row heading on the discontinuities in insurance coverage (Panel A) or insurance “generosity” (measured by the incidence of multiple coverage, Panel B) across six ethnicity-education groups (rows 1−4) or nine state-ethnicity groups (rows 5−8 and 9−12).<xref ref-type="fn" rid="FN15">15</xref> Column 2 reports the corresponding R-squared coefficients. These should be close to 1 if the change in the outcome variable at age 65 is driven by the measured change in insurance status. Columns 3−5 summarize the pre-65 disparities, while columns 6−8 show the predicted changes in the disparities at 65, computed by multiplying the estimate of δ<sup>1</sup> or δ<sup>2</sup> by the difference in the jumps in coverage or generosity for the disparate groups (from column 4 of <xref ref-type="table" rid="T1">Table 1</xref>).</p><p id="P40">Looking first at the measures of access to care in rows 1−3, it appears that the changes across groups at age 65 are closely related to the corresponding changes in insurance coverage. Reaching the Medicare eligibility age is estimated to close 25−40 percent of the inter-group disparity in delaying or not getting care, and 74 percent of the gap in the likelihood of a regular doctor visit. This contrasts with the estimated changes in the probability of a hospital stay (row 4), which are slightly negatively related to the increases in insurance coverage. We also fit versions of <xref ref-type="disp-formula" rid="FD5">equation (4)</xref> that related these outcomes to the discontinuities in multiple insurance coverage and managed care, but these had less explanatory power.</p><p id="P41">In contrast to access to care, the entries in rows 5−8 show no evidence of a link between insurance coverage and hospital admissions. If anything, there appears to be a negative relationship between increases in insurance coverage and the size of the RD in admissions for bypasses and hip/knee replacements. The results in Panel B yield a similar conclusion for the link between multiple coverage and overall admissions, or admissions for diagnostic heart procedures. For bypass surgery and hip/knee replacement surgery, however, there is more consistent evidence of a link. The R-squared coefficient is particularly high for hip and knee surgery, suggesting that the widening disparities in admissions for hip and knee replacements are attributable to the fact that whites are more likely to obtain supplemental coverage after 65 than blacks or Hispanics.</p></sec>
19079738|VII. Conclusions|('method', 0.7890306636211549)|('other', 0.2109693363788451)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" sec-type="conclusions" id="S7"><title>VII. Conclusions</title><p id="P42">In this paper we use the discrete changes generated by the rules of the Medicare program to identify the impact of health insurance on access to care and utilization. The Medicare eligibility threshold at age 65 is associated with an increase in overall insurance coverage and a narrowing of coverage disparities across different subgroups. There is also an increase in the incidence of multiple coverage and a reduction in managed care, concentrated among higher educated and non-minority groups, as people with insurance prior to 65 enroll in fee-for-service Medicare and supplementary coverage plans.</p><p id="P43">We find that the onset of Medicare eligibility leads to increases in the use of medical care services, with a pattern of gains across groups that varies with the type of service. Routine doctor visits and access to care increase more for groups that previously lacked coverage, and experience the largest gains in coverage at age 65. Overall hospitalizations increase sharply, but the patterns of gains across groups differ by type of admission. For certain elective hospital admissions, including hip and knee replacements and bypass surgery, the increases are larger for groups that are more likely to have Medicare combined with supplemental coverage after 65. For other conditions like heart failure that are mainly treated by drugs, all groups show very small increases in hospitalization rates at 65. Coupled with evidence of a redistribution of the caseload across hospitals of different ownership types, these patterns suggest that the rise in hospitalization at 65 is driven by an interaction between the increase in insurance “generosity” at 65 – specifically for groups who move to fee-for-service Medicare with supplemental coverage – and the existence of profitable treatments (like bypass surgery) for certain diagnoses.</p></sec>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I. Income inequality and the distribution of heights</title>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P3">Suppose that each person’s adult height is an increasing and concave function of income. Then mean population height will depend, not only on mean income, but on the distribution of income, <xref rid="R10" ref-type="bibr">Steckel (1995)</xref>. For example, if the underlying individual relationship is quadratic, mean height will be a positive function of mean income and a negative function of the variance of income. This proposition depends only on the existence of a concave relationship between height and income, albeit between <italic>adult</italic> height and <italic>childhood</italic> income. It does not require that income be the only determinant of height and it is indeed consistent with an account in which the epidemiological environment in childhood is the dominant factor.</p>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P4">A relationship between inequality in income and inequality in heights is relatively easy to establish in the case of two groups, for example men and women, or boys and girls. This is parallel to the historical case, where groups born in better times were taller as adults, though as always the effects may be overridden by variations in disease. To the extent that boys and girls of the same cohort experience the same epidemiological environment, variations in the differences in adult height of men and women will reflect nutritional differences or differences in access to healthcare in their childhood. There is also a biological theory of sexual dimorphism, according to which males of a species become larger in response to the need to compete with other males for females so that, for example, males are relatively larger in species that are relatively more polygamous. In the Indian context, this suggests the hypothesis that males will be relatively taller in places where the ratio of females to males is lowest and where more women are “missing.” Such an effect would reinforce the effects of nutritional or health discrimination against women; men are larger in order to compete with other men for the relatively small pool of women, which itself comes about because of the nutritional and health advantage of boys over girls.</p>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P5">The relationship between income inequality—as in standard measures such as the gini coefficient—and inequality of heights is harder to establish with any generality. The argument in the literature is an intuitive one that parallels the argument about groups—if height indicates income, then inequality in income should show up in inequality in heights—but this will not hold in general. If height is a concave increasing function of income, second-order stochastic dominance in the distributions of income will be inherited by the distribution of heights. But when we compare the inequality of distributions, we look at distributions scaled by their means and use Lorenz dominance, not second-order stochastic dominance, and Lorenz dominance will typically not be passed from the income to the height distribution. Taking again the example where height is a quadratic function of income, the variance of heights depends on the second, third, and fourth moments of the income distribution, and if we measure inequality independently of the mean by using the coefficient of variation—as we would do for incomes—we obtain an expression that depends on the first four moments of income and so is not a function of any standard measure of income inequality. And even this takes no account of distribution of other components of adult heights, most obviously genetic effects, and their possible covariance with income.</p>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">However, there are special cases that yield relatively simple results. For example, if the logarithm of height is a linear function of the logarithm of income, so that</p>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<disp-formula xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>ln</mml:mi><mml:mspace width="0.2em"/><mml:msub><mml:mi>h</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mspace width="0.2em"/><mml:mi>ln</mml:mi><mml:mspace width="0.2em"/><mml:msub><mml:mi>y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">for height <italic>h</italic> of individual <italic>i</italic>, with income <italic>y<sub>i</sub></italic> and other factors <italic>ε<sub>i</sub></italic> including genetics, as well as the effects of idiosyncratic childhood disease. Under the (strong) assumption that these other factors are distributed independently of the logarithm of income, we</p>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<disp-formula xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ln</mml:mi><mml:mspace width="0.2em"/><mml:mi>h</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ε</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msup><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mspace width="0.2em"/><mml:mi>var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>ln</mml:mi><mml:mspace width="0.2em"/><mml:mi>y</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
19169418|None|('method', 0.8325343641321209)|('other', 0.16746563586787921)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">so that the two inequality measures are linearly related across populations, at least provided that the genetic and other variation is constant. But this result is clearly fragile. For example, if in (1) we replace the logarithm of height by its level, the variance of height itself will have the form (2), but the coefficient of variation will also depend on the mean of log <italic>y</italic>.</p>
19305517|None|('method', 0.8799625885871539)|('other', 0.12003741141284589)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">1. The Udaipur Rural Health Survey</title>
19305517|None|('method', 0.8799625885871539)|('other', 0.12003741141284589)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P3">We collected data between January 2002 and August 2003 in 100 hamlets in Udaipur district, Rajasthan, India. Udaipur is one of the poorest districts of India, with a large tribal population and an unusually high level of female illiteracy (at the time of the 1991 census, only 5 percent of women were literate in rural Udaipur). The survey was conducted in collaboration with two local institutions: Seva Mandir, an NGO that works, among other things, on health in rural Udaipur, and Vidhya Bhawan, a consortium of schools, teaching colleges, and agricultural colleges, who supervised the administration of the survey. The sample frame consisted of all the hamlets in the 362 villages where Seva Mandir operates in at least one hamlet.<xref ref-type="fn" rid="FN2">1</xref> The sample was stratified according to access to a road (out of the 100 hamlets, 50 hamlets are at least 500 meters away from a road). Hamlets within each stratum were selected randomly, with a probability of being selected proportional to the hamlet population. We then selected 10 households in each of 100 hamlets using simple random sampling, and all individuals were surveyed within each household.</p>
19305517|None|('method', 0.8799625885871539)|('other', 0.12003741141284589)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P4">The data collected include four components: (i) a village survey, where we obtained a village census, a description of the village’s physical infrastructure, and a list of health facilities commonly used by villagers (100 villages); (ii) a facility survey, where we collected detailed information on activities, types and cost of treatment, referrals, availability of medication and quality of physical infrastructure in all public facilities (143 facilities) serving the sample villages, all “modern” private facilities mentioned in the village surveys or in the household interviews (we have surveyed 85 facilities so far, but this survey is ongoing), and a sample of the traditional healers mentioned in the village surveys (225 facilities were surveyed); (iii) a weekly visit to all public facilities serving the villages (143 facilities in total, with 49 visits per facility on average) where we checked whether the facility was open, and if so, who was present; and (iv) a household and individual survey, covering 5,759 individuals in 1,024 households. The data cover information on economic well-being, integration in society, education, fertility history, perception of health and subjective well-being, and experience with the health system (public and private), as well as a small array of direct measures of health (hemoglobin, blood pressure, weight and height, peak flow meter measurement).</p>
19724661|None|('method', 0.964865371637882)|('other', 0.03513462836211788)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
19724661|None|('method', 0.964865371637882)|('other', 0.03513462836211788)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Appendix</label><media xlink:href="NIHMS88907-supplement-Appendix.doc" mimetype="application" mime-subtype="msword" xlink:type="simple" id="d36e205" position="anchor"/></supplementary-material>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IV. Estimation Strategy</title>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P24">An intervention that successfully targets methamphetamine precursors should increase the cost and difficulty of producing high-quality methamphetamine, thereby increasing price and reducing purity. Consequently, we expect some reduction in the prevalence of methamphetamine use. Because methamphetamine consumption can directly cause a spectrum of adverse health effects ranging from dependence to overdose, the intervention should also reduce the incidence of adverse health outcomes. But the impact on crime may vary depending on the type of crime.</p>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P25">We begin our analysis by documenting the effect of the intervention in the methamphetamine precursor market on price and purity. Because the STRIDE data are too sparse to generate county-level measures of price and purity, we document the impact of the intervention on price and purity by examining the statewide time series.</p>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P26">We then examine the impact of the intervention on methamphetamine consumption. Unfortunately, there are no surveys large enough to generate monthly, county-level measures. For this reason, we use hospitalizations with a mention of amphetamine use as a proxy for methamphetamine prevalence. We estimate the following regression to evaluate the first-stage relationship between the intervention and methamphetamine consumption: <disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mi>I</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mi>A</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mi>X</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>ϕ</mml:mi></mml:mrow><mml:mi>m</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P27">The dependent variable <italic>H<sub>itm</sub></italic> is the log of amphetamine-related hospitalizations. The subscripts indicate the county <italic>i</italic>, year <italic>t</italic>, and month <italic>m</italic>. The explanatory variable of interest, the instrument <italic>I<sub>tm</sub></italic>, takes on a value of one during the peak effect of the intervention between August 1995 and September 1996.<xref rid="FN23" ref-type="fn">23</xref> The regression controls include the log of cocaine, heroin, marijuana, and alcohol admissions <italic>A<sub>itm</sub></italic>, the shares of the population that are black and Hispanic and in particular age groups <italic>X<sub>itm</sub></italic>, and fixed effects for the county <italic>η</italic>, year <italic>ϕ</italic>, and month <italic>φ</italic>. For all regressions, we compute the heteroskedasticity robust standard errors and cluster on county (<xref ref-type="bibr" rid="R2">Marianne Bertrand, Esther Duflo, and Sendhil Mullainathan 2004</xref>). We confine our analysis period to January 1994 to December 1997 in order to avoid confounding our results with elements of the Methamphetamine Control Act, which took effect in early 1998.</p>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P28">After documenting that there is a strong first-stage relationship between the intervention and our proxy for methamphetamine consumption, we estimate the relationship between consumption and adverse health effects. As noted previously, the lack of county-level measures of price, purity, and consumption compel us to use amphetamine-related hospitalizations as a proxy for consumption.<xref rid="FN24" ref-type="fn">24</xref></p>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P29">To generate credible estimates of the causal relationship between methamphetamine and adverse health effects, we use the intervention as a source of exogenous variation in consumption in <xref rid="FD2" ref-type="disp-formula">equation (2)</xref>. This addresses the problems with omitted variables that are likely to bias cross-sectional or panel estimates. Using this instrumental variables approach, we first examine whether the reduction in methamphetamine use induced substitution to other drugs, which could offset some of the benefits of the intervention. We then examine the impact on treatment admissions for methamphetamine and other substances. Finally, we estimate how the reduction in methamphetamine use affected crime. The model is specified as</p>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P30"><disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mi>H</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mi>A</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mi>X</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>ϕ</mml:mi></mml:mrow><mml:mi>m</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mrow><mml:mi mathvariant="italic">itm</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where <italic>Y<sub>itm</sub></italic> is the log of adverse outcomes (i.e., drug treatment admissions, reported crimes, and drug-related arrests) in county <italic>i</italic>, year <italic>t</italic>, and month <italic>m</italic>. We use the intervention as an instrument for amphetamine-related hospitalizations <italic>H<sub>itm</sub></italic>. As noted previously, the lack of county-level measures for price, purity, and consumption motivates this approach.</p>
20543969|None|('method', 0.6718813685939032)|('other', 0.32811863140609676)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P31">A reduction in methamphetamine availability is likely to have different effects on property, violent, and drug crimes. The impact of the reduced availability on property crime depends on the price elasticity of consumption. When faced with a substantial price increase, do users substantially reduce use, substitute another drug, or simply pay higher prices? If users quit, either because of the higher prices or decreased availability, property crime may decline. It is possible, however, that the reduced purity and increased prices due to the supply shock may result in an increase in property crime among more dependent users who are unwilling or unable to reduce their consumption.<xref rid="FN25" ref-type="fn">25</xref> The reduced availability might result in a decrease in incidents due to the pharmacological effects of methamphetamine. This suggests we may see fewer violent crimes committed by drug abusers suffering from drug-induced psychosis. Violence resulting from enforcement of property rights is also likely to decline, if it changes at all, because there are fewer dealers competing over territory.<xref rid="FN26" ref-type="fn">26</xref> Drug arrests are likely to decline because there are fewer transactions for the police to interdict when the market shrinks.</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I. Theoretical analysis</title>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P3">We start with the model of <xref rid="R5" ref-type="bibr">Michael Grossman (1972</xref>, <xref rid="R6" ref-type="bibr">2000</xref>) and modify it to analyze ways that socio-emotional attributes could affect health. The Grossman model is a multi-period model that demonstrates how changes in health affect individual well-being. In the model health affects utility directly and also has implications for individuals’ earnings because it determines the amount of healthy time that an individual has available to devote to the labor market. An individual’s health status at any point in time is determined by his initial stock of health capital, depreciation, and investments to health that the individual makes through a household production process that combines market-purchased inputs such as medical care with time spent within the household producing health. The Grossman model specifies a role for cognitive skills via its analysis of the effect of education on health. We argue that the claims made about education levels are applicable to non-cognitive skills as well. Socio-emotional attributes may raise the efficiency of household production just as education does in the standard Grossman model.</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P4">Let increases in the health stock be generated according to the following household production function: <disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>;</mml:mo><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>S</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P5"><italic>I</italic> represents gross investment, <italic>M</italic> the amount of medical care the household purchases, <italic>TH</italic> the amount of time the household devotes to the production of health, and <italic>E</italic> represents education and is taken to be exogenous in the model. In addition to these variables, which are each present in <xref rid="R6" ref-type="bibr">Grossman (2000)</xref>, we use <italic>S</italic> to represent socio-emotional attributes that are relevant for the production of health.</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">Household production of health affects the stock of health capital (<italic>H</italic>) as follows: <disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>H</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>I</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula> where <italic>δ</italic> gives the depreciation rate of the health capital stock.</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">Individuals choose optimal <italic>H</italic>, along with desired levels of the other choice variables by maximizing lifetime utility,</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8"><disp-formula id="FD3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>Lifetime</mml:mtext><mml:mspace width="0.16667em"/><mml:mtext>utility</mml:mtext><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mspace width="0.16667em"/><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mo>…</mml:mo><mml:mn>..</mml:mn><mml:msup><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mi>n</mml:mi></mml:msup><mml:msub><mml:mrow><mml:mi>U</mml:mi></mml:mrow><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mi>n</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mi>n</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula> where “<italic>h</italic>” represents the service flow from the health stock, i.e. <italic>h<sub>t</sub></italic> = ∅́<italic><sub>t</sub>H<sub>t</sub></italic>, and <italic>Z</italic> is a consumption good.<xref ref-type="fn" rid="FN4">3</xref> While Grossman’s original formulation of the model did not explicitly include discounting, our modified version of the model introduces a discount factor <italic>β</italic> because allowing individuals to discount the future provides a way of capturing the effect that future-orientation has on health behavior; and, as noted earlier, the literature covering non-cognitive skills identifies being future-oriented as an example of a non-cognitive skill.</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">As in <xref rid="R6" ref-type="bibr">Grossman (2000)</xref> households maximize utility subject to a time constraint and a budget constraint.</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P10"><disp-formula id="FD4"><label>(4)</label><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>W</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Ω</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula> and</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<disp-formula xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="FD5"><label>(5)</label><mml:math id="M5" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mn>0</mml:mn><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mi>z</mml:mi></mml:msup><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mi>m</mml:mi></mml:msup><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mn>0</mml:mn><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>W</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>t</mml:mi></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:mrow></mml:math></disp-formula>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11"><xref rid="FD4" ref-type="disp-formula">Equation (4)</xref> indicates that time spent working in the labor market (<italic>TW</italic>) and time spent in the household production of health (<italic>TH</italic>) are constrained by the amount of time an individual has available, which is equal to the individual’s time endowment (<italic>Ω</italic>) minus the amount of time that the individual is sick (“<italic>TL</italic>”). <italic>TL</italic> is influenced by health: <italic>∂TL<sub>t</sub>/∂H<sub>t</sub></italic> &lt; 0. <xref rid="FD5" ref-type="disp-formula">Equation (5)</xref> stipulates that the sum of expenditures cannot exceed total earnings from the labor market. <italic>P<sup>z</sup></italic> gives the price of the consumption good <italic>Z</italic>, and <italic>P<sup>m</sup></italic> represents the price of medical inputs (<italic>M</italic>). The variable “<italic>w</italic>” denotes the market wage, and “<italic>r</italic>” denotes the market interest rate.</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P12">In addition to incorporating a new term in the household production function and introducing a discount factor into the specification of the utility function, our modified model makes one additional change to the Grossman framework. We modify it to allow the possibility that consumption of certain goods may have adversely affect health. This allows us to analyze adverse health behaviors such as smoking or drinking. Let <italic>∂<sub>t</sub></italic>=<italic>∂<sub>t</sub>(Z<sub>t</sub>)</italic> where <italic>∂δ<sub>t</sub>/∂Z<sub>t</sub></italic> &gt; 0. This allows consumption goods that are bad for one’s health, such as cigarettes or alcohol, to contribute to deterioration of the health capital stock.</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P13">The Lagrangean for the individual’s optimization exercise can be written as,</p>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<disp-formula xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="FD6"><label>(6)</label><mml:math id="M6" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mn>0</mml:mn><mml:mi>n</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msup><mml:msub><mml:mrow><mml:mi>u</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>h</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="false">]</mml:mo><mml:mo>+</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi>A</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">∑</mml:mi><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mi mathvariant="normal">Ω</mml:mi></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">∑</mml:mi><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>H</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">∑</mml:mi><mml:msub><mml:mrow><mml:mi>w</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:msub><mml:mrow><mml:mi>T</mml:mi><mml:mi>L</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:mi mathvariant="normal">∑</mml:mi><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mi>m</mml:mi></mml:msup><mml:msub><mml:mrow><mml:mi>M</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mi>z</mml:mi></mml:msup><mml:msub><mml:mrow><mml:mi>Z</mml:mi></mml:mrow><mml:mi>t</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>r</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>t</mml:mi></mml:msup></mml:mrow></mml:mfrac><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
20953279|None|('method', 0.8365857804441299)|('other', 0.16341421955587018)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P14">Maximizing (<xref rid="FD6" ref-type="disp-formula">6</xref>) with respect to <italic>TH, Z, H</italic> and <italic>M</italic> yields a series of first order conditions. These can be used to draw insights about the effects that non-cognitive skills have on health behavior.</p>
20953279|None|('method', 0.6337110872432976)|('other', 0.36628891275670256)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II. Empirical research</title>
20953279|None|('method', 0.6337110872432976)|('other', 0.36628891275670256)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P15">This paper’s empirical research analyzes data from the Panel Study of Income Dynamics (PSID) to ascertain the relationship between a number of different socio-emotional attributes and drinking and exercising.<xref ref-type="fn" rid="FN5">4</xref> Our dataset consists of individuals who were household heads in 1972.<xref ref-type="fn" rid="FN6">5</xref> The health behaviors that we analyze are measured at a number of different points in time, however. For instances in which a health behavior is measured in a year other than 1972, we impose a restriction requiring the individual to be head of household in both years under observation.<xref ref-type="fn" rid="FN7">6</xref> Alcohol consumption represents an example of an instance in which an individual chooses a <italic>Z</italic> variable that raises his health stock depreciation rate. Exercising provides an example of a way that health can be produced in the household; it therefore serves as our measure of the use of <italic>TH</italic> to generate improvements in the health capital stock. Data on drinking were collected in the 1968 and 1972 waves. Information about exercising is available in 1986 and 1999.<xref ref-type="fn" rid="FN8">7</xref> Due to space limitations we report results for only one year for each variable.<xref ref-type="fn" rid="FN9">8</xref></p>
20953279|None|('method', 0.6337110872432976)|('other', 0.36628891275670256)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">The non-cognitive skills that we analyze in this paper are the degree to which an individual is future-oriented, and self-efficacy. There is already limited research linking each of these personality dispositions to specific disease outcomes, although most of this literature relies on small samples. Because our two traits of interest are unlikely to represent biological causes of disease, we argue that their effect would obtain through the behaviors that individuals engage in.</p>
20953279|None|('method', 0.6337110872432976)|('other', 0.36628891275670256)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P17">What do we see in terms of evidence for or against the proposition that non-cognitive skills have an effect on health behavior if we use data from the PSID? We estimate an equation from the modified Grossman model for each dependent variable in order to test the model’s predictions that the choice of <italic>Z</italic> and <italic>TH</italic> will be influenced by the exogenous variables of the system: the price of medical inputs (<italic>P<sup>m</sup></italic>), the individual’s level of education (<italic>E</italic>), the current wage, expected future earnings, and non-cognitive skills.<xref ref-type="fn" rid="FN10">9</xref> The basic regression equation is,</p>
20953279|None|('method', 0.6337110872432976)|('other', 0.36628891275670256)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P18"><disp-formula id="FD7"><label>(7)</label><mml:math id="M7" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mspace width="0.16667em"/><mml:mi mathvariant="italic">current</mml:mi><mml:mspace width="0.16667em"/><mml:mi mathvariant="italic">wag</mml:mi><mml:msub><mml:mrow><mml:mi>e</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mspace width="0.16667em"/><mml:mi mathvariant="italic">future</mml:mi><mml:mspace width="0.16667em"/><mml:msub><mml:mrow><mml:mi mathvariant="italic">earnings</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mn>3</mml:mn></mml:msub><mml:mspace width="0.16667em"/><mml:msub><mml:mrow><mml:msup><mml:mrow><mml:mi>P</mml:mi></mml:mrow><mml:mi>m</mml:mi></mml:msup></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mn>4</mml:mn></mml:msub><mml:mspace width="0.16667em"/><mml:msub><mml:mrow><mml:mi>E</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mn>5</mml:mn></mml:msub><mml:mspace width="0.16667em"/><mml:mi mathvariant="italic">future</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">orientation</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mn>6</mml:mn></mml:msub><mml:mspace width="0.16667em"/><mml:mi mathvariant="italic">self</mml:mi><mml:mrow><mml:mo>−</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">efficacy</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula> where “<italic>y</italic>” represents a health behavior, and <italic>i</italic> indexes individuals. All regressions were estimated using logistic regressions. <xref rid="T1" ref-type="table">Table 1</xref> reports the estimated coefficients, standard errors and odds ratios. All data are weighted using the PSID’s statistical weights.</p>
20953279|None|('method', 0.6337110872432976)|('other', 0.36628891275670256)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P19">As shown in the table, the current wage is positively associated with drinking. This is consistent with an income effect. As predicted by the Grossman model, the sign for the future earnings term is negative.<xref ref-type="fn" rid="FN11">10</xref> A rise in future earnings reduces the odds of engaging in unhealthy behavior because future earnings represent a cost of consuming consumption goods that are bad for one’s health (because they lower the future health stock, subsequently increasing sick days and time lost at work in future periods). We use health insurance as a proxy for <italic>P<sup>m</sup></italic> in our regressions because an individual with health insurance will have lower out-of-pocket costs for medical care than an individual with no health insurance. The positive sign for the coefficient on the health insurance variable is consistent with the modified Grossman model, which predicts that one would expect a rise in unhealthy behaviors as the price of medical care falls, but the variable is not statistically significant. Contrarily, our future-oriented variable is statistically significant and it is negatively associated with drinking, as expected. An increase in <italic>β</italic> raises the marginal benefit from investment (<italic>I</italic>) and the marginal efficiency of the health capital stock, causing the individual to choose higher levels of <italic>H</italic> and <italic>I</italic>. The results in <xref rid="T1" ref-type="table">Table 1</xref> indicate that individuals who are future-oriented have about a 7 percent lower odds of drinking than individuals who are not. Self-efficacy is also negatively associated with drinking.</p>
20953279|None|('method', 0.6337110872432976)|('other', 0.36628891275670256)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P20">For exercising, the coefficient for future earnings is positive and statistically significant. A rise in future earnings represents a payoff to producing health because production of health yields a higher stock of <italic>H</italic> and more time available in the future to spend in the labor market earning income as a result. The coefficient for the health insurance variable is negative, suggesting that exercise is negatively associated with having health insurance. This is consistent with the model’s prediction that a fall in the price of medical care can induce individuals to devote less time to exercising. It represents a standard substitution effect in production: If the cost of one input rises, one expects a shift into the second input. We also find that being future-oriented is positively associated with exercise. Future-oriented individuals have a higher odds of exercising than individuals who are not future-oriented (17 percent greater). Finally, self-efficacy is associated with a greater odds of exercising. This is consistent with the hypothesis that having well-developed non-cognitive skills could have effects that are similar to education. A rise in self-efficacy may increase the marginal productivity of <italic>TH</italic> if efficacious individuals are better at using time to produce health than non-efficacious individuals are. This would cause the optimal <italic>TH</italic> to rise.</p>
21103385|None|('method', 0.9002570432661201)|('other', 0.09974295673388002)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II. Data and Empirical Strategy</title>
21103385|A. Data|('method', 0.9002570432661201)|('other', 0.09974295673388002)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>A. Data</title><p id="P19">For our analysis, we use a comprehensive database of all medical utilization data for four of the CalPERS plans between January 2000 and September 2003. We focus on a panel of Medicare supplemental plan members who were continuously enrolled in their plan during our sample period, noting that this sample is not necessarily representative of the Medicare population. The resulting dataset includes information on medical utilization by 70,912 members; 93 percent of these members were over the age of 65 in January 2000.</p><p id="P20">By selecting a sample of continuously enrolled individuals, we risk mismeasuring the population responsiveness of individuals to copayment changes. If individuals switch out of plans raising copayments, and the individuals who switch have a sensitivity of medical care utilization with respect to price that is higher (or lower) than average, then our estimated elasticities in this sample will be biased downward (or upward) in absolute value. Such switching, however, does not seem to be of sufficient importance to bias our results. We find, for example, that 92 percent of the members who were enrolled in our PPOs in February 2000 remained enrolled in the same plan in February 2001, despite the anticipated copayment increases in February 2001. Indeed, this 92 percent retention rate was slightly <italic>higher</italic> than the 91 percent retention rate, over the same period, at HMOs that were not expecting a copayment increase. Similarly, 92 percent of the members who were enrolled in our HMOs in February 2001 remained enrolled in the same plan in February 2002. Again, despite the January 2002 copayment increase, the HMO retention rate was slightly <italic>higher</italic> than the 90 percent retention rate for the PPOs over the same period.<xref ref-type="fn" rid="FN7">7</xref> As a result, when we reestimate our models using the full sample of enrollees (including individuals who both enter and exit our plans), we get almost identical results to those presented here.<xref ref-type="fn" rid="FN8">8</xref></p><p id="P21">For each individual, we measure office visit utilization by the number of medical encounters that occurred in an office or outpatient setting during the month. We measure drug utilization by the number of prescriptions filled during the month. We measure hospital utilization using an indicator for whether the individual spent any days in the hospital during the month.</p><p id="P22">In our analysis, we compute an average of each utilization measure for each plan in each month, which yields 180 observations in our final dataset (45 months × 4 plans). Thus, each of the 180 observations on a utilization measure in our final dataset reflects the average utilization per person among all continuously enrolled members of a single plan in a given month. In order to document the impact of the policy change on copayments, we also calculate average copayments and deductibles across all visits (or prescription drug purchases) for each plan in each month. Each of the 180 observations on copayments in our final dataset reflects the average copayment per visit (or prescription drug purchase) in a single plan in a single month.<xref ref-type="fn" rid="FN9">9</xref></p><p id="P23">We analyze the impact of these policy changes on medical spending as well as utilization. Ideally, we would observe the payments associated with every medical encounter, and we would redo our analysis using these payments as the dependent variable. In practice, however, there is not any financial information on payments attached to HMO claims. We therefore pursue an alternative approach where we use available data on total payments from PPO claims to impute total payments to each claim based on the primary diagnosis category of the office visit (or the National Drug Code (NDC) of the prescription drug), and the average payment for an office visit with that diagnosis category (or for that specific drug) among all PPO claims. Following Medicare Part B policy, we assume that Medicare made 80 percent of the total payments for office visits and that the supplemental insurance plan paid the difference between the remaining 20 percent and any patient copayments. For drugs, we assume that the supplemental insurance plan made all payments above the patient copayments.</p><p id="P24">For hospitalizations, where Medicare's share of total payments is not a fixed percentage, we followed a different methodology. Total hospital payments are the sum of imputed supplemental insurance payments, imputed Medicare payments, and any actual cost sharing paid by the patient. We imputed the first component based on the diagnosis code of the hospitalization and the average insurance payment for hospitalizations with the same diagnosis in the PPO data. We imputed Medicare's payments based on the diagnosis code of the hospitalization and the average Medicare payment for hospitalizations with that diagnosis code, using the universe of Medicare claims in the state of California during our sample period.<xref ref-type="fn" rid="FN10">10</xref> For cost sharing, we used the actual amounts that were reported in the data. We then constructed total hospital payments as the sum of these three payments.</p><p id="P25">A clear concern with our approach for physician and hospital visits is that we assign the <italic>average</italic> payments per diagnosis, whereas ideally we would like to use the <italic>marginal</italic> payments for the given admission. The bias from using average rather than marginal payments is unclear, but we have explored one exercise to assess its importance. Among those admitted to the hospital, we have regressed length of hospital stay on the policy dummy in our difference-in-difference framework. If the marginal patients admitted due to higher physician/drug copayments are very different from the average patient admitted, we should see a marginal change in the length of stay for hospital patients. In fact, there is no significant effect on length of stay, providing crude evidence that the marginal and average patients are not very different.</p></sec>
21103385|B. Empirical Strategy|('method', 0.9002570432661201)|('other', 0.09974295673388002)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>B. Empirical Strategy</title><p id="P26">Our analysis of this quasi-experimental change in CalPERS policy is fairly straightforward. We begin by estimating difference-in-difference models of the form <disp-formula id="FD1"><mml:math display="block" id="M1" overflow="scroll"><mml:mrow><mml:mi>U</mml:mi><mml:mi>T</mml:mi><mml:mi>I</mml:mi><mml:msub><mml:mi>L</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mi>H</mml:mi><mml:mi>I</mml:mi><mml:mi>P</mml:mi><mml:mi>A</mml:mi><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi>p</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mi>t</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mrow><mml:mi>p</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where <italic>UTIL</italic> is a measure of utilization (or out-of-pocket costs) for plan <italic>p</italic> in month <italic>t</italic>, <italic>α</italic> is a constant term, <italic>HIPAY</italic> is a dummy for increased copayments in plan <italic>p</italic> in month <italic>t</italic> (specifically, an interaction of an indicator variable for being in a plan where greater cost sharing is instituted and an indicator for being in the post-increase era), and <italic>δp</italic> and <italic>λt</italic> are plan and month fixed effects, respectively.<xref ref-type="fn" rid="FN11">11</xref> In this model, the effect of the copayment change is identified by <italic>β</italic>, which measures the change in utilization in the plans with a copayment change relative to those without. For each type of utilization, we estimate two models of this type: one that separately identifies effects on PPOs (focusing on data from January 2000 to December 2001), and another that separately identifies effects on HMOs (focusing on data from February 2001 to September 2003). Regressions are weighted by the number of plan members who are continuously enrolled during our sample period in each plan.</p><p id="P27">There are two potential problems with this approach. First, utilization is likely autocorrelated within plans; this autocorrelation causes the standard errors in ordinary regressions to be understated. To address this issue, we estimate our regressions using generalized least squares (GLS) allowing for plan-specific autocorrelation as well as plan-specific heteroskedasticity.<xref ref-type="fn" rid="FN12">12</xref></p><p id="P28">Second, there may be underlying trends in utilization, which can confound the estimation of the causal effects that we are interested in. A particularly worrisome source of such trends for the HMO analysis is the earlier PPO policy change. That is, our difference-in-difference analysis for the HMO policy change compares the change in utilization in the HMOs between the prepolicy period (February 2001–December 2001) and the postpolicy period (January 2002–September 2003) to the change in utilization in the PPOs over the same periods. If the policy change in the PPOs had immediate effects in February 2001, this is not a problem. But it is possible that utilization in the PPOs adjusted slowly to the PPO policy change, with full adjustment only by the end of 2001. If this were the case, absent any other change, there would be a negative utilization difference between 2001 and 2002 for the PPO, leading to a spurious positive difference-in-difference estimate of the effect of the 2002 policy change on HMO utilization. To deal with this concern, we present dynamic models of the policy change effect, estimating separate treatment effects for each quarter before and after the policy change.<xref ref-type="fn" rid="FN13">13</xref> In this way, we can examine whether any changes in utilization in 2002 represent the effects of a slow-moving relative trend or a sharp break when the policy is put in place. If the dynamic model indicates the latter, it suggests that we are not just picking up the dynamic effects of the PPO policy change.</p></sec>
21103385|C. Means|('method', 0.9002570432661201)|('other', 0.09974295673388002)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>C. Means</title><p id="P29"><xref ref-type="table" rid="T1">Table 1</xref> presents the means of the data. We show the mean utilization rate and copayments for each type of utilization for HMOs and PPOs in each year. Once again, we have no preperiod data for the PPO policy change for office visits due to data limitations. Several discontinuities that preview our ensuing difference-in-difference specifications are apparent in these tabulations. First, average copayments for an office visit jump from $0.14 in 2001 to $10.11 in 2002 for the HMOs, while they remain flat in the (control) PPO plans over time.<xref ref-type="fn" rid="FN14">14</xref> Over the same period, average office visits fell by 0.03 per member per month in the HMOs (relative to an increase of 0.07 visits per member per month in the PPOs, which experienced no copayment increase). Thus, the means suggest a differential decline in office visits for HMO members at the time that office visit copayments increased for them.</p><p id="P30">Average out-of-pocket payments for a prescription drug increased from $6.93 in 2000 to $13.50 in 2001 for PPOs. Over the same period, average drug utilization rose by 0.09 prescriptions per member per month in the PPOs, relative to an increase of 0.16 prescriptions per member per month in the HMOs, which had not yet experienced a drug copayment increase. These means, then, suggest the possibility of a relative decline in drug utilization resulting from the increased drug copayments for the PPOs in 2001. For the HMO policy change, the means show an increase in prescription drug copayments in 2002, and a decrease in prescriptions per member per month in the HMOs between 2001 and 2002, relative to an increase in the PPOs during the same period.</p><p id="P31">Finally, we show means for hospitalizations for each year and type of plan. All hospitalization rates in <xref ref-type="table" rid="T1">Table 1</xref> and in later regression tables are multiplied by 10,000 in order to make the numbers easier to read. Hospitalization rates increase over time for both types of plans throughout the sample period, presumably reflecting the aging of our panel.</p></sec>
21103385|None|('method', 0.9164233750981738)|('other', 0.08357662490182612)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
21103385|None|('method', 0.9164233750981738)|('other', 0.08357662490182612)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>1</label><media xlink:href="NIHMS250526-supplement-1.zip" xlink:type="simple" id="N0x19680cd0N0x1a3bd910" position="anchor" mimetype="application" mime-subtype="x-zip-compressed"/></supplementary-material>
21253439|None|('method', 0.9457713009619562)|('other', 0.05422869903804386)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II. Empirical Approach</title>
21253439|None|('method', 0.9457713009619562)|('other', 0.05422869903804386)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P18">To investigate the nature of private information in the long-term care insurance market, we draw on a rich dataset that contains the respondents’ own assessments of their nursing home risk, as well as data on ex post risk occurrence, insurance coverage, precautionary activities, and a full set of health and demographic indicators that are sufficiently detailed to allow us to proxy the insurers’ risk categorization. Our empirical strategy proceeds in three simple steps. First, we demonstrate that individuals have private information about their risk type and that this private information is positively correlated with insurance coverage. Second, we show that despite this private information, the equilibrium does not exhibit the positive correlation between insurance coverage and the use of long-term care predicted by unidimensional models of asymmetric information. These two sets of findings point mechanically to the existence of a second form of unobserved heterogeneity—heterogeneity in preferences—which offsets the risk-based selection and obscures the expected positive correlation between insurance coverage and risk occurrence. In the third step of the analysis, we present direct evidence of the form of this offsetting preference-based selection.</p>
21253439|A. Data|('method', 0.9457713009619562)|('other', 0.05422869903804386)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" sec-type="methods" id="S5"><title>A. Data</title><p id="P19">Our individual-level survey data are from the Asset and Health Dynamics (AHEAD) cohort of the Health and Retirement Study (HRS). At baseline this cohort is representative of the non-institutionalized population born in 1923 or earlier and their spouses. <xref rid="APP1" ref-type="app">Appendix A</xref> provides more detail on the data and our sample. The average age of our respondents when we observe them in 1995 is 78, and 11 percent have long-term care insurance. These respondents are followed over time, allowing us to observe actual nursing home use from 1995 to 2000. Sixteen percent of our initial community-based sample enters a nursing home at some point during this five-year period.</p><p id="P20">Central to our analysis is a measure of individual beliefs about nursing home use. We take advantage of a question in AHEAD that directly asks respondents about their perceived likelihood of nursing home use. The specific question we use from the 1995 survey is: “Of course nobody wants to go to a nursing home, but sometimes it becomes necessary. What do you think are the chances that you will move to a nursing home in the next five years?” Individuals are asked to give a response on a scale of zero to 100, which we rescale to be between zero and one. Their responses may reflect information about their health status and thus their chance of needing nursing care. They may also reflect their alternatives to nursing care should they need it, such as the willingness of a spouse or child to take care of them, or their insurance coverage.</p><p id="P21">On several dimensions the subjective responses to this question appear reasonable. Individual predictions appear to be correct on average; the average self-reported probability of nursing home use over the five-year period is 18 percent, while 16 percent of the responders actually enter a nursing home over the five-year period. We also find that self-reported nursing home entry probabilities covary in sensible ways with known risk factors; they are higher for women than for men, and increase monotonically with age and with deteriorating health status. These results are consistent with other work that has found sensible covariance patterns for self-reported mortality probabilities and characteristics such as the individual’s age or health status (<xref ref-type="bibr" rid="R26">Daniel S. Hamermesh, 1985</xref>; <xref ref-type="bibr" rid="R51">V. Kerry Smith et al., 2001</xref>; <xref ref-type="bibr" rid="R31">Michael D. Hurd and McGarry, 2002</xref>).</p><p id="P22">One well-known drawback with self-reported probabilities, however, is the propensity of respondents to report round figures such as 0, 50, or 100 percent (<xref ref-type="bibr" rid="R30">Hurd and Mc-Garry, 1995</xref>;<xref ref-type="bibr" rid="R24">Li Gan et al., 2005</xref>). The preponderance of focal responses suggests that individuals may not be comfortable reporting probabilistic answers, and may not in fact even think in these terms. If individuals use probabilistic information in making insurance purchase decisions, but are unable to translate these latent probabilities into numbers when faced with a survey question, our results are likely to produce underestimates of the extent of the individual’s information.<xref rid="FN7" ref-type="fn">6</xref></p><p id="P23">We supplement the AHEAD data with information obtained directly from insurance companies about the information they collect from applicants and their risk classification practices. We draw on the application forms used by several large long-term care insurance companies which reveal the set of individual characteristics the companies observe, and on the industry’s actuarial model of nursing home utilization, which itself is a function of these observed characteristics.</p></sec>
21253439|B. Econometric Approach|('method', 0.9457713009619562)|('other', 0.05422869903804386)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>B. Econometric Approach</title><p id="P24">The first step of our analysis is to examine the relationship between an individual’s beliefs about his subsequent nursing home utilization, on the one hand, and his actual subsequent nursing home utilization or his current long-term care insurance holdings, on the other. We therefore estimate the following two probits: <disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Prob</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>CARE</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="bold-italic">B</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Prob</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>LTCINS</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>δ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="bold-italic">B</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p id="P25">CARE is a binary variable for whether the individual went into a nursing home in the five years between 1995 and 2000. LTCINS is a binary variable for whether the individual has long-term care insurance in 1995. The coefficient of interest in each equation is that on <italic>B</italic>, the individual’s self-reported beliefs (measured in 1995) of his probability of entering a nursing home between 1995 and 2000. <bold><italic>X</italic></bold> is a vector of covariates to control for the risk classification that would be assigned to the individual by insurance companies in 1995.<xref rid="FN8" ref-type="fn">7</xref></p><p id="P26">The second step of our analysis is to implement the standard positive correlation test for asymmetric information. To do so we employ two approaches used in the literature (the results are quite similar across the two). In one approach, we follow <xref ref-type="bibr" rid="R9">Chiappori and Salanie (2000)</xref> and estimate a bivariate probit of insurance coverage and risk occurrence, conditional on the risk classification variables (<bold><italic>X</italic></bold>). This is equivalent to estimating the probits in (<xref rid="FD1" ref-type="disp-formula">1</xref>) and (<xref rid="FD2" ref-type="disp-formula">2</xref>) simultaneously, with the beliefs variable (<italic>B</italic>) omitted from the regression. The key variable of interest is the correlation between the error terms (<italic>ρ</italic>). A unidimensional model of asymmetric information predicts that residuals will be positively correlated (<italic>ρ</italic> &gt; 0) and an inability to reject the null hypothesis that <italic>ρ</italic> = 0 constitutes a failure to reject the null of symmetric information.<xref rid="FN9" ref-type="fn">8</xref></p><p id="P27">Our second approach follows the work of <xref ref-type="bibr" rid="R23">Finkelstein and Poterba (2004)</xref> and estimates a probit model of nursing home use as a function of insurance coverage, controlling for risk classification: <disp-formula id="FD3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Prob</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mtext>CARE</mml:mtext><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>X</mml:mi><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mtext>LTCINS</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p id="P28">The positive correlation prediction is that <italic>β</italic><sub>2</sub> &gt; 0. Note that <italic>β</italic><sub>2</sub> does not have a causal interpretation. In a pure moral hazard model, the coefficient would represent the causal effect of insurance coverage on care utilization. In an adverse selection model, however, the causality is reversed and private information about expected care utilization affects insurance demand.</p><p id="P29">In the final step in our empirical work, we provide several examples of additional individual characteristics that are not used in the insurer’s risk classification, but that when added on the right-hand sides of <xref rid="FD1" ref-type="disp-formula">equations (1)</xref> and <xref rid="FD2" ref-type="disp-formula">(2)</xref>, have opposite signed relationships with CARE and with LTCINS.</p></sec>
21253439|C. Controlling for Risk Classification|('method', 0.9457713009619562)|('other', 0.05422869903804386)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>C. Controlling for Risk Classification</title><p id="P30">Any analysis of private information, whether the approach we undertake in the first part of our analysis or the standard positive correlation test in our second step, requires that we condition on the risk classification of the individual by insurance companies (<bold><italic>X</italic></bold>). This conditioning allows us to test for the existence of <italic>residual</italic> private information, which is the economically meaningful question.</p><p id="P31">Using insurance applications from five leading long-term care insurance companies, we determined what individual characteristics insurance companies observe. All of them collect a limited set of demographic information—age, gender, marital status, and age of spouse—as well as similar and extremely detailed information on current health and on health history. This same information is observable in AHEAD, which collects extremely rich and detailed information on current health and medical history, as well as standard demographic data. We can therefore accurately replicate the insurer’s information set.</p><p id="P32">Our preferred approach is to control for the insurance companies’ actuarial prediction of the individual’s risk type, because it is this measure that is used to generate the price the individual is charged. We generated the insurance companies’ prediction of the probability the individual will go into a nursing home over a five-year period using the same actuarial model that is employed by many of the firms in the industry; the model and its pedigree are described in detail in <xref ref-type="bibr" rid="R46">James Robinson (1996)</xref>, <xref ref-type="bibr" rid="R47">Robinson (2002)</xref>, and <xref ref-type="bibr" rid="R3">Brown and Finkelstein (2004a)</xref>.<xref rid="FN10" ref-type="fn">9</xref> The predictions depend nonparametrically on the individual’s age, sex, and membership in one of seven different health states (defined by the number of limitations to instrumental activities of daily living (IADLs), the number of limitations to activities of daily living (ADLs), and the presence or absence of cognitive impairments). As noted, all of this information is available in the AHEAD. This measure provides a parsimonious way of controlling for nonlinear (and nonparametric) interactions between the observed characteristics of the individual used by the actuaries in pricing insurance and care utilization.<xref rid="FN11" ref-type="fn">10</xref></p><p id="P33">One potential issue with this approach is that we are implicitly assuming that none of the information that is collected by the insurance company, but omitted from the actuarial model, is used in pricing the policies. This assumption appears broadly consistent with insurance company practice. Companies offer age-specific prices with only two or three broad health-based rate classifications within each age (<xref ref-type="bibr" rid="R41">Murtaugh et al., 1995</xref>; <xref ref-type="bibr" rid="R1">American Council of Life Insurers, 2001</xref>; <xref ref-type="bibr" rid="R56">Weiss, 2002</xref>), and do not further adjust premiums over time if the characteristics of the individual change.<xref rid="FN12" ref-type="fn">11</xref> However, we cannot rule-out the possibility that this information is somehow used by the insurance company in determining which of the two or three broad health-based rate classifications to assign the individual to, or whether the company agrees to insure the individual in the first place. Therefore, we also present results from an alternative approach, which we term the “application information” specification. In this specification, we attempt to control for everything insurance companies observe about the individual. We include a full set of single year of age dummies, all of the demographic information that insurance companies collect in their applications (sex, marital status, and age of spouse), and over 35 indicator variables for each of the detailed current health and health history characteristics collected by any insurance company.<xref rid="FN13" ref-type="fn">12</xref> To be conservative, we also include indicator variables for the household’s income quartile and asset quartile, even though we found only one company that collected any financial information.<xref rid="FN14" ref-type="fn">13</xref> Finally, to allow for possible nonlinearities among these various characteristics, we also include a complete set of two-way and three-way interactions between age, sex, and the health variables that are included in the actuarial model (ADLs, IADLs, and cognitive impairment). The “application information” specification thus invokes a more finely defined categorization of risk than insurance companies likely use in pricing.<xref rid="FN15" ref-type="fn">14</xref></p></sec>
21552505|None|('method', 0.8704729425901601)|('other', 0.12952705740984016)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I. Data and Empirical Framework</title>
21552505|None|('method', 0.8704729425901601)|('other', 0.12952705740984016)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">Our analysis uses individual-level data from the Health and Retirement Study (HRS). We use the original HRS cohort to examine the holding of term life insurance and private acute health insurance among people age 51 to 61 in 1992. We use a second HRS cohort, the Asset and Health Dynamics (AHEAD) sample, to examine Medigap insurance, long-term care insurance, and annuities among people age 65 to 90 in 1995. We examine contemporaneous reports of medical care use, and also use the panel nature of these data to track mortality and nursing home outcomes for individuals in both cohorts through 2002. The working paper version (<xref rid="R6" ref-type="bibr">Cutler, Finkelstein, and McGarry 2008</xref>) contains more detailed information on the definitions of the variables we use, as well as summary statistics.</p>
21552505|None|('method', 0.8704729425901601)|('other', 0.12952705740984016)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">Our basic test is to examine how measures of risk tolerance are related to the occurrence of risk, and to whether the individual has insurance. Risk tolerance is not easily measured. We proxy for risk tolerance using five measures of behaviors that likely capture individual risk aversion: smoking; drinking; job-based mortality risk; receipt of preventive health care; and use of seat belts. While each of these variables will reflect factors in addition to risk tolerance, results that are consistent across the variables suggest that risk tolerance is an important part of their variability. We have also examined the relationship between the behavior measures and a proxy for risk aversion based on respondents’ reported willingness to engage in various hypothetical income gambles. The two are moderately related (see working paper for results), which is consistent with prior analyses (Robert <xref rid="R1" ref-type="bibr">Barsky et al. 1997</xref>).</p>
21552505|None|('method', 0.8704729425901601)|('other', 0.12952705740984016)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">Our estimating equations are of the form: <disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtext>I</mml:mtext><mml:msub><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="italic">insurance</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="italic">Behavior</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mi mathvariant="normal">Γ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>ε</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>;</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="italic">Riskoccurrence</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mrow><mml:mi mathvariant="italic">Behavior</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mi mathvariant="normal">Π</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula> where I(<italic>insurance</italic>)<italic><sub>i</sub></italic> is an indicator variable for whether the individual has a particular type of insurance, <italic>Riskoccurrence<sub>i</sub></italic> is a measure of the occurrence of the risk the insurance in question would cover, <italic>Behavior<sub>i</sub></italic> is one of our measures of risk tolerance, and <italic>X</italic> represents covariates.</p>
21552505|None|('method', 0.8704729425901601)|('other', 0.12952705740984016)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">We use five measures of insurance holdings: whether the individual has term life insurance in 1992, whether the individual has private acute health insurance in 1992 (through either an employer or the nongroup market)<xref ref-type="fn" rid="FN3">2</xref>, whether the individual has an annuity in 1995, whether the individual has Medicare supplemental coverage in 1995 (termed “Medigap”) to cover some of the expenses not insured by the public Medicare insurance, and whether the individual has long-term-care insurance in 1995. The corresponding risk occurrence measures for these five insurance products are: whether the individual dies by 2002 (for life insurance), whether the individual reports having entered a hospital in the previous two years (for acute health insurance), whether the individual survives to 2002 (for annuities), contemporaneous medical expenses not covered by Medicare (for Medigap), and whether the individual goes into a nursing home by 2002 (for long-term-care insurance). <xref ref-type="fn" rid="FN4">3</xref></p>
21552505|None|('method', 0.8704729425901601)|('other', 0.12952705740984016)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P10">Our behavioral measures are relatively standard. Smoking behavior is defined as current smoking status. Drinking is a dummy variable for whether the individual has three or more drinks per day (a common measure of problem drinking). Job risk is defined as the mortality rates per 100,000 employees in the individual’s industry-occupation cell (for the HRS) or occupation cell (for the AHEAD). We also construct two measures of active steps individuals can take to reduce mortality and healthy risk: the fraction of gender-appropriate preventive health activity undertaken,<xref ref-type="fn" rid="FN5">4</xref> and whether the individual reports always wearing a seat belt. For our 1995 AHEAD sample, we observe these measures contemporaneously in 1995. Unfortunately, for the 1992 HRS sample, these measures are first available in 1996; we observe them for people who are alive at that age.</p>
21552505|None|('method', 0.8704729425901601)|('other', 0.12952705740984016)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">On average, in our 1992 sample of near-elderly, 27 percent of people smoke, 5 percent have a drinking problem, and the average mortality risk by industry-occupation cell is 4 fatalities per 100,000 employees. The average person undertakes 60 percent of gender-appropriate health activities, and 80 percent report always wearing a seat belt. Smoking rates are substantially lower (7.6 percent) in our 1995 sample of the elderly, reflecting the strong difference in mortality by smoking status at older ages, but the other characteristics are similar.</p>
21687831|None|('method', 0.6351203680883837)|('other', 0.36487963191161626)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">III. Impact of Learning HIV Status</title>
21687831|A. Theoretical and Measurement Considerations|('method', 0.6351203680883837)|('other', 0.36487963191161626)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>A. Theoretical and Measurement Considerations</title><p id="P38">In a standard expected utility framework, individuals do not receive any additional utility from learning their HIV status. Testing is beneficial only to the extent that it provides new information that can be used for updating behavior.<xref rid="FN12" ref-type="fn">12</xref> However, it is theoretically ambiguous how the knowledge of HIV status affects sexual behavior and, in particular, the demand for condoms. For those diagnosed HIV-positive, the direct benefits of using condoms fall because (if safe sex is costly) there is no longer any need of protection. However, HIV-positive individuals who are sufficiently altruistic may exhibit a higher demand for condoms after learning their status. On the other hand, if infected individuals behave selfishly, there may be a decrease in the demand for condoms (<xref ref-type="bibr" rid="R59">Stephane Mechoulan 2004</xref>). For HIV-negatives, it is similarly ambiguous: the benefit from using condoms—i.e., to remain uninfected—may increase after diagnosis; however, the lack of need to protect a sexual partner may cause condom use to fall.<xref rid="FN13" ref-type="fn">13</xref> Thus, how learning HIV results affects sexual behavior is ultimately an empirical question.</p><p id="P39">Previous studies examining the effects of HIV testing on sexual behavior have not only been inconclusive, but also suffer from selection bias in terms of which individuals chose to learn their results.<xref rid="FN14" ref-type="fn">14</xref> In this study, however, the randomly assigned VCT center distances and monetary incentives serve as exogenous instruments for knowledge of status. Nevertheless, several estimation challenges and limitations remain.</p><p id="P40">One challenge to measuring the demand for safe sex in response to HIV testing is that sexual behavior is difficult to measure and self-reports may be unreliable. Prior research has found that sexual behavior, such as number of sexual partners, is likely to be underreported and that contraceptive use is sometimes overreported (<xref ref-type="bibr" rid="R61">Landon Myer, C. Morroni, and B. G. Link 2004</xref>; <xref ref-type="bibr" rid="R1">Susan Allen et al. 2003</xref>). Because of the potential bias of self-reports, the primary outcome variable used to measure the demand for safe sex in this paper is the actual purchase of condoms from survey interviewers. To mitigate potential reporting biases during follow-up interviews, every effort was made to conduct interviews privately with an interviewer of the same sex as the respondent, who had no part in the HIV testing or in giving results.</p><p id="P41">It is important to keep in mind that condom purchases may not reflect the true demand for safe sex. If knowledge of HIV status increases abstinence, the demand for condoms could fall in response to obtaining test results. Also, the impact of learning HIV status on condom purchases is likely to differ between those with a sexual partner and those without. And because partnership may be endogenous to learning HIV results (<xref ref-type="bibr" rid="R68">Georges Reniers 2005</xref>), I differentiate between those who were and who were not sexually active at the time of the baseline survey (before testing). It is worth noting, however, that there were no significant changes in marriage or partnership attributable to learning HIV status between the time of the HIV results being available and the follow-up survey (not shown).</p></sec>
21687831|B. Summary Statistics of Sexual Activity and Condom Use|('method', 0.6351203680883837)|('other', 0.36487963191161626)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" sec-type="conclusions" id="S10"><title>B. Summary Statistics of Sexual Activity and Condom Use</title><p id="P42">In the baseline 2004 survey, 76 percent of the follow-up sample reported having had sex during the previous year (<xref rid="T2" ref-type="table">Table 2</xref>, panel B). In the follow-up 2005 survey, 62 percent of the sample reported having had sex during the previous two months (<xref rid="T2" ref-type="table">Table 2</xref>, panel D). Of those who reported having sex, only 3.3 percent reported having sex with more than one partner, although the majority of these individuals were polygamous men. At the time of the follow-up survey, respondents were also asked if they had purchased condoms at any time between the opportunity to obtain test results and the follow-up interviews: only 8 percent of the sample reported purchasing condoms during those two months. In terms of the subsidized condoms that were offered at the end of the follow-up interview, 24 percent purchased at least one condom; of those who purchased any condoms, the average number purchased was 3.7 (<xref rid="T2" ref-type="table">Table 2</xref>, panel D). This rate of condom purchases is similar to the condom use reported in the 2004 main survey, where 21 percent of all respondents reported using a condom with a sexual partner during the prior year (<xref rid="T2" ref-type="table">Table 2</xref>, panel B). Only three individuals purchased the maximum possible number of condoms. Men were more likely to purchase than women: 31 percent of men purchased condoms while 18 percent of women purchased at least one condom. However, conditional on purchasing any condoms, men and women purchase the same number, on average (not shown). Among HIV-positives, men and women were equally likely to purchase condoms at the follow-up survey. Among all respondents, married and unmarried respondents were equally likely to purchase condoms. However, purchase of condoms did vary by reported sexual activity: condoms were purchased by 26 percent of respondents who in 2004 reported having had sex in the prior year as opposed to 21 percent of those who reported not having had sex.</p></sec>
21687831|C. Receiving HIV-Positive and Negative Diagnoses|('method', 0.6351203680883837)|('other', 0.36487963191161626)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>C. Receiving HIV-Positive and Negative Diagnoses</title><p id="P43">Panel A of <xref rid="F5" ref-type="fig">Figure 5</xref> presents the percent purchasing condoms among those who knew and did not know their HIV status. For HIV-positive respondents, those who obtained their test results were more than twice as likely to purchase condoms as those who did not, while among HIV-negative individuals, condom purchase did not vary significantly by knowledge of HIV status (<xref rid="F5" ref-type="fig">Figure 5</xref>, panel B).</p><p id="P44">I measure the effects of learning HIV results with the following regression:<disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="italic">α</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">GotResults</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="italic">GotResults</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi mathvariant="italic">HIV</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">HIV</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic">μ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">ɛ</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><italic>Y</italic> indicates condom purchase at the time of the follow-up survey (as measured by whether the respondent purchased condoms or the total number of condoms purchased) or if the respondent reported having sex; and <italic>GotResults</italic> indicates knowledge of HIV status. The fact that individuals choose to learn their HIV status means that OLS estimates are likely to be biased, but estimating the effects of knowing HIV status with exogenous instruments provides unbiased estimates. In particular, I instrument <italic>GotResults</italic> with being offered any incentive, the amount of the incentive, the amount of the incentive squared, the distance from the HIV result center, and distance-squared. <xref rid="T6" ref-type="table">Table 6</xref> presents first-stage OLS regressions; the <italic>F</italic>-statistics for this specification and sample of sexually active respondents are equal to 74.98 and 193.29, respectively. To account for differential effects among men and women, I also include interactions with gender:<disp-formula id="FD3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mtable><mml:mtr><mml:mtd><mml:mrow><mml:msub><mml:mi mathvariant="italic">GotResults</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi mathvariant="italic">α</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">Any</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">Amt</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msubsup><mml:mi mathvariant="italic">Amt</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">Dist</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:msubsup><mml:mi mathvariant="italic">Dist</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="italic">Any</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi mathvariant="italic">Male</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>7</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="italic">Amt</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi mathvariant="italic">Male</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>8</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi mathvariant="italic">Amt</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>×</mml:mo><mml:msub><mml:mi mathvariant="italic">Male</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd/><mml:mtd/><mml:mtd columnalign="left"><mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mn>9</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="italic">Dist</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:msub><mml:mi mathvariant="italic">Male</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">β</mml:mi><mml:mrow><mml:mn>10</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi mathvariant="italic">Dist</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>×</mml:mo><mml:msub><mml:mi mathvariant="italic">Male</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:msup><mml:mi mathvariant="bold">X</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic">μ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="italic">ɛ</mml:mi><mml:mrow><mml:mi mathvariant="italic">ij</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p><p id="P45">In <xref rid="FD2" ref-type="disp-formula">equation (2)</xref>, <italic>GotResults×HIV</italic> represents the differential effect of receiving an HIV-positive diagnosis, and this is instrumented with the same set of instruments as in (<xref rid="FD3" ref-type="disp-formula">3</xref>) above, interacted by HIV status. Because the monetary incentives and distances to VCT centers were both exogenously assigned to each individual, they are uncorrelated with the error term. In the analysis, although the measure of purchasing condoms is binary, estimates do not differ greatly from a nonlinear specification. Both specifications are presented.</p><p id="P46">Covariates, <bold>X</bold>, include age, age-squared, a dummy for male, simulated average distance to the VCT center, and district dummies. It is also important to point out that the IV estimates in (<xref rid="FD2" ref-type="disp-formula">2</xref>) are local average treatment effects (LATE), which represent a weighted average per-unit treatment effect, where the weight is proportional to the number of people affected by the instruments, not necessarily equal to the average treatment effect (<xref ref-type="bibr" rid="R46">Guido W. Imbens and Angrist 1994</xref>; <xref ref-type="bibr" rid="R6">Angrist and Imbens 1995</xref>; <xref ref-type="bibr" rid="R7">Angrist et al. 1996</xref>). Also, while I account for some heterogeneous treatment effects by including interactions with gender, there may be other differential effects of the incentive and distance that are not included in the IV analysis (see <xref ref-type="bibr" rid="R46">Imbens and Angrist 1994</xref>; <xref ref-type="bibr" rid="R41">Heckman and Jeffrey Smith 1997</xref>; <xref ref-type="bibr" rid="R40">Heckman 2001</xref>; <xref ref-type="bibr" rid="R42">Heckman et al. 2006</xref>).<xref rid="FN15" ref-type="fn">15</xref></p><p id="P47">I first examine the effects of receiving an HIV diagnosis on condom purchases and reported sexual activity among those who reported having sex at the time of the baseline survey: 63 percent of HIV-negative and 66 percent of HIV-positive individuals.<xref rid="FN16" ref-type="fn">16</xref> Note that this reduces the sample of HIV-positives for the analysis and thus much of the focus of the analysis is among the HIV-negatives or pooled regressions. Row 1 of <xref rid="T7" ref-type="table">Table 7</xref> shows no significant effects of learning HIV-negative results on any measure of condom purchase or recent sexual activity among those who had sex at baseline (<xref rid="T7" ref-type="table">Table 7</xref>, columns 2, 4, 6, and 8). However, the standard errors of the IV estimates are large, making it impossible to reject “no impact of learning HIV-negative status.”</p><p id="P48">Overall, while HIV-positive individuals were significantly less likely to purchase condoms from the survey interviewers or report purchasing condoms on their own, <italic>receiving</italic> an HIV-positive diagnosis resulted in an increase in condom purchases. Among those with a sexual partner at the time of the 2004 baseline survey, those obtaining HIV-positive results were 25 percentage points more likely to purchase condoms than HIV-positive persons who did not learn their results (although statistically insignificant in the IV specification of <xref rid="T7" ref-type="table">Table 7</xref>, column 2). This result is statistically significant when measuring the total number of condoms purchased as an outcome, where the average number of condoms purchased increased by 1.69 condoms after receiving an HIV-positive diagnosis (<xref rid="T7" ref-type="table">Table 7</xref>, column 4). The <italic>p</italic>-value of the total impact of receiving an HIV-positive diagnosis is 0.07, presented in <xref rid="T7" ref-type="table">Table 7</xref>.</p><p id="P49">Recall that the condoms sold during the follow-up study were subsidized in price and were offered for purchase at the respondent’s home–significantly lowering the cost of travel to obtain condoms at local stores. In regards to the nonsubsidized condoms, respondents were asked if they had purchased any condoms during the two months after that test results were available at the VCT centers. There is a positive, although statistically insignificant, relationship between receiving an HIV-positive test result and the reported purchase of nonsubsidized condoms during the two months after HIV test results were available in the OLS, but not in the IV (<xref rid="T7" ref-type="table">Table 7</xref>, columns 5 and 6). There is also a negative (also statistically insignificant) relationship between receiving HIV-positive results on the probability of having sex at follow-up (<xref rid="T7" ref-type="table">Table 7</xref>, column 8).</p><p id="P50">Theoretically, if individuals who were more likely to practice safe sex were also more likely to choose to learn their HIV status and also purchase more condoms at the follow-up, not accounting for selection bias would overestimate the true impact of learning HIV results on later sexual behavior. However, comparing the OLS estimates to the IV estimates of the impact of learning HIV results on condom purchases (<xref rid="T7" ref-type="table">Table 7</xref>) indicates no consistent pattern across each column, and the differences between the OLS and IV estimates are neither large nor statistically significant for either HIV-negative or HIV-positive individuals (not shown).</p><p id="P51">Several of the outcome variables in <xref rid="T7" ref-type="table">Table 7</xref> are binary, possibly warranting a nonlinear estimation strategy. However, estimation of binary regression models with binary endogenous variables is difficult and there are often problems with convergence or concavity of the log likelihood surface (<xref ref-type="bibr" rid="R31">David A. Freedman and Jasjeet S. Sekhon 2008</xref>; see also <xref ref-type="bibr" rid="R76">Edward Vytlacil and Nese Yildiz 2007</xref>; <xref ref-type="bibr" rid="R8">Jacob Nielsen Arendt and Anders Holm 2006</xref>). One strategy suggested by <xref ref-type="bibr" rid="R39">Heckman (1978)</xref> is to estimate a bivariate probit model. In order to estimate the effects of learning HIV results on the likelihood of purchasing any condoms using this nonlinear strategy, it is necessary to divide the sample by HIV status and estimate the effect of obtaining HIV test results on positive and negative individuals separately. Because the sample is not pooled among HIV-positives and HIV-negatives, the nonlinear estimates presented in <xref rid="T8" ref-type="table">Table 8</xref> are not directly comparable to those in <xref rid="T7" ref-type="table">Table 7</xref>. I therefore present linear OLS and IV estimates as well as the marginal probit and marginal biprobit (accounting for endogeneity) estimates on the impact of learning HIV results on condom purchases among HIV-positives and negatives.<xref rid="FN17" ref-type="fn">17</xref></p><p id="P52">The linear results in column 2, <xref rid="T8" ref-type="table">Table 8</xref>, do not differ substantively from the nonlinear biprobit specification in column 4, <xref rid="T8" ref-type="table">Table 8</xref>; however, the magnitudes of the coefficients and statistical significance do vary slightly. In particular, while the coefficient on <italic>GotResults</italic> does not differ greatly among the HIV-negatives (<xref rid="T8" ref-type="table">Table 8</xref>, panel B), among HIV-positives the coefficient in the nonlinear case is statistically significant at the 99 percent level (<xref rid="T8" ref-type="table">Table 8</xref>, panel A). The coefficient is also greater in the bivariate probit specification than in the linear model, suggesting an even larger effect of learning HIV-positive results on the likelihood of purchasing condoms. On the other hand, the difference between the two specifications may be due in part to the small sample size of HIV-positives. Given the difficulties with this estimation, including in particular the fact that it is necessary to separate the samples when doing the biprobit estimation, the linear IV specification in <xref rid="T7" ref-type="table">Table 7</xref> remains the preferred estimation model.<xref rid="FN18" ref-type="fn">18</xref></p><p id="P53">The results in <xref rid="T7" ref-type="table">Table 7</xref> and <xref rid="T8" ref-type="table">Table 8</xref> together suggest that overall, while there was no impact of receiving an HIV-negative diagnosis, receiving an HIV-positive diagnosis had positive effects on subsequent condom purchases. In the linear specification, the estimated impact of learning HIV-positive results on the likelihood of purchasing any condoms is large, although statistically insignificant at traditional confidence levels (<xref rid="T7" ref-type="table">Table 7</xref>, column 2). However, there is a statistically significant effect of learning HIV-positive results on the total number of condoms purchased (<xref rid="T7" ref-type="table">Table 7</xref>, column 4). In the nonlinear case, the coefficient on <italic>GotResults</italic> is statistically significant and large (<xref rid="T8" ref-type="table">Table 8</xref>, column 4): an HIV-positive individual who learned his HIV status was 37 percentage points more likely to purchase condoms than an HIV-positive individual who did not learn his results.</p></sec>
21687831|D. Other Considerations|('method', 0.6351203680883837)|('other', 0.36487963191161626)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>D. Other Considerations</title><p id="P54">It is possible that respondents who knew themselves to be HIV-positive were motivated to purchase condoms solely out of guilt, believing (incorrectly) that the interviewer knew their status. If this were the case, they may have purchased only one condom as a token, keeping the remaining money. However, only two of all the HIV-positives purchased a single condom; and omitting these individuals or coding their purchases as zero does not affect any of the results. Although impossible to rule out, this suggests that guilt or shame may not have been a large factor in the observed increase in condom sales among HIV-positives learning their results. Moreover, if HIV-positives purchased condoms solely out of guilt or social pressure, this would mean that the results of these analyses are upper bounds of the true impact of learning HIV status. Another consideration is that the outcome variable is condoms <italic>purchased</italic> rather than condoms <italic>used</italic> during sexual activity—which would also contribute to the results being an upward bias of the actual effect of learning HIV-positive results.<xref rid="FN19" ref-type="fn">19</xref> It is also possible that respondents purchased condoms with the intention of reselling the condoms, rather than using them. To the extent that resale is uncorrelated with the randomly assigned incentives and distance, this would not threaten the internal validity of results.</p><p id="P55">There were no differential effects of learning HIV-negative status on condom purchases between those who were and were not sexually active at the baseline (<xref rid="T9" ref-type="table">Table 9</xref>). There were also no differential effects of learning HIV status (either positive or negative) on condom purchases among other observable respondent characteristics. For example, although men on average were more likely to purchase condoms than women, there were no differences in the impact of learning HIV status on purchases by gender. There were also no differences by age, or ever having attended school (not shown). Learning HIV-positive or negative results did not significantly affect having discussions with friends or spouses about condoms or AIDS. Respondents were also asked about their attitudes about condoms. These attitudes were strong determinants of purchasing condoms; for example, those who “agreed” that condoms were acceptable to use with a spouse were twice as likely to purchase condoms as those who “disagreed.” However, there were no effects of receiving either a positive or negative diagnosis on attitudes about condoms among either HIV-positive or negative individuals (not shown).</p><p id="P56">Thus, it appears that individuals learning their HIV-positive status incur private costs to protect their sexual partners by purchasing condoms. It is important to note that the effects are greatest among those who are sexually active at the time condoms are made available to them to be purchased. There is no statistically significant effect on the likelihood of engaging in sexual intercourse after receiving an HIV-positive diagnosis. There was no significant effect of learning HIV-negative results on the purchase of condoms or on the likelihood of having sex two months after learning HIV-negative results.</p></sec>
21857716|None|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Part II: Data</title>
21857716|None|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P26">Our primary data source is a longitudinal sample of prescription drug records from the Wolters Kluwer (WK) Company. They are the largest “switch” operator in the prescription drug market: they collect the electronic claims from pharmacies and pass them on to the Pharmacy Benefit Managers (PBMs) and insurance companies that will pay the claims. After adjudicating the claim, it is passed back through the switch to the pharmacy. WK performs this function for a large sample of pharmacies throughout the U.S. Once pharmacies are in their sample, there is a 93% chance that they remain enrolled, so this is effectively a longitudinal sample of pharmacies. On average the claims captured by the WK system represent almost 31% of all 3<sup>rd</sup> party prescription claims filled in the U.S.<xref ref-type="fn" rid="FN8">8</xref> The geographic distribution of these data is very closely representative of the geographic distribution of 3<sup>rd</sup> party claims as well; the correlation between the WK market share and the overall 3<sup>rd</sup> party market share across each of the states is 0.86.</p>
21857716|None|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P27">WK keeps a longitudinal file that tracks prescription drug use for more than 100 million persons in the U.S. They have made available to us for research purposes a longitudinal sample of prescription claims for any individuals age 65 and over in 2005.</p>
21857716|None|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P28">These data are crucial because they are the only available data (of which we are aware) that contain information both on specific drug utilization by elders and on plan choice. Information about specific drug utilization is key because plan costs vary tremendously based on drug utilization, as we discuss below.</p>
21857716|None|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P29">We begin with a sample of 1.53 million elders who (a) have a Part D claim with coverage of any sort (e.g. past the deductible), (b) are not employer-insured, dual eligibles or eligible for low-income subsidies/partial subsidies, (c) have claims for only one region of the country, (d) have no claims with missing payment information, (e) are in the sample of consistently reporting pharmacies, and (f) have data for both 2005 and 2006. This data file has a rich set of information about every drug claim for individuals in the longitudinal sample, including information on: month in which the prescription was filled; county of location of the pharmacy; a depersonalized patient id which allows longitudinal patient linkages; patient age; NDC code for the drug; quantity measures (days supply, dosage, package size); patient and insurer payments; and insurer or PBM name. The total drug price is computed as the sum of patient and insurer payments; one or both of these values are blank for a small fraction of claims, and individuals with these claims are dropped. We constructed a crosswalk between the drug ID variable in the claims data and the NDC numbers listed on the formulary using a file from First Data Bank. To allow for the possibility of substitution if individuals were enrolled in a different plan, we constructed a coarser drug ID variable which is unique only up to drug name and assumed that individuals could substitute to the cheapest drug with the same name were they enrolled in an alternative plan.</p>
21857716|None|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P30">WK has created a sample for us that links longitudinally all claims from elders that fill prescriptions at a pharmacy in their sample. Thus, there are three types of attrition from the sample. First, elders may die (in which case we still observe all of their claims). Second, pharmacies may enter or leave the sample. This can be addressed by using only pharmacies that are continuously in their sample.<xref ref-type="fn" rid="FN9">9</xref> Finally, individuals may switch pharmacies. If the switch is to a pharmacy within the WK sample, then the company does a detailed statistical match to ensure that the patient is captured and matched to other prescriptions (based on the de-identified form of data fields such as first name, last name, date of birth, year of birth, gender, health insurance id and zip code). If the switch is outside of the WK sample, then the individuals will be lost to this sample.</p>
21857716|None|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P31">Unfortunately, there is no way to capture such transitions. So long as these transitions are not correlated with premiums, it will not bias our price elasticity estimate; so long as they are not correlated with plan cost sharing provisions, they will lead only to a general understatement of out-of-pocket spending that will lead us to overstate that coefficient.</p>
21857716|None|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P32">We can assess their importance by taking advantage of the fact that Wolters Kluwer provided us with a coverage level variable which indicates the proportion of pharmacies in each county which are covered by Wolters Kluwer. We have rerun our models on the 10% of counties where WK covers at least 40% of all third-party prescriptions, and our results are very similar to what we report below. This suggests that attrition is not significantly biasing our results.</p>
21857716|The CMS Plans Database|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>The CMS Plans Database</title><p id="P33">We obtain information on availability of Part D plans and specific plan features directly from four files provided by CMS: the plan information file, the beneficiary cost file, the formulary file and the geographic locator file. The plan information file lists plan names and identifiers, and regions/counties in which plans are offered. The beneficiary cost file contains copays and coinsurance rates for different tiers of each plan. The formulary file contains a list of all the drugs that are included on the formulary for each plan. The geographic locator file allows us to identify all the Social Security Administration (SSA) counties that correspond to different PDP and MA regions.</p><p id="P34">The major strength of the CMS data is that it allows us to fully parameterize any elder’s plan choice set based on their location. We have used these data to build a “cost calculator” that mimics the calculator provided on Medicare’s web site. This calculator uses a given set of prescriptions for a given elder to compute their projected out of pocket spending in each plan available in their county.</p></sec>
21857716|Matching patients to their Part D Plan|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Matching patients to their Part D Plan</title><p id="P35">One challenging aspect of the WK data is that we know each patient’s county and the name of the company that provides the Part D plan that is covering each prescription, but not specifically which Part D plan offered by that company is covering the prescription. For example, we know that an elder is covered by a Humana product, but not whether it is Humana Complete, Humana Enhanced, etc.</p><p id="P36">Fortunately, we can resolve this matching problem in most cases by using a combination of county code, company name, and copayment structure. For each claim and each of the plans within the same company offered in a particular county, we check if the copay that the patient paid for this claim matches any of the prescribed copays of the plan. We assign a person to a plan if most of their claims match to the same unique Part D plan. We carry out this exercise for each month. To confirm that a person has been matched to a correct Part D plan, we look at all the months together and insist that a person be consistently matched to the same plan in each month from June 2006 on, since enrollment into Part D plans was open until May 15<sup>th</sup> 2006.</p><p id="P37">Of the approximately 1.53 million individuals in our sample, 50.5% were matched to Part D plans. The remainder were excluded either because they had a large number of non-Part D claims (implying that they have some other form of coverage), because they had too few claims to reliably match, or because their copays were inconsistent with the copays listed for Part D plans in their region.</p><p id="P38">Of the matched individuals, 57.1% were uniquely matched to a Part D plan, and 42.9% were multiply matched (meaning that more than one Part D plan was consistent with their copays). While the unique matches are clear, excluding multiple matches leads us to misstate the proportion of enrollment in some plans. This problem is especially severe among Humana plans because Humana offers several plans which differ only in the deductible and donut hole coverage and thus cannot generally be distinguished on the basis of copays. While comprising 20% of all matches, Humana plans are only 10% of unique matches. To deal with this problem, we include both unique and multiple matches, with multiple matches randomly assigned to one of the plans to which they are matched with probability equal to the proportion of total national enrollment in that plan in 2006.<xref ref-type="fn" rid="FN10">10</xref></p></sec>
21857716|Construction of Out of Pocket Cost Variables|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Construction of Out of Pocket Cost Variables</title><p id="P39">The total enrollee costs of Part D can be decomposed into premiums, which are known for certain at the time of plan choice, and the distribution of out of pocket costs given the information available at the time when plans are chosen. Our focus is on estimating the distribution of costs given all of the information potentially available to individuals at the time when they make their choice. There are three reasons that estimating this distribution is challenging: first, we only observe realized out of pocket costs for the plan in which an individual is enrolled; second, we observe only a single realization of out of pocket costs for each individual (making it impossible to compute a variance measure); and third, we do not observe all of the information available to individuals at the time when they make their choice.</p><p id="P40">To handle the first difficulty, we assume that the set of 2006 claims is fixed and would remain constant had the individual in question chosen a different plan; that is, we assume no moral hazard. This assumption allows us to use the calculator to determine what each individual’s realized costs would be for each plan in their choice set. Given typical estimates of the elasticity of prescription drug utilization in the range of 0.2 to 0.5, and considering that this would only impact our results to the extent that individuals have sufficient foresight to take into account future utilization effects in their plan choices, this is a fairly innocuous assumption, as shown in Appendix A available in the online version of this paper.</p><p id="P41">To handle the second difficulty, we sample realized costs from 200 individuals who are “identical” to the individual in question at the time when the plan choice is made. In practice, we define “identical” as individuals with the same decile of 2005 drug expenditures, 2005 days supply of branded drugs and 2005 days supply of generic drugs; after extensive searching, we found that this combination provided the best prediction of 2006 prescription drug spending based on 2005 characteristics. We therefore assign each individual to one of 1000 cells demarcated by the interacted deciles of these measures. We restrict our sample to individuals for whom there are at least 200 other individuals in their cell, and we use these 200 individuals in each cell to compute both our rational expectations measure of utilization in 2006 (described below) and our variance measure.</p><p id="P42">The third difficulty is that individuals may actually know more than can be predicted given 2005 costs at the time when they make their plan choices. Intuitively, we can attempt to determine whether individuals know more than can be predicted given 2005 costs by analyzing whether their choices are sensitive to the component of the variation in realized costs across plans which cannot be predicted given 2005 characteristics. We discuss a model of this type in Part V.</p></sec>
21857716|Final Sample Creation|('method', 0.6538775966221896)|('other', 0.34612240337781036)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Final Sample Creation</title><p id="P43">Under Part D individuals could enroll not only in a stand alone PDP plan, but also in a more comprehensive MA plan; we distinguish between individuals matched to MA and those matched to PDP plans based on copay and exclude the former. We focus just on PDP plans (and therefore, just on individuals who chose PDP plans) because MA plans involve broader health care decisions which are beyond the scope of our data (e.g. regarding HMOs and fee-for-service plans). This exclusion is justified by the “independence of irrelevant alternatives” assumption that underlies our logit modeling, as discussed (and tested) further below. We also exclude individuals who have fewer than 500 observations in their state or fewer than 100 observations in their brand/state cell to increase the speed of estimation of the model by reducing the required number of brand/state fixed effects; this restriction has no effect on our final results.</p><p id="P44">Our final sample consists of 477,393 individuals. The typical patient in this sample is almost 75 years old, three-fifths are female, and they have an average of 34 claims per year. Their total prescription drug spending averages $1711 per year. While some individuals were enrolled in Part D for the full year, others enrolled as late as May. The average total premiums paid after enrollment was $287 and the average OOP costs paid out over the same period was $666. This is the sample used in the efficient frontier analysis below. In our conditional logit models, we randomly subsample 20% of these individuals for computational reasons. We estimate the more computationally demanding random coefficients models on a randomly chosen subsample of 15,000 patients.</p><p id="P45">The distribution of enrollees across Part D plans is highly correlated in this final sample with the national facts on PDP enrollment provided by CMS. The correlation between the share by brand in our sample and the CMS sample is 0.98, and the correlation between the share of our sample in the top 10 plans is correlated with the CMS reported share in those plans at 0.89 (the correlation for the top 100 plans is 0.91).</p></sec>
21857716|None|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Part IV: Base Model of Part D Plan Choice</title>
21857716|None|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P53">In this section, we extend the efficient frontier analysis presented above by considering several discrete choice models. These models serve three general purposes in our setting. First, they allow us to control for additional plan characteristics such as plan quality. Second, they allow us to understand more precisely how preferences combine with choice set characteristics so we can forecast how individuals might choose in counterfactual choice environments. Third, they allow us to quantify the welfare consequences of choices.</p>
21857716|None|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P54">We begin by specifying a CARA utility model with a normally distributed cost distribution:<disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mi>U</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mi>γ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>W</mml:mi><mml:mo>−</mml:mo><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:mtext>where</mml:mtext><mml:mspace width="thinmathspace"/><mml:mi>C</mml:mi><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></disp-formula>In this case, indirect utility is given by:<disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mtext mathvariant="italic">EU</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mi>C</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mtext>exp</mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mi>γ</mml:mi><mml:mi>μ</mml:mi><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mi>γ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where α = −exp(γ<italic>W</italic>) is a constant. A first-order Taylor expansion about the point (μ<sup>′</sup>, σ<sup>2<sup>′</sup></sup>) yields:<disp-formula id="FD3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>≈</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow/></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>′</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi>α</mml:mi><mml:mi>γ</mml:mi><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>′</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>μ</mml:mi><mml:mo>−</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>α</mml:mi><mml:msup><mml:mi>γ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>′</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>−</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>′</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>We can write total costs as <italic>C</italic> = π + <italic>OOP</italic> and since π is known for any given plan, <italic>Var</italic>(<italic>C</italic>) = <italic>Var</italic> (<italic>OOP</italic>) = σ<sup>2</sup> and μ = <italic>E</italic>(<italic>C</italic>) = π + <italic>E</italic>(<italic>OOP</italic>) = π + μ<sup>2</sup>. Adding an error term (and dropping constant terms) we can rewrite <xref ref-type="disp-formula" rid="FD3">equation (3)</xref> as:<disp-formula id="FD4"><label>(4)</label><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:mi>u</mml:mi><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>α</mml:mi><mml:mi>γ</mml:mi><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:msup><mml:mn>2</mml:mn><mml:mo>′</mml:mo></mml:msup></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>π</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>α</mml:mi><mml:msup><mml:mi>γ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:msup><mml:mo>*</mml:mo><mml:mo>′</mml:mo></mml:msup></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:msup><mml:mn>2</mml:mn><mml:mo>′</mml:mo></mml:msup></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mo>ε</mml:mo></mml:mrow></mml:math></disp-formula></p>
21857716|None|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P55">This maps into a conditional logit model of plan choice where the utility of individual <italic>i</italic> from choosing plan <italic>j</italic> is given by:<disp-formula id="FD5"><label>(5)</label><mml:math id="M5" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mtext mathvariant="italic">ij</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>μ</mml:mi><mml:mrow><mml:mtext mathvariant="italic">ij</mml:mtext></mml:mrow><mml:mo>*</mml:mo></mml:msubsup><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mtext mathvariant="italic">ij</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">x</mml:mi><mml:mi mathvariant="bold-italic">j</mml:mi></mml:msub><mml:mi mathvariant="bold-italic">λ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">q</mml:mi><mml:mrow><mml:mi mathvariant="bold-italic">b</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold-italic">j</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mi mathvariant="bold-italic">δ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mo>ε</mml:mo><mml:mrow><mml:mtext mathvariant="italic">ij</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula>with β<sub>0</sub> = β<sub>1</sub> = −αγ<italic>u</italic>(μ<sup>*<sup>′</sup></sup>, σ<sup>2<sup>′</sup></sup>) and <inline-formula><mml:math id="M6" overflow="scroll"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>α</mml:mi><mml:msup><mml:mi>γ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>μ</mml:mi><mml:msup><mml:mo>*</mml:mo><mml:mo>′</mml:mo></mml:msup></mml:msup><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:msup><mml:mn>2</mml:mn><mml:mo>′</mml:mo></mml:msup></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. In this equation <bold><italic>x</italic></bold> represents any financial plan characteristics which impacts choice, <bold><italic>q<sub>b(j)</sub></italic></bold> represents plan quality ratings and other non-financial aspects of plans (which vary only across brands), and ∈<sub><italic>ij</italic></sub> are i.i.d. type I extreme value random variables.</p>
21857716|None|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P56">This gives us <inline-formula><mml:math id="M7" overflow="scroll"><mml:mrow><mml:mi>γ</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:msub><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:math></inline-formula> which allows us to map the ratio of the coefficients on the variance of costs and the coefficient on the mean of costs into the coefficient of absolute risk aversion. This assumes that wealth is constant across all states of the world: the only risk facing individuals is uncertainty about the distribution of out of pocket costs. The same expression would hold if we added idiosyncratic risk that was uncorrelated with prescription drug expenditures, but it is not implausible that there would be correlated risks: in states of the world where prescription drug expenditures are higher, other medical expenditures are higher as well. Such correlated risks would tend to bias upwards our already low estimates of risk aversion.</p>
21857716|None|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P57">We include in our model several financial plan characteristics beyond premiums, out of pocket costs, and the variance of out pocket costs. These are: the deductible of the plan; a dummy for whether the plan covers all donut hole expenditures; a dummy for whether the plan covers generic expenditures in the donut hole only; and a cost-sharing index. The cost sharing index is calculated for each plan as the average percentage of expenditures covered by the plan between the deductible and the donut hole. This variable differs from expected out of pocket costs in that it has the same value for everyone in the sample for each plan, and because it is not directly impacted by whether plans have deductibles or donut hole coverage. We also include two measures of plan quality: the share of the top 100 drugs used by elders that is included in the plan’s formulary and a quality index. The quality index is computed by CMS on a 1–5 scale by aggregating consumer ratings at the brand level collected along 17 dimensions which are categorized as “Customer Service,” “Drug Pricing Information” (availability / rate of price changes), and “Using Your Plan to Get Your Prescription Filled”.</p>
21857716|None|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P58">Identification is a natural concern in this context. All of the plan characteristics included in our model may be endogenous due to unobserved demand factors, and they may be biased by correlation with unobserved plan characteristics. To address this concern, we observe and include in our model all of the publicly available information that might be used by individuals to make their choices. We also consider models where we control for a full set of brand dummies, as well as a full set of interactions of state dummies with brand dummies. When we include brand dummies, the coefficient on the quality index (which is measured at the brand level) is no longer separately identified although it can be recovered by a GLS regression of these dummies on the quality variable. When brand-state dummies are included, coefficients on plan characteristics such as the premium, deductible and donut hole coverage are identified by the variation across plans offered by the same brands in a given state.<xref ref-type="fn" rid="FN13">13</xref></p>
21857716|None|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P59">Even with these fixed effects, it is possible that premiums are endogenous because they are set based on brand-state specific assessments of demand conditions. If premiums are higher in regions where insurers anticipate more demand for their particular plan (relative to other plans offered by the same insurer), our estimate of the coefficient on premiums will be biased towards zero since individuals will appear to be less averse to higher premiums. To the extent that these factors make high premiums appear less undesirable than they actually are, our conclusion that premiums are overweighted relative to out of pocket costs would be strengthened, as would our estimates of the welfare loss due to consumer mistakes.<xref ref-type="fn" rid="FN14">14</xref></p>
21857716|Restrictions on Preferences|('method', 0.9474336360942568)|('other', 0.05256636390574327)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Restrictions on Preferences</title><p id="P60">The model laid out above suggests three natural restrictions on preferences which extend the efficient frontier concept to the discrete choice setting.</p><sec id="S13"><title>Restriction 1: β<sub>0</sub> = β<sub>1</sub></title><p id="P61">This restriction states that the coefficient on premiums should equal the coefficient on expected out of pocket costs. Controlling for the risk characteristics of plans, individuals should be willing to pay exactly one dollar in additional premiums for coverage which reduces expected out of pocket costs by one dollar. If this restriction fails to hold, individuals are not choosing on the efficient frontier: they could switch to alternative plans with comparable risk characteristics but lower total costs.</p></sec><sec id="S14"><title>Restriction 2: <bold>λ</bold> = <bold>0</bold></title><p id="P62">This restriction states that financial plan characteristics other than premiums, expected out of pocket costs and the variance of out of pocket costs do not impact choices. Individuals should not care about deductibles, donut hole coverage or copays <italic>per se</italic>; they should only care about these factors to the extent that they impact the distribution of out of pocket costs. Once we control for this distribution, these factors should be redundant.</p></sec><sec id="S15"><title>Restriction 3: β<sub>2</sub> &lt; <bold>0</bold></title><p id="P63">This restriction states that individuals should be risk averse.</p><p id="P64">While these restrictions follow naturally from utility maximization with full information and standard preferences, the model from which they are derived makes several important functional form assumptions: we assume that the distribution of out of pocket costs can be summarized by its mean and variance, that indirect utility is a linear function of this mean and variance, and that the errors are i.i.d. type I extreme value. In Appendix A, we show that the restrictions assumed in the previous section still hold even when these functional forms assumptions are weakened.<xref ref-type="fn" rid="FN15">15</xref> Of course, it is always possible to write down preferences that would violate the above restrictions, but these restrictions are generally compatible with commonly used expected utility functions given the observed cost distributions.</p></sec></sec>
22801457|None|('method', 0.9998909587623136)|('other', 0.000109041237686375)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Material and Methods</title>
22801457|Specimen Preparation|('method', 0.9998909587623136)|('other', 0.000109041237686375)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Specimen Preparation</title><p id="P11">Fourteen unembalmed human cadaveric cervical specimens (C2-T1) were harvested from 9 men and 5 women whose mean age at death was 55 years (range 36–66 years). Based on direct inspection and plain film x-rays, no spine had evidence of fracture of the vertebral elements or ankylosis of the intervertebral disc. Specimens were stored frozen at a temperature of −20°C. At the time of testing, the cervical spine specimens were thawed to room temperature in a bath of saline and dissected free of all musculature and other nonligamentous soft tissue. All osteoligamentous structures were preserved.</p><p id="P12">Bone mineral density (BMD) was determined from lateral scans of the vertebral bodies at the C4-C6 levels using dual energy x-ray absorptiometry (DEXA), and the cadaveric specimens were separated into two groups of seven with closely matched BMDs (0.949 ± 0.207 g/cm<sup>2</sup> in the standard corpectomy group, 0.949 ± 0.192 g/cm<sup>2</sup> in the skip corpectomy group). Household wood screws were inserted in the exposed distal ends of C2 and T1, and the screw heads and parts of the exposed terminal vertebrae were potted in cylindrical aluminum fixtures using polymethylmethacrylate.</p></sec>
22801457|Surgical Procedures|('method', 0.9998909587623136)|('other', 0.000109041237686375)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Surgical Procedures</title><p id="P13">One group of seven specimens received a standard three-level corpectomy and fibular strut graft. C3-C4, C4-C5, C5-C6, and C6-C7 discectomies were performed first by using scalpel, curette, and pituitary rongeurs, simulating clinical procedures. The dissection proceeded to the medial border of the Luschka joints. After removal of the disc material and transection of the posterior longitudinal ligament, a corpectomy channel approximately 1.5 cm wide was created through the C4, C5, and C6 vertebral bodies using a high-speed pneumatic drill (Medtronic Midas Rex, Fort Worth, TX). Posterior longitudinal ligament remnants were removed. The rostral and caudal vertebral endplates were flattened, and a shelf of bone approximately 2 mm high was created in the posterior 5 mm of each endplate to prevent dislodgment of the graft posteriorly. A strut graft from cadaveric fibula or iliac crest was also prepared with a high-speed drill for each specimen and sized to provide a good fit, as would be done clinically. The graft was pushed posteriorly until it contacted the posterior shelf of bone.</p><p id="P14">The second group of seven specimens received the three-level skip corpectomy construct. The middle vertebra (C5) was left intact while C4 and C6 received 1-level corpectomies. Rostrally and caudally, the C5 vertebra was drilled at an angle in the posteriormost 2–3 mm of the endplates to provide a trajectory to decompress the posterior part of the C5 vertebra. This undercutting technique simulates the decompression that would typically be performed clinically and that is necessary to achieve decompression comparable to that of a three-level corpectomy. A shelf of bone was also created in the posterior 5 mm of each endplate within the corpectomy defects, and cadaveric strut grafts were sized and inserted using the aforementioned technique.</p><p id="P15">A nonconstraining titanium anterior cervical plate (ACP system, Codman, Johnson &amp; Johnson Professional Inc., Raynham, MA) was applied to the specimens of both groups from C3 to C7 (<xref rid="F1" ref-type="fig">Figure 1</xref>). Plate length was selected according to the dimensions of each specimen (74–96 mm). In the standard three-level corpectomy group, two screws were inserted in C3 and two screws in C7 for a total of 4 screws. Likewise, skip corpectomy specimens received screws in C3 and C7, and two additional screws were placed in the intermediate intact vertebra (C5) (total of 6 screws).</p><p id="P16">The self-tapping 12-mm long screws (outer diameter 4 mm) were cannulated with a 1.25-mm core and instrumented with strain gauges with the intention of directly measuring pullout forces. However, the strain gauge data proved unreliable and were not used. Cannulation and gauging did not affect the screw threads and therefore should not have affected the screw’s holding strength or deformability under the load range studied.</p></sec>
22801457|Flexibility Tests|('method', 0.9998909587623136)|('other', 0.000109041237686375)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Flexibility Tests</title><p id="P17">Multidirectional flexibility tests were used to document the stability of the constructs. Nondestructive, nonconstraining pure moments were applied to specimens using a servohydraulic test system (MTS Systems, Minneapolis, MN) in conjunction with a system of strings and pulleys.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Before data were collected, specimens were preconditioned three times at 1.0 Nm for 60 seconds followed by 60 seconds at zero load. After preconditioning, data were acquired at 2 Hz while specimens were loaded in 0.25-Nm increments to a maximum of 1.0 Nm. At each increment, loading was held for 45 seconds. This peak load (1.0 Nm) is the same as previously used in testing multilevel corpectomy constructs,<sup><xref rid="R32" ref-type="bibr">32</xref></sup> but it was less than is typical for flexibility testing of shorter or more robust cervical constructs.<sup><xref rid="R33" ref-type="bibr">33</xref></sup></p><p id="P18">Motion was recorded independently at C3, C4, C5, C6, and C7 from infrared-emitting diodes glued to the ends of three 1.25-mm diameter surgical guide wires inserted in each vertebra. Diode motion was recorded stereophotogrammetrically (Optotrak 3020, Northern Digital, Waterloo, ON, Canada). The anatomical coordinate system of each motion segment was related to marker position by using a digitizing probe (accessory to the Optotrak).<sup><xref rid="R34" ref-type="bibr">34</xref></sup> Custom software converted the marker coordinates to angles about each anatomical axis, represented independently at C3-C4, C4-C5, C5-C6 and C6-C7. Angles were determined using the “tilt/twist” method, which represents two vertebrae in a motion segment as stacked cylinders.<sup><xref rid="R35" ref-type="bibr">35</xref></sup></p></sec>
22801457|Data Analysis|('method', 0.9998909587623136)|('other', 0.000109041237686375)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Data Analysis</title><p id="P19">Based on the raw data, the angular range of motion (ROM), lax zone (LZ), and stiff zone (SZ) were quantified during all loading modes to assess construct stability. The ROM refers to the angle of the spine during application of the maximum load (1.0 Nm), whereas the LZ and SZ refer to the portions of the ROM where motion occurs with little or substantial resistance, respectively.<sup><xref rid="R36" ref-type="bibr">36</xref></sup> The transition angle from LZ to SZ was determined by linearly extrapolating load vs. angle data from the upper SZ to zero load. For separating flexion from extension, the neutral position was defined as the midpoint of the bidirectional LZ. Data were determined in terms of degrees and also as dimensionless ratios normalized to the intact condition. Normalization mitigates the effects of variability in stiffness naturally expected in human cadaveric specimens. Results were compared between groups using nonpaired two-tailed Student’s t-tests. Within each group, one-way repeated-measures analysis of variance was used to assess whether contributions of individual motion segments to the total ROM differed among constructs. In all comparisons, a probability value less than 0.05 was considered significant.</p></sec>
22801457|Finite Element Analysis|('method', 0.9998909587623136)|('other', 0.000109041237686375)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>Finite Element Analysis</title><p id="P20">Bony geometry and spacing for a three-dimensional model of C3-C7, including intervening discs, were obtained from a computed tomography (CT) scan of a cadaveric human spine from a 43-year-old male using Scan-FE software (Simpleware, Exeter, UK). The CT scan was captured using a LightSpeed scanner (General Electric Medical Systems, Milwaukee, WI) with axial slice spacing of 0.625 mm.</p><p id="P21">Geometry was meshed using ICEM (ANSYS, Inc., Canonsburg, PA). Cortical bone was meshed with shell elements and cancellous bone with 10-node tetrahedral elements. Different material properties were assigned to each. Cortical bone elastic modulus was E = 12 GPa. Poisson’s ratio was υ = 0.3. Cancellous bone material properties were set at E = 100 MPa and υ = 0.2. Constant cortical thickness (0.28 mm) and nonlinear material properties were assumed. Ligamentous elements representing interspinous ligaments, capsular ligaments, and ligamentum flavum were included. Anterior longitudinal ligament, posterior longitudinal ligament, and intervertebral disc were simulated in the intact model but were removed in the instrumented models. The intervertebral disc was represented as 63% annulus fibrosus and as 37% nucleus pulposus using a Mooney-Rivlin formulation to simulate incompressible hyperelastic behavior of annulus and nucleus.</p><p id="P22">Titanium plates (2.58 mm thick) and screws were modeled using 10-node tetrahedral elements with an elastic modulus of 113 GPa and Poisson’s ratio of 0.3. Since the parameter of interest was axial load on screws and not screw-bone mechanics, screws were modeled as smooth cylinders (without threads) of 5.0 mm diameter and with immovable interface between screw and bone. Because of difficulties modeling plate-bone contact, plates were represented elevated away from the bone by 1 mm.</p><p id="P23">The finite element model was validated by comparing the ROMs from simulations of the intact condition during flexion, extension, lateral bending, and axial rotation to the mean experimental data obtained from the flexibility tests. Simulations gave ROM values that were within 10% of experimental data during all loading modes, indicating acceptable accuracy. It was expected that simulations would appear more stable than experimental data with hardware in place because of the rigid screw-bone interface.</p><p id="P24">Simulations of three conditions were run using ANSYS Mechanical v.12.0. (ANSYS, Inc.). One condition modeled a standard corpectomy with a four-level plate and four screws; the second condition modeled a skip corpectomy with a four-level plate and six screws. The third condition modeled a skip corpectomy with a four-level plate and four screws (<xref rid="F2" ref-type="fig">Figure 2</xref>). Pure moment loads of 1.5 Nm were applied to a point offset above C3 and connected to multiple nodes on C3 via bar elements, avoiding stress concentration that would occur if the moment was applied to one node. C7 was fixed along the inferior vertebral endplate.</p><p id="P25">The computations were performed on a 4-processor (Intel Xeon) 3.0 GHz personal computer with 16 gigabytes of RAM. Solutions of models required approximately 1.5 hours of computational time for each loading modality.</p><p id="P26">After simulations were completed, axial forces on each screw were calculated through a cross-section (area = 19.6 mm<sup>2</sup>) of the shaft of each screw. The cross section was 2.0 mm distal to the point where the screw passed the inside surface of the plate.</p></sec>
23336723|None|('method', 0.9137412690603001)|('other', 0.08625873093969998)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Method</title>
23336723|Sample and Procedures|('method', 0.9137412690603001)|('other', 0.08625873093969998)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Sample and Procedures</title><p id="P18">The data analyses in this report are based on data from a subset of the 559 (56% female) participants in the ongoing Family Transitions Project (FTP; see <xref rid="R8" ref-type="bibr">Conger &amp; Conger, 2002</xref>, for an overview of the study). The ethnic/racial background was predominately European American and largely reflected the underlying demographics of rural Iowa. The FTP was started in 1994 when the Iowa Youth and Families Project and the Iowa Single Parent Project were merged to follow the focal participants as they transitioned from adolescence to adulthood (see <xref rid="R8" ref-type="bibr">Conger &amp; Conger, 2002</xref>). The MPQ was first administered to this sample in 1994. A thorough description of the personality trait development of the FTP sample from 1994 to 2003 is reported in <xref rid="R11" ref-type="bibr">Donnellan et al. (2007)</xref> whereas other details of this project can be found in <xref rid="R8" ref-type="bibr">Conger and Conger (2002)</xref>.</p><p id="P19">Participants completed self-reports of personality using the MPQ during Years 1 and 10 of the FTP (primarily collected during calendar year 1994 and 2003, respectively), self-reports of work characteristics and income during Years 8, 10, and 12 (collected primarily during calendar years 2001, 2003, and 2005 respectively), and had at least one parent complete an informant report of personality during Year 1. We refer to these waves by the primary year of data collection for the remainder of the report. The average age of FTP participants in 1994 was 18.11 years (<italic>SD</italic> = .42; Median = 18.10), 25.77 years in 2001 (<italic>SD</italic> = .46; Median = 25.70), 27.75 years in 2003 (<italic>SD</italic> = .47; Median = 27.70) and 29.59 years in 2005 (<italic>SD</italic> = .42; Median = 29.60). These ages were calculated by comparing birthdates with interview dates. All respondents were paid approximately $10 per hour of participation.</p><p id="P20">We restricted the sample used in these analyses to those participants with some personality data who were also employed during at least one of the 2001, 2003, and 2005 assessments. As seen in <xref rid="T1" ref-type="table">Table 1</xref>, 442 had self-reported personality information in 1994, 423 had parent-reported personality information in 1994, and 420 had self-reported personality information in 2003. Of the 423 who had parent-reported personality information in 1994, 383 (91%) had work characteristic information in 2001 whereas those numbers dropped to 361(85%) and 351 (83%) in 2003 and 2005, respectively. Of the 442 participants that had self-reported personality data from 1994, 400 (90%) had work characteristic information in 2001, 375 (85%) had this information in 2003, and 362 (82%) had this information in 2005. Finally, of the 420 who had personality information in 2003, 384 (91%) had work characteristic information in 2001, 387 (92%) had work characteristic information in 2003, and 354 (84%) had work information in 2005.</p></sec>
23336723|Measures - Personality|('method', 0.9137412690603001)|('other', 0.08625873093969998)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Measures - Personality</title><sec id="S13"><title>Self-Reports of Personality</title><p id="P21">Participants completed the 155-item Multidimensional Personality Questionnaire – Brief Form (MPQ-BF; <xref rid="R38" ref-type="bibr">Patrick, Curtin, &amp; Tellegen, 2002</xref>) in both 1994 and 2003. Participants responded to each item using a dichotomous scale (mostly true-false items), and responses were averaged to create scales. The means and standard deviations are presented in <xref rid="T1" ref-type="table">Table 1</xref>, and the reliabilities are presented in <xref rid="T2" ref-type="table">Table 2</xref>. Ten of the 11 primary scales of the MPQ can be organized into the four broad dimensions investigated in the current paper (e.g., <xref rid="R39" ref-type="bibr">Roberts et al., 2001</xref>; <xref rid="R40" ref-type="bibr">Roberts et al., 2003</xref>):</p><p id="P22"><bold><italic>Agentic Positive Emotionality</italic></bold> was calculated by averaging the items on the Achievement and Social Potency primary scales. <bold><italic>Communal Positive Emotionality</italic></bold> was calculated by averaging the items on the Well-Being and Social Closeness primary scales. <bold><italic>Negative Emotionality</italic></bold> was calculated by averaging the items on the Aggression, Alienation, and Stress Reaction primary scales. <bold><italic>Constraint</italic></bold> was calculated by averaging the items on the Control, Harm Avoidance, and Traditionalism primary scales.<sup><xref ref-type="fn" rid="FN2">1</xref></sup></p></sec><sec id="S14"><title>Parent Reports of Personality</title><p id="P23">A 33-item informant report of the MPQ developed by Tellegen (e.g., <xref rid="R15" ref-type="bibr">Harkness, Tellegen, &amp; Waller, 1995</xref>) was used to obtain reports of personality from the parents of the focal participants in 1994. Mothers and fathers independently rated their child on a 5-point scale that asked them to compare their child on a particular trait to other individuals of the same age and sex. We calculated scales by averaging mother and father reports. Descriptive statistics are presented in <xref rid="T1" ref-type="table">Table 1</xref>, and reliability coefficients are presented in <xref rid="T2" ref-type="table">Table 2</xref>. More details on the parent reports of personality are available in <xref rid="R11" ref-type="bibr">Donnellan et al. (2007)</xref>.</p></sec></sec>
23336723|Measures – Workplace Conditions and Income|('method', 0.9137412690603001)|('other', 0.08625873093969998)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S15"><title>Measures – Workplace Conditions and Income</title><sec id="S16"><title>Workplace conditions</title><p id="P24">Participants completed a 52-item questionnaire that assessed workplace conditions using a 1 (strongly agree) to 5 (strongly disagree) scale in 2001, 2003, and 2005. All items were then scored so that higher values indicated more positive working conditions. The item pool was drawn from diverse sources (e.g., <xref rid="R21" ref-type="bibr">Jencks, Perman, &amp; Rainwater, 1988</xref>; <xref rid="R24" ref-type="bibr">Karasek, 1990</xref>) and some items were created specifically for the Family Transitions Project. The measure was intended to assess several domains of work experience (see <xref rid="R57" ref-type="bibr">Spenner, 1988</xref>) including self-determination at work, work pressures, the presence of material benefits, and work fit.</p></sec><sec id="S17"><title>Income</title><p id="P25">Participants reported how much they earned “per hour, week, month, or year in this job” in 2001, 2003, and 2005. In addition, participants reported “how many hours per week on average” they worked at their main job and how many weeks they worked at the job during the past 12 months (including paid vacation time). We transformed these responses into an annual income variable. Thus, if participants reported monthly income, we multiplied this amount by 12. If participants reported weekly income, we multiplied this amount by the number of weeks they reported working at their job. If participants reported hourly income, we multiplied this amount by the number of hours they reported working per week (on average) and the number of weeks they reported working in the past 12 months. The rank-order stability of income from 2001 to 2003, 2001 to 2005, and 2003 to 2005 was .58, .52, and .58, respectively.</p></sec></sec>
23336723|Control Variables|('method', 0.9137412690603001)|('other', 0.08625873093969998)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S18"><title>Control Variables</title><sec id="S19"><title>GPA</title><p id="P26">In 1994 participants were asked which letter grade (A, A-, B+, and so on through F) was closest to their grade point average. We assigned a numerical value to each letter grade using a traditional 0 to 4 GPA scale (<italic>M</italic> = 2.76, <italic>SD</italic> = 1.15, Median = 3.00).</p></sec><sec id="S20"><title>Indicators of Family of Origin Socioeconomic Status (SES)</title><p id="P27">It is potentially important to assess whether young adult outcomes can be explained by pre-existing socioeconomic conditions. Socioeconomic status is typically conceptualized as broad composite reflecting social position (see e.g., <xref rid="R9" ref-type="bibr">Conger &amp; Donnellan, 2007</xref>). In practice, it is often measured using indicators of income, education, and occupational prestige. In the current report, we used household income, both parents’ education, and both parents’ occupational prestige to create a composite measure of SES. We standardized the parents’ self-report of their gross annual income (<italic>M</italic> = $45,479, <italic>SD</italic> = $38,635), years of education as of 1994 (<italic>M</italic> = 13.68, <italic>SD</italic> = 2.17 for fathers; <italic>M</italic> = 13.55, <italic>SD</italic> = 1.75 for mothers), and occupational prestige as of 1994 (<italic>M</italic> = 43.55, <italic>SD</italic> = 11.50 for fathers; <italic>M</italic> = 44.42, <italic>SD</italic> = 13.83 for mothers). Mothers’ and fathers’ education level were correlated (<italic>r</italic> = .39) as was their occupational prestige scores (<italic>r</italic> = .17). We standardized all 5 variables and averaged them to create a composite indicator of family of origin socioeconomic status.</p></sec></sec>
23592716|None|('method', 0.98197486505219)|('other', 0.018025134947809995)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Methods</title>
23592716|None|('method', 0.98197486505219)|('other', 0.018025134947809995)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">We wish to assess the accuracy and discrimination of a risk model using cohort data that is independent of the data used for model development. When the covariates <italic>x</italic> needed by the model are available for all subjects, we can use the model to assign a risk <italic>r</italic> = <italic>f(x)</italic> to each subject, and then partition the cohort into <italic>L</italic> subgroups having similar risks. (In the Discussion section we describe alternatives to such grouping of subjects.) Our goal is to estimate the parameter θ = (γ,π) and the covariance matrix of the estimate θ̂ = (γ̂,π̂). Here γ = (γ<sub>1</sub>,…,γ<sub><italic>L</italic>−1</sub>) specifies the subject’s multinomial group membership probabilities with<inline-formula><mml:math id="M1" overflow="scroll"><mml:msub><mml:mi>γ</mml:mi><mml:mi>L</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mo>γ</mml:mo><mml:mn>ℓ</mml:mn></mml:msub></mml:math></inline-formula>, and π = (π<sub>1</sub>,…,π<sub><italic>L</italic></sub>) specifies the risk-group-specific outcome probabilities. The estimate θ̂ then allows assessment of model accuracy and discrimination. For example, accuracy can be assessed with the bias statistic <disp-formula id="FD1"><label>(1)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mi>B̂</mml:mi><mml:mo>=</mml:mo><mml:mi>B</mml:mi><mml:mo stretchy="true">(</mml:mo><mml:mi>θ̂</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>L</mml:mi></mml:msubsup><mml:msub><mml:mi>γ̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>π̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>r</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>,</mml:mo></mml:math></disp-formula> where <italic>r</italic><sub>ℓ</sub> is the mean assigned risk in group ℓ, ℓ = 1,…,<italic>L</italic>. The null hypothesis <italic>B</italic>(θ) = 0 (i.e., that the model is well-calibrated to the population risks) can be tested by referring the Wald statistic <italic>B̂</italic> / <italic>SD</italic>(<italic>B̂</italic>) to a standard Gaussian distribution, or referring the Hosmer-Lemeshow statistic <italic>n</italic>(<bold>π̂</bold> −<bold>r</bold>)<sup><italic>T</italic></sup> Σ̂<sup>−1</sup> (<bold>π̂</bold> − <bold>r</bold>) to a chi-square distribution on <italic>L</italic> degrees of freedom.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Here Σ̂ is an estimate of the covariance matrix of π̂ and <bold>r</bold> = <italic>r</italic><sub>1</sub>,…,<italic>r<sub>L</sub></italic> with <italic>r</italic><sub>ℓ</sub> denoting the mean assigned risk in group ℓ, ℓ = 1,…,<italic>L</italic>. Model discrimination can be assessed via the concordance statistic<sup><xref rid="R11" ref-type="bibr">11</xref></sup><disp-formula id="FD2"><label>(2)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mover accent="true"><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi><mml:mo stretchy="true">(</mml:mo><mml:mi>θ̂</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>L</mml:mi></mml:msubsup><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>′</mml:mo><mml:mo>&gt;</mml:mo><mml:mi>ℓ</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>γ̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:msub><mml:mi>γ̂</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>′</mml:mo></mml:mrow></mml:msub><mml:mfrac><mml:mrow><mml:msub><mml:mi>π̂</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>′</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>π̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:mi>π̂</mml:mi><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>π̂</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>L</mml:mi></mml:msubsup><mml:msubsup><mml:mi>γ̂</mml:mi><mml:mi>ℓ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mfrac><mml:mrow><mml:msub><mml:mi>π̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>π̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:mi>π̂</mml:mi><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>π̂</mml:mi><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:math></disp-formula></p>
23592716|None|('method', 0.98197486505219)|('other', 0.018025134947809995)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P12">In <xref ref-type="disp-formula" rid="FD2">(2)</xref>, <inline-formula><mml:math id="M4" overflow="scroll"><mml:mi>π̂</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>L</mml:mi></mml:msubsup><mml:msub><mml:mi>γ̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:msub><mml:mi>π̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:math></inline-formula> is an estimate of the outcome prevalence in the population. Estimates for the variances of these and other measures of model performance can be obtained from the estimated covariance matrix of θ̂ using a standard Taylor series expansion (the “delta method").</p>
23592716|2.1. Complete cohort sampling|('method', 0.98197486505219)|('other', 0.018025134947809995)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1. Complete cohort sampling</title><p id="P13">Suppose we have used a risk model to assign to each of <italic>n</italic> subjects a probability of outcome development during a future period [0,<italic>t</italic><sub>*</sub>), and that we use these assigned risks to classify the subjects into <italic>L</italic> risk groups. We observe the risk group and survival data (<italic>T</italic>,ε)of each subject, where <italic>T</italic> is time from risk assignment to the first of outcome occurrence, death, <italic>t</italic><sub>*</sub> or last observation, and ε = (ε<sub>1</sub>,ε<sub>2</sub>), where ε<sub>1</sub> and ε<sub>2</sub> are indicators for outcome occurrence and death, respectively. Times to outcome or death are unobserved for censored subjects, who at time <italic>T</italic> &lt; <italic>t</italic><sub>*</sub> were last observed alive and outcome-free (ε = (0,0)). Our goal is to use these data to estimate the risk-group-specific outcome probabilities π<sub>1</sub>,…,π<sub><italic>L</italic></sub>, where π<sub>ℓ</sub> = Pr[<italic>T</italic> &lt; <italic>t</italic><sub>*</sub>,ε<sub>1</sub> = 1] among subjects in risk group ℓ, ℓ = 1,…,<italic>L</italic>. In terms of competing risk theory, π<sub>ℓ</sub> = <italic>F</italic><sub>ℓ1</sub> (<italic>t</italic><sub>*</sub>), where <disp-formula id="FD3"><label>(3)</label><mml:math id="M5" display="block" overflow="scroll"><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mo stretchy="false">∫</mml:mo><mml:mn>0</mml:mn><mml:mi>t</mml:mi></mml:msubsup><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mtext>exp</mml:mtext><mml:mo stretchy="true">{</mml:mo><mml:mo>−</mml:mo><mml:msubsup><mml:mo stretchy="false">∫</mml:mo><mml:mn>0</mml:mn><mml:mi>x</mml:mi></mml:msubsup><mml:mo stretchy="true">[</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo stretchy="true">]</mml:mo><mml:mi>d</mml:mi><mml:mi>u</mml:mi><mml:mo stretchy="true">}</mml:mo><mml:mi>d</mml:mi><mml:mi>x</mml:mi></mml:math></disp-formula> is the cumulative incidence function for an event of type τ, τ = 1,2, with λ<sub>ℓτ</sub> (·) denoting the event τ hazard in risk group ℓ. It is straightforward to show that, conditional on the counts <italic>n</italic><sub>ℓ</sub> of subjects in the <italic>L</italic> risk groups, the survival data within different risk groups are independent, and their distribution does not depend on the vector γ of multinomial group membership probabilities. Therefore the asymptotic covariance matrix Ω of the maximum likelihood estimate θ̂ is block diagonal, with blocks Γ and Σ, where Γ = <italic>diag</italic>(γ) −γγ<sup><italic>T</italic></sup> is the covariance matrix of the multinomial estimate γ̂ = <italic>n</italic><sup>−1</sup> (<italic>n</italic><sub>1</sub>,…,<italic>n</italic><sub><italic>L</italic>−1</sub>) and Σ is the diagonal matrix whose diagonal entries are the asymptotic variances of the π̂<sub>ℓ</sub>, ℓ = 1,…,<italic>L</italic>.</p><p id="P14">Since the cumulative incidence function <italic>F</italic><sub>ℓτ</sub> (<italic>t</italic>) of <xref ref-type="disp-formula" rid="FD3">(3)</xref> is completely specified by the event-specific hazard functions λ<sub>ℓτ</sub>, τ = 1,2, we can estimate the outcome probabilities π<sub><italic>l</italic></sub> by obtaining NPMLEs of these hazards and using them in <xref ref-type="disp-formula" rid="FD3">(3)</xref>.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R19" ref-type="bibr">19</xref></sup> (See also Kalbfleisch and Prentice<sup><xref rid="R14" ref-type="bibr">14</xref></sup> Section 8.23, p. 254.) Specifically, let <italic>M<sub>l</sub></italic> denote the number of distinct event times in subgroup <italic>l</italic>, with <inline-formula><mml:math id="M6" overflow="scroll"><mml:mi>M</mml:mi><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>L</mml:mi></mml:msubsup><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:math></inline-formula>. The risk-group- and event-specific hazard functions are replaced by the <italic>2M</italic>-dimensional vector λ = (λ<sub>1</sub>,…,λ<sub><italic>L</italic></sub>), where <disp-formula id="FD4"><label>(4)</label><mml:math id="M7" display="block" overflow="scroll"><mml:msub><mml:mi>λ</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>21</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn><mml:msub><mml:mi>M</mml:mi><mml:mi>l</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>2</mml:mn><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:math></disp-formula> is the 2<italic>M</italic><sub>ℓ</sub>-dimensional vector of discrete hazards taking values at the <italic>M</italic><sub>ℓ</sub> distinct event times 0 &lt; <italic>t</italic><sub>ℓ1</sub> &lt; ⋯ &lt; <italic>t</italic><sub>ℓ<italic>M</italic><sub>ℓ</sub></sub> &lt; <italic>t</italic><sub>*</sub> among subjects in group ℓ, ℓ = 1,…,<italic>L</italic>. We show in Section 1 of the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref> that the NPMLE is (γ̂,λ̂) with γ̂ = <italic>n</italic><sup>−1</sup> (<italic>n</italic><sub>1</sub>,…,<italic>n</italic><sub><italic>L</italic>−1</sub>) and λ̂ = (λ̂<sub>1</sub>,…,λ̂<sub><italic>L</italic></sub>), where λ̂<sub>ℓ</sub> is given by <xref ref-type="disp-formula" rid="FD4">(4)</xref> with λ<sub>ℓτ<italic>m</italic></sub> replaced by λ̂<sub>ℓτ<italic>m</italic></sub> = <italic>d</italic><sub>ℓτ<italic>m</italic></sub> / <italic>n</italic><sub>ℓ<italic>m</italic></sub>, <italic>m</italic> = 1,…,<italic>M</italic><sub>ℓ</sub>, ℓ = 1,…,<italic>L</italic>, τ = 1, 2. Here <italic>n</italic><sub>ℓ<italic>m</italic></sub> and <italic>d</italic><sub>ℓτ<italic>m</italic></sub> are the counts of subjects in group ℓ who at time <italic>t</italic><sub>ℓ<italic>m</italic></sub> are at risk and fail of event τ, respectively. We now estimate θ as θ̂ = (γ̂,π̂), where π̂ = (π̂<sub>1</sub>,…,π̂<sub><italic>L</italic></sub>) with <disp-formula id="FD5"><mml:math id="M8" display="block" overflow="scroll"><mml:msub><mml:mi>π̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>φ</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mi>λ̂</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>M</mml:mi><mml:mi>ℓ</mml:mi></mml:msub></mml:msubsup><mml:msub><mml:mi>λ̂</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:msubsup><mml:mo>∏</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>′</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>λ̂</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>λ̂</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>2</mml:mn><mml:mi>m</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>L</mml:mi><mml:mo>,</mml:mo></mml:math></disp-formula> and empty products equal one. In the absence of censoring, π̂<sub><italic>l</italic></sub> reduces to the simple binomial proportion of subjects in group ℓ who develop the outcome during the risk period.</p><p id="P15">The large sample properties of the π̂<sub>ℓ</sub>were derived by Gill<sup><xref rid="R20" ref-type="bibr">20</xref></sup> using the theory of counting processes and stochastic integrals (see the summaries in Chapter IV of Andersen et al.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> and Chapter 5 of Kalbfleisch and Prentice<sup><xref rid="R14" ref-type="bibr">14</xref></sup>). Specifically, <inline-formula><mml:math id="M9" overflow="scroll"><mml:msqrt><mml:mi>n</mml:mi></mml:msqrt><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>π̂</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> is asymptotically normally distributed with mean 0 and variance Σ<sub><italic>l</italic></sub> given by a Taylor series expansion of π<sub>ℓ</sub> = φ<sub>ℓ</sub>(λ<sub>ℓ</sub>) about λ<sub>ℓ</sub> of <xref ref-type="disp-formula" rid="FD4">(4)</xref>, as described in Section 1 of the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>. The resulting variance estimate Σ̂<sub>ℓ</sub> agrees with that of Dinse and Larson<sup><xref rid="R19" ref-type="bibr">19</xref></sup> and Gaynor et al.<sup><xref rid="R21" ref-type="bibr">21</xref></sup></p></sec>
23592716|2.2. Extension to two-stage sampling|('method', 0.98197486505219)|('other', 0.018025134947809995)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.2. Extension to two-stage sampling</title><p id="P16">The two-stage sampling design as applied to epidemiological data has been described elsewhere<sup><xref rid="R22" ref-type="bibr">22</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> and we review it briefly in the context of risk model validation. In stage 1, we obtain enough easily available covariate and outcome data to classify subjects into <italic>C</italic> sampling categories. In stage 2 we independently sample subjects in category c with pre-specified Bernoulli probability <italic>p<sub>c</sub></italic> &gt; 0, <italic>c</italic> = 1,…,<italic>C</italic>. We then assemble all covariates (both inexpensive and costly), assign model risks, and classify into risk groups only the subjects sampled at stage 2.</p><p id="P17">We use this design to obtain weighted estimates of the group membership probabilities γ<sub>ℓ</sub> and the event-specific hazards λ<sub>ℓ</sub> of <xref ref-type="disp-formula" rid="FD4">(4)</xref>. As described for complete data, we then estimate θ = (γ,π) by transforming these estimates to cumulative incidence estimates. Specifically, let <italic>Q<sub>c</sub></italic> denote the set of subjects in category c, and let <italic>Q̅<sub>c</sub></italic> denote the subset of subjects sampled in stage 2, with <italic>p̂<sub>c</sub></italic> = |<italic>Q̅<sub>c</sub></italic>| / |<italic>Q<sub>c</sub></italic>|, <italic>c</italic> = 1,…,<italic>C</italic>. The weighted estimate for (γ,λ) satisfies the Horvitz-Thompson estimating equation <inline-formula><mml:math id="M10" overflow="scroll"><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>u</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> where <italic>u<sub>i</sub></italic> is the efficient score for the nonparametric likelihood equation described in <xref ref-type="supplementary-material" rid="SD1">equation (S.3) of the Supplement</xref>, and the weight <disp-formula id="FD6"><label>(5)</label><mml:math id="M11" display="block" overflow="scroll"><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>C</mml:mi></mml:msubsup><mml:msubsup><mml:mi>p̂</mml:mi><mml:mi>c</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mi>I</mml:mi><mml:mo stretchy="true">(</mml:mo><mml:mi>i</mml:mi><mml:mo>∈</mml:mo><mml:msub><mml:mi>Q̅</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:math></disp-formula> is the inverse of the observed sampling probability for those sampled at stage 2 and 0 for other subjects.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> (In this equation, <italic>I(E)</italic> is the indicator function, taking value 1 if event <italic>E</italic> occurs and zero otherwise. It has been shown<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> that it is asymptotically more efficient to use the observed sampling probability <italic>p̂<sub>c</sub></italic> rather than the chosen value <italic>p<sub>c</sub></italic>.) In clear analogy with the complete sampling case, the solution (γ̂,λ̂) to this estimating equation has components γ̂<sub>ℓ</sub> = <italic>ñ</italic><sub>ℓ</sub> / <italic>n</italic> and λ̂<sub>ℓτ<italic>m</italic></sub> = <italic>d̃</italic><sub>ℓτ<italic>m</italic></sub> / <italic>ñ</italic><sub>ℓ<italic>m</italic></sub>, where <italic>ñ</italic><sub>ℓ</sub> is the upweighted count of subjects in group ℓ, and <italic>ñ</italic><sub>ℓ<italic>m</italic></sub> and <italic>d̃</italic><sub>ℓτ<italic>m</italic></sub> are upweighted counts of subjects who at time <italic>t<sub>m</sub></italic> are at risk and fail of type τ, respectively. It well known that the estimating equation <inline-formula><mml:math id="M12" overflow="scroll"><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>n</mml:mi></mml:msubsup><mml:msub><mml:mi>a</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:msub><mml:mi>u</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> is unbiased; thus the estimate θ̂ = (γ̂,π̂) obtained by transforming (γ̂,λ̂) is consistent for θ; moreover the asymptotic covariance matrix θ̂ can be estimated consistently as described in Section 1 of the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>. While general theory is lacking, empirical evidence and results in special cases<sup><xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> suggest that the usual asymptotic normality holds.</p><p id="P18">The asymptotic covariance matrix of the two-stage estimate θ̂ may be unreliable when the number <italic>L</italic> of risk groups is large and some of them are sparsely populated. This may be a particular problem with two-stage sampling using small (&lt;20%) second stage sampling probabilities. In these circumstances, bootstrap covariance estimates provide a practical alternative. Section 1.3 of the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref> contains specifications for a bootstrap estimate of the covariance matrix of the weighted estimate θ̂.</p></sec>
23592716|2.3. Choosing a two-stage design|('method', 0.98197486505219)|('other', 0.018025134947809995)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.3. Choosing a two-stage design</title><p id="P19">An important question is how to choose a partition C of <italic>C</italic> sampling categories and corresponding sampling probabilities <italic>p<sub>1</sub></italic>,…,<italic>p<sub>C</sub></italic> to minimize the variance of an estimate <italic>f</italic>(θ̂) for some key parameter. For example, <italic>f</italic>(θ̂) might be the model’s bias statistic <italic>B</italic>(θ̂) of equation <xref ref-type="disp-formula" rid="FD1">(1)</xref> or its concordance statistic <italic>AUC</italic>(θ̂) of equation <xref ref-type="disp-formula" rid="FD2">(2)</xref>. We show in <xref ref-type="supplementary-material" rid="SD1">Supplement (Section S.1.2)</xref> that the variance of a statistic <italic>f</italic>(θ̂) obtained from two-stage sampling is the sum of its variance under complete sampling plus a penalty term <italic>P</italic> = <italic>P</italic>(C,<italic>p</italic>) that depends on the parameter (γ,λ), the partition C and the vector <italic>p</italic> of sampling probabilities <italic>p<sub>1</sub></italic>,…,<italic>p<sub>C</sub></italic>. So minimizing the variance of <italic>f</italic>(θ̂) is equivalent to minimizing this penalty. To do so we must:<list list-type="alpha-lower" id="L1"><list-item><p id="P20">specify an approximate value for (γ,λ);</p></list-item><list-item><p id="P21">specify a set of one or more possible partitions C and for each calculate the penalty <italic>P</italic>(C,<italic>p</italic>) as a function of the sampling probabilities <italic>p</italic>=<italic>p<sub>1</sub></italic>,…,<italic>p<sub>C</sub></italic>; and</p></list-item><list-item><p id="P22">for each partition C, search in the unit cube of dimension <italic>C-1</italic> for the sampling probabilities <italic>p<sub>1</sub></italic>,…,<italic>p<sub>C</sub></italic> that minimize <italic>P,</italic> subject to a constraint on the total size of the stage-2 sample.</p></list-item></list></p><p id="P23">As noted by Neyman,<sup><xref rid="R17" ref-type="bibr">17</xref></sup> specifying the parameter (γ,λ) in step (a) presents a dilemma: if we knew this parameter we would not need the study! This catch-22 is similar to the problem of designing a study to maximize the probability of rejecting a null hypothesis about the mean of a distribution, when the optimal design depends on the value of the unknown mean. Such problems are typically addressed by using external information and available data to approximate the parameters, which are then used to select an approximately optimal design. For the current problem, the investigator has access to the inexpensive covariates and survival data for all subjects sampled in stage 1: only their costly covariates are unknown. Thus all available relevant information can be used to impute the subjects’ costly covariates. This imputation allows assignment of model risks, classification of subjects into the <italic>L</italic> risk groups, and use of subjects’ survival data to specify an approximate value for (γ,λ) as needed for step (a). We illustrate this approach in the application to ovarian cancer in Section 4.</p><p id="P24">For step (b), we know of no formal scheme for choosing partitions likely to yield precise estimates for any given target parameter <italic>f</italic> (θ). As illustrated in Sections 3 and 4, different target parameters can require different types of partition. For rare outcomes, an intuitively good design is one that samples all the outcome-positive subjects, but only a fraction of the outcome-negative ones, and an even smaller fraction of the less informative outcome-unknown subjects. In other circumstances it may be advantageous to oversample subjects whose available covariates suggest high outcome risk. After determining the best sampling probabilities for each of several target parameters and each of several partitions C, one can then select a partition with acceptably small variances for the parameters of greatest interest.</p><p id="P25">Step (c) involves choosing sampling probabilities <italic>p<sub>1</sub></italic>,…,<italic>p<sub>C</sub></italic> to allow in stage 2 only a fraction <italic>k/n</italic> of the <italic>n</italic> stage-1 subjects. Thus we require <inline-formula><mml:math id="M13" overflow="scroll"><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>C</mml:mi></mml:msubsup><mml:msub><mml:mi>ŵ</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:msub><mml:mi>p</mml:mi><mml:mi>c</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo>/</mml:mo><mml:mi>n</mml:mi></mml:math></inline-formula>, where <italic>ŵ<sub>c</sub></italic> is the proportion of stage-1 subjects in category c. For given values<italic>ŵ<sub>c</sub></italic>, this constraint implies that any <italic>C-1</italic> sampling probabilities determine the remaining one. So finding the optimal probabilities for a partition C involves searching within the (<italic>C-1</italic>)-dimensional unit cube using constrained minimization software. In the following sections, we used the Brent’s one-dimensional search<sup><xref rid="R26" ref-type="bibr">26</xref></sup> for C =2 and the simplex method of Nelder and Meade<sup><xref rid="R27" ref-type="bibr">27</xref></sup> for C =3, both implemented with the R-routine <italic>constrOPTIM</italic>.</p></sec>
23592716|None|('method', 0.9604510059263675)|('other', 0.039548994073632535)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3. Numerical studies</title>
23592716|None|('method', 0.9604510059263675)|('other', 0.039548994073632535)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P26">We used simulations and constrained optimization to examine the performance of complete and two-stage sampling for evaluating risk models. In the simulations we generated data for cohorts sampled from two hypothetical populations. For Population 1 the outcome is rare (overall prevalence of 1%), and for Population 2 it is more common (prevalence of 10%). We assumed that potential times to outcome occurrence, death and censoring were independently and exponentially distributed. The risk groups were determined by two covariates <italic>x<sub>1</sub></italic> and <italic>x<sub>2</sub></italic> taking five discrete values: (<italic>x<sub>1</sub></italic>, <italic>x<sub>2</sub></italic>) = <italic>(1,1), (1,2), (1,3), (2,1), (2,2)</italic>. <xref ref-type="table" rid="T1">Table 1A</xref> gives the population distribution across the five risk groups, and the corresponding outcome hazards. We assumed a single competing mortality hazard λ<sub>2</sub> = 0.01 for all individuals in both populations, and we took the risk period to be the time interval from <italic>t</italic> = 0 to <italic>t</italic> = <italic>t</italic><sub>*</sub> = 1. The risk-group-specific outcome probabilities shown in <xref ref-type="table" rid="T1">Table 1A</xref> were determined from equation <xref ref-type="disp-formula" rid="FD3">(3)</xref> as <disp-formula id="FD7"><mml:math id="M14" display="block" overflow="scroll"><mml:msub><mml:mi>π</mml:mi><mml:mi>ℓ</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>0.01</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="true">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mrow><mml:mi>ℓ</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mn>0.01</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="true">]</mml:mo><mml:mo>,</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo>.</mml:mo></mml:math></disp-formula></p>
23592716|3.1. Simulations|('method', 0.9604510059263675)|('other', 0.039548994073632535)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>3.1. Simulations</title><p id="P27">In each of 1000 replications, we generated censored times to outcome development or death for a cohort of size n = 30,000 (Population 1) or n = 3,000 (Population 2). Times to censoring were exponentially distributed with hazard λ<sub>3</sub> = 0.30, independently of times to outcome and death. Outcome-positive subjects were those who developed the outcome before the minimum of death, censoring, and risk period termination at time <italic>t</italic><sub>*</sub> = 1. The expected proportions of subjects positive, negative and unknown for outcome development during the period were, respectively, 0.9%, 73.5%, and 25.6% for Population 1, and 8.8%, 66.8% and 24.4% for Population 2.</p><p id="P28"><xref ref-type="table" rid="T1">Table 1B</xref> shows the means across replications of the estimated outcome probabilities and their theoretical standard deviations (TSDs), for complete and two-stage sampling. The TSDs were obtained from the estimated covariance matrix of θ̂ described in the <xref ref-type="supplementary-material" rid="SD1">supplement</xref>. The two-stage sampling included k/n = 1/5 of the stage-1 subjects sampled in stage 2. We chose an outcome-based partition with <italic>C = 3</italic> categories containing subjects whose outcomes were positive, negative and unknown, and a covariate-based partition with <italic>C = 2</italic> categories containing subjects whose values for the covariate <italic>x<sub>1</sub></italic> were <italic>x<sub>1</sub></italic> = 1 and <italic>x<sub>1</sub></italic> = 2. (The rationale for these partitions is described below in Section 3.2.) For each partition, the sampling probabilities were chosen to minimize the variance of the concordance statistic, as described in Section 2.3.</p><p id="P29">Comparison of the risk estimates in <xref ref-type="table" rid="T1">Table 1B</xref> with their true values in <xref ref-type="table" rid="T1">Table 1A</xref> suggests that they are unbiased; moreover the TSDs agree well with the empirical standard deviations (ESDs), i.e., the SDs of the π̂<sub>ℓ</sub> across the 1000 replications. We also computed bootstrap-based SD estimates for both complete and two-stage sampling and found that they agreed well with both the TSDs and the ESDs (data not shown). As expected, the two-stage estimates are less precise than those obtained from complete sampling. The precision loss is relatively mild for the outcome-based partition, but more serious for the covariate-based partition. These results do not differ strongly between the two populations, with one exception. In Population 1 (rare outcome), the risk estimates from outcome-based sampling are more precise in all risk groups, while in Population 2 (more common outcome), they are less precise than those of covariate-based sampling in the highest two risk groups. This difference suggests that while outcome-based sampling will generally perform well for rare outcomes (prevalence &lt; 10%), its performance for more common outcomes is less predictable.</p></sec>
23592716|3.2. Constrained optimization|('method', 0.9604510059263675)|('other', 0.039548994073632535)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>3.2. Constrained optimization</title><p id="P30">The simulations address how well the risk-group-specific outcome probabilities are estimated with complete and two-stage sampling. However summary performance measures such as model bias and concordance involve not only the risk-group-specific outcome probabilities π<sub>ℓ</sub>, but also the risk-group membership probabilities γ<sub>ℓ</sub>, and there is need to evaluate the performance of two-stage designs in estimating these measures. Our objective now is to examine and compare the optimal sampling probabilities and corresponding true standard deviations (SDs) of estimated performance measures across different design choices and outcome prevalences when the model generating the data is known. Accordingly, we used the populations and generating models of <xref ref-type="table" rid="T1">Table 1A</xref> to obtain the optimal sampling probabilities and calculate the corresponding true SDs for the bias and concordance statistics, using the methods described in Section 1.4 of the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>. In practice, the true model is unknown and must be approximated using the covariate and survival data available for stage-1 subjects, as we illustrate with CTS ovarian cancer data in Section 4.</p><p id="P31">We consider the SD of bias and concordance statistics obtained from a cohort of size 30,000 sampled from Population 1 (outcome prevalence of 1%) and a cohort of size 3,000 sampled from Population 2 (outcome prevalence of 10%). We again consider the outcome- and covariate-based partitions shown in <xref ref-type="table" rid="T1">Table 1B</xref>. We chose the outcome-based partition to investigate the relative contribution to performance estimates of subjects with the three types of outcome. We chose the covariate-based partition to investigate the circumstance when one covariate (<italic>x<sub>1</sub></italic>) is available for all cohort subjects but another (<italic>x<sub>2</sub></italic>) must be ascertained. <xref ref-type="table" rid="T1">Table 1A</xref> shows that subjects with <italic>x<sub>1</sub> = 2</italic> comprise the highest two risk groups and only 10% of the population; therefore we wanted to determine the relative contribution of these subjects to precision measures.</p><p id="P32"><xref ref-type="table" rid="T2">Table 2A</xref> shows the optimal two-stage sampling probabilities for these two partitions, and <xref ref-type="table" rid="T2">Table 2B</xref> shows the corresponding SDs of the bias statistic <italic>B̂</italic> and concordance statistic <inline-formula><mml:math id="M15" overflow="scroll"><mml:mover accent="true"><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover></mml:math></inline-formula>. For comparison, <xref ref-type="table" rid="T2">Table 2B</xref> also includes the SDs corresponding to complete sampling. The results in <xref ref-type="table" rid="T2">Table 2B</xref> for the optimal outcome-based designs indicate that it’s best to sample all outcome-positive subjects for rare outcomes but not for more common ones. In the latter case however, the precision loss from sampling all outcome-positive subjects is not great – for example, <italic>SD</italic>(<italic>B̂</italic>) increased from 0.016 to 0.017, an increase of 6%, and <inline-formula><mml:math id="M16" overflow="scroll"><mml:mi>S</mml:mi><mml:mi>D</mml:mi><mml:mo stretchy="true">(</mml:mo><mml:mover accent="true"><mml:mrow><mml:mi>A</mml:mi><mml:mi>U</mml:mi><mml:mi>C</mml:mi></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo stretchy="true">)</mml:mo></mml:math></inline-formula> increased from 0.0256 to 0.0260, an increase of 1% (data not shown). As expected, outcome-negative subjects are sampled more heavily than censored ones, but the optimal sampling ratio depends on outcome prevalence. In contrast, results for the two covariate-based designs do not vary strongly with outcome prevalence. Comparison across the outcome-based and covariate-based partitions shows that the former gives more precise estimates of both performance measures for rare outcomes, but not for more common ones. Specifically, when outcome prevalence is 10%, model bias is estimated more precisely by the best covariate-based partition, which oversamples subjects with <italic>x<sub>1</sub> = 2</italic>, that is, subjects in the sparsely populated highest two risk groups.</p><p id="P33">We conclude this section with two observations about complete sampling. First, as shown in <xref ref-type="table" rid="T2">Table 2B</xref>, the SD of the concordance statistic is the same for a cohort from Population 1 of size 30,000 and a cohort from Population 2 of 3,000. This suggests that the precision of this statistic depends more on the number of outcome-positive subjects (which is roughly 270 for both types of cohort) than on the total number of subjects. Second, as expected, other simulations (data not shown) revealed severe upward bias for outcome probability estimates obtained by excluding censored subjects and performing a standard binomial-based analysis only on the remaining outcome-positive and outcome-negative subjects.</p></sec>
23592716|None|('method', 0.9093795738611529)|('other', 0.09062042613884731)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4. Example</title>
23592716|None|('method', 0.9093795738611529)|('other', 0.09062042613884731)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P34">We illustrate the complete and two-stage sampling methods by using them to assess the performance of ovarian cancer risk models applied to subjects in the California Teachers Study (CTS) described in the Introduction. We first assess the accuracy and discrimination of a nongenetic model (Model 1) in the entire cohort, and we use this complete data assessment as the gold standard for results using the two-stage design. We then show how available covariates, outcome data and Model 1 risks can be used to find two-stage designs that minimize the variance of estimated gains in sensitivity and specificity associated with an expanded model (Model 2) involving additional costly genetic covariates.</p>
23592716|4.1 CTS cohort subjects|('method', 0.9093795738611529)|('other', 0.09062042613884731)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>4.1 CTS cohort subjects</title><p id="P35">Among all 133,429 subjects, <italic>n</italic> = 40,139 met the eligibility criteria described in Section 3 of the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref> and comprise the cohort. We used the nongenetic risk model described in the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref> (hereafter called Model 1) to assign each subject a 12-year ovarian cancer risk. We took the follow-up time for each subject to be the number of days between cohort entry and the first occurrence of ovarian cancer diagnosis, death, last observation, or 12 years of follow-up. Among eligible subjects, 227 (0.6%) developed invasive epithelial ovarian cancer within 12 years of cohort entry (outcome-positive subjects), and 26,887 (67%) died from other causes or survived the period without ovarian cancer (outcome-negative subjects). An additional 13,025 subjects (32%) were alive and free of ovarian cancer at last observation, but had not accrued the full 12 years of follow-up. These subjects were classified as outcome-unknown. Since most of them were observed for at least 10 years of the 12-year follow-up period, their inclusion in the analysis substantially reduces the estimated outcome probabilities.</p></sec>
23592716|4.2. Assessment of Model 1|('method', 0.9093795738611529)|('other', 0.09062042613884731)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>4.2. Assessment of Model 1</title><p id="P36"><xref ref-type="fig" rid="F1">Figure 1</xref> shows two plots of points (<italic>r̅</italic><sub>ℓ</sub>, π̂<sub>ℓ</sub>) corresponding to <italic>L=5</italic> estimated quintiles of Model 1 risk. Here <italic>r̅</italic><sub>ℓ</sub> is the mean assigned risk and π̂<sub>ℓ</sub> is the estimated outcome probability among subjects in quintile ℓ, ℓ=1,…,5. The points in the left panel were estimated from the complete sample of all <italic>n = 40,139</italic> subjects, and those in the right panel from two-stage sampling with C = 2 sampling categories: 1) all 227 ovarian cancer cases, sampled with probability <italic>p<sub>1</sub> = 1</italic>, and 2) all other subjects, sampled with probability <italic>p<sub>2</sub> = 0.1</italic>. As evident in the figure, the two designs yield nearly identical estimates for the outcome probabilities and their standard deviations (SDs). We also found good agreement between the theoretical and bootstrap SD estimates (data not shown). There was evidence of model bias (Hosmer-Lemeshow statistic <inline-formula><mml:math id="M17" overflow="scroll"><mml:msubsup><mml:mi>χ</mml:mi><mml:mn>5</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>11.7</mml:mn></mml:math></inline-formula> (P=0.04) for complete sampling and <inline-formula><mml:math id="M18" overflow="scroll"><mml:msubsup><mml:mi>χ</mml:mi><mml:mn>5</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>14.8</mml:mn></mml:math></inline-formula> (P=0.01) for the two-stage sampling). Model discrimination was poor: the estimated AUCs were 0.59 (0.55–0.62) and 0.58 (0.54–0.62) for complete and two-stage sampling respectively. The poor discrimination reinforces other observations<sup><xref rid="R28" ref-type="bibr">28</xref></sup> that existing markers for increased ovarian cancer risk cannot adequately discriminate those who will develop the disease from those who will not.</p></sec>
23592716|4.3 Choice of two-stage design for assessing an expanded model|('method', 0.9093795738611529)|('other', 0.09062042613884731)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>4.3 Choice of two-stage design for assessing an expanded model</title><p id="P37">Model 1 involves only existing CTS covariates and not costly biospecimen analysis. Of clinical interest is the discrimination gained from an expanded model that also includes genotypes for ovarian cancer susceptibility alleles. However cost issues prevent genotyping the entire cohort, and a two-stage design is needed. Here we illustrate how the available covariates and survival data of the 40,139 stage-1 subjects, together with external information, can be used to partition these subjects into sampling categories and select sampling probabilities that minimize the variance of a parameter estimate of interest. For example, we have seen that the discrimination of Model 1 is poor, and we may want to estimate the improvement gained by augmenting Model 1 with subjects’ carrier statuses for rare pathogenic mutations of the breast/ovarian cancer susceptibility genes BRCA1 and BRCA2 in an expanded Model 2, such as the one described in the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>. Moreover suppose budgetary constraints limit the genetic testing to 7,000 of the 40,139 subjects. The question is: how to choose sampling categories and stage-2 sampling probabilities to estimate the discriminatory gain for Model 2, using the 7000 stage-2 subjects who are genotyped and assigned risks according to both models?</p><p id="P38">We address this question by determining two-stage designs that minimize the variances of estimates for the gains in sensitivity and specificity associated with Model 2. We took a model's sensitivity to be the probability that it designates an outcome-positive subject as high risk (12-year risk ≥ 3%), and its specificity to be the probability that it designates an outcome-negative subject as low risk (12-year risk &lt;3%). We then classified the women in <italic>L = 4</italic> risk groups indexed as <italic>j,k</italic>, <italic>j = 1,2, k = 1,2</italic>, as determined by their risk statuses (1 = low risk, 2 = high risk) according to Models 1 and 2, respectively. The <xref ref-type="supplementary-material" rid="SD1">Supplement</xref> contains expressions for the sensitivity and specificity gains for Model 2, as functions of θ = (γ,π), with γ = (γ<sub>11</sub>,γ<sub>12</sub>,γ<sub>21</sub>) and π = (π<sub>11</sub>,π<sub>12</sub>,π<sub>21</sub>,π<sub>22</sub>).</p><p id="P39">As noted in Section 2.3, finding an optimal design involves three steps: a) choosing an approximate value for θ; b) choosing partition(s) C and calculating for each the penalty term <italic>P</italic>(C,<italic>p</italic>) of <xref ref-type="supplementary-material" rid="SD1">equation (S.11)</xref> as a function of <italic>p</italic>; and c) searching for the sampling probabilities <italic>p</italic> that minimize <italic>P</italic>. To accomplish step (a), we used each stage-1 subject’s available covariates to impute her BRCA1 and BRCA2 carrier statuses. Specifically, we used her personal and family cancer history in the software BRCAPRO<sup><xref rid="R29" ref-type="bibr">29</xref></sup> to assign her probabilities of carrying a mutation of BRCA1 and BRCA2, and then used these probabilities to randomly assign her a carrier status for each gene. We then used her BRCA1 and BRCA2 carrier statuses and available covariates to assign her a Model 2 risk and, coupled with her Model 1 risk, classified her in one of the four risk groups. <xref ref-type="table" rid="T3">Table 3</xref> shows the ovarian cancer risk distribution resulting from this classification. The table also shows the approximate outcome probabilities π<sub><italic>jk</italic></sub> obtained from the event-specific survival data of the stage-1 subjects in each risk group. These results provided approximate parameter values for step (a). For these parameters, Model 1 sensitivity and specificity were, respectively, 2.2% and 98.5%, with corresponding values for Model 2 of 8.4% and 98.6%. These values give a sensitivity gain of 6.2% and a small specificity gain of 0.1% for Model 2 compared to Model 1.</p><p id="P40">In step (b) we selected two partitions. The first is outcome-based with <italic>C=3</italic> sampling categories (positive, negative and unknown ovarian cancer status). The second is based on both outcome and nongenetic covariates, with C=3 categories: outcome-positive, other subjects in the highest Model 1 risk quintile, and all other subjects. For each of these two partitions and each of the two target measures (sensitivity gain and specificity gain), we determined the penalty <italic>P</italic> as a function of the sampling probabilities <italic>p,</italic> as described in Section 1.3 of the <xref ref-type="supplementary-material" rid="SD1">Supplement</xref>. In step (c) we determined the sampling probabilities that minimize <italic>P</italic>.</p><p id="P41"><xref ref-type="table" rid="T4">Table 4</xref> shows the optimal sampling probabilities and corresponding SDs for each target measure and each partition. These results illustrate several points. First, the two partitions differ little in their optimal performances, with a slight edge for the second partition compared to the first. Second, regardless of the partition chosen, the designs optimal for sensitivity gain include all outcome-positive subjects, while the ones optimal for specificity gain include only 6–7% of these subjects. Thus even for outcomes of low prevalence, some parameters may be estimated more efficiently by sampling only a fraction of the outcome-positive subjects. However, since we typically want precise estimates for gains in both sensitivity and specificity, and since for rare outcomes the SDs of sensitivity gain estimates substantially exceed the SDs of specificity gain estimates, the designs that optimize sensitivity at the expense of slight suboptimality for specificity will tend to dominate design decisions.</p></sec>
23592716|None|('method', 0.7914886816545393)|('other', 0.2085113183454608)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5. Discussion</title>
23592716|None|('method', 0.7914886816545393)|('other', 0.2085113183454608)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P42">We have used cohort data to evaluate the accuracy and discrimination of personal risk models in the presence of censoring due to incomplete follow-up. In so doing we have adopted the common practice of classifying subjects into discrete groups determined by assigned risk, and estimating the actual outcome probabilities within these groups. Such discretization facilitates assessment of model accuracy using the bias statistic and analogous Hosmer-Lemeshow chi-squared test statistic. Moreover using quantiles of assigned risk as the risk groups avoids groups with too few subjects for adequate assessment. However these advantages are offset by the costs of clumping individual risks into broad groups, with consequent loss of sharpness in model assessment. Alternatives to the quantile approach based on nearest-neighbor methods have been proposed,<sup><xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> but their properties need further evaluation in simulations and data. In the absence of censoring, the maximum likelihood estimates of the discrete outcome probabilities are simple binomial proportions of subjects who develop the outcome during the risk period. With censoring, however, this approach leads to biased risk estimates, because it fails to account for all subjects' times at risk, and competing risk analysis is needed. For this Dinse and Larson<sup><xref rid="R19" ref-type="bibr">19</xref></sup> argue against direct estimation of the desired outcome probabilities, but instead recommend estimating the event-specific hazards, and converting these hazard estimates to outcome probability estimates.</p>
23592716|None|('method', 0.7914886816545393)|('other', 0.2085113183454608)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P43">We have proposed a two-stage sampling design for using cohort data to assess the performances of externally derived risk models in circumstances when assigning risks to all subjects is infeasible. We also describe methods for using the resulting data to efficiently estimate relevant performance parameters. When the sampling categories are based on subjects’ outcomes, the two-stage design is similar in spirit to the case-cohort design of Prentice<sup><xref rid="R32" ref-type="bibr">32</xref></sup> for regression analysis of survival data under a Cox proportional hazards model. If used to evaluate risk models, the case-cohort design would assign risks to all outcome-positive subjects and to a randomly selected subset of the entire cohort. This design yields outcome probability estimates identical to those of the two-stage design with sampling categories consisting of: a) outcome positive subjects, and b) all other subjects. However the variances of the two estimates differ, since those from the case-cohort design must accommodate any overlap between the sampled subcohort and the set of outcome-positive subjects. Moreover the two-stage design is more flexible for evaluating risk models as it allows stage-2 sampling from an arbitrary partition of subjects into sampling categories.</p>
23592716|None|('method', 0.7914886816545393)|('other', 0.2085113183454608)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P44">We have provided consistent estimates for the theoretical covariance matrices of the weighted estimates, and we have proposed corresponding bootstrap covariance estimates. General asymptotic theory is lacking but the empirical evidence suggests that the usual normality results hold. The proposed theoretical and bootstrap dispersion estimates both agreed well with the empirical ones used as the gold standard. The simulations, numerical calculations and application to data from the California Teachers Study illustrate several points. First, determining optimal design choices requires estimating performance gains associated with the costly covariates, which are unobserved at completion of the first sampling stage. Thus one needs reasonable estimates of the subjects' values for these covariates, and the relative optimality of different design choices depends on the accuracy of these estimates. Second, the design with optimal efficiency for one parameter need not be so for other parameters of interest, and trade-offs will be required. For example, optimal precision for some parameter estimates may require sampling only a fraction of outcome-positive subjects, even with uncommon outcomes. As a general rule, however, sampling all outcome-positive subjects and more outcome-negative than censored subjects can be expected to perform reasonably well in most circumstances.</p>
23592716|None|('method', 0.7914886816545393)|('other', 0.2085113183454608)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P45">An R program entitled "Risk Model Assessment Program (RMAP)", which provides estimates for outcome probabilities, the associated covariance matrices and graphical examination of model performance, is freely available at &lt;<ext-link ext-link-type="uri" xlink:href="http://www.stanford.edu/ggong/rmap/index.html">http://www.stanford.edu/ggong/rmap/index.html</ext-link>&gt;.</p>
23592716|None|('method', 0.9279731712255495)|('other', 0.07202682877445052)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
23592716|None|('method', 0.9279731712255495)|('other', 0.07202682877445052)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>supplementary</label><media xlink:href="NIHMS562440-supplement-supplementary.pdf" orientation="portrait" xlink:type="simple" id="d37e2431" position="anchor"/></supplementary-material>
23683057|None|('method', 0.9153647574833148)|('other', 0.08463524251668514)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. MODEL-INDEPENDENT BENCHMARK ANALYSIS</title>
23683057|2.1. Nonparametric BMD estimation|('method', 0.9153647574833148)|('other', 0.08463524251668514)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.1. Nonparametric BMD estimation</title><p id="P7">We continue to assume a binomial structure for quantal-response data: <italic>Y<sub>i</sub></italic> ~ indep. Bin. (<italic>N<sub>i</sub></italic>, <italic>R</italic>(<italic>x<sub>i</sub></italic>)), <italic>i</italic> = 1, …, <italic>m</italic>. The sample proportions are written as <italic>p<sub>i</sub></italic> = <italic>Y<sub>i</sub></italic>/<italic>N<sub>i</sub></italic> and we assume the dose values are ordered such that 0 = <italic>x</italic><sub>1</sub> &lt; <italic>x</italic><sub>2</sub> &lt; ··· &lt; <italic>x<sub>m</sub></italic>. Rather than rely on any parametric specifications on the dose-response function, however, we follow our previous construction<sup>(<xref rid="R32" ref-type="bibr">32</xref>)</sup> and only oblige <italic>R</italic>(·) to satisfy simple continuity and monotonicity assumptions. That is, we require <italic>R</italic>(<italic>x</italic>) to be a continuous function with non-negative first derivative <italic>R</italic>′(<italic>x</italic>) ≥ 0 over <italic>x</italic> ≥ 0.</p><p id="P8">We view the monotonized sequence {<italic>R</italic>(<italic>x</italic><sub>1</sub>), <italic>R</italic>(<italic>x</italic><sub>2</sub>), …, <italic>R</italic>(<italic>x<sub>m</sub></italic>)} as the preliminary estimation target, for which the unique maximum likelihood estimator (MLE) is the isotonic sequence<sup>(<xref rid="R33" ref-type="bibr">33</xref>)</sup></p><disp-formula id="FD1"><label>(2.1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo>max</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>u</mml:mi><mml:mo>≤</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:mspace width="0.16667em"/><mml:munder><mml:mo>min</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:mi>v</mml:mi><mml:mo>≤</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munder><mml:mspace width="0.16667em"/><mml:mfrac><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>u</mml:mi></mml:mrow><mml:mi>v</mml:mi></mml:msubsup><mml:msub><mml:mi>Y</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>u</mml:mi></mml:mrow><mml:mi>v</mml:mi></mml:msubsup><mml:msub><mml:mi>N</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:math></disp-formula><p id="P9">This ensures <italic>p̃</italic><sub>1</sub> ≤ ··· ≤ <italic>p̃<sub>m</sub></italic>, and may be obtained via the well-known pool-adjacent-violators (PAV) algorithm<sup>(<xref rid="R34" ref-type="bibr">34</xref>)</sup>. To find a model-independent, isotonic estimator of the function <italic>R</italic>(<italic>x</italic>) we construct a linear interpolating spline from the PAV estimates <italic>p̃<sub>i</sub></italic>: <disp-formula id="FD2"><label>(2.2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mover accent="true"><mml:mi>R</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.38889em"/><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>;</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.16667em"/><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mi>x</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula> for <italic>i</italic> = 1, …, <italic>m</italic> − 1, and <italic>R̃</italic>(<italic>x<sub>m</sub></italic>) = <italic>p̃<sub>m</sub></italic>. From this, we build an isotonic estimator for <italic>R<sub>E</sub></italic>(<italic>x</italic>) as the corresponding linear interpolator connecting the suitably adjusted, monotonized, pointwise estimates of the <italic>extra</italic> risks at each <italic>x<sub>i</sub></italic>: <disp-formula id="FD3"><label>(2.3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>R</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>E</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.38889em"/><mml:mo>=</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>;</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.38889em"/><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mi>x</mml:mi><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula> for <italic>i</italic> = 1, …, <italic>m</italic> − 1, and <italic>R̃<sub>E</sub></italic>(<italic>x<sub>m</sub></italic>) = (<italic>p̃<sub>m</sub></italic> − <italic>p̃</italic><sub>1</sub>)/(1 − <italic>p̃</italic><sub>1</sub>). If <italic>R̃</italic>(<italic>x</italic>) satisfies the monotonicity and continuity constraints we impose above, so will the corresponding <italic>R̃<sub>E</sub></italic>(<italic>x</italic>).</p><p id="P10">Now, for notational convenience, denote BMD<sub>100BMR</sub> as <italic>ξ</italic><sub>100BMR</sub>. Given the model-independent, isotonic estimator in (<xref rid="FD3" ref-type="disp-formula">2.3</xref>), a similarly model-independent estimator for <italic>ξ</italic><sub>100BMR</sub> is available by inverting <italic>R̃<sub>E</sub></italic>(<italic>x</italic>) at the specified BMR and calculating the smallest positive solution; i.e., <italic>ξ̃</italic><sub>100BMR</sub> = min{<italic>x: R̃<sub>E</sub></italic>(<italic>x</italic>) ≥ BMR}. Since <italic>R̃<sub>E</sub></italic>(<italic>x</italic>) is a form of continuous, linear interpolating spline, we can write this model-independent estimator in closed form: <disp-formula id="FD4"><label>(2.4)</label><mml:math id="M4" display="block" overflow="scroll"><mml:mtable columnalign="left" columnspacing="2pt"><mml:mtr><mml:mtd><mml:msub><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mn>100</mml:mn><mml:mtext>BMR</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mtext>BMR</mml:mtext><mml:mo>-</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow><mml:mrow><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>-</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle></mml:mrow></mml:mfrac><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.38889em"/><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&lt;</mml:mo><mml:mtext>BMR</mml:mtext><mml:mo>&lt;</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mspace width="0.38889em"/><mml:mtext>for</mml:mtext><mml:mspace width="0.16667em"/><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.38889em"/><mml:mtext>BMR</mml:mtext><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mspace width="0.38889em"/><mml:mtext>for</mml:mtext><mml:mspace width="0.16667em"/><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>;</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mtext>BMR</mml:mtext><mml:mo>-</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.38889em"/><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mo>&lt;</mml:mo><mml:mtext>BMR</mml:mtext><mml:mo>&lt;</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mtext>for</mml:mtext><mml:mspace width="0.16667em"/><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.38889em"/><mml:mtext>BMR</mml:mtext><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mrow><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>i</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:mrow></mml:mfrac></mml:mstyle><mml:mtext>for</mml:mtext><mml:mspace width="0.16667em"/><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula></p><p id="P11">(We discuss below possible strategies to accommodate the unusual case when BMR &gt; {<italic>p̃<sub>m</sub></italic> − <italic>p̃</italic><sub>1</sub>}/{1 − <italic>p̃</italic><sub>1</sub>}.) We showed<sup>(<xref rid="R32" ref-type="bibr">32</xref>)</sup> that <italic>ξ̃</italic><sub>100BMR</sub> possesses desirable statistical qualities: under suitable regularity conditions it converges to the target value <italic>ξ</italic><sub>100BMR</sub>, is asymptotically unbiased, and has a large-sample distribution converging to a Gaussian (‘normal’) form.</p></sec>
23683057|2.2. Model-independent bootstrap BMDLs|('method', 0.9153647574833148)|('other', 0.08463524251668514)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.2. Model-independent bootstrap BMDLs</title><p id="P12">Unfortunately, we also discovered<sup>(<xref rid="R32" ref-type="bibr">32</xref>)</sup> that the asymptotic variance of <italic>ξ̃</italic><sub>100BMR</sub> depends critically on the underlying risk function <italic>R</italic>(<italic>x</italic>). Since under our basic premise we are unwilling to fully specify the form of <italic>R</italic>(<italic>x</italic>), this makes it difficult to employ the asymptotic features of <italic>ξ̃</italic><sub>100BMR</sub> for constructing a corresponding BMDL. For building confidence limits on an ED<sub>50</sub>, Bhattacharya and Kong<sup>(<xref rid="R31" ref-type="bibr">31</xref>)</sup> encountered an analogous predicament with their similarly constructed, isotonic, <inline-formula><mml:math id="M5" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mtext>ED</mml:mtext><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mn>50</mml:mn></mml:msub></mml:math></inline-formula> estimator. Their solution was to appeal instead to the bootstrap<sup>(<xref rid="R35" ref-type="bibr">35</xref>)</sup>, and their nonparametric bootstrap-based inferences achieved respectable stability. Following their lead, we also consider the bootstrap to build model-independent BMDLs.</p><p id="P42">Appeal to bootstrapping for construction of confidence limits in risk assessment has seen increasing application, and is becoming an accepted approach for calculating critical risk-analytic quantities such as the BMDL. Most authors employ it under some form of parametric specification, however<sup>(<xref rid="R36" ref-type="bibr">36</xref>–<xref rid="R39" ref-type="bibr">39</xref>)</sup>. Here, we follow our previous construction<sup>(<xref rid="R32" ref-type="bibr">32</xref>)</sup> and describe a bootstrap-based approach for building BMDLs with the model-independent estimator from (<xref rid="FD4" ref-type="disp-formula">2.4</xref>). In keeping with our general estimation strategy, we do not assume any parametric form for <italic>R</italic>(<italic>x</italic>), although we do continue to impose our continuity and monotonicity assumptions. We also continue to assume a binomial parent distribution for the data.</p><p id="P13">To perform the nonparametric bootstrapping, we begin with the original proportions <italic>Y<sub>i</sub></italic>/<italic>N<sub>i</sub></italic> and resample each <italic>m</italic>-dose quantal response <italic>B</italic> &gt; 0 times. That is, in the <italic>b</italic>th resample at each <italic>x<sub>i</sub></italic> we generate the pseudo-random variate <inline-formula><mml:math id="M6" overflow="scroll"><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> from Bin.(<italic>N<sub>i</sub></italic>, <italic>Y<sub>i</sub></italic>/<italic>N<sub>i</sub></italic>), <italic>i</italic> = 1, …, <italic>m; b</italic> = 1, …, <italic>B</italic>. We then apply the PAV algorithm to the <inline-formula><mml:math id="M7" overflow="scroll"><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula>s to yield the monotonized bootstrap sequence</p><disp-formula id="FD5"><mml:math id="M8" display="block" overflow="scroll"><mml:msubsup><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:munder><mml:mo>max</mml:mo><mml:mrow><mml:mn>1</mml:mn><mml:mo>≤</mml:mo><mml:mi>u</mml:mi><mml:mo>≤</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:munder><mml:mspace width="0.16667em"/><mml:munder><mml:mo>min</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>≤</mml:mo><mml:mi>v</mml:mi><mml:mo>≤</mml:mo><mml:mi>m</mml:mi></mml:mrow></mml:munder><mml:mspace width="0.16667em"/><mml:mfrac><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>u</mml:mi></mml:mrow><mml:mi>v</mml:mi></mml:msubsup><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup></mml:mrow><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>u</mml:mi></mml:mrow><mml:mi>v</mml:mi></mml:msubsup><mml:msub><mml:mi>N</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:math></disp-formula><p id="P14">From these we produce an isotonic bootstrap estimate of the extra risk via (<xref rid="FD3" ref-type="disp-formula">2.3</xref>). Denote this as <inline-formula><mml:math id="M9" overflow="scroll"><mml:msubsup><mml:mover accent="true"><mml:mi>R</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mi>E</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>. We then apply (<xref rid="FD4" ref-type="disp-formula">2.4</xref>) to find a bootstrapped <inline-formula><mml:math id="M10" overflow="scroll"><mml:msubsup><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>b</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula>. (For simplicity here we suppress the BMR subscript on <italic>ξ̃</italic>, but it is understood that all these operations are conducted for a fixed, pre-specified BMR.) Following previously validated suggestions<sup>(<xref rid="R37" ref-type="bibr">37</xref>,<xref rid="R40" ref-type="bibr">40</xref>)</sup> for the number, <italic>B</italic>, of bootstrap resamples, we work with <italic>B</italic> = 2000.</p><p id="P15">Two special cases that require attention occur when <italic>Y<sub>i</sub></italic> = 0 or when <italic>Y<sub>i</sub></italic> = <italic>N<sub>i</sub></italic> at any <italic>i</italic>. If so, the resampling will always produce <inline-formula><mml:math id="M11" overflow="scroll"><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> or <inline-formula><mml:math id="M12" overflow="scroll"><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>b</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula>, respectively, generating no new bootstrap information<sup>(<xref rid="R41" ref-type="bibr">41</xref>)</sup>. Various remedies for this are possible<sup>(<xref rid="R38" ref-type="bibr">38</xref>)</sup>; in keeping with our nonparametric strategy, we refrain from applying any parametric-model constructs. Instead, we add a small constant <italic>ε</italic> &gt; 0 to the numerator and twice it to the denominator of the observed proportions <italic>Y<sub>i</sub></italic>/<italic>N<sub>i</sub></italic>. That is, whenever <italic>Y<sub>i</sub></italic> = 0 or <italic>Y<sub>i</sub></italic> = <italic>N<sub>i</sub></italic>, we replace <italic>Y<sub>i</sub></italic>/<italic>N<sub>i</sub></italic> with {<italic>Y<sub>i</sub></italic> + <italic>ε</italic>}/{<italic>N<sub>i</sub></italic> + 2<italic>ε</italic>}. This <italic>shrinks</italic> the proportion away from 0 or from 1 and towards <inline-formula><mml:math id="M13" overflow="scroll"><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mstyle></mml:math></inline-formula>. (Shrinkage towards any fixed value is admittedly arbitrary, and we chose <inline-formula><mml:math id="M14" overflow="scroll"><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mstyle></mml:math></inline-formula> simply as an objective, default, shrinkage target. If in practice a different target were available based on experiment- or stimulus-specific considerations, it could easily be employed instead.) We experimented with a variety of possible values for <italic>ε</italic>, and found that only a slight amount of shrinkage was necessary to stabilize the bootstrap calculations. We settled on <inline-formula><mml:math id="M15" overflow="scroll"><mml:mi>ε</mml:mi><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>4</mml:mn></mml:mfrac></mml:mstyle></mml:math></inline-formula>, i.e., whenever <italic>Yi</italic> = 0 or <italic>Yi</italic> = <italic>Ni</italic>, replace <italic>Yi</italic>/<italic>Ni</italic> with <inline-formula><mml:math id="M16" overflow="scroll"><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>4</mml:mn></mml:mfrac></mml:mstyle><mml:mo stretchy="false">}</mml:mo><mml:mo>/</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mstyle><mml:mo stretchy="false">}</mml:mo></mml:math></inline-formula>.</p><p id="P16">To find a lower 100(1 − <italic>α</italic>)% confidence limit on the BMD, we collect the <inline-formula><mml:math id="M17" overflow="scroll"><mml:msubsup><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>b</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula>s together to produce a bootstrap distribution for <italic>ξ̃</italic>. From this, we apply the well-known percentile method<sup>(<xref rid="R42" ref-type="bibr">42</xref>)</sup>: order the <italic>B</italic> bootstrapped <inline-formula><mml:math id="M18" overflow="scroll"><mml:msubsup><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>b</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> values into <inline-formula><mml:math id="M19" overflow="scroll"><mml:msubsup><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>≤</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>≤</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≤</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>B</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> and select as the BMDL the lower <italic>α</italic>th percentile: <inline-formula><mml:math id="M20" overflow="scroll"><mml:msub><mml:munder accentunder="true"><mml:mi>ξ</mml:mi><mml:mo>_</mml:mo></mml:munder><mml:mrow><mml:mn>100</mml:mn><mml:mtext>BMR</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>α</mml:mi><mml:mi>B</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula>. This represents a model-independent, nonparametric BMDL for use in risk assessment practice.</p></sec>
23683057|None|('method', 0.93136320010747)|('other', 0.06863679989253016)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3. BMDL PERFORMANCE EVALUATION</title>
23683057|None|('method', 0.93136320010747)|('other', 0.06863679989253016)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P17">Previously<sup>(<xref rid="R32" ref-type="bibr">32</xref>)</sup> we studied the performance of our model-independent BMDL, <italic><underline>ξ</underline></italic><sub>100BMR</sub>, via a series of Monte Carlo simulations. The BMDL exhibited generally stable coverage characteristics, but some undercoverage—i.e., coverage rates below the nominal 100(1 − <italic>α</italic>)% level—occurred for very small sample sizes and very shallow dose-response patterns. Our earlier focus was on introducing the isotonic estimation method and exploring its theoretical properties, however, and so our study was limited to a small, illustrative selection of dose-response functions. We recognized that more complete evaluations were needed to study the operating characteristics of our model-independent BMDL. Here, we expand upon our previous results to study how the isotonic method operates over a broader range of possible dose-response models/shapes.</p>
23683057|3.1. Simulation design|('method', 0.93136320010747)|('other', 0.06863679989253016)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8" sec-type="methods"><title>3.1. Simulation design</title><p id="P18">Our focus is on the empirical coverage characteristics of the bootstrap-based confidence limit <italic><underline>ξ</underline></italic><sub>100BMR</sub>. We set the BMR to a standard default level BMR = 0.10 <sup>(<xref rid="R8" ref-type="bibr">8</xref>)</sup>, and operate at 95% nominal coverage. We employ either four dose levels, <italic>x</italic> = 0, 0.25, 0.5, 1.0, corresponding to a standard design in cancer risk experimentation<sup>(<xref rid="R43" ref-type="bibr">43</xref>)</sup>, or six dose levels, <italic>x</italic> = 0, 0.0625, 0.125, 0.25, 0.50, 1.0, expanding on the four-dose geometric spacing. We also include a modified six-dose design <italic>x</italic> = 0, 0.1, 0.2, 0.4, 0.6, 1.0 that gives less focus to doses near <italic>x</italic> = 0, to study how/if this affects the BMDL <italic><underline>ξ</underline></italic><sub>100BMR</sub>.</p><p id="P19">For simplicity, equal numbers of subjects, <italic>N<sub>i</sub></italic> = <italic>N</italic>, are taken per dose group. We fix the total sample size at (or as near as possible to) <inline-formula><mml:math id="M21" overflow="scroll"><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>m</mml:mi></mml:msubsup><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>100</mml:mn><mml:mo>,</mml:mo><mml:mn>200</mml:mn><mml:mo>,</mml:mo><mml:mn>400</mml:mn><mml:mo>,</mml:mo><mml:mtext>or</mml:mtext><mml:mspace width="0.16667em"/><mml:mn>4000</mml:mn></mml:mrow></mml:math></inline-formula>, producing per-dose sample sizes of <italic>N</italic> = 25, 50, 100, or 1000 for the four-dose design and <italic>N</italic> = 16, 33, 66, or 666 for the six-dose designs.</p><p id="P43">For the underlying dose-response patterns we employ models corresponding to a variety of functions available from the U.S. EPA’s BMDS software program for performing BMD calculations<sup>(<xref rid="R44" ref-type="bibr">44</xref>)</sup>. <xref rid="T1" ref-type="table">Table I</xref> provides a selection of four two-parameter and four three-parameter dose-response models. These are taken from a collection of dose-response forms chosen by Wheeler and Bailer<sup>(<xref rid="R36" ref-type="bibr">36</xref>)</sup> in their studies of (parametric) estimators for the BMD. [Wheeler and Bailer did not include the log-logistic model (3B) in all their calculations, although they did present it as a possible data generating model. They also presented a possible data generating model based on the gamma cumulative distribution function (c.d.f.), but did not use it in their calculations. In a similar vein, we do not consider the gamma model here.] In our earlier work<sup>(<xref rid="R32" ref-type="bibr">32</xref>)</sup> we studied a subset of the models in <xref rid="T1" ref-type="table">Table I</xref>: the two-stage (3A), log-probit (3C), and Weibull (3D). Thus for these three models the simulation outcomes we give here replicate the results we reported previously. Notice that certain models impose constraints on selected parameters; these are listed in <xref rid="T1" ref-type="table">Table I</xref> to correspond with typical constraints we find in the environmental toxicology literature. In the table, for the log-probit model (3C) we define <italic>R</italic>(0) = <italic>γ</italic><sub>0</sub>. Note that the quantal-linear model (2A) may also be referred to as the ‘one-stage’ model (a form of ‘multi-stage’ model) or as the ‘complementary-log’ model. This may equivalently appear as <italic>R</italic>(<italic>x</italic>) = <italic>γ</italic><sub>0</sub> + (1 − <italic>γ</italic><sub>0</sub>)(1 − <italic>e</italic><sup>−<italic>β</italic><sub>1</sub></sup><italic>x</italic>), where <italic>γ</italic><sub>0</sub> = 1 − <italic>e</italic><sup>−<italic>β</italic><sub>0</sub></sup>.</p><p id="P20">To set the simulation parameters for each model, we fix the risk <italic>R</italic>(<italic>x</italic>) at three doses: <inline-formula><mml:math id="M22" overflow="scroll"><mml:mi>x</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mstyle><mml:mo>,</mml:mo><mml:mn>1</mml:mn></mml:math></inline-formula>. Based on typical patterns seen in cancer risk assessment<sup>(<xref rid="R41" ref-type="bibr">41</xref>,<xref rid="R45" ref-type="bibr">45</xref>)</sup>, background risks at <italic>x</italic> = 0 are set between 1% and 30%, and the other risk levels are increased to produce a variety of (strictly) increasing forms, ending with high-dose risks at <italic>x</italic> = 1 between 10% and 90%. Using the specifications at <italic>x</italic> = 0 and <italic>x</italic> = 1 we solve for two unknown parameters. This completes determination of the two-parameter models (2A–2D). For the three-parameter models (3A–3D), we additionally employ the response specification at <inline-formula><mml:math id="M23" overflow="scroll"><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mstyle><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> to solve for the third unknown parameter. The actual specifications and resulting parameter configurations for the various models are given in <xref rid="T2" ref-type="table">Table II</xref>; we also include the corresponding values of <italic>ξ</italic><sub>10</sub>.</p><p id="P21">For each parameter configuration (labeled A–F), 2000 individual, pseudo-binomial, data sets are simulated and as noted in §2.2, <italic>B</italic> = 2000 bootstrap samples are generated from each data set to produce the corresponding empirical coverage value. Notice then that the approximate standard p error of the estimated coverage over all 2000 simulated data sets is <inline-formula><mml:math id="M24" overflow="scroll"><mml:msqrt><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0.05</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>0.95</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>2000</mml:mn></mml:mrow></mml:msqrt><mml:mo>=</mml:mo><mml:mn>0.005</mml:mn></mml:math></inline-formula>, and this never exceeds <inline-formula><mml:math id="M25" overflow="scroll"><mml:msqrt><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>2000</mml:mn></mml:mrow></mml:msqrt><mml:mo>=</mml:mo><mml:mn>0.011</mml:mn></mml:math></inline-formula>. All of our calculations are performed with the R statistical programming environment<sup>(<xref rid="R46" ref-type="bibr">46</xref>)</sup>.</p></sec>
23683057|3.2. Infinite BMDs|('method', 0.93136320010747)|('other', 0.06863679989253016)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>3.2. Infinite BMDs</title><p id="P22">An unusual artifact we uncovered while conducting our Monte Carlo computations was that for some very shallow dose-response patterns, calculation of a nonparametric BMD can sometimes break down. One obvious case is when the BMR is set too high, so that the isotonic extra risk estimator never reaches the desired benchmark response over the range of the doses, i.e., <italic>R̃<sub>E</sub></italic>(<italic>x</italic>) &lt; BMR, for all <italic>x</italic> ≤ <italic>x<sub>m</sub></italic>. If so, there is no solution to the BMD-defining relationship <italic>R̃<sub>E</sub></italic>(<italic>ξ</italic>) = BMR. Of course, if the extra risk were estimated using a fully parametric (non-decreasing) function one would simply extrapolate the function outside of the dose range to find the solution. To imitate this strategy with our nonparametric estimator, suppose that <italic>R̃<sub>E</sub></italic>(<italic>x</italic>) from (<xref rid="FD3" ref-type="disp-formula">2.3</xref>) is linear and strictly increasing along its final segment between <italic>x<sub>m</sub></italic><sub>−1</sub> and <italic>x<sub>m</sub></italic>. Then if <italic>R̃<sub>E</sub></italic>(<italic>x</italic>) &lt; BMR ∀<italic>x</italic> ≤ <italic>x<sub>m</sub></italic>, we simply extend this final line segment past <italic>x<sub>m</sub></italic> until it crosses the horizontal BMR line, and solve for <italic>ξ̃</italic><sub>100BMR</sub> at that intersection point. While admittedly one should apply any such extrapolations past the range of the data with great caution, this strategy nonetheless allows us to report an objective estimate for the BMD in this unusual case.</p><p id="P23">The extrapolative estimate for the BMD will still fail if the final line segment from (<xref rid="FD3" ref-type="disp-formula">2.3</xref>) is flat, i.e., if <italic>p̃<sub>m</sub></italic><sub>−1</sub> = <italic>p̃<sub>m</sub></italic> (or when <italic>p̃<sub>m</sub></italic><sub>−2</sub> = <italic>p̃<sub>m</sub></italic><sub>−1</sub> = <italic>p̃<sub>m</sub></italic>, etc.). When this occurs, the data are in effect telling us that the observed dose response cannot attain the BMR, no matter how large <italic>x</italic> grows. Correspondingly, in such an instance we simply drive the estimator <italic>ξ̃</italic><sub>100BMR</sub> to ∞, or, equivalently, report it as undefined. In the extreme, this also occurs if the <italic>p̃<sub>i</sub></italic>s all equal each other. In this case, (<xref rid="FD3" ref-type="disp-formula">2.3</xref>) will produce <italic>R̃<sub>E</sub></italic>(<italic>x</italic>) = 0, so we again are forced to drive <italic>ξ̃</italic><sub>100BMR</sub> to ∞.</p><p id="P24">Somewhat perniciously, this issue of undefined or infinite BMDs was not uncommon with some of the very shallow dose-response configurations in <xref rid="T2" ref-type="table">Table II</xref>, especially configurations ‘A’ and ‘C’. Particularly at the smaller sample sizes, such shallow configurations could even produce non-monotone response patterns in the simulated data, despite the fact that the underlying <italic>R</italic>(<italic>x</italic>) function was strictly increasing. This forced the PAV algorithm to ‘flatten out’ the estimated extra risk over a large portion of the dose range, and when this occurred near the upper end of the range we encountered the infinite-BMD phenomenon.</p><p id="P25">Operationally, when any ‘infinite’ <italic>ξ̃</italic><sub>100BMR</sub> was observed in our bootstrap procedure, we set the estimate equal to machine infinity. If this occurred for more than 100(1 − <italic>α</italic>)% of the bootstrapped <italic>ξ̃</italic><sup>*</sup>s, we defined <italic><underline>ξ</underline></italic><sub>100BMR</sub> itself as ‘infinite’, and viewed this as failure to cover the true <italic>ξ</italic><sub>100BMR</sub>.</p></sec>
23683057|3.3. Simulation results|('method', 0.93136320010747)|('other', 0.06863679989253016)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10" sec-type="results"><title>3.3. Simulation results</title><p id="P26">We summarize the empirical coverage results from our Monte Carlo study in a series of tables. Recall that we fix BMR = 0.10 and operate at nominal 95% coverage. Each initial table displays empirical coverage results recorded for all model configurations and sample sizes except the quantal-linear model (2A); we will discuss model 2A in greater detail below. <xref rid="T3" ref-type="table">Table III</xref> presents the results for the geometric four-dose design with <italic>x</italic> = 0, 0.25, 0.50, 1.0: therein, coverages lie near and generally within Monte Carlo sampling variability of the nominal 95% level. Some undercoverage is observed at the lowest per-dose sample size of <italic>N</italic> = 25 and/or with the (shallow) response configurations ‘A’ and, to a lesser extent, ‘B’; however, conservative overcoverage is at least as prevalent. Indeed, averaged across the seven models (2B–2D and 3A–3D) in <xref rid="T3" ref-type="table">Table III</xref>, the empirical coverages as a function of sample size are at or near the 95% nominal level: 94.22% for <italic>N</italic> = 25, 94.76% for <italic>N</italic> = 50, 95.84% for <italic>N</italic> = 100, and 96.95% for <italic>N</italic> = 1000.</p><p id="P27"><xref rid="T4" ref-type="table">Table IV</xref> presents the results for the geometric six-dose design with <italic>x</italic> = 0, 0.0625, 0.125, 0.25, 0.50, 1.0: coverage patterns therein appear slightly more stable on average than those seen in <xref rid="T3" ref-type="table">Table III</xref>, although there are also more extreme cases of undercoverage. These again occur at the lowest per-dose sample size <italic>N</italic> = 25 and/or with the (shallow) response configuration ‘A’. Overall, average empirical coverages across the seven models 2B–2D and 3A–3D are again close to nominal: 94.61% for <italic>N</italic> = 25, 95.96% for <italic>N</italic> = 50, 96.88% for <italic>N</italic> = 100, and 97.15% for <italic>N</italic> = 1000. As might be expected, decreasing the per-dose sample sizes while increasing the number of doses yields greater stability at larger sample sizes, but this effect appears to reverse somewhat when sample sizes drop.</p><p id="P28">Results for the modified six-dose design with <italic>x</italic> = 0, 0.1, 0.2, 0.4, 0.6, 1.0 are given in <xref rid="T5" ref-type="table">Table V</xref>. The pattern of coverage is roughly similar to that in <xref rid="T4" ref-type="table">Table IV</xref>, although somewhat larger undercoverage is evidenced at <italic>N</italic> = 25. Overall, average empirical coverages across the seven models 2B–2D and 3A–3D are 93.30% for <italic>N</italic> = 25, 95.19% for <italic>N</italic> = 50, 96.00% for <italic>N</italic> = 100, and 96.20% for <italic>N</italic> = 1000. At least for these designs, deemphasizing doses near to zero appeared to have limited impact.</p><p id="P29">On balance, our simulation results exhibit generally stable large-sample coverage characteristics for the model-independent, bootstrapped limit <italic><underline>ξ</underline></italic><sub>100BMR</sub> at the standard level of BMR = 0.10. Slight undercoverage is evidenced in selected instances, more so when sample sizes are small. We previously identified a possible explanation for this behavior<sup>(<xref rid="R32" ref-type="bibr">32</xref>)</sup>, where we found that the PAV-based estimator in (<xref rid="FD4" ref-type="disp-formula">2.4</xref>) exhibits slight negative bias when applied to convex response patterns. Negative bias in the estimator can translate to more conservative lower confidence bounds for the BMDL. On a relative scale the bias was not exceptional, however, and in fact is not wholly unexpected: bias can be a recurring issue with isotonic regression estimators<sup>(<xref rid="R47" ref-type="bibr">47</xref>)</sup>. Indeed, the effect moderated as sample sizes increased. Nonetheless, this suggests that the method should be applied when sufficient data are available to help validate its asymptotic motivation.</p><p id="P30">We also conducted Monte Carlo coverage evaluations for the case of BMR = 0.01. While less common, this smaller BMR may be employed in practice when sufficient data are available to support inferences at extreme low doses<sup>(<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R14" ref-type="bibr">14</xref>)</sup>. Our results (not shown) were generally similar to those seen above; in particular, the coverage rates again drove towards the nominal 95% level as the sample size increased. At the lowest sample sizes, however, they appeared much more variable, and often in the direction of undercoverage. We encountered a few empirical coverage rates that dropped below 50% with some of the low-response-rate models, especially configurations ‘A’ and ‘B’. This is, in fact, consistent with practical benchmarking experience: when response rates are very small at low doses, and if the <italic>N<sub>i</sub></italic>s do not counter by being fairly large, insufficient information will be available to perform effective inferences if the BMR is set very low. We therefore urge caution in practice when employing these methods with very small sample sizes, particularly with low-response patterns.</p></sec>
23683057|3.4. Simulation results for the (concave) quantal-linear model|('method', 0.93136320010747)|('other', 0.06863679989253016)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11" sec-type="results"><title>3.4. Simulation results for the (concave) quantal-linear model</title><p id="P31">Our Monte Carlo results for the quantal-linear model (2A) differed from the general trends seen with the other seven models in <xref rid="T1" ref-type="table">Table I</xref>, hence we discuss these separately. Among all the models we study, the quantal linear model (2A) is the only strictly <italic>concave</italic> form. That is, since model 2A has <italic>R</italic>(<italic>x</italic>) = 1−exp{−<italic>β</italic><sub>0</sub> − <italic>β</italic><sub>1</sub><italic>x</italic>} and <italic>β</italic><sub>1</sub> ≥ 0, its first derivative is non-negative: <italic>R′</italic>(<italic>x</italic>) = <italic>β</italic><sub>1</sub> exp{−<italic>β</italic><sub>0</sub> − <italic>β</italic><sub>1</sub><italic>x</italic>} ≥ 0 for all <italic>x</italic> &gt; 0. As with the rest of the models in <xref rid="T1" ref-type="table">Table I</xref>, this produces an increasing dose response. (For the trivial case where <italic>β</italic><sub>1</sub> = 0 the dose response will be flat and of no risk-analytic interest.) For <italic>β</italic><sub>1</sub> &gt; 0, however, the second derivative is <inline-formula><mml:math id="M26" overflow="scroll"><mml:msup><mml:mi>R</mml:mi><mml:mo>″</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:msubsup><mml:mi>β</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>exp</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mo>-</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>x</mml:mi><mml:mo stretchy="false">}</mml:mo><mml:mo>&lt;</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> for all <italic>x</italic> &gt; 0 and therefore the dose response increases at a decreasing rate: a concave function.</p><p id="P44">This feature impacts our linear interpolator. A concave response function will, more often than not, produce concave dose-response patterns in the <italic>p̃<sub>i</sub></italic>s from (<xref rid="FD1" ref-type="disp-formula">2.1</xref>), and linearly interpolating a concave-increasing pattern can lead to underestimation of the extra risk. This translates as overestimation of <italic>ξ̃</italic><sub>100BMR</sub>. The corresponding lower confidence bounds would, in turn, be driven up. If variation in the data is tight this could push them past the true, underlying vale of <italic>ξ</italic><sub>100BMR</sub>, collapsing the coverage rates. With very small numbers of doses, <italic>m</italic>, and large per-dose sample sizes, <italic>N<sub>i</sub></italic>, the rates can drop well below their nominal level. In theory the issue would quickly be remedied by increasing <italic>m</italic>, since the theoretical properties of (<xref rid="FD4" ref-type="disp-formula">2.4</xref>) obtain as both min{<italic>N<sub>i</sub></italic>} and <italic>m</italic> grow large without limit. With small <italic>m</italic>, however, the potential undercoverage can be dramatic.</p><p id="P45">This effect was evidenced in our Monte Carlo coverage evaluations. <xref rid="T6" ref-type="table">Table VI</xref> presents Model 2A’s small-sample coverage rates for our model-independent, bootstrap BMDL <italic><underline>ξ</underline></italic><sub>100BMR</sub> at the standard level of BMR = 0.10, and with nominal coverage set to 95%. Notice the large numbers of entries below 0.95 (the zero coverage value, 0.0000, for the four-dose design under configuration ‘F’ at <italic>N</italic> = 1000 is <italic>not</italic> a typographical error). In <xref rid="T2" ref-type="table">Table II</xref>, one can determine that concavity in Model 2A increases as the configuration index moves from ‘A’ to ‘F’. Thus two clear trends emerge in <xref rid="T6" ref-type="table">Table VI</xref>: (i) coverage performance worsens as the concavity of the model increases, and (ii) adding more doses improves the performance more often than it debilitates it. In addition, comparing the two six-dose designs shows that as more sample information is placed closer to the true BMD—which of course is impossible in practice without knowledge of that true value—the coverage locates closer to its nominal level.</p><p id="P46">The coverage results in <xref rid="T6" ref-type="table">Table VI</xref> warn that our PAV-based benchmark estimator should be applied to concave dose-response patterns with caution. For shallow response patterns (configurations ‘A’–’C’), coverage is roughly similar to that seen in <xref rid="T3" ref-type="table">Tables III</xref>–V. With greater concavity comes greater instability, however, leading to extreme degradation with the extremely concave configuration ‘F’.</p><p id="P47">This begs the question, how much concavity is too much? As reviewed above, the second derivative of <italic>R</italic>(·) measures concavity in the response. Thus as a first approximation we can quantify the concavity in any data set by calculating how the <italic>slope</italic> of the isotonically estimated response function (<xref rid="FD2" ref-type="disp-formula">2.2</xref>) changes from <italic>x<sub>i</sub></italic> to <italic>x<sub>i</sub></italic><sub>+1</sub>.</p><p id="P32">Specifically, given PAV-based estimates <italic>p̃<sub>i</sub></italic> from (<xref rid="FD1" ref-type="disp-formula">2.1</xref>), write the slope between each adjacent pair as Δ<italic><sub>i</sub></italic> = {<italic>p̃<sub>i</sub></italic><sub>+1</sub> − <italic>p̃<sub>i</sub></italic>}/{<italic>x<sub>i</sub></italic><sub>+1</sub> − <italic>x<sub>i</sub></italic>}, <italic>i</italic> = 1, …, <italic>m</italic> − 1. The change in these slopes is <inline-formula><mml:math id="M27" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>i</mml:mi><mml:mo>′</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>/</mml:mo><mml:mo>{</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>}</mml:mo></mml:math></inline-formula>, <italic>i</italic> = 1, …, <italic>m</italic> − 2. Then, e.g., the average change in slope, <inline-formula><mml:math id="M28" overflow="scroll"><mml:msup><mml:mover accent="true"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mo>′</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>m</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mfrac></mml:mstyle><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>m</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>i</mml:mi><mml:mo>′</mml:mo></mml:msubsup></mml:math></inline-formula>, quantifies concavity in the isotonically estimated response: smaller (more negative) values of Δ̄′ indicate greater concavity. Note, however, that concavity far away from the BMD has little effect on the coverage for the BMDL <italic><underline>ξ</underline></italic><sub>100BMR</sub>. More pertinent for our purposes is a measure of <italic>local</italic> concavity near the estimated benchmark point. For instance, suppose the calculated BMD lies between two dose values. Then, to measure local concavity we might average the two corresponding values of Δ′ associated with those bracketing doses. That is, define a measure of local concavity, Δ̃′, as</p><disp-formula id="FD6"><label>(3.1)</label><mml:math id="M29" display="block" overflow="scroll"><mml:msup><mml:mover accent="true"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mo>′</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mrow><mml:mo>{</mml:mo><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>1</mml:mn><mml:mo>′</mml:mo></mml:msubsup></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.16667em"/><mml:msub><mml:mi>x</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mn>100</mml:mn><mml:mtext>BMR</mml:mtext></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mfrac><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mo>′</mml:mo></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>i</mml:mi><mml:mo>′</mml:mo></mml:msubsup></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.16667em"/><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mn>100</mml:mn><mml:mtext>BMR</mml:mtext></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mspace width="0.16667em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo>′</mml:mo></mml:msubsup></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.16667em"/><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mn>100</mml:mn><mml:mtext>BMR</mml:mtext></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>m</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mn>0</mml:mn></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mtext>if</mml:mtext><mml:mspace width="0.16667em"/><mml:msub><mml:mi>x</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>ξ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mrow><mml:mn>100</mml:mn><mml:mtext>BMR</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><p id="P33">The latter specification for Δ̃′ when <italic>ξ̃</italic><sub>100BMR</sub> ≥ <italic>x<sub>m</sub></italic> is based on our suggestion in §3.2 to extrapolate along a straight-line segment to define <italic>R̃<sub>E</sub></italic> beyond the upper range of the data. A possible alternative in this case is to take <inline-formula><mml:math id="M30" overflow="scroll"><mml:msup><mml:mover accent="true"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mo>′</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mi>m</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mo>′</mml:mo></mml:msubsup></mml:math></inline-formula>. In any case, similar to Δ̄′, smaller (more negative) values of Δ̃′ indicate greater local concavity.</p><p id="P48">We computed Δ̃′ for each design/parameter configuration combination in <xref rid="T6" ref-type="table">Table VI</xref>, to study how this measure correlates with unstable coverage performance. [Since we had available the true dose response information from <xref rid="T2" ref-type="table">Table II</xref>, we used <italic>R</italic>(<italic>x<sub>i</sub></italic>) in place of <italic>p̃<sub>i</sub></italic> and <italic>ξ</italic><sub>100BMR</sub> in place of <italic>ξ̃</italic><sub>100BMR</sub> for the calculations.] The results appear in <xref rid="T7" ref-type="table">Table VII</xref>. As expected, the concavity measure for the shallow configurations ‘A’–’C’ is fairly close to zero. The remaining, more-curvilinear configurations show smaller (more negative) local concavity, and correspond to patterns of greater coverage instability in <xref rid="T6" ref-type="table">Table VI</xref>. As a first step, therefore, we recommend that when the data indicate local concavity dropping below about Δ̃′&lt; −0.3 for <italic>m</italic> = 4 doses or Δ̃′ &lt; −0.6 for <italic>m</italic> = 6 doses, our PAV-based linear interpolator may not be appropriate for use in constructing BMDLs. (But, see the discussion in §5, below.)</p></sec>
23683057|None|('method', 0.9374427037939118)|('other', 0.0625572962060882)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4. EXAMPLE: FORMALDEHYDE CARCINOGENESIS IN LABORATORY ANIMALS</title>
23683057|None|('method', 0.9374427037939118)|('other', 0.0625572962060882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P34">Formaldehyde, CH<sub>2</sub>O, is a well-known industrial compound, exposure to which can be extensive in a variety of occupational and environmental settings. To explore the toxic and carcinogenic potential of the chemical, Schlosser <italic>et al.</italic><sup>(<xref rid="R48" ref-type="bibr">48</xref>)</sup> reported on nasal squamous cell carcinomas observed in laboratory rats after chronic, two-year, inhalation exposure. The CH<sub>2</sub>O exposure dose, <italic>x</italic>, is actually a concentration (in ppm) here, and so technically we will compute benchmark concentrations (BMCs) based on the quantal carcinogenicity data. Six CH<sub>2</sub>O concentrations were studied: <italic>x</italic> = 0.0, 0.7, 2.0, 6.0, 10.0, and 15.0 ppm. Since intercurrent mortality can occur in such chronic-exposure studies, the final tumor incidences were adjusted for potential differences in animal survival. <xref rid="T8" ref-type="table">Table VIII</xref> lists the survival-adjusted proportions.</p>
23683057|None|('method', 0.9374427037939118)|('other', 0.0625572962060882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P35">Of interest is calculation of the BMC, and more importantly a 95% lower confidence limit, BMCL, to help inform risk characterization on this potential carcinogen. (Our analysis here is intended primarily to illustrate the nonparametric, model-independent methodology, and not to supersede the larger risk analysis reported by Schlosser <italic>et al.</italic><sup>(<xref rid="R48" ref-type="bibr">48</xref>)</sup> or by any previous authors regarding CH<sub>2</sub>O carcinogenicity.) We make only the (reasonable) assumption that the true dose response is continuous and monotone non-decreasing over <italic>x</italic> ≥ 0, and operate at BMR = 0.10. From <xref rid="T8" ref-type="table">Table VIII</xref> the observed response is already non-decreasing, so the per-concentration PAV estimates <italic>p̃<sub>i</sub></italic> are simply the observed proportions: <italic>p̃</italic><sub>1</sub> = <italic>p̃</italic><sub>2</sub> = <italic>p̃</italic><sub>3</sub> = 0, <inline-formula><mml:math id="M31" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>4</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>3</mml:mn><mml:mn>113</mml:mn></mml:mfrac></mml:mstyle><mml:mo>,</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>5</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>21</mml:mn><mml:mn>34</mml:mn></mml:mfrac></mml:mstyle></mml:math></inline-formula>, and <inline-formula><mml:math id="M32" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>6</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>150</mml:mn><mml:mn>182</mml:mn></mml:mfrac></mml:mstyle></mml:math></inline-formula>. Constructing the isotonic extra risk estimator in (<xref rid="FD3" ref-type="disp-formula">2.3</xref>) and setting it equal to BMR = 0.10 produces the model-independent estimate <italic>ξ̃</italic><sub>10</sub> = 6.497 ppm.</p>
23683057|None|('method', 0.9374427037939118)|('other', 0.0625572962060882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P36">For the BMCL we apply the percentile bootstrap as described in §2.2. To do so we first check that local concavity near the BMC as measured by (<xref rid="FD6" ref-type="disp-formula">3.1</xref>) is acceptable: we see <italic>x</italic><sub>4</sub> = 6.0 &lt; <italic>ξ̃</italic><sub>10</sub> = 6.50 so take <inline-formula><mml:math id="M33" overflow="scroll"><mml:msup><mml:mover accent="true"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mo>′</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mstyle><mml:mo stretchy="false">{</mml:mo><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>3</mml:mn><mml:mo>′</mml:mo></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>4</mml:mn><mml:mo>′</mml:mo></mml:msubsup><mml:mo stretchy="false">}</mml:mo></mml:math></inline-formula>. From <xref rid="T8" ref-type="table">Table VIII</xref> we find Δ<sub>3</sub> = 0.007, Δ<sub>4</sub> = 0.148, and Δ<sub>5</sub> = 0.041, with <inline-formula><mml:math id="M34" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>3</mml:mn><mml:mo>′</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mo>+</mml:mo><mml:mn>0.035</mml:mn></mml:math></inline-formula> and <inline-formula><mml:math id="M35" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mn>4</mml:mn><mml:mo>′</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mo>-</mml:mo><mml:mn>0.027</mml:mn></mml:math></inline-formula>. Thus <inline-formula><mml:math id="M36" overflow="scroll"><mml:msup><mml:mover accent="true"><mml:mi mathvariant="normal">Δ</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mo>′</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mstyle scriptlevel="1"><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:mstyle><mml:mo stretchy="false">(</mml:mo><mml:mn>0.035</mml:mn><mml:mo>-</mml:mo><mml:mn>0.027</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>0.004</mml:mn></mml:math></inline-formula>. This is near zero and positive, indicating slight local <italic>convexity</italic> in the neighborhood of <italic>ξ̃</italic><sub>10</sub>. Hence, no problematic issues with potential dose-response concavity are evidenced and we proceed with our nonparametric bootstrap BMCL.</p>
23683057|None|('method', 0.9374427037939118)|('other', 0.0625572962060882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P49">For the bootstrap, we generate <italic>B</italic> = 2000 resamples from the original data, and find no occurrences of infinite <italic>ξ̃</italic><sup>*</sup>s. Our 95% BMCL is the lower 5th percentile from this distribution: <italic><underline>ξ</underline></italic><sub>10</sub> = 6.332 ppm. By comparison, Schlosser <italic>et al.</italic><sup>(<xref rid="R48" ref-type="bibr">48</xref>)</sup> reported a BMC<sub>10</sub> of 6.90 ppm with corresponding 95% BMCL<sub>10</sub> = 6.25 ppm under the log-probit model, a BMC<sub>10</sub> of 6.40 ppm with corresponding 95% BMCL<sub>10</sub> = 6.22 ppm under a form of the Weibull model, and a BMC<sub>10</sub> of 6.40 ppm with corresponding 95% BMCL<sub>10</sub> = 6.22 ppm under a form of multi-stage model. All sets of values rest in similar ranges, and provide comparable points of departure for conducting further risk-analytic calculations on formaldehyde carcinogenicity. Thus while our model-independent approach operates similarly to established parametric analyses for these data, it also provides an added benefit: it frees the risk assessor from uncertainties about the quality of any parametric assumptions made to support the benchmark computations.</p>
23708680|None|('method', 0.9999379025276027)|('other', 6.209747239725085e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
23708680|None|('method', 0.9999379025276027)|('other', 6.209747239725085e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">This was a prospective chart review of 512 patients, consecutively enrolled into HIV care from October 2004 to June 2007 at the Centre for the AIDS Programme of Research in South Africa (CAPRISA) eThekwini HIV-TB clinic. Patients were eligible for inclusion if they were HIV-positive, ART-naïve, and at least 18 years-old. TB/HIV co-infection was present in 128 patients (27.5%) either at ART initiation or during follow-up.</p>
23708680|None|('method', 0.9999379025276027)|('other', 6.209747239725085e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">Prior to initiating ART, health care workers (HCW) administered questionnaires to patients, capturing demographic and socioeconomic information. Patients were grouped into four educational levels: primary school or less, some secondary school, completed secondary school, or attended college or university.</p>
23708680|None|('method', 0.9999379025276027)|('other', 6.209747239725085e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">South African TB and HIV guidelines were used for all study patients.(<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref>) Patients presented for clinical review and adherence assessment weekly for the first two weeks of treatment and monthly thereafter. Health education and adherence literacy were standard of care at each study visit. Laboratory assessments were performed at screening and every 6 months, unless clinically indicated. Monitoring for TB sputum conversion was performed at screening, after the intensive phase of TB therapy, 1 month before the end of TB therapy, and whenever clinically indicated.</p>
23708680|None|('method', 0.9999379025276027)|('other', 6.209747239725085e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">Definitions of immunologic and virologic response were based on WHO guidelines.(<xref rid="R26" ref-type="bibr">26</xref>) Data was routinely collected by program staff, captured using standardized templates, and entered into a study database.</p>
23708680|None|('method', 0.9999379025276027)|('other', 6.209747239725085e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P10">Fisher’s exact tests and analysis of variance were used to compare differences in categorical and continuous data between the different education groups. An adjusted p-value was calculated using generalized estimating equation (GEE) models. A square-root transformation was applied to CD4+ count to ensure normality when comparing change from baseline between the education groups. Multivariate proportional hazards models were used to assess mortality and, separately, immunological response between low and high education groups. Stratified analyses for each education group and gender were also performed. All analyses were performed using SAS statistical software version 9.3 (SAS Institute Inc., Cary).</p>
23708680|None|('method', 0.9999379025276027)|('other', 6.209747239725085e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">The study was approved by the University of KwaZulu-Natal Biomedical Research Ethics Committee (E248/05).</p>
23758133|None|('method', 0.9937926584856742)|('other', 0.006207341514325739)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Methods</title>
23758133|2.1 Turf fibers, crumb rubber infill, and field samples|('method', 0.9937926584856742)|('other', 0.006207341514325739)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1 Turf fibers, crumb rubber infill, and field samples</title><p id="P6">New crumb infill (n=9) and new turf fiber products (n=8) were obtained from an architectural firm that specialized in artificial turf installation. Actual field samples were collected from seven New Jersey area communities that use crumb rubber infill products for athletic fields. This was accomplished by sweeping the infill material into a clean plastic shovel using new brushes and storing the crumb rubber collected in new Ziploc bags at room temperature until subsampled for analysis. For the selected fields, information was obtained on the manufacturer, age of the field, and general use of the field. All samples underwent the same bio-fluid extraction for SVOCs and metals. The “total” extractable fraction was measured by direct solid phase micro-extraction (SPME) for SVOCs and nitric acid extraction digestion for metals and used as the basis for the bio-accessibility comparisons.</p></sec>
23758133|2.2 Bio-fluid extractions|('method', 0.9937926584856742)|('other', 0.006207341514325739)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.2 Bio-fluid extractions</title><p id="P7">Using prepared synthetic solutions (<xref rid="T1" ref-type="table">Table I</xref>), bio-accessibility analyses for metals and SVOCs were performed for the following three routes of exposure: digestive system, respiratory system, and dermal. The artificial fluids used in these extracts have been documented to be functional analogs of actual biological fluids in previous studies. <sup>(<xref rid="R22" ref-type="bibr">22</xref>–<xref rid="R26" ref-type="bibr">26</xref>)</sup> Briefly, for the digestive system 200 mg of infill or a 4cm × 4cm piece of turf was extracted with 8 ml of the artificial saliva and 100 ml of gastric fluid (pH = 1.4 ± 0.2) for 2 hours at 37°C while being shaken at 30 RPM. Half the extract was then shaken again for 2 h after adding 100 ml of intestinal fluid, adjusted to a pH of 6.5 ± 0.1 and then the two digestive extracts were recombined and shaken for 2 more hours to simulate the digestive process. For the dermal pathway, approximately 200 mg of infill or a 4cm × 4cm piece of turf was extracted with 20 ml of the sweat solution by shaking at 30 RPM in a water bath at 37°C for 1 hr. For the respiratory system, approximately 100 mg of infill or a 4cm × 4cm piece of turf was extracted with 10 ml of the synthetic lung solution by shaking at 30 RPM at 37°C for 24 hours. The metals were extracted using a nitric acid microwave digestion procedure and analyzed by Inductively Coupled Plasma/Mass Spectroscopy (ICP/MS).<sup>(<xref rid="R26" ref-type="bibr">26</xref>)</sup> Mixed standards were prepared in nitric acid daily for the target metals selected based on their prevalence in the turf materials determined by qualitative scans and potential adverse health effect. Quality assurance checks were run routinely.</p><p id="P8">The SVOCs were analyzed using a direct solid phase micro extraction (DI-SPME) to concentrate the semi-volatile organic analytes from 10 mL of the biofluid extract followed by GC/MS. The GC/MS ion trap was operated in the EI positive mode and scanned between 40 and 600 amu to obtain maximum information about each peak. Quantification of the PAHs was done by comparison to commercially purchased standards. For the SVOC characterization, the mass spectrum acquired from each analyte was matched to a mass spectrum from the NIST/EPA/NIH 2008 mass spectral library database of more than 64,000 compounds, with a &gt;70% fit required for a positive identification. Approximately half the peaks were found to match an entry in the NIST library. The peaks with the top 10% area abundances were compared to the compounds listed in a series of toxicological databases (US EPA PALs, ATSDR Toxicology Profiles, ATSDR MRL 2010, CERCLA Priority Hazardous List 2007, EPA Final AEGLs, EPA Drinking Water Advisory, and Environment, Health and Safety Online Carcinogens) to identify potential compounds of concern. Of the several hundred compounds identified in the top 10% area abundances the only compound identified that was listed in any of the toxicological databases was toluene. Listings of the compounds in the various biofluids are given in the <xref rid="SD1" ref-type="supplementary-material">Supplementary Material</xref>. It includes a large number and variety of organic materials identified at very low concentrations but for which no hazard data are currently in toxicological databases used for regulatory purposes.</p><p id="P9">The nitric acid extraction was conducted by digesting the acid soluble fraction of approximately 0.2g of sample in a microwave pressure vessel containing 2mL of concentrated nitric acid under high temperature and pressure for 30 minutes. A total SVOC analysis was done by directly analyzing several grams of turf or infill by SPME coupled to GC/MS analysis.</p></sec>
23758133|2.3 Blanks for QA/QC|('method', 0.9937926584856742)|('other', 0.006207341514325739)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.3 Blanks for QA/QC</title><p id="P10">A single blank was run with each set of sample extracts. Since the salts used to prepare the artificial biofluids contained trace levels of metals, several of the blanks had detectable metal concentrations. To evaluate whether a blank correction was needed for any metal above the limit of detection the following criteria was used: if the sample value was less than twice the blank value then the sample concentration was replaced by twice the blank value, otherwise the blank value was subtracted from the sample extract concentration (see the <xref rid="SD1" ref-type="supplementary-material">Supplementary Material</xref> for the blank levels in the different extracts).</p><p id="P11">Blank samples of each biofluid were also analyzed for SVOCs using the same protocol as those used to extract turf samples. Compounds found to be present in the blank were not included in the list of compounds evaluated for toxicological properties. Standards spiked into blank samples were measured along with other figures of merit when the method was developed. The coefficient of variance (CV) was compound dependent as expected but ranged from 2.3 to 12%. The linearity for the compounds that were quantified were almost all 1 – 50 ppb and the method detection limits ranged from 0.3 to 1 ppb, all well below the quantitation of analyte when reported. Benzo(a) pyrene had a much higher detection limit (40 ppb) as it was not retained well on the fiber. While the expectation of homogeneity of a manufactured product may have been greater than observed, the measurement of a lower level analyte under very inhomogeneous extraction conditions was not unexpected. The CV for the method demonstrated that it was within expected analytical reproducibility.</p></sec>
23758133|2.4 Risk Assessment|('method', 0.9937926584856742)|('other', 0.006207341514325739)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.4 Risk Assessment</title><p id="P12">Based upon the analytical results below, a risk assessment for potential metal exposure was conducted in accordance with standard EPA risk assessment guidance for non-cancerous health endpoints.<sup>(<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R28" ref-type="bibr">28</xref>)</sup> No risk assessment was conducted for the SVOCs, since no regulated SVOCs were detected in the bioextracts and in most circumstances the values were not quantifiable. Routes of exposure that were considered in this assessment included dermal, ingestion, and inhalation pathways. Values were calculated for field samples only, since they were considered the most representative estimate of exposure. Male and female exposure values were averaged. Exposure was assumed to occur 3 hours per day, 130 days a year, and across five age groups (age ≥ 6 to &lt; 11 years; age ≥ 11 to &lt; 16 years; age ≥ 16 to &lt; 19 years; age ≥ 19 years to &lt; 39 years). For the lead risk assessment we considered two age groups: ≥ 2 to &lt; 6 years and age ≥ 6 to &lt; 7 years. In order to be as conservative as possible, the largest measured concentrations of each analyte were used for the screening values. If all samples were below the limit of detection (LOD) the largest LOD value for that compound was used. EPA recommended age specific body weight were applied to each group to determine dermal, ingestion, and inhalation doses (age ≥ 6 to &lt; 11 years, 31.8 kg; age ≥ 11 to &lt; 16 years, 56.8 kg; age ≥ 16 to &lt; 19 years 71.6 kg; age ≥ 19 years to &lt; 39 years, 80 kg).<sup>(<xref rid="R28" ref-type="bibr">28</xref>)</sup></p><p id="P13">Skin contact with the turf from sliding or running on the field was considered as the primary route of dermal exposure. Since dermal exposure can differ by the sport and the amount of equipment and clothing worn by athletes, soccer was considered as a worst case scenario for dermal exposure. Skin adherence factors used in this study were 0.04 mg/cm<sup>2</sup> (children playing) and 0.012 mg/cm<sup>2</sup> (adult soccer players).<sup>(<xref rid="R27" ref-type="bibr">27</xref>)</sup>The following surface area to body weight averages were used: children age ≥ 6 to &lt; 11 years 352 cm<sup>2</sup>/kg; children age ≥ 11 to &lt; 16 years 288 cm<sup>2</sup>/kg; children age ≥ 16 to &lt; 19 years 257 cm<sup>2</sup>/kg; and adults age ≥ 19 years 246 cm<sup>2</sup>/kg. <sup>(<xref rid="R28" ref-type="bibr">28</xref>)</sup> Chemical specific skin absorption fractions used were: 0.01 for beryllium, chromium, copper, lead, magnesium, titanium, selenium, silver, and vanadium; 0.03 for arsenic; and 0.001 for cadmium.<sup>(<xref rid="R27" ref-type="bibr">27</xref>)</sup> Dermal reference doses were calculated by the product of the ingestion reference dose and the gastrointestinal absorption factor (arsenic 100%; cadmium 2.5%; chromium 2.5%; copper 67.5%; lead 35%; vanadium 2.6%).<sup>(<xref rid="R27" ref-type="bibr">27</xref>, <xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>)</sup></p><p id="P14">Ingestion could be an important route of exposure to children since they have a greater propensity for hand-to-mouth contact and pica behavior compared to adults; although incidental ingestion by adults during sport related activities cannot be ignored. Ingestion rates used in this risk assessment were 50 mg/day for children and 20 mg/day for adults.<sup>(<xref rid="R28" ref-type="bibr">28</xref>)</sup></p><p id="P15">Based upon the study objectives and available resources, air samples were not collected in the laboratory or the field. Therefore, we relied on air measurements collected at artificial turf fields from previous studies to estimate the bio-accessible concentrations of metals for the risk assessment. Two studies were identified that published PM<sub>10</sub> (particles with an aerodynamic size &lt;10 μm) concentrations.<sup>(<xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R14" ref-type="bibr">14</xref>)</sup> One field in North Carolina was sampled for PM<sub>10</sub> at four different locations on two separate days. Concentrations ranged from 14.2 μg/m<sup>3</sup> to 33.4 μg/m<sup>3</sup> depending on the field location and day.<sup>(<xref rid="R31" ref-type="bibr">31</xref>)</sup> Five fields in Connecticut were sampled and concentrations ranged from 4.5 μg/m<sup>3</sup> to 16.5 μg/m<sup>3.(<xref rid="R14" ref-type="bibr">14</xref>)</sup> To be conservative, we used the largest PM<sub>10</sub> concentration for the risk assessment (33.4 μg/m<sup>3</sup>). This value was then multiplied by the maximum concentration that was found in the lung bio-fluid extract for each metal which in most cases was the LOD. The 95<sup>th</sup> percentile male and female combined inhalation rate was used for each age strata: children age ≥ 6 to &lt; 11 years 17.0 m<sup>3</sup>/day; children age ≥ 11 to &lt; 16 years 19.3 m<sup>3</sup>/day; children age ≥ 16 to &lt; 19 years 20.8 m<sup>3</sup>/day; and adults age ≥ 19 years 22.4 m<sup>3</sup>/day.<sup>(<xref rid="R28" ref-type="bibr">28</xref>)</sup> Inhalation reference doses were calculated from inhalation reference concentrations using standard EPA equations. <sup>(<xref rid="R32" ref-type="bibr">32</xref>)</sup></p><p id="P16">The EPA does not publish a reference dose for lead since toxicological effects can occur at low concentrations in children. To protect against permanent neurological effects the Centers for Disease Control and Prevention (CDC) recommends that children’s (age 1 to 5 years old) blood lead levels (BLL) not exceed 5 μg/dL.<sup>(<xref rid="R33" ref-type="bibr">33</xref>)</sup> To predict BLL we used the EPA’s Integrated Exposure Uptake Biokinetic Model for Lead in Children (IEUBK) Version 1.1. The model only predicts BLL in children younger than 7 years old. We evaluated two exposure scenarios in this risk assessment: children potentially using artificial turf fields for soccer and other sports (6–7 years old); and younger children that who may also use the field for non-sporting activities (2–6 years old). To calculate BLLs, we used the maximum measured bioavailable lead concentration of 260 mg/kg, a PM<sub>10</sub> concentration of 33.4 μg/m<sup>3</sup>, exposure duration of 3 hours, and a soil ingestion rate of 50 mg/day for both age groups. No other sources of lead exposures were considered and default age specific ventilation rates were used.</p></sec>
23758133|None|('method', 0.943841750985895)|('other', 0.05615824901410513)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
23758133|None|('method', 0.943841750985895)|('other', 0.05615824901410513)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Supplementary Data</label><media xlink:href="NIHMS565643-supplement-Supplementary_Data.pdf" orientation="portrait" xlink:type="simple" id="d37e606" position="anchor"/></supplementary-material>
23839025|None|('method', 0.9998402151379893)|('other', 0.00015978486201080882)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
23839025|None|('method', 0.9998402151379893)|('other', 0.00015978486201080882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P12">Subject data was obtained from the Michigan Spinal Stenosis Study II, an NIH-funded, ethical review board approved research study which involved subjects recruited from a university hospital neurosurgery and orthopedic surgery clinic. Qualified subjects must have been offered surgery for spinal stenosis by a surgeon, as reflected in the medical record. The subjects affirmed that ambulating two-hundred yards was difficult for them due to pain which they attributed to spinal stenosis and not due to another musculoskeletal or neurologic condition. Subjects were screened for previous back surgery, cardiopulmonary precautions for ambulation testing, contraindications to MRI scanning (metal, obesity, unmanageable claustrophobia), relative contraindications or technical barriers to electromyographic testing (coumadinization, severe immune disorder, extreme obesity, 3+ or greater pitting edema, or implanted electrodes such as defibrillators), and risk factors for neuromuscular disease (diabetes, alcohol more than 12 drinks per week, personal or familial neuromuscular disease, or history of previous significant focal lower limb nerve injury). Potential subjects with any other medical disorder of a level of severity that might interfere with daily walking were eliminated. Finally, subjects were required to be legally competent and willing to travel to the clinic at their own expense for testing.</p>
23839025|None|('method', 0.9998402151379893)|('other', 0.00015978486201080882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P13">All participants were screened against confounding medical problems, such as diabetic neuropathy, peripheral vascular disease, musculoskeletal disease, and history of significant injury to the lower limb.</p>
23839025|None|('method', 0.9998402151379893)|('other', 0.00015978486201080882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P14">As part of the MSSS-II study protocol, each subject completed a thorough questionnaire, which included basic demographic, medical, social, family, and spine history items. The questionnaire also included the Tampa Scale, a tool to measure kinesiophobia and psychometric factors of chronic pain <sup><xref rid="R14" ref-type="bibr">14</xref></sup>; the Walking Impairment Questionnaire <sup><xref rid="R15" ref-type="bibr">15</xref></sup>; the Swiss Spinal Stenosis Scale, which is an outcome questionnaire about the patient’s symptom severity, physical function, and surgery satisfaction <sup><xref rid="R16" ref-type="bibr">16</xref></sup>; The Center for Epidemiological Studies Depression scale (CES-D) scale which is an inventory of the subject’s mood and behavior in the week prior to filling out the questionnaire <sup><xref rid="R17" ref-type="bibr">17</xref></sup>; and the SF-36, a comprehensive questionnaire that provides a summary of various aspects of the subjects’ perception of their mental and physical quality of life <sup><xref rid="R18" ref-type="bibr">18</xref></sup>. These and other questions offered important information about the location and level of pain, participants’ emotional status, physical impairment level, family history, medical history, work status, and satisfaction with surgery if applicable.</p>
23839025|None|('method', 0.9998402151379893)|('other', 0.00015978486201080882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P15">Subjects were called on average one year following participation in the MSSS-II study; the shortest amount of time between a subject finishing the MSSS-II and receiving the follow-up call was two and a half months and the longest amount of time was three years. Subjects were asked whether they had undergone spine surgery since participation, their level of satisfaction with the treatment they had received (surgical or other) and their current level of pain. Feedback was also obtained on participation in the MSSS-II for other purposes.</p>
23839025|None|('method', 0.9998402151379893)|('other', 0.00015978486201080882)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">The sample was divided into “surgery” and “no surgery” groups. Demographics of the groups were compared with t-tests and chi-squares using SPSS/PASW v.17 software. Study variables, based on the various scales on the patient questionnaires were also evaluated for differences between groups. Significantly different variables as well as the visual analog scale (VAS) rating of average pain in the past week, age, and body mass index (BMI), were evaluated for collinearity using Analysis of Variance (ANOVA). Based on this multivariate analysis, three important factors – Role Limiting, Emotional (RLE) and Comparative Health (CH) (both subscales from the SF-36), and quality of life (QoL, as rated by subjects) – were selected for further analysis in a binary logistic regression.</p>
23959975|None|('method', 0.9953780610067149)|('other', 0.004621938993285279)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Method</title>
23959975|Participants|('method', 0.9953780610067149)|('other', 0.004621938993285279)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Participants</title><p id="P10">Our methods and analyses aligned with <xref rid="R23" ref-type="bibr">Hmelo-Silver and Pfeffer (2004)</xref>, who investigated mental models of aquaria across different levels of expertise: middle school students (n=11), pre-service teachers (n=11), and experts (n=8). We used their sample sizes (which are typical for mental models research; <xref rid="R38" ref-type="bibr">Singer et al., 2012</xref>) as a guideline for our own. Our participants were 13 ninth grade students and 18 teachers from an urban school district in Nebraska, and 7 domain experts in virology. All were paid for their participation. Half of the teachers taught at the middle school level and half taught at the high school level. The majority of the teachers (13 of 18) taught science as their primary subject. Each of the virology experts possessed an advanced graduate or medical degree and over 10 years of experience working in virology. Participants were selected on the basis of their participation in a two-week immersive program, the Omaha Science Media Project (<ext-link ext-link-type="uri" xlink:href="http://www.worldofviruses.unl.edu/osmp.shtml">http://www.worldofviruses.unl.edu/osmp.shtml</ext-link>), in which students and teachers created videos and radio programs while spending time in virology research laboratories.</p></sec>
23959975|Materials|('method', 0.9953780610067149)|('other', 0.004621938993285279)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Materials</title><p id="P11">An interview protocol guided the interviewer to cover the eight main topic areas listed above. The protocol contained prompts to encourage the participant to discuss these topics and to probe the participant’s responses more deeply for structural, behavioral, and functional beliefs. For example, the section of the interview about the external appearance of the virus was initiated by asking the participant to describe what a virus looks like. If the participant stated that a virus has “parts on the outside,” then they would be asked to describe what the parts look like, what they do, and what purpose they serve. Prompts for each of the eight key topics are listed in the <xref ref-type="app" rid="APP1">Appendix</xref>. The protocol also helped to ensure that participants discussed the topics in roughly the same order and at a comparable level of detail, while at the same time providing enough flexibility to allow us to capture variations in participants’ mental models.</p><p id="P12">The interviews were recorded using a digital video camera with a microphone. The student interviews were conducted in a quiet room during their participation in the Omaha Science Media Project. The teachers were interviewed before the program in a convenient location, such as their home or office. Experts were interviewed in their office or lab.</p></sec>
23959975|Procedure|('method', 0.9953780610067149)|('other', 0.004621938993285279)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Procedure</title><p id="P13">A trained experimenter interviewed each participant individually. The participant was seated across from the interviewer, and the camera was focused on the participant. At the onset of the interview, the participant was told: “This conversation is for me to find out what you think about viruses. This isn’t about whether your ideas are right or wrong – many of the questions that I’ll ask don’t have a right or wrong answer. I’m just interested in your ideas. Even if you feel you are uncertain, I’d like to hear what’s on your mind. I might ask you to expand on some of your answers, just so that I have a clearer idea about what you are saying.” The interviewer never provided feedback about the accuracy of the participant’s responses; however, the interviewer was instructed to elicit a high level of detail from the participant, and to use prompts when necessary. Each interview began with the same question: what is a virus? The interviews then proceeded on to each of the eight key topics in the order specified above, using the prompts shown in the <xref ref-type="app" rid="APP1">Appendix</xref> when needed. When the participant responded to all of the experimenter’s follow up questions about a topic, or stated that he/she had provided as much detail as they could, a new topic was introduced. There was no standard way to transition to a new interview topic. If a topic had already been mentioned, the interviewer might say: “Let’s bring back the topic of…” If a topic had not been mentioned, they might say: “Let’s move on to the topic of…” Each interview lasted from 60 to 90 minutes.</p></sec>
23959975|Data coding|('method', 0.9953780610067149)|('other', 0.004621938993285279)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Data coding</title><p id="P14">Audio from each interview was transcribed and coded using a system created and refined by two primary researchers and a virologist. The coding captured each participant’s discussion of the eight key topics identified above. To explore expertise-related differences in the depth of their explanations, we coded participants’ responses for the presence of structural, behavioral, and functional descriptions (cf. <xref rid="R23" ref-type="bibr">Hmelo-Silver &amp; Pfeffer, 2004</xref>). For example, if a participant mentioned the specific contents of the virus (e.g., “chemicals, proteins, and germs”, or “nucleic acid, DNA, and RNA”), then this was response was coded as giving a <italic>structural</italic> description of this topic. If participants described how the contents acted (e.g., “DNA splits”, or “DNA uses the enzymes of the host cell”), then we coded their responses as providing a <italic>behavioral</italic> description. These responses were considered behavioral because they describe the mechanism through which a function, i.e., virus replication, is accomplished. Finally, if participants described the purpose or role of a behavior or structure (e.g., “splitting allows the virus to reproduce”, or “the virus DNA uses the host DNA to replicate”), then their utterance was coded as a <italic>functional</italic> description.</p><p id="P15">Two independent research assistants scored each interview for the presence or absence of structures, behaviors, and functions with high reliability (Cohen’s Kappa = .88). Disagreements between the coders were resolved through discussions involving one of the primary researchers.</p><p id="P16">Our qualitative analyses involved identifying the causal claims that participants made about each topic. We created causal schematic diagrams to display the various <italic>entities</italic>—such as the virus and host cell—and <italic>parts</italic>—such as the virus DNA/RNA and the host cell receptors—that participants discussed. The entities and parts are connected in the diagrams through the <italic>relations</italic> that the participants stated, including causal, spatial, and featural relations. The resulting causal diagrams can be taken as a representation of a specific mental model for a topic.</p></sec>
24033137|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24033137|Cell Cultures|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Cell Cultures</title><p id="P4">JB6 Cl41 mouse epidermal skin cells were grown in MEM medium containing 100 units/ml penicillin/streptomycin (Corning Life Sciences) and 5% FBS (Atlanta Biologicals) at 37°C and 5% CO<sub>2</sub> in a humidified incubator. Stably transfected JB6 Cl41 cells containing a pCMV5-Flag-MSK1-A195/NH<sub>2</sub> terminal kinase dead vector (a generous gift from Dr. Yong Yeon Cho, The Hormel Institute, University of Minnesota) were grown under similar conditions.</p></sec>
24033137|Treatments|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Treatments</title><p id="P5">Cells were pretreated with either 50 μm PD 98059, 10 μm SB 202190, 10 μm H89 or a combination of the aforementioned inhibitors (Sigma-Aldrich) 1 h prior to UVB irradiation. UVB light was generated by two 15 W UVB lamps (UVP Inc.) and measured by a UVB meter (UVP Inc.) to determine intensity. Media from the cells to be treated was removed and the cells exposed to the UVB light to obtain a dose of 50 mJ/cm<sup>2</sup>. After treatment the media was returned and the cells incubated until sample collection.</p></sec>
24033137|Western Blot Analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Western Blot Analysis</title><p id="P6">Following treatment, cell lysates were collected at 6 and 24 h time points post UVB irradiation. Whole cell lysates were collected using PhosphoSafe lysis buffer (Sigma-Aldrich) according to the manufacturer’s recommended protocol. Upon collection, samples were prepped and 20–30 μg of protein ran on 10% SDS-polyacrylamide gel. The samples were then transferred to a nitrocellulose membrane and blocked with 5% milk in TBS-T for 1–3 hrs (depending on protein of interest) before being incubated overnight (~18 hrs) with antibodies targeting MSK1, Phospho-T581 MSK1 or β-actin (Santa Cruz Biotechnology). Bands were visualized using the appropriate HRP-conjugated secondary antibodies (Santa Cruz Biotechnology) and exposed to radiosensitive film (HyBlot CL, Denville Scientific).</p></sec>
24033137|Electromoblilty Shift Assay|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Electromoblilty Shift Assay</title><p id="P7">Cytoplasmic and nuclear lysates were prepared in a step wise fashion using Sucrose Buffer (0.32 M sucrose, 10 mM Tris HCl, 3 mM CaCl<sub>2</sub>, 2 mM MgOAc, 0.1 mM EDTA, 0.5% NP-40, 1 mM DTT) to collect cytoplasmic proteins and a Low Salt Buffer (20 mM HEPES, 1.5 mM MgCl<sub>2</sub>, 20 mM KCl, 0.2 mM EDTA, 25% glycerol, 0.5 mM DTT) and High Salt Buffer (Low Salt Buffer with 800 mM KCl and 1% NP-40) to collect nuclear proteins. NF-κB consensus sequence (Santa Cruz Biotechnology) was radiolabeled with <sup>32</sup>P according to the following procedure: 200 ng oligo was incubated with 150 μCi (50 ρmol) [γ-<sup>32</sup>P]-ATP (3000 Ci/mmol 10 mCi/ml, Perkin Elmer), 20 units T4 Kinase, 10X Labeling Buffer (New England Biolabs) and diH<sub>2</sub>O (to give a total of 50 μL) for 1 h at 37° C. The probe was then purified with a QIAquick Nucleotide Removal Kit (Qiagen) according to the manufacturers protocol. The resultant solution was then diluted 15 fold (200 μL to 3000 μL) in TE buffer. For the binding reaction, 30 μg of nuclear lysates were incubated with 1 μL labeled probe, 2 μg poly-dIdC, 5X Binding Buffer (50 mM Tris HCl pH 8.0, 750 mM KCl, 2.5 mM EDTA, 0.5% Triton-X 100, 62.5% glycerol, 1 mM DTT) and diH<sub>2</sub>O (to give 40 μL) for 30 min at room temperature. Samples were then loaded onto a 5% non-denaturing polyacrylamide gel and ran in 0.5X TBE Buffer. Gels were dried and exposed to radiosensitive film at −80° C for 12–48 h to visualize bands. For competition tests and supershift assays, 20 ng unlabeled probe or 1 μg antibodies specific for p50/p65 NF-κB (respectively) were added to the binding reaction prior to the addition of the labeled probe.</p></sec>
24033137|Immunohistochemical staining|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Immunohistochemical staining</title><p id="P8">Cells were plated into a 12-well plate containing glass slide cover slips to allow for mounting then treated with UVB irradiation and specific inhibitors as previously mentioned. Cells were then fixed with a 3.7% formaldehyde/PBS solution for 15 min, washed in PBS and permeabilized in a solution of PBS containing 0.1% TritonX-100 (Sigma-Aldrich). Following an additional PBS rinse, cells were blocked for 1 h (2 mg/mL BSA in PBS) and incubated overnight (~18 h) at 4° C with primary p65 NF-κB antibody binding buffer (200 fold antibody [Santa Cruz Biotechnology] dilution in PBS containing 10 mg/ml BSA and 0.3% TritonX-100). Cells were then rinsed with PBS and incubated with FITC-conjugated secondary antibody buffer (400 fold antibody [Santa Cruz Biotechnology] dilution in PBS containing 10 mg/ml BSA and 0.3% TritonX-100) for 1 h at room temperature, rinsed with PBS and mounted on slides using VectaSheild mounting medium (Vector Laboratories, Inc.) and visualized on a Nikon Eclipse E600 microscope.</p></sec>
24058203|None|('method', 0.8290636402521414)|('other', 0.1709363597478584)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I. Data, Measures, and Methods</title>
24058203|None|('method', 0.8290636402521414)|('other', 0.1709363597478584)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P3">We focus on geographic variation in three sets of outcomes: 1) prescribing patterns, measured by both total pharmacy spending and the ratio of generic drug use to overall drug use; 2) non-drug medical spending, both in total and decomposed into spending on a group of services we term institutional care (inpatient hospital, hospice, skilled nursing home care, rehabilitation facilities, and home care since it often is used following a hospital admission) and non-institutional care (physician, including for convenience inpatient physician services, and other outpatient spending); and 3) the quality of care, including both the quality of prescribing patterns and the quality of primary care.</p>
24058203|None|('method', 0.8290636402521414)|('other', 0.1709363597478584)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P4">Our primary data source is individual-level Medicare claims data. More specifically, we use individual-level demographic, pharmacy, and medical claims data from a 5 percent random sample of Medicare beneficiaries who are enrolled in stand-alone prescription drug (Part D) plans in 2007. We restricted our study sample to beneficiaries who were between 65 and 99 years of age in 2007, alive on December 31 2007, and enrolled for a full year in Part A (institutional care as defined above), Part B (non-institutional care as defined above), and a stand-alone Part D (prescription drug) plan. This sample excludes individuals enrolled in Medicare Advantage (Part C) plans, as well as Medicare beneficiaries who have drug coverage through their prior or current employer because either medical or drug claims data for these beneficiaries are not available. In 2010, 38 percent of Medicare beneficiaries were enrolled in plans like those we excluded (<xref rid="R1" ref-type="bibr">Centers for Medicare &amp; Medicaid Services, 2010a</xref>). We assigned the resulting sample of 533,170 individuals to an HRR on the basis of the beneficiary’s ZIP Code of residence. The spending measures include payments made by drug plans, the patient, Medicare, and any supplementary insurance.</p>
24058203|None|('method', 0.8290636402521414)|('other', 0.1709363597478584)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P5">We deflated medical spending by the county-level wage index using the beneficiary’s county of residence (we only deflated 72 percent of spending because not all of the spending is local labor). We did not similarly deflate drug spending because the geographic price variation was trivial; price indices for 34 prescription drug plan (PDP) regions (except for Alaska) were consistently within two percent of the national price index at the median (<xref rid="R3" ref-type="bibr">Thomas MaCurdy et al., 2009</xref>).</p>
24058203|None|('method', 0.8290636402521414)|('other', 0.1709363597478584)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">Medicare Advantage (MA) plan enrollment varies geographically, which could introduce variation attributable to selection into our measures. To explore this, we calculated penetration rates for MA plans for each HRR using tabulations of the CMS Enrollment File, 2007. We distinguished between two types of plans: private fee-for-service (PFFS) plans and coordinated care plans (MA managed care – mostly Health Maintenance Organizations). Both the PFFS and coordinated care plans are paid a fixed amount per enrollee by Medicare, but PFFS does not have a network and pays physicians per service - like traditional Medicare – so selection patterns could differ for the two types. Data on the overall utilization of the MA population are not yet available, so, like the Dartmouth Atlas of Healthcare data (<xref rid="R6" ref-type="bibr">The Dartmouth Atlas Project, 2010b</xref>), our spending and quality measures encompass only traditional Medicare enrollees.</p>
24058203|None|('method', 0.8290636402521414)|('other', 0.1709363597478584)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">We assessed how the quality of care varies in several ways. We obtained the number of discharges for ambulatory care-sensitive conditions (ACSCs) per 1000 Medicare beneficiaries for each HRR from the Dartmouth Atlas (<xref rid="R6" ref-type="bibr">The Dartmouth Atlas Project, 2010b</xref>). ACSCs are illnesses that should usually not result in hospitalizations if they have been well-managed through outpatient care – that is, they represent medical utilization that is potentially preventable. For example, with proper medication and management of care, most people should not require hospitalization for hypertension (high blood pressure). We capture the quality of prescription use through two measures from the Healthcare Effectiveness Data and Information Set (HEDIS): the percentage of beneficiaries using medications considered sufficiently high-risk for elderly patients that they should be avoided, and the percentage of beneficiaries with dementia, hip fracture, or chronic renal failure who are exposed to potentially harmful drug-disease interactions (<xref rid="R4" ref-type="bibr">National Committee for Quality Assurance, 2010</xref>) (<xref rid="R8" ref-type="bibr">Yuting Zhang, Katherine Baicker and Joseph P. Newhouse, 2010b</xref>). Spending on these drugs constitutes 2 percent of total drug spending (<xref rid="R8" ref-type="bibr">Yuting Zhang, et al., 2010b</xref>).</p>
24058203|None|('method', 0.8290636402521414)|('other', 0.1709363597478584)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">After adjusting for factor prices, we estimated regression models at the individual level for each outcome variable. We used linear regression for pharmacy, hospital, physician, and total non-drug medical spending and logistic regression to estimate the proportion of using high-risk drugs and potentially-harmful drug-disease interactions. In each model, we included 306 HRR indicators, demographic variables, including age (5-year age group indicators from 65-69 to 95-99), gender, and race; characteristics of Part D insurance coverage, including whether the individual received a low-income-subsidy (LIS) and the type of coverage, if any, in the Part D coverage gap; and the Centers for Medicare &amp; Medicaid Services Hierarchical Condition Categories (CMS-HCCs) risk score in the medical spending regression and the analogous CMSRxHCC score for pharmaceutical spending in the drug spending regression (<xref rid="R2" ref-type="bibr">Centers for Medicare &amp; Medicaid Services, 2010b</xref>). (The discharges for ACSCs are not adjusted for CMSHCCs, but the correlations we report below are not sensitive to our inclusion of these risk adjusters.) We used these estimates to calculate an adjusted value for each outcome variable for each HRR, turning on the relevant HRR fixed effect and setting the values of all covariates to their national average. This measure thus captures variation in outcomes at the HRR level that is purged of variation in population characteristics across HRRs.</p>
24058203|None|('method', 0.8290636402521414)|('other', 0.1709363597478584)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">We report several measures that illustrate the extent of geographic variation in each outcome across HRRs, including ratios of 90<sup>th</sup> percentile to the 10<sup>th</sup> percentile; ratios of the 75<sup>th</sup> percentile to the 25<sup>th</sup> percentile; and coefficients of variation. We also investigate the correlations between our outcome measures and report Pearson correlation coefficients.</p>
24108269|None|('method', 0.8745167757750717)|('other', 0.12548322422492827)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Multilevel models for modelling growth trajectories</title>
24108269|2.1. Multilevel models|('method', 0.8745167757750717)|('other', 0.12548322422492827)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.1. Multilevel models</title><p id="P7">Multilevel modelling is one approach that can be used to overcome some of the challenges in modelling longitudinal data. After selecting the appropriate function for age in order to model the average relationship between age and length/height or weight (or any other variable measured longitudinally(<xref rid="R13" ref-type="bibr">13</xref>)), individual-level (level 2) random effects for the intercept and age coefficient(s) capture each individual's deviation from the average trajectory. These individual summaries of the growth trajectory can be extracted and related to later outcomes using a two-step process (<xref rid="R14" ref-type="bibr">14</xref>-<xref rid="R17" ref-type="bibr">17</xref>) or in a single-step process in multivariate models(<xref rid="R13" ref-type="bibr">13</xref>;<xref rid="R18" ref-type="bibr">18</xref>). Individual-specific occasion-level (level 1) residuals are also estimated; these capture measurement error, i.e. the deviation of observed measures from values predicted by the model (<xref rid="R19" ref-type="bibr">19</xref>).</p><p id="P8">In contrast to z-score based analysis approaches, multilevel modelling can capture the shape of growth over time, rather than relying on standardising the scale and variance of growth measures. The changing measurement over time can be explicitly modelled. There is also more flexibility in terms of the data structure; there is no requirement for individuals to have been measured at the same ages (<xref rid="R19" ref-type="bibr">19</xref>), and varying numbers of measurements between individuals can be incorporated. All individuals with at least one observation can contribute to the model under the assumption that data are missing at random (MAR), i.e., that the probability of an observation being missing is related to other observed variables for that individual, but does not depend on the true value of the missing observation (<xref rid="R20" ref-type="bibr">20</xref>). A random slopes model for linear change in an outcome can be written: <disp-formula id="FD1"><label>(1)</label><mml:math display="block" id="M1" overflow="scroll"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>×</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>×</mml:mo><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula> where <italic>y<sub>ij</sub></italic> is the weight for individual <italic>j</italic> at time <italic>i</italic>, and <inline-formula><mml:math display="inline" id="M2" overflow="scroll"><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∼</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mn>0</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> and (<italic>u</italic><sub>0 </sub><sub><italic>j</italic></sub> ,<italic>u</italic><sub>1</sub><sub><italic>j</italic></sub> ) follow a bivariate normal distribution with means of zero and covariance <disp-formula id="FD2"><mml:math display="block" id="M3" overflow="scroll"><mml:mrow><mml:msub><mml:mi>Ω</mml:mi><mml:mi>u</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mtable><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mn>0</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow/></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mn>01</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>u</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula> Here, <italic>β</italic><sub>0</sub> and <italic>β</italic><sub>1</sub>(the “fixed” coefficients) represent the average intercept and slope respectively, and <italic>u</italic><sub>0 </sub><sub><italic>j</italic></sub> and <italic>u</italic><sub>1 </sub><sub><italic>j</italic></sub> (the “random” coefficients) represent the deviation from the average intercept and slope (respectively) for individual <italic>j</italic>. The Best Linear Unbiased Predictions of these residuals are shrunk towards the mean, with estimates for individuals with greater variation (for example, those with fewer growth measures) having greater shrinkage (<xref rid="R21" ref-type="bibr">21</xref>). The occasion-level residuals <italic>e<sub>0ij</sub></italic> represent the measurement error, and have constant variance, but the model can be extended to incorporate a complex variance structure at the occasion-level (<xref rid="R22" ref-type="bibr">22</xref>).</p></sec>
24108269|2.2 Modelling non-linear growth|('method', 0.8745167757750717)|('other', 0.12548322422492827)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.2 Modelling non-linear growth</title><p id="P9">The simple multilevel model for growth shown above represents linear change in the outcome over time. For most biological processes, growth is non-linear. This non-linearity can be incorporated into multilevel models in several ways. One method would be to impose a transformation on either the growth measurements or on age, such that the relationship is approximately linear (<xref rid="R23" ref-type="bibr">23</xref>). This approach is, however, not very flexible and results in growth curves that are difficult to interpret. A more flexible approach is to model the non-linearity by including non-linear age functions in a multilevel model. This requires the best-fitting function of time to be selected. Quadratic or cubic models may fit the data well, but if not, a broader range of curves could be considered by using fractional polynomial models; an approach that has been described in detail elsewhere (<xref rid="R24" ref-type="bibr">24</xref>;<xref rid="R25" ref-type="bibr">25</xref>). Briefly, a series of models are run using each of eight powers of age (-2,-1,-0.5,0,0.5,1,2,3, where a power of zero is the log function), followed by models incorporating each combination of pairs of these powers. For more complex curves, all combinations of multiple powers can also be compared (<xref rid="R26" ref-type="bibr">26</xref>). The best-fitting of these models is then selected, often by comparing the deviance across each model. The equation for a model with two powers of age, <italic>p1</italic> and <italic>p2</italic>, in a multilevel framework is as follows: <disp-formula id="FD3"><label>(2)</label><mml:math display="block" id="M4" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi mathvariant="normal">y</mml:mi><mml:mi>ij</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi mathvariant="normal">j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="thickmathspace"/><mml:mtext>if</mml:mtext><mml:mspace width="thickmathspace"/><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>≠</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi mathvariant="normal">y</mml:mi><mml:mi>ij</mml:mi></mml:msub><mml:mo>=</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi mathvariant="normal">j</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msup><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mi>l</mml:mi><mml:mi>o</mml:mi><mml:mi>g</mml:mi><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">u</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">e</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mspace width="thickmathspace"/><mml:mtext>if</mml:mtext><mml:mspace width="thickmathspace"/><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> where <italic>β<sub>0</sub></italic>, <italic>β<sub>1</sub>and β<sub>2</sub></italic> are the fixed coefficients describing the average shape of the trajectory, and <italic>u<sub>kj</sub></italic> describe the deviation of individual <italic>j</italic>'s trajectory from this average.</p></sec>
24108269|2.3. Linear spline multilevel models|('method', 0.8745167757750717)|('other', 0.12548322422492827)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.3. Linear spline multilevel models</title><p id="P10">A well-fitting multilevel model estimating a curve can be very useful for describing the average pattern of growth, or for assessing the relationship between early exposures and later growth. However, such models are not very conducive to exploring associations between growth and later outcomes, or for comparing growth across populations, since the polynomial terms (and their associations with other variables) are not easily interpreted. One approach that can yield more interpretable growth coefficients is to use a series of linear splines, joined at ‘knot points’, to model the growth trajectory. These models have also been referred to as piecewise linear or broken stick. As an example, a multilevel linear spline model for weight with knots at 3 and 12 months would allow different linear slopes from 0-3 months, 3-12 months, and beyond 12 months, with these slopes varying between individuals.</p><p id="P11">We define <italic>c</italic> knotpoints at times t<sub>k</sub>, k=1,...,c, and define t<sub>0</sub>=0, t<sub>c+1</sub>=max(time). For person <italic>j</italic>, with weight<italic><sub>ij</sub></italic> observed at time t<italic><sub>ij</sub></italic> we create <italic>c</italic>+1 splines <italic>s<sub>ijk</sub></italic>: <disp-formula id="FD4"><mml:math display="block" id="M5" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>For</mml:mi><mml:mspace width="thickmathspace"/><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>.</mml:mo><mml:mo>.</mml:mo><mml:mi mathvariant="normal">c</mml:mi><mml:mo>:</mml:mo><mml:mspace width="1em"/></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi mathvariant="normal">s</mml:mi><mml:mi>ijk</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="thickmathspace"/><mml:mtext>if</mml:mtext><mml:mspace width="thickmathspace"/><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mrow><mml:mi mathvariant="normal">k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow/></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi mathvariant="normal">s</mml:mi><mml:mi>ijk</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mi>ij</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mrow><mml:mi mathvariant="normal">k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mspace width="thickmathspace"/><mml:mtext>if</mml:mtext><mml:mspace width="thickmathspace"/><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&lt;</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow/></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mi mathvariant="normal">s</mml:mi><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mrow><mml:mi mathvariant="normal">k</mml:mi><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mspace width="thickmathspace"/><mml:mtext>if</mml:mtext><mml:mspace width="thickmathspace"/><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>&gt;</mml:mo><mml:msub><mml:mi mathvariant="normal">t</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula> In the multilevel context, a model with <italic>c</italic> knots would then be of the form: <disp-formula id="FD5"><label>(3)</label><mml:math display="block" id="M6" overflow="scroll"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula> where <italic>β<sub>0</sub></italic>,...,<italic>β<sub>c+1</sub></italic> are the fixed coefficients describing the average intercept and average slope between each set of knots, <italic>u<sub>kj</sub></italic> describe the deviation for individual <italic>j</italic> from the average slope between knots <italic>k</italic>-1 and <italic>k</italic>, and <italic>u<sub>0j</sub></italic> is the deviation of individual <italic>j</italic>'s intercept from the average intercept.</p><p id="P12">Several methods for selecting the number and position of knot points are available. We have previously used fractional polynomials to derive a smooth function for the curve, and used the derivatives of this curve to inform the number and position of the knot points (<xref rid="R8" ref-type="bibr">8</xref>;<xref rid="R15" ref-type="bibr">15</xref>). Another possibility would be to start with a large number of knot points, gradually reducing the number until a ‘smooth’ curve is achieved. Other options could be to place knot points at the centiles of the distribution of age, or use stepwise regression to select knots where there is statistical evidence of a difference between the linear slopes either side of the knot point (<xref rid="R27" ref-type="bibr">27</xref>). Subject knowledge of the underlying biology of growth patterns may also inform the choice of knot point positioning, as may the availability of data – studies with few measurement occasions may only be able to place knot points at the mean age of each data collection. In section 3, we describe the process of knot point selection in our example cohorts.</p></sec>
24108269|None|('method', 0.5526804180682994)|('other', 0.4473195819317006)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3. Description of example birth cohort studies</title>
24108269|None|('method', 0.5526804180682994)|('other', 0.4473195819317006)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P13">In this paper, we describe the application of linear spline multilevel models to child growth data in the Avon Longitudinal Study of Parents and Children (ALSPAC) and in the Pelotas 2004 cohort. Details of these two cohorts are provided below. Full details of the remaining three cohorts from which we draw examples (Born in Bradford(<xref rid="R28" ref-type="bibr">28</xref>), Generation XXI and Probit(<xref rid="R29" ref-type="bibr">29</xref>)) are provided in the online supplement; brief details are shown in <xref ref-type="table" rid="T1">Tables 1</xref> and <xref ref-type="table" rid="T2">2</xref>, and are discussed throughout the manuscript where insights can be drawn that are not possible from ALSPAC and the Pelotas 2004 cohort.</p>
24108269|3.1 The Avon Longitudinal Study of Parents and Children (ALSPAC)|('method', 0.5526804180682994)|('other', 0.4473195819317006)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>3.1 The Avon Longitudinal Study of Parents and Children (ALSPAC)</title><sec id="S9"><title>3.1.1 Description of cohort</title><p id="P14">The Avon Longitudinal Study of Parents and Children (ALSPAC) is a prospective cohort study investigating the health and development of children in the South-West of England, the full details of which are published elsewhere (<xref rid="R30" ref-type="bibr">30</xref>;<xref rid="R31" ref-type="bibr">31</xref>). Pregnant women resident in one of three Bristol-based health districts with an expected date of delivery between 1 April 1991 and 31 December 1992 were invited to take part in the study. Of these women, 14,541 were recruited. From these pregnancies, there were 14,062 live-born children, 13,988 of whom were alive at one year. Follow-up has included parent- and child-completed questionnaires, links to routine data, and clinic attendance.</p></sec><sec id="S10"><title>3.1.2 Description of child growth data</title><p id="P15">Length/height and weight data for the children are available from several sources. Birth length and weight are available for most children. Between birth and age five years, measures are available from routine child health clinics for most children, and from research clinic measurements on a random 10% subsample of the cohort. All cohort members were invited to research clinics from age seven onwards. Across all ages parent-reported measures are available. Full details of the measurement protocols are provided in the web supplement. After the exclusion of multiple births (whose growth rates differ considerably from singletons), at least one growth measurement is available for 14,048 children. These children have a combined total of 106,933 length/height measurements and 120,081 weight measurements (median number of measurements per individual 7 for length/height and 8 for weight, interquartile ranges 5 to 9 and 5 to 11 respectively; minimum and maximum number of measurements per child was 1-36 for height and 1-34 for weight).</p></sec></sec>
24108269|3.2 The Pelotas 2004 birth cohort|('method', 0.5526804180682994)|('other', 0.4473195819317006)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>3.2 The Pelotas 2004 birth cohort</title><sec id="S12"><title>2.4.1 Description of cohort</title><p id="P16">From 1/1/2004 to 31/12/2004 inclusive, a population-based birth cohort study attempted to enrol all births from mothers resident in the urban area of the city of Pelotas, Southern Brazil. Births were identified by daily visits to the five maternity hospitals. Mothers were interviewed soon after delivery. Of the 4,263 live births in Pelotas during 2004, 4,231 were enrolled in the cohort study. Follow-ups were done at home at mean (SD) ages 3.0 (0.1), 11.9 (0.2), 23.9 (0.4) and 49.5 (1.7) months; note the small inter-individual variation in the ages at follow-up occasions, which was made possible by the strategy of visiting children in their own homes and planning the visits individually to be as close to the target follow-up age as possible. Further information about the methodology of the 2004 Pelotas birth cohort study is described in detail elsewhere (<xref rid="R32" ref-type="bibr">32</xref>).</p></sec><sec id="S13"><title>3.2.2 Description of child growth data</title><p id="P17">In addition to birth length and weight, length/height and weight were measured at each follow-up; see supplementary material for detailed protocols. The sample size for inclusion in this paper is 4,188 singletons, with a combined total of 19,721 length/height measurements and 19,688 weight measurements (median number of measurements per individual 5 for both length/height and weight, interquartile range 5 to 5 because most children attended all follow-ups).</p></sec></sec>
24108269|3.3. Comparisons between the cohorts|('method', 0.5526804180682994)|('other', 0.4473195819317006)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S14"><title>3.3. Comparisons between the cohorts</title><p id="P18">In addition to differences in year of birth, socioeconomic factors, etc between the cohorts (<xref ref-type="table" rid="T1">Table 1</xref>), there are data differences that have implications for the application of linear spline multilevel models. Within ALSPAC, growth measurements are available from routine health records, from research clinics, and from parent-completed questionnaires. The likely differential accuracy of these measurement sources must be taken into account within the model. The Pelotas 2004 cohort has defined follow-up ages of birth, 3 months, 1, 2 and 4 years. There is very little inter-individual variation in the ages at which children were measured. This is in stark contrast to all of the other four cohorts, which have a much broader spread of ages at measurement. This has implications for model development – in Pelotas 2004 there is little option but to fit the knot points at or around the target ages for follow-ups, whereas in the other four cohorts, models can be tested and compared placing the knot points at various ages. PROBIT combines research clinic and routine healthcare measurements, with very high levels of participation. The Born in Bradford cohort participants are approximately fifty percent of white ethnicity and fifty percent of Pakistani ethnicity. Given the likely differences in growth trajectories between these groups, it is appropriate to model this from the outset. Generation XXI has the greatest frequency of measurements in all the five cohorts. The density of measurements in early infancy means that an additional knot point in the first weeks of life can be included.</p></sec>
24108269|None|('method', 0.9798786144136239)|('other', 0.02012138558637607)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4. Application of linear spline multilevel models for childhood growth</title>
24108269|4.1. Selection of the number and position of knot points|('method', 0.9798786144136239)|('other', 0.02012138558637607)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S16"><title>4.1. Selection of the number and position of knot points</title><p id="P19">The differing data structures necessitated a different strategy to identify and select the knot points within each cohort (<xref ref-type="fig" rid="F1">Figure 1</xref>, Supplementary Figure 1, <xref ref-type="table" rid="T2">Table 2</xref>). Within ALSPAC, growth measurements were available over most of the age range birth to ten years owing to the use of routine health visitor measurements and the wide variability in ages at clinic attendance and completion of questionnaires. Thus there was very little restriction in where the knot points for the linear spline model could be placed. The approach used in this cohort was to estimate the curve that best described the growth data using fractional polynomials, and use this to estimate the approximate number and location of knot points. The best fitting fractional polynomial was established for both length/height and weight by comparing the log likelihood values from models containing one or two age terms. For both height and weight, the best fitting fractional polynomial had the age powers age<sup>3</sup> and age<sup>1/2</sup>. For weight in males, the fixed part of the equation for this best-fitting fractional polynomial was:<list list-type="simple" id="L1"><list-item><p id="P20">weight<sub>ij</sub> = β<sub>0</sub> + β<sub>1</sub>(<italic>t<sub>ij</sub></italic>)<sup>3</sup> + β<sub>2</sub>(<italic>t<sub>ij</sub></italic>)<sup>1/2</sup></p></list-item><list-item><p id="P21">where:</p></list-item><list-item><p id="P22"><italic>t<sub>ij</sub></italic>=age (weeks divided by ten) +0.01 at time <italic>i</italic> for individual <italic>j</italic></p></list-item><list-item><p id="P23">β<sub>0</sub>=2.92 (se=0.023)</p></list-item><list-item><p id="P24">β<sub>1</sub>=0.0007 (se=0.0000004)</p></list-item><list-item><p id="P25">β<sub>2</sub>=3.02 (se=0.006)</p></list-item></list> Note that 0.01 is added to all ages in order to make all ages above zero because some of the fractional polynomial models include log(age) terms. The mean trajectory indicated by the best-fitting fractional polynomial models for length/height and weight in males for the ALSPAC cohort are shown in Supplementary Figure 2. These models indicated that for both weight and length/height, there appeared to be a phase of rapid growth in the first few months of life followed by a slightly slower rate of growth for the rest of infancy (up to approximately one year). For length/height, this was followed by a slightly slower rate of growth between about one and three years and a slower still rate of growth after about three years of age. For weight, the rate of growth seemed to increase after about age seven. In order to select the number and position of knot points, we fit linear spline models with all combinations of the following knot points: Length/Height: early infancy knot point at 2, 3, 4, 5, or 6 months, late infancy knot point at 8, 9, 10, 11, 12, 13, 14, 15, or 16 months, and early childhood knot point at every one month interval between 24 and 48 months. Weight: early infancy knot point at 2, 3, 4, 5, or 6 months, late infancy knot point at 8, 9, 10, 11, 12, 13, 14, 15, or 16 months, early childhood knot point at every one month interval between 24 and 48 months, and late childhood knot point at every one month interval between 60 and 108 months. The ‘best-fitting’ model was selected on the basis of comparing the log likelihoods from each of these models, for males and females separately. This identified the following knot points: for weight for boys knots were birth, 4, 11 and 80 months and for girls were birth, 4, 10 and 80 months; for length/height for boys knot points were birth, 3, 10 and 29 months and for girls were birth, 2, 11 and 32 months. However, for ease of interpretation, presentation of results, and combination of males and females in analyses, we sought to simplify the model. Thus we assessed whether the following knot points resulted in adequate model fit in a model combining males and females, but allowing different average intercepts and slopes by gender: knot points at 3 months, 1 year and 3 years for length/height, and 3 months, 1 year and 7 years for weight. This simplification of the model did not result in appreciably worse model fit (Supplementary Table 1).</p><p id="P26">Within the Pelotas 2004 cohort, growth measurements are only available from follow-ups, around which there is relatively little variability in the participants’ ages at attendance (<xref ref-type="fig" rid="F1">Figure 1</xref>). We therefore fit models in the Pelotas data with the knot points at the planned ages of follow-ups (three months, one year and two years). The slopes for the rate of weight gain between one and two years and two and four years were almost identical. Therefore the final model for weight was chosen as having two knot points, at three months and one year.</p><p id="P27">Knot points for BiB and Generation XXI were selected in a similar manner to ALSPAC. Knot points of 4 and 9 months were found to fit the data best in BiB. In Generation XXI, in addition to 3 and 12 months, a knot point in very early infancy (10 days) was included in the weight trajectory model in order to improve model fit. A slightly different process of knot point selection was used in Probit, which aimed to select the knot points leading the best fit to the fractional polynomial model. Full details for these 3 cohorts are provided in the supplementary material.</p></sec>
24108269|4.2. Including covariates|('method', 0.9798786144136239)|('other', 0.02012138558637607)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S17"><title>4.2. Including covariates</title><p id="P28">In all cohorts, interactions between gender and the intercept and each slope were fitted. Within BiB, interaction terms allowed different average intercepts and slope for White British and Pakistani ethnic groups. Within ALSPAC and BiB, measurements were available from multiple sources with different measurement error. In both cohorts, a dichotomous indicator of measurement source was included in the models as a fixed effect, representing measured (research clinic or health worker) versus parent-reported in ALSPAC, and research clinic versus health worker in BiB. Separating the research clinic and health worker measurements in the ALSPAC model did not improve model fit and so was deemed unnecessary.</p><p id="P29">The growth trajectory in the ALSPAC cohort, with separate intercepts and slopes for males and females and a fixed effect for measurement source, can therefore be represented by the following equation: <disp-formula id="FD6"><label>(4)</label><mml:math display="block" id="M7" overflow="scroll"><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mn>0</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi mathvariant="normal">k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi mathvariant="normal">c</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:munderover><mml:mrow><mml:mo>(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi mathvariant="normal">k</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>l</mml:mi></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>m</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mi>e</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>)</mml:mo></mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mrow><mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mi>s</mml:mi><mml:mi>o</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>c</mml:mi><mml:mi>e</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula> where β<sub>0</sub> is the fixed coefficient describing the average intercept in females, β<sub>1</sub> is the fixed coefficient describing the difference in average intercept between males and females, β<sub>k</sub> are the fixed coefficients describing the average linear slopes in females, β<sub>l</sub> are the fixed coefficients describing the difference in average linear slopes between males and females, β<sub>3</sub> is the fixed coefficient describing the average difference for measurements from parent-reported questionnaires compared with those from research clinics or health workers, u<sub>kj</sub> describe the deviation for individual j from the average slope between knots k-1 and k, and u<sub>0j</sub> is the deviation of individual j's intercept from the average intercept.</p></sec>
24108269|4.2. Complex level 1 variation|('method', 0.9798786144136239)|('other', 0.02012138558637607)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S18"><title>4.2. Complex level 1 variation</title><p id="P30">Since the scale and measurement error of height and weight vary over time, it is desirable to measure the potentially complex nature of level 1 variation. We did this by allowing the within-individual (occasion-level, level 1) variances to vary with time. The way in which complex level 1 variation is modelled varies between outcomes and between datasets, and can make a considerable difference to model convergence and model fit. Possible approaches to parameterising age as a level 1 random effect include as a continuous term, or as each of the linear splines. The details of which functions of age were modelled as complex level 1 variation in each model are provided in the supplementary material.</p><p id="P31">Inclusion of an occasion-level random effect for the measurement source variable in ALSPAC or BiB, gender in all cohorts, or ethnicity in BiB did not improve the differences between observed and predicted measurements, so fixed effects were decided to be sufficient. In each model, we assumed that there was no correlation between the occasion-level random effects. Thus the occasion-level variance/covariance matrix had all off-diagonal terms set to zero.</p></sec>
24108269|4.3. Modelling the variance-covariance matrix of individual-level random effects|('method', 0.9798786144136239)|('other', 0.02012138558637607)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S19"><title>4.3. Modelling the variance-covariance matrix of individual-level random effects</title><p id="P32">We put no constraints on the individual-level variance/covariance matrix for most models. However, for both the Pelotas and BiB length/height models, we could not estimate the covariance between the individual-level random effects for birth length and growth between 0 to 3/4 months. If these covariances were estimated, the model estimated a negative variance for the level 2 random effects for growth between birth and 3/4 months. Similarly, the covariance between birth weight and weight gain between 0-10 days could not be estimated in Generation XXI. This possibly reflects the lower frequency of measurement occasions in Pelotas, and the lack of measured birth length in BiB. Variation between individuals increased gradually over time, whereas that within individuals increased sharply from birth and more slowly after 1 year.</p></sec>
24108269|4.4. Model checking|('method', 0.9798786144136239)|('other', 0.02012138558637607)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S20"><title>4.4. Model checking</title><p id="P33">For all cohorts, most individuals had at least one growth measurement within each time period defined by the linear splines (Supplementary Table 2). One exception was the length trajectories for BiB, where birth length was not measured. For the purposes of comparison in this paper, we have estimated the length trajectories from birth for BiB, but it should be noted that the estimates for birth length will less reliable in BiB than in the other cohorts due to the lack of measured birth length. In order to check the influence of missing birth length on this model, we also fitted models with age centred at 2 weeks and at one month; model fit was similar and estimated mean growth rates in the first period were also similar.</p><p id="P34">Model fit, as judged by the differences between observed growth measurements and those predicted by the models, was good in all models (<xref ref-type="table" rid="T3">Table 3</xref> and Supplementary Table 3). For all cohorts, the individual- and occasion-level residuals were approximately normally distributed (<xref ref-type="fig" rid="F1">Figure 1</xref> and Supplementary Figure 3). There is some evidence that deviation from normality increased as measurements became more sparse, generally as the children get older within each cohort.</p><p id="P35">We plotted the residuals from a linear regression between consecutive level-1 residuals for the same individual against the time difference between the consecutive measures (Supplementary Figure 4) and saw no evidence of autocorrelation. In order to verify that models were not dominated by individuals with either very few or very many growth measures (those with many measures in particular may have different growth patterns compared with the average, e.g. they may be being measured frequently because of failure to thrive), sensitivity analysis were conducted excluding individuals with less than the 25<sup>th</sup> centile number of measurements or more than the 75<sup>th</sup> centile number of measurements. As an example, within the ALSPAC models this resulted in coefficients and individual-level residuals that had correlations ≥0.90 compared with the model including all individuals. An alternative check that we could have performed to check this assumption would be to only include a certain number of measurements for individuals with many measures.</p></sec>
24108269|4.5. Growth patterns within each birth cohort study|('method', 0.9798786144136239)|('other', 0.02012138558637607)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S21"><title>4.5. Growth patterns within each birth cohort study</title><p id="P36">Within each cohort, similar patterns of growth were seen such that rapid length/height growth and weight gain in early infancy were followed by a slowing down of growth in later infancy and early childhood (<xref ref-type="table" rid="T4">Table 4</xref> and Supplementary Table 4). In ALSPAC, where data is available for older ages than the other cohorts, rates of weight gain began to increase again between ages seven and ten years (Figure 4). Rates of growth are broadly similar across the cohorts; the greatest differences are seen at birth, with greater similarity between the cohorts in terms of postnatal growth.</p><p id="P37">The variances and covariances of the level 2 random effects show broadly similar patterns across all cohorts (Supplementary Table 5).</p></sec>
24108269|None|('method', 0.8685449973563503)|('other', 0.13145500264364995)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
24108269|None|('method', 0.8685449973563503)|('other', 0.13145500264364995)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Online-only supplementary material</label><media xlink:href="NIHMS580219-supplement-Online-only_supplementary_material.doc" orientation="portrait" xlink:type="simple" id="d37e1753" position="anchor"/></supplementary-material>
24142472|None|('method', 0.999647385367262)|('other', 0.0003526146327379052)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
24142472|Devices|('method', 0.999647385367262)|('other', 0.0003526146327379052)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Devices</title><p id="P7">IFAST devices were fabricated following previously-described conventional soft lithography techniques<sup><xref rid="R21" ref-type="bibr">21</xref></sup>. In brief, master molds were created by exposing SU-8 photoresist (Microchem, Newton, MA) to UV light through patterned photomasks (Image Setter, Madison, WI). Sylgard 184 polydimethylsiloxane (PDMS) (Dow Corning, Midland, MI) was mixed 10:1 with curing agent, degassed, poured on the master, and cured for four hours at 80°C. Cured devices were applied to cyclic olefin copolymer backing via conformal contact. The devices included multiple aqueous wash wells to ensure contaminants such as red blood cells were removed.</p></sec>
24142472|Blood Samples|('method', 0.999647385367262)|('other', 0.0003526146327379052)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Blood Samples</title><p id="P8">Human whole blood samples from anonymous healthy donors were purchased from Valley Biomedical (Winchester, VA). Samples were validated to be HIV-, hepatitis-, and syphilis-free by the supplier before delivery, and were stored in disodium-EDTA anticoagulant at 4°C. Samples were sequentially numbered and processed immediately upon arrival, as extended storage adversely impacts leukocyte populations<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R22" ref-type="bibr">22</xref></sup>; however, the supplier’s disease testing and shipping took ≥ 3 days, potentially depressing the CD4 count.</p></sec>
24142472|T4 Quant Kit Operation|('method', 0.999647385367262)|('other', 0.0003526146327379052)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>T4 Quant Kit Operation</title><p id="P9">The T4 Quant Kit was operated as directed by the manufacturer. Briefly, 125µL of whole blood were added to 350µL phosphate buffered saline (PBS) and 25µL of anti-CD14 PMPs in an Eppendorf tube. The mixture was incubated on a rotator at room temperature for ten minutes, and then the tube was placed on a magnetic rack for two minutes to perform monocyte depletion. While on the magnet, 200µL of the supernatant blood were pipetted to a new tube containing 200µL PBS and 25µL anti-CD4 PMPs, incubated, and placed on the magnet rack as above. Following two minutes of magnetic separation, the supernatant was aspirated and discarded. The PMP-bound CD4 cells were then washed in 500µL PBS, magnetically pelleted, and resuspended in 50µL Dynal lysis buffer containing 1:1000 Hoechst 33342 DNA dye (Molecular Probes, Eugene, OR). After five minutes of lysis, the solution was diluted in 50µL PBS, the PMPs were pulled aside via the magnet, and the solution was added to a hemocytometer and imaged on an Olympus IX81 fluorescence microscope (Olympus Corporation of the Americas, Center Valley, PA). Cell counts were performed in ImageJ (NIH, Bethesda, MD) and a dilution factor of two was applied to obtain a CD4<sup>+</sup> T<sub>H</sub> cell count per µL of whole blood.</p></sec>
24142472|IFAST Operation|('method', 0.999647385367262)|('other', 0.0003526146327379052)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>IFAST Operation</title><p id="P10">First, monocytes were removed from the samples to prevent counting them as CD4 cells. 2.5µL of whole blood were incubated with 5µL anti-CD14 PMPs and 42.5µL PBS with 5mM EDTA, 1% Tween20, and 0.1% w/v bovine serum albumin (BSA) in a microcentrifuge tube at room temperature for 10 minutes. The solution was loaded via pipette into an IFAST input and the remaining wells were filled with 10µL Fluorinert FC40 oil (Sigma-Aldrich, St. Louis, MO) and 10µL PBS containing 0.01% Tween20 in alternating fashion by pipette. In this report, each oil to aqueous transition constitutes a “wash.” Monocytes were removed by pulling the anti-CD14 PMPs through the immiscible barriers (<xref ref-type="fig" rid="F1">Fig. 1</xref>).</p><p id="P11">To isolate CD4 cells, half of the remaining monocyte-depleted blood was transferred to a new microcentrifuge tube and incubated with 5µL anti-CD4 PMPs and 20µL PBS for 10 minutes at room temperature. Following incubation, the sample was loaded into a new IFAST device and PMP-bound CD4 cells were isolated via the magnet.</p><p id="P12">A fluorescent intracellular dye was used to image and enumerate captured cells. Calcein AM (Molecular Probes, Eugene, OR) was diluted 1:200 in PBS containing 0.1% w/v BSA in the aqueous output well (30µL volume) and the cells were incubated therein for 10 minutes before further analysis.</p></sec>
24142472|Capture Efficiency|('method', 0.999647385367262)|('other', 0.0003526146327379052)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Capture Efficiency</title><p id="P13">To test isolation efficiency, samples were “re-probed” to confirm that the vast majority of target cells were captured upon a single isolation. The IFAST protocol was modified such that both PMP varieties were run twice in series. The anti-CD14-bound cells from the first incubation were imaged and counted, then the remaining input blood was re-incubated with new anti-CD14 PMPs and another isolation was performed in a another IFAST. This provided two counts of cells bound by the same PMP type, indicating what fraction of target cells went uncaptured in the first isolation. The process was repeated on the same samples with CD4 PMPs.</p><p id="P14">In order to compare the CD4 counts obtained by the T4 Quant Kit and IFAST, CD4 cells isolated by IFAST were resuspended in the T4 Quant Kit’s lysis buffer, incubated, and imaged as described in the Kit’s protocol, above.</p></sec>
24142472|Cell Quantitation|('method', 0.999647385367262)|('other', 0.0003526146327379052)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Cell Quantitation</title><p id="P15">Captured cells were initially counted on-chip in IFAST devices by fluorescence microscopy. PMP-bound cells were re-dispersed in the Calcein AM-containing output well and incubated in the dark for 10 minutes at room temperature. The entire output well was then imaged using a 10× objective lens on an IX70 fluorescence microscope (Olympus Corporation of the Americas, Center Valley, PA) on an automated stage directed by a custom journal program in MetaMorph® imaging software (Molecular Devices LLC, Sunnyvale, CA). Images were processed via background subtraction and thresholding in ImageJ. The total counts of fluorescent cells in each device were divided by the volume of whole blood inputted to the CD4 isolation (1.25µL) to yield cells/µL.</p><p id="P16">An inexpensive fluorometer was implemented to distinguish CD4 counts in mock immunocompromised blood. Mock immunocompromised blood was prepared by incubating whole blood with both anti-CD14 and anti-CD4 PMPs simultaneously and isolating the cells in an IFAST device. New whole blood was mixed with this depleted blood to constitute “immunocompromised” blood at several different CD4 counts (e.g., a 50:50 mixture of whole:depleted blood has 50% of the whole blood’s CD4 count). CD4 cells were isolated from these mixtures according to the IFAST protocol above and analyzed in a Qubit® 2.0 Fluorometer (Invitrogen, Carlsbad, CA). PMP-bound cells were re-suspended in PBS containing Calcein AM in Qubit® microtubes (200µL total volume) and incubated for 10 minutes in the dark at room temperature. Fluorescence was quantified by using a 470nm LED from the Qubit®’s dsDNA quantification protocol. Total relative fluorescence units (RFU) readings were collected in triplicate for each of three samples per blood dilution. A linear response between inputted whole blood fraction and detected fluorescence was obtained, even at low CD4 counts.</p></sec>
24142472|None|('method', 0.8740512629726679)|('other', 0.1259487370273321)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
24142472|None|('method', 0.8740512629726679)|('other', 0.1259487370273321)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Figure S1</label><media xlink:href="NIHMS651889-supplement-Figure_S1.pdf" orientation="portrait" xlink:type="simple" id="d37e506" position="anchor"/></supplementary-material>
24142472|None|('method', 0.8740512629726679)|('other', 0.1259487370273321)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD2"><label>Video SV1</label><media xlink:href="NIHMS651889-supplement-Video_SV1.flv" orientation="portrait" xlink:type="simple" id="d37e510" position="anchor" mimetype="video"/></supplementary-material>
24148148|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24148148|Cell culture|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Cell culture</title><p id="P6">The normal human fibroblast cell line NHF1-hTERT was derived from neonatal foreskin fibroblasts (<xref rid="R24" ref-type="bibr">24</xref>) and immortalized by ectopic expression of the catalytic subunit of human telomerase (<xref rid="R18" ref-type="bibr">18</xref>). The xeroderma pigmentosum variant (XPV) cell line GM02359-hTERT (XP115L0) was derived in the laboratory of Dr. Roger A. Shultz (University of Texas Southwestern Medical Center, Dallas, TX; [<xref rid="R25" ref-type="bibr">25</xref>]) and clone 1B (<xref rid="R26" ref-type="bibr">26</xref>) was compared with NHF1 in the studies reported here. Cells were cultured in minimum essential medium (MEM) supplemented with 2 mM L-glutamine and 10% fetal calf serum. GM02359-hTERT cells were additionally supplemented with 1× MEM nonessential amino acids (Gibco). All cell cultures were maintained at 37°C in humidified 95% air and 5% CO<sub>2</sub>.</p></sec>
24148148|Irradiation|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Irradiation</title><p id="P7">Cells were rinsed in phosphate-buffered saline (PBS) prior to irradiation and all cell culture plates were irradiated with lids removed. UVC irradiations were performed with a germicidal fluorescent lamp (Sylvania G8T5, 90% emission at 254 nm). UVB irradiations were performed with two Philips TL20W/01 NB-UVB fluorescent lamps emitting between 300 and 315 nm, with a maximum emission at 312 nm. Sunlight simulating UVA–UVB irradiations were performed with four Houvalite F20T12BL/HO PUVA lamps; this source emits wavelengths between 300 and 400 nm (94.3% UVA and 5.7% UVB), with a peak at 350 nm; hence, it is identified in the text as either the UVA–UVB or the solar simulator source. UVC irradiations were performed with no liquid in the plates, whereas PBS was used to cover the cultures during UVB and UVA–UVB exposures (as detailed below). Sham-irradiated plates were handled the same way minus the exposure to UVR. These control plates were covered with aluminum foil and placed in the irradiation chamber along with those exposed to the highest fluence used in the experiment. Lamp irradiance was measured using a UVX Digital Radiometer (UVP, LLC) and the following sensors: UVX-25 (250–290 nm range, calibrated at 254 nm), UVX-31 (280–340 nm range, calibrated at 310 nm) and UVX-36 (335–380 nm range, calibrated at 365 nm).</p></sec>
24148148|Cytoxicity|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Cytoxicity</title><p id="P8">UVR-induced inhibition of [<sup>3</sup>H]-thymidine incorporation was measured as an index of cytotoxicity, as described previously (<xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref>). This short-term assay for inhibition of cell proliferation yields results in close agreement with those based on reduction in efficiency of colony formation (<xref rid="R27" ref-type="bibr">27</xref>). Logarithmically growing cells were seeded in 6-well plates at 1000 cells per well. The following day, cells were rinsed with PBS and irradiated with increasing fluences of the specified UVR sources; 500 μL or 1 mL PBS was used to cover cells in each well during irradiation with UVB or UVA–UVB, respectively. Approximately 72 h post irradiation, cells were pulse labeled for 60 min at 37°C in medium containing 2 μCi mL<sup>−1</sup> [<sup>3</sup>H]-thymidine. Afterward, the plates were placed on ice and the wells rinsed 2× with cold PBS. Cells were then fixed in 5% trichloroacetic acid (TCA) for 30 min and rinsed 2× with 5% TCA and 2× with 95% ethanol. Fixed cells were allowed to dry overnight and then dissolved for 1 h in 1 mL of 0.3 M sodium hydroxide. Equal volumes of solubilized cells were analyzed by liquid scintillation counting.</p></sec>
24148148|Immuno-slot-blot quantification of CPD|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Immuno-slot-blot quantification of CPD</title><p id="P9">Cell cultures were irradiated in 10 cm dishes after rinsing and removing the liquid from the plates (UVC), or while covered with 2 mL (UVB) or 6 mL (UVA–UVB) PBS. DNA from irradiated cells was purified using a Qiagen DNeasy Blood and Tissue kit, using RNase A to remove RNA in the samples, and CPD quantified as published (<xref rid="R29" ref-type="bibr">29</xref>). After denaturation at 100°C for 10 min, 200 ng of DNA was combined with an equal volume of 2 M ammonium acetate and placed on ice. Each DNA sample was spotted onto a nitrocellulose membrane (equilibrated in 1 M ammonium acetate) in triplicate, using a Minifold slot-blot manifold (Schleicher &amp; Shuell). Membranes were then washed in 5× saline sodium citrate buffer for 15 min in a 37°C water bath and dried in a vacuum oven for 30 min at 80°C. After blocking in 5% powdered milk in TBST (0.5% Tween-20, 10 mM Tris-HCl, 10 mM NaCl, pH 7.4), membranes were probed with mouse anti-CPD antibody (Cosmo-Bio, NMDND001). Following secondary antibody application (HRP-conjugated, GE Healthcare), enhanced chemiluminescence (ECL) was used to detect on film the antibody-dependent signal from each DNA band. Densitometry of film bands was performed using an Alpha Innotech Fluor-Chem HD2. Each membrane contained a standard curve prepared from UVC-irradiated calf-thymus DNA, in which the CPD density had previously been determined by radioimmunoassay (RIA).</p></sec>
24148148|Radioimmunoassay|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Radioimmunoassay</title><p id="P10">Radioimmunoassay was used to quantify CPD and 6-4PP. RIA is a competitive binding assay between radiolabeled DNA and sample DNA for antisera raised against UV-irradiated DNA. DNA damage frequencies in samples used for the standard curve were determined using HPLC tandem mass spectrometry (Thierry Douki, CEA, Grenoble). These details, as well as those concerning the specificities of the RIAs and standards used for quantification, are described in (<xref rid="R30" ref-type="bibr">30</xref>–<xref rid="R32" ref-type="bibr">32</xref>).</p></sec>
24148148|Western blotting and antibodies|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Western blotting and antibodies</title><p id="P11">Cells were harvested by trypsinization 1 h after irradiation, pelleted and flash frozen in liquid nitrogen. Cell pellets were resuspended in urea lysis buffer (8 M urea, 5 M NaH<sub>2</sub>PO<sub>4</sub>, 1 M Tris-HCl pH 8) for 30 min on ice and then clarified by centrifugation at 16 000 × <bold><italic>g</italic></bold> and 4°C. Protein concentrations were determined using the Bio-Rad Protein Assay kit. Protein lysates were combined with equal volumes of loading buffer (125 mM Tris pH 6.8, 20% glycerol, 10% <italic>β</italic>-mercaptoethanol, 4% sodium dodecyl sulfate, 0.05% bromo-phenol blue) and equal amounts of protein were loaded onto BioRad Criterion-TGX 4%–15% gradient gels (run at approximately 150–200 V for 2–4 h). Size-separated proteins were transferred (100 mA, overnight) onto a nitrocellulose membrane, and blocked in 5% powdered milk in TBST. The following antibodies were used: rabbit anti-P-CHK1 S345 (2348s Cell Signaling), mouse anti-CHK1 (SC-8408, Santa Cruz) and goat anti-ACTIN (SC-1616, Santa Cruz). Following incubation with secondary antibody (HRP-conjugated, GE Healthcare), bands were visualized on film by ECL. Densitometry of film bands was performed using an Alpha Innotech Fluor-Chem HD2.</p></sec>
24148148|Velocity sedimentation|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Velocity sedimentation</title><p id="P12">The steady-state size distribution of nascent DNA was determined 45 min after UV irradiation by centrifugation in an alkaline sucrose density gradient as described previously (<xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R33" ref-type="bibr">33</xref>). Cells were plated onto 60 mm culture dishes and their DNA uniformly prelabeled by incubation with 5–10 nCi mL<sup>−1</sup> [<sup>14</sup>C]-thymidine for at least 36 h during logarithmic growth. Medium containing [<sup>14</sup>C]-thymidine was removed and the cultures incubated overnight in fresh, label-free medium. The following morning, this medium was collected and reserved for use during the post irradiation incubation. Cells were covered with 2 mL PBS during exposure to the solar simulator source. After UV irradiation, cells were incubated for 30 min in the reserved medium and then pulse labeled with 25 μCi mL<sup>−1</sup> [<sup>3</sup>H]-thymidine for 15 min. Cells were washed, then scraped on ice into 0.1 M NaCl, 0.01 M EDTA (pH 8) and 0.5 mL added to an equal volume of lysis buffer (1 M NaOH, 0.02 M EDTA) on top of an alkaline sucrose gradient (5%–20% sucrose in 0.4 M NaOH, 2 M NaCl, 0.01 M EDTA). These gradients were left under fluorescent lighting for 45 min and then centrifuged in a Beckman SW32Ti rotor at 25 000 rpm (46 800–106 800 <bold><italic>g</italic></bold>) and 20°C for 5 h. Gradients were fractionated into equal volumes through a hole punctured in the bottom of the centrifuge tube and acid-precipitable material filtered onto glass microfiber filters (Whatman GF/C 24 mm), which were then analyzed by liquid scintillation counting. All experiments included cells prelabeled with [<sup>14</sup>C]-thymidine, but not pulse labeled with [<sup>3</sup>H]-thymidine, which were used to measure the <sup>14</sup>C CPM values detected in the <sup>3</sup>H channel (spillover) during liquid scintillation counting. Normalized <sup>3</sup>H CPM were the counts in each fraction detected in the <sup>3</sup>H channel, corrected for the <sup>14</sup>C spillover, and divided by the total <sup>14</sup>C in the gradient (proportional to the number of cells analyzed).</p></sec>
24148148|HAT selection|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>HAT selection</title><p id="P13">Cells used for mutagenesis experiments were preselected for functional HPRT by expanding cultures for 10–14 days in medium supplemented with 1× HAT (<xref rid="R34" ref-type="bibr">34</xref>). The 100× lyophilized HAT solution contains 10 mM sodium hypoxanthine, 40 M aminopterin and 1.6 mM thymidine. Aliquots of HAT selected cells were stored frozen in liquid nitrogen. A new aliquot was used for every <italic>HPRT</italic> mutagenesis experiment; cells were replated directly in culture medium without HAT and expanded for 10–14 days prior to mutagenesis experiments.</p></sec>
24148148|Mutagenesis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Mutagenesis</title><p id="P14">Cells were plated at 5 × 10<sup>5</sup> per 10 cm dish (2 dishes per treatment) and irradiated the following day. Cell cultures were irradiated after rinsing and removing the liquid from the plates (UVC), or while covered with 6 mL PBS (UVA–UVB). These cultures were maintained in logarithmic growth for 4–6 population doublings prior to selection. <italic>HPRT</italic> mutants were selected by plating 4 × 10<sup>4</sup> cells per 10 cm dish (55 dishes per treatment) in medium containing 40 μM 6-thioguanine. Colony-forming efficiency was determined at the time of mutant selection by plating 400 cells per dish in medium lacking 6-thioguanine. After 2 weeks, colonies were fixed in 3:1 methanol:acetic acid and stained with 0.05% crystal violet. Colonies with more than 50 cells were counted. Mutation frequencies were calculated from the number of plates without any mutant colonies, using the Poisson distribution as follows: (−ln [number of plates without 6-thioguanine resistant colonies/total number of plates])/([number of cells plated for selection] × [colony-forming efficiency at time of selection]).</p></sec>
24148148|Statistical methods|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Statistical methods</title><p id="P15">Statistical comparisons were performed to determine whether 6-4PP density, cytotoxicity, CHK1 phosphorylation, inhibition of replicon initiation, inhibition of DNA strand growth and mutagenicity varied significantly between different sources of UVR. The linear regression model was used to carry out the data analysis for estimating various parameters of interest with appropriate 95% confidence intervals, and hypothesis testing. Specifically, the linear model was used to model the density of 6-4PP and the inhibition of DNA strand growth as response variables with the density of CPD, the radiation source and their interactions as covariates. Wald statistics were used to determine the statistical significance of the comparisons. The Wilcoxon rank-sum test was used to do the group-wise comparisons at different CPD levels and sources of UVR for cell survival percentage, normalized ratios of PCHK1 to total CHK1, inhibition of replicon initiation and the mutation frequencies. Exact test statistics were used to determine the statistical significance of the comparisons. All statistical analyses were performed using SAS 9.3 (SAS Institute Inc., Cary, NC).</p></sec>
24148148|None|('method', 0.9590535080663006)|('other', 0.04094649193369937)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
24148148|None|('method', 0.9590535080663006)|('other', 0.04094649193369937)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><media xlink:href="NIHMS566706-supplement-supplement_1.pdf" orientation="portrait" xlink:type="simple" id="d37e848" position="anchor"/></supplementary-material>
24201013|None|('method', 0.9999190916198724)|('other', 8.090838012757088e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Materials and Methods</title>
24201013|2.1. Sequence design and motion correction|('method', 0.9999190916198724)|('other', 8.090838012757088e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1. Sequence design and motion correction</title><sec id="S4"><title>2.1.1. Spatial localization</title><p id="P17">VOI localization in our 3D-MRSI measurements was achieved by a B<sub>1</sub>-insensitive LASER sequence (<xref rid="R3" ref-type="bibr">Andronesi et al., 2012</xref>; <xref rid="R4" ref-type="bibr">Andronesi et al., 2010</xref>; <xref rid="R15" ref-type="bibr">Garwood and DelaBarre, 2001</xref>). Excitation was performed by a non-selective adiabatic half passage pulse (HS8 modulation; duration 4 ms; bandwidth 5 kHz). Three pairs of Gradient Offset Independent Adiabatic (GOIA) pulses (W16,4 modulation; 3.5 ms duration and 20 kHz bandwidth) guaranteed accurate LASER localization with low power requirements and negligible chemical shift displacement errors (<xref rid="R4" ref-type="bibr">Andronesi et al., 2010</xref>; <xref rid="R33" ref-type="bibr">Tannus and Garwood, 1997</xref>). A minimum echo time (TE) of 27 ms can be achieved by eliminating spoilers for the first five GOIA pulses. Our data were acquired with a TE of 30 ms to allow comparison with the bulk of the MRSI papers that use PRESS excitation.</p><p id="P18">Time efficient data acquisition was achieved by spiral encoding in the (k<sub>x</sub>,k<sub>y</sub>)-plane using constant-density spiral trajectories (<xref rid="R1" ref-type="bibr">Adalsteinsson et al., 1998</xref>). Gradient delays of 8 μs between the ADC and the X and Y gradients were measured, and corrected for in the reconstruction. Phase encoding gradients were superimposed over the last Z-spoiler gradient of the LASER sequence to encode along the z direction. This resulted in a cylindrical 3D-coverage of the k-space by a stack of spirals.</p></sec><sec id="S5"><title>2.1.2. Volumetric navigator</title><p id="P19">For the detection of real-time motion and B<sub>0</sub>-field distortion a dual-contrast, multi-shot 3D-EPI navigator was inserted prior to the water suppression module of the 3D-MRSI sequence. This vNav determined the required shim, frequency, and head pose changes (if any) once per TR, and allowed corrections within the same TR. The vNav protocol parameters selected for this study were: TR 17 ms; TE<sub>1</sub>/TE<sub>2</sub> 7/9.4 ms; matrix 32×32; 18 slices; FOV 256×256×144 mm<sup>3</sup>; 8 mm isotropic resolution; bandwidth 3906 Hz/pixel; flip angle 2°. The small flip angle does not observably affect the spins available for excitation (<xref rid="R18" ref-type="bibr">Hess et al., 2011</xref>). The two imaging contrasts (i.e., TE<sub>1</sub>/TE<sub>2</sub>) were generated with interleaved partition acquisitions. Additional reference k-space lines for N/2-ghosting correction were measured. The total navigator duration was 612 ms. The navigator was positioned over the subject’s brain using a “setter” sequence that was run prior to the 3D-MRSI sequence adjustment. Besides positioning, the “setter” sequence allows definition of all important vNav sequence parameters including TR, TE<sub>1</sub>/TE<sub>2</sub>, flip angle, FOV, slices, matrix size, readout bandwidth, and echo spacing. This “setter” sequence takes only one second and adjusts the protocol parameters of the vNav that is subsequently run inside the 3D-MRSI sequence.</p><p id="P20">For each TR, pose changes are computed online by co-registering the magnitude image (i.e., the first TE<sub>1</sub> contrast) of the current vNav (<xref rid="F1" ref-type="fig">Figure 1</xref>) to the initial vNav, using PACE (Prospective Acquisition Correction) (<xref rid="R34" ref-type="bibr">Thesen et al., 2000</xref>). This information was used to update all imaging gradients and RF pulses responsible for VOI and FOV positioning. In addition, field maps (<xref rid="F1" ref-type="fig">Figure 1</xref>) were reconstructed from phase maps of both contrasts using PRELUDE (Phase Region Expanding Labeller for Unwrapping Discrete Estimates) (<xref rid="R19" ref-type="bibr">Jenkinson, 2003</xref>). Two sets of zero-/first-/second-order shim terms were calculated online, one for the MRSI VOI and one for the navigator FOV. The shim estimate for the navigator was calculated using an unweighted least squares regression. The shim estimate for the VOI used a weighted least squares regression, where the weighting of each navigator voxel is according to its intersection with the VOI. Only zero- and first-order shim terms were applied. Second-order shim terms were obtained, but could not be updated with available hardware. All online calculations were performed in less than 150 ms. Thus, the total block, including navigator acquisition (612 ms) and online processing (150 ms), takes ~760 ms. Navigator acquisition, updating, and all of the image reconstruction was fully implemented and integrated on the scanner.</p></sec><sec id="S6"><title>2.1.3. Real-time sequence updating</title><p id="P21">When moving a VOI that is determined by gradient-modulated pulses, simply adding a constant frequency offset for the selective pulses is not sufficient. For gradient-modulated pulses (e.g., GOIA), the total phase modulation <italic>ϕ<sub>total</sub></italic> that determines slice thickness and position has a slice-offset Z-dependent component, <italic>ϕ<sub>off</sub></italic>, and an offset-independent component, <italic>ϕ<sub>iso</sub></italic>. For real-time changes in position offset <italic>z</italic>, only the gradient-modulated <italic>G(τ)</italic> and <italic>z</italic>-dependent <italic>ϕ<sub>off</sub></italic> has to be updated each TR: <disp-formula id="FD1"><label>(Eq.1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:msub><mml:mi>ϕ</mml:mi><mml:mi mathvariant="italic">total</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>z</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mi mathvariant="italic">iso</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mi mathvariant="italic">off</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>z</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>ϕ</mml:mi><mml:mi mathvariant="italic">iso</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mrow><mml:munderover><mml:mo>∫</mml:mo><mml:mn>0</mml:mn><mml:mi>t</mml:mi></mml:munderover><mml:mrow><mml:mi>γ</mml:mi><mml:mi>z</mml:mi><mml:mi>G</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>τ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>·</mml:mo><mml:mi>d</mml:mi><mml:mi>τ</mml:mi></mml:mrow></mml:mrow></mml:math></disp-formula></p><p id="P22">For FOV readjustments, phase encoding and spiral encoding were updated independently. Phase encoding in the z-direction was updated by adding a constant excitation phase roll during sequence run-time to account for translation as traditionally performed for off-center MRSI scans.</p><p id="P23">Offsets in the spiral-encoded directions, i.e. in the (k<sub>x</sub>,k<sub>y</sub>)-plane cannot be corrected for using a constant phase roll, because of non-cartesian k-space sampling. Therefore, motion in the x/y-plane is corrected for during online image reconstruction by adding a corresponding phase roll in the x- and y-directions before gridding and combination of the different temporal and angular interleaves.</p><p id="P24">Real-time rotations updates were implemented by rotating the phase encoding and spiral encoding gradients per vNav output. The reference frequency and phase of the excitation pulse, refocusing pulses, water suppression pulses, and ADC readout were updated according to the vNav. Shim updating was performed during each TR prior to water suppression.</p></sec></sec>
24201013|2.2. Scanner hardware|('method', 0.9999190916198724)|('other', 8.090838012757088e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>2.2. Scanner hardware</title><p id="P25">All <italic>in vivo</italic> measurements were performed on a 3T TIM Trio MR scanner (Siemens Healthcare, Erlangen, Germany) using the body coil for transmission and a standard 12-channel head coil (Siemens Healthcare, Erlangen, Germany) for signal reception. Localization phantom measurements were performed using the body coil for signal reception and transmission, to allow the simulation of large translations (i.e., up to 10 cm).</p></sec>
24201013|2.3. Phantoms|('method', 0.9999190916198724)|('other', 8.090838012757088e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.3. Phantoms</title><p id="P26">For localization and frequency drift tests, two different phantoms were used. The first phantom was a cylindrical, multi-compartment phantom that contained water and three tubes, each filled with a chemical compound of different spectral appearance (i.e., acetate, ethanol, and isopropyl alcohol) and with similar concentrations. Different amounts of Gd-DPTA (Magnevist) were used to reduce overall T<sub>1</sub> relaxation times and to enable good visual differentiation of the three tubes and surrounding water (<xref rid="F2" ref-type="fig">Figures 2</xref>–<xref rid="SD2" ref-type="supplementary-material">5</xref>). The second phantom was a spherical spectroscopy phantom (i.e., containing brain metabolites).</p><sec id="S9"><title>2.3.1. Localization correction</title><p id="P27">The accuracy of the implemented prospective ShMoCo was verified using the multi-compartment phantom by performing different kinds of movement, which included translation of at most 5–8 cm, and rotations between 30°–45° (note: the maximum possible movement is limited by the registration algorithm to 8° rotation and 2 cm translation per TR). To investigate the accurate correction for both rotation and translation in phase-encoded and spiral-encoded directions, the following standardized movement patterns were performed: (a) right-left (spiral-encoded in-plane) translation; (b) head-feet (phase-encoded through-plane) translation; (c) transversal (spiral-encoded in-plane) rotation; and (d) coronal (phase/spiral-encoded through-plane) rotation (<xref rid="F2" ref-type="fig">Figures 2</xref>–<xref rid="SD2" ref-type="supplementary-material">5</xref>).</p><p id="P28">For each movement pattern, four measurements were performed and compared: 1) one static measurement without ShMoCo; 2) one static measurement with ShMoCo; 3) one motion-degraded measurement without ShMoCo; and 4) one motion-degraded measurement with ShMoCo during the acquisition.</p><p id="P29">The following measurement parameters were used for phantom testing: TR/TE 1500/30 ms; 0.25cc isotropic voxels; 32×32×16 matrix; no interpolation; FOV 200×200×100 mm<sup>3</sup>; VOI 120×120×60 mm<sup>3</sup>; spectral acquisition bandwidth 1.25 kHz; two temporal and ten angular interleaves; one average; four preparation scans; no water suppression; TA 8:08 min. An automated gradient echo imaging-based shimming routine was used to set the initial B<sub>0</sub> shim.</p></sec><sec id="S10"><title>2.3.2. Scanner frequency drift/B<sub>0</sub> correction</title><p id="P30">Frequency drift during a 3D-MRSI scan with standard-resolution in a static spherical brain metabolite phantom was assessed using the following 3D-MRSI protocol: TR/TE 1600/30 ms; 20×20×12 matrix; FOV 200×200×120 mm<sup>3</sup>; VOI 80×80×80 mm<sup>3</sup>; spectral acquisition bandwidth 1.25 kHz; two temporal and four angular interleaves; eight averages; TA 20:35 min.</p></sec></sec>
24201013|2.4. 3D-MRSI of human subjects|('method', 0.9999190916198724)|('other', 8.090838012757088e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11" sec-type="subjects"><title>2.4. 3D-MRSI of human subjects</title><p id="P31">For <italic>in vivo</italic> validation, four measurement sessions were performed on three healthy volunteers (two males, one female; age, 31±1years). Institutional Review Board approval and written, informed consent was obtained. For all three volunteers, standard-resolution scans (i.e., 20×20×12 matrix with 1cc isotropic resolution) were performed with moderate motion. In addition, one volunteer was also measured a second time using longer high-resolution scans (i.e., 25×25×12 matrix with 0.5cc isotropic resolution) with more severe motion.</p><p id="P32">Each <italic>in vivo</italic> measurement session began with a structural MEMPRAGE sequence (<xref rid="R38" ref-type="bibr">van der Kouwe et al., 2008</xref>) to guide initial VOI localization. To save measurement time, only the most likely motion patterns for <italic>in vivo</italic> situations were performed (i.e., right-left head rotation, chin up-down rotation, head-feet translation). The motion patterns were kept simple to ensure good reproducibility.</p><p id="P33">After each motion-degraded experiment, the volunteers were instructed to return to their original position. Localizer images were repeatedly acquired to validate that the subjects had indeed returned to their initial position. To further ensure the reproducibility of initial head position relative to the VOI/FOV adjustment, AutoAlign was run prior to each MRSI scan (<xref rid="R5" ref-type="bibr">Benner et al., 2006</xref>; <xref rid="R40" ref-type="bibr">van der Kouwe et al., 2005</xref>). Gradient echo imaging based shimming was repeated after each motion scan to set the initial B<sub>0</sub> shim. All subjects were briefed and trained in a short test session prior to the actual movement experiments. For standard resolution MRSI, the volunteers were instructed to move their head slowly over a time span of one minute per motion task. and there was only one type of motion task tested during a given scan. For the high resolution MRSI scan, all three motion tasks were performed during the same scan, each task for one minute separated by equally spaced static periods. An audio cue was given at the start and end of each movement subtask.</p><sec id="S12"><title>2.4.1. Short standard-resolution scan – moderate motion</title><p id="P34">All volunteers performed a total of eight scans. This included four sets of experiments with each set focusing on one of four specific (motion) tasks (i.e., static case, right-left head rotation by 22±3°, chin up-down rotation by 14±2°, head-feet translation by 20±2 mm). Each set consisted of two measurements: one with and one without ShMoCo. Excluding training and instructions, each measurement session was ~70–90 min long.</p><p id="P35">The following <italic>in vivo</italic> 3D-MRSI sequence parameters were used: TR/TE 1600/30 ms; 1cc isotropic voxels; 20×20×12 matrix interpolated to a 32×32×16 matrix; FOV 200×200×120 mm<sup>3</sup>; VOI 110×90×50 mm<sup>3</sup>; bandwidth 1.25 kHz; two temporal and four angular interleaves; two averages; four preparation scans; TA 5:14 min.</p></sec><sec id="S13"><title>2.4.2. Long high-resolution scan – severe motion</title><p id="P36">One volunteer also performed three longer measurements. As there was no difference expected between static high-resolution scans with and without ShMoCo based on the previously evaluated standard-resolution scans as well as previous reports (<xref rid="R17" ref-type="bibr">Hess et al., 2012</xref>; <xref rid="R18" ref-type="bibr">Hess et al., 2011</xref>) and to shorten the total measurement protocol, only one static scan was performed. Thus, there was one static and two complex motion tasks (i.e., combination of right-left head rotation by 20°, chin up-down rotation by 14°, and head-feet translation by 20 mm)(<xref rid="F4" ref-type="fig">Figure 6</xref>).</p><p id="P37">The following <italic>in vivo</italic> 3D-MRSI sequence parameters were used: TR/TE 1600/30 ms; 0.5cc isotropic voxels; 25×25×12 matrix interpolated to a 32×32×16 matrix; FOV 200×200×96 mm<sup>3</sup>; VOI 110×88×50 mm<sup>3</sup>; bandwidth 1.25 kHz; two temporal and six angular interleaves; four averages; four preparation scans; TA 15:28 min.</p></sec></sec>
24201013|2.5. Data evaluation and statistical analysis|('method', 0.9999190916198724)|('other', 8.090838012757088e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S14"><title>2.5. Data evaluation and statistical analysis</title><p id="P38">Statistical analysis was performed and plots were created using SPSS (v15.0; Chicago, Ill).</p><p id="P39">Localization accuracy and spectral quality were evaluated qualitatively (i.e., visual assessment of spectral quality and metabolic maps) and quantitatively (i.e., linewidth, SNR, metabolic ratios, Cramer-Rao lower bounds (CRLB)). For quantitative evaluation, a mask was drawn, which excluded ventricles and voxels that were partly outside the VOI and only voxels inside this mask were further processed. All <italic>in vivo</italic> spectra were quantified by LCModel software (<xref rid="R30" ref-type="bibr">Provencher, 2001</xref>), and metabolic ratios, as well as spectral quality parameters (i.e., SNR and linewidth of NAA) were calculated. The mean and the standard deviation of the metabolitic ratios, the SNR, linewidth, and CRLB were determined inside the mask to assess global changes in spectral quality and quantification.</p><p id="P40">To investigate also local changes, Bland-Altman plots were drawn for metabolic ratios, the SNR, linewidth, and CRLB using the static measurement without ShMoCo as the reference standard. The parameter means and the limits of agreement (1.96 times the standard deviation) were derived. Paired t-tests across all voxels and subjects were performed for all parameters to compare the reference standard (i.e., for standard resolution scans – static scan without ShMoCo; for high resolution scan – static scan with ShMoCo) with all remaining scans. A p&lt;.05 was considered statistically significant.</p></sec>
24220038|None|('method', 0.9995969241236775)|('other', 0.0004030758763224758)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24220038|Subjects|('method', 0.9995969241236775)|('other', 0.0004030758763224758)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3" sec-type="subjects"><title>Subjects</title><p id="P7">Eleven healthy, right-handed volunteers (mean age, 26 years; range: 22–35 years; 2 females), with no known history of motor impairment participated in this study, after obtaining written informed consent approved by the local ethics committee. Exclusion criteria were: professional musicians for potentially bilateral increased use of upper extremities and smokers for possible brain structure and functional changes induced by nicotine administration and addiction (<xref rid="R46" ref-type="bibr">Lee et al., 2013</xref>). One subject played the violin non-professionally. All subjects were naive to the experimental setup.</p></sec>
24220038|Body Machine Interface|('method', 0.9995969241236775)|('other', 0.0004030758763224758)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Body Machine Interface</title><p id="P8">Body Machine Interfaces (BMI) translate signals derived from body motions into commands for external devices (see (<xref rid="R15" ref-type="bibr">Casadio et al., 2012</xref>) for a review). Subjects controlled a computer cursor with bilateral simultaneous movements of the shoulders and upper arms. The body signals were recorded non-invasively with four infrared video cameras (V100, Naturalpoint Inc., OR, USA) that tracked four small, low cost, active infrared markers (two on the shoulders and the other two on the upper arms), and converted into the two coordinates of the cursor in real-time with a custom software package (Modification of a C++ Software Development Kit supplied by Naturalpoint). This was a many-to-one map where each cursor location corresponded to an entire range of body configurations. Shoulder and upper arm positions were captured at 75 samples per second and the cursor position was displayed in real time on a LCD computer screen (OpenGL software) with visual feedback rate of 60Hz.</p><p id="P9">This BMI seeks a low-dimensional subspace of control signals within a higher dimensional space of upper body movements that remain available to the tetraplegic users of powered wheelchairs. Briefly, this BMI is based on:</p><list list-type="alpha-lower" id="L1"><list-item><p id="P10">Capturing upper body motions using four infrared cameras to track four active infrared sources attached to the subject’s upper-body garments (<xref rid="F1" ref-type="fig">Figure 1</xref>). These sensors acquired eight signals (two for each camera).</p></list-item><list-item><p id="P11">Extracting the structure of movement variance in the space of body motion signals with principal component analysis (<xref rid="R41" ref-type="bibr">Jolliffe, 2002</xref>).</p></list-item><list-item><p id="P12">Establishing a linear correspondence from the sub-space of maximal mobility (SSMM) to the space of control signals. The SSMM is defined by the two highest principal eigenvectors of the body signals capturing the highest amount of motion.</p></list-item><list-item><p id="P13">Converting to a cursor control signal with real-time feedback.</p></list-item></list><p id="P14">At the beginning of each training session, subjects calibrated the interface by performing self-selected free upper body motions. The map between the body and the control space of the cursor was defined during this calibration phase and remained calibrated within each session. To establish the body/cursor map, the interface allowed subjects to choose the movements that they preferred or found easier to perform. Although it is possible to move the cursor with the movement of only one shoulder, no specific instructions were given on how to control the cursor. The body movements were highly symmetric and they all chose the same strategy to move the cursor:</p><list list-type="alpha-lower" id="L2"><list-item><p id="P15">forward - both shoulders moved forward and/or up;</p></list-item><list-item><p id="P16">backward - both shoulders moved backward;</p></list-item><list-item><p id="P17">right - the right shoulder moved backward the left shoulder moved forward;</p></list-item><list-item><p id="P18">left - the right shoulder moved forward and the left shoulder moved backward.</p></list-item></list></sec>
24220038|Training|('method', 0.9995969241236775)|('other', 0.0004030758763224758)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Training</title><p id="P19">Subjects performed visuo-spatial motor training tasks over 9 sessions: 2 to 3 sessions per week for a total of 3 to 4 weeks of training. Each session lasted about 1 hour (from a minimum of 50 minutes to a maximum of 60 minutes). Each training session contained four tasks (i) reaching test, where subjects performed 30 center-out movements (ii) 10 minutes of driving a wheelchair in a virtual environment, (iii) 25–35 minutes playing a Tetris-like game and (iv) a repeat of the reaching test in the first step. The training time for Tetris varied between 25 and 35 min to maintain the total amount of practice with the BMI constant across sessions and subjects. Therefore the Tetris training time depended on the duration of both the reaching task and the calibration procedures. The Tetris time was shorter in the early sessions and became longer during the later training sessions.</p><p id="P20">At the beginning and the end of each session, the subject’s performance was tested in a reaching task where subjects controlled the cursor in a continuous space. Starting from the same central position, subjects moved the cursor toward one out of six possible peripheral locations presented in random order and equi-spaced over a circle with five centimeters radius. No visual feedback was provided for the first 0.4 seconds after the cursor left the initial position in two randomly selected trials per direction. To quantify skill learning, accuracy (reaching error), smoothness (jerk index), and duration of the movements were computed as follows: (1) Accuracy (reaching error), i.e., the distance between the cursor and the target, after 0.4 s, with and without visual feedback. A smaller error indicated improved performance, i.e., subjects moved faster and/or aimed better at the target. (2) Smoothness (jerk index), the third derivative of cursor position normalized with respect to the duration and the path length of the trajectory according to Teulings et al. (<xref rid="R59" ref-type="bibr">Teulings et al., 1997</xref>). A smaller jerk index means more smooth movements. (3) Movement duration: the time elapsed between the beginning and the end of the movement. As the threshold for detecting the movement, we considered the 10% of the peak speed. A shorter duration means faster speed.</p><p id="P21">When playing Tetris, subjects activated a virtual keyboard by moving from a central key to four surrounding keys, left, right, top and bottom to manipulate different shapes of falling objects. Completing a horizontal line of ten blocks without gaps caused the row of blocks to disappear, thus clearing the shaft. When subjects improved their performance, the game entered a more challenging level where the shapes fall at a faster rate. The game failed when the stack of pieces reached the top of the shaft and new pieces were unable to enter. Subjects repeated the game until the time limit allocated for Tetris (see above) was reached. The average rows cleared per minute was recorded for each session.</p><p id="P22">For the task of driving in a simulated environment, subjects controlled a virtual wheelchair over paths with increasing difficulty. The virtual environment for wheelchair navigation has a visual feedback rate of 30 Hz (Wheelchair Net Software 2.1, Oregon Research Institute). The vehicle can either advance or back-up along a line perpendicular to the screen or can turn, both clockwise and counterclockwise. Therefore the virtual wheelchair was operated by two commands specifying: a forward/backward linear speed <italic>v</italic> and a right/left turning speed <italic>ω</italic>. Average driving speed was recorded during 10 minute driving sessions.</p></sec>
24220038|Statistical analysis|('method', 0.9995969241236775)|('other', 0.0004030758763224758)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Statistical analysis</title><p id="P23">The Wilcoxon signed-rank test was performed to evaluate the effect of training on motor skill performance. We compared the performance of the first and last sessions in terms of accuracy (reaching error), smoothness (jerk index), and speed (duration) of the movements in the reaching tasks, rows cleared per minute in the Tetris game; and average driving speed of the wheelchair in the simulated environment. The significance level was set to p=0.05.</p></sec>
24220038|MRI Data Acquisition|('method', 0.9995969241236775)|('other', 0.0004030758763224758)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>MRI Data Acquisition</title><p id="P24">MR imaging data were collected within one week prior to the start of training (two 10 min DTI sessions) and within 2 days of completion of training (one 10 min DTI session). Pre-training (baseline) image collection consisted of two DTI sessions where subjects were asked to leave after the first DTI session and re-enter the scanner after 30 min for the second DTI session. These two pre-training sessions serve as within subject control and were compared with each other to test the reliability of DTI at baseline, then concatenated into one long session to optimize the diffusion tensor estimation before comparing with post training to investigate training effect (<xref rid="R42" ref-type="bibr">Jung et al., 2010</xref>; <xref rid="R49" ref-type="bibr">Monnig et al., 2013</xref>).</p><p id="P25">MR imaging data were collected using a 3.0 Tesla Siemens Tim Trio MR scanner with a 32-channel head coil and B17 software. Whole brain diffusion tensor imaging data (60 directions, TR/TE=9000/83ms, 2×2×2 mm, 72 slices, b value=1000 s/mm<sup>2</sup>, in-plane matrix resolution, 112 × 130, flip angel=90°, GRAPPA with acceleration factor of 2) plus 8 images with no diffusion b=0 s/mm<sup>2</sup> interleaved throughout the acquisition starting at the beginning of the sequence and after each block of 10 diffusion weighted images were acquired.</p></sec>
24220038|Diffusion Data Analysis|('method', 0.9995969241236775)|('other', 0.0004030758763224758)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Diffusion Data Analysis</title><sec id="S9"><title>FA, MD, AD, RD estimation</title><p id="P26">All analyses were conducted with FSL Diffusion Toolbox (FDT) (version 4.1.7, <ext-link ext-link-type="uri" xlink:href="www.fmrib.ox.ac.uk/fsl">www.fmrib.ox.ac.uk/fsl</ext-link>, FMRIB, Oxford, UK) (<xref rid="R39" ref-type="bibr">Jenkinson et al., 2012</xref>). DTI data were motion and eddy current corrected before the diffusion tensor was calculated for each voxel. Fractional anisotropy (FA) maps were derived based on the 3 eigenvalues (λ<sub>1</sub>, λ<sub>2</sub> and λ<sub>3</sub>) of each tensor, i.e. <inline-formula><mml:math id="M1" overflow="scroll"><mml:mi>F</mml:mi><mml:mi>A</mml:mi><mml:mo>=</mml:mo><mml:msqrt><mml:mfrac><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:msqrt><mml:mfrac><mml:msqrt><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>2</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:msqrt><mml:msqrt><mml:mrow><mml:msubsup><mml:mi>λ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>λ</mml:mi><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:msqrt></mml:mfrac></mml:math></inline-formula>. Mean Diffusivity (MD) maps were derived as the average of the 3 eigenvalues, i.e. <inline-formula><mml:math id="M2" overflow="scroll"><mml:mi>M</mml:mi><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow><mml:mn>3</mml:mn></mml:mfrac></mml:math></inline-formula>. Axial Diffusivity (diffusion along the principle diffusion directions) is the eigenvalue of the principle diffusion direction, i.e. λ<sub>1</sub>. Radial Diffusivity (diffusion perpendicular to the principle diffusion directions) maps were derived as the mean of the other 2 eigenvalues, i.e. <inline-formula><mml:math id="M3" overflow="scroll"><mml:mi>R</mml:mi><mml:mi>D</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>λ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>3</mml:mn></mml:msub></mml:mrow><mml:mn>2</mml:mn></mml:mfrac></mml:math></inline-formula>.</p></sec><sec id="S10" sec-type="results"><title>Tract-based spatial statistics (TBSS)</title><p id="P27">To localize brain changes, voxelwise statistical analysis of the FA data was carried out using TBSS (Tract-Based Spatial Statistics, see (<xref rid="R56" ref-type="bibr">Smith et al., 2006</xref>) for full details). First using the 1mm isotropic FA standard-space template (FMRIB58_FA) as a target, all FA data were aligned into a common standard space using the nonlinear registration tool FNIRT (<xref rid="R2" ref-type="bibr">Andersson et al., 2007a</xref>, <xref rid="R3" ref-type="bibr">b</xref>). Next, the mean FA image across all subjects and all time points was created and thinned to create a mean FA skeleton (thresholded at 0.2), which represents the centers of all tracts common to the group. Each subject’s aligned FA data were then projected onto this skeleton and the resulting data were fed into voxel-wise cross-subject statistical analysis. A two sample paired t-test was used to compare between pre and post training, i.e. design matrix contained one regressor for differences between pre and post training, and 11 additional regressors for individual subject means. Two t-contrasts (pre &lt; post training and pre &gt; post training) were estimated. Similarly a two sample paired t-test was used to compare two baseline sessions (baseline 1&gt; 2 and baseline 1&lt;2 were estimated.). 5000 permutations were run to test for statistical significance using the ‘randomise’ command in FSL as described by Smith et al. (<xref rid="R56" ref-type="bibr">Smith et al., 2006</xref>). The statistical maps were corrected for multiple comparisons (P<sub>FWE</sub> &lt; 0.025, multiple comparison corrected for two contrasts: pre- &lt; post- training and pre- &gt; post- training) using threshold-free cluster enhancement (TFCE). Significant clusters from the analysis were separately masked and anatomically identified using the JHU ICBM-DTI-81 white-matter atlas in FSL (<xref rid="R36" ref-type="bibr">Hua et al., 2008</xref>).</p></sec><sec id="S11"><title>Region of interest (ROI) analysis</title><p id="P28">Four major clusters (contains more than 200 voxels) that showed learning induced changes were identified on the FA skeleton based on TBSS results. Detailed analyses within these four clusters were performed to confirm and help interpret the findings from TBSS. (1) The mean FA values within four major clusters for skeletonized FA maps for baseline 1, baseline 2, the two baselines concatenated, and post training were extracted. (2) To better understand the changes in FA, the mean MD, AD, and RD within each of the four major ROIs were calculated for each subject. The average change post training relative to baseline was calculated at the group level. (3) Four major clusters were de-projected onto each individual subject’s native-space FA map for each scanning session. This allowed us to confirm that the voxels showing significant effects were indeed located within the white matter in each individual by visual inspection (individual results not shown).</p></sec><sec id="S12"><title>Tractography</title><p id="P29">We used tractography to better understand the spatial location and connectivity of the white matter fibers identified by the four ROIs. To identify white matter tracts associated with changes in FA, the major four clusters showing significant learning induced differences on the skeleton were de-projected to each individual’s native space and probabilistic tractography was performed with the native ROI clusters acting as the seed masks (<xref rid="R7" ref-type="bibr">Behrens et al., 2007</xref>) using Bedpostx and probtracx commands in FSL. Briefly, bedpostx runs Markov Chain Monte Carlo sampling to build up distributions on principal diffusion directions at each brain voxel, which allows modeling of crossing fibers. Probtracx then repetitively samples from the distributions of voxel-wise principal diffusion directions, each time computing a streamline through these local samples to generate a probabilistic streamline or a sample from the distribution at the location of the true streamline. By taking many such samples, the posterior distribution on the streamline location or the connectivity distribution was determined. All brain voxels will have a value representing the connectivity value between that voxel and the seed voxel (i.e., the number of samples that pass through that voxel). Pathways in individual subjects were thresholded to include only voxels that had 10% of maximum value (<xref rid="R65" ref-type="bibr">Zarei et al., 2007</xref>), binarized, transformed to standard MNI space, and then overlaid to produce population probability maps for each pathway reflecting the proportion of the population in which a tract was present.</p></sec><sec id="S13"><title>FA correlation with motor performance</title><p id="P30">We calculated the correlation with FA change and motor performance gain. In the major four clusters that showed significant differences for learning, an average FA change (post minus pre) for each individual within all four major clusters was calculated and correlated with their behavior motor performance gain (i.e. performance improvement from final session compared to initial session of training) using spearman rank correlation. The motor performance indicators include speed (duration), smoothness (jerk index), and accuracy (reaching error) of the movement from the reaching test; the average lines cleared rows per minute from the Tetris game; and average driving speed of the virtual wheelchair. The three parameters from reaching test were averaged across all movements (with and without visual feedback) in each session. False discovery rate (FDR) correction was used to correct for multiple comparisons.</p></sec></sec>
24240844|None|('method', 0.9975479157361209)|('other', 0.002452084263879045)|<p>Written consent for publication was obtained from the patient.</p>
24257969|Methods|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<title>Methods</title>
24257969|Setting and participants|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec3"><title>Setting and participants</title><p>We recruited study participants from the Medical and Surgical Intensive Care Units (MICU and SICU, respectively) at the Vanderbilt University Medical Center (Nashville, TN). The Institutional Review Board at Vanderbilt University approved the study and the trial was registered with clinicaltrials.gov (NCT01270269). Prior to any study interventions, written consent was obtained from patients or their authorized surrogates (with re-consent obtained, when indicated, once patients were cognitively able).</p></sec>
24257969|Eligibility criteria|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec4"><title>Eligibility criteria</title><p>We screened the MICU and SICU censuses daily to identify adult patients (at least 18 years old) being treated for respiratory failure and/or septic, cardiogenic or hemorrhagic shock who resided within 120 miles of Nashville, TN. We excluded patients who had already been critically ill for more than 72 h since the opportunity to administer <italic toggle="yes">early</italic> cognitive and physical therapy had passed, those who had been in the ICU for more than 5 days in the previous 30 days, those who were unlikely to benefit from rehabilitation targeting acute declines in cognitive or functional status due to a moribund state, severe pre-existing dementia or physical disability in activities of daily living (e.g., bathing, dressing, etc.), or were unlikely to continue the intervention in the outpatient setting because of active substance abuse, active psychiatric disorder, or homelessness. After obtaining informed consent, but prior to randomization, patients or their surrogates completed the short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) [<xref ref-type="bibr" rid="CR10">10</xref>] and the Katz activities of daily living (ADL) questionnaire [<xref ref-type="bibr" rid="CR11">11</xref>], respectively, to detect pre-existing dementia and physical disability not evident during the initial screening process. These questionnaires demonstrate good agreement when completed by either the patient or surrogates [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. We excluded those scoring more than 3.3 on the IQCODE or more than 3 on the Katz ADL.</p></sec>
24257969|Study procedures|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec5"><title>Study procedures</title><p>We used a computer-generated permuted-block randomization scheme to determine intervention group allocation, which was printed on tri-folded forms placed in consecutively numbered, sealed, opaque envelopes that were not opened until after informed consent was obtained and inclusion and exclusion criteria were verified. We assigned patients in a 1:1:2 manner to one of three groups: usual care, early physical therapy only, or early cognitive plus physical therapy.</p><p>Each day, all mechanically ventilated patients were managed with coordinated spontaneous awakening and spontaneous breathing trials [<xref ref-type="bibr" rid="CR14">14</xref>]. Twice daily, we assessed each patient’s level of consciousness using the Richmond Agitation–Sedation Scale (RASS) [<xref ref-type="bibr" rid="CR15">15</xref>] and delirium status using the Confusion Assessment Method for the ICU (CAM-ICU) [<xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Usual care patients received physical therapy after it was ordered by the treating clinicians and per the routine hospital treatment protocol and schedule (typically 1–2 sessions per week). No cognitive therapy interventions were performed as part of usual care. As described in detail previously (and in the electronic supplementary material), patients in the early physical therapy only group underwent a once-daily physical therapy session, and patients in the cognitive plus physical therapy group received twice-daily 20-min cognitive therapy sessions along with a once-daily physical therapy session [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec>
24257969|Inpatient cognitive therapy|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec6"><title>Inpatient cognitive therapy</title><p>An interdisciplinary team of critical care physicians, nurses, and neuropsychologists developed the in-hospital cognitive therapy protocol by compiling a series of exercises we deemed to be both cognitively challenging and diverse in nature. These exercises focused on orientation, memory, attention, and problem solving (see Fig. <xref rid="Fig1" ref-type="fig">1</xref>) [<xref ref-type="bibr" rid="CR9">9</xref>]. The cognitive therapy protocol was guided by the patient’s RASS assessment immediately preceding the session and advanced patients through a progressively more difficult series of exercises delivered by the interdisciplinary study team that included physicians and nurses.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Inpatient intervention protocols began within 24 h of study enrollment and continued until hospital discharge for the cognitive therapy intervention or until the patient had independently ambulated more than 200 feet and required no assistance in performing activities of daily living (ADLs) on two consecutive study days for the physical/occupational therapy intervention. The study protocol has been described in detail previously with an overview presented in the electronic supplementary materials [<xref ref-type="bibr" rid="CR9">9</xref>]. Briefly, cognitive therapy was delivered in two 20-min sessions each day. We chose exercises that targeted neurocognitive domains commonly impaired in the critically ill including orientation (e.g., orientation exercises), memory/attention (e.g., digit span forward, digit span reverse, noun recall, paragraph recall, and letter–number sequences), delayed memory (e.g., digit span reverse), and problem-solving/processing speed (e.g., matrix puzzles, ‘real world’ exercises, and pattern recognition). Physical therapy was delivered in a single session each day. <italic toggle="yes">RASS</italic> Richmond agitation–sedation scale, <italic toggle="yes">ROM</italic> range of motion, <italic toggle="yes">ADL</italic> activities of daily living</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2013_3136_Fig1_HTML.gif" id="MO1" position="float" orientation="portrait"/></fig></p></sec>
24257969|Inpatient physical and occupational therapy|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec7"><title>Inpatient physical and occupational therapy</title><p>Physical and occupational therapy interventions, modeled after those previously described in the literature [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR17">17</xref>] and the existing ICU mobility protocol at our institution (but with an emphasis on earlier and more frequent delivery). The protocol advanced patients from passive range of motion exercises to independent ambulation, guided by the patient’s RASS and was titrated to allow patients to reach their ‘maximal functional milestone’ as rapidly as possible (see Fig. <xref rid="Fig1" ref-type="fig">1</xref>) under the guidance of physical and occupational therapists [<xref ref-type="bibr" rid="CR9">9</xref>].</p></sec>
24257969|Outpatient cognitive therapy|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec8"><title>Outpatient cognitive therapy</title><p>Patients randomized to cognitive plus physical therapy during the hospitalization who demonstrated either impaired executive functioning or impaired functional mobility at the time of hospital discharge were instructed that they would continue cognitive therapy on an outpatient basis in the form of a 12-week, 6-session, in-home, cognitive therapy program using goal management training (GMT) [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR20">20</xref>]. GMT is an established, protocolized cognitive rehabilitation program that specifically targets executive functioning, a domain of significant importance for independent functioning [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. Patients who were discharged to a nursing home or rehabilitation facility received GMT once they returned home, with ‘make-up’ sessions performed to complete as many of the six in-home GMT sessions as possible within the 12-week follow-up period.</p></sec>
24257969|Feasibility outcome assessment|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec9"><title>Feasibility outcome assessment</title><p>The primary aim of this study was to establish the feasibility of delivering cognitive therapy early during critical illness. Therefore, we recorded data on the number of patients to whom the cognitive therapy protocol was delivered, the number of days of cognitive therapy performed, the timing of initiation of cognitive therapy, exercises performed during each cognitive therapy session, and the duration of each session.</p><p>Secondary feasibility outcomes were the number of patients who received physical therapy, the number of days of physical therapy received, timing of initiation of physical therapy, exercises performed during each physical therapy session, and duration of these sessions. Finally, we also recorded the number of outpatient GMT sessions performed by eligible patients who were randomized to the cognitive plus physical therapy group.</p></sec>
24257969|Follow-up outcomes assessment|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec10"><title>Follow-up outcomes assessment</title><p>While the main purpose of the study was to gather feasibility data, researchers blinded to all study interventions and details regarding the patient’s hospital course collected data on cognitive, functional, and health-related quality of life (HRQOL) outcome measures at 3 months following hospital discharge. Patients were instructed not to disclose details regarding study interventions they had received.</p><p>Additionally, we collected secondary clinical outcomes data including days free of delirium and coma, days free of mechanical ventilation, ICU and hospital lengths of stay, and mortality. Finally, we assessed executive functioning, global cognitive status, and functional mobility at the time of hospital discharge.</p></sec>
24257969|Data and study management|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec11"><title>Data and study management</title><p>We collected all study data using an electronic data capture tool hosted at Vanderbilt University (REDCap, project-redcap.org) [<xref ref-type="bibr" rid="CR22">22</xref>]. An independent monitoring committee reviewed safety data following the enrollment of 30 and 60 patients, respectively.</p></sec>
24257969|Statistical analyses|('method', 0.9955026155654154)|('other', 0.004497384434584627)|<sec id="Sec12"><title>Statistical analyses</title><p>We enrolled participants until 60 had been discharged alive from the hospital. This sample size was chosen on the basis of our overarching objective of obtaining feasibility data for both the inpatient and outpatient interventions as well as the resource availability of the research team. Thus, the study was not powered to allow determination of the efficacy of the interventions. Nevertheless, we collected follow-up outcome data to inform future early cognitive rehabilitation trials. We chose the total achievement score on the Tower test from the Delis-Kaplan Executive Function System [<xref ref-type="bibr" rid="CR23">23</xref>], at 3-month follow-up as the primary follow-up outcome. Secondary follow-up outcomes included results from a battery of cognitive, functional, and HRQOL outcomes assessed at 3-month follow-up.</p><p>We analyzed all data with an intention-to-treat approach. Feasibility outcomes were analyzed using descriptive statistics. Follow-up outcomes data were analyzed using the Kruskal–Wallis test or the Pearson Chi-square test to compare groups with respect to cognitive, functional, and HRQOL outcomes. Analysis of ICU length of stay, survival, and other time-to-event outcomes were performed using the Kaplan–Meier product limit method and log-rank testing. We used R (version 2.13, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.r-project.org">www.r-project.org</ext-link>) for all statistical analyses. Data are presented as median (interquartile range) unless otherwise noted.</p></sec>
24257969|None|('method', 0.8475749245391178)|('other', 0.15242507546088205)|<sec id="Sec19"><p><supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2013_3136_MOESM1_ESM.docx" mimetype="application" mime-subtype="msword" position="float" orientation="portrait"><caption><p>Supplementary material 1 (DOCX 50 kb)</p></caption></media></supplementary-material></p></sec>
24269274|None|('method', 0.992621162020589)|('other', 0.007378837979410946)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 Materials and Methods</title>
24269274|2.1 Participants|('method', 0.992621162020589)|('other', 0.007378837979410946)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3" sec-type="subjects"><title>2.1 Participants</title><p id="P6">Participants were recruited through the M.I.N.D (Medical Investigation of Neurodevelopmental Disorders) Institute of the University of California, Davis (UCD), as part of the Autism Phenome Project. Diffusion imaging data were acquired from typically developing children including 41 males and 25 females (<xref rid="T1" ref-type="table">Table 1</xref>). Participants were recruited as part of a study on autism spectrum disorder, though children with ASD were not included in the present study. Inclusion criteria for the typically developing children included scores within ± 1.5 standard deviations of the mean on all subscales of the Mullens Scales of Early Development. Handedness was assessed by means of behavioral examination. Exclusion criteria were physical contraindications to MRI, diagnosis with a pervasive developmental disorder, specific language impairment or any known developmental, neurological, or behavioral problems. All children were native English speakers. The UCD institutional review board approved this study, and informed consent was obtained from the parent or guardian of each participant.</p></sec>
24269274|2.2 Imaging Procedures|('method', 0.992621162020589)|('other', 0.007378837979410946)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.2 Imaging Procedures</title><p id="P7">MRI scans were acquired during natural nocturnal sleep at the UC Davis Imaging Research Center using a 3T Siemens Trio whole-body MRI system (Siemens Healthcare, Inc., Erlangen, Germany) equipped with an 8-channel head coil (Invivo, Inc., Gainesville, Fl). The scanner room was decorated to be child-friendly with colorful wall hangings, pillows and stuffed animals. Earplugs and/or headphones were used to attenuate scanner noise and children were closely monitored during scanning. This approach has proven highly successful with a success rate of over 85% (<xref rid="R64" ref-type="bibr">Nordahl et al., 2008</xref>).</p><p id="P8">For all participants, images were obtained using a three-dimensional T1-weighted MPRAGE sequence (TR 2170 ms; TE 4.86 ms; matrix 256 x 256; 192 slices in the sagittal direction, 1.0 mm isotropic voxels, scan time: 8 m 6 s) and a diffusion-weighted, spin echo, echo planar imaging sequence (“ep2d_diff”, number of slices: 72, slice thickness: 1.9 mm, slice gap: 0.0, matrix size: 128x128, voxel size: 1.9 mm isotropic, phase encoding direction: anterior to posterior (A≫P), phase partial Fourier: 5/8, TR: 11500, TE: 91, scan time: 6 m 56 s), with effective b-value 700 mm<sup>2</sup>/s, 30 gradient directions, and five b =0 images acquired at equally spaced intervals over the scan time. T2-weighted images were also obtained for clinical evaluation when possible (i.e. when the child remained asleep). All MPRAGE and available T2 scans were reviewed by a pediatric neuroradiologist and screened for significant, unexpected clinical findings.</p><p id="P9">Images were acquired from October 2007 to June 2011. In August 2009, the Siemens 3T Trio MRI system was upgraded to a Trio Total Imaging Matrix (TIM) MRI System running version VB15A operating system software. All the VA25A sequences were upgraded and mapped to their corresponding VB15A sequences with no parameter changes having an effect on image quality or appearance, except for the diffusion-weighted sequence. For this sequence, the spatial resolution, b-value, and diffusion gradient directions were preserved, but parameters were changed to reduce the geometric distortion of the images, and the impact of the geometric distortion on the image analysis. Specifically, the phase encoding direction was changed from ‘anterior to posterior’ (A≫P) to ‘posterior to anterior’ (P≫A), to eliminate tissue compression in the anterior temporal and frontal lobes, and the iPAT option (GRAPPA) was used with a factor 2 acceleration to permit shorter TE and reduced effective echo spacing for reduced geometric distortion at all voxels. The phase partial Fourier factor was increased from 5/8 to 6/8 to partially compensate for the factor 2 reduction in data acquired using GRAPPA. The use of GRAPPA allowed TE to be reduced from 91ms to 81ms, and echo spacing to be reduced from 0.83 ms to 0.69 ms. It also allowed TR to be reduced from 11500ms to 8500ms, and scan time from 6 m 56 s to 5 m 23 s. Although the diffusion gradient parameters (directions and b-value) were not changed, the reduction in geometric distortion caused averaging (over the local tissue to determine each voxel value) to be different in the pre-upgrade versus post-upgrade images. Thus, there are likely to be differences in the diffusion parameters in regions with reduced geometric distortion. To control for these differences, we included MRI system upgrade status (pre-upgrade, post-upgrade) as a nuisance covariate for all statistical analyses involving diffusion parameters. In the current study, 29 scans (10 females, 20 males) were acquired before the scanner upgrade and 37 scans were acquired (15 females, 22 males) afterwards (Fisher’s exact test, p = 0.62).</p></sec>
24269274|2.3 Image Processing and Diffusion Tensor Calculation|('method', 0.992621162020589)|('other', 0.007378837979410946)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.3 Image Processing and Diffusion Tensor Calculation</title><p id="P10">T1-weighted structural image preprocessing follows <xref rid="R62" ref-type="bibr">Nordahl et al. (2011)</xref> and included removal of nonbrain tissue using the Oxford Center for Functional MRI of the Brain (FMRIB) brain extraction tool (BET; <xref rid="R85" ref-type="bibr">Smith, 2002</xref>) and correction of main field (B0) inhomogeneities using the nonparametric nonuniform-intensity normalization method (N3; <xref rid="R84" ref-type="bibr">Sled et al., 1998</xref>). DTI data were processed using the Vistalab (Stanford Vision and Imaging Science and Technology) diffusion MRI software suite. The raw DTI dicom images were converted to 4-D nifti format and volumes and motion artifacts were excluded. DTI images were aligned to the motion-corrected mean of the non-diffusion weighted (b = 0) images using a rigid body algorithm. DTI images were then resampled to 2-mm isotropic voxels with eddy-current and motion correction using a 7th-order b-spline algorithm based on SPM5. Vistalab image processing software is available as part of the open-source mrDiffusion package available at <ext-link ext-link-type="uri" xlink:href="http://white.stanford.edu/software/">http://white.stanford.edu/software/</ext-link>.</p><p id="P11">Diffusion tensors were fitted to the resampled DTI data using a least squares fit and the RESTORE algorithm that also removed outliers from the tensor estimation (<xref rid="R11" ref-type="bibr">Chang et al., 2005</xref>). The diffusion tensor model produces measures describing the diffusion characteristics of each voxel. Eigenvalues (λ1, λ2, λ3) from the diffusion tensor are used to compute axial diffusivity (λ1), radial diffusivity (λ2+λ3/2), mean diffusivity (λ1+λ2+λ3/3) and fractional anisotropy (√(1/2)√((λ1-λ2)<sup>2</sup>+(λ2-λ2)<sup>2</sup>+(λ3-λ1)<sup>2</sup>)/√(λ1<sup>2</sup>+λ2<sup>2</sup>+λ3<sup>2</sup>) (<xref rid="R70" ref-type="bibr">Pierpaoli and Basser, 1996</xref>). Axial diffusivity (AD) describes diffusion parallel to the principle diffusion direction (i.e. along the long axis of a fascicle of fibers) and has been related to changes in axon integrity such as during axonal degeneration (<xref rid="R49" ref-type="bibr">Kim et al., 2007</xref>; <xref rid="R86" ref-type="bibr">Song et al., 2003</xref>; <xref rid="R89" ref-type="bibr">Sun et al., 2006</xref>; <xref rid="R91" ref-type="bibr">Thomalla et al., 2004</xref>). Radial diffusivity (RD) describes diffusion perpendicular to the principle diffusion direction and is decreased with reduced axonal myelination or axon tract density (<xref rid="R86" ref-type="bibr">Song et al., 2003</xref>; <xref rid="R87" ref-type="bibr">2002</xref>; <xref rid="R93" ref-type="bibr">Tyszka et al., 2006</xref>; <xref rid="R108" ref-type="bibr">Zhang et al., 2009</xref>). Mean diffusivity (MD) and fractional anisotropy (FA) are summative measures that describe average total diffusion and a normalized standard deviation of the three diffusion directions, respectively.</p></sec>
24269274|2.4 Automatic Fiber Quantification|('method', 0.992621162020589)|('other', 0.007378837979410946)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.4 Automatic Fiber Quantification</title><p id="P12">We used Automatic Fiber Quantification (AFQ) software tools to identify 18 white matter tracts in each participant’s brain. AFQ and consists primarily of steps: (1) whole-brain tract tractography (2) ROI-based tract segmentation and cleaning (3) quantification. After ROI-based segmentation, fiber tracts were cleaned using a statistical outlier rejection algorithm. First each fiber in a fiber group is sampled to 99 equidistant nodes. Then the spread of fibers at each node is represented as a 3 dimensional gaussian distribution and any fiber that is more than 5 standard deviation from the core (mean) of the tract is removed. The procedure is repeated until there are no more fiber outliers. Diffusion properties are then calculated along the trajectory of the fiber group by interpolating the image value (FA, MD, AD, RD) at each node along each fiber. Tract Profiles of each parameter are then calculated as a weighted sum of each fiber’s value at a given node where a fiber is weighted based on its Mahalanobis distance from the core or mean location of the tract. AFQ tractography yields tracts similar to those seen in other reports in this participant age range (<xref rid="F1" ref-type="fig">Figure 1</xref>, <xref rid="R41" ref-type="bibr">Huang et al., 2006</xref>; <xref rid="R92" ref-type="bibr">Trivedi et al., 2009</xref>; <xref rid="R100" ref-type="bibr">Wolff et al., 2012</xref>). Furthermore, tractography results generally match the overall shape and anatomical paths seen in older children and adults (<xref rid="R34" ref-type="bibr">Goodlett et al., 2009</xref>; <xref rid="R24" ref-type="bibr">Hermoye et al., 2006</xref>; <xref rid="R41" ref-type="bibr">Huang et al., 2006</xref>; <xref rid="R55" ref-type="bibr">Lebel et al., 2012</xref>). AFQ is described in greater detail in <xref rid="R104" ref-type="bibr">Yeatman et al. 2012b</xref>.</p><p id="P13">Because AFQ uses strict criterion for tract identification, it did not identify all 18 tracts in each participant. As might be expected, image quality was a significant determinant of AFQ’s ability to segment and identify tracts, and there was greater success with scans acquired after the scanner and sequence update (see Imaging Procedures above). Details regarding tract identification rates and their influence on the total N used in analysis are shown in <xref rid="T2" ref-type="table">Table 2</xref>.</p><p id="P14">For the most part, tract identification did not differ in the left and right hemisphere. However, both the cingulum and arcuate fasciculus had greater probability of identification in the left hemisphere than in the right (left cingulum 85%, right cingulum 71%, Fisher’s exact test p &lt; 0.05; Left arcuate fasciculus 87%, right arcuate fasciculus 52%, Fisher’s exact test p &lt; 0.001). Difficulty in identifying the right arcuate fasciculus using tractography is a consequence of the right tract exhibiting higher curvature and greater partial voluming with the superior longitudinal fasciculus compared to the left arcuate fasciculus (<xref rid="R9" ref-type="bibr">Catani et al., 2007</xref>; <xref rid="R53" ref-type="bibr">Lebel and Beaulieu, 2009</xref>; <xref rid="R61" ref-type="bibr">Mishra et al., 2010</xref>; <xref rid="R105" ref-type="bibr">Yeatman et al., 2011</xref>). Laterality of cingulum diffusion parameters has been previously reported in adults (<xref rid="R32" ref-type="bibr">Gong et al., 2005a</xref>). The significant asymmetry in all four diffusion parameters for the cingulum likely contributed to the difference in identification rates and is discussed in more detail below.</p><p id="P15">Tract identification was also not influenced by participant sex with the exception of the right and left inferior longitudinal fascicles (ILF; Fisher’s exact test, <italic>p</italic>s &lt; 0.001). These tracts were identified less often in males than in females. Sex differences in diffusion parameters have been found in the ILF previously (<xref rid="R13" ref-type="bibr">Choi et al., 2010</xref>) and in the current study (see Effects of Sex below). If diffusion is lower in males through much of this tract’s bundle, this may lead to a greater chance of exclusion during tractography.</p></sec>
24269274|2.5 Statistical Approach|('method', 0.992621162020589)|('other', 0.007378837979410946)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>2.5 Statistical Approach</title><p id="P16">For each subject, AD, RD, MD, and FA were calculated at 99 nodes between the two defining ROIs for each tract. For all differential analysis, separate three-way mixed-design analyses of co-variance (ANCOVA) were conducted for the continuous dependent variables (AD, RD, MD, FA). Hemisphere and nodes were used as repeated measures and sex as a between-group measure. For hemisphere analysis in the forceps major and minor nodes 1–49 were compared to nodes 50–99. Participant age was included as a continuous covariate while handedness and scanner status were controlled.</p><p id="P17">Mauchly’s test of sphericity (<xref rid="R59" ref-type="bibr">Mauchly, 1940</xref>) was used to test for violations of sphericity and the Greenhouse-Geisser correction (<xref rid="R35" ref-type="bibr">Greenhouse and Geisser, 1959</xref>) was applied when sphericity was violated. Follow-up one-way ANCOVAs and Bonferroni-corrected pairwise comparisons were used to further investigate significant main-effects and interactions identified in the omnibus tests. Because the repeated measure of nodes was nested within the repeated measure of hemisphere, pairwise comparisons of hemisphere mean differences (averaged across nodes) were considered useful and informative in the absence of significant omnibus hemisphere effects. For correlations between age and diffusion properties, partial correlations controlling for scanner upgrade status were used. For all analyses, results are expressed as mean ± SEM (standard error of the mean), and a p-value less than 0.05 was considered statistically significant.</p></sec>
24269569|None|('method', 0.9556091408511905)|('other', 0.0443908591488094)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24269569|Participants|('method', 0.9556091408511905)|('other', 0.0443908591488094)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3" sec-type="subjects"><title>Participants</title><p id="P9">14 healthy paid male and female volunteers, age range 19–30 years participated in the study. All volunteers were right-handed and reported to have normal hearing and normal or corrected-to-normal vision. The protocol was approved by the University of California, Berkeley Institutional Review Board and all participants signed an informed consent before participating in the study.</p></sec>
24269569|Study design|('method', 0.9556091408511905)|('other', 0.0443908591488094)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Study design</title><p id="P10">This study used the same paradigm and an identical stimulus-set to that reported in <xref rid="R32" ref-type="bibr">Gazzaley et al. (2008)</xref>. EEG was recorded while participants performed a selective face/scene delayed-recognition task (<xref ref-type="fig" rid="F1">Fig. 1</xref>) to assess WM in the setting of distracting information (<xref rid="R32" ref-type="bibr">Gazzaley et al., 2008</xref>). Participants were given prior knowledge as to which stimulus type was relevant and irrelevant. Each trial contained two faces and two scenes presented sequentially in a randomized order (cue period), each being displayed for 800 ms (200 ms ISI), followed by a 9 s delay period in which the images were to be remembered and mentally rehearsed. After the delay, a third image appeared (Probe) for a duration of 1 s (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The participant was asked to respond with a button press (as quickly as possible without sacrificing accuracy) whether the third image (Probe) matched one of the previous images. Participants were given the following instructions: remember faces (ignore scenes, hereafter, Face Memory), remember scenes (ignore faces, hereafter, Scene Memory) or passively view all stimuli (hereafter, Passive View).</p><p id="P11">When the probe image appeared, it was composed of a face in the face memory condition, and a scene in the scene memory condition. In Passive View, participants were instructed to relax and view the stimuli without trying to remember them. Instead of a probe image, an arrow was presented and participants were required to make a button press indicating the direction of the arrow (<xref ref-type="fig" rid="F1">Fig. 1</xref>). The task was presented in 3 separate runs (20 trials each) with each of the three conditions in random order. Conditions and stimuli were counterbalanced across participants.</p><p id="P12">Each participant received either placebo or donepezil (5 mg, orally) on two different visits. Drug administration was double blind, and the order of drug and placebo administration was counterbalanced across participants.</p></sec>
24269569|Stimuli|('method', 0.9556091408511905)|('other', 0.0443908591488094)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Stimuli</title><p id="P13">The stimuli consisted of grayscale images of faces and natural scenes. All face and scene images were novel across all conditions and across all runs of the experiment. Images were 225 pixels wide and 300 pixels tall (14 × 18 cm) and subtended ~5 by 6° of visual angle (participants were ~172 cm from the screen). The face stimuli consisted of a variety of neutral-expression male and female faces across a large age range. The gender of the face stimuli was held constant within each trial, and each stimulus was used in only one trial.</p></sec>
24269569|EEG recording and waveform analysis|('method', 0.9556091408511905)|('other', 0.0443908591488094)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>EEG recording and waveform analysis</title><p id="P14">ERPs were recorded from a 64 channel cap with Ag/AgCl active electrodes (Biosemi Active Two EEG system, Amsterdam, Netherlands) positioned according to the 10–20 international system. Four electrodes, above and below the right eye, and on the outer can thus of each eye served to record eye movements (EOG). Participants were instructed to avoid eye movements, blinking and body movements as much as possible, and to keep their gaze on the center of the screen during task performance. The EEG was sampled at a rate of 256 Hz and stored for off-line analysis. Continuous individual records were subjected to a 0.5–30 Hz band-pass filtering (FIR rectangular filter).</p><p id="P15">Nuisance components of horizontal eye movements and blinks were removed offline in Matlab (The Mathworks, Natick, MA) using EEGLAB (<ext-link ext-link-type="uri" xlink:href="http://sccn.ucsd.edu/eeglab/index.html">http://sccn.ucsd.edu/eeglab/index.html</ext-link>) (<xref rid="R21" ref-type="bibr">Delorme and Makeig, 2004</xref>). Epochs of EEG from200 to 800 ms post-stimulus onset free of excessive electrical interference (b100 μV) were selectively averaged only for the irrelevant faces stimuli of the Scene Memory condition (Remember Scenes condition). Thus, in total, 120 epochs were collected per participant (20 trials × 3 blocks × 2 facial stimuli).</p></sec>
24269569|ERP measures and electrode selection|('method', 0.9556091408511905)|('other', 0.0443908591488094)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>ERP measures and electrode selection</title><p id="P16">The ERPs were time-locked to the onset of the irrelevant faces (from the Scene Memory task). Selection of electrodes for peak identification analysis was a two-stage process. First, several electrodes were selected for each ERP component of interest based on a previous parcellation (<xref rid="R48" ref-type="bibr">Luo et al., 2010</xref>) with the addition of the temporo-occipital electrodes, P9/P10, here. Specifically, for the P1 component, electrodes Pz, P3, P4, POz, PO3, and PO4 were selected for statistical analysis (50–150 ms); N170 (120–220 ms) was analyzed at the P7, P8, P9, P10, PO7, and PO8 electrode sites; P3 (300–500 ms) was analyzed at the following 15 electrode sites (FCz, FC3, FC4, Cz, C3, C4, CPz, CP3, CP4, Pz, P3, P4,POz, PO7, and PO8).</p><p id="P17">Next, electrodes for statistical analyses were chosen by their maximal value at the group level from each of the above clusters (<xref rid="R32" ref-type="bibr">Gazzaley et al., 2008</xref>). Thus, each ERP component was finally represented by a single electrode chosen from its corresponding multiple electrode cluster based on its maximum amplitude. Only in the case of the P1 component there was a discrepancy between the maximum-amplitude electrodes of placebo and donepezil, respectively, and the maximum amplitude electrode in the donepezil condition was finally chosen as the representative electrode. For the P1 component PO3 was selected; for N170 electrode, P10 was selected; and for P3 electrode, PO8 was selected.</p><p id="P18">We conducted repeated measures analyses of variance (ANOVA) with Treatment (donepezil, placebo) and Component (P1, N170, P3) as fixed factors and Participants as a random factor. Using planned contrasts, we compared the amplitude and latency values between treatments for each of the components.</p></sec>
24269569|BNA analysis|('method', 0.9556091408511905)|('other', 0.0443908591488094)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>BNA analysis</title><sec id="S9"><title>General principles of the BNA algorithm</title><p id="P19">BNA is based on identifying patterns of phase-locked evoked activity and it relates network dynamics to several network parameters. Specifically, the Brain Network Activation (BNA) algorithm exploits the inter-participant sequential <italic>temporal</italic> co-occurrence of pairs of ERP peaks (event-pairs) extracted from signals that were band-pass filtered into different <italic>frequency</italic> ranges and that emerged in different <italic>spatial</italic> locations. Thus, BNA captures the dynamic integration of event-pairs of specific temporal relations, spatial locations and frequencies into a unified functional network. Hence, BNA relies on a tridimensional analysis (<xref rid="R91" ref-type="bibr">Stephane et al., 2012</xref>) of time-dependent event-pairs across a group of participants. It is noteworthy that BNA describes functional connections which are not based on correlations of oscillatory activity (e.g., <xref rid="R8" ref-type="bibr">Brázdil et al., 2013</xref>) but rather on the temporal co-occurring pairs of ERP peaks.</p><p id="P20">As mentioned above, the information regarding the temporal co-occurring event-pairs which form into patterns is extracted from the participants of the <italic>group</italic>. That is, only if a specific sequential activation pattern of co-occurring ERP peaks is common across participants included in the group it will be considered as the characteristic group's network. Therefore, the coordinated activity in time, location and frequency depicted in the BNA group's network imply that the spatiotemporal functional dependencies of regional neuronal activities in different frequency bands represent functional links common to and characteristic of a specific population (e.g. healthy controls, Alzheimer disease patients). Individual brain activation patterns are compared against the group's network to determine the degree of similarity between the two in terms of network dynamics. The degree of similarity is measured by the BNA score as detailed in “Single participant level process and the BNA score” below.</p><p id="P21">The BNA method allows an encompassing description of brain activation using a graph as the formal representation of a network in which the nodes represent events defined in time, location and frequency-band, and the edges represent consistent temporal activity among nodes. This is a suitable and convenient formal representation of the sequence of time-dependent activations that occur in different frequency-bands and scalp-locations. This formal representation allows a comparison between entire networks representing different groups or conditions as well as the comparison of the single participant to the group by comparing between different multidimensional graphs. This approach is in accordance with the view that cognition results from dynamic interactions of distributed brain areas operating in large-scale networks (<xref rid="R10" ref-type="bibr">Bressler and Menon, 2010</xref>).</p></sec><sec id="S10"><title>Detailed description of the BNA algorithm: Two main processes</title><p id="P22">The BNA analysis involves two independent processes (<xref ref-type="fig" rid="F2">Figs. 2A–H</xref>), a group level pattern recognition process (blue arrows, <xref ref-type="fig" rid="F2">Fig. 2</xref>) and a single participant level similarity evaluation process (red arrows, <xref ref-type="fig" rid="F2">Fig. 2</xref>). The group level process does not consist on averaging across participants, which masks variability within the group, but is rather based on identifying the largest common denominator of activation across participants while still preserving the inter-subject variability of individual participants (for more details see sub-section “Group level process” below).</p><p id="P23">At the group level, patterns are extracted from EEG data recorded from members of a group of participants, all of whom have undergone the same task. In the single participant level process, EEG data from a single participant external to the group, who underwent the same task, is evaluated against a set of extracted group patterns. A BNA score reflecting the degree of congruity between the participant's pattern of activation and that of the group's is assigned for each individual participant. The two processes will now be described in more detail.</p><sec id="S11"><title>Group level process</title><p id="P24">The first stage in the group level pattern recognition process involves <italic>data preprocessing</italic> (<xref ref-type="fig" rid="F2">Figs. 2A–C</xref>). At this stage continuous individual records undergo initial band-pass pass filtering followed by artifact rejection and band-passing to the conventional EEG frequency bands: delta (0.5–4 Hz), theta (3–8 Hz), alpha (7–13 Hz) and beta (12–30 Hz). All overlapping frequency bands were used in the next steps of the analysis to reduce loss of information. The outcome of this analysis stage is a set of EEG time-domain waveform signals per individual frequency band per electrode location. Next, the continuous filtered data is segmented into epochs, sorted according to stimulus type and averaged within each separate frequency band to obtain the ERPs. For further details see “EEG recording and waveform analysis” above.</p><p id="P25">Second, <italic>salient event extraction</italic> is performed (<xref ref-type="fig" rid="F2">Figs. 2D, E</xref>). This stage reduces an individual's continuous ERP record into a set of discrete events (peaks and troughs) representing waveforms in each of the frequency bands defined above. For each participant all the minimal and maximal peaks from all frequency bands and electrodes that surpassed a specific threshold are selected for further analysis as follows. Initially, the average frequency band is calculated based on the high and low boundaries of the given frequency band. Next, the percentage threshold, which is the inverse of the average frequency, is computed per frequency band. Finally, the number of peaks selected for analysis is determined by the percentage threshold of the highest normalized peaks (see <xref ref-type="app" rid="APP1">Appendix A</xref>, “Normalization procedure”). This procedure ensures that signals are adequately represented across frequency bands. The selected peaks are considered salient events, each with a defined latency, amplitude, frequency band and location on the scalp, i.e., in a four dimensional space (<xref ref-type="fig" rid="F2">Figs. 2D, E</xref>).</p><p id="P26">Following the salient-event waveform extraction stage described above, in the third stage, <italic>network analysis</italic> is performed (<xref ref-type="fig" rid="F2">Figs. 2F, G</xref>). In this stage, BNA identifies functional networks that provide stimulus and task-related structures in the <italic>time</italic>–<italic>location</italic>–<italic>frequency</italic> space of the EEG. BNA first locates clusters that include all or most participants in the group. Each cluster represents a single activity (negative or positive ERP peak) common to the group, over a defined location on the scalp, within a narrow frequency band and with narrow latency and amplitude ranges (this cluster will hereafter be referred to as a group common 'unitary event'). Following unitary event extraction, the algorithm seeks time-dependent ‘event-pairs', defined as any two salient events (ERP peaks) in a single participant, each of which is included in a separate unitary event at a given scalp location and at a given frequency band and that maintain a specific temporal relation between them. The BNA algorithm extracts spatiotemporal patterns composed of a set of such temporally-dependent event-pairs contained in multiple unitary events. Previously it was shown that volume conduction is unlikely to be responsible for the temporal contingency between events (<xref rid="R84" ref-type="bibr">Shahaf et al., 2012</xref>).</p><p id="P27">Each of the events comprising an event-pair is obeying an absolute temporal constraint on its latency (i.e. the <italic>absolute time</italic> constraint) and both of the events are obeying a relative temporal constraint for the inter-event interval (i.e. the <italic>relative time</italic> constraint) across a group of participants. Specifically, the <italic>absolute time</italic> is the latency of an event locked to stimulus onset, while the <italic>relative time</italic> is the time difference between the latencies of the events comprising the event-pair. The group pattern is then composed of all pairs of temporally co-occurring events that are common to the group from all electrode locations/frequencies. The term ‘temporally co-occurring’ refers to a fixed relative time between the two events in each of the participant's event-pairs.</p><p id="P28">Event-pair identification consists of a sliding adjustable rectangular window which searches for clusters of event-pairs across all participants (<xref ref-type="fig" rid="F3">Fig. 3</xref>). The horizontal side of the rectangle represents the absolute time of events while the vertical side represents the interevent interval. The plane bounded by the rectangle defines a cluster of event-pairs satisfying both absolute and relative time constraints in order to locate collections of tightly-spaced points with a minimum number of participants determined by a threshold (see <xref rid="R84" ref-type="bibr">Shahaf et al., 2012</xref>). This defined collection of event-pairs across individual participants is represented in the group network that preserves inter-subject variability and therefore allows the comparison of the individual activation to the group's pattern.</p></sec><sec id="S12"><title>Single participant level process and the BNA score</title><p id="P29">The single participant level similarity evaluation process (red arrows) involves three stages of which the first two (data preprocessing and salient event extraction) (<xref ref-type="fig" rid="F2">Figs. 2A–E</xref>) are identical to the first two stages of the group level process. In the third stage, event-pairs from single participants, that did not participate in the group network, are compared to corresponding event-pairs in the group network (<xref ref-type="fig" rid="F2">Fig. 2H</xref>) to assess the degree of similarity between the two. The comparison results in a BNA score with a value ranging between 0 and 100, where 100 designates complete congruence in terms of the network activation pattern between the single participant and the group's pattern that functions as a reference brain network.</p><p id="P30">More specifically, the BNA score is the measure of the functional similarity between the activation pattern of a single participant and the group's network in terms of the sequence of the temporal co-occurrence of event-pairs. The timing parameters that define co-occurrence are associated with event pairs of specific spatial locations and frequencies and therefore the BNA score reflects the similarity level between the activation pattern of the single participant and the group's network in all three dimensions: time, location and frequency (for the exact calculation of the BNA score see <xref ref-type="app" rid="APP2">Appendix B</xref>, “BNA score computation”).</p><p id="P31">For computing the BNA score, individual activation that was recorded for participants under placebo can be assessed against the reference group network under donepezil and vice versa (that is, the treatments could be swapped between the single-participant level and the group level). This possible incongruence of conditions between the individual and the group level while computing the BNA score is made possible since the extraction of activation patterns is divided into two independent processes: the single participant level and the group level process, respectively. This incongruence between conditions could be evident, for example, when BNA scores obtained for participants treated with placebo are separately computed against each reference (group) network of placebo and donepezil, respectively.</p><p id="P32">The single participant BNA score could be applied to entire networks as described above or else to sub-networks, that is, portions of the network, hereafter termed sub-BNA (sBNA) analysis. sBNA may be employed to calculate the single participant BNA score relative to a sub-network that is a-priori selected for post-hoc analyses.</p></sec></sec><sec id="S13"><title>Comparing the mean BNA score between networks</title><p id="P33">To test whether the placebo and/or the donepezil network significantly differentiated between placebo and donepezil treatments, individual network activity scores were first computed. That is, individual BNA scores were calculated by comparing the single participant activity to the placebo and donepezil group characteristic networks. These computations yielded placebo network BNA scores and donepezil network BNA scores, respectively. Placebo network BNA scores and donepezil network BNA scores were computed separately for each treatment, i.e. once when the participants received placebo and once when they received donepezil, yielding two sets of scores per network.</p><p id="P34">Then, Wilcoxon signed-rank test was used to test significance of within-group differences in BNA scores obtained in each of the treatments, placebo and donepezil, respectively. Since the computation of a BNA score consists of a comparison between the single participant activity and the group pattern she/he participated in, it is inherently biased due to over-fitting. Therefore, a leave-one-subject-out (LOSO) cross-validation method was used to compute the placebo or donepezil network BNA scores (see further details in <xref ref-type="app" rid="APP3">Appendix C</xref>, “BNA scores: placebo vs. donepezil”).</p></sec><sec id="S14"><title>Correlation analyses</title><p id="P35">To test whether the donepezil network could serve as a model of WM performance, Spearman's rho correlation coefficients were used to examine the relationship between donepezil network BNA score and WN performance. We computed the correlation between performance in the WM task (i.e. accuracy = percent of correct responses) and the donepezil network BNA scores both obtained under placebo. We also tested the ability of BNA to predict beneficial effects of donepezil by calculating the correlation between the donepezil network BNA score for participants under placebo and the difference in WM performance between placebo and donepezil (donepezil minus placebo). Each of the above correlations was re-computed for the theta–alpha sub-network using sub-BNA (sBNA) analysis (see “sBNA post-hoc analyses” below).</p></sec><sec id="S15"><title>sBNA post-hoc analyses</title><p id="P36">The single participant BNA score could be applied to entire networks as described above or to sub-networks, that is, portions of the network, termed sub-BNA (sBNA) analysis. Thus, we employed sBNA to compute the BNA scores for a sub-network of the donepezil characteristic network (i.e. sBNA scores) that included only theta–alpha connections. This sub-network was chosen based on previous findings in the literature indicating its importance in gating relevant information in the context of WM tasks (as indicated in the Introduction). A prefrontal/occipito-parietal theta–alpha sub-network constituting a unique portion of the donepezil characteristic network was chosen for further analysis using sBNA.</p><p id="P37">The sBNA was defined based on the literature emphasizing the roles of the frontal and prefrontal regions in top-down control (see a summary in <xref rid="R40" ref-type="bibr">Kawasaki et al., 2010</xref>) and on the findings indicating that the functional connections between the frontal theta and posterior alpha regions support working memory (<xref rid="R40" ref-type="bibr">Kawasaki et al., 2010</xref>; <xref rid="R57" ref-type="bibr">Moran et al., 2010</xref>; <xref rid="R102" ref-type="bibr">Zanto et al., 2011</xref>). For extracting the sBNA we chose to focus on frontal and central electrode sites. All possible connections between the frontal/central theta and occipital–parietal alpha nodes were examined. For the frontal and central regions the following electrodes were included: FP1, AF7, AF3, F1, F3, F5, Fpz, Fp2, AF8, AF4, AFz, Fz, F2, F4, F6, FC5, FC3,FC1, C1, C3, C5, CP5, CP3, CP1, CPz, FC6, FC4, FC2, FCz, Cz, C2, C4, C6, CP6, CP4, and CP2. For the occipito-parietal regions the following electrode sites were included: P1, P3, P5, P7, P9, PO7, PO3, POz, Pz, P2, P4, P6, P8, P10, PO8, and PO4. Note that inclusion of electrodes for sBNA analysis was determined on the basis of the relevant regions of interest and not on the basis of the observed specific node activations observed in the donepezil characteristic network as described in the Results section (Placebo and donepezil characteristic networks).</p></sec></sec>
24269576|None|('method', 0.9999745524365461)|('other', 2.544756345378911e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
24269576|Animal preparation|('method', 0.9999745524365461)|('other', 2.544756345378911e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Animal preparation</title><p id="P7">All procedures were approved by the Duke Institutional Animal Care and Use Committee. Pregnant C57BL/6 dams were obtained from the Jackson Laboratories (The Jackson Laboratory, Bar Harbor, ME). Food and water were provided to the dam ad libitum. Mouse neonates at PND2, 7, 14 and 22 (<italic>n</italic> = 4 for each postnatal stage) and PND56 (<italic>n</italic> = 2) were anesthetized with Nembutal and perfusion fixed. Briefly, a catheter was inserted into the left ventricle of the mouse heart. The animal was perfused with a peristaltic pump with 20 cc of warm (37 °C) 0.9% saline followed by 20 cc of 10% buffered formalin (Buffered Formalde-Fresh; Fisher Scientific) (<xref rid="R16" ref-type="bibr">Johnson et al., 2002</xref>). After perfusion fixation, the heads of the mice were stored in 20% buffered formalin overnight before imaging experiments in the following day. The perfused mouse brain was kept within the skull to prevent any potential damage to the brain caused by surgical removal. Each age group contained animals from all litters to minimize litter effect.</p></sec>
24269576|MRI|('method', 0.9999745524365461)|('other', 2.544756345378911e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>MRI</title><p id="P8">The specimens were sealed tightly inside a cylindrical tube (length 30mm and diameter 11mm) filled with Fomblin. The perfusion-fixed mouse brains were scanned on a 9.4 T (400 MHz) 89-mm-diameter vertical bore Oxford magnet with shielded coil providing gradients of 1600 mT/m and a GE EXCITE MR imaging console (GE Healthcare, Waukesha, WI). To obtain magnetic susceptibility maps, the specimens were scanned with a 3D gradient echo sequence (GRE), TE = 20 ms, TR = 200 ms, FOV = 22×11×11 mm<sup>3</sup>, matrix size = 368×184×184 and flip angle 40°. After a GRE acquisition, the tube that contained the brain was rotated by some angles along the long axis of the tube which was perpendicular to the <bold>B</bold><sub>0</sub>. A total of 7 to 9 orientations were imaged. For the DTI maps a 3D spin echo sequence was used with parameters: matrix size = 165×82×82 with a b-value = 1000 s/mm<sup>2</sup>, TE = 12 ms, TR = 2.5 s. Six encoding directions were used. The encoding directions are (1, 0, 1), (1, 0, −1), (1, 1, 0), (1, −1, 0), (0, 1, 1), and (0, 1, −1).</p></sec>
24269576|Image processing and analysis|('method', 0.9999745524365461)|('other', 2.544756345378911e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Image processing and analysis</title><p id="P9">The pixel size was adjusted by <bold>k</bold>-space truncation to isotropic 60µm for all gradient echo images. Phase data from the GRE were reconstructed, unwrapped and large background phase was removed with the spherical-mean-value filter followed by a deconvolution operation (<xref rid="R38" ref-type="bibr">Schweser and Lehr, 2010</xref>) using a 3D-mask that segments the brain from the skull. The mask was created with ITK-SNAP (<xref rid="R41" ref-type="bibr">Yushkevich et al., 2006</xref>). Quantitative magnetic susceptibility value was computed for each voxel iteratively using the LSQR algorithm (<xref rid="R24" ref-type="bibr">Liu, 2010</xref>) by inverting the following formula: <disp-formula id="FD1"><label>[1]</label><mml:math id="M1" display="block" overflow="scroll"><mml:mi>Δ</mml:mi><mml:mi>f</mml:mi><mml:mo>=</mml:mo><mml:mi>γ</mml:mi><mml:msub><mml:mi>μ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>·</mml:mo><mml:mi>F</mml:mi><mml:msup><mml:mi>T</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="true">[</mml:mo><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>3</mml:mn></mml:mfrac><mml:mo>−</mml:mo><mml:mfrac><mml:msub><mml:mi>k</mml:mi><mml:mi>z</mml:mi></mml:msub><mml:msup><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mo stretchy="true">)</mml:mo><mml:mi>F</mml:mi><mml:mi>T</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>χ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="true">]</mml:mo></mml:math></disp-formula>where Δ<italic>f</italic> is the frequency shift (after unwrapping and background phase removal) and χ is the quantitative and macroscopic magnetic susceptibility (<xref rid="R32" ref-type="bibr">Salomir et al., 2003</xref>). Note that susceptibility calculated this way is relative to the Larmor frequency (the mean of the whole brain). Any paramagnetic and diamagnetic susceptibility is relative to this reference.</p><p id="P10">Regions-of-interest (ROI) in three white matter structures-corpus callosum (CC), anterior commissure (AC), and fornix system (FS) (including the fimbria) - were manually and conservatively segmented using ITK-SNAP based on FA maps. These regions-of-interest were then scaled onto the QSM maps to match their resolution using Convert3D (part of ITK-SNAP). The weighted average of each ROI and its standard deviation were calculated, giving us quantitative data for the susceptibility, anisotropy and diffusivity of each structure.</p><p id="P11">Gradient echo images acquired different orientations were registered to the first orientation using FSL-FLIRT. The resulting transformation matrix was used to coregister susceptibility maps with FSL-FLIRT (<xref rid="R15" ref-type="bibr">Jenkinson et al., 2002</xref>). Fiber orientation of each ROI was obtained from major eigenvectors of the diffusion tensor, thus allowing us to evaluate the dependence of susceptibility on the angle of the fibers with respect to B<sub>0</sub>. The process was repeated for each of the 5 different postnatal stages. Due to the spatial constraints of the small solenoid RF coil used to achieve maximal SNR, the brain was only rotated around the anterior-posterior axis. This setup is sufficient to evaluate susceptibility anisotropy but insufficient to evaluate the full susceptibility tensor as described by Eq. 7 of Li et al (<xref rid="R23" ref-type="bibr">Li et al., 2012</xref>) which requires rotation around two axes perpendicular to B<sub>0</sub>.</p><p id="P12">Diffusion tensor images were analyzed as described previously (<xref rid="R2" ref-type="bibr">Basser and Pierpaoli, 1996</xref>). To minimize variations induced by potential temperature fluctuations, the mean diffusivity was normalized by ensuring that the mean diffusivity of the fluid within the ventricles was the same at all ages. The ventricles of PND2 were used as the reference. This normalization did not affect FA values.</p><p id="P13">All numerical analyses were performed in Matlab R2010a (Mathworks, Natick, MA). The calculations were performed on a Linux cluster comprised of 61 computing nodes with 8 CPU cores and a total of 1.76TB of memory, although they can be performed on a typical desktop computer as well (<xref rid="R22" ref-type="bibr">Li et al., 2011</xref>).</p></sec>
24269576|Histological analysis|('method', 0.9999745524365461)|('other', 2.544756345378911e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Histological analysis</title><p id="P14">Histological examinations were performed after the MRI scans. Coronal 2-µm thick slices were stained with either a myelin staining agent (LFB-Luxol Fast Blue) or an iron staining agent (PPB - Perl’s Prussian Blue) only (no eosin or other counter-stain was used). As a control for iron staining, three slices of human liver tissue were also stained with PPB with the same protocol simultaneously. Slides were imaged using Axioscop2 FSmot optical microscope with EC Plan-Neofluar Zeiss Lens at 10 × magnification, 0.3 aperture under the same settings and light conditions. The other settings were: pixel size = 1.96 µm, 12-Bit depth RGB color, matrix size = 456×344 with 3×3 binning, 5-ms exposure time in tile mode. Background shading effects of picture tiling were removed using a blank image with Matlab. Using ImageJ (US National Institutes of Health) the mean transmitted light intensity (luminosity) of a specific white matter region (external capsule) was assessed with age in contrast to a neighboring gray matter area (contrast = 1 − [(lumWM − lumGM)/maxlum]) and weighted to the white background. Note that lumWM represents the luminosity of white matter, lumGM for luminosity of gray matter and maxlum for maximum luminosity.</p></sec>
24269576|X-Ray Spectroscopy|('method', 0.9999745524365461)|('other', 2.544756345378911e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>X-Ray Spectroscopy</title><p id="P15">Scanning electron microscopy (SEM) with energy dispersive X-ray spectroscopy (EDS) was performed on a PND22 slice using a Hitachi S-4700 Cold Field Emission Scanning Electron Microscope to detect iron. At first the slice was coated with gold in a vacuum chamber. Then SEM was used to draw an accurate FOV on the white matter structure (external capsule) and an adjacent gray matter area, the atoms of which were later excited with an electron beam. The resulting X-rays are measured by an energy-dispersive spectrometer to create a histogram of all the detected element percentages by weight.</p></sec>
24269576|Statistics|('method', 0.9999745524365461)|('other', 2.544756345378911e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Statistics</title><p id="P16">Magnetic susceptibility and diffusion measurements were correlated with histological data. Statistical analysis for the correlation was performed with SPSS (16.0.2 SPSS Inc.).</p></sec>
24269576|None|('method', 0.9161680993631307)|('other', 0.0838319006368692)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
24269576|None|('method', 0.9161680993631307)|('other', 0.0838319006368692)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>01</label><media xlink:href="NIHMS560560-supplement-01.doc" orientation="portrait" xlink:type="simple" id="d37e764" position="anchor"/></supplementary-material>
24295508|None|('method', 0.9994296540375374)|('other', 0.0005703459624627551)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS &amp; METHODS</title>
24295508|Mice and diets|('method', 0.9994296540375374)|('other', 0.0005703459624627551)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Mice and diets</title><p id="P5">Four-week-old C57BL/6J male mice (atherosclerosis susceptible strain, The Jackson Laboratories, Bar Harbor ME) were randomly divided into two groups: control chow diet and an atherogenic HF diet (TD 90221, Harlan Teklad, Madion, WI; including 1.25% cholesterol, 15.8% fat and 0.5% cholate)(<xref rid="R30" ref-type="bibr">Parhami, Tintut et al. 2001</xref>; <xref rid="R33" ref-type="bibr">Sage, Lu et al. 2011</xref>; <xref rid="R31" ref-type="bibr">Pirih, Lu et al. 2012</xref>). Animals were started on the diet 12 weeks prior to the implant placement (<xref ref-type="fig" rid="F1">figure 1A</xref>). The experimental protocols were reviewed and approved by the Chancellor’s Animal Research Committee of UCLA.</p></sec>
24295508|Implant placement|('method', 0.9994296540375374)|('other', 0.0005703459624627551)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Implant placement</title><p id="P6">Under general gas anesthesia, an incision in the lateral aspect of the femur was created, and a pilot hole was made using a 1/2 mm round carbide burr with high speed. The sterile custom-made cylindrical smooth-type tapered titanium implants (1 × 2 mm) were placed by push-fit in the diaphysis of the left femur, perpendicular to its long axis (bicortically) (<xref ref-type="fig" rid="F1">figure 1B</xref>), and the wound was sutured. Animals were given antibiotics (sulfamethoxazole and trimethoprim oral suspension, USP; 850 μg/170 μg per mL) for 7 days. The animals were then sacrificed at 4 or 8 weeks after implant placement (<xref ref-type="fig" rid="F1">Figure 1A</xref>).</p></sec>
24295508|Serum analysis|('method', 0.9994296540375374)|('other', 0.0005703459624627551)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Serum analysis</title><p id="P7">Blood was collected by heart puncture, and serum was sent to the UCLA Division of Laboratory Animal Medicine to analyze levels of cholesterol, triglyceride and glucose.</p></sec>
24295508|Evaluation of implant osseointegration|('method', 0.9994296540375374)|('other', 0.0005703459624627551)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Evaluation of implant osseointegration</title><p id="P8">At necropsy, femurs were procured and fixed for 48 hours in 10% formalin. The femurs were scanned by micro-computed tomography (μCT; SkyScan 1172; Kontich, Belgium)(<xref rid="R1" ref-type="bibr">Aghaloo, Kang et al. 2011</xref>) .The entire implant site was selected as the region-of-interest (ROI).</p><p id="P9">All quantitative measurements were performed on the midsection of the implant, and analysis was conducted on its proximal, distal, lateral, and medial sides. The bone-to-implant contact (BIC) was considered the sum of all regions of contact between bone (two coronal and two sagittal) and implant (μm)/whole implant length from the first to the last BIC (μm)×100, and measured using the Dolphin 11.0 Imaging software (Chatsworth, CA, USA).</p></sec>
24295508|Implant push-in test|('method', 0.9994296540375374)|('other', 0.0005703459624627551)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Implant push-in test</title><p id="P10">The implant push-in test was performed as described by Ogawa <italic>et al</italic> (<xref rid="R28" ref-type="bibr">Ogawa, Ozawa et al. 2000</xref>). In brief, femurs were embedded in autopolymerizing resin in a custom made mold, in which the bottom flat surface was parallel to the top surface of the implant. The Instron machine (Instron 5544 Electro-mechanical Testing System, Instron, Canton, MA, USA) contained a steel-pushing rod (0.8mm diameter) that applied a load on the implant at a speed of 1 mm/min while simultaneously recording values. The push-in value was determined as the breakpoint load, which is the maximum load prior to a drop in the load-displacement curve (<xref rid="R28" ref-type="bibr">Ogawa, Ozawa et al. 2000</xref>).</p></sec>
24295508|Statistical analysis|('method', 0.9994296540375374)|('other', 0.0005703459624627551)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Statistical analysis</title><p id="P11">Two-tailed Student’s <italic>t</italic>-test was performed to compare the effects of the chow diet and the HF diet groups. Results are presented as the mean ± SEM of measurements, considering statistically significant values of <italic>p</italic> &lt; 0.05.</p></sec>
24305060|None|('method', 0.9953317374353386)|('other', 0.004668262564661343)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24305060|Participants|('method', 0.9953317374353386)|('other', 0.004668262564661343)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8" sec-type="subjects"><title>Participants</title><p id="P12">The sample for the current study was composed of adults diagnosed with ADHD (see <xref rid="T1" ref-type="table">Table 1</xref> for a summary). Participants were recruited from the community via advertisements, word of mouth, and referrals from local clinics. Inclusion criteria included age 18–50 years; met <italic>DSM-IV</italic> (APA, 1994) criteria for ADHD; intellectual functioning ≥ 80; <italic>T</italic>-score ≥ 65 on the Conners’ Adult ADHD Rating Scale-Self-Report (CAARS; <xref rid="R20" ref-type="bibr">Conners, Erhardt, &amp; Sparrow, 1999</xref>) for either the Inattentive Symptoms subscale, Hyperactive-Impulsive Symptoms subscale, Total DSM-IV Symptoms subscale, or ADHD Index; Clinical Global Impression score ≥ 4; and were generally healthy (i.e., no major medical problems). Participants were not required to have received a diagnosis of ADHD prior to study participation. Exclusion criteria included: met criteria for an <italic>DSM-IV</italic> Axis I disorder other than ADHD that was the primary diagnosis and required clinical intervention; an Axis II disorder diagnosis; unable to attend sessions; and anticipated substantial changes in psychiatric medication treatment status (i.e., changes in type or dose of medication in the next six months). Comorbidity was not an exclusion criterion providing that ADHD symptoms were the primary concern and target for treatment according to the clinician performing the assessment (a PhD-level licensed clinical psychologist) and study participant. Participants taking psychotropic medications were allowed to participate and encouraged to continue their treatment with minimal changes throughout the study—any changes during the course of the study were recorded. Two participants in the treatment group reported changes in their psychiatric medication regimen during their enrollment. One participant was prescribed Percocet (five 2.5mg/325mg tablets) to take for tooth pain during week two of treatment, whereas another participant stopped taking a prescription for Adderall XR for seven days during week six of treatment. The latter change in medication status was unplanned. None of the participants in the waitlist reported any changes in medication use during their enrollment. This study was approved by the local IRB.</p></sec>
24305060|Measures|('method', 0.9953317374353386)|('other', 0.004668262564661343)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Measures</title><sec id="S10"><title>Screening and Diagnostic Measures</title><p id="P13">Following informed consent, demographic information and medical, psychiatric, and substance use histories were collected at a screening visit. IQ was assessed by the Kaufman Brief Intelligence Test, Second Edition (<xref rid="R39" ref-type="bibr">Kaufman &amp; Kaufman, 2004</xref>). The Childhood ADHD Symptom Scale-Self-Report (<xref rid="R8" ref-type="bibr">Barkley &amp; Murphy, 2006</xref>) and the Conners Adult ADHD Rating Scale (CAARS)-Self-Report (<xref rid="R20" ref-type="bibr">Conners et al., 1999</xref>) were administered, followed by the Conners Adult Diagnostic Interview for <italic>DSM-IV</italic> (CAADID; <xref rid="R24" ref-type="bibr">Epstein, Johnson, &amp; Conners, 2000</xref>) to assess full ADHD diagnostic criteria. The computerized Structured Clinical Interview for the <italic>DSM-IV</italic> (SCID; <xref rid="R29" ref-type="bibr">First, Spitzer, Williams, &amp; Gibbon, 2002</xref>) and follow-up clinical interviewing to assess Axis I disorders was also conducted. All interviews were administered by a PhD-level clinical psychologist.</p></sec><sec id="S11"><title>Treatment outcome</title><p id="P14">Assessments of response to treatment included (a) self-report rating scales and clinician-administered interviews completed in the laboratory, (b) EF laboratory tasks, and (c) self-report rating scales completed <italic>via</italic> electronic diary outside of the laboratory.</p></sec><sec id="S12"><title>Treatment outcome: Rating scales and clinician interviews</title><p id="P15">ADHD symptoms were assessed in the laboratory with the self-report and un-blinded clinician rating versions of the Current ADHD Symptoms Scale (<xref rid="R8" ref-type="bibr">Barkley &amp; Murphy, 2006</xref>). In addition to assessing all 18 symptoms for ADHD from the <italic>DSM-IV</italic>, this measure assesses 10 different domains that could be impacted by these symptoms (e.g., “In your home life with your immediate family”). Participant ratings for this scale ranged from 1 (“not all or rarely”) to 4 (“very often”). This scale or similar versions are widely administered in adult ADHD psychosocial treatment outcome research (e.g., <xref rid="R36" ref-type="bibr">Hirvikoski et al., 2011</xref>; <xref rid="R57" ref-type="bibr">Safren et al., 2005</xref>, <xref rid="R58" ref-type="bibr">2010</xref>; <xref rid="R74" ref-type="bibr">Zylowska et al., 2008</xref>). Similar to past treatment outcome studies (e.g., <xref rid="R57" ref-type="bibr">Safren et al., 2005</xref>, <xref rid="R58" ref-type="bibr">2010</xref>), ADHD symptoms were assessed within the past week.</p><p id="P16">EF rating scales included the Deficits in Executive Functioning Scale (DEFS; <xref rid="R5" ref-type="bibr">Barkley, 2011</xref>) and the Behavior Rating Inventory of Executive Functioning-Adult Version (BRIEF-A; <xref rid="R56" ref-type="bibr">Roth, Isquith, &amp; Gioia, 2005</xref>). The DEFS included the 89-item self-report form and the 20-item clinician interview form. Response options for both versions of the DEFS ranged from 1 (“never or rarely”) to 4 (“very often”). The DEFS includes five subscales measuring various facets of EF and an overall total score. The DEFS has high internal consistency (<xref rid="R13" ref-type="bibr">Biederman et al., 2008</xref>; <xref rid="R28" ref-type="bibr">Fedele, Hartung, Canu, &amp; Wilkowski, 2010</xref>), good test-retest reliability (<xref rid="R5" ref-type="bibr">Barkley, 2011</xref>), good discriminant validity (<xref rid="R13" ref-type="bibr">Biederman, et al., 2008</xref>; <xref rid="R28" ref-type="bibr">Fedele, et al., 2010</xref>), and is associated with various indices of impairment that suggests good ecological validity (<xref rid="R7" ref-type="bibr">Barkley &amp; Fischer, 2011</xref>; <xref rid="R10" ref-type="bibr">Barkley &amp; Murphy, 2010b</xref>; <xref rid="R13" ref-type="bibr">Biederman, et al., 2008</xref>). For the current study, the DEFS was modified to assess EF behaviors over the past week. The BRIEF-A is a 75-item self-report form with response options ranging from 1 (“never”) to 3 (“often”). The BRIEF-A assesses EF behaviors over the past 30 days. The BRIEF-A yields an overall total score (i.e., Global Executive Composite) that is composed of two index scores (i.e., the Behavioral Regulation Index and Metacognitive Index). The Behavioral Regulation index contains four subscales (Inhibit, Shift, Emotional Control, and Self-Monitor) and the Metacognitive Index is composed of five subscales (Initiate, Working Memory, Plan/Organize, Task Monitor, and Organization of Materials). The BRIEF-A has excellent internal consistency for the three main higher order indices, excellent test-retest reliability, and has demonstrated convergent and divergent validity (<xref rid="R56" ref-type="bibr">Roth, et al., 2005</xref>). Internal consistency of the nine subscales ranges from acceptable to good (<xref rid="R32" ref-type="bibr">Giancola, Godlaski, &amp; Roth, 2012</xref>).</p><p id="P17">Emotion dysregulation was assessed by the Difficulties in Emotion Regulation Scale (DERS; <xref rid="R33" ref-type="bibr">Gratz &amp; Roemer, 2004</xref>) and the Distress Tolerance Scale (DTS; <xref rid="R63" ref-type="bibr">Simons &amp; Gaher, 2005</xref>).The DERS is a 36-item scale that assesses how often emotionally dysregulated behavior occurs on a scale from 1 (“almost never”) to 5 (“almost always”). The DERS has high internal consistency, good test-retest reliability, and adequate construct and predictive validity (<xref rid="R33" ref-type="bibr">Gratz &amp; Roemer, 2004</xref>). The DTS is a 15-item scale with response options ranging from 1 (“strongly agree”) to 5 (“strongly disagree”). The DTS measures distress tolerance, which is a construct proposed to be a component of emotional dysregulation (<xref rid="R44" ref-type="bibr">Leyro, Zvolensky, &amp; Bernstein, 2010</xref>). Higher scores on this scale indicate higher tolerance for psychological distress. The DTS has demonstrated good internal consistency, in addition to convergent and discriminant validity (<xref rid="R63" ref-type="bibr">Simons &amp; Gaher, 2005</xref>). Both the DERS and DTS were modified to assess behavior over the past week.</p></sec><sec id="S13"><title>Treatment outcome: Laboratory tasks</title><p id="P18">To measure components of EF, the following laboratory tasks were administered: the Attention Network Task (ANT; <xref rid="R25" ref-type="bibr">Fan &amp; Posner, 2004</xref>), which is a computerized test measuring alerting (maintaining a vigilant state of preparedness), orienting (selecting a stimulus among multiple inputs), and conflict (prioritizing among competing tasks); Conners’ Continuous Performance Test (CPT; <xref rid="R21" ref-type="bibr">Conners, 1995</xref>), which is a measure of response inhibition; the Digit Span Test (<xref rid="R67" ref-type="bibr">Wechsler, 2008</xref>), which is a measure of working memory; and the Trail Making Test (<xref rid="R55" ref-type="bibr">Reitan, 1979</xref>), which assesses attentional set-shifting and inhibition. These tasks were selected primarily based on findings from <xref rid="R74" ref-type="bibr">Zylowska et al. (2008)</xref>.</p></sec><sec id="S14"><title>Treatment outcome: EMA</title><p id="P19">ADHD and EF symptoms were assessed via electronic diary as well. All 18 DSM-defined ADHD symptoms (<xref rid="R1" ref-type="bibr">APA, 2000</xref>) were administered to assess inattentive and hyperactive-impulsive ADHD symptoms at the moment of each assessment on a scale from 1 (“not at all”) to 5 (“extremely”). The DEFS (20-item) and an abbreviated BRIEF-A (27-item) were administered to assess EF at the moment of each assessment on a scale from 1 (“not at all”) to 5 (“extremely”). For the BRIEF-A, three items from each subscale were selected. These items were selected based on the magnitude of the correlation that item had with total scores (self-reported) reported in the BRIEF-A manual (<xref rid="R56" ref-type="bibr">Roth et al., 2005</xref>). The three highest magnitudes were chosen for each subscale.</p></sec><sec id="S15"><title>Feasibility and treatment acceptability</title><p id="P20">Feasibility was assessed by examining treatment group attrition and session attendance. Consistent with past adult ADHD treatment outcome research (<xref rid="R36" ref-type="bibr">Hirvikoski et al., 2011</xref>), attrition of &lt;25% and attendance of ≥ 75% of sessions were set to establish feasibility. Homework compliance was also considered for feasibility. Therapists completed an item assessing the degree to which each group member was compliant with homework immediately after each session. Therapists provided a rating on a scale of 1 (not at all) to 5 (extremely strong). Treatment acceptability was evaluated based on responses to an evaluation questionnaire adapted from (<xref rid="R16" ref-type="bibr">Bramham et al., 2009</xref>), which assessed how satisfactory participants felt that the treatment was overall (ranging from 1–7 with 7 indicating the highest rating of treatment satisfaction). Additional acceptability items assessed participant perceptions about the extent of ADHD psychoeducation they received, how the content was relevant to their experiences, whether the techniques/strategies introduced were understandable, if they were confident about regularly using the techniques taught, and if they would recommend mindfulness training to other adults with ADHD (on a scale ranging from 1 [not at all] to 4 [extremely]).</p></sec></sec>
24305060|Procedures|('method', 0.9953317374353386)|('other', 0.004668262564661343)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S16"><title>Procedures</title><p id="P21">Three laboratory visits were required: screening, baseline assessment, and eight-week assessment. Fifty-nine potential participants completed a telephone prescreen and 26 were invited for an in-person screening. Among the reasons for being excluded following telephone prescreening included: received cognitive-behavioral therapy for ADHD or mindfulness training in the past two years (<italic>n</italic> = 8), scheduling difficulty (<italic>n</italic> = 11), diagnosed with a substance use disorder requiting treatment (<italic>n</italic> = 1), outside of required age range (<italic>n</italic> = 7), diagnosed with a non-substance use Axis I disorder other than ADHD requiring treatment (<italic>n</italic> = 2), chronic medical problems (<italic>n</italic> = 1), diagnosed with an Axis II disorder (<italic>n</italic> = 1), and other reasons (<italic>n</italic> = 2)<sup><xref ref-type="fn" rid="FN2">1</xref></sup>. Among the 26 invited for the in-person screening, four failed the in-person screening for various reasons (<italic>n</italic> = 2 for anticipated substantial changes in their psychiatric medication status, <italic>n</italic> = 1 for not meeting diagnostic criteria for ADHD, and <italic>n</italic> = 1 for initiating psychotherapy involving aspects of mindfulness at the time of the assessment). A total of 22 subjects were enrolled. Participants were stratified by ADHD medication status and otherwise randomized to the treatment group (<italic>n</italic> = 11) or waitlist control group (<italic>n</italic> = 11). Two participants in the waitlist group dropped out soon after randomization due to (a) a substantial change in psychiatric medication status and (b) time constraints that restricted participation. <xref rid="F1" ref-type="fig">Figure 1</xref> summarizes sample recruitment. <xref rid="T1" ref-type="table">Table 1</xref> summarizes sample characteristics.</p><p id="P22">Following office screening visits conducted by a Master’s level research coordinator and a Ph.D. clinical psychologist, participants were stratified by ADHD medication status and randomized to a treatment or waitlist group. A waitlist group was chosen to control for the effects of time between assessments. Baseline and eight-week assessments were conducted within two weeks immediately prior to and following treatment for the treatment group. During both visits, medications were taken as prescribed. Dosage amount and timing of dosage was assessed to ensure uniformity. Ecological momentary assessments for two-day periods during baseline and eight-week assessments were also conducted. For these assessments, participants carried an electronic diary with them for two days and completed questionnaires about their behavior at that moment when prompted by an audible alarm (see below).</p><sec id="S17"><title>EMA Procedures</title><p id="P23">Participants received individual electronic diary training during baseline assessment visits. Assessment questionnaire and a random alarm mechanism were designed with Entryware Designer software version 6.3 developed by Techneos Systems, Inc. The electronic diaries were administered on Treo 755P handheld computers. After completing training in the use of the handheld electronic diaries (approximately 30 minutes), participants began a two-day sampling period. During this period, participants were prompted to complete an EMA entry by alarm. Alarm entries took approximately 2–4 minutes. These entries included questions about the participant’s situation, affect, ADHD symptoms, and EF symptoms. ADHD and EF symptoms were considered in the current study. Alarm entries were initiated by an audible alarm approximately every 1.25 hours during waking hours to result in approximately 10 alarms daily. If participants did not respond within two minutes after the alarm sounded (six audible beeps), the electronic diary would not allow the participant to respond, a missed alarm was recorded, and the alarm would reset to go off approximately 10 to 20 minutes later. If participants did respond within two minutes of an alarm, they were provided the option to choose “snooze” (the alarm would sound five minutes later), “skip” (the alarm would be delayed and sound 30–40 minutes later) or “answer.” Participants were instructed on how to turn off the audible alarm while they slept, and for short periods during the day when it may be dangerous (e.g., driving) or inappropriate (e.g., showering) to respond. Participants were allowed to choose how long to temporarily turn off the alarm, though the alarm did not require reactivation as it was programmed to automatically resume.</p></sec><sec id="S18"><title>Mindfulness Meditation Training</title><p id="P24">The Mindful Awareness Practices (MAPs) for ADHD program (<xref rid="R74" ref-type="bibr">Zylowska et al., 2008</xref>) was administered (see (<xref rid="R46" ref-type="bibr">Mitchell, et al., submitted</xref>) and <xref rid="R74" ref-type="bibr">Zylowska et al., 2008</xref>, for more thorough descriptions) by a PhD-level clinical psychologist. This eight-week program was composed of weekly group therapy sessions lasting 2.5hrs and involved daily at-home practice. To complement material discussed in session, participants received a resource that facilitates use of mindfulness skills and is based on the MAPs program: <italic>The Mindfulness Prescription for Adult ADHD</italic> (<xref rid="R73" ref-type="bibr">Zylowska, 2012</xref>). This included a book that details various mindfulness practices taught in the group and a CD audio program that provided instruction for formal mindfulness meditation exercises (ranging from approximately 5–15 minutes). Any explicit directions on cognitive-behavioral therapy techniques within the book were removed prior to dispensing them to participants to minimize the potential influence of other treatment modalities. In the treatment itself, cognitive-behavioral therapy techniques are introduced during the final session (e.g., use of a calendar and reminders to encourage mindfulness meditation practices). Although this is an application of skills that are also taught in manualized cognitive behavioral approaches (e.g., <xref rid="R57" ref-type="bibr">Safren, Perlman, Sprich, &amp; Otto, 2005</xref>; <xref rid="R64" ref-type="bibr">Solanto, 2011</xref>), these skills are introduced in the context of supporting mindfulness practice only. Explicit instruction and demonstration of these cognitive-behavioral strategies are not provided as they are in manualized CBT interventions for adult ADHD.</p><p id="P25">Waitlist participants did not engage in any changes to any pre-existing treatments during the eight week period. After the eight-week assessment, waitlist group participants were administered the same treatment as the treatment group.</p><p id="P26">Participants were compensated up to US$115 for completing the study and an additional US$50 for returning electronic diary equipment at the end of the study.</p></sec></sec>
24305060|Data Reduction and Analysis|('method', 0.9953317374353386)|('other', 0.004668262564661343)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S19"><title>Data Reduction and Analysis</title><sec id="S20"><title>Electronic diary data reduction</title><p id="P27">EMA entries that were not completed within 25 minutes were removed. This time restriction resulted in removal of 26 alarm entries across the entire sample. A total of 797 readings were analyzed for the current study. Across the baseline and eight-week assessments (i.e., four days of EMA entries), the mean number of EMA entries was 39.85 (SD = 5.37, range 26–48).</p></sec><sec id="S21"><title>Data analysis</title><p id="P28">A repeated measures mixed design analysis of variance (ANOVA) was conducted with group status (treatment, waitlist) as the between subjects factor and time (baseline assessment, 8-week assessment) as the within subjects factor. Group by time interactions were considered to assess changes between groups over the two time points. Dependent variables included ADHD symptoms, functioning associated with ADHD symptoms, EF, and emotion dysregulation. All analyses were conducted with SPSS 19.0, with the exception of EMA analyses, which were conducted with SAS 9.2 (<xref rid="R59" ref-type="bibr">SAS Inc., 2008</xref>). To account for the nesting of multiple observations within subjects, EMA data were analyzed using generalized estimating equations (<xref rid="R71" ref-type="bibr">Zeger, Liang, &amp; Albert, 1988</xref>). Group by time interactions were considered for these analyses. Effect sizes were also computed for continuous outcome variables (<italic>d</italic> = Meanchange<sub>score treatment group</sub> − Meanchange<sub>score comparison group</sub>/SD<sub>pooled</sub>). A decrease of ≥ 30% of symptom severity scores was also considered for ADHD symptoms, EF and emotion dysregulation total scale scores, which is consistent with guidelines used in other adult ADHD psychosocial treatment trials (<xref rid="R58" ref-type="bibr">Safren et al., 2010</xref>; <xref rid="R65" ref-type="bibr">Solanto et al., 2010</xref>; <xref rid="R74" ref-type="bibr">Zylowska, et al., 2008</xref>).</p></sec></sec>
24305957|None|('method', 0.9999880696510733)|('other', 1.1930348926764905e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
24305957|Materials|('method', 0.9999880696510733)|('other', 1.1930348926764905e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Materials</title><p id="P5">The MA/CAΔ protein substrate and its DNA construct have been described.<sup><xref rid="R12" ref-type="bibr">12</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> Purified HIV-1 protease (PR) was purified from <italic>Escherichia coli</italic> inclusion bodies as described previously.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> FlAsH tag (Lumino Green in-Cell Labeling Kit, #12589-057) was purchased from Invitrogen (Grand Island, NY). Dithiothreitol (DTT) (43815), EDTA (E5391), HEPES (H3375), and HIV Protease Substrate 1 (H6660) were obtained from Sigma-Aldrich (St. Louis, MO). DMSO (2951) was purchased from EMD (Waltham, MA). Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) Criterion TGX Stain-Free gel (5678124) and SDS-PAGE loading buffer were obtained from Bio-Rad (Hercules, CA). The 384-well microplates (3575) were from Corning (Tewksbury, MA).</p></sec>
24305957|Chemical Library|('method', 0.9999880696510733)|('other', 1.1930348926764905e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Chemical Library</title><p id="P6">The library was selected from 170,000 compounds that have passed more than one of the four Lipinski drug-like properties,<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup> have less than 10 rotatable bonds, and have passed all of the four-dozen reactivity filters proposed by Hann et al.<sup><xref rid="R22" ref-type="bibr">22</xref></sup> and Pearce et al.<sup><xref rid="R23" ref-type="bibr">23</xref></sup> The 24,000 selected compounds were dissolved in DMSO and shaken overnight at 300 rpm on a G10 Gyrotary (New Brunswick Scientific, Edison, NJ). Each orthogonal pooled library (OPL) was constructed as described earlier.<sup><xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> Briefly, we used a Janus Pipetting Workstation (PerkinElmer, Waltham, MA) to transfer 10 μL of a 10-mM compound from ten 96-well source plates to five 384-well plates. Each well from the source plate was delivered twice and recombined with wells from the other nine plates. The pools in the 384-well plates contained 10 compounds at 1 μM in 100 μL. Screening data from OPL were de-convoluted using the10XYZ OpenHTS module (CeuticalSoft, Inc., Hudson, NY).<sup><xref rid="R26" ref-type="bibr">26</xref></sup></p></sec>
24305957|Liquid-Handling Robotics|('method', 0.9999880696510733)|('other', 1.1930348926764905e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Liquid-Handling Robotics</title><p id="P7">Assay reactions were prepared in 384-well plates. Compounds were added to the wells with a 384-tip liquid-handling robot (NanoScreen NSX 1536) equipped with low-volume tips (#30 ulnc; NanoScreen, Charleston, SC). Substrates and enzymes were added with a MultiDrop Combi (5840400; Thermo Fisher, Waltham, MA) with a small cassette head (24073290).</p></sec>
24305957|Fluorescent Polarization Assay|('method', 0.9999880696510733)|('other', 1.1930348926764905e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Fluorescent Polarization Assay</title><p id="P8">Fluorescent labeling of the substrate: Purified 2.3 μM MA/CAΔ was incubated with 0.2 μM FlAsH in 50 mM HEPES at pH 6.8 with 1 mM DTT at room temperature for 1 h. Then, 13 μL of a 2.3-μM labeled substrate was added to assay plates containing either 3 μL of 10 μM of inhibitors (columns 3–22) or 1% DMSO (columns 1–2 and 23–24). After incubation for 15 min at room temperature, HIV-1 protease was added to columns 1 to 22. Heat-inactivated protease was added to columns 23 to 24. We have also found that saquinavir at 50 nM produced the same inhibition as heat-inactivated protease (data not shown). The final proteolysis reaction contained 1 μM MA/CAΔ 1 μM inhibitors and 100 nM protease.</p><p id="P9">After a 2-h proteolysis at 37 °C, FP values were measured, with excitation at 485 nm and emission at 530 nm using an Aquest GT Microplate Reader (Molecular Devices, Sunnyvale, CA). The data were analyzed using software from ScreenAble Solutions (Chapel Hill, NC).</p></sec>
24305957|Fluorescent Assay of HIV Protease Substrate 1|('method', 0.9999880696510733)|('other', 1.1930348926764905e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Fluorescent Assay of HIV Protease Substrate 1</title><p id="P10">The assay was carried out as described above for the FP assay, except HIV protease substrate 1 instead of MA/CAΔ was used. The fluorescence was measured with excitation at 340 nm and emission at 490 nm using an EnVision Microplate Reader (PerkinElmer).</p></sec>
24305957|Gel Assay|('method', 0.9999880696510733)|('other', 1.1930348926764905e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Gel Assay</title><p id="P11">A HIV-1 PR assay was performed as described for the FP assay, except that 2 μM FlAsH was used during the labeling procedure. After 2 h, 20 μL of the reaction was stopped with 4× SDS-PAGE sample buffer, analyzed by SDS-PAGE, and visualized using a gel scanner (Bio-Rad) with excitation at 488 nm and emission at 530 nm.</p></sec>
24305957|Data Analysis|('method', 0.9999880696510733)|('other', 1.1930348926764905e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Data Analysis</title><p id="P12">Percent inhibition values for the FP assay and fluorescent assay values from each plate were analyzed using ScreenAble software. The Z′ for each plate<sup><xref rid="R27" ref-type="bibr">27</xref></sup> was determined using columns 1 and 2 as positive controls and 23 and 24 as negative controls. IC<sub>50</sub> values were calculated with 95% confidence intervals based on a sigmoidal dose-response curve using a four- or three-parameter logistic equation featured in the GraphPad software (GraphPad Software, La Jolla, CA). The GraphPad Prism 5.0 program produced the graphic representations in the figures.</p></sec>
24335852|None|('method', 0.9998700013326131)|('other', 0.00012999866738693468)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and methods</title>
24335852|Animals|('method', 0.9998700013326131)|('other', 0.00012999866738693468)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Animals</title><p id="P8">Male Sprague-Dawley rats (150–175 g, Harlan) were housed in a climate-controlled room with a 12-hour light/dark cycle (lights on at 7:00 a.m.) with food and water ad libitum. Studies were performed while animals were on their light cycle between the times of 7:00 a.m. and 7:00 p.m. All procedures were performed in compliance with the National Institutes of Health (NIH) guidelines for use of laboratory animals and with the regulations of the Institutional Animal Care and Use Committee (IACUC) of the University of Arizona. Behavioral studies were performed by an experimenter blinded to the treatment conditions.</p></sec>
24335852|Induction of latent sensitization|('method', 0.9998700013326131)|('other', 0.00012999866738693468)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Induction of latent sensitization</title><p id="P9">Rats were maintained under light anesthesia (2% isoflurane in room air at 1 l/minute) and surgically implanted (Day 0) with osmotic minipumps (Alzet, Cupertino, CA, USA; model 2001) to constantly deliver sumatriptan (0.6 mg/kg/day) or 0.9% saline at a nominal flow rate of 1 µl/hour for seven days (<xref rid="R21" ref-type="bibr">21</xref>). Sumatriptan was provided by Neuraxon Inc. The minipumps were removed on Day 6 under isoflurane anesthesia.</p></sec>
24335852|Recording of electrical stimulation-induced CSD events|('method', 0.9998700013326131)|('other', 0.00012999866738693468)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Recording of electrical stimulation-induced CSD events</title><p id="P10">On Day 20 (i.e. 14 days after minipump removal), rats were anesthetized with divided doses of urethane until surgical anesthesia was obtained (mean dose: 1.8 g/kg, intraperitoneally (i.p.)). Urethane was used to provide very long-lasting anesthesia without significant effect on CSD initiation and propagation (<xref rid="R22" ref-type="bibr">22</xref>). Anesthetized rats were mounted in a stereotaxic headholder and body temperature was maintained at 37°C with a feedback-controlled heating pad. As described previously (<xref rid="R23" ref-type="bibr">23</xref>), the skull was exposed and burr holes made to place the 1 mm ball tips of Ag/AgCl recording electrodes on the dura of the frontal and parietal cortices (2.0 mm right lateral, 1.5 mm anterior and 2.5 mm posterior to bregma, respectively). The reference electrode was located on the midline, 11.5 mm posterior to bregma or over the left hemisphere (6.5 mm posterior and 3 mm lateral to bregma). The free ends of the electrodes were soldered to a multipin connector (Continental Connector, Hatfield, PA). A pair of coated tungsten electrodes, with tips 1 mm apart (A–M systems, WA, 98382) was inserted 1.2 mm into cortical tissue through a burr hole over the visual cortex. Two small machine screws were threaded into the skull and the entire electrode assembly was secured with acrylic. The animal was then placed on a feedback-controlled heating pad in a Faraday cage for electroencephalographic (EEG) recordings. The presence of EEG burst suppression was used as an indicator of anesthetic overdose; consequently, animals showing burst suppression were not used in the study.</p><p id="P11">Electrical signals were acquired through a DC amplifier (15A12, Grass Instruments) to process DC potentials and an AC amplifier (15A54, Grass Instruments) to process the EEG potentials (<xref rid="R23" ref-type="bibr">23</xref>). Data were digitized at 100 Hz and recorded with Gamma v.4.9 (Astro-Med Inc) and analyzed offline. Recordings were begun at least 30 minutes prior to any manipulations to allow stabilization and to provide for a refractory period for any CSDs that might have been initiated as a result of surgery (<xref rid="R20" ref-type="bibr">20</xref>). Thirty minutes prior to initiating the electrical stimulation protocol, rats received an i.p. injection of either vehicle or topiramate (Janssen Pharmaceuticals Inc, Raritan, NJ), which was obtained from the pharmacy and prepared as a suspension (<xref rid="R24" ref-type="bibr">24</xref>). Electrical stimulation (Isolated Pulse Stimulator Model 2100; A–M Systems) was applied at four-minute intervals with charge increasing from 10 µC to 7000 µC by varying both current intensity and duration (<xref rid="R24" ref-type="bibr">24</xref>). The stimulation began with 1 mA for 10 msec and increased in steps of 25, 50, 100, 200, 300, 400 msec, then at 2 mA for 300, 800, 1000 msec, 3 mA for 400 msec, 4 mA for 400, 500, 1000 msec, 5 mA for 1000 msec, 6 mA for 1000 msec, and 7 mA for 1000 msec (<xref rid="R24" ref-type="bibr">24</xref>). The stimulation protocol was terminated once a CSD occurred. CSD events were identified by a marked reduction in EEG amplitude along with a corresponding change in membrane potential (i.e. DC shift) (<xref rid="R25" ref-type="bibr">25</xref>). If a CSD did not occur then the animal was assigned a threshold corresponding to the highest charge obtained.</p></sec>
24335852|Behavioral testing for tactile sensitivity|('method', 0.9998700013326131)|('other', 0.00012999866738693468)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Behavioral testing for tactile sensitivity</title><p id="P12">Behavioral thresholds to evoked stimuli were determined by applying calibrated von Frey filaments perpendicularly to the periorbital region and the plantar aspect of the hindpaw until a withdrawal response was elicited. The 50% withdrawal thresholds were determined by the Dixon “up and down” method (<xref rid="R21" ref-type="bibr">21</xref>,<xref rid="R26" ref-type="bibr">26</xref>–<xref rid="R28" ref-type="bibr">28</xref>). Additional groups of rats were exposed to bright light for one hour while in their home cages. A pair of halogen shop lights were placed 350 cm from both of the larger sides of the clear Plexiglas cage to deliver between 1300 lux to 1500 lux, approximating full daylight. With these parameters, temperature change inside the cage varied by less than 1°C. Periorbital and hind-paw sensory thresholds were measured every hour for six hours after exposure. The bright light stress was repeated 24 hours after the first exposure and behavioral sensory thresholds were assessed at hourly intervals for 6 hours.</p></sec>
24335852|Immunohistochemistry for trigeminal nucleus caudalis (TNC) Fos|('method', 0.9998700013326131)|('other', 0.00012999866738693468)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Immunohistochemistry for trigeminal nucleus caudalis (TNC) Fos</title><p id="P13">Two hours after eliciting either a CSD or after bright light stress, the anesthetized rats were perfused, transcardially, with 1X phosphate-buffered saline and then 4% paraformaldehyde. Coronal sections (30 µm thick) of the caudal medulla were permeabilized with 0.2% TritonX100, blocked with 5% normal goat serum and incubated overnight with rabbit polyclonal anti-Fos (Santa Cruz, SC-52, 1:25,000). The sections were incubated with biotinylated anti-rabbit antibody followed by the ABC complex (Vectastain Elite ABC kit, Vector Labs) and Tyramide Signal Amplification detection (TSA Plus Fluorescein Kit, Perkin Elmer). Slides were mounted in Vectashield mounting medium (Vector Lab Inc). Photomicrographs of 10 to 15 caudal medullary sections per rat, at increments of 100 µm, were examined with ImageJ, by an experimenter blinded to the treatments, for Fos-positive nuclear puncta within the outer laminae of the TNC ipsilateral to the cortical hemisphere receiving electrical stimulation. The numbers of Fos-positive profiles found per section was recorded, and data presented as median and interquartile range for each treatment group.</p></sec>
24335852|Statistical analyses|('method', 0.9998700013326131)|('other', 0.00012999866738693468)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Statistical analyses</title><p id="P14">CSD stimulation thresholds were compared among groups with the Kruskal-Wallis test followed by Dunn’s Multiple Comparison Test to identify significant differences among groups, as were the Fos counts in TNC sections. The behavioral paradigms, DC shifts and propagation speeds were analyzed by analysis of variance (ANOVA) followed by Tukey’s correction for multiple comparisons. In addition, Fast Fourier Transform (FFT) analyses were performed on EEG traces taken at 60-second intervals prior to CSD and centered within the CSD in order to detect changes in EEG amplitude and power. Comparisons for the stimulation threshold to initiate a CSD, DC deflection, CSD duration, propagation time, spectral power, and amplitude among the treatment groups were analyzed by ANOVA followed by Tukey’s correction for multiple analysis.</p></sec>
24356862|Methods|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<title>Methods</title>
24356862|Study design|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec3"><title>Study design</title><p>Between April 2011 and February 2012 we conducted a prospective, partially blinded RCT at the medical and surgical ICU of Ghent University Hospital. Criteria for inclusion were the need for antibiotic treatment with PTZ and/or MEM, age of ≥18 years, and the presence of an arterial catheter. Patients were excluded in the case of pregnancy and/or lactation, allergy to the administered medication, impaired renal function {estimated glomerular filtration rate as assessed by the CKD–EPI equation of &lt;80 mL/min [<xref ref-type="bibr" rid="CR28">28</xref>]}, hemoglobin of &lt;7 g/dL, or do-not-resuscitate orders or if the patient was expected not to survive the first 48 h.</p><p>Patients were randomly assigned to the control group, receiving conventional dosing, or the intervention group, subjected to TDM-guided dosing which consisted of daily monitoring of the antibiotic plasma concentration, followed by dosing adjustment if the concentration did not meet the predefined target. In the control group, antimicrobial concentration was also measured daily, but the treating physician was blinded to the results, and the data were used for comparison only. Total duration of the study was 7 days. Patients were followed up until hospital discharge.</p><p>All antibiotics were administered according to the extended infusion protocol used at Ghent University Hospital: patients received a loading dose (1 g MEM or 4 g PTZ) administered over 30 min, followed immediately by the first extended infusion dose of either antibiotic (1 g MEM or 4 g PTZ) at 6-h (PTZ) or 8-h (MEM) intervals. Extended infusion doses were administered over 3 h using a syringe pump. All antibiotics were administered via a central venous catheter.</p><p>Target concentrations in the intervention group were in line with those reported previously using TDM in critically ill patients. It is traditionally accepted that maintaining concentrations above the minimal inhibitory concentration (MIC) of the causative organisms during 40–70 % of the time is adequate. However, recent studies suggest that higher targets are needed in critically ill patients. Given the fact that concentrations four to fivefold greater than the MIC are associated with maximal bactericidal activity [<xref ref-type="bibr" rid="CR29">29</xref>–<xref ref-type="bibr" rid="CR31">31</xref>], the PK/PD target in this study was set at 100 % <italic toggle="yes">f</italic>T<sub>&gt;4MIC</sub> [percentage of time during a dosing interval that the free (<italic toggle="yes">f</italic>) drug concentration exceeded 4 times the MIC] as in previous studies [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR32">32</xref>].</p><p>Based on actual antibiotic concentrations, dosing of intervention patients then followed a pre-established algorithm (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Until the MIC of the causative microorganism was known, the epidemiological cutoff of wild-type <italic toggle="yes">Pseudomonas</italic> spp. (16 mg/L for PTZ and 2 mg/L for MEM) was targeted, and this MIC was used for all calculations in the study as we only investigated the effect of dose adaptation in the first 72 h—the time it would usually take to determine a MIC of the actual infecting organism. Target trough concentrations were therefore &gt;64 mg/L for PTZ and &gt;8 mg/L for MEM, respectively (&gt;4× MIC). In the case of lower concentrations, dosing frequency was increased as a first step in the intervention (4 g/0.5 g every 4 h for PTZ and 1 g every 6 h for MEM). If MEM concentrations remained below the target, the dose was increased by 50 %. If these adjustments failed to reach the targets, no further actions were taken. In patients with trough concentrations of &gt;10× MIC, the antibiotic dose was decreased by 50 % or the dosing frequency reduced if this had been increased in an earlier step.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Therapeutic drug monitoring (TDM)-based dose adaptation strategy. <italic toggle="yes">MIC</italic> Minimal inhibitory concentration, <italic toggle="yes">MEM</italic> meropenem. <italic toggle="yes">Asterisk</italic> see text for details</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2013_3187_Fig1_HTML.gif" id="MO1" position="float" orientation="portrait"/></fig></p></sec>
24356862|Endpoints|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec4"><title>Endpoints</title><p>Target attainment defined as 100 % <italic toggle="yes">f</italic>T<sub>&gt;MIC</sub> and 100 % <italic toggle="yes">f</italic>T<sub>&gt;4MIC</sub> within the first 72 h of treatment were the primary endpoints. The <italic toggle="yes">f</italic>T<sub>&gt;MIC</sub> and <italic toggle="yes">f</italic>T<sub>&gt;4MIC</sub> at 72 h were compared between the intervention and control groups, as well as between baseline and at 72 h after initiation of treatment. Although fourfold the MIC was the target of the intervention, we also wanted to study the effect of the intervention on a more conservative PK target, hence 100 % <italic toggle="yes">f</italic>T<sub>&gt;MIC</sub> was also used as an endpoint.</p><p>Secondary endpoints were absolute values of <italic toggle="yes">f</italic>T<sub>&gt;MIC</sub> and <italic toggle="yes">f</italic>T<sub>&gt;4MIC.</sub></p><p>Clinical response at the end of the study (day 7) was evaluated by two of the authors. Resolution was defined as the disappearance of all signs and symptoms related to infection, improvement was defined as a marked or moderate reduction in the severity and/or number of signs and symptoms of infection and failure was defined as insufficient lessening of the signs and symptoms of infection to qualify as improvement, including death. Response to therapy was also evaluated by bacterial persistence at day 7.</p></sec>
24356862|Patient data collection|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec5"><title>Patient data collection</title><p>Relevant data were retrieved from the hospital’s Electronic Patient File and the unit’s Patient Data Management System and included demographic parameters (gender, age), weight, length, date of hospital/ICU admission and discharge, start and end date of the antibiotic treatment with PTZ/MEM, comorbidities, admission diagnosis, type of infection, Acute Physiology And Chronic Health Evaluation (APACHE)-II score, daily Sequential Organ Failure Assessment (SOFA) score, daily body temperature, urinary output and outcome (survival or death) including cause of death. The following laboratory results were recorded: white blood cell count, platelet count, fibrinogen, C-reactive protein, serum creatinine, urinary creatinine and microbiological data.</p></sec>
24356862|Study samples|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec6"><title>Study samples</title><p>Blood samples were collected daily; during the first 3 days mid-dose (i.e. halfway the dosing interval) and trough samples were obtained and during the last 4 days of the study only trough concentrations were determined. On the first study day, the first sample (baseline concentration) was drawn after at least three completed infusions of the antibiotic. Twenty-four-hour urinary creatinine clearance was measured throughout the study period. The calculated creatinine clearance was corrected for the body surface area.</p></sec>
24356862|Sample analysis|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec7"><title>Sample analysis</title><p>The TDM samples were analysed at the Department of Laboratory Medicine of Ghent University Hospital. PTZ and MEM concentrations were assayed by validated ultra-high performance liquid chromatography–tandem mass spectrometry using oxacillin as an internal standard [<xref ref-type="bibr" rid="CR33">33</xref>].</p><p>Sample preparation consisted of protein precipitation using acetonitrile and subsequent dilution. A 5-μL sample was injected onto a BEH C<sub>18</sub> column (1.7 μm, 100 mm × 2.1 mm) (Waters Corp., Milford, MA), kept at 50 °C. The mobile phase consisted of 0.1 % formic acid in water and 0.1 % formic acid in acetonitrile at a flow rate of 0.350 mL/min. Separated compounds were detected with the Waters<sup>®</sup> TQD mass spectrometer, which operated in positive electrospray ionisation, using a compound-specific multiple reaction monitoring method. The run time was 5.5 min. The method was linear between 4 and 250 mg/L for PTZ and between 2 and 80 mg/L for MEM. Imprecision and inaccuracy were found to be &lt;15 % at high, medium and low concentrations. Concentrations considered to be below the linear range were reported as &lt;4 mg/L for PTZ and as &lt;2 mg/L for MEM. System performance was monitored by analysing three internal quality control samples at low, medium and high concentrations in each run.</p></sec>
24356862|PK and PD calculations|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec8"><title>PK and PD calculations</title><p>One concentration (C<sub>1</sub>) was taken halfway through the dosing interval; the second sample was a trough concentration (C<sub>2</sub>). Using these two concentrations, it is possible to calculate the elimination constant (Eq. <xref rid="Equ1" ref-type="disp-formula">1</xref>).<disp-formula id="Equ1"><label>1</label><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:mtext>ek</mml:mtext><mml:mspace width="0.166667em"/><mml:mo>·</mml:mo><mml:mspace width="0.166667em"/><mml:mi>t</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math><tex-math id="M2">\documentclass[12pt]{minimal}				\usepackage{amsmath}				\usepackage{wasysym} 				\usepackage{amsfonts} 				\usepackage{amssymb} 				\usepackage{amsbsy}				\usepackage{mathrsfs}				\usepackage{upgreek}				\setlength{\oddsidemargin}{-69pt}				\begin{document}$$ C_{2} = C_{1} - {\text{ek}}\,{ \cdot }\,t .$$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2013_3187_Article_Equ1.gif" position="anchor" orientation="portrait"/></alternatives></disp-formula></p><p>Assuming one-compartmental first-order kinetics, these data are sufficient to calculate the time within the dosing interval when the concentration drops beneath a certain threshold (1 or 4× MIC).</p></sec>
24356862|Power analysis|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec9"><title>Power analysis</title><p>The power analysis computed a required sample size of 16 patients per study group, taking into account a one-sided test with α = 0.05, β = 0.20 and an expected increase of target attainment (with trough concentrations of at least 4× MIC as a target) from 50 to 90 % of the patients. Taking into account a dropout rate of 20 %, 20 patients per group were projected.</p></sec>
24356862|Statistical analysis|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec10"><title>Statistical analysis</title><p>Statistical analysis was performed using IBM<sup>®</sup> SPSS<sup>®</sup> Statistics ver. 19.0 (SPSS Inc., Chicago, IL). Data for continuous variables are expressed as median values with interquartile ranges (IQR), and those for categorical variables as numbers and percentages. The Mann–Whitney <italic toggle="yes">U</italic> test for comparison of median values and the Friedman test or the Wilcoxon matched-pairs signed-ranks test were used where appropriate. Proportions were compared using 2 × 2 tables and the χ<sup>2</sup>-test or Fisher’s exact test as appropriate. A <italic toggle="yes">p</italic> value of ≤0.05 was considered to be statistically significant.</p></sec>
24356862|Ethics|('method', 0.9994141064285498)|('other', 0.0005858935714501631)|<sec id="Sec11"><title>Ethics</title><p>The study was approved by the Ethics Committee of the Ghent University Hospital (registration number 2010/814) and approved by the Belgian regulatory agency (B67021020250). Written informed consent was obtained from the patient or his/her legal representative.</p></sec>
24366966|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">METHODS</title>
24366966|Data|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Data</title><p id="P11">Data from waves I, II and IV of the National Longitudinal Study of Adolescent Health (Add Health) contractual dataset were utilized (<xref rid="R19" ref-type="bibr">Harris, 2009</xref>). Add Health is a prospective cohort study of a nationally-representative sample of young persons enrolled in grades 7-12 in the 1994-95 school year (Wave I) (<xref rid="R20" ref-type="bibr">Harris, 2011</xref>). Follow-up interviews were conducted in 1996 (Wave II), 2001 (Wave III), and 2007-08 (Wave IV). Add Health utilized a multistage probability clustered sampling design to obtain its original Wave I sample. The first stage of sampling was a stratified, random sample of all public and private high schools in the U.S. A feeder school was also recruited from each participating community. In-school surveys were attempted with all students attending participating schools; a total of 90,118 were completed. In the second Wave I sampling stage, a sample of adolescents was drawn for in-depth in-home interviews, consisting of a random core sample plus selected special oversamples; a total of 20,745 interviews were conducted at this stage. At Wave II, most students (except Wave I seniors) were eligible for re-interview; at Waves III and IV, all respondents to the Wave I in-home interview were eligible for re-interview. A total of 15,701 interviews were conducted at Wave IV (80.3% response rate). Sampling weights adjusted for both unequal probabilities of selection into the original sample and for loss to follow-up. The original Add Health study was approved by the Institutional Review Board (IRB) at the University of North Carolina at Chapel Hill; the present secondary analysis was deemed exempt from review by the Tulane University Biomedical IRB.</p><p id="P12">We applied a number of inclusion criteria for our analyses. First, we limited to females who participated in Wave IV, as that was the only Wave by which all respondents had completed their teenage years and thus had complete data on teen births. Second, we limited our analysis to female participants with valid sampling weights in order to make generalizations to the wider U.S. population, and to adjust for attrition across waves. Third, we limited to females whose first births occurred during adolescence and after Wave II to ensure the temporal ordering of predictors and outcomes. Fourth, we limited analyses to first singleton live births (n=655). Finally, we limited to females with complete information on all covariates. This left us with an analysis sample of 558 teen births. There were no statistically significant differences between included and excluded cases on any of the measured variables except for race (30.11% and 34.12% were Black in included and excluded cases, respectively; p=0.04).</p></sec>
24366966|Measures|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Measures</title><sec id="S9"><title>Outcomes</title><p id="P13">At Wave IV girls were asked about previous pregnancies and their outcomes. If they had gotten pregnant, they were asked “How did this pregnancy end?”, with options of abortion, ectopic/tubal, miscarriage, stillbirth, and livebirth. If they indicated they had given birth, they were asked “How much did the baby weigh at birth?”, “Was [baby's name] born before or after [his/her] due date?” and then “How many weeks or days early/late was [baby's name] born?” This was subtracted from 40 weeks to calculate gestational age.</p></sec><sec id="S10"><title>Partner Violence Predictors</title><p id="P14">At Wave II girls were asked about their romantic and non-romantic relationship history in the last 18 months. Up to 3 romantic partners and up to 3 non-romantic partners were reported by adolescent girls. For each partner, they were asked “Did [INITIALS] call you names, insult you, or treat you disrespectfully in front of others?” [Insulting]; “Did [INITIALS] swear at you?”[Swearing]; “Did [INITIALS] threaten you with violence?”[Threatening]; “Did [INITIALS] push or shove you?”[Pushing] and “Did [INITIALS] throw something at you that could hurt you?” [Throwing]. Responses were dichotomized into 0=no, 1=yes. If respondents answered “yes” to “Insulting,” “Swearing” or “Threatening” for ANY reported relationship, they were coded as “Ever had verbal abuse”. If they answered “yes” to “Pushing” or “Throwing” for ANY reported relationship, they were coded as “Ever had physical abuse”. Girls who reported no relationships were coded as not having experienced abuse.</p></sec><sec id="S11"><title>Mediators</title><p id="P15">Based on prior literature, we examined a number of potential mediators between dating violence and birth outcomes. First, <italic>timing of prenatal care initiation</italic> was based on two questions asked about each pregnancy reported at Wave IV: “During this pregnancy with [partner] did you ever visit a doctor, nurse-midwife or other health care provider for prenatal care, that is, for one or more pregnancy check-ups?” and “How many weeks pregnant were you at the time of your first prenatal care visit?” Responses to these two questions were combined and recoded to reflect prenatal care initiation in the first trimester versus no use or late initiation of prenatal care. Second <italic>cigarette smoking</italic> during pregnancy was assessed at Wave IV for each pregnancy reported. Respondents were asked to report on an ordinal scale how many cigarettes they smoked during their pregnancy (none / a few cigarettes but not every week / a few cigarettes a week but not every day / 10 or fewer a day / 11-20 a day / 21-30 a day / 31 or more a day). We combined responses into a dichotomous variable (yes / no) due to sparseness across smoker frequencies in the sample. Third, <italic>BMI category</italic> (underweight, normal, overweight, obese) was determined through adolescents’ self-reported height and weight at Wave I. This measure was included as a proxy for disordered eating.</p></sec><sec id="S12"><title>Controls</title><p id="P16">We drew upon our previous analysis of predictors of birth outcomes in this cohort to determine confounders (<xref rid="R21" ref-type="bibr">Harville et al., 2012</xref>). This analysis indicated effects of race, age at pregnancy, age at Wave I, and parental education. Self-reported race was categorized as Black / non-Black. Parental education was measured as the higher of either co-residential mother or father: less than high school diploma, high school diploma/general equivalency degree (GED) or higher. All such variables were measured at Wave I. Ethnicity (Hispanic vs. not) did not predict the outcomes in both the prior and current sample and thus was excluded.</p><p id="P17">Two other theoretically-relevant controls were also included. The <italic>time interval</italic> between Wave II interviews and the birth, in addition to interactions between this time interval and reports of verbal and physical partner abuse, were included. We included these variables to test whether partner violence experiences reported at Wave II more strongly influenced pregnancies that occurred soon after the reported abuse. Adolescent girls’ experience of <italic>sexual abuse</italic> and <italic>physical abuse</italic> in their family-of-origin were also included, to test the distinct contributions of partner violence and family-of-origin violence. At the wave IV interview, participants were asked to recall any maltreatment experience before age 18. We created two variables from the following questions: “Before your 18th birthday, how often did a parent or adult caregiver hit you with a fist, kick you, or throw you down on the floor, into a wall, or down stairs?” [Family physical abuse] and “How often did a parent or other adult caregiver touch you in a sexual way, force you to touch him or her in a sexual way, or force you to have sexual relations?” [Family sex abuse]. Responses were dichotomized into 0=never, 1=one or more times.</p></sec></sec>
24366966|Analyses|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>Analyses</title><p id="P18">All analyses were conducted in SAS (SAS Institute, Cary, North Carolina) using survey procedures, which apply population weights and adjust standard errors for non-independence between observations due to school-based sampling. All analyses were conducted stratified on race (Black vs. non-Black) based on prior research suggesting different predictors of birth outcomes according to race (<xref rid="R21" ref-type="bibr">Harville et al., 2012</xref>). We began with descriptive statistics (means and percentages) for all analysis variables, statistically comparing their distributions in Black versus non-Black teen mothers. We also conducted bivariate analyses (linear ordinary least squares [OLS] regression and ANOVA) to test the crude relationships between analysis variables and birth outcomes (gestational age and birth weight). We next implemented multivariable OLS models to examine the adjusted relationship between partner violence and birth outcomes. Because of the potential for dating abuse experiences to be more salient for births that occurred closer to Wave II interview, we tested interaction terms between pre-pregnancy dating violence victimization and length of time between Wave II and birth; only significant interactions were maintained. Finally, for cases when dating violence was significantly related to birth outcomes, we tested possible mediators. We followed the approach of Baron and Kenny (<xref rid="R2" ref-type="bibr">Baron &amp; Kenny, 1986</xref>), and thus limited examination of mediators to those variables which were significantly associated with both the predictor and outcome in bivariate analyses. To assess mediation, we added the potential mediator(s) to full models and examined changes in dating violence effect estimates.</p></sec>
24376069|None|('method', 0.9988593654272027)|('other', 0.0011406345727971968)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24376069|Subjects|('method', 0.9988593654272027)|('other', 0.0011406345727971968)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8" sec-type="subjects"><title>Subjects</title><p id="P10">Five right-handed subjects (4 men, 1 woman, ages 23-27) free from neurological and musculoskeletal disorders and five subjects (1 man, 4 women, ages 50-58) whose stroke occurred 1.5-25 years prior to enrollment gave informed consent to participate in this study, which was approved by the Northwestern University Institutional Review Board. We included stroke survivors who had 1) hemiparesis with moderate to severe impairment of the affected arm (score of 12-40 on the upper-extremity portion of the Fugl-Meyer Motor Assessment, FMA-UE<sup><xref rid="R13" ref-type="bibr">13</xref></sup>), 2) exhibited co-activation of the biceps and anterior deltoid muscles determined by clinical observations during FMA-UE and by subjects' performance using the MCI during the initial screening process, and 3) a single, unilateral, ischemic stroke at least 1 year prior to enrollment. We excluded those who had 1) significant pain in the upper limbs or spine, 2) substantial sensory loss in the affected upper arm, 3) significant vision loss, 4) cognitive impairment severe enough to affect digit span and understanding of task-related instructions, or 5) participated in another arm-motor study within 30 days of the start of this study. Subjects were allowed to continue their usual exercise or physical therapy regimens, but not allowed to start a new regimen during the study. All stroke subjects had right-sided hemiparesis (FMA-UE score 19 ± 3, mean ± SD).</p></sec>
24376069|Behavioral Task|('method', 0.9988593654272027)|('other', 0.0011406345727971968)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Behavioral Task</title><p id="P11">Subjects sat in a chair with their right arm in an armrest. Healthy subjects' arms were held in a semi-pronated position (to make it more difficult to decouple biceps and brachioradialis) and immobilized with cushioned restraints at the hand, wrist and upper forearm. Stroke subjects' impaired arms were held in a prone position.</p><p id="P12">Subjects performed isometric contractions of multiple muscles to move the cursor (circle, radius 1.5 cm, <xref rid="F1" ref-type="fig">Figure 1A</xref>) from a square target in the center of a monitor to a randomly-presented target near the outer edge of the monitor—a modified center-out task<sup><xref rid="R14" ref-type="bibr">14</xref></sup> (<xref rid="F1" ref-type="fig">Figure 1B</xref>). Activation of each muscle was mapped to one of four directions within the 2-D cursor space (see <italic>Muscle Mapping</italic>). The center target corresponded to zero net muscle activation (resting position). Each trial started after holding the cursor in the center target for 512 ms, when an outer target appeared and the center target disappeared. Outer targets were located at a distance of 12 cm from the center target in all sessions except the first 5 and first 2 sessions for subjects 1 and 2, respectively; in these first few sessions they were located 7 cm from the center. (Distance was increased to make the task more challenging after it was noted to be too easy for these subjects.) When the cursor reached the outer target it changed color, and subjects were required to hold the cursor there for at least 33 ms (and up to 512 ms) to achieve success.</p></sec>
24376069|Cursor Control Signal|('method', 0.9988593654272027)|('other', 0.0011406345727971968)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Cursor Control Signal</title><p id="P13">We derived cursor position in real time using EMGs from multiple arm muscles. Surface EMG was recorded with bipolar electrodes spaced 1 cm apart, amplified with a gain of 1000 (Delsys Bagnoli), digitally sampled at 1 kHz (National Instruments USB-6229) and collected using a customized program in BCI2000.<sup><xref rid="R15" ref-type="bibr">15</xref></sup> The electrode positions were marked at the end of the session with a henna marker to ensure the same location in the next session.</p><p id="P14">The control signals in each direction were derived from EMGs by low-pass filtering at 500 Hz, rectifying, high-pass filtering at 20 Hz, and then convolving with a 400-ms rectangular window. The vector sum of the control signals determined the 2-D cursor position.</p><p id="P15">At the start of each session, subjects were instructed to produce two maximum voluntary contractions (MVCs) of each muscle independently. To avoid fatigue, the control signals were scaled by a factor that allowed cursor movement to the targets at a relatively comfortable level of contraction (∼42% of the MVC). Since EMG activation levels sometimes varied due to slight changes in electrode placement or skin impedance, we sometimes altered the gains across sessions, to make the effort level similar across sessions. However, the gains remained the same across all trials within each session.</p></sec>
24376069|Muscle Mapping|('method', 0.9988593654272027)|('other', 0.0011406345727971968)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Muscle Mapping</title><p id="P16">Each subject performed two tasks in each session: a training task that used 2 outer targets and a “generalization” task that used 8 outer targets. In the training task, the two co-activating muscles (biceps brachii and brachioradialis for healthy subjects, anterior deltoid and biceps brachii for stroke survivors) were mapped to orthogonal directions and only these two muscle signals were summed to form the control signal (<xref rid="F1" ref-type="fig">Figure 1C</xref>). Thus, <italic>subjects could only succeed in the task if they learned to decouple the co-activating muscles</italic>. We also designed an 8-target task to attempt to assess the extent to which subjects could generalize the learned decoupling to a different task. In the 8-target task, the two co-activating muscles were mapped to opposite horizontal directions. In healthy subjects, an independent muscle (triceps) was added in the direction of brachioradialis to make the task more challenging. Two other muscles not typically co-activated with these muscles (flexor and extensor digitorum superficialis for healthy subjects, triceps and either posterior deltoid or flexor digitorum superficialis in stroke subjects) were mapped in opposite vertical directions. Subjects were informed of the specific directions corresponding to activation of each recorded muscle (mapping direction, <xref rid="F1" ref-type="fig">Figure 1C</xref>).</p><p id="P17">In some stroke subjects, the affected muscles retained some spontaneous muscle activity (mainly in biceps and flexor digitorum) when trying to relax,<sup><xref rid="R16" ref-type="bibr">16</xref>,<xref rid="R17" ref-type="bibr">17</xref></sup> which prevented the cursor from reaching the center target. Therefore we subtracted the baseline activity of each muscle (0.5-s window starting 1 s after the completion of a trial) from the corresponding control signal for the next trial.</p></sec>
24376069|Experimental Paradigm|('method', 0.9988593654272027)|('other', 0.0011406345727971968)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Experimental Paradigm</title><p id="P18">Healthy subjects participated in three sessions separated up to one week. In each session, they performed 10 minutes of the 8-target task (pre-training), 20 minutes of the training task, and 10 minutes of the 8-target task (post-training). Stroke subjects participated in three sessions per week for 6 weeks. In each session, they performed 10 minutes of the pre-training task, 30 minutes of the training task, and another 10 minutes of the post-training task. For analysis, the first and last 2.5 minutes (for healthy) or 5 minutes (for stroke) of training were denoted early and late training, respectively.</p></sec>
24376069|Performance and outcome measures|('method', 0.9988593654272027)|('other', 0.0011406345727971968)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>Performance and outcome measures</title><p id="P19">We quantified subjects' performance in controlling the MCI via three different metrics: success rate (percentage of targets successfully acquired), time to target (TT, time between the outer target appearance and the cursor entering the target), and path length (PL, cumulative distance the cursor traveled in each trial, normalized by the distance between center and outer targets).</p><p id="P20">We defined the level of co-activation between muscles as the Pearson correlation coefficient (R) between the filtered EMGs (control signals) during the period from outer target appearance to the end of the outer target hold time on consecutive trials that were concatenated. Statistical significance was assessed using paired t-tests.</p><p id="P21">To investigate the contribution of each muscle to movement to each target in more detail, we computed muscle tuning curves.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> These were computed from the average control signal during the outer target hold period for each trial during the post-training task and aligned to the mapping direction of each muscle.</p><p id="P22">Finally, we evaluated FMA-UEs before the first session and at the end of the last session. We surveyed subjects after the study using the following questions:<list list-type="order" id="L1"><list-item><p id="P23">Did you notice any improvement in your arm function during the study? If so, what improved?</p></list-item><list-item><p id="P24">Was the amount of training too little, too much, or just right?</p></list-item><list-item><p id="P25">Did you enjoy participating in the study?</p></list-item><list-item><p id="P26">How would you recommend changing the MCI training paradigm to make it more enjoyable?</p></list-item></list></p></sec>
24435201|Materials and methods|('method', 0.9982746332448649)|('other', 0.001725366755135007)|<title>Materials and methods</title>
24435201|Subjects|('method', 0.9982746332448649)|('other', 0.001725366755135007)|<sec id="Sec3"><title>Subjects</title><p>The study subjects were drawn from the validation of biomarkers in acute lung injury diagnosis (VALID) study, an ongoing prospective, multi-ICU cohort study of critically ill patients at Vanderbilt University Medical Center, a tertiary medical center in Nashville, TN. The inclusion criteria and exclusion criteria of VALID have been reported previously and are described in the supplemental appendix [<xref ref-type="bibr" rid="CR32">32</xref>]. Specifically, patients with severe chronic lung disease were excluded, but patients with other underlying comorbidities including advanced cancer and HIV were not excluded. The study was approved by the Vanderbilt University Institutional Review Board.</p><p>For this analysis, we included patients enrolled between January 2006 and February 2010 who had or developed acute lung injury (ALI)/ARDS during the first 4 days after admission to the ICU. During the study period, there were a total of 2,181 total patients enrolled in VALID of whom, 1,894 had at least one risk factor for ARDS. Of these, the current study focused on the 646 who met the American European consensus conference (AECC) criteria for ALI/ARDS [<xref ref-type="bibr" rid="CR33">33</xref>].</p></sec>
24435201|Data collection|('method', 0.9982746332448649)|('other', 0.001725366755135007)|<sec id="Sec4"><title>Data collection</title><p>Data collection and definitions have been described previously [<xref ref-type="bibr" rid="CR32">32</xref>]. Diagnosis of ALI/ARDS was defined by the AECC definition (PaO<sub>2</sub>/FiO<sub>2</sub> ≤300 mmHg for ALI and PaO<sub>2</sub>/FiO<sub>2</sub> ≤200 mmHg for ARDS) [<xref ref-type="bibr" rid="CR33">33</xref>], and could be established at any time during the first 4 days in the ICU. Both mechanically ventilated (defined as invasive mechanical ventilation within 4 days of AECC ALI/ARDS diagnosis) and not mechanically ventilated patients meeting AECC criteria were included in our primary analysis. In a sensitivity analysis, we also considered the Berlin definition for ARDS [<xref ref-type="bibr" rid="CR34">34</xref>, <xref ref-type="bibr" rid="CR35">35</xref>]. Berlin severity levels were defined as mild (200 mmHg &lt;PaO<sub>2</sub>/FiO<sub>2</sub> ≤300 mmHg with PEEP or CPAP ≥5 cmH<sub>2</sub>O), moderate (100 mmHg &lt;PaO<sub>2</sub>/FiO<sub>2</sub> ≤200 mmHg with PEEP ≥5 cmH<sub>2</sub>O), and severe (PaO<sub>2</sub>/FiO<sub>2</sub> ≤100 mmHg with PEEP ≥5 cmH<sub>2</sub>O). For both AECC and Berlin definitions, the ratio of pulse oximetric saturation to fraction of inspired oxygen (SpO<sub>2</sub>/FiO<sub>2</sub>) was used as a validated surrogate for PaO<sub>2</sub>/FiO<sub>2</sub> among patients without an arterial blood gas measurement at the time of ALI/ARDS diagnosis: SpO<sub>2</sub>/FiO<sub>2</sub> = 64 + 0.84 × (PaO<sub>2</sub>/FiO<sub>2</sub>) [<xref ref-type="bibr" rid="CR36">36</xref>]. The discharge location for patients who survived hospitalization was categorized as home, rehabilitation hospital, nursing home, hospice, or other acute care hospital. The lung injury score [<xref ref-type="bibr" rid="CR37">37</xref>], Brussels organ failure [<xref ref-type="bibr" rid="CR38">38</xref>], and definitions for sepsis, pneumonia, aspiration, and trauma are included in the supplemental appendix.</p></sec>
24435201|Outcome measures|('method', 0.9982746332448649)|('other', 0.001725366755135007)|<sec id="Sec5"><title>Outcome measures</title><p>All patients were followed until death or for at least 1 year after study enrollment. Short-term mortality was defined as all-cause mortality during hospitalization. Long-term mortality was defined as all-cause mortality 1 year following enrollment in VALID in patients who survived to hospital discharge. Patient deaths were identified by medical record review and query of the social security death index (SSDI) [<xref ref-type="bibr" rid="CR39">39</xref>]. Causes of death were determined by review of death certificate data obtained from the Tennessee Vital Records Office of the Tennessee Department of Health. Underlying causes of death were categorized as infection, malignancy (primary, metastatic, or hematologic), cardiovascular, respiratory, gastrointestinal/hepatic, trauma, or other causes (listed in supplemental appendix) based on ICD-9 coding of the primary cause of death on the death certificate.</p></sec>
24435201|Statistical analysis|('method', 0.9982746332448649)|('other', 0.001725366755135007)|<sec id="Sec6"><title>Statistical analysis</title><p>We used <italic toggle="yes">t</italic> tests, chi-squared tests, and Fisher’s exact tests as appropriate to compare baseline demographics and clinical risk factors across groups. Descriptive statistics and McNemar’s were used to compare in-hospital and 1-year mortality. Since all events were accounted for over the year of follow-up, logistic regression was used to analyze associations between candidate risk factors and mortality. Kaplan–Meier survival plots demonstrate the time from discharge to death in hospital survivors and the log-rank test was used to estimate differences according to discharge location. Clinical characteristics associated with 1-year mortality with <italic toggle="yes">P</italic> &lt; 0.10 on bivariable analysis were entered into a stepwise elimination model to retain potential risk factors if they remained associated at a <italic toggle="yes">P</italic> value of less than 0.05. Because of the modest number of outcomes, the forward stepwise elimination was used to maintain model parsimony. In a sensitivity analysis, we analyzed only patients meeting the Berlin definition of ARDS [<xref ref-type="bibr" rid="CR34">34</xref>]. Analyses were performed using STATA version 10 (STATA Corp, College Station, TX). Statistical significance was defined as a two-tailed <italic toggle="yes">P</italic> &lt; 0.05 for all analyses.</p></sec>
24435201|None|('method', 0.8263839478230809)|('other', 0.17361605217691886)|<sec id="Sec15"><p><supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2013_3186_MOESM1_ESM.doc" mimetype="application" mime-subtype="msword" position="float" orientation="portrait"><caption><p>Supplementary material 1 (DOC 79 kb)</p></caption></media></supplementary-material></p></sec>
24435203|Methods|('method', 0.9909379939199203)|('other', 0.009062006080079761)|<title>Methods</title>
24435203|Identification of trials|('method', 0.9909379939199203)|('other', 0.009062006080079761)|<sec id="Sec3"><title>Identification of trials</title><p>Studies were identified using computerized literature searches of MEDLINE, EMBASE, LILACS, and Cochrane Central Register of Controlled Trials. The following Medical Subject Headings (MeSH) and keywords were combined to retrieve relevant articles: <italic toggle="yes">randomized controlled trial</italic> OR <italic toggle="yes">controlled clinical trial</italic> OR <italic toggle="yes">random*</italic> OR <italic toggle="yes">trial</italic> OR <italic toggle="yes">groups</italic> AND <italic toggle="yes">prone position</italic> (MeSH) OR <italic toggle="yes">supine position</italic> (MeSH) OR <italic toggle="yes">patient positioning</italic> (MeSH) OR <italic toggle="yes">prone</italic> OR <italic toggle="yes">proning</italic> OR supine AND <italic toggle="yes">respiratory distress syndrome, adult</italic> (MeSH) OR <italic toggle="yes">acute lung injury</italic> OR <italic toggle="yes">ARDS</italic> OR <italic toggle="yes">respiratory distress syndrome</italic> OR <italic toggle="yes">respiratory failure</italic>.</p></sec>
24435203|Selection of studies|('method', 0.9909379939199203)|('other', 0.009062006080079761)|<sec id="Sec4"><title>Selection of studies</title><p>Using the PICOS framework [<xref ref-type="bibr" rid="CR26">26</xref>], two independent reviewers (SBM, SS) applied criteria to evaluate studies for inclusion. Disagreement in study selection was addressed through evaluation by a third reviewer (JRB) and final determination achieved by team consensus. Eligible studies involved adult patients meeting the Berlin definition of ARDS [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR27">27</xref>], including those previously classified as having acute lung injury (PaO<sub>2</sub>:FiO<sub>2</sub> 201–300 mmHg) under the 1994 American-European Consensus Conference definition [<xref ref-type="bibr" rid="CR28">28</xref>]. Studies were required to assess the intervention prone positioning compared to supine positioning during conventional mechanical ventilation. Co-interventions in addition to prone positioning were permitted. Studies that did not report mortality were excluded. Only randomized controlled trials were eligible.</p></sec>
24435203|Data extraction|('method', 0.9909379939199203)|('other', 0.009062006080079761)|<sec id="Sec5"><title>Data extraction</title><p>Two authors (JRB, SBM) independently extracted data using a standardized data collection form. Discrepancies in collected data were addressed through team consensus. One included trial, Taccone et al. [<xref ref-type="bibr" rid="CR18">18</xref>], stratified at randomization according to moderate or severe ARDS (PaO<sub>2</sub>:FiO<sub>2</sub> 100–200 or &lt;100 mmHg). It was decided before data extraction to treat this trial as two separate studies in the meta-analysis because prior post hoc analyses have suggested the benefit of prone positioning may vary with ARDS severity [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>].</p></sec>
24435203|Evaluation of primary outcome|('method', 0.9909379939199203)|('other', 0.009062006080079761)|<sec id="Sec6"><title>Evaluation of primary outcome</title><p>The primary outcome was risk ratio (RR) of death at 60 days among patients assigned to prone compared to supine positioning. When not directly reported, 60-day mortality was determined by digitally enhancing the Kaplan-Meier plot to measure directly the relative distance from zero of the product limit estimator at 60 days [<xref ref-type="bibr" rid="CR29">29</xref>]. In one study [<xref ref-type="bibr" rid="CR15">15</xref>], neither 60-day mortality nor a Kaplan–Meier plot was available; the corresponding author provided the required information.</p></sec>
24435203|Quality assessment|('method', 0.9909379939199203)|('other', 0.009062006080079761)|<sec id="Sec7"><title>Quality assessment</title><p>Study quality was evaluated by considering concealment of allocation, completeness of follow-up, blinded analysis, crossover between study arms, post hoc exclusions, and early trial discontinuation. The Jadad score for randomized trials [<xref ref-type="bibr" rid="CR30">30</xref>] was not considered because blinding of patients or caregivers to the study intervention was not possible.</p></sec>
24435203|Statistical analysis|('method', 0.9909379939199203)|('other', 0.009062006080079761)|<sec id="Sec8"><title>Statistical analysis</title><p>The primary outcome of 60-day mortality was chosen a priori because it represents the maximum follow-up interval reported in all studies selected for analysis. Potential sources of heterogeneity considered a priori were use of low tidal volume ventilation, duration of respiratory failure prior to prone positioning, and dose (in hours/day) of prone positioning [<xref ref-type="bibr" rid="CR25">25</xref>]. Before data extraction, an analysis plan was developed to account for anticipated sources of heterogeneity, consisting of stratification by high (&gt;8 ml/kg predicted body weight, PBW) versus low (≤8 ml/kg PBW) mean baseline tidal volume.</p><p>Initial meta-analysis was carried out using random effects models to calculate risk ratios with 95 % confidence intervals for each included study and a combined risk ratio for all studies. This method was selected for its proven ability to account for within- and between-study variability [<xref ref-type="bibr" rid="CR31">31</xref>]. Heterogeneity was quantified with the Q-statistic and <italic toggle="yes">I</italic><sup><italic toggle="yes">2</italic></sup> index. Cumulative meta-analysis was also performed to evaluate the potential effects of gradual widespread adoption of lung-protective ventilation and other advances in critical care over time.</p><p>To evaluate whether tidal volume was a significant source of inter-study heterogeneity, additional random effects models were developed after stratifying by mean baseline tidal volume. Unrestricted maximum likelihood mixed effects regression was performed to evaluate for a dose-response relationship between mortality (log risk ratio) and mean baseline tidal volume (ml/kg PBW). Random effects models also were used to evaluate the effect of high (≥12 h/day) versus low (&lt;12 h/day) proning dose.</p><p>To evaluate for publication bias, a funnel scatter plot of sample and effect size was constructed. Publication bias was also assessed via Begg-Mazumdar rank correlation and Egger’s regression to account for selection bias impact on the overall combined significance of the results. The meta-analysis was conducted using Comprehensive Meta-Analysis v2 (Biostat, Eaglewood, NJ, USA) with conscious effort to follow PRISMA guidelines [<xref ref-type="bibr" rid="CR32">32</xref>].</p></sec>
24477452|Materials and method|('method', 0.998972864384724)|('other', 0.0010271356152759337)|<title>Materials and method</title>
24477452|None|('method', 0.998972864384724)|('other', 0.0010271356152759337)|<p>Specimens were collected by placing beef liver at woodlands at Hacettepe University, Beytepe Campus. <italic toggle="yes">Lucilia sericata</italic> specimens were identified using a Leica MZ16 A stereoscopic microscope system according to the identification keys by Zumpt [<xref ref-type="bibr" rid="CR16">16</xref>], Greenberg and Kunich [<xref ref-type="bibr" rid="CR6">6</xref>] at the Biocriminal Entomology Laboratory in the Hacettepe University biology department.</p>
24477452|None|('method', 0.998972864384724)|('other', 0.0010271356152759337)|<p><italic toggle="yes">Lucilia sericata</italic> specimens were reared in a square, net cage measuring 21 × 21 × 21 cm in a Sanyo MIR-253 cooled incubator. Each cage was supplied with cotton soaked with sugary water for feeding (sugary water was prepared as approximately 20 g of sugar mixed in 0.5 l water, according to Catts and Haskell [<xref ref-type="bibr" rid="CR17">17</xref>]). In addition, fresh beef liver was placed for oviposition. For the pupation process of the postfeeding larvae, 26 × 16 × 15-cm and 17 × 11 × 7-cm rectangular rearing containers supplied with sawdust were used. After the postfeeding larvae pupated, they were sacrificed using hot water. From the prepupae stage, they were removed from the sawdust using forceps and put into a 3-cm-diameter screw cap with labels. On average, one or two individuals were dissected and photographed hourly. When the features of the pupae couldn’t be seen, the dissected specimen number was increased.</p>
24477452|None|('method', 0.998972864384724)|('other', 0.0010271356152759337)|<p>In this study, the prepupae stage was taken as point zero for time calculations for each of three temperatures; when the puparium was white and when the pseudocephalon, which is located at the anterior part of the larvae, was completely withdrawn [<xref ref-type="bibr" rid="CR6">6</xref>]. Pupae were killed, dissected, and photographed according to the hour calculations based on the elapsed time between point zero and adult emergence, and then stored in 80 % alcohol [<xref ref-type="bibr" rid="CR3">3</xref>].</p>
24477452|None|('method', 0.998972864384724)|('other', 0.0010271356152759337)|<p><italic toggle="yes">Lucilia sericata</italic> is a warm-adapted species, therefore, it is common between April–November in Ankara [<xref ref-type="bibr" rid="CR8">8</xref>]. Considering the summer season monthly temperature averages during the summer season for Ankara, 20°, 25°, and 30° were preferred for our study, with 25° believed to be the optimal development temperature.</p>
24523143|None|('method', 0.9988994826548533)|('other', 0.001100517345146755)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
24523143|None|('method', 0.9988994826548533)|('other', 0.001100517345146755)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">The Institutional Review Boards of the New Mexico Veteran Affairs Healthcare System and Hershey Medical Center approved the study protocol. Prior to participation, all subjects gave informed consent according to the Declaration of Helsinki<sup><xref rid="R12" ref-type="bibr">12</xref></sup>.</p>
24523143|Participants|('method', 0.9988994826548533)|('other', 0.001100517345146755)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" sec-type="subjects" id="S8"><title>Participants</title><p id="P9">A total of 30 subjects participated in this study [16 healthy controls, 7 left hemisphere damaged (LHD) patients, 7 right hemisphere damaged (RHD) patients]. All control subjects self-reported current right-handedness, and all stroke patients self reported right-handedness prior to stroke. All stroke patients were examined at least 6 months after stroke. Subjects were excluded if they had a history of or current (i) substance abuse or other significant psychiatric diagnosis (e.g., psychosis); (ii) non-stroke neurological diagnoses for the stroke patients and all neurological diagnoses for the control subjects; or (iii) peripheral movement restrictions, such as neuropathy or orthopedic disorders. Measures of hemiparesis<sup><xref rid="R13" ref-type="bibr">13</xref></sup>, and auditory comprehension<sup><xref rid="R14" ref-type="bibr">14</xref></sup> were used to characterize the degree of impairment in stroke patients across different domains. None of the stroke patients in our study demonstrated unilateral visual neglect, as confirmed by performance on the line cancellation task<sup><xref rid="R15" ref-type="bibr">15</xref></sup>.</p></sec>
24523143|Experimental setup and task|('method', 0.9988994826548533)|('other', 0.001100517345146755)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Experimental setup and task</title><p id="P10">The experimental setup is shown in <xref ref-type="fig" rid="F1">Figure 1</xref>. Subjects sat facing a table with both their left and right arm supported over a horizontal surface by an air-jet system to eliminate the effects of gravity and reduce friction. This support allowed patients to perform the task with both arms, without demonstrating or reporting fatigue. Two start circles, targets, and the subject's fingertips (represented by an on-screen cursor) were displayed on a mirror using an HDTV positioned horizontally above the mirror. The mirror blocked the direct vision of the subject's arm, but reflected the visual display to give the illusion that the display was in the same horizontal plane as the fingertip. Position and orientation of the forearm and upper-arm segments were sampled using a Flock of Birds (Ascension Technology®) system at 130 Hz. The positions of the index finger tip, lateral epicondyle of the humerus and the acromion, directly posterior to the acromio-clavicular joint were digitized using a stylus that was rigidly attached to a 6-DOF Flock of Birds sensor. As sensor data were received, the 3D position of the above-mentioned landmarks was computed using custom software, with the X-Y plane parallel to the tabletop. We used the computed X-Y coordinates of the fingertip to define the projected cursor position.</p><p id="P11">The experimental task involved reaching to 32 targets, presented one at a time, across the workspace in front of the subject (<xref ref-type="fig" rid="F1">Figure 1</xref>). Prior to the start of each trial, the two start circles and cursors (representing the fingertip of each arm) were displayed on the screen. Each start circle required the arm to be positioned at 30° shoulder flexion and 75° elbow flexion, as depicted in <xref ref-type="fig" rid="F1">Figure 1</xref>. All subjects exhibited full active range of motion in the horizontal plane, when supported against gravity by the air-sled system. To initiate the trial, the subject brought both the cursors into the start circles and after a 500 ms delay, one of the targets appeared on the screen along with an audio-visual “go” signal, which cued the subjects to initiate a single, rapid movement toward the target. The subjects were free to choose whichever arm they wanted to perform the reaching movement. Once the trial was completed, the subjects returned their fingertips to the start positions to begin a new trial. The 32 targets were pseudo-randomly presented over a session of 512 trials, such that no target was presented consecutively.</p></sec>
24523143|Measures|('method', 0.9988994826548533)|('other', 0.001100517345146755)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Measures</title><p id="P12">To quantitatively determine the preference for using the dominant or premorbidly-dominant right arm, right arm preference was computed as a ratio of the number of reaches performed using the right arm to the number of reaches performed using the left arm for each subject (<xref ref-type="fig" rid="F3">Figure 3A</xref>). We also quantified the percentage of contralesional arm reaches to all targets (<xref ref-type="fig" rid="F3">Figure 3B</xref>) and to the targets on the body's midline, which were equidistant from either arm's starting location (<xref ref-type="fig" rid="F3">Figure 3C</xref>) in the stroke patients. In order to assess the effect of workspace region on arm choice, we computed the average frequency of right and left arm reaches to each target across subjects and used these data to identify the midline of reaching frequency (RF Midline) using a linear approximation to points in space that yielded 50% of right arm reaches at each row of targets (see <xref ref-type="fig" rid="F4">Figure 4</xref>). We also quantified the offset of the RF Midline from the body's midline at each row of targets. This RF Midline offset was computed as a percentage of the distance from the midline of the body and the extreme left or right target at each row<sup><xref rid="R6" ref-type="bibr">6</xref></sup>.</p></sec>
24523143|Statistical Analysis|('method', 0.9988994826548533)|('other', 0.001100517345146755)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Statistical Analysis</title><p id="P13">The arm choice between the three groups (control, LHD, RHD) was analyzed using a one-way ANOVA with group as the factor and right arm preference as the dependent measure. Contralesional arm reaching performances between LHD and RHD groups were analyzed using a one-way ANOVA with laterality of damage (left or right) as a factor and the percentage of contralesional arm use as the dependent measure. RF Midline Offset was analyzed using a 2-way ANOVA with row (1/2/3/4) and group (control, LHD, RHD) as factors. When warranted, post-hoc analyses were performed using Tukey HSD test, which corrects for multiple comparisons<sup><xref rid="R16" ref-type="bibr">16</xref></sup>. Statistical significance levels were set to 0.05. All statistical analyses were carried out using the software JMP (SAS Institute Inc., USA).</p></sec>
24525568|None|('method', 0.9998550374049231)|('other', 0.00014496259507695494)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24525568|Diabetes Empowerment Program|('method', 0.9998550374049231)|('other', 0.00014496259507695494)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Diabetes Empowerment Program</title><p id="P7">The Diabetes Empowerment Program is a culturally tailored diabetes self-management intervention serving African Americans on the South Side of Chicago.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> The DEP has been described in detail elsewhere, but briefly, it is a 10-week program that combines culturally tailored diabetes education with skills training in patient/provider communication and shared decision making.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> The DEP had successful class retention; 78% of the 51 DEP participants completed at least 7 of the 10 class sessions and 38% of participants attended all 10 sessions.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Inclusion criteria were African American race, diagnosis of type 2 diabetes, and an established primary care physician. Participants were excluded if blind, as the audiovisual resources utilized by the program had not been appropriately tailored for this population. The DEP used a variety of strategies designed to enhance program retention. These strategies were predominantly classified under the larger categories of program logistics, participant contact, curriculum design, incentives, and acknowledgements (<xref rid="T1" ref-type="table">Table 1</xref>).<sup><xref rid="R18" ref-type="bibr">18</xref>-<xref rid="R24" ref-type="bibr">24</xref></sup></p></sec>
24525568|Study Design|('method', 0.9998550374049231)|('other', 0.00014496259507695494)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Study Design</title><p id="P8">Qualitative research methods using a framework approach were used to explore facilitators of diabetes education retention among urban African Americans.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> Four focus groups (n = 29) and 7 in-depth individual interviews (n = 7) were conducted. Moderators experienced in interpersonal communication and not directly affiliated with the DEP led the interviews and discussions. Interviews lasted approximately 60 minutes, and each focus group lasted approximately 90 minutes. Interviews and focus groups were conducted over a 1-year period until theme saturation was met.</p></sec>
24525568|Setting and Participant Sample|('method', 0.9998550374049231)|('other', 0.00014496259507695494)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Setting and Participant Sample</title><p id="P9">The study was conducted in Chicago among former participants in the Diabetes Empowerment Program (parent study) 3 to 6 months after program completion. Study patients received their care at an academic medical center or a federally qualified health center affiliated with the medical center. After receiving approval from the Institutional Review Board, former Diabetes Empowerment Program participants, regardless of attendance rates, were invited by telephone (up to 3 attempts) and letter to participate in either a focus group or in-depth interview. Participants were allocated to 1 of these 2 groups based on participant’s personal schedule and availability. Each interview and focus group was held at the participants’ primary care clinic (and corresponding site of DEP). Study participants received a $20 gift card to a local grocery store as an incentive.</p></sec>
24525568|Study Instruments|('method', 0.9998550374049231)|('other', 0.00014496259507695494)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Study Instruments</title><p id="P10">The research team developed topic guides to explore participants’ beliefs about programmatic aspects that were key to successful retention in the DEP. Topic guides were based on retention strategies described by 2 studies: a systematic review of study retention and a qualitative investigation of retention in behavioral interventions.<sup><xref rid="R27" ref-type="bibr">27</xref>,<xref rid="R28" ref-type="bibr">28</xref></sup> This guide was utilized in both the focus groups and interviews. A moderator asked participants about various components of the program (eg, the efficacy of the shared decision-making component, the role of narrative, etc) and then specifically asked participants to identify and discuss factors that influenced their attendance. Discussion about retention began with the open-ended question “What made the diabetes program something that you were willing to come to regularly?” and was followed by probes regarding content of class, presentation of material, educators, gifts, and so on.</p></sec>
24525568|Data Collection and Analysis|('method', 0.9998550374049231)|('other', 0.00014496259507695494)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Data Collection and Analysis</title><p id="P11">The focus group and individual interviews were recorded and transcribed verbatim. A framework approach was used for data analysis. With this method, the analysis is inductive or “grounded” in the original accounts provided by patients, but the analysis begins deductively from preset aims and objectives.<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> Three coders reviewed the initial 2 focus group transcripts. These coders then met as a group to determine uniform coding themes and guidelines. Using these guidelines, 2 coders independently reviewed the focus group and one-on-one interview transcripts and met to discuss discrepancies and reach an agreement in order to ensure interrater reliability. The codebook was developed iteratively to incorporate new codes and themes and to modify and refine the definitions of the codes and themes. The coders recorded and tracked discrepancies, conclusions, and modifications and continued data collection and analysis until theme saturation had been met. A member of the research team analyzed theme saturation and coding results using Atlas.ti 4.2 software.</p></sec>
24562549|Introduction and methodology|('method', 0.8030584819432331)|('other', 0.196941518056767)|<title>Introduction and methodology</title>
24562549|None|('method', 0.8030584819432331)|('other', 0.196941518056767)|<p>Hyponatraemia, defined as a serum sodium concentration &lt;135 mmol/L, is the most common disorder of body fluid and electrolyte balance encountered in clinical practice. Hyponatraemia is present in 15–20 % of emergency admissions to hospital and occurs in up to 20 % of critically ill patients [<xref ref-type="bibr" rid="CR1">1</xref>]. It can lead to a wide spectrum of clinical symptoms, from subtle to severe or even life threatening [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>] and is associated with increased mortality, morbidity and length of hospital stay in patients presenting with a range of conditions. Despite this, the management of patients remains problematic. The prevalence of hyponatraemia in widely different conditions and the fact that hyponatraemia is managed by clinicians with a broad variety of backgrounds, has fostered diverse institution- and speciality-based approaches to diagnosis and treatment.</p>
24562549|None|('method', 0.8030584819432331)|('other', 0.196941518056767)|<p>Against this background, the European Society of Intensive Care Medicine (ESICM), the European Society of Endocrinology (ESE) and the European Renal Association–European Dialysis and Transplant Association (ERA–EDTA), represented by European Renal Best Practice (ERBP) have developed this Clinical Practice Guideline on the diagnostic approach and treatment of hyponatraemia as a joint venture of three societies representing specialists with a natural interest in hyponatraemia. In addition to a rigorous approach to methodology and evaluation, we were keen to ensure the document focused on patient-important outcomes and had utility for clinicians involved in every-day practice.</p>
24562549|None|('method', 0.8030584819432331)|('other', 0.196941518056767)|<p>The ERBP methods support team searched The Cochrane Database of Systematic Reviews (May 2011), DARE (May 2011), CENTRAL (May 2011) and MEDLINE (1946 to May, week 4, 2011) for both questions on diagnosis and treatment. To identify limits for the increase in serum sodium concentration above which the risk of osmotic demyelination starts to rise, they searched MEDLINE from 1997 onwards under the assumption that earlier reports would describe more dramatic increases and would not contribute to helping us set an upper limit.</p>
24562549|None|('method', 0.8030584819432331)|('other', 0.196941518056767)|<p>A member of the ERBP methods support team screened all titles and abstracts to discard the clearly irrelevant ones. All members of the guideline development group completed a second screening. All abstracts that did not meet the inclusion criteria were discarded. Any discrepancies at this stage were resolved by group consensus. The methods support team retrieved full texts of potentially relevant studies and two reviewers examined them for eligibility independently of each other. The reviewer duos always included one content specialist and a methodologist of the ERBP methods support team. Any discrepancies were resolved by consensus. If no consensus could be reached, the disagreement was settled by group arbitrage. The evidence for outcomes on therapeutic interventions from included systematic reviews and randomised controlled trials was presented using the ‘Grading of Recommendations Assessment, Development and Evaluation (GRADE) toolbox’ developed by the international GRADE working group (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.gradeworkinggroup.org/">http://www.gradeworkinggroup.org/</ext-link>).</p>
24562549|None|('method', 0.8030584819432331)|('other', 0.196941518056767)|<p>The guideline underwent external peer review before publication.</p>
24562549|None|('method', 0.8030584819432331)|('other', 0.196941518056767)|<p>This condensed version of the Clinical Practice Guideline on Diagnosis and Treatment of Hyponatraemia focuses on recommendations on diagnosis and treatment of hyponatraemia, the full version of the guidelines, additionally covering conflict of interest, purpose and scope, methods of guideline development and pathophysiology of hyponatraemia, is available as electronic supplemental material (ESM).</p>
24562549|Diagnosis of hyponatraemia|('method', 0.8815247132714691)|('other', 0.11847528672853092)|<title>Diagnosis of hyponatraemia</title>
24562549|Classification of hyponatraemia|('method', 0.8815247132714691)|('other', 0.11847528672853092)|<sec id="Sec3"><title>Classification of hyponatraemia</title><sec id="Sec4" sec-type="box"><title>Definition of hyponatraemia based on biochemical severity</title><p>We define ‘mild’ hyponatraemia as a biochemical finding of a serum sodium concentration between 130 and 135 mmol/L as measured by ion specific electrode.</p><p>We define ‘moderate’ hyponatraemia as a biochemical finding of a serum sodium concentration between 125 and 129 mmol/L as measured by ion specific electrode.</p><p>We define ‘profound’ hyponatraemia as a biochemical finding of a serum sodium concentration &lt;125 mmol/L as measured by ion specific electrode.</p></sec><sec id="Sec5" sec-type="box"><title>Definition of hyponatraemia based on time of development</title><p>We define ‘acute’ hyponatraemia as hyponatraemia that is documented to exist &lt;48 h. We define ‘chronic’ hyponatraemia as hyponatraemia that is documented to exist for at least 48 h. If the hyponatraemia cannot be classified, we consider it being chronic, unless there is clinical or anamnestic evidence of the contrary (Tables <xref rid="Tab1" ref-type="table">1</xref>, <xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>(Table 5 of the online document): classification of symptoms of hyponatraemia</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Severity</th><th align="left" rowspan="1" colspan="1">Symptom</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Moderately severe</td><td align="left" rowspan="1" colspan="1">Nausea without vomiting</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Confusion</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Headache</td></tr><tr><td align="left" rowspan="1" colspan="1">Severe</td><td align="left" rowspan="1" colspan="1">Vomiting</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Cardio-respiratory distress</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Abnormal and deep somnolence</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Seizures</td></tr><tr><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">Coma (Glasgow Coma Scale ≤8)</td></tr></tbody></table><table-wrap-foot><p>The guideline development group wants to underscore that these symptoms can also be induced by other conditions. Clinical and anamnestic data should be taken into account when assessing the causal relation between the hyponatraemia and a certain symptom (i.e. to assess whether the symptom has been caused by the hyponatraemia or the hyponatraemia by the underlying condition/symptom). The less pronounced (e.g. mild) the biochemical degree of hyponatraemia, the more caution should be taken when considering that the hyponatraemia is the cause of the symptoms. This list is not exhaustive, and all symptoms that can be signs of cerebral oedema should be considered as severe or moderate symptoms that can be caused by hyponatraemia</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>(Table 8 of the online document): drugs and conditions associated with acute hyponatraemia (&lt;48 h)</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">Postoperative phase</td></tr><tr><td align="left" rowspan="1" colspan="1">Post-resection of the prostate, post-resection of endoscopic uterine surgery</td></tr><tr><td align="left" rowspan="1" colspan="1">Polydipsia</td></tr><tr><td align="left" rowspan="1" colspan="1">Exercise</td></tr><tr><td align="left" rowspan="1" colspan="1">Recent thiazides prescription</td></tr><tr><td align="left" rowspan="1" colspan="1">3,4-Methyleendioxymethamfetamine (MDMA, XTC)</td></tr><tr><td align="left" rowspan="1" colspan="1">Colonoscopy preparation</td></tr><tr><td align="left" rowspan="1" colspan="1">Cyclophosphamide (intravenous)</td></tr><tr><td align="left" rowspan="1" colspan="1">Oxytocin</td></tr><tr><td align="left" rowspan="1" colspan="1">Recently started desmopressin therapy</td></tr><tr><td align="left" rowspan="1" colspan="1">Recently started terlipressin, vasopressin</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec6" sec-type="box"><title>Definition of hyponatraemia based on symptoms</title><p>We define ‘moderately symptomatic’ hyponatraemia as any biochemical degree of hyponatraemia in the presence of moderately severe symptoms of hyponatraemia (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p>We define ‘severely symptomatic’ hyponatraemia as any biochemical degree of hyponatraemia in the presence of severe symptoms of hyponatraemia (Table <xref rid="Tab1" ref-type="table">1</xref>).<list list-type="bullet"><list-item><p>Why did we choose to set definitions?</p></list-item></list></p><p>Hyponatraemia can be classified based on different parameters. These include serum sodium concentration, rate of development, symptom severity, serum osmolality, and volume status. For this guideline, we wanted the classification to be consistent and clear so all users would have a correct understanding of the terminology used. We also wanted to make the classification directly relevant for patient management. However, treatment strategies cannot be adequately classified with reference to a single criterion. Hence, treatment strategies have been classified according to combinations of these criteria.<list list-type="bullet"><list-item><p>What are these definitions based on?</p></list-item></list></p><p><italic toggle="yes">Classification based on serum sodium concentration</italic></p><p>Authors mostly use the terms ‘mild’, ‘moderate’, and ‘severe’ [<xref ref-type="bibr" rid="CR4">4</xref>–<xref ref-type="bibr" rid="CR6">6</xref>]. We have chosen to replace ‘severe’ by ‘profound’ to avoid confusion with the classification based on symptoms, for which we have reserved the term ‘severe’. The definitions of mild, moderate and profound hyponatraemia in published research are variable; especially the threshold used to define profound hyponatraemia for which values have ranged from 110 to 125 mmol/L [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>]. Several studies report that when serum sodium concentrations drop below 125 mmol/L, symptoms become more common [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR9">9</xref>–<xref ref-type="bibr" rid="CR13">13</xref>], and the correction to normonatraemia necessitates careful monitoring to avoid overly rapid correction [<xref ref-type="bibr" rid="CR14">14</xref>].</p><p><italic toggle="yes">Classification based on duration and speed of development</italic></p><p>Published research suggests using a threshold of 48 h to distinguish “acute” from “chronic” hyponatraemia. Brain oedema seems to occur more frequently when hyponatraemia develops in &lt;48 h [<xref ref-type="bibr" rid="CR15">15</xref>–<xref ref-type="bibr" rid="CR18">18</xref>]. Experimental studies also suggest that the brain needs approximately 48 h to adapt to a hypotonic environment, achieved mainly by extruding sodium, potassium, chloride and organic osmoles from its cells [<xref ref-type="bibr" rid="CR19">19</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. Before adaptation, there is a risk of brain oedema, because the lower extracellular osmolality promotes a shift of water into the cells. However, once adaptation is completed, brain cells can again sustain damage if the serum sodium concentration increases too rapidly. Breakdown of the myelin sheath insulating individual neurons can result in what is called the osmotic demyelination syndrome [<xref ref-type="bibr" rid="CR22">22</xref>–<xref ref-type="bibr" rid="CR25">25</xref>]. Consequently, it is important to distinguish between acute and chronic hyponatraemia to assess whether someone is at greater risk of immediate brain oedema than of osmotic demyelination [<xref ref-type="bibr" rid="CR26">26</xref>]. Unfortunately, in clinical practice, the distinction between acute and chronic hyponatraemia is often unclear, particularly for patients presenting to the emergency room. It is often unknown when the serum sodium concentration has started decreasing. If classifying hyponatraemia as acute or chronic is not possible, we have decided to consider the hyponatraemia as being chronic, unless there are reasons to assume it is acute (Table 10). There is a good reason for this approach. Chronic hyponatraemia is much more common than acute hyponatraemia and should be managed accordingly to avoid osmotic demyelination [<xref ref-type="bibr" rid="CR27">27</xref>, <xref ref-type="bibr" rid="CR28">28</xref>].</p><p><italic toggle="yes">Classification based on symptoms</italic></p><p>We have divided symptoms of hyponatraemia into ‘moderately severe’ and ‘severe’. The distinction is based on selected observations in acute hyponatraemia; those who subsequently die more often experience what we define as severe symptoms than those who live [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Moderately severe symptoms caused by brain oedema are less frequently associated with death. Nevertheless, they may rapidly progress to more severe symptoms associated with an adverse outcome.</p><p>We have purposefully omitted the category ‘asymptomatic’ as we felt this might create confusion. Patients are probably never truly ‘asymptomatic’ in the strictest sense of the word. Very limited and subclinical signs such as mild concentration deficits are seen even with mild hyponatraemia [<xref ref-type="bibr" rid="CR29">29</xref>].</p><p>A classification based on symptoms aims to reflect the degree of brain oedema and the extent of immediate danger. It allows matching treatment to the immediate risk, with more aggressive treatment for symptoms that are more severe. Nevertheless, a classification based only on symptom severity has several shortcomings. First, symptoms of acute and chronic hyponatraemia may overlap [<xref ref-type="bibr" rid="CR29">29</xref>]. Second, patients with acute hyponatraemia can present without clear symptoms, but go on to develop moderately severe to severe symptoms within hours [<xref ref-type="bibr" rid="CR15">15</xref>]. Third, symptoms of hyponatraemia are nonspecific. Consequently, assessment of symptoms needs to happen with caution. Clinicians need to be wary that symptoms can be caused by conditions other than hyponatraemia; by other conditions in combination with hyponatraemia; or by conditions that cause the hyponatraemia. In general, one should be particularly careful when attributing moderately severe to severe symptoms to hyponatraemia when the biochemical degree of hyponatraemia is only mild (Table <xref rid="Tab1" ref-type="table">1</xref>).</p><p><italic toggle="yes">Classification based on serum osmolality</italic></p><p>As this guideline aimed to cover the aspects of diagnosis and treatment specifically of hypotonic hyponatraemia, we needed to define what distinguishes hypotonic from non-hypotonic hyponatraemia. Because this distinction is a necessary first step in the diagnostic evaluation of any hyponatraemia, we have devoted a separate chapter to this topic (chapter 8.2). For reasons of completeness, we briefly mention it here. A <italic toggle="yes">measured</italic> serum osmolality &lt;275 mOsm/kg always indicates hypotonic hyponatraemia, as effective osmolality can never be higher than total or measured osmolality. In contrast, if <italic toggle="yes">calculated</italic> osmolality &lt;275 mOsm/kg, the hyponatraemia can be hypotonic, isotonic or hypertonic, depending on which osmotically active agents are present and whether or not they are incorporated in the formula [<xref ref-type="bibr" rid="CR30">30</xref>].</p><p><italic toggle="yes">Classification based on volume status</italic></p><p>Patients with hyponatraemia may be hypovolaemic, euvolaemic, or hypervolaemic [<xref ref-type="bibr" rid="CR31">31</xref>]. Many traditional diagnostic algorithms start with a clinical assessment of volume status [<xref ref-type="bibr" rid="CR32">32</xref>]. However, it is often not clear if volume status in this context refers to the extracellular fluid volume, to the effective circulating volume or to the total body water. In addition, the sensitivity and specificity of clinical assessments of volume status are low, potentially leading to misclassification early in the diagnostic tree [<xref ref-type="bibr" rid="CR33">33</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. Therefore, we have used the terms ‘effective circulating volume’ and ‘extracellular fluid volume’ throughout the text to reduce ambiguity.<list list-type="bullet"><list-item><p>Note of caution</p></list-item></list></p><p>We wanted the classification of hyponatraemia to be consistent, easy to use and helpful for both differential diagnosis and treatment. Hyponatraemia can be classified according to different factors, each with advantages and pitfalls depending on the clinical setting and situation. We have prioritized the criteria such that we would obtain a classification that would be clinically relevant and as widely applicable as possible.</p><p>Nevertheless, the user should keep in mind that differential diagnosis of hyponatraemia is difficult and no classification can be 100 % accurate in every situation. We emphasize that the different classifications of hyponatraemia are not mutually exclusive, and that classification should always occur with the clinical condition and the possibility of combined causes of hyponatraemia in mind.</p></sec></sec>
24562549|Confirming hypotonic and excluding non-hypotonic hyponatraemia|('method', 0.8815247132714691)|('other', 0.11847528672853092)|<sec id="Sec7" sec-type="box"><title>Confirming hypotonic and excluding non-hypotonic hyponatraemia</title><p>We recommend excluding hyperglycaemic hyponatraemia by measuring the serum glucose concentration and correcting the measured serum sodium concentration for the serum glucose concentration if the latter is increased. (1D)</p><p>Hyponatraemia with a measured osmolality &lt;275 mOsm/kg always reflects hypotonic hyponatraemia. (not graded)</p><p>Accept as ‘hypotonic hyponatraemia’ a hyponatraemia without evidence for causes of non-hypotonic hyponatraemia as listed in Table <xref rid="Tab3" ref-type="table">3</xref>. (not graded)<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>(Table 10 of the online document): causes of non-hypotonic hyponatraemia</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Setting</th><th align="left" rowspan="1" colspan="1">Serum osmolality</th><th align="left" rowspan="1" colspan="1">Examples</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Presence of “effective” osmoles that raise serum osmolality and can cause hyponatraemia</td><td align="left" rowspan="1" colspan="1">Isotonic or hypertonic</td><td align="left" rowspan="1" colspan="1">Glucose [<xref ref-type="bibr" rid="CR35">35</xref>]<break/>Mannitol [<xref ref-type="bibr" rid="CR38">38</xref>]<break/>Glycine [<xref ref-type="bibr" rid="CR39">39</xref>]<break/>Histidine–tryptophane–ketoglutarate [<xref ref-type="bibr" rid="CR40">40</xref>]<break/>Hyperosmolar radiocontrast media [<xref ref-type="bibr" rid="CR41">41</xref>]<break/>Maltose [<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Presence of “ineffective” osmoles that raise serum osmolality but do not cause hyponatraemia</td><td align="left" rowspan="1" colspan="1">Isotonic or hyperosmolar</td><td align="left" rowspan="1" colspan="1">Urea [<xref ref-type="bibr" rid="CR43">43</xref>]<break/>Alcohols [<xref ref-type="bibr" rid="CR43">43</xref>]<break/>Ethylene-glycol [<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left" rowspan="1" colspan="1">Presence of endogenous solutes that cause pseudohyponatraemia (laboratory artifact)</td><td align="left" rowspan="1" colspan="1">Isotonic</td><td align="left" rowspan="1" colspan="1">Triglycerides [<xref ref-type="bibr" rid="CR44">44</xref>]<break/>Cholesterol [<xref ref-type="bibr" rid="CR44">44</xref>]<break/>Protein intravenous immunoglobulins [<xref ref-type="bibr" rid="CR45">45</xref>]<break/>Monoclonal gammapathies [<xref ref-type="bibr" rid="CR46">46</xref>]</td></tr></tbody></table></table-wrap></p><p>Advice for clinical practice</p><p>Estimates of the serum sodium concentration corrected for the presence of hyperglycaemia can be obtained from the following equations [<xref ref-type="bibr" rid="CR35">35</xref>]:<disp-formula id="Equa"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mrow><mml:mi>C</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.277778em"/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>=</mml:mo><mml:mspace width="0.277778em"/><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>+</mml:mo><mml:mspace width="0.277778em"/><mml:mn>2.4</mml:mn><mml:mspace width="0.277778em"/><mml:mo>×</mml:mo><mml:mspace width="0.277778em"/><mml:mfrac><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>G</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mo>cos</mml:mo><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>d</mml:mi><mml:mi>l</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.277778em"/><mml:mo>-</mml:mo><mml:mspace width="0.277778em"/><mml:mn>100</mml:mn><mml:mspace width="0.277778em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>d</mml:mi><mml:mi>l</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>100</mml:mn><mml:mspace width="0.277778em"/><mml:mi>m</mml:mi><mml:mi>g</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>d</mml:mi><mml:mi>l</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><tex-math id="M2">\documentclass[12pt]{minimal}				\usepackage{amsmath}				\usepackage{wasysym} 				\usepackage{amsfonts} 				\usepackage{amssymb} 				\usepackage{amsbsy}				\usepackage{mathrsfs}				\usepackage{upgreek}				\setlength{\oddsidemargin}{-69pt}				\begin{document}$$ Corrected\;serum\;[Na^{ + } ]\; = \;measured\;[Na^{ + } ]\; + \;2.4\; \times \;\frac{[Glu\cos e\;(mg/dl)\; - \;100\;(mg/dl)]}{100\;mg/dl} $$\end{document}</tex-math></alternatives></disp-formula><disp-formula id="Equb"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M3"><mml:mrow><mml:mi>C</mml:mi><mml:mi>o</mml:mi><mml:mi>r</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>c</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>=</mml:mo><mml:mspace width="0.277778em"/><mml:mi>m</mml:mi><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>s</mml:mi><mml:mi>u</mml:mi><mml:mi>r</mml:mi><mml:mi>e</mml:mi><mml:mi>d</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>+</mml:mo><mml:mspace width="0.277778em"/><mml:mn>2.4</mml:mn><mml:mspace width="0.277778em"/><mml:mo>×</mml:mo><mml:mspace width="0.277778em"/><mml:mfrac><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>G</mml:mi><mml:mi>l</mml:mi><mml:mi>u</mml:mi><mml:mo>cos</mml:mo><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.277778em"/><mml:mo>-</mml:mo><mml:mspace width="0.277778em"/><mml:mn>5.5</mml:mn><mml:mspace width="0.277778em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>L</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mn>5.5</mml:mn><mml:mspace width="0.277778em"/><mml:mi>m</mml:mi><mml:mi>m</mml:mi><mml:mi>o</mml:mi><mml:mi>l</mml:mi><mml:mo stretchy="false">/</mml:mo><mml:mi>L</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:math><tex-math id="M4">\documentclass[12pt]{minimal}				\usepackage{amsmath}				\usepackage{wasysym} 				\usepackage{amsfonts} 				\usepackage{amssymb} 				\usepackage{amsbsy}				\usepackage{mathrsfs}				\usepackage{upgreek}				\setlength{\oddsidemargin}{-69pt}				\begin{document}$$ Corrected\;[Na^{ + } ]\; = \;measured\;[Na^{ + } ]\; + \;2.4\; \times \;\frac{[Glu\cos e\;(mmol/L)\; - \;5.5\;(mmol/L)]}{5.5\;mmol/L} $$\end{document}</tex-math></alternatives></disp-formula>where [Na<sup>+</sup>] is the serum sodium concentration, [Glucose] is the serum glucose concentration.</p><p>This translates into adding 2.4 mmol/L to the measured serum sodium concentration for every 5.5 mmol/L (100 mg/dL) incremental rise in serum glucose concentration above a standard serum glucose concentration of 5.5 mmol/L (100 mg/dL).</p><p>Alternatively, the estimated value of the corrected serum sodium concentration across a range of serum glucose concentrations can be obtained from (ESM Table 10).</p></sec>
24562549|Which parameters to use for differentiating causes of hypotonic hyponatraemia? (Fig. <xref rid="Fig1" ref-type="fig">1</xref>)|('method', 0.8815247132714691)|('other', 0.11847528672853092)|<sec id="Sec8" sec-type="box"><title>Which parameters to use for differentiating causes of hypotonic hyponatraemia? (Fig. <xref rid="Fig1" ref-type="fig">1</xref>)</title><p>We recommend interpreting urine osmolality of a spot urine sample as a first step. (1D)<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>(Fig. 6 of the online document): algorithm for the diagnosis of hyponatraemia</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2014_3210_Fig1_HTML.gif" id="MO3" position="float" orientation="portrait"/></fig></p><p>If urine osmolality ≤100 mOsm/kg, we recommend accepting relative excess water intake as a cause of the hypotonic hyponatraemia. (1D)</p><p>If urine osmolality &gt;100 mOsm/kg, we recommend interpreting the urine sodium concentration on a spot urine sample taken simultaneously with a blood sample. (1D)</p><p>If urine sodium concentration ≤30 mmol/L, we suggest accepting low effective arterial volume as a cause of the hypotonic hyponatraemia. (2D)</p><p>If urine sodium concentration &gt;30 mmol/L, we suggest assessing extracellular fluid status and use of diuretics to further differentiate likely causes of the hyponatraemia. (2D)</p><p>We suggest against measuring vasopressin for confirming the diagnosis of SIADH. (2D)</p><p>Advice for clinical practice<list list-type="bullet"><list-item><p>Correct interpretation of laboratory measurements requires contemporaneous collection of blood and urine specimens.</p></list-item><list-item><p>For practical reasons, urine osmolality and sodium concentration are best determined in the same urine sample.</p></list-item><list-item><p>If clinical assessment indicates the volume of extracellular fluid is not overtly increased and the urine sodium concentration &gt;30 mmol/L, exclude other causes of hypotonic hyponatraemia before implicating SIAD. Consider using the diagnostic criteria listed in Tables <xref rid="Tab4" ref-type="table">4</xref>, <xref rid="Tab5" ref-type="table">5</xref> and looking for known causes of SIAD.<table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>(Table 6 of the online document): diagnostic criteria for the syndrome of inappropriate antidiuresis</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left" rowspan="1" colspan="1">Essential criteria</td></tr><tr><td align="left" rowspan="1" colspan="1"> Effective serum osmolality &lt;275 mOsm/kg</td></tr><tr><td align="left" rowspan="1" colspan="1"> Urine osmolality &gt;100 mOsm/kg at some level of decreased effective osmolality</td></tr><tr><td align="left" rowspan="1" colspan="1"> Clinical euvolaemia</td></tr><tr><td align="left" rowspan="1" colspan="1"> Urine sodium concentration &gt;30 mmol/L with normal dietary salt and water intake</td></tr><tr><td align="left" rowspan="1" colspan="1"> Absence of adrenal, thyroid, pituitary or renal insufficiency</td></tr><tr><td align="left" rowspan="1" colspan="1"> No recent use of diuretic agents</td></tr><tr><td align="left" rowspan="1" colspan="1">Supplemental criteria</td></tr><tr><td align="left" rowspan="1" colspan="1"> Serum uric acid &lt;0.24 mmol/L (&lt;4 mg/dL)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Serum urea &lt;3.6 mmol/L (&lt;21.6 mg/dL)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Failure to correct hyponatraemia after 0.9 % saline infusion</td></tr><tr><td align="left" rowspan="1" colspan="1"> Fractional sodium excretion &gt;0.5 %</td></tr><tr><td align="left" rowspan="1" colspan="1"> Fractional urea excretion &gt;55 %</td></tr><tr><td align="left" rowspan="1" colspan="1"> Fractional uric acid excretion &gt;12 %</td></tr><tr><td align="left" rowspan="1" colspan="1"> Correction of hyponatraemia through fluid restriction</td></tr></tbody></table><table-wrap-foot><p>Adapted from Schwartz et al. [<xref ref-type="bibr" rid="CR36">36</xref>] and Janicic et al. [<xref ref-type="bibr" rid="CR37">37</xref>]</p></table-wrap-foot></table-wrap><table-wrap id="Tab5" position="float" orientation="portrait"><label>Table 5</label><caption><p>(Table 11 of the online document): differences between SIADH and cerebral salt wasting</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">SIADH</th><th align="left" rowspan="1" colspan="1">Cerebral salt wasting</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Serum urea concentration</td><td align="left" rowspan="1" colspan="1">Normal–low</td><td align="left" rowspan="1" colspan="1">Normal–high</td></tr><tr><td align="left" rowspan="1" colspan="1">Serum uric acid concentration</td><td align="left" rowspan="1" colspan="1">Low</td><td align="left" rowspan="1" colspan="1">Low</td></tr><tr><td align="left" rowspan="1" colspan="1">Urine volume</td><td align="left" rowspan="1" colspan="1">Normal–low</td><td align="left" rowspan="1" colspan="1">High</td></tr><tr><td align="left" rowspan="1" colspan="1">Urine sodium concentration</td><td align="left" rowspan="1" colspan="1">&gt;30 mmol/L</td><td align="left" rowspan="1" colspan="1">&gt;&gt;30 mmol/L</td></tr><tr><td align="left" rowspan="1" colspan="1">Blood pressure</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Normal–orthostatic hypotension</td></tr><tr><td align="left" rowspan="1" colspan="1">Central venous pressure</td><td align="left" rowspan="1" colspan="1">Normal</td><td align="left" rowspan="1" colspan="1">Low</td></tr></tbody></table><table-wrap-foot><p>Adapted from Sherlock et al. [<xref ref-type="bibr" rid="CR47">47</xref>] and Brimioulle et al. [<xref ref-type="bibr" rid="CR48">48</xref>]</p></table-wrap-foot></table-wrap></p></list-item><list-item><p>Consider primary or secondary adrenal insufficiency as an underlying cause of the hypotonic hyponatraemia.</p></list-item><list-item><p>Kidney disease complicates differential diagnosis of hyponatraemia. Besides possibly contributing to the hyponatraemia, the ability of the kidneys to regulate urine osmolality and urine sodium is often diminished, much like with the use of diuretics. As urine osmolality and sodium may no longer reflect the effects of the regular hormonal axes regulating water and sodium homeostasis, any diagnostic algorithm for hyponatraemia must be used with caution in patients with kidney disease.</p></list-item><list-item><p>The water-loading test is generally not helpful for differential diagnosis of hypotonic hyponatraemia and may be dangerous in this setting.</p></list-item></list></p></sec>
24562549|Treatment of hypotonic hyponatraemia|('method', 0.90800685795471)|('other', 0.09199314204528987)|<title>Treatment of hypotonic hyponatraemia</title>
24562549|None|('method', 0.90800685795471)|('other', 0.09199314204528987)|<p>How to use the treatment recommendations</p>
24562549|None|('method', 0.90800685795471)|('other', 0.09199314204528987)|<p>The advice provided in this chapter follows a specific hierarchy as illustrated in Fig. <xref rid="Fig2" ref-type="fig">2</xref>. Individual recommendations and statements can only be correctly interpreted and implemented if considered within this structure.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>(Fig. 7 of the online document): algorithm for the management of hypotonic hyponatraemia (the <italic toggle="yes">numbers in the yellow boxes</italic> refer to the online full guideline document)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="134_2014_3210_Fig2_HTML.gif" id="MO4" position="float" orientation="portrait"/></fig></p>
24562549|None|('method', 0.90800685795471)|('other', 0.09199314204528987)|<p>The guideline development group felt that with severe or moderately severe symptoms, the risk of brain oedema outweighs the risk of osmotic demyelination syndrome. They felt it justifies urgent treatment in these conditions, irrespective of biochemical degree or timing (acute versus chronic) of hyponatraemia. Conversely, the guideline development group believed that in the absence of severe or moderately severe symptoms, there is time for diagnostic assessment, and cause-specific treatment is the most reasonable approach.</p>
24562549|None|('method', 0.90800685795471)|('other', 0.09199314204528987)|<p>For a correct interpretation of the algorithm in Fig. <xref rid="Fig2" ref-type="fig">2</xref>, it is crucial to understand that for correctly classifying symptoms as ‘severe’ or ‘moderately severe’, there must be sufficient confidence that the symptoms are caused by hyponatraemia. If hyponatraemia is mild and symptoms are severe or moderately severe (Table 5 of the online document), the guideline development group advises to only accept causality in exceptional cases. Consequently, generally, chapters <xref rid="Sec10" ref-type="sec">3.1</xref>, <xref rid="Sec14" ref-type="sec">3.2</xref>, and <xref rid="Sec15" ref-type="sec">3.3</xref> are not applicable when hyponatraemia is mild. It is also essential to understand that the guideline development group distinguishes between targets and limits. A target is a goal one is aiming for; it is the change in serum sodium concentration that one wishes and expects to achieve with a particular treatment. In contrast, a limit is a change in serum sodium concentration one does not want to exceed and if surpassed, requires prompt counter-regulating intervention as described in chapter 9.5 (ESM). In addition, the reader should bear in mind that the absolute numbers provided as ‘targets’ or ‘limits’ should always be interpreted in the clinical context of the individual patient.</p>
24562549|Hyponatraemia with severe symptoms|('method', 0.90800685795471)|('other', 0.09199314204528987)|<sec id="Sec10"><title>Hyponatraemia with severe symptoms</title><sec id="Sec11"><title>First hour management, regardless of whether hyponatraemia is acute or chronic</title><p>We recommend prompt intravenous infusion of 150 mL 3 % hypertonic saline or equivalent over 20 min. (1D)</p><p>We suggest checking the serum sodium concentration after 20 min while repeating an infusion of 150 mL 3 % hypertonic saline or equivalent over the next 20 min. (2D)</p><p>We suggest repeating therapeutic recommendations 3.1.1.1 and 3.1.1.2 twice or until a target of 5 mmol/L increase in serum sodium concentration is achieved. (2D)</p><p>Manage patients with severely symptomatic hyponatraemia in an environment where close biochemical and clinical monitoring can be provided. (not graded)</p></sec><sec id="Sec12" sec-type="box"><title>Follow up management in case of improvement of symptoms after a 5 mmol/L increase in serum sodium concentration in the first hour, regardless of whether hyponatraemia is acute or chronic</title><p>We recommend stopping the infusion of hypertonic saline. (1D)</p><p>We recommend keeping the intravenous line open by infusing the smallest feasible volume of 0.9 % saline until cause-specific treatment is started. (1D)</p><p>We recommend starting a diagnosis specific treatment if available, aiming at least to stabilize sodium concentration. (1D)</p><p>We recommend limiting the increase in serum sodium concentration to a total of 10 mmol/L during the first 24 h and an additional 8 mmol/L during every 24 h thereafter until the serum sodium concentration reaches 130 mmol/L. (1D)</p><p>We suggest checking the serum sodium concentration after 6 and 12 h, and daily afterwards until the serum sodium concentration has stabilised under stable treatment. (2D)</p></sec><sec id="Sec13" sec-type="box"><title>Follow up management in case of no improvement of symptoms after a 5 mmol/L increase in serum sodium concentration in the first hour, regardless of whether the hyponatraemia is acute or chronic</title><p>We recommend continuing an intravenous infusion of 3 % hypertonic saline or equivalent aiming for an additional 1 mmol/L/h increase in serum sodium concentration (1D).</p><p>We recommend stopping the infusion of 3 % hypertonic saline or equivalent when the symptoms improve, the serum sodium concentration increases 10 mmol/L in total or the serum sodium concentration reaches 130 mmol/L, whichever occurs first (1D).</p><p>We recommend additional diagnostic exploration for other causes of the symptoms than hyponatraemia (1D).</p><p>We suggest checking the serum sodium concentration every 4 h as long as an intravenous infusion of 3 % hypertonic saline or equivalent is continued (2D).</p><p>Advice for clinical practice<list list-type="bullet"><list-item><p>Prompt infusion of hypertonic saline may save lives. However, preparing a 3 % hypertonic saline infusion takes time and errors may occur in calculating the required amount of sodium chloride. Therefore, it may be wise for the pharmacy to store pre-prepared 150 mL bags of 3 % hypertonic saline. It ensures that solutions are prepared under sterile conditions, by either the pharmacist or the manufacturer, and are available for immediate infusion without having to prepare them on the spot.</p></list-item><list-item><p>Consider using weight based (2 mL/kg) rather than the fixed 150 mL infusion volumes of 3 % hypertonic saline in case of obviously deviant body composition.</p></list-item><list-item><p>Do not expect patients with severe symptoms to completely recover immediately, as it may take some time for the brain to fully recover. Be aware that sometimes it may not be possible to assess an improvement in symptoms, e.g. because the patient is intubated and sedated. In these cases, we advise to follow guidance as described under 9.1.2.</p></list-item><list-item><p>Keep in mind that if hypokalaemia is present, correction of the hypokalaemia will contribute to an increase in serum sodium concentration.</p></list-item><list-item><p>To achieve the 1 mmol/L/h increase advised in 9.1.2.1, the formula of Adrogué–Madias [<xref ref-type="bibr" rid="CR32">32</xref>] may be used, but keep in mind that the actual increase may exceed the calculated increase:<disp-formula id="Equc"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M5"><mml:mrow><mml:mi>C</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.277778em"/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>=</mml:mo><mml:mspace width="0.277778em"/><mml:mfrac><mml:mrow><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>-</mml:mo><mml:mspace width="0.277778em"/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.277778em"/><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>y</mml:mi><mml:mspace width="0.277778em"/><mml:mi>w</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.277778em"/><mml:mo>+</mml:mo><mml:mspace width="0.277778em"/><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:math><tex-math id="M6">\documentclass[12pt]{minimal}				\usepackage{amsmath}				\usepackage{wasysym} 				\usepackage{amsfonts} 				\usepackage{amssymb} 				\usepackage{amsbsy}				\usepackage{mathrsfs}				\usepackage{upgreek}				\setlength{\oddsidemargin}{-69pt}				\begin{document}$$ Change\;in\;serum\;[Na^{ + } ]\; = \;\frac{infusate\;[Na^{ + } ]\; - \;serum\;[Na^{ + } ]}{total\;body\;water\; + \;1} $$\end{document}</tex-math></alternatives></disp-formula><disp-formula id="Equd"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M7"><mml:mrow><mml:mi>C</mml:mi><mml:mi>h</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>g</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mspace width="0.277778em"/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>=</mml:mo><mml:mspace width="0.277778em"/><mml:mfrac><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>+</mml:mo><mml:mspace width="0.277778em"/><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>f</mml:mi><mml:mi>u</mml:mi><mml:mi>s</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msup><mml:mi>K</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mspace width="0.277778em"/><mml:mo>-</mml:mo><mml:mspace width="0.277778em"/><mml:mi>s</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mi>u</mml:mi><mml:mi>m</mml:mi><mml:mspace width="0.277778em"/><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>N</mml:mi><mml:msup><mml:mi>a</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow><mml:mrow><mml:mi>t</mml:mi><mml:mi>o</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mi>l</mml:mi><mml:mspace width="0.277778em"/><mml:mi>b</mml:mi><mml:mi>o</mml:mi><mml:mi>d</mml:mi><mml:mi>y</mml:mi><mml:mspace width="0.277778em"/><mml:mi>w</mml:mi><mml:mi>a</mml:mi><mml:mi>t</mml:mi><mml:mi>e</mml:mi><mml:mi>r</mml:mi><mml:mspace width="0.277778em"/><mml:mo>+</mml:mo><mml:mspace width="0.277778em"/><mml:mn>1</mml:mn></mml:mrow></mml:mfrac></mml:mrow></mml:math><tex-math id="M8">\documentclass[12pt]{minimal}				\usepackage{amsmath}				\usepackage{wasysym} 				\usepackage{amsfonts} 				\usepackage{amssymb} 				\usepackage{amsbsy}				\usepackage{mathrsfs}				\usepackage{upgreek}				\setlength{\oddsidemargin}{-69pt}				\begin{document}$$ Change\;in\;serum\;[Na^{ + } ]\; = \;\frac{{(infusate\;[Na^{ + } ]\; + \;infusate\;[K^{ + } ])\; - \;serum\;[Na^{ + } ]}}{total\;body\;water\; + \;1} $$\end{document}</tex-math></alternatives></disp-formula></p></list-item></list></p><p>where [Na<sup>+</sup>] is the sodium concentration in mmol/L, [K<sup>+</sup>] is the potassium concentration in mmol/L. The numerator in formula 1 is a simplification of the expression in formula 2, with the value yielded by the equation in mmol/L. The estimated total body water (in litres) is calculated as a fraction of body weight. The fraction is 0.6 in nonelderly men and 0.5 in nonelderly women; and 0.5 and 0.45 in elderly men and women respectively. Normally, extracellular and intracellular fluids account for 40 and 60 % of total body water respectively.</p></sec></sec>
24562549|Hyponatraemia with moderately severe symptoms|('method', 0.90800685795471)|('other', 0.09199314204528987)|<sec id="Sec14" sec-type="box"><title>Hyponatraemia with moderately severe symptoms</title><p>We recommend starting prompt diagnostic assessment. (1D)</p><p>Stop, if possible, medications and other factors that can contribute to or provoke the hyponatraemia. (not graded)</p><p>We recommend cause-specific treatment. (1D)</p><p>We suggest immediate treatment with a single intravenous infusion of 150 mL 3 % hypertonic saline or equivalent over 20 min. (2D)</p><p>We suggest aiming for a 5 mmol/L/24 h increase in serum sodium concentration. (2D)</p><p>We suggest limiting the increase in serum sodium concentration to 10 mmol/L in the first 24 h and 8 mmol/L during every 24 h thereafter, until a serum sodium concentration of 130 mmol/L is reached. (2D)</p><p>We suggest checking the serum sodium concentration after one, 6 and 12 h. (2D)</p><p>We suggest additional diagnostic exploration for other causes of the symptoms if the symptoms do not improve with an increase in serum sodium concentration. (2D)</p><p>We suggest considering to manage the patient as in severely symptomatic hyponatraemia if the serum sodium concentration further decreases despite treating the underlying diagnosis. (2D)</p></sec>
24562549|Acute hyponatraemia without severe or moderately severe symptoms|('method', 0.90800685795471)|('other', 0.09199314204528987)|<sec id="Sec15" sec-type="box"><title>Acute hyponatraemia without severe or moderately severe symptoms</title><p>Make sure that the serum sodium concentration has been measured using the same technique as used for the previous measurement and that no administrative errors in sample handling have occurred. (not graded)</p><p>If possible, stop fluids, medications and other factors that can contribute to or provoke the hyponatraemia. (not graded)</p><p>We recommend starting prompt diagnostic assessment. (1D)</p><p>We recommend cause-specific treatment. (1D)</p><p>If the acute decrease in serum sodium concentration exceeds 10 mmol/L, we suggest a single intravenous infusion of 150 mL 3 % hypertonic saline or equivalent over 20 min. (2D)</p><p>We suggest checking the serum sodium concentration after 4 h, using the same technique as used for the previous measurement. (2D)</p></sec>
24562549|Chronic hyponatraemia without severe or moderately severe symptoms|('method', 0.90800685795471)|('other', 0.09199314204528987)|<sec id="Sec16" sec-type="box"><title>Chronic hyponatraemia without severe or moderately severe symptoms</title><sec id="Sec17"><title>General management</title><p>Stop non-essential fluids, medications and other factors that can contribute to or provoke the hyponatraemia. (not graded)</p><p>We recommend cause-specific treatment. (1D)</p><p>In mild hyponatraemia, we suggest against treatment with the sole aim of increasing the serum sodium concentration. (2C)</p><p>In moderate or profound hyponatraemia, we recommend avoiding an increase in serum sodium concentration of &gt;10 mmol/L during the first 24 h and &gt;8 mmol/L during every 24 h thereafter. (1D)</p><p>In moderate or profound hyponatraemia, we suggest checking the serum sodium concentration every 6 h until the serum sodium concentration has stabilised under stable treatment. (2D)</p><p>In case of unresolved hyponatraemia, reconsider the diagnostic algorithm and ask for expert advice. (not graded)</p></sec><sec id="Sec18" sec-type="box"><title>Patients with expanded extracellular fluid</title><p>We recommend against a treatment with the sole aim of increasing the serum sodium concentration in mild or moderate hyponatraemia. (1C)</p><p>We suggest fluid restriction to prevent further fluid overload. (2D)</p><p>We recommend against vasopressin receptor antagonists. (1C)</p><p>We recommend against demeclocycline. (1D)</p></sec><sec id="Sec19" sec-type="box"><title>Patients with syndrome of inappropriate antidiuresis</title><p>In moderate or profound hyponatraemia, we suggest restricting fluid intake as first- line treatment. (2D)</p><p>In moderate or profound hyponatraemia, we suggest the following can be considered equal second line treatments: increasing solute intake with 0.25–0.50 g/kg/day of urea or a combination of low dose loop diuretics and oral sodium chloride. (2D)</p><p>In moderate or profound hyponatraemia, we recommend against lithium or demeclocycline. (1D)</p><p>In moderate hyponatraemia, we do not recommend vasopressin receptor antagonists. (1C)</p><p>In profound hyponatraemia, we recommend against vasopressin receptor antagonists. (1C)</p></sec><sec id="Sec20" sec-type="box"><title>Patients with contracted circulating volume</title><p>We recommend restoring extracellular volume with intravenous infusion of 0.9 % saline or a balanced crystalloid solution at 0.5–1.0 mL/kg/h. (1B)</p><p>Manage patients with haemodynamic instability in an environment where close biochemical and clinical monitoring can be provided. (not graded)</p><p>In case of haemodynamic instability, the need for rapid fluid resuscitation overrides the risk of an overly rapid increase in serum sodium concentration. (not graded)</p><p>Advice for clinical practice<list list-type="bullet"><list-item><p>A sudden increase in urine output to &gt;100 mL/h signals increased risk of overly rapid rise in serum sodium concentration. If vasopressin activity is suddenly suppressed, as happens when intravascular volume is restored in hypovolaemia, free water clearance can dramatically increase, resulting in serum sodium concentrations rising more rapidly than expected. If urine output suddenly increases, we would advise measuring the serum sodium concentration every 2 h until it has stabilised under stable treatment. The implicit advice to monitor urine output does not imply we advise a bladder catheter solely for this purpose. Most patients will be able to void spontaneously and collect urine for output monitoring.</p></list-item><list-item><p>As a means of increasing solute intake, we suggest daily intake of 0.25–0.50 g/kg urea can be used. The bitter taste can be reduced by combining it with sweet tasting substances. The pharmacist may be asked to prepare the following as sachets: urea 10 g + NaHCO<sub>3</sub> 2 g + citric acid 1.5 g + sucrose 200 mg, to be dissolved in 50–100 mL water. This will result in a more palatable, slightly sparkling solution.</p></list-item></list></p></sec></sec>
24562549|What to do in case hyponatraemia is corrected too rapidly?|('method', 0.90800685795471)|('other', 0.09199314204528987)|<sec id="Sec21" sec-type="box"><title>What to do in case hyponatraemia is corrected too rapidly?</title><p>We recommend prompt intervention for re-lowering the serum sodium concentration if it increases &gt;10 mmol/L during the first 24 h or &gt;8 mmol/L in any 24 h thereafter. (1D)</p><p>We recommend discontinuing the on-going active treatment. (1D)</p><p>We recommend consulting an expert to discuss if it is appropriate to start an infusion of 10 mL/kg body weight of electrolyte-free water (e.g. glucose solutions) over 1 h under strict monitoring of urine output and fluid balance. (1D)</p><p>We recommend consulting an expert to discuss if it is appropriate to add intravenous desmopressin 2 μg, with the understanding that this should not be repeated more frequently than every 8 h. (1D)</p></sec>
24562607|None|('method', 0.9984785847200705)|('other', 0.001521415279929594)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Sample</title>
24562607|None|('method', 0.9984785847200705)|('other', 0.001521415279929594)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P15">Potential participants were randomly selected from each reservation's health clinic records. Inclusion criteria were patients 18 years or older, type 2 diabetes diagnosis, and self-identified as American Indian. Clinic partners were trained on probability sampling methods to generate a random sample of 150 patients from their lists. Selected patients were mailed a welcome letter, an informational project brochure, and a contact information card with mail and phone-in options to decline participation. Trained community interviewers contacted non-declining recruits to schedule interviews. Consenting participants were given a pound of locally cultivated wild rice and a $30 cash incentive. Paper-and-pencil interviewer administered surveys were completed in participants’ location of choice, most often in private spaces within homes. The time to complete each survey ranged between approximately 1.5 - 3 hours.</p>
24562607|None|('method', 0.9984785847200705)|('other', 0.001521415279929594)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">Identifying information linked to surveys was removed and replaced with an ID number by project coordinators prior to sending to the university-based team. Out of a total initial eligible sample of 289 individuals, 218 participants completed surveys for a study response rate of 75.4%.</p>
24562607|Measures|('method', 0.9984785847200705)|('other', 0.001521415279929594)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Measures</title><sec id="S9"><title>Mental &amp; Emotional Health</title><p id="P17">Four major mental and emotional constructs are included in these analyses. <italic>Depressive Symptoms</italic> were measured by scored responses (0 to 3, where 0 = not at all, 1 = several days, 2 = more than half the days, 3 = almost every day) to nine items (PHQ-9<sup><xref rid="R29" ref-type="bibr">29</xref></sup>) assessing symptoms of depression experienced in the two weeks prior to survey participation. The final summed score of all nine items included a possible range of 0 to 27 and had excellent reliability (Cronbach's α = .98). <italic>Anxiety</italic> was measured by responses to Beck Anxiety Inventory<sup><xref rid="R30" ref-type="bibr">30</xref></sup> items assessing degree of impact of 21 anxiety symptoms (0 = not at all, 1 = mildly, 2= moderately, and 3 = severely bothered). The summed value of all items was calculated for a total possible range of 0 to 63, with Cronbach's α= .95. <italic>Anger</italic> was measured with the Tri-Ethnic Anger scale,<sup><xref rid="R31" ref-type="bibr">31</xref></sup> including responses to 6 questions about frequency (most, some, or none of the time) of anger-related emotions (e.g., mad, feel like hitting someone, quick tempered). The mean response for all 6 items was calculated, and Cronbach's α= .78. <italic>Apathy</italic> was measured with responses to 8 items adapted from the Apathy Evaluation Scale.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Participants were asked to indicate frequency (from “not at all” to “a lot”) during the 4 weeks prior to the interview of various thoughts, feelings, and activities indicating apathy (e.g., interest in new experiences, approaching life with intensity, having motivation), with higher scores indicating a greater degree of apathy. Cronbach's α for the resulting summed index = .67.</p></sec><sec id="S10"><title>Health Outcomes</title><p id="P18">All physical health outcomes were measured with items from the Michigan Diabetes Research and Training Center Diabetes Care Profile.<sup><xref rid="R33" ref-type="bibr">33</xref></sup><italic>Physical limitations</italic> is a measure of health-impaired moderate activities like moving a table, pushing a vacuum, bowling, or playing golf (no limitation = 0, a little limitation = 1, a lot of limitation = 2). For ease of interpretation, a dichotomized version of the variable was used in cross tabulation tables (0 = none, a little, 1 = a lot). <italic>Hyperglycemia</italic> (high blood glucose) was assessed by the following question: How many days in the last month have you had high blood sugar with symptoms such as thirst, dry mouth and skin, increased sugar in the urine, less appetite, nausea, or fatigue? Responses were coded as 1 = 0 times; 2 = 1 – 3 times; 3 = 4 – 6 times; 4 = 7 – 12 times; and 5 = more than 12 times. A dichotomized version of this variable was used in cross tabulation tables (0 = none, 1 = any hyperglycemia). The last health outcome assessed was <italic>comorbidities</italic>, or reports of eye, heart/circulatory, bladder, kidney or urinary, or foot/leg problems. This measure is a count index of 21 potential comorbid conditions, thus resulting in a possible range in scores from 0 – 21.</p></sec><sec id="S11"><title>Control Variables</title><p id="P19">Several control variables were also included. <italic>Gender</italic> was coded 0 = male, 1 = female. Although all participants in this study sought medical care at clinics located on reservation, some lived off reservation lands. This was controlled for this with a dummy variable where 0 = off reservation and 1 = on reservation. <italic>Per capital household income</italic> was measured by asking respondents to indicate their overall household income within $10,000 ranges. The final measure included the midpoints of these ranges divided by the number of people living within households. The <italic>number of years the participant had diabetes</italic> and self-reported <italic>age</italic> in years was also controlled for.</p></sec></sec>
24619110|None|('method', 0.9877001085566087)|('other', 0.012299891443391105)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 Formulation for subhazard frailty models</title>
24619110|None|('method', 0.9877001085566087)|('other', 0.012299891443391105)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">Suppose that the data consist of censored time-to-event observations collected from <italic>q</italic> centers (or clusters). We also assume that there are <italic>L</italic> distinct event types in each center. For subject <italic>j</italic> of center <italic>i</italic>, let <italic>T<sub>ij</sub></italic> be the time to the first event and let <italic>ε<sub>ij</sub></italic> ∈ {1, 2, …, <italic>L</italic>} be the corresponding cause of event (<italic>i</italic> = 1,…,<italic>q</italic>, <italic>j</italic> = 1,…, <italic>n<sub>i</sub></italic>, <italic>n</italic> = Σ<italic><sub>i</sub>n<sub>i</sub></italic>). Then observable random variables become <italic>Y<sub>ij</sub></italic> = min(<italic>T<sub>ij</sub>, C<sub>ij</sub></italic>) and <italic>ξ<sub>ij</sub></italic> = <italic>I</italic>(<italic>T<sub>ij</sub> ≤ C<sub>ij</sub></italic>)<italic>ε<sub>ij</sub></italic>, where <italic>C<sub>ij</sub></italic> is the independent censoring time, <italic>ξ<sub>ij</sub></italic> ∈ {0, 1, 2, …<italic>, L</italic>} and <italic>I</italic>(·) is the indicator function. The CIF of events from cause 1 (i.e. <italic>ε<sub>ij</sub></italic> = 1) is defined by<disp-formula id="FD1"><mml:math id="M1" display="block" overflow="scroll"><mml:msub><mml:mi>F</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula> which represents the probability that an individual will experience an event of Type 1 by time <italic>t</italic>. The corresponding hazard function of subdistribution (subhazard function) is defined by<disp-formula id="FD2"><mml:math id="M2" display="block" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>1</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munder><mml:mi>lim</mml:mi><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>t</mml:mi><mml:mo>→</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:munder><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>t</mml:mi></mml:mrow></mml:mfrac><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo>{</mml:mo><mml:mi>t</mml:mi><mml:mo>≤</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mi>t</mml:mi><mml:mo>+</mml:mo><mml:mi mathvariant="normal">Δ</mml:mi><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:mi>t</mml:mi><mml:mo>∪</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>&lt;</mml:mo><mml:mi>t</mml:mi><mml:mo>∩</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>≠</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo><mml:mspace width="0.2em"/><mml:mo>=</mml:mo><mml:mspace width="0.2em"/><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:mo>{</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo><mml:mo>/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi><mml:mo>.</mml:mo></mml:math></disp-formula>For simplicity, in this paper we consider the two event types (<italic>L</italic> = 1, 2). Thus, <italic>ξ<sub>ij</sub></italic> ∈ {0, 1, 2} it is 1 for an event of interest, 2 for a competing event and 0 for censoring.</p>
24619110|None|('method', 0.9877001085566087)|('other', 0.012299891443391105)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">Fine and Gray<sup><xref rid="R3" ref-type="bibr">3</xref></sup> first introduced a way to directly associate the effects of covariates with CIF, which models the subhazard for the event of interest, <italic>L</italic> = 1. Furthermore, Katsahian et al.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> and Christian<sup><xref rid="R7" ref-type="bibr">7</xref></sup> have extended Fine-Gray model to a subhazard frailty model with only one random component (i.e. random center effect) to analyze multi-center competing risks data.</p>
24619110|None|('method', 0.9877001085566087)|('other', 0.012299891443391105)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">In this paper we show that, for the purpose of more systematic analysis, the model above needs to be extended to a general subhazard frailty model allowing multiple random components (e.g. random center and random treatment effect) and their correlation, as in Ha et al.<sup><xref rid="R10" ref-type="bibr">10</xref></sup>. Here, random treatment effect means random treatment-by-center interaction. In particular, a model allowing for the correlation between random center and random treatment effects can properly account for the heterogeneities from the treatment effect across centers as well as between-center variation.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Denote by <italic>v<sub>i</sub></italic> = (<italic>v<sub>i</sub></italic><sub>0</sub><italic>, v<sub>i</sub></italic><sub>1</sub>, …<italic>, v<sub>ir</sub></italic><sub>−1</sub>)<italic><sup>T</sup></italic> an <italic>r</italic>-dimensional vector of unobserved log-frailties (random effects) associated with the <italic>i</italic>th (<italic>i</italic> = 1, …<italic>, q</italic>) center. Note that in (<xref ref-type="disp-formula" rid="FD3">1</xref>), <italic>u<sub>i</sub></italic> = exp(<italic>v<sub>i</sub></italic>) (i.e. <italic>v<sub>i</sub></italic> = log <italic>u<sub>i</sub></italic>) are referred to frailties<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup>. As described in Fine and Gray<sup><xref rid="R3" ref-type="bibr">3</xref></sup> and Ha et al.<sup><xref rid="R19" ref-type="bibr">19</xref></sup>, we assume that given <italic>v<sub>i</sub></italic>, (<italic>T<sub>ij</sub>, ε<sub>ij</sub></italic>) and <italic>C<sub>ij</sub></italic>, <italic>j</italic> = 1, …<italic>, n<sub>i</sub></italic>, are conditionally independent, and that given <italic>v<sub>i</sub></italic>, <italic>C<sub>ij</sub></italic>, <italic>j</italic> = 1, …<italic>, n<sub>i</sub></italic>, are non-informative about <italic>v<sub>i</sub></italic>. Suppose that we are interested in assessing the effects of covariates on the conditional CIF for cause 1 given the log-frailties <italic>v<sub>i</sub></italic>, defined by <italic>F</italic><sub>1</sub>(<italic>t|v<sub>i</sub></italic>) = <italic>Pr</italic>(<italic>T<sub>ij</sub> ≤ t, ε<sub>ij</sub></italic> = <italic>v<sub>i</sub></italic>). The conditional subhazard function for cause 1 given <italic>v<sub>i</sub></italic>, <inline-formula><mml:math id="M3" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mi>d</mml:mi><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:mo>{</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo><mml:mo>/</mml:mo><mml:mi>d</mml:mi><mml:mi>t</mml:mi></mml:math></inline-formula>, is modeled as<disp-formula id="FD3"><label>(1)</label><mml:math id="M4" display="block" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula> where <inline-formula><mml:math id="M5" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> is the unknown baseline subhazard function,<disp-formula id="FD4"><mml:math id="M6" display="block" overflow="scroll"><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></disp-formula> is the linear predictor for the log-hazard, and <italic>x<sub>ij</sub></italic> = (<italic>x<sub>ij</sub></italic><sub>1</sub>, …<italic>, x<sub>ijp</sub></italic>)<italic><sup>T</sup></italic> and <italic>z<sub>ij</sub></italic> = (<italic>z<sub>ij</sub></italic><sub>1</sub>, …<italic>, z<sub>ijr</sub></italic>)<italic><sup>T</sup></italic> are <italic>p</italic> × 1 and <italic>r</italic> × 1 covariate vectors corresponding to fixed effects <italic>β</italic> = (<italic>β</italic><sub>1</sub>, …<italic>, β<sub>p</sub></italic>)<italic><sup>T</sup></italic> and log-frailties <italic>v<sub>i</sub></italic>, respectively. We assume that the log-frailties <italic>v<sub>i</sub></italic> are independent and follow a multivariate normal distribution, <italic>v<sub>i</sub> ~ N<sub>r</sub></italic>(0, Σ<italic><sub>i</sub></italic>(<italic>θ</italic>)), where the covariance matrix Σ<italic><sub>i</sub></italic>(<italic>θ</italic>) depends on a vector of unknown parameters <italic>θ</italic>. The normal distribution has been used for modelling multi-component<sup><xref rid="R20" ref-type="bibr">20</xref></sup> and correlated frailties<sup><xref rid="R9" ref-type="bibr">9</xref></sup>.</p>
24619110|None|('method', 0.9877001085566087)|('other', 0.012299891443391105)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">Model (<xref ref-type="disp-formula" rid="FD3">1</xref>) includes some well-known models as special cases. In a multicenter medical study, let <italic>v<sub>i</sub></italic><sub>0</sub> be a random intercept or random center effect that modifies the baseline risk for center <italic>i</italic>, and let <italic>v<sub>i</sub></italic><sub>1</sub> be associated with the treatment effect, i.e., a random treatment effect (or random treatment-by-center interaction). In (<xref ref-type="disp-formula" rid="FD3">1</xref>), if we consider <italic>z<sub>ij</sub></italic> = 1 and <italic>v<sub>i</sub></italic> = <italic>v<sub>i</sub></italic><sub>0</sub> for all <italic>i, j</italic>, this becomes the random center or shared frailty model<sup><xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup> with<disp-formula id="FD5"><label>(2)</label><mml:math id="M7" display="block" overflow="scroll"><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></disp-formula> where <inline-formula><mml:math id="M8" display="inline" overflow="scroll"><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> for all <italic>i</italic>. Model (<xref ref-type="disp-formula" rid="FD5">2</xref>) can be extended as follows. Let <italic>β</italic><sub>1</sub> be the main treatment effect associated with the treatment indicator <italic>x<sub>ij</sub></italic><sub>1</sub> and let <italic>β<sub>m</sub></italic> (<italic>m</italic> = 2, …<italic>, p</italic>) be the fixed effects corresponding to the covariates <italic>x<sub>ijm</sub></italic>. Our two random components leads to a bivariate model<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> with<disp-formula id="FD6"><label>(3)</label><mml:math id="M9" display="block" overflow="scroll"><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>m</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mrow><mml:mi>p</mml:mi></mml:munderover><mml:mrow><mml:msub><mml:mi>β</mml:mi><mml:mi>m</mml:mi></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ijm</mml:mi></mml:msub></mml:mrow></mml:mstyle><mml:mo>,</mml:mo></mml:math></disp-formula> which is easily derived by taking <italic>z<sub>ij</sub></italic> = (1<italic>, x<sub>ij</sub></italic><sub>1</sub>)<italic><sup>T</sup></italic> and <italic>v<sub>i</sub></italic> = (<italic>v<sub>i</sub></italic><sub>0</sub><italic>, v<sub>ij</sub></italic><sub>1</sub>)<italic><sup>T</sup></italic> in (<xref ref-type="disp-formula" rid="FD3">1</xref>). Here, to maintain the invariance of model to parametrization of the treatment effect we allow a general covariance matrix<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> between <italic>v<sub>i</sub></italic><sub>0</sub> and <italic>v<sub>i</sub></italic><sub>1</sub> within a cluster: <disp-formula id="FD7"><label>(4)</label><mml:math id="M10" display="block" overflow="scroll"><mml:mstyle displaystyle="true"><mml:msub><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:mo>≡</mml:mo></mml:mstyle><mml:mrow><mml:mo>(</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mtd><mml:mtd><mml:msub><mml:mi>σ</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mi>σ</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:mtd><mml:mtd><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula> where the correlation is denoted by <italic>ρ</italic> = <italic>σ</italic><sub>01</sub>/(<italic>σ</italic><sub>0</sub><italic>σ</italic><sub>1</sub>). The bivariate normal model (<xref ref-type="disp-formula" rid="FD6">3</xref>) with (<xref ref-type="disp-formula" rid="FD7">4</xref>) is very useful for investigating heterogeneity in the baseline risk and the treatment effect across centers.</p>
24619110|None|('method', 0.9733895540067294)|('other', 0.0266104459932706)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3 H-likelihood estimation</title>
24619110|None|('method', 0.9733895540067294)|('other', 0.0266104459932706)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P10">In this section we show how to construct systematically the h-likelihood estimation procedure for fitting the semiparametric subhazard frailty model (<xref ref-type="disp-formula" rid="FD3">1</xref>). For this, we first show how to construct the h-likelihood, and then propose the estimation procedure. The general case for incomplete (censoring) data is presented here as in Pintilie<sup><xref rid="R1" ref-type="bibr">1</xref></sup> because the proposed method can be directly applied to complete (no censoring) data.</p>
24619110|3.1 H-likelihood construction|('method', 0.9733895540067294)|('other', 0.0266104459932706)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>3.1 H-likelihood construction</title><p id="P11">Let <italic>y</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub> denotes the <italic>k</italic>th (<italic>k</italic> = 1, …<italic>, D</italic>) smallest distinct event time of Type 1 among the <italic>y<sub>ij</sub></italic>’s, where <italic>y<sub>ij</sub></italic> is the observed value of <italic>Y<sub>ij</sub></italic> and <italic>D</italic> is the total number of distinct Type 1 events. Let <italic>R</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub> denotes the risk set at <italic>y</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub>: <disp-formula id="FD8"><mml:math id="M11" display="block" overflow="scroll"><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>R</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>:</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>≥</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mspace width="0.2em"/><mml:mtext>or</mml:mtext><mml:mspace width="0.2em"/><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mspace width="0.2em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.2em"/><mml:msub><mml:mi>ε</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>≠</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo><mml:mo>.</mml:mo></mml:math></disp-formula>Note that as compared to the classical Cox model, the risk set <italic>R</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub> comprises individuals who have not failed from any cause by <italic>y</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub> but also those who have previously failed from competing causes.<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> Since the functional form of baseline subhazard function <inline-formula><mml:math id="M12" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> is unknown, following Breslow’s<sup><xref rid="R21" ref-type="bibr">21</xref></sup> idea and the reformulation (equation (3.4), page 80) used by Fan and Li<sup><xref rid="R22" ref-type="bibr">22</xref></sup> without competing risks, at each <italic>y<sub>ij</sub></italic>, the baseline cumulative subhazard function <inline-formula><mml:math id="M13" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">Λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> can be written as<disp-formula id="FD9"><mml:math id="M14" display="block" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">Λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mi>I</mml:mi><mml:mo>{</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∈</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>}</mml:mo></mml:mrow></mml:mstyle><mml:mo>,</mml:mo></mml:math></disp-formula> where <inline-formula><mml:math id="M15" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> is the subhazard function for cause 1 events at <italic>y</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub>. Let <italic>δ<sub>ij</sub></italic> = <italic>I</italic>(<italic>ξ<sub>ij</sub></italic> = 1) be an event indicator representing whether subject <italic>j</italic> of center <italic>i</italic> experiences a Type 1 event. Along the lines of Lee and Nelder<sup><xref rid="R13" ref-type="bibr">13</xref></sup> and Ha et al.<sup><xref rid="R19" ref-type="bibr">19</xref></sup>, the hierarchical loglikelihood (h-likelihood) for subhazard frailty models (<xref ref-type="disp-formula" rid="FD3">1</xref>) is defined by<disp-formula id="FD10"><label>(5)</label><mml:math id="M16" display="block" overflow="scroll"><mml:mi>h</mml:mi><mml:mo>=</mml:mo><mml:mi>h</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>,</mml:mo></mml:math></disp-formula> where<disp-formula id="FD11"><mml:math id="M17" display="block" overflow="scroll"><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>{</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>}</mml:mo><mml:mo>−</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:mo>{</mml:mo><mml:msubsup><mml:mi mathvariant="normal">Λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mspace width="0.2em"/><mml:mo>=</mml:mo><mml:mspace width="0.2em"/><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:mo>[</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mi>I</mml:mi><mml:mo>{</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∈</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>}</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle><mml:mo>]</mml:mo></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math></disp-formula> is the sum of the logarithm of the conditional density function for <italic>Y<sub>ij</sub></italic> and <italic>δ<sub>ij</sub></italic> given <italic>v<sub>i</sub></italic>, i.e. the ordinary log-likelihood for censored survival data given <italic>v<sub>i</sub></italic>, <inline-formula><mml:math id="M18" display="inline" overflow="scroll"><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo>;</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>, and<disp-formula id="FD12"><mml:math id="M19" display="block" overflow="scroll"><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo>;</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mo stretchy="false">[</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:mi>det</mml:mi><mml:mo>{</mml:mo><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:msub><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>v</mml:mi><mml:mi>i</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:msub><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></disp-formula> is the logarithm of the density function for <italic>v<sub>i</sub></italic> with parameters <inline-formula><mml:math id="M20" display="inline" overflow="scroll"><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:msub><mml:mi>σ</mml:mi><mml:mn>01</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msup></mml:math></inline-formula>, i.e. the log-likelihood for <italic>v<sub>i</sub></italic>, and <inline-formula><mml:math id="M21" display="inline" overflow="scroll"><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mi>β</mml:mi><mml:mo>+</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:math></inline-formula>. Here, <inline-formula><mml:math id="M22" display="inline" overflow="scroll"><mml:mi>v</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>v</mml:mi><mml:mn>1</mml:mn><mml:mi>T</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msubsup><mml:mi>v</mml:mi><mml:mi>q</mml:mi><mml:mi>T</mml:mi></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msup></mml:math></inline-formula>, <inline-formula><mml:math id="M23" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>011</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mi>D</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msup></mml:math></inline-formula>, and <italic>d</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub> is the number of the events of interest at <italic>y</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub>. As the number of <inline-formula><mml:math id="M24" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo>’</mml:mo><mml:mi mathvariant="normal">s</mml:mi></mml:math></inline-formula> can increase with the number of distinct event times, the function <inline-formula><mml:math id="M25" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> is potentially of high dimension. Accordingly, for estimation of (<italic>β, v</italic>) Ha et al.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> proposed the use of the profiled h-likelihood <italic>h</italic>* from which <inline-formula><mml:math id="M26" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup></mml:math></inline-formula> in (<xref ref-type="disp-formula" rid="FD10">5</xref>) is eliminated: <disp-formula id="FD13"><label>(6)</label><mml:math id="M27" display="block" overflow="scroll"><mml:msup><mml:mi>h</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:mi>h</mml:mi><mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi mathvariant="normal">λ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msubsup><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>,</mml:mo></mml:math></disp-formula> where<disp-formula id="FD14"><mml:math id="M28" display="block" overflow="scroll"><mml:msubsup><mml:mover accent="true"><mml:mi mathvariant="normal">λ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:msub><mml:mo>∑</mml:mo><mml:mrow><mml:mspace width="0.2em"/><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∈</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:math></disp-formula> are solutions of the estimating equations, <inline-formula><mml:math id="M29" display="inline" overflow="scroll"><mml:mo>∂</mml:mo><mml:mi>h</mml:mi><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, for <italic>k</italic> = 1, …<italic>, D</italic>. Note here that<disp-formula id="FD15"><mml:math id="M30" display="block" overflow="scroll"><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msubsup><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi mathvariant="normal">λ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup></mml:mrow></mml:msub></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:msubsup><mml:mover accent="true"><mml:mi mathvariant="normal">λ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:mstyle></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mspace width="0.2em"/><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:mrow><mml:mo>{</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∈</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle></mml:math></disp-formula> with a constant term Σ<italic><sub>k</sub> d</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub>{log <italic>d</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub> −1} eliminated, so that <italic>h</italic>* becomes the penalized partial likelihood (PPL)<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>: see also Appendix C of Ha et al.<sup><xref rid="R10" ref-type="bibr">10</xref></sup>. In particular, the first term, <inline-formula><mml:math id="M31" display="inline" overflow="scroll"><mml:mstyle displaystyle="true"><mml:msub><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:msubsup><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup></mml:mstyle></mml:math></inline-formula>, of <italic>h*</italic> in (<xref ref-type="disp-formula" rid="FD13">6</xref>) can be viewed as the log-partial likelihood for the Fine-Gray model given <italic>v<sub>i</sub></italic>, by treating the observed event times <italic>y<sub>ij</sub></italic>’s as complete outcomes.</p><p id="P12">In the case of right censoring under competing risks, Fine and Gray<sup><xref rid="R3" ref-type="bibr">3</xref></sup> developed a weighted score function based on the complete-data partial likelihood. Thus the inverse probability of censoring weighting (IPCW) by Fine and Gray<sup><xref rid="R3" ref-type="bibr">3</xref></sup> can be equally applied to the first term of <italic>h*</italic> as in Pintilie<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> and Katsahian et al.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> Accordingly, a weighted partial h-likelihood <inline-formula><mml:math id="M32" display="inline" overflow="scroll"><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> based on the IPCW is defined by<disp-formula id="FD16"><label>(7)</label><mml:math id="M33" display="block" overflow="scroll"><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>w</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>+</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:munder><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>2</mml:mn><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mstyle><mml:mo>.</mml:mo></mml:math></disp-formula>Here<disp-formula id="FD17"><mml:math id="M34" display="block" overflow="scroll"><mml:msubsup><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>w</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi mathvariant="italic">ij</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>δ</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mi>k</mml:mi></mml:munder><mml:mrow><mml:msub><mml:mi>d</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:mrow><mml:mo>{</mml:mo><mml:mstyle displaystyle="true"><mml:munder><mml:mo>∑</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∈</mml:mo><mml:msub><mml:mi>R</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:mrow></mml:munder><mml:mrow><mml:msub><mml:mi>w</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mstyle><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:mstyle></mml:mrow></mml:mstyle><mml:mo>,</mml:mo></mml:math></disp-formula> where<disp-formula id="FD18"><mml:math id="M35" display="block" overflow="scroll"><mml:msub><mml:mi>w</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>w</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mover accent="true"><mml:mi>G</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mover accent="true"><mml:mi>G</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>∧</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:math></disp-formula> is the weight of subject <italic>j</italic> of center <italic>i</italic> at <italic>y</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub>, and <italic>Ĝ</italic>(<italic>·</italic>) is the Kaplan-Meier estimate of the survival function for the censoring times. Here, <italic>w<sub>ij</sub></italic> = 1 as long as individuals have not failed (i.e. <italic>y<sub>ij</sub> ≥ y</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub>; the first condition of <italic>R</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub>), whereas <italic>w<sub>ij</sub></italic> ≤ 1 and decreasing over time if they failed from Type 2 (i.e. <italic>y<sub>ij</sub> ≤ y</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub> and <italic>ε<sub>ij</sub></italic> ≠ 1; the second condition of <italic>R</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub>)<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup>. Note that <inline-formula><mml:math id="M36" display="inline" overflow="scroll"><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> in (<xref ref-type="disp-formula" rid="FD16">7</xref>) is an extension of the weighted log-partial likelihood<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R24" ref-type="bibr">24</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> for the Fine-Gray model to the subhazard frailty models (<xref ref-type="disp-formula" rid="FD3">1</xref>). We can show that, under the subhazard shared model (<xref ref-type="disp-formula" rid="FD5">2</xref>), <inline-formula><mml:math id="M37" display="inline" overflow="scroll"><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> is also equivalent to the PPL of Katsahian et al.<sup><xref rid="R6" ref-type="bibr">6</xref></sup>, by combining <italic>R</italic><sub>(</sub><italic><sub>k</sub></italic><sub>)</sub> and <italic>w<sub>ij</sub></italic> as in (<xref ref-type="disp-formula" rid="FD33">17</xref>) of <xref rid="APP1" ref-type="app">Appendix</xref>.</p></sec>
24619110|3.2 Estimation procedure|('method', 0.9733895540067294)|('other', 0.0266104459932706)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>3.2 Estimation procedure</title><p id="P13">Now, Ha et al.’s<sup><xref rid="R10" ref-type="bibr">10</xref></sup> procedures for standard correlated frailty models without competing risks can be extended to the subhazard model (<xref ref-type="disp-formula" rid="FD3">1</xref>) by using <inline-formula><mml:math id="M38" display="inline" overflow="scroll"><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> in (<xref ref-type="disp-formula" rid="FD16">7</xref>). That is, given frailty parameters <italic>θ</italic>, the maximum h-likelihood (MHL) estimators of <italic>τ</italic> = (<italic>β<sup>T</sup>, v<sup>T</sup></italic>)<italic><sup>T</sup></italic> are obtained by solving the joint estimating equations, <inline-formula><mml:math id="M39" display="inline" overflow="scroll"><mml:mo>∂</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:mi>τ</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>. In <xref rid="APP1" ref-type="app">Appendix</xref> we show that given <italic>θ</italic>, the joint equations lead to Ha and Lee’s<sup><xref rid="R26" ref-type="bibr">26</xref></sup> MHL estimator score equations for <italic>τ</italic>: <disp-formula id="FD19"><label>(8)</label><mml:math id="M40" display="block" overflow="scroll"><mml:mo>(</mml:mo><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msup><mml:mi>X</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi>W</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mi>X</mml:mi></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msup><mml:mi>X</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi>W</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mi>Z</mml:mi></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msup><mml:mi>Z</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi>W</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mi>X</mml:mi></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msup><mml:mi>Z</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi>W</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mi>Z</mml:mi><mml:mo>+</mml:mo><mml:mi>U</mml:mi></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo><mml:mo>(</mml:mo><mml:mfrac linethickness="0"><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover></mml:mfrac><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac linethickness="0"><mml:mrow><mml:msup><mml:mi>X</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msup></mml:mrow><mml:mrow><mml:msup><mml:mi>Z</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msup></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula> where <italic>X</italic> and <italic>Z</italic> are <italic>n</italic> × <italic>p</italic> and <italic>n</italic> × <italic>q</italic>* model matrices for <italic>β</italic> and <italic>v</italic> whose <italic>ij</italic>th row vectors are <inline-formula><mml:math id="M41" display="inline" overflow="scroll"><mml:msubsup><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mi>T</mml:mi></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M42" display="inline" overflow="scroll"><mml:msubsup><mml:mi>z</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mi>T</mml:mi></mml:msubsup></mml:math></inline-formula>, respectively, <italic>W</italic>* is the symmetric weight matrix given in (<xref ref-type="disp-formula" rid="FD30">16</xref>) of <xref rid="APP1" ref-type="app">Appendix</xref>, and <inline-formula><mml:math id="M43" display="inline" overflow="scroll"><mml:mi>U</mml:mi><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi mathvariant="script">l</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mi>v</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>=</mml:mo><mml:mtext>BD(</mml:mtext><mml:msubsup><mml:mo>∑</mml:mo><mml:mn>1</mml:mn><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mi>q</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mtext>)</mml:mtext></mml:math></inline-formula> is a <italic>q*</italic> × <italic>q*</italic> matrix; <italic>q*</italic> = <italic>q</italic> × <italic>r</italic> and BD(·) denotes a block diagonal matrix. Here <italic>w*</italic> = <italic>W *η</italic>+(<italic>δ</italic>−<italic>μ</italic>) with <italic>η</italic> = <italic>Xβ</italic>+<italic>Zv</italic> and <inline-formula><mml:math id="M44" display="inline" overflow="scroll"><mml:mi>μ</mml:mi><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:mi>w</mml:mi><mml:mo>+</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:msubsup><mml:mi mathvariant="normal">Λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo>+</mml:mo><mml:mi>η</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>. Note the <inline-formula><mml:math id="M45" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup></mml:math></inline-formula> terms in both <italic>W *</italic> and <italic>w*</italic> are evaluated at <inline-formula><mml:math id="M46" display="inline" overflow="scroll"><mml:msubsup><mml:mover accent="true"><mml:mi mathvariant="normal">λ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mn>01</mml:mn><mml:mi>k</mml:mi></mml:mrow><mml:mi>w</mml:mi></mml:msubsup></mml:math></inline-formula> given in (<xref ref-type="disp-formula" rid="FD30">16</xref>) of <xref rid="APP1" ref-type="app">Appendix</xref>. For the Fine-Gray model<sup><xref rid="R3" ref-type="bibr">3</xref></sup> without frailty, they reduce to a simple form: <disp-formula id="FD20"><mml:math id="M47" display="block" overflow="scroll"><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>X</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi>W</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mi>X</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:msup><mml:mi>X</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msup><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mo>.</mml:mo></mml:math></disp-formula>We thus see that the estimating <xref ref-type="disp-formula" rid="FD19">equations (8)</xref> provide new generalized iterative least squares equations for the Fine-Gray model: see also Ha and Lee<sup><xref rid="R26" ref-type="bibr">26</xref></sup>.</p><p id="P14">For estimation of <italic>θ</italic> we use the adjusted partial h-likelihood (i.e. restricted h-likelihood<sup><xref rid="R14" ref-type="bibr">14</xref></sup>) <inline-formula><mml:math id="M48" display="inline" overflow="scroll"><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>, given by<disp-formula id="FD21"><label>(9)</label><mml:math id="M49" display="block" overflow="scroll"><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mrow><mml:mo>[</mml:mo><mml:mrow><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:mi>det</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mi>π</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow><mml:mo>]</mml:mo></mml:mrow><mml:mo stretchy="false">|</mml:mo></mml:mrow><mml:mrow><mml:mi>τ</mml:mi><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></disp-formula> where <inline-formula><mml:math id="M50" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>T</mml:mi></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>T</mml:mi></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="M51" display="inline" overflow="scroll"><mml:msub><mml:mi>H</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>;</mml:mo><mml:mi>τ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula> is an information matrix for <italic>τ</italic>. Note that <inline-formula><mml:math id="M52" display="inline" overflow="scroll"><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> is a function of <italic>θ</italic> only because it has already eliminated <italic>τ</italic> from <inline-formula><mml:math id="M53" display="inline" overflow="scroll"><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> and that the additional term in (<xref ref-type="disp-formula" rid="FD21">9</xref>) is an adjusted form for such elimination<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>, leading to restricted maximum likelihood (REML) estimator for <italic>θ</italic>. The REML estimator for <italic>θ</italic> are obtained by solving iteratively<disp-formula id="FD22"><label>(10)</label><mml:math id="M54" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>0.</mml:mn></mml:math></disp-formula>Note here that<disp-formula id="FD23"><mml:math id="M55" display="block" overflow="scroll"><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mtext>tr</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msup><mml:mo>∑</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msup><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>T</mml:mi></mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:msup><mml:mo>∑</mml:mo><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:mtext>tr</mml:mtext><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>H</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>w</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>H</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:mi>θ</mml:mi></mml:mrow></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:math></disp-formula> where Σ = BD(Σ<sub>1</sub>, …, Σ<italic><sub>q</sub></italic>) is the <italic>q*</italic> × <italic>q*</italic> block diagonal matrix and <inline-formula><mml:math id="M56" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>H</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>H</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>;</mml:mo><mml:mi>τ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mrow><mml:mi>τ</mml:mi><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub></mml:math></inline-formula>. Here, the <xref ref-type="disp-formula" rid="FD22">equations (10)</xref> are solved using the Newton-Raphson method with the Hessian matrix, <inline-formula><mml:math id="M57" display="inline" overflow="scroll"><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula>. Note that in implementing (<xref ref-type="disp-formula" rid="FD22">10</xref>) we allow the <inline-formula><mml:math id="M58" display="inline" overflow="scroll"><mml:mo>∂</mml:mo><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:mi>θ</mml:mi></mml:math></inline-formula> term<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R14" ref-type="bibr">14</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> and that the computations of <inline-formula><mml:math id="M59" display="inline" overflow="scroll"><mml:mo>∂</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>H</mml:mi><mml:mo stretchy="false">^</mml:mo></mml:mover><mml:mi>w</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:mi>θ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="M60" display="inline" overflow="scroll"><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula> follow those of Ha et al.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> using <italic>p<sub>τ</sub></italic>(<italic>h*</italic>).</p><p id="P15">The approximated standard-error (SE) estimates for <inline-formula><mml:math id="M61" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>−</mml:mo><mml:mi>τ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="M62" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> are obtained from the inverses of the corresponding Hessian matrices, <inline-formula><mml:math id="M63" display="inline" overflow="scroll"><mml:msub><mml:mi>H</mml:mi><mml:mi>w</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="M64" display="inline" overflow="scroll"><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula>, respectively.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> In particular, Fine and Gray<sup><xref rid="R3" ref-type="bibr">3</xref></sup> proposed a robust/sandwich variance estimator to estimate <inline-formula><mml:math id="M65" display="inline" overflow="scroll"><mml:mi>var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> using an empirical process theory because the martingale properties break down under the Fine-Gray model due to the use of IPCW and thus the standard asymptotic theories are no longer valid. Furthermore, in the subhazard frailty model (<xref ref-type="disp-formula" rid="FD5">2</xref>) with one frailty term Katsahian and Boudreau<sup><xref rid="R27" ref-type="bibr">27</xref></sup> presented a robust variance estimator of <inline-formula><mml:math id="M66" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> using Gray’s<sup><xref rid="R28" ref-type="bibr">28</xref></sup> method, estimated from<disp-formula id="FD24"><label>(11)</label><mml:math id="M67" display="block" overflow="scroll"><mml:mi>V</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>τ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>H</mml:mi><mml:mi>w</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:msub><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msubsup><mml:mi>H</mml:mi><mml:mi>w</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>,</mml:mo></mml:math></disp-formula> where <italic>τ</italic> = (<italic>β<sup>T</sup>, v<sup>T</sup></italic>)<italic><sup>T</sup></italic> and <inline-formula><mml:math id="M68" display="inline" overflow="scroll"><mml:msub><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mi>H</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>w</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>;</mml:mo><mml:mi>τ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msubsup><mml:mi mathvariant="script">l</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>w</mml:mi></mml:mrow><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:math></inline-formula>. However, the proposed method, <inline-formula><mml:math id="M69" display="inline" overflow="scroll"><mml:msubsup><mml:mi>H</mml:mi><mml:mi>w</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:math></inline-formula>, has been also used as a variance estimator in the context of the PPL: see Verweij and Van Houwelingen<sup><xref rid="R29" ref-type="bibr">29</xref></sup> and Therneau et al.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> We investigate the performance of the two variances of <inline-formula><mml:math id="M70" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> by simulation studies in next section. Accordingly, the current estimation procedure can be implemented by replacing the risk indicator matrix in Ha et al.’s<sup><xref rid="R10" ref-type="bibr">10</xref></sup> procedure with a weighted risk indicator matrix (i.e. <italic>M</italic> in (<xref ref-type="disp-formula" rid="FD33">17</xref>) of <xref rid="APP1" ref-type="app">Appendix</xref>) which contains both the weights <italic>w</italic> and the risk set <italic>R</italic> used for modelling the subhazard function: see also Ruan and Gray.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Further quantities (e.g. confidence intervals of frailties) are also directly applied.</p><p id="P16">In summary, the estimates of <italic>τ</italic> and <italic>θ</italic> are obtained by alternating between the two estimating <xref ref-type="disp-formula" rid="FD19">equations (8)</xref> and (<xref ref-type="disp-formula" rid="FD22">10</xref>) until convergence is achieved<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup>. At convergence, we compute the SEs of <inline-formula><mml:math id="M71" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>τ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>−</mml:mo><mml:mi>τ</mml:mi></mml:math></inline-formula> and <inline-formula><mml:math id="M72" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula>. Note that the h-likelihood procedure performs well under any restrictions for cluster size <italic>n<sub>i</sub></italic> such as <italic>n<sub>i</sub></italic> = 1 and unbalanced cases.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup> The <xref ref-type="disp-formula" rid="FD19">equations (8)</xref>, which estimates all random effects simultaneously from the weighted h-likelihood in (<xref ref-type="disp-formula" rid="FD16">7</xref>), may influence the consistency of fixed parameters (<italic>β, θ</italic>), particularly for a small cluster size <italic>n<sub>i</sub></italic>. However, here the resulting biases decrease quickly as <italic>n</italic> rather than <italic>q</italic> increases<sup><xref rid="R26" ref-type="bibr">26</xref>,<xref rid="R31" ref-type="bibr">31</xref></sup>: see also the simulation results of Section 4. Furthermore, when <italic>n<sub>i</sub></italic> is very small, the biases can be further reduced using the Laplace approximation based on the h-likelihood: see Lee et al.<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p><p id="P17">For a subhazard shared frailty model (<xref ref-type="disp-formula" rid="FD5">2</xref>), the procedures proposed by Katsahian et al.<sup><xref rid="R6" ref-type="bibr">6</xref></sup> and Katsahian and Boudreau<sup><xref rid="R27" ref-type="bibr">27</xref></sup> are based on the PPL<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>. Given frailty parameters <italic>θ</italic>, the PPL and h-likelihood methods provide the same estimates for <italic>β</italic> and <italic>v</italic>. However, the two methods do not yield the same final results for <italic>β</italic> and <italic>v</italic> because they give different estimators for <italic>θ</italic>.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup> That is, the PPL method ignores the <inline-formula><mml:math id="M73" display="inline" overflow="scroll"><mml:mo>∂</mml:mo><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:mi>θ</mml:mi></mml:math></inline-formula> term in solving the estimating equations of <italic>θ</italic>, given in (<xref ref-type="disp-formula" rid="FD22">10</xref>); this leads to an underestimation of the parameters <italic>θ</italic>, particularly when the cluster size <italic>n<sub>i</sub></italic> is small: see also simulation results by Ha and Lee<sup><xref rid="R26" ref-type="bibr">26</xref></sup> and Christian<sup><xref rid="R7" ref-type="bibr">7</xref></sup>.</p></sec>
24619110|None|('method', 0.9769865301193839)|('other', 0.02301346988061605)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 Simulation study</title>
24619110|None|('method', 0.9769865301193839)|('other', 0.02301346988061605)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P18">Simulation study is conducted to evaluate the performance of the proposed method under the subhazard frailty models (<xref ref-type="disp-formula" rid="FD6">3</xref>) with a general correlation structure (<xref ref-type="disp-formula" rid="FD7">4</xref>) by using 1000 replications of simulated data.</p>
24619110|None|('method', 0.9769865301193839)|('other', 0.02301346988061605)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P19">The simulated data are generated using a method similar to that of Fine and Gray<sup><xref rid="R3" ref-type="bibr">3</xref></sup> and Katsahian and Boudreau<sup><xref rid="R27" ref-type="bibr">27</xref></sup>. We consider two covariates <italic>x<sub>ij</sub></italic> = (<italic>x<sub>ij</sub></italic><sub>1</sub><italic>, x<sub>ij</sub></italic><sub>1</sub>)<italic><sup>T</sup></italic> and a bivariate normal (BN) random effect <italic>v<sub>i</sub></italic> = (<italic>v<sub>i</sub></italic><sub>0</sub><italic>, v<sub>i</sub></italic><sub>1</sub>)<italic><sup>T</sup></italic> with mean 0 and covariance matrix having <inline-formula><mml:math id="M74" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula>, <inline-formula><mml:math id="M75" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M76" display="inline" overflow="scroll"><mml:msub><mml:mi>σ</mml:mi><mml:mn>01</mml:mn></mml:msub></mml:math></inline-formula>. The conditional subdistribution for Type 1 events given <italic>x<sub>ij</sub></italic> and <italic>v<sub>i</sub></italic> is given by<disp-formula id="FD25"><mml:math id="M77" display="block" overflow="scroll"><mml:msub><mml:mi>F</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>P</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>T</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>≤</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:math></disp-formula> where <italic>p</italic> = <italic>P</italic> (<italic>ε<sub>ij</sub></italic> = <italic>x<sub>ij</sub></italic> = (0, 0)<italic>, v<sub>i</sub></italic> = (0, 0)) is the proportion of Type 1 events and <inline-formula><mml:math id="M78" display="inline" overflow="scroll"><mml:msubsup><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>. Here <italic>β</italic><sub>11</sub> and <italic>β</italic><sub>12</sub> are regression parameters for Type 1 events. Thus the conditional distribution function of <italic>T<sub>ij</sub></italic> given a Type 1 event as well as <italic>x<sub>ij</sub></italic> and <italic>v<sub>i</sub></italic> is given by<disp-formula id="FD26"><label>(12)</label><mml:math id="M79" display="block" overflow="scroll"><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>t</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>p</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:math></disp-formula>Times to Type 1 event of interest are then generated from the distribution function above (<xref ref-type="disp-formula" rid="FD26">12</xref>) using the probability integral transformation, conditional on <italic>x<sub>ij</sub></italic> and <italic>v<sub>i</sub></italic>. The conditional subdistribution for Type 2 events is simply obtained by taking <italic>P</italic> (<italic>ε<sub>ij</sub></italic> = <italic>x<sub>ij</sub>, v<sub>i</sub></italic>) = 1 − <italic>P</italic> (<italic>ε<sub>ij</sub></italic> = <italic>x<sub>ij</sub>, v<sub>i</sub></italic>) and using an exponential distribution with rate <inline-formula><mml:math id="M80" display="inline" overflow="scroll"><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> for <italic>P</italic> (<italic>T<sub>ij</sub> ≤ t|ε<sub>ij</sub></italic> = 2<italic>, x<sub>ij</sub>, v<sub>i</sub></italic>), where <inline-formula><mml:math id="M81" display="inline" overflow="scroll"><mml:msubsup><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>21</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>22</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula>, and <italic>β</italic><sub>21</sub> and <italic>β</italic><sub>22</sub> are regression parameters for Type 2 events. Thus the conditional distribution function of <italic>T<sub>ij</sub></italic> given a Type 2 event as well as <italic>x<sub>ij</sub></italic> and <italic>v<sub>i</sub></italic> is given by<disp-formula id="FD27"><label>(13)</label><mml:math id="M82" display="block" overflow="scroll"><mml:mi>F</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>exp</mml:mi><mml:mo>{</mml:mo><mml:mo>−</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mi>t</mml:mi><mml:mo>}</mml:mo><mml:mo>.</mml:mo></mml:math></disp-formula>As before, Type 2 event times (times-to-CR event) are generated from the distribution function (<xref ref-type="disp-formula" rid="FD27">13</xref>) using the probability integral transformation.</p>
24619110|None|('method', 0.9769865301193839)|('other', 0.02301346988061605)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P20">Following Fine and Gray<sup><xref rid="R3" ref-type="bibr">3</xref></sup> and Katsahian and Boudreau<sup><xref rid="R27" ref-type="bibr">27</xref></sup>, we consider the two cases of the true parameter values for <italic>p</italic> and <italic>β</italic>:<list list-type="simple" id="L1"><list-item><p id="P21">Case A: (<italic>p, β</italic><sub>11</sub><italic>, β</italic><sub>12</sub><italic>, β</italic><sub>21</sub><italic>, β</italic><sub>22</sub>) = (0.3, 0.5, 0.5, −0.5, 0.5),</p></list-item><list-item><p id="P22">Case B: (<italic>p, β</italic><sub>11</sub><italic>, β</italic><sub>12</sub><italic>, β</italic><sub>21</sub><italic>, β</italic><sub>22</sub>) = (0.6, 1, −1, 1, 1).</p></list-item></list></p>
24619110|None|('method', 0.9769865301193839)|('other', 0.02301346988061605)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P23">Following Katsahian and Boudreau<sup><xref rid="R27" ref-type="bibr">27</xref></sup>, we also consider the three sample sizes: <inline-formula><mml:math id="M83" display="inline" overflow="scroll"><mml:mi>n</mml:mi><mml:mo>=</mml:mo><mml:mstyle displaystyle="true"><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>q</mml:mi></mml:msubsup><mml:msub><mml:mi>n</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mstyle></mml:math></inline-formula> with <italic>n</italic> = 200, 400 and 1000, and (<italic>q, n<sub>i</sub></italic>) = (20, 10), (20, 20) and (50, 20). The covariates <italic>x<sub>ij</sub></italic><sub>1</sub> are generated from a Bernoulli random variable with probability 0.5 in order to mimic the binary treatment covariate of the multi-center study, and <italic>x<sub>ij</sub></italic><sub>2</sub> are from a standard normal distribution. The covariance parameters of the random effects are <inline-formula><mml:math id="M84" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0.5</mml:mn></mml:math></inline-formula> and <italic>σ</italic><sub>01</sub> = −0.25, leading to <italic>ρ</italic> = −0.5. Though not reported here, we found similar results for <italic>σ</italic><sub>01</sub> = 0.25. Censoring times are generated from a Uniform(<italic>a</italic>, <italic>b</italic>) distribution where the values of <italic>a</italic> and <italic>b</italic> were empirically selected to achieve the approximate right censoring rate, low (around 25%) and high (around 50%). That is, in Case A we used Uniform(1, 2.6) and Uniform(0.45, 1) for the censoring rates 25% and 50%, respectively, and in Case B we used Uniform(0.2, 1.7) and Uniform(0, 0.7) for the censoring rates 25% and 50%, respectively.</p>
24619110|None|('method', 0.9769865301193839)|('other', 0.02301346988061605)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P24">For the 1000 replications we computed the mean, standard deviation (SD), and the mean of the estimated standard errors (denoted by SE1) for <inline-formula><mml:math id="M85" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>11</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>12</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="M86" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>σ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>01</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mi>T</mml:mi></mml:msup></mml:math></inline-formula>, respectively. The SE1s for <inline-formula><mml:math id="M87" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M88" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> are, respectively, obtained from <inline-formula><mml:math id="M89" display="inline" overflow="scroll"><mml:msubsup><mml:mi>H</mml:mi><mml:mi>w</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>v</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>}</mml:mo></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula> and <inline-formula><mml:math id="M90" display="inline" overflow="scroll"><mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mo>−</mml:mo><mml:msup><mml:mo>∂</mml:mo><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi>p</mml:mi><mml:msub><mml:mi>β</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mo>∂</mml:mo><mml:msup><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>}</mml:mo></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. For comparison of standard errors of <inline-formula><mml:math id="M91" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:math></inline-formula>, we calculated the mean of estimated standard errors (denoted by SE2) using a robust variance formula in (<xref ref-type="disp-formula" rid="FD24">11</xref>). All computations were done using SAS/IML. The simulation results are summarized in <xref rid="T1" ref-type="table">Table 1</xref>.</p>
24619110|None|('method', 0.9769865301193839)|('other', 0.02301346988061605)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P25">Our method overall performs well even when the censoring rate is as high as 50%. In particular, the increase of <italic>n</italic> or <italic>n<sub>i</sub></italic>, rather than <italic>q</italic>, reduces bias more effectively: see also Ha and Lee<sup><xref rid="R26" ref-type="bibr">26</xref></sup>. In <xref rid="T1" ref-type="table">Table 1</xref>, the SD is the empirical estimates of <inline-formula><mml:math id="M92" display="inline" overflow="scroll"><mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mi>var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>, and SE1 and SE2 are the averages of the proposed and robust standard-error estimates for <inline-formula><mml:math id="M93" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></inline-formula>, respectively. Our <inline-formula><mml:math id="M94" display="inline" overflow="scroll"><mml:mtext>SE</mml:mtext><mml:mn>1</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> work well as judged by the very good agreement between SE1 and SD. Similarly, our SE1s for <inline-formula><mml:math id="M95" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> also perform well. On the other hand, the <inline-formula><mml:math id="M96" display="inline" overflow="scroll"><mml:mtext>SE</mml:mtext><mml:mn>2</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>11</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> are seriously underestimated even if <italic>n</italic> increases, but the <inline-formula><mml:math id="M97" display="inline" overflow="scroll"><mml:mtext>SE</mml:mtext><mml:mn>2</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>12</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> work well. A possible reason is that the SE2 may be sensitive to the random-effect structures because <italic>β</italic><sub>11</sub> depends on the random treatment-by-center interaction (<italic>v<sub>i</sub></italic><sub>1</sub>) via the same covariates <italic>x<sub>ij</sub></italic><sub>1</sub>, but <italic>β</italic><sub>12</sub> does not. The trends in <xref rid="T2" ref-type="table">Table 2</xref> are similar to those evident in <xref rid="T1" ref-type="table">Table 1</xref>. In particular, with a smaller sample as in <italic>n</italic> = 200 the biases of frailty-parameter estimators <inline-formula><mml:math id="M98" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> are largely reduced, as compared to those in <xref rid="T1" ref-type="table">Table 1</xref>.</p>
24619110|None|('method', 0.9769865301193839)|('other', 0.02301346988061605)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P26">In addition, we carried out the simulation studies of Cases A and B above under a subhazard shared frailty mode1 (<xref ref-type="disp-formula" rid="FD5">2</xref>) with <inline-formula><mml:math id="M99" display="inline" overflow="scroll"><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>11</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>12</mml:mn></mml:msub><mml:msub><mml:mi>x</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M100" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula>. Here, for the censoring and covariate patterns, we follow the schemes of Katsahian and Boudreau<sup><xref rid="R27" ref-type="bibr">27</xref></sup>. Furthermore, the performances of likelihood ratio tests (LRT) based on the h-likelihood are evaluated for testing <inline-formula><mml:math id="M101" display="inline" overflow="scroll"><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> versus <inline-formula><mml:math id="M102" display="inline" overflow="scroll"><mml:msub><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, which lies on the boundary of the parameter space. The LRT statistics are calculated as <inline-formula><mml:math id="M103" display="inline" overflow="scroll"><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:mo>{</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>β</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo></mml:math></inline-formula>, where <inline-formula><mml:math id="M104" display="inline" overflow="scroll"><mml:msub><mml:mi>p</mml:mi><mml:mi>β</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> is the likelihood value under <inline-formula><mml:math id="M105" display="inline" overflow="scroll"><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> (i.e. <italic>v<sub>i</sub></italic><sub>0</sub> = 0 for all <italic>i</italic>). For the purpose, we investigate the nominal level and power of the LRT at the 5% level based on the asymptotic chi-square mixture distribution, <inline-formula><mml:math id="M106" display="inline" overflow="scroll"><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>χ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>χ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula> which gives critical value 2.71 at 5% level.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Here <inline-formula><mml:math id="M107" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> ranges from 0, 0.1 to 1. The conclusions obtained are as follows (see also <xref ref-type="supplementary-material" rid="SD1">Tables S1 and S2 in Supplementary Material</xref>): (i) The trends of the estimates of the fixed parameters(<italic>β</italic><sub>1</sub><italic>, θ</italic>) are quite similar to those presented in <xref rid="T1" ref-type="table">Table 1</xref>, except for the standard errors for <inline-formula><mml:math id="M108" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:math></inline-formula>. We have found that the results of SE1 and SE2 for <inline-formula><mml:math id="M109" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> are about the same; here <italic>x<sub>ij</sub></italic><sub>1</sub> depends on <italic>β</italic><sub>11</sub>, but not the random center effect <italic>v<sub>i</sub></italic><sub>0</sub>. (ii) The LRT statistic under <inline-formula><mml:math id="M110" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> is somewhat conservative because the observed size (i.e. the observed rate of rejecting <italic>H</italic><sub>0</sub> at the 5% level under <inline-formula><mml:math id="M111" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>) is less than the nominal level 5% as shown in Katsahian and Boudreau<sup><xref rid="R27" ref-type="bibr">27</xref></sup>, but it becomes closer to the nominal level 5% with sample size <italic>n<sub>i</sub></italic> or <italic>n</italic>, especially for the Case B. (iii) The power of all tests increases as <inline-formula><mml:math id="M112" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> and/or <italic>n</italic> increase. These results indicate that the LRT statistic overall performs well under the shared model (<xref ref-type="disp-formula" rid="FD5">2</xref>).</p>
24619110|None|('method', 0.9809309937827368)|('other', 0.01906900621726319)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">5 A practical example</title>
24619110|5.1 The data|('method', 0.9809309937827368)|('other', 0.01906900621726319)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>5.1 The data</title><p id="P27">We re-examine the data from the B-14 randomized multicenter breast cancer trial conducted by the NSABP<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup>. The 2,817 eligible patients from 167 distinct centers were followed up for about 20 years since randomization. The number of patients per center varied from 1 to 241, with a mean of 16.9 and median of 8. The patients were randomized to one of two treatment arms, tamoxifen (1413 patients) or placebo (1404 patients). The average age of patients was 55 and the average tumor size was about 2 centimeters. The aim of this analysis is to investigate the effect of treatment on local or regional recurrence. Here we consider two event types. The first type is local or regional recurrence (Type 1) and the second type is a new primary cancer, distance recurrence or death (Type 2); only the event that occurs firstly is of interest in this analysis, so that the repeated event times are not considered. <xref rid="T3" ref-type="table">Table 3</xref> gives the number of first observed event types in this data set; Type 1 is an event of interest (314 patients; 11.15%), Type 2 is an event of competing risk (1303 patients; 46.25%), and no-events until the last follow-up are censoring (1200 patients; 42.60%).</p><p id="P28"><xref rid="T3" ref-type="table">Table 3</xref> also shows the number of first observed event types by two treatment arms. <xref rid="F1" ref-type="fig">Figure 1</xref> presents the estimated CIFs<sup><xref rid="R1" ref-type="bibr">1</xref></sup> for the two treatment arms. The tamoxifen group has lower CIFs compared to placebo group for both Type 1 and Type 2. For Type 1 the difference of CIFs of two arms seems to be large, whereas for Type 2 it does not. In particular, the estimated probability that a patient of tamoxifen group will experience Type 1 event within ten years after surgery is 5%, while for a patient of placebo group it is 10%.</p></sec>
24619110|5.2 Analyses using subhazard models|('method', 0.9809309937827368)|('other', 0.01906900621726319)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>5.2 Analyses using subhazard models</title><p id="P29">For the data analysis we consider the three covariates of interest: treatment (<italic>x<sub>ij</sub></italic><sub>1</sub> is 1 for tamoxifen and 0 for placebo), age (<italic>x<sub>ij</sub></italic><sub>2</sub>) and tumor size (<italic>x<sub>ij</sub></italic><sub>3</sub>) as continuous covariates. Let <italic>v<sub>i</sub></italic><sub>0</sub> and <italic>v<sub>i</sub></italic><sub>1</sub> be random center effects and random treatment effects (i.e. random treatment-by-center interaction), respectively. Following Ha et al.<sup><xref rid="R10" ref-type="bibr">10</xref></sup>, we consider the three submodels of (<xref ref-type="disp-formula" rid="FD3">1</xref>) for the time to Type 1 event, which include the proportional subhazards model without random effects (i.e. Fine-Gray model) and two subhazard frailty models. In other words, we consider the following three models, <inline-formula><mml:math id="M113" display="inline" overflow="scroll"><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mrow><mml:mn>1</mml:mn><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mi>v</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi mathvariant="normal">λ</mml:mi><mml:mn>01</mml:mn><mml:mi>s</mml:mi></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>η</mml:mi><mml:mi mathvariant="italic">ij</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> with <italic>η<sub>ij</sub></italic> allowing two frailty structures (M2 and M3): Here (<italic>v<sub>i</sub></italic><sub>0</sub><italic>, v<sub>i</sub></italic><sub>1</sub>) <italic>~ BN</italic> means that <inline-formula><mml:math id="M114" display="inline" overflow="scroll"><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>, <inline-formula><mml:math id="M115" display="inline" overflow="scroll"><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> and <italic>ρ</italic> = Corr(<italic>v<sub>i</sub></italic><sub>0</sub><italic>, v<sub>i</sub></italic><sub>1</sub>).<list list-type="simple" id="L2"><list-item><p id="P30">M1 (F-G): <italic>η<sub>ij</sub></italic> = <italic>β</italic><sub>1</sub><italic>x<sub>ij</sub></italic><sub>1</sub> + <italic>β</italic><sub>2</sub><italic>x<sub>ij</sub></italic><sub>2</sub> + <italic>β</italic><sub>3</sub><italic>x<sub>ij</sub></italic><sub>3</sub>;</p></list-item><list-item><p id="P31">M2 (Center): <italic>η<sub>ij</sub></italic> = <italic>v<sub>i</sub></italic><sub>0</sub> + <italic>β</italic><sub>1</sub><italic>x<sub>ij</sub></italic><sub>1</sub> + <italic>β</italic><sub>2</sub><italic>x<sub>ij</sub></italic><sub>2</sub> + <italic>β</italic><sub>3</sub><italic>x<sub>ij</sub></italic><sub>3</sub>, with <inline-formula><mml:math id="M116" display="inline" overflow="scroll"><mml:msub><mml:mi>v</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula>;</p></list-item><list-item><p id="P32">M3 (Corr): <italic>η<sub>ij</sub></italic> = <italic>v<sub>i</sub></italic><sub>0</sub> + (<italic>β</italic><sub>1</sub> + <italic>v<sub>i</sub></italic><sub>1</sub>)<italic>x<sub>ij</sub></italic><sub>1</sub> + <italic>β</italic><sub>2</sub><italic>x<sub>ij</sub></italic><sub>2</sub> + <italic>β</italic><sub>3</sub><italic>x<sub>ij</sub></italic><sub>3</sub>, with (<italic>v<sub>i</sub></italic><sub>0</sub><italic>, v<sub>i</sub></italic><sub>1</sub>) <italic>~ BN</italic>,</p></list-item></list>where ‘F-G’, ‘Center’ and ‘Corr’ indicate Fine-Gray model without frailties, subhazard frailty model with the random center effect <italic>v<sub>i</sub></italic><sub>0</sub> and subhazard correlated frailty model with <italic>ρ</italic> = Corr(<italic>v<sub>i</sub></italic><sub>0</sub><italic>, v<sub>i</sub></italic><sub>1</sub>), respectively. Here M3 (<inline-formula><mml:math id="M117" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M118" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, <italic>ρ</italic> ≠ 0) is our full model and the others are various simplifications of it by assuming null components, i.e. M1 (<italic>v<sub>i</sub></italic><sub>0</sub> = 0<italic>, v<sub>i</sub></italic><sub>1</sub> = 0; <inline-formula><mml:math id="M119" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M120" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>) and M2 (<italic>v<sub>i</sub></italic><sub>1</sub> = 0; <inline-formula><mml:math id="M121" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>, <inline-formula><mml:math id="M122" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>). The estimation results are listed in <xref rid="T4" ref-type="table">Table 4</xref>.</p><p id="P33">In all the three subhazard models the two fixed effects (<italic>β<sub>j</sub>, j</italic> = 1, 2) are significant, except for <italic>β</italic><sub>3</sub>. In particular, the use of tamoxifen (tamoxifen = 1) significantly reduces the risk of local or regional recurrence (Type 1 event) as compared to patients who receive placebo (placebo= 0). We also observe that overall, there are no substantial changes in the fixed-effects estimates, although the effect of main treatment (<italic>β</italic><sub>1</sub>) becomes slightly weaker due to the increased standard error when the two random components and their correlation are included as in M3. In M2 and M3, the variance components (<inline-formula><mml:math id="M123" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> and <inline-formula><mml:math id="M124" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula>) indicate the amount of variation between centers in baseline risk (i.e. center effect) and in the treatment effect, respectively. Here, the estimate and SE of <inline-formula><mml:math id="M125" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula> are relatively larger than those of <inline-formula><mml:math id="M126" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:math></inline-formula>, which is also confirmed in <xref rid="F2" ref-type="fig">Figure 2</xref>. Furthermore, the correlated model M3 explains the degree of dependency between the two random components (i.e. the random center effect <italic>v</italic><sub>0</sub> and the random treatment-by-center interaction <italic>v</italic><sub>1</sub>). The estimate of <inline-formula><mml:math id="M127" display="inline" overflow="scroll"><mml:mi>ρ</mml:mi><mml:mspace width="0.2em"/><mml:mo stretchy="false">(</mml:mo><mml:mover accent="true"><mml:mi>ρ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mn>0.721</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> gives a negative value, indicating that the two predicted random components (<inline-formula><mml:math id="M128" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>0</mml:mn></mml:msub></mml:math></inline-formula> and <inline-formula><mml:math id="M129" display="inline" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mn>1</mml:mn></mml:msub></mml:math></inline-formula>) have a negative correlation. In particular, the estimate of <italic>β</italic><sub>1</sub> in M3 is negative; we see that a decreasing value of <italic>v<sub>i</sub></italic><sub>1</sub> corresponds to a larger treatment effect. Thus, the negative correlation leads to the conclusion that treatment confers more benefit in centers with a higher baseline risk. This is consistent with the findings by Rondeau et al.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> in the context of meta-analysis and by Ha et al.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> in that of multi-center trials.</p></sec>
24619110|5.3 Investigating and testing for heterogeneity|('method', 0.9809309937827368)|('other', 0.01906900621726319)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>5.3 Investigating and testing for heterogeneity</title><p id="P34">We demonstrate how to investigate heterogeneity related to treatment effect over centers using confidence intervals<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> for frailties of the individual centers. Note that the standard intervals using <inline-formula><mml:math id="M130" display="inline" overflow="scroll"><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> in (<xref ref-type="disp-formula" rid="FD21">9</xref>) can be null due to zero estimation of the variance components, especially for small sample sizes or small variance components.<sup><xref rid="R18" ref-type="bibr">18</xref>,<xref rid="R33" ref-type="bibr">33</xref>,<xref rid="R34" ref-type="bibr">34</xref></sup> Thus we follow Ha et al.’s<sup><xref rid="R18" ref-type="bibr">18</xref></sup> modification of (<xref ref-type="disp-formula" rid="FD21">9</xref>) to deal with such shrinkage issue<sup><xref rid="R12" ref-type="bibr">12</xref></sup> for frailty. That is, for estimation of frailty parameters <italic>θ</italic> we use a further adjusted likelihood, defined by<disp-formula id="FD28"><label>(14)</label><mml:math id="M131" display="block" overflow="scroll"><mml:msub><mml:mi>p</mml:mi><mml:mtext>adj</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>τ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>log</mml:mi><mml:mspace width="0.2em"/><mml:mi>det</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mo>∑</mml:mo><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula> which leads to non-negative variance-component estimators. Following Ha et al.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> and (<xref ref-type="disp-formula" rid="FD28">14</xref>), the individual (1 − <italic>α</italic>)-level h-likelihood confidence intervals for the unidimensional components <italic>v<sub>k</sub></italic> of random effects <italic>v</italic> are of the form<disp-formula id="FD29"><label>(15)</label><mml:math id="M132" display="block" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>k</mml:mi></mml:msub><mml:mo>±</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>·</mml:mo><mml:mtext>SE</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>k</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula> where <inline-formula><mml:math id="M133" display="inline" overflow="scroll"><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:math></inline-formula> maximizes the profile h-likelihood <inline-formula><mml:math id="M134" display="inline" overflow="scroll"><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup></mml:math></inline-formula> in (<xref ref-type="disp-formula" rid="FD16">7</xref>), <italic>z<sub>α</sub></italic><sub>/2</sub> is the normal quantile with probability <italic>α</italic>/2 in the right tail, and <inline-formula><mml:math id="M135" display="inline" overflow="scroll"><mml:mtext>SE</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>k</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>v</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> are obtained from <inline-formula><mml:math id="M136" display="inline" overflow="scroll"><mml:mi>H</mml:mi><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo>;</mml:mo><mml:mover accent="true"><mml:mi>β</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo>,</mml:mo><mml:mover accent="true"><mml:mi>v</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup></mml:math></inline-formula>. In particular, Ha et al.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> have shown via numerical studies that in a general class of frailty models without competing risks, the adjusted h-likelihood interval (<xref ref-type="disp-formula" rid="FD29">15</xref>) preserves well the nominal interval. <xref rid="F2" ref-type="fig">Figure 2</xref> shows the estimates and 95% confidence intervals<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R18" ref-type="bibr">18</xref></sup> for the random effects in the 167 centers using the subhazard correlated model M3. Here, centers are ordered by the number of patients entered. <xref rid="F2" ref-type="fig">Figures 2(a)</xref> and <xref rid="F2" ref-type="fig">2(b)</xref> give the confidence intervals for the random center effect (<italic>v<sub>i</sub></italic><sub>0</sub>) and the random treatment-by-center interaction (<italic>v<sub>i</sub></italic><sub>1</sub>), respectively. Overall, the lengths of the intervals are seen to decrease as the number of patients per center increases: see also Vaida and Xu<sup><xref rid="R8" ref-type="bibr">8</xref></sup> and Ha et al.<sup><xref rid="R10" ref-type="bibr">10</xref></sup>.</p><p id="P35"><xref rid="F2" ref-type="fig">Figure 2(a)</xref> indicates overall homogeneity in the baseline risk across 167 centers (i.e. no variation in random center effect). <xref rid="F2" ref-type="fig">Figure 2(b)</xref> also shows there is no substantial variation in the effect of treatment across centers although three centers (148, 164 and 165) among 167 centers noticeably stand out. Note here that the centers (148, 165) and 164 provide the lowest and the highest treatment-by-center interactions, respectively, but that the corresponding three intervals include zero; this indicates there is little treatment-by-center interaction in this data set. Thus, in this multicenter trial there is little variation in the treatment effects across centers and the treatment is shown to be effective, These results suggest that the treatment effect may be generalized to a broader patient population as in the findings by Yamaguchi and Ohashi<sup><xref rid="R35" ref-type="bibr">35</xref></sup> and Ha et al.<sup><xref rid="R10" ref-type="bibr">10</xref></sup></p><p id="P36">Now, we show this heterogeneity can also be tested via the restricted h-likelihood in (<xref ref-type="disp-formula" rid="FD21">9</xref>). Recently, Katsahian and Boudreau<sup><xref rid="R27" ref-type="bibr">27</xref></sup> proposed how to test such heterogeneity (i.e. variation in random center effect) using the PPL method under the subhazard model (M2) with random center effect only. However, the heterogeneities from random treatment-by center interaction as well as random center effect should be simultaneously tested. For this purpose we again consider the three models in Section 5.2. Note that although we report the SEs of the <italic>σ</italic><sup><xref rid="R2" ref-type="bibr">2</xref></sup>s in <xref rid="T4" ref-type="table">Table 4</xref>, one should not use them for testing <inline-formula><mml:math id="M137" display="inline" overflow="scroll"><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>.<sup><xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R10" ref-type="bibr">10</xref></sup> Firstly, the null hypothesis <inline-formula><mml:math id="M138" display="inline" overflow="scroll"><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula> (i.e. no center effect) lies on the boundary of the parameter space. Consider the difference of deviance <inline-formula><mml:math id="M139" display="inline" overflow="scroll"><mml:mo>−</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:mi>v</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>h</mml:mi><mml:mi>w</mml:mi><mml:mo>∗</mml:mo></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:math></inline-formula> between two models (M1 and M2). As shown in the simulation study of Section 4, under the null hypothesis this LR test statistic asymptotically follows a chi-square mixture <inline-formula><mml:math id="M140" display="inline" overflow="scroll"><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>χ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>χ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula>.<sup><xref rid="R10" ref-type="bibr">10</xref>,<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R36" ref-type="bibr">36</xref></sup> From <xref rid="T4" ref-type="table">Table 4</xref>, we obtain the deviance difference between M1 and M2 to be 1.1 (p-value=0.147), indicating that the random center effect is not significant (i.e. <inline-formula><mml:math id="M141" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>0</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>). Furthermore, the difference in deviance between M2 and M3 is 3.7 (p-value=0.106) with an asymptotic <inline-formula><mml:math id="M142" display="inline" overflow="scroll"><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>χ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>χ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:math></inline-formula> statistic<sup><xref rid="R37" ref-type="bibr">37</xref></sup>, leading to <inline-formula><mml:math id="M143" display="inline" overflow="scroll"><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:math></inline-formula>. Accordingly, we find that there are no substantial variations for the baseline risk and treatment effect over centers, which confirms the homogeneity evident in <xref rid="F2" ref-type="fig">Figure 2</xref>.</p></sec>
24619110|None|('method', 0.8795823682796204)|('other', 0.1204176317203797)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
24619110|None|('method', 0.8795823682796204)|('other', 0.1204176317203797)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Ha-Supple</label><media xlink:href="NIHMS926818-supplement-Ha-Supple.pdf" orientation="portrait" xlink:type="simple" id="d36e8154" position="anchor"/></supplementary-material>
24648440|None|('method', 0.9997943646099313)|('other', 0.00020563539006871736)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24648440|Study Sample|('method', 0.9997943646099313)|('other', 0.00020563539006871736)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Study Sample</title><p id="P9">The total study sample was 649 adults who were aged 18 to 65 years and residents of Indiana. A convenience sample of participants from 14 public libraries (n = 342, 53%) and the emergency room of Wishard Hospital (n = 62, 10%) and individuals responding online (n = 245, 37%) through a research registry (<ext-link ext-link-type="uri" xlink:href="http://INResearch.org">INResearch.org</ext-link>) were recruited from June to July 2012. These 3 settings were chosen to maximize representation of diverse groups that have been underrepresented in prior genetic utilization research. INResearch is a registry of more than 900 research volunteers. The Indianapolis Public Library system has 23 sites around the city, offering resources and services for learning as well as to promote the social and economic interests of its communities. Wishard Hospital is the safety-net health system of Indianapolis, with a special emphasis on vulnerable populations. The Wishard Hospital emergency room and library sites in lower socioeconomic neighborhoods were specifically chosen to obtain the broadest representation of demographic, socioeconomic status, and literacy. The study was approved by the Indiana University Institutional Review Board.</p></sec>
24648440|Questionnaire|('method', 0.9997943646099313)|('other', 0.00020563539006871736)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Questionnaire</title><p id="P10">Consistent with standard survey development procedures,<sup><xref rid="R45" ref-type="bibr">45</xref></sup> survey questions were developed by one of the authors, using extant literature on the assessment of attitudes, beliefs, and behaviors associated with genetic testing in T2DM and other chronic diseases. An initial sample of 75 items were created and distributed to 5 experts in the fields of psychology, sociology, and anthropology for evaluation. Following revisions, items were piloted in a group of 10 participants for clarity of wording. Based on feedback, items were then edited, resulting in a total of 59 items. Demographic, personal, and family medical history and psychosocial and behavioral factors related to interest in genetic testing for T2DM risk prediction were included in the final survey instrument. Demographic, perceived health, diabetes risk, and medical history questions were adapted from standardized questionnaires. Genetics knowledge was adapted from existing questionnaires.</p><p id="P11">To capture the widest variety of attitudinal and behavioral constructs related to genetic testing, psychosocial questions were informed Health Belief Model, the Theory of Planned Behavior and Reasoned Action, the Social Cognitive Theory, the Transactional Model of Stress and Coping, and the Precaution Adoption Process Model. Questions relating to constructs developed or adopted by these behavior change models included perceived health, perceived risk, awareness, knowledge, worry, motivation, utility, barriers, trust, and intention. The questions were designed to query participants about genetics, genetic testing, T2DM, and T2DM risk.</p><p id="P12">Questions relating to worry about risk of T2DM were measured with a 7-point Likert scale. All other questions used a 5-point Likert scale. Items (n = 5) assessing knowledge of genetics or genetic literacy were scored with 1 point given to each question answered correctly and summed to create a genetics knowledge total score (range = 0–5). A score of 4 or greater indicated high levels of knowledge about genetic testing.</p><p id="P13">Questionnaires were self-administered through paper or web-based versions, available in English or Spanish (1.8% of total surveys). The online questionnaire was distributed to prospective participants registered at Indiana’s volunteer research participant registry. The printed version of the questionnaire was handed to eligible participants by trained interviewers at the public libraries or the emergency department waiting room of Wishard Hospital. After completing the survey, each study participant was compensated with a $10 gift card and offered educational materials describing diabetes, risk factors and symptoms, and the Genetic Information Nondiscrimination Act (or GINA bill). All materials were available in both English and Spanish.</p></sec>
24648440|Statistical Analyses|('method', 0.9997943646099313)|('other', 0.00020563539006871736)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Statistical Analyses</title><p id="P14">SAS 9.3 was used for all statistical analyses. A total sample of 649 individuals completed the questionnaire. Individuals were excluded based on self-reported diabetes (n = 50) and body mass index &lt; 15 kg/m<sup>2</sup> (n = 1). Of these, only individuals self-reporting the following characteristics were included in the current analyses: self-reported race as black or white, 1 or more risk factors for T2DM (body mass index, family history of T2DM, or gestational diabetes), and a response to the item evaluating perceived risk of developing T2DM as <italic>likely</italic> (RA) or <italic>unlikely</italic> (RUA). This resulted in a final sample of 265 participants. RUA individuals were defined as those reporting low perceived risk and having at least 1 risk factor T2DM (body mass index &gt; 25 kg/m<sup>2</sup>, family history, or gestational diabetes; n = 169). RA individuals were defined as rating themselves with high perceived risk and at least 1 risk factor for T2DM (n = 69). The dependent variable was individuals reporting interest in genetic testing to predict future risk of developing T2DM (<italic>yes</italic> vs <italic>no</italic>/<italic>not sure</italic>). Univariate logistic regression analyses were performed by RA/RUA status. Independent variables (n = 47) included demographic variables, motivation, knowledge, or intention to engage in genetic testing for T2DM risk prediction. Variables reaching significance at <italic>P</italic> = .001 or better (Bonferroni correction for 46 independent tests) or were psychosocially relevant and age, sex, ethnicity, recruitment location were entered into multivariate logistic regression models for RA and RUA separately.</p></sec>
24652057|None|('method', 0.9980036415606091)|('other', 0.001996358439390918)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24652057|Sample|('method', 0.9980036415606091)|('other', 0.001996358439390918)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Sample</title><p id="P10">This cross-sectional study was an ancillary study to the ongoing multi-center SEARCH for Diabetes in Youth Study (SEARCH).<sup><xref rid="R14" ref-type="bibr">14</xref></sup> SEARCH was designed to estimate the prevalence and incidence of diabetes among a diverse cohort of youth in the US, and to characterize diabetes-related health outcomes and their risk factors including barriers to care and quality of care. SEARCH is currently identifying newly diagnosed diabetes patients (baseline participants), as well as following up with patients diagnosed with diabetes five or more years ago (follow-up participants). The sample population for the present report was a convenience sample of SEARCH Study participants with T1DM who attended baseline or follow-up study visits at the SEARCH Carolina Site with research clinics in Greenville, Charleston, and Columbia South Carolina between 25 May 2012 and 3 October 2012. These three research clinic sites were not necessarily where the study participants received their diabetes care. SEARCH baseline and SEARCH follow-up participants were both used in order to determine how understanding of mid-level providers differed among patients who had been diagnosed with diabetes recently, compared to those who had longer diabetes durations. Baseline and follow-up participants were different individuals with T1DM; some of whom were recently diagnosed with diabetes (baseline participants) and others of whom had been diagnosed with diabetes at least five years prior (follow-up participants).</p><p id="P11">The baseline study visit underway during this ancillary study data collection time period included participants who were diagnosed in 2012. T1DM participants eligible for the baseline study visit included all participants who were ≥ 10 years of age at diagnosis (regardless of type or race/ethnicity), all minority participants (regardless of age at diagnosis), and a 50% sample of non-Hispanic white participants &lt; 10 years of age at diagnosis. SEARCH follow-up visits underway during this ancillary study included participants with longer diabetes durations, who were diagnosed between 2002-2006 or in 2008, who had completed at least one previous study visit, had diabetes for ≥ 5 years, and completed their most recent SEARCH visit &gt; 2 years ago.</p></sec>
24652057|Research Design|('method', 0.9980036415606091)|('other', 0.001996358439390918)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Research Design</title><p id="P12">A cross-sectional, observational study design was chosen, as the SEARCH study had an appropriate patient population to collect meaningful data from, and the desired outcome of the study was to better understand how pediatric patients and their parents understood mid-level providers. The study was not interested in changing the experience of patients and their families, and there was not a specific sub-population to be queried, therefore this study design worked well for the scope of the study, and the nature of the data to be collected.</p></sec>
24652057|Measures|('method', 0.9980036415606091)|('other', 0.001996358439390918)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Measures</title><p id="P13">In addition to the usual SEARCH surveys, an additional survey specific to issues related to mid-level providers (<xref ref-type="fig" rid="F1">Figure 1</xref>) was sent to all study participants with T1DM who scheduled a baseline or follow-up visit during the study period. The survey was completed by the person with diabetes if he/she was ≥18 years of age or their parent/guardian if the person with diabetes was &lt;18 years of age. Surveys were collected at the time of the visit. The survey addressed the participants’ use of, perceived access to, and understanding of mid-level providers in diabetes care. The mid-level providers included in the survey were dietitians, nurse practitioners (NPs), physician assistants (PAs), and medical social workers (MSWs). Demographic data were from the initial participant survey, which was completed by participants or their parent/guardian shortly after diagnosis and before their SEARCH baseline visit.</p></sec>
24652057|Statistical analysis|('method', 0.9980036415606091)|('other', 0.001996358439390918)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Statistical analysis</title><p id="P14">All data were analyzed using SAS 9.3 software (SAS Institute, Cary, North Carolina). Mean proportions for each provider were compared to dietitians (referent) using t-tests stratified by baseline and follow-up participants. Due to small sample sizes, Fisher's Exact Tests were used to evaluate associations between survey questions. Values are presented as mean (SD) or %. Statistical significance was considered for P&lt; 0.05.</p></sec>
24659194|Materials and methods|('method', 0.7476079806605258)|('other', 0.252392019339474)|<title>Materials and methods</title>
24659194|None|('method', 0.7476079806605258)|('other', 0.252392019339474)|<p>Between January 2001 and December 2010, 73 consecutive patients with a diagnosis of septic arthritis of the glenohumeral joint were operated on in two separate institutions. Fifty-nine patients were excluded because infection followed a previous surgical procedure (osteosynthesis, shoulder arthroplasty, open rotator cuff repair and arthroscopic procedure). Four additional patients were excluded because the infection was diagnosed early in its clinical course, and these patients underwent arthroscopic irrigation and debridement with a satisfactory clinical outcome. The remaining ten patients were all treated for late sequelae of septic arthritis of the shoulder. A retrospective review of all clinical documentation was performed using our computer database. There were eight men and two women with a mean age of 67.9 years (range 62–74 years). All patients were referred with a diagnosis of a painful, arthritic shoulder and had failed prior non-operative treatment measures by other physicians. All patients complained of severe, unremitting pain and progressive functional impairment of the shoulder. The duration of symptoms before a diagnosis of septic arthritis was made ranged between 2.5 and 5 months. Eight of ten patients previously underwent three or more intra-articular or subacromial shoulder injections. All eight of these patients reported worsening of their pain/symptoms in the period immediately following the injections. Four patients had a history of diabetes, and two had a history of rheumatoid arthritis.</p>
24659194|None|('method', 0.7476079806605258)|('other', 0.252392019339474)|<p>Preoperative clinical examination in all patients showed no evidence of erythema, swelling, fluid collection, fistula or any other signs consistent with infection. Range of motion (ROM) was assessed clinically, and all patients demonstrated reduced ROM in all planes. Pain level was recorded using a visual analogue scale (VAS), and functional assessment was recorded using Constant and DASH scores.</p>
24659194|None|('method', 0.7476079806605258)|('other', 0.252392019339474)|<p>Three patients had a previous documented temperature between 37.5 and 39 °C; all other patients reported no history of fever. Blood cultures were performed in these three patients and found to be negative. Laboratory analysis revealed an elevated WBC count between 12.0 and 14.0 G/l in only three patients. Average C-reactive protein (CRP) was 128 mg/l (range 84–144), and average erythrocyte sedimentation rate (ESR) was 58 mm/h (range 38–86).</p>
24659194|None|('method', 0.7476079806605258)|('other', 0.252392019339474)|<p>Radiographic evaluation demonstrated varying degrees of destruction of glenohumeral joint (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). These findings were confirmed on CT scan in all patients (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a, b). In addition, all patients underwent preoperative MRI that demonstrated glenohumeral effusion with high signal intensity and proliferative synovitis. In two cases, a subdeltoid abscess was observed (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Bone scintigraphy with Tc99 was performed in all patients and failed to show any abnormalities in other joints or bone segments. Three patients underwent preoperative aspiration of the affected shoulder under ultrasound guidance, and in two of these patients, the diagnosis of infection was confirmed and causative organism identified.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>AP X-ray in a 68-year-old man with 4, 5 months of history of shoulder pain and limited range of motion. A large area of erosion of the humeral head is observed</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_317_Fig1_HTML.jpg" id="MO1" position="float" orientation="portrait"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>a</bold> Axial CT scan of the same patient as seen in Fig. <xref rid="Fig1" ref-type="fig">1</xref> demonstrating destruction of the humeral head and also at the level of glenoid articular surface. <bold>b</bold> 3D CT reconstruction showing extensive destruction of glenohumeral joint related to septic arthritis</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_317_Fig2_HTML.jpg" id="MO2" position="float" orientation="portrait"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>MRI showing intra-articular high-signal joint fluid associated with a subdeltoid abscess</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_317_Fig3_HTML.jpg" id="MO4" position="float" orientation="portrait"/></fig></p>
24659194|None|('method', 0.7476079806605258)|('other', 0.252392019339474)|<p>Surgery was performed in the modified beach chair position under general anesthesia with an interscalene block for postoperative pain control. A deltopectoral approach was utilized to access the glenohumeral joint. In cases where the subscapularis tendon was still intact, a tenotomy was performed; otherwise, a direct arthrotomy was carried out. After humeral head dislocation, resection of the remnant humeral head and thorough debridement of all dead and infected bone and soft tissue, including the rotator cuff, was carried out. The glenoid surface was then exposed, labrum was excised, and gentle resurfacing of the articular cartilage with reamers was performed. We ream the glenoid articular surface in order to complete the removal of all infected tissue including any pathologic cartilage as well as to assist in the preparation of the glenoid for possible delayed prosthetic reconstruction. Nine liters of normal saline solution was used to do an extensive pulsatile lavage of joint. In all cases, a handmade antibiotic spacer was inserted. In seven cases, a 1/3 tubular plate was used, and in three cases, a titanium humeral nail was used (Fig. <xref rid="Fig4" ref-type="fig">4</xref>). The antibiotic spacer was made using 40 g of bone cement, 4 g of vancomycin, 1 g of gentamycin and 2 g of cefazolin. After reduction of the spacer in the glenohumeral joint, any remaining viable rotator cuff tissue was repaired using non-absorbable suture to help stabilize the antibiotic spacer and create a pseudocapsule around the glenohumeral joint. The deltopectoral interval and subcutaneous tissues were then closed over a drain in all cases. Of note, multiple intraoperative fluid and tissue cultures were taken at varying stages of the surgical procedure in all cases.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>AP X-ray at 3-month follow-up with spacer in place. Humeral height and offset are relatively well preserved</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_317_Fig4_HTML.jpg" id="MO5" position="float" orientation="portrait"/></fig></p>
24659194|None|('method', 0.7476079806605258)|('other', 0.252392019339474)|<p>Postoperatively, all patients were immobilized in a sling with the arm in slight abduction and neutral rotation for 3 weeks. The drain was removed after 48 h. Patients were started with immediate passive ROM of the operated shoulder and discharged once intravenous antibiotic therapy was finalized. The mean duration of hospitalization was 24 days (range 17–32). Patients were followed clinically with laboratory analysis and radiographic evaluation until 1 year from surgery.</p>
24659196|Patients and methods|('method', 0.9993825819501139)|('other', 0.0006174180498860416)|<title>Patients and methods</title>
24659196|None|('method', 0.9993825819501139)|('other', 0.0006174180498860416)|<p>Between 2001 and 2005, 42 patients were managed at our institution for complex proximal humeral fractures and received a shoulder hemiarthroplasty (HA). The mean age at the time of surgery was 73.4 years (range 46–91), and a low-energy fall was the main cause of fracture (77.4 %). The other causes were mainly street accidents and fall from stairs. X-ray examination was immediately conducted in the Emergency Department. The patients were studied before surgery with computed tomography (CT) and three-dimensional reconstruction in order to achieve better characterization of fracture pattern and fragments displacement. Fracture pattern and indication for HA were assessed by the two senior authors (M.G. and F.F.). The index procedure was performed within 21 days from trauma (range 3–21 days). After surgery, patients were routinely evaluated at 1, 3, 6, 12 months, and annually thereafter (with little variability depending on patients’ compliance to the follow-up program). Furthermore, patients were evaluated from the functional and radiographic site in the setting of the present study, at an average of 7.2 years from surgery (range 5–9, 8 years), with application of clinical tests for quantitative analysis. At the time of the study, four patients had died for unrelated causes, five were lost, three were unwilling to participate in the study, and three were unable to participate because of multiple medical morbidities.</p>
24659196|None|('method', 0.9993825819501139)|('other', 0.0006174180498860416)|<p>We included in this retrospective study a total of 27 patients. In this series, 5 were men and 22 women, and mean age at the time of surgery was 71.9 (range 46–88). The right arm was involved in 16 cases (59.7 %) and the left arm in 11 (40.3 %). Referring to the clinical records and according to the Neer classification, indications for surgery were 3-part fracture–dislocation in four patients, 4-part fracture in 11 patients, 4-part fracture–dislocation in seven patients and head-splitting fracture in five patients. All of patients were managed with HA implantation by mean of a Neer II prosthesis (3 M, St. Paul, MN, USA) in 17, or a SMR modular prosthesis (LIMA-LTO, San Daniele, Italy) in 10. The prosthetic implant was cemented in all but 3 cases.</p>
24659196|None|('method', 0.9993825819501139)|('other', 0.0006174180498860416)|<p>Patients were operated on by the same shoulder specialized surgeon (M.G.) and were managed with standard technique. A second generation cephalosporin was used for antibiotic prophylaxis, administered before surgery and continued for 2 days postoperatively. Antithromboembolic prophylaxis was constantly used by mean of a low-molecular weight heparin. In the beach-chair position, a deltopectoral incision was made, the cephalic vein exposed and lateralized or dissected and the conjoined tendon medialized. After identification of the long head of the biceps and its groove, every fracture fragment was characterized. The greater and the lesser tuberosities were identified, separated and distracted using a non-absorbable 2/0 Ethibond (Ethicon Inc., USA). The displaced humeral head size was measured to determine the adequate prosthetic head dimension. After preparing the humeral canal, two or three holes were drilled near its proximal margin and a 2/0 Ethibond inserted, for successive vertical stabilization between the shaft and the tuberosities. After trials, the definitive prosthesis was implanted and the tuberosities fixed to each other and to the humeral shaft using the previously passed sutures. In most cases, cancellous bone was harvested from the humeral head and inserted in the gap under the prosthetic head. Eventual rotator cuff discontinuities were managed using a 2/0 Ethibond (Ethicon inc. USA). A suction drain was always positioned and removed 2 days after surgery. The operated shoulders were immobilized with a sling in adduction and internal rotation for 4 weeks. Active movements at the elbow were allowed starting at 14 days after surgery. Passive-assisted exercises for shoulder range of motion begun 4 weeks after surgery and pendulum exercises as well. Depending on the obtained recovery of the passive range on motion, active-assisted exercises begun 6 weeks after surgery and not before, always starting with isometric exercises. The rehabilitation program lasted 6–12 months, with 2–3 meetings for week.</p>
24659196|None|('method', 0.9993825819501139)|('other', 0.0006174180498860416)|<p>Clinical outcomes were assessed at follow-up visits using the Constant–Murley scoring system (CM score; 0–100) [<xref ref-type="bibr" rid="CR10">10</xref>] without correction for sex and age. In reference to range of motion (ROM), active forward flexion and external rotation are indicated as <italic toggle="yes">degrees</italic>; internal rotation receives from 10 points (interscapular region) to 0 points (lateral thigh), pain receives 15 points (none) to 0 points (severe) and strength receives 1 point for pound (max 25). A goniometer was used to measure ROM. Strength was measured as resisted elevation against a spring balance dynamometer (max 25 pounds). Subjective functional assessment was studied with the DASH outcome measure and the simple shoulder test (SST-12) [<xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>]. Subjective satisfaction was studied through patients self-assessing into one of three groups: satisfied, moderately satisfied and unsatisfied with respect to treatment outcome.</p>
24659196|None|('method', 0.9993825819501139)|('other', 0.0006174180498860416)|<p>True anteroposterior, transthoracic and axillary radiographs of the shoulders were used for radiological assessment. These were indicated as <italic toggle="yes">tuberosities complication</italic>: the absence of bone callus formation or the evidence of fracture line upon radiography (non-union), the presence of superior or posterior migration of the great tuberosity (malposition) or the evidence of tuberosities resorption. The acromionhumeral (acromionprosthesis) distance (AHD) was considered <italic toggle="yes">reduced</italic> if at least 25 % of superior migration of the humerus was present, upon true anteroposterior radiograph, with respect to early postoperative control, as previously described by Antuña et al. [<xref ref-type="bibr" rid="CR13">13</xref>]. Furthermore, radiographs were studied for presence of glenoid arthritis, heterotopic bone formation as well as for signs of prosthetic loosening (continue radiolucent lines, implant subsidence). All of the above mentioned radiographic parameters were reported as categorical variables (i.e. present or not present).</p>
24659196|None|('method', 0.9993825819501139)|('other', 0.0006174180498860416)|<p>We reported categorical variables as frequencies (percent) and continuous variables as means ± standard deviations (SD). For comparing continuous variables, we used the Mann–Whitney <italic toggle="yes">U</italic> test for two unpaired groups and the Kruskal–Wallis test for more than two groups. The Fisher’s exact probability test was used for comparing categorical variables. Spearman’s rank correlation was used when looking for statistical dependence between two variables. A <italic toggle="yes">p</italic> value &lt; .05 was considered to be statistically significant.</p>
24659197|Materials and methods|('method', 0.5783173000646623)|('other', 0.42168269993533775)|<title>Materials and methods</title>
24659197|None|('method', 0.5783173000646623)|('other', 0.42168269993533775)|<p>The proposed system is based on preoperative MRI findings and intraoperative observation. Rupture is defined as irreparable if intraoperative tissue mobilization and release techniques cannot achieve tendon reduction to its footprint, as described by Curtis et al. [<xref ref-type="bibr" rid="CR30">30</xref>].</p>
24659197|None|('method', 0.5783173000646623)|('other', 0.42168269993533775)|<p>Within the proposed system, the status of each rotator cuff tendon is described in terms of integrity/tearing and amenability to repair based on grade of fatty degeneration. The tendons are numbered sequentially: 1, supraspinatus; 2, infraspinatus; 3, teres minor; and 4, subscapularis. Tearing is described as follows: an intact tendon is graded as 0; a torn but reparable tear with good healing potential (Fuchs stage I–II/Goutallier stage 0–II) is given a plus sign (+); a torn but reparable tendon with poor healing potential (Fuchs stage III/Goutallier stage III–IV) is assigned a minus sign (−); and a torn but irreparable tendon is merely indicated by tendon number [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p>
24659197|None|('method', 0.5783173000646623)|('other', 0.42168269993533775)|<p>A formula describing the state of each tendon is thus generated intraoperatively for each patient as shown in Fig. <xref rid="Fig1" ref-type="fig">1</xref>. For the sake of simplicity, intact tendons may be omitted. The system allows describing the great variability of possible irreparable RCTs with a practical, informative and immediate formula.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Scheme demonstrating irreparable rotator cuff tears described according to the proposed classification system</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_320_Fig1_HTML.gif" id="MO1" position="float" orientation="portrait"/></fig></p>
24659198|Materials and methods|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<title>Materials and methods</title>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>During a 3-year period (June 2009–June 2012), 19 patients aged ≥70 years underwent RSA for the treatment of proximal humeral fractures at the authors’ Institution.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>All the patients were women, with an average age of 75 years (range 70–83; SD ± 3.8) at the time of injury. The surgical procedure was performed after a minimum of 4 days and a maximum of 14 days from trauma (mean 8.2 ± 3.06). The dominant arm was involved in 16 patients.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>Criteria of exclusion for treatment included severe cognitive impairment, pathologic fractures or comorbidities entailing an unacceptable anesthesiological risk (ASA &gt; 4). None of the patients were institutionalized at the time of hospital admission.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>Most common medical comorbidities included hypertension (ten patients), cardiac arrhythmias (seven patients) and diabetes (four patients).</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>Fractures were classified according to Neer’s criteria: there were 4 three-part fractures, 9 four-part fractures, 3 three-part (1 with a concomitant fracture of the anterior glenoid) and 2 four-part fracture dislocations, and 1 head-splitting fracture with diaphyseal extension.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>Two patients presented with complications related to the fracture. An acute occlusion of the subclavian artery, caused by a displaced bony fragment, occurred in one patient and required an emergency surgical intervention consisting in sole removal of the bone fragments and limb revascularization; the reverse prosthesis was then implanted after 8 days. Another patient suffered a traumatic injury of the axillary nerve (neuropraxia) with temporary deltoid palsy and skin hypoesthesia in the deltoid region; RSA was performed after 9 days, when neurological recovery became evident.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>Perioperative antibiotic and antithromboembolic prophylaxis was carried out in all patients according to standardized protocols.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>The same surgical procedure was performed by a single experienced surgeon (F.G.) on all the patients of this series, using the Delta Xtend Reverse Shoulder System (DePuy Synthes, Warsaw, USA) with the cemented humeral component.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>Intraoperatively, a massive rotator cuff tear was detected in nine patients (47 %); the teres minor tendon was always present.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>Passive motion was started on the first postoperative day, and the patients were allowed to use the operated shoulder for activities of daily living after 1 month. All the patients but one were assisted in the rehabilitation program by a physiotherapist.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>At follow-up, the patients were evaluated clinically and radiographically. The absolute, relative and normalized Constant scores [<xref ref-type="bibr" rid="CR2">2</xref>] and the Shoulder Pain and Disability Index (SPADI) score [<xref ref-type="bibr" rid="CR3">3</xref>] were used for the clinical evaluation. We chose the SPADI score for its simplicity, since other questionnaires included items that could hardly be administered or applied to our study population. X-rays were taken in A-P view in external rotation and A-P view on the scapular plane (true A-P) in order to evaluate tuberosity healing and inferior scapular notching. Radiographs were evaluated by an independent observer.</p>
24659198|None|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<p>A possible correlation between clinical outcome and radiographic appearance of the tuberosity fragment (healed vs. resorbed) was also investigated at follow-up.</p>
24659198|Surgical technique|('method', 0.9381619235272738)|('other', 0.061838076472726065)|<sec id="Sec3"><title>Surgical technique</title><p>The patient is placed on the operative table in a beach-chair position; the shoulder is covered by an adhesive surgical drape with iodine. The skin incision starts from the coracoid tip and runs distally and laterally for about 10 cm to the middle deltoid region, keeping away from the anterior axillary fold.</p><p>A standard deltopectoral approach is used for exposing the fracture site. The tendon of the long head of the biceps, if present, is sectioned and tenodesed at the level of the pectoralis major tendon.</p><p>The lesser tuberosity and the subscapularis tendon (with the anterior capsule) are isolated and resected; the anterior circumflex vessels are ligated in order to avoid bleeding.</p><p>Once the anterior tissues are removed, the gleno-humeral joint and the remaining fracture fragments of the proximal humerus are easily exposed. The articular fragment of the humeral head is removed, while the greater tuberosity with the posterior cuff is carefully preserved. The supraspinatus tendon is usually resected to avoid superior pull on the tuberosity fragment.</p><p>The glenoid components of the reverse prosthesis are implanted according to the standard technique: reaming of the glenoid, baseplate implantation and fixation with screws, glenosphere assembling on the baseplate.</p><p>The humeral canal is reamed manually until a delicate bite is felt on the inner wall of the humeral shaft. A specifically designed Positioning Jig (DePuy Synthes, Warsaw, USA) is applied to the proximal part of the diaphyseal fragment in order to assist the surgeon in implanting the humeral component in the desired degree of retroversion and height (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Positioning Jig (DePuy Synthes, USA). <bold>a</bold> The jig consists of a big clamp (<italic toggle="yes">large arrow</italic>) that grasps the diaphysis, and a small clamp (<italic toggle="yes">thin arrow</italic>) fixed to the prosthesis. A sliding mechanism (<italic toggle="yes">dotted arrow</italic>) allows downward and upward movements of the stem for length assessment. <bold>b</bold> Intraoperative view of the jig holding the trial humeral component</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_321_Fig1_HTML.jpg" id="MO1" position="float" orientation="portrait"/></fig></p><p>In all the patients of this series, the humeral component was placed in 20° of retroversion. The preferred height was assessed empirically by reducing the trial humeral component, held securely by the jig, into the glenosphere: in this way, joint stability and mobility, as well as soft tissue tension, were easily evaluated before implantation of the definitive humeral stem (Fig. <xref rid="Fig2" ref-type="fig">2</xref>).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Pictures showing intraoperative evaluation of shoulder motion and stability with the trial humeral component held by the jig (<italic toggle="yes">arrows</italic>): <bold>a</bold> abduction and external rotation (the frame is a magnification of the detail); <bold>b</bold> forward elevation</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_321_Fig2_HTML.jpg" id="MO2" position="float" orientation="portrait"/></fig></p><p>After removal of the trial component, the jig is left in place in order to allow a precise reproduction of the predefined position with the definitive stem. If fixation is achieved with cement (as was always done in this series of patients), the jig is useful for preventing accidental displacement of the humeral component while the methacrylate is polymerizing.</p><p>After humeral cup assembly and joint reduction, the greater tuberosity with the posterior cuff is firmly reattached to the prosthesis and to the humeral diaphysis by means of high resistance sutures (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Autologous bone chips, harvested from the humeral head, can be placed at the interface between the tuberosity and the diaphysis in order to enhance bone healing.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Intraoperative view at the end of the procedure with the shoulder in external rotation: the greater tuberosity and the posterior cuff have been reattached to the prosthesis and the humeral diaphysis (<italic toggle="yes">arrow</italic>), while the anterior aspect of the implant is left uncovered since the subscapularis has not been repaired (<italic toggle="yes">arrow point</italic>)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_321_Fig3_HTML.jpg" id="MO3" position="float" orientation="portrait"/></fig></p><p>A suction drain is placed deeply into the wound before subcutaneous and skin closure.</p></sec>
24659201|Materials and methods|('method', 0.994253479429345)|('other', 0.005746520570655072)|<title>Materials and methods</title>
24659201|None|('method', 0.994253479429345)|('other', 0.005746520570655072)|<p>The study model was a case–control retrospective study. The “cases” included the implant that sustained a dislocation. These were compared to patients with stable implants (Controls). All patients that underwent reverse shoulder replacement surgery at our institution from January 2003 were considered eligible for this study. The patients were included in case of consistency of the prosthetic model (Delta Xtend, Depuy, Johnson &amp; Johnsons) and availability of preoperative and immediate postoperative imaging of the affected limb, including antero-posterior and axillary X-rays views.</p>
24659201|None|('method', 0.994253479429345)|('other', 0.005746520570655072)|<p>Glenoid inclination was calculated according to previously standardized methods: inclination of the native glenoid (<italic toggle="yes">α</italic>) was determined on preoperative X-rays [<xref ref-type="bibr" rid="CR8">8</xref>] (Fig. <xref rid="Fig1" ref-type="fig">1</xref>); inclination of glenosphere (<italic toggle="yes">β</italic>) was determined on immediate postoperative radiographic exams [<xref ref-type="bibr" rid="CR9">9</xref>] (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The tilt of the glenosphere, expressed as an angle, was determined by the equation <italic toggle="yes">β</italic> − <italic toggle="yes">α</italic>.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Glenoid inclination is determined by the angle between the reference line from the superior medial angle of the scapula to the superior margin of the glenoid and the line parallel to the glenoid face. In figure, the supplementary angle of <italic toggle="yes">α</italic> (180° − <italic toggle="yes">α</italic>) is shown</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_324_Fig1_HTML.jpg" id="MO1" position="float" orientation="portrait"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Inclination of glenosphere is determined using a line parallel to the base plate and perpendicular to the central screw. In figure, the line parallel to the central screw and the line perpendicular to that line (angle of 90°) are shown. The perpendicular line is considered parallel to the base plate, and the inclination can be calculated based on the reference line drawn from the superior medial angle of the scapula to the superior end of the glenoid</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_324_Fig2_HTML.jpg" id="MO2" position="float" orientation="portrait"/></fig></p>
24659201|None|('method', 0.994253479429345)|('other', 0.005746520570655072)|<p>The disabilities of the arm, shoulder and hand (quick DASH) questionnaire was administered at the time of study to evaluate the quality of living [<xref ref-type="bibr" rid="CR10">10</xref>]. The quick DASH consists mainly of an 11-item disability/symptom scale, scored by 5 scale levels: 1 = no difficulty/symptoms, 2 = mild difficulty/symptoms, 3 = moderate difficulty/symptoms, 4 = severe difficulty/symptoms and 5 = extreme difficulty (unable to do)/symptoms. All scores were transformed into a scaling system from 0 = best function/no symptoms to 100 = worst function/symptoms. The DASH total score is determined by [(sum of n response)/n−1] × 25. Clinical and radiological data collections were performed by a single independent operator who did not take part into surgery.</p>
24659201|None|('method', 0.994253479429345)|('other', 0.005746520570655072)|<p>Statistical analysis was conducted using a statistical software (SPSS version 17, SPSS Inc., Chicago, IL, USA), and a nonparametric test (Mann–Whitney) was executed to study the association between the tilt of the glenoid component and number of dislocations. The association was considered statistically significant at a value of <italic toggle="yes">p</italic> &lt; 0.05.</p>
24659201|Surgical technique|('method', 0.994253479429345)|('other', 0.005746520570655072)|<sec id="Sec3"><title>Surgical technique</title><p>The patient was prepared in a beach chair position with the upper limb totally free and placed along the body. A standard deltoid-pectoral approach with a subscapularis tenotomy was adopted.</p><p>The posterior cuff and the greater tuberosity were freed from the overlying deltoid taking care not to injure the axillary nerve inferiorly. The humeral head was dislocated and a cutting guide positioned. Humeral head was resected with 20° of retroversion according to previous authors [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The humeral diaphysis was prepared with progressive drills and the humeral component implanted. With special retractors, positioned below the sub-glenoid tubercle, the humerus was displaced exposing the glenoid that was deprived of osteophytes. By means of a cutter guided, the central hole on the glenoid was performed. The guide was positioned, so that its lower rim was superposed on the lower rim of the glenoid [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR11">11</xref>], trying to obtain a 10° inferior tilt of the implant. The glenosphere base plate was positioned according to a press-fit technique with additional screws to stabilize the implant. The glenosphere was implanted on the base plate with a dedicated screw. The implant was reduced. Stability of the system was tested and the definitive polyethylene implant positioned. Subscapularis repair was carefully performed. The shoulder was then immobilized in a sling with the arm in abduction and neutral rotation.</p></sec>
24659201|Results|('method', 0.658795666772424)|('other', 0.34120433322757593)|<title>Results</title>
24659201|None|('method', 0.658795666772424)|('other', 0.34120433322757593)|<p>Ninety-nine implants were performed at our institution with the analyzed prosthetic model. Thirty-three fit the inclusion criteria, representing the study population. Out of the remaining patients, 49 have not have performed all the X-rays at our institution, whereas 17 did not have adequate projections.</p>
24659201|None|('method', 0.658795666772424)|('other', 0.34120433322757593)|<p>The study included patients with a mean age of 72 years (range 57–85 years), including 24 (73 %) women and 9 (27 %) men. The dominant limb was affected in 19 cases (57.5 %). At the time of study, the median follow up was 32 months.</p>
24659201|None|('method', 0.658795666772424)|('other', 0.34120433322757593)|<p>The indication to reverse shoulder replacement was based on the following diagnosis:<list list-type="bullet"><list-item><p>rotator cuff arthropathy in 23 patients (69.7 %)</p></list-item><list-item><p>proximal humeral fracture in 7 patients (21.2 %)</p></list-item><list-item><p>pseudo-paralytic shoulder with massive rotator cuff tear in 1 patient (3.03 %)</p></list-item><list-item><p>revisions of a previous prosthesis in 2 patients (6.06 %) including 1 total arthroplasty and 1 humeral hemiarthroplasty.</p></list-item></list></p>
24659201|None|('method', 0.658795666772424)|('other', 0.34120433322757593)|<p>Dislocation occurred in 3 patients (9.09 %). Two patients (6.06 %) sustained an atraumatic episode within the first 2 months after surgery, while 1 (3.03 %) occurred after an accidental fall 1 year after surgery. A closed reduction and conservative treatment was performed for the first patient; Open reduction and conservative treatment for the second patient and open reduction with revision of glenoid component in the last one. In 2 out of the 3 patients with a shoulder dislocation, the implants were made in acute fracture settings.</p>
24659201|None|('method', 0.658795666772424)|('other', 0.34120433322757593)|<p>The <italic toggle="yes">α</italic> and <italic toggle="yes">β</italic> angle were, respectively, 74.1° (range 65.3°–79.2°) and 83.5° (range 65.3°–90.9°). The average tilt of the glenosphere measured 9.4° (range −6.9° to 12.9°). The average tilt in the stable 30 patients was 10.2° (range 6.4°–13.2°). Tilt in patients with atraumatic instability measured, respectively, −6.9° (superior tilt) and 2.4°, while it was 8.3° for the patient with traumatic instability. The association between the tilt of glenosphere and atraumatic dislocation was significant (<italic toggle="yes">p</italic> = 0.009).</p>
24659201|None|('method', 0.658795666772424)|('other', 0.34120433322757593)|<p>29 out of the 33 patients included completed the quick DASH questionnaire. The average value was 24.3 (range 6.8–72.7). In the absence of joint instability, the average measured 20.7 (range 6.8–40.9), versus 70.4 (range 68–74) in case of dislocation (<italic toggle="yes">p</italic> = 0.006).</p>
24659201|None|('method', 0.658795666772424)|('other', 0.34120433322757593)|<p>Although quick DASH score was superior in men than in women (17.5 versus 27.2), the association between quick DASH score and gender was not significant (<italic toggle="yes">p</italic> = 0.1).</p>
24659202|Patients and methods|('method', 0.9969928107589746)|('other', 0.003007189241025339)|<title>Patients and methods</title>
24659202|Study population|('method', 0.9969928107589746)|('other', 0.003007189241025339)|<sec id="Sec3"><title>Study population</title><p>From January 2006 to December 2012, twenty-six subjects those who underwent UCL reconstruction for chronic UCL insufficiency were retrospectively enrolled. Fifteen of them were available to be assessed at a mean follow-up of 36 months (min 12, max 72). All patients enrolled gave their informed consent to be included in the study, which was approved by the Local Ethics committee (prot. no. 0.1131/2013/I.5/206) and performed in accordance with the Ethical Standards of the 1964 Declaration of Helsinki as revised in 2000. We used an autologous palmaris longus graft in five cases (33 %) and a semitendinosus allograft in 10 cases (77 %) (Bone bank allograft, Rizzoli Orthopedic Institute, Bologna, Italy). Six patients were overhead athletes, four were overhead heavy workers, and five had a previous trauma including dislocation or subluxation of the elbow.</p><p>Demographic and anthropometric features of the study population are reported in the Table <xref rid="Tab1" ref-type="table">1</xref>.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic and anthropometric data of the study population</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="1" colspan="1">Variable</th><th align="left" rowspan="1" colspan="1">Data</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Patients (no.)</td><td align="left" rowspan="1" colspan="1">15</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean age (years ± SD)</td><td align="left" rowspan="1" colspan="1">38 ± 2.35</td></tr><tr><td align="left" rowspan="1" colspan="1">Gender (M/F) (%)</td><td align="left" rowspan="1" colspan="1">12/3 (80/20)</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean height (cm ± SD)</td><td align="left" rowspan="1" colspan="1">174 ± 2.42</td></tr><tr><td align="left" rowspan="1" colspan="1">Mean weight (kg ± SD)</td><td align="left" rowspan="1" colspan="1">73 ± 2.11</td></tr><tr><td align="left" colspan="2" rowspan="1">Side</td></tr><tr><td align="left" rowspan="1" colspan="1"> Right/left (%)</td><td align="left" rowspan="1" colspan="1">10/5 (66/34)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Dominant</td><td align="left" rowspan="1" colspan="1">9/6 (60/40)</td></tr><tr><td align="left" rowspan="1" colspan="1"> Follow-up (months) (range)</td><td align="left" rowspan="1" colspan="1">36 (12–72)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">SD</italic> standard deviation</p></table-wrap-foot></table-wrap></p></sec>
24659202|Clinical assessment and outcome measures|('method', 0.9969928107589746)|('other', 0.003007189241025339)|<sec id="Sec4"><title>Clinical assessment and outcome measures</title><p>Overall, patients complained for elbow pain during sport and work activities and had positive signs for medial ligament injuries, including the valgus stress test [<xref ref-type="bibr" rid="CR13">13</xref>] and the milking maneuver [<xref ref-type="bibr" rid="CR14">14</xref>]. Magnetic resonance imaging (MRI) was performed in all cases to confirm the UCL injuries. We used the ultrasound (US) to document the presence or absence of a palmaris longus to the wrist, and we also searched for tendon features (length and width) to evaluate its suitability for a surgical reconstruction.</p><p>The outcome measures were the Mayo Elbow Performance Score (MEPS) [<xref ref-type="bibr" rid="CR15">15</xref>]; Oxford Elbow Score (OES) [<xref ref-type="bibr" rid="CR16">16</xref>]; the Disabilities of the Arm, Shoulder, and Hand (DASH) [<xref ref-type="bibr" rid="CR17">17</xref>]; and the Conway–Jobe Scale [<xref ref-type="bibr" rid="CR18">18</xref>]. Measurements were taken independently by two examiners who had not been involved in the surgical procedures. The OES is a 12-item multiple choice questionnaire with a final score ranging from 0 to 48 and classified as poor (0–19), fair (20–29), good (30–39), and excellent (40–48).</p><p>The DASH is a self-reported questionnaire scored in two components: the disability/symptom questions (30 items, scored 1–5) and the optional high-performance sport/music or work section (4 items, scored 1–5). The assigned values for all completed responses are simply summed and averaged and finally transformed to a score out of 100 by subtracting one and multiplying by 25. A higher score indicates greater disability.</p><p>The Conway–Jobe Scale was applied to assess the level of competition in professional athletes and was scored as<list list-type="bullet"><list-item><p>Excellent: return to pre-injury level of competition for more than one season.</p></list-item><list-item><p>Good: return to play at a lower level of competition for more than one season.</p></list-item><list-item><p>Fair: able to play regularly at a recreational level.</p></list-item><list-item><p>Poor: unable to play at any level.</p></list-item></list></p></sec>
24659202|X-ray and ultrasound assessment|('method', 0.9969928107589746)|('other', 0.003007189241025339)|<sec id="Sec5"><title>X-ray and ultrasound assessment</title><p>Overall, population underwent a radiographic evaluation of the operated elbow, including anteroposterior (AP) and true lateral elbow view [<xref ref-type="bibr" rid="CR19">19</xref>]. The AP was performed with the elbow fully extended and the forearm supinated, allowing optimal visualization of the medial and lateral epicondyles, radiocapitellar joint, and estimation of the carrying angle [<xref ref-type="bibr" rid="CR20">20</xref>]. The lateral view was obtained with the elbow in 90° of flexion and the forearm in neutral (thumb up) position [<xref ref-type="bibr" rid="CR20">20</xref>]. A true lateral radiograph allowed a good visualization of the ulnotrochlear joint, coronoid process, and olecranon process and highlighted the “teardrop” appearance formed by the boundaries of the coronoid and olecranon fossae [<xref ref-type="bibr" rid="CR21">21</xref>]. Ultrasonography was performed using a GE Logiq seven machine with a high-frequency linear transducer of 7.5–14 MHz; the transducer was placed in the coronal plane (long axis) with its cranial aspect over the medial epicondyle so that the hyperechoic bony contours of the medial epicondyle and ulnotrochlear articulation will be seen [<xref ref-type="bibr" rid="CR6">6</xref>]. Compared to the original anterior fibrillar band of the UCL, the graft appeared as a more hyperechoic compact “cordlike” band that lay just deep to the common flexor tendon. The US allows to follow the course of the graft from the isometric origin on the anteroinferior aspect of the medial epicondyle to the ulnar insertion closeness to the sublime tubercle. Dynamic US was also performed to evaluate the tensile properties and the resistance of the neoligament with the application of valgus stress on the elbow.</p></sec>
24659202|Surgical technique|('method', 0.9969928107589746)|('other', 0.003007189241025339)|<sec id="Sec6"><title>Surgical technique</title><p>All surgical procedures were performed by same two surgeons (GP and GM). A medial approach was used for MCL reconstruction, with the incision extending from the medial epicondyle to the proximal ulnar metaphysis. The ulnar nerve was isolated; the isometric origin of the anterior band of the MCL on the anteroinferior aspect of the medial epicondyle was identified, preserving the origin of flexor–pronator tendons. After exposure of the sublime tubercle on the medial aspect of the proximal ulna, humeral and ulnar tunnels were bored with a 5.0-mm cutter and rounded with a suture passer to foster the passage of the graft, which was then fixed using a figure-of-eight configuration (five cases) or a docking technique (eight cases); in two cases, we used an interference screws of 5 mm × 23 mm (Arthrex Inc, Naples, Fl, USA) to fix the graft on the humeral side. After the fixation, the end of the graft was holded on themselves, stitched up with non-absorbable sutures (Terofil 0.4 mm), and reinforced with capsular stitches; the ulnar nerve was transposed in the subcutaneous tissues. The wound was closed in layers, and the arm was placed in a hinged orthosis.</p><p>Early passive mobilization was carefully begun on the 15th postoperative day protected with an hinged orthosis &lt;90° of flexion–extension. The elbow was removed by the orthosis within 30th postoperative day [<xref ref-type="bibr" rid="CR22">22</xref>]. Elastic resistance exercises were allowed at 60 days and heavy work or sports activity after 90 days.</p></sec>
24659202|Statistical analysis|('method', 0.9969928107589746)|('other', 0.003007189241025339)|<sec id="Sec7"><title>Statistical analysis</title><p>Statistical analysis was performed using the Wilcoxon signed-rank test for paired data to assess the difference between pre- and postoperative clinical scores. Correlations between patient’s features (age, gender, height, weight) and clinical scores were sought using nonparametric Spearman’s test. Bravais–Pearson correlation coefficient was used to search the difference between the two independent observations.</p></sec>
24659204|Methods|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<title>Methods</title>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>From November 2011 to March 2012, we enrolled 101 right-handed subjects (23 males and 78 females). They were all aged between 50 and 65 years (average age 55); all of them were administrative employees of our university and particularly skilled with the use of writing and data collection programs (like Microsoft Word and Microsoft Excel—almost 5 h per day). None of the subjects suffered by diseases that could compromise their working ability.</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>Initially, the subjects were instructed about the test run. Each subject was asked to undergo two tests: (1) a written test (which had to be made without [first text] and with the braces in neutral [second text] and internal position [third text]) (first test) and (2) compilation of a questionnaire (second test). The first test consisted in three parts.</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>First part: to write a text (first text), using Microsoft Word, and make an Excel table. Both the written proofs were dictated from one of us. Another author wrote down all the writing mistakes, committed by the subject, and the total time needed to write text and table. No mistakes were corrected during the test to avoid to increase the running time.</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>Second part: the right upper limb was immobilized with a shoulder brace (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) (Imb-700, Fgp), which kept the arm at the side with abduction of 15° (brace A). All the phases of the first part were repeated; text and table were different from those of the first part (second text).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Shoulder brace that kept the arm at the side with abduction of 15° (brace A)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_327_Fig1_HTML.jpg" id="MO1" position="float" orientation="portrait"/></fig></p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>Third part: the right upper limb was immobilized with a shoulder brace (Fig. <xref rid="Fig2" ref-type="fig">2</xref>) (Gumifix, Tielle Camp) which kept the arm in internal rotation (brace B). Again, all the phases of the previous two parts were repeated using new text and table (third text).<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Shoulder brace that kept the arm in internal rotation (brace B)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_327_Fig2_HTML.jpg" id="MO2" position="float" orientation="portrait"/></fig></p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>The Word tests and the Excel tables were chosen by specialists in spoken and written language disorders who guaranteed on the same difficulty degree. A previous analysis conducted on 20 administrative right-handed volunteers (aged 48–65 years) showed that the times needed to write the three texts without the braces were almost superimposable. The three texts consisted of 300 words, easy to understand. In addition, to reduce the differences between the three parts, the texts were extrapolated from the same novel. Each table consisted of 50 boxes arranged in 5 columns and 10 lines. Each box contained two numbers and one letter.</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>Furthermore, the order in which the three parts of the test were performed was randomized to avoid the possible influence of deconcentration and fatigue on the results.</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>At the end of the second and third parts, a questionnaire, consisting of ten questions relative to subjective and interpersonal discomfort caused by the braces was administered (second test) (Fig. <xref rid="Fig3" ref-type="fig">3</xref>) Subjects were asked to indicate in each question, on an analogic scale, the amount of discomfort they had experienced during the second and third part of the first test, simply placing a slash (“/”) on the line that accurately corresponded with their discomfort. The line measured 10 cm, and each centimeter corresponded to 1 point (0–100 scale). The further to the right subjects put their “/,” the higher was the grade of discomfort. We defined the “discomfort index” (DI) as the sum of the scores of the ten questions. We arbitrarily distinguished four discomfort degrees: mild, moderate, severe and very severe. According to the DI, the patient was assigned to one of four degrees: mild (DI 0–25), moderate (DI 25.1–50), severe (DI 50.1–75) and very severe (DI 75.1–100) (Fig. <xref rid="Fig4" ref-type="fig">4</xref>).<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Second test: subjective discomfort questionnaire</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_327_Fig3_HTML.gif" id="MO3" position="float" orientation="portrait"/></fig><fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Discomfort index (DI) scale</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="12306_2014_327_Fig4_HTML.gif" id="MO4" position="float" orientation="portrait"/></fig></p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>At the end of the second part, the subject was asked to indicate the preferred brace to work with.</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>We calculated the arithmetic mean of the time of writing and of the average number of mistakes in the first, second and third part of the first test. Moreover, to verify the existence of a statistically significant difference (defined as no overlap of data) between the average times and number of mistakes in any part of the first test, we set the <italic toggle="yes">p</italic> value of 0.02 (CI 98 %).</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>Finally, we used the Pearson coefficient to verify the statistical correlation between the writing times of the first, second and third part of the first test.</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>As like as the first one, we calculated the arithmetic mean of the scores of the answers of the questionnaire (second test). Then, we divided the patients into four groups according to their DI.</p>
24659204|None|('method', 0.9648604376820976)|('other', 0.03513956231790241)|<p>Finally, we set the <italic toggle="yes">p</italic> value at 0.02 to verify the existence of a statistically significant difference (defined as no overlap of data) between the average scores for each answer.</p>
24670990|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24670990|Strains, plasmids, and growth conditions|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Strains, plasmids, and growth conditions</title><p><italic>Escherichia coli</italic> DH5α was used as the cloning host. <italic>Pichia pastoris</italic> GS115 (<italic>His</italic><sup>−</sup>, Novagen) was used as the heterologous expression host. Plasmid pPIC9K (Novagen) was used as gene expression vector. The recombinant plasmid pPIC9K-proRCLS4-3 contained the gene coding the thermostable lipase S4-3 (<xref rid="bib21" ref-type="bibr">21</xref>).</p><p>The recombinant <italic>P. pastoris</italic> was enrichment-cultivated in buffered glycerol-complex medium [10 g/l yeast extract, 20 g/l peptone, 100 mM potassium phosphate (pH 6.0), 13.4 g/l yeast nitrogen base (YNB), 4 × 10<sup>−4</sup> g/l biotin, and 10 g/l glycerol] and induction-cultivated in buffered methanol-complex medium [10 g/l yeast extract, 20 g/l peptone, 100 mM potassium phosphate (pH 6.0), 13.4 g/l YNB, 4 × 10<sup>−4</sup> g/l biotin, and 5 g/l methanol]. <italic>E. coli</italic> was cultivated in Luria-Bertani medium (10 g/l tryptone, 5 g/l yeast extract, and 10 g/l NaCl). <italic>P. pastoris</italic> GS115 was grown and maintained in yeast extract peptone dextrose medium (YPD) (10 g/l yeast extract, 20 g/l peptone, and 20 g/l dextrose). The minimal dextrose medium plate (20 g/l dextrose, 100 mM potassium phosphate (pH 6.0), 13.4 g/l YNB, and 4 × 10<sup>−4</sup> g/l biotin) was used for selection of <italic>His</italic><sup>+</sup> transformants. The YPD-G418 plate containing 0.25 g/l geneticin was used for selection of <italic>Pichia</italic> transformants.</p></sec>
24670990|Mutagenesis and construction of the lipase expression vector|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Mutagenesis and construction of the lipase expression vector</title><p>The plasmids for the expression of genes of an S4-3 lipase variant generated from the lid of S4-3 swapped with that from RML (S4-3M) and an S4-3 lipase variant generated from the lid of S4-3 swapped with that from AnFaeA (S4-3N) were constructed as follows: The lid replacement was carried out by the overlap extension PCR strategy (<xref rid="bib23" ref-type="bibr">23</xref>). A pair of end-primers, Pro-F (5′-TCAAG­ATC<italic>CCTAGG</italic>GTTCCTGTTGCTGGTCATAAAGGTTC-3′, italics indicate <italic>Avr</italic>II) and Pro-R (5′-AATTCCAGT<italic>GCGGCCGC</italic>TTACAA­ACAGCTTCCTTCG-3′, italics indicate <italic>Not</italic>I), the primers RMLF (5′-TTTACTGATTATTCTCCTGTCAAGGGCGCCAAAG-3′) and RMLR (5′-CCTTGACAGGAGAATAATCAGTAAAAACAAAAG­TCAAATCAGCAATCCAGTTTCTAATAGAAGAAGAACCACGGAAAGTAACATAGATGG-3′) for S4-3M, and the primers NigerF (5′-ACCTTTACTGATTATTCTCCTGTCAAGGGCGCC-3′) and NigerR (5′-GAATAATCAGTAAAGGTGTAGTTAGTATCCAAT­T­GCAAGTTAGTATCAGAACCAGTACCACGGAAAGTAAC-3′) for S4-3N, annealing to the overlap regions, were used to introduce the new lid. The PCR product was digested by <italic>Avr</italic>II and <italic>Not</italic>I, gel purified, and then ligated into pPIC9K digested with the same enzymes. The recombinant plasmids named as pPIC9K-proRCLS4-3M and pPIC9K-proRCLS4-3N were confirmed by PCR and DNA sequencing.</p></sec>
24670990|Transformation of <italic>P. pastoris</italic> and selection of <italic>His<sup>+</sup></italic> recombinants|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Transformation of <italic>P. pastoris</italic> and selection of <italic>His<sup>+</sup></italic> recombinants</title><p><italic>P. pastoris</italic> GS115 was transformed with 1 μg of <italic>Sal</italic>I-linearized expression vector by electroporation. The <italic>His</italic><sup>+</sup> transformants were obtained on minimal dextrose medium plate. The resistant genetic transformants were screened on YPD-G418 plate. The insertion and methanol metabolization were checked by PCR. The PCR amplifications were carried out according to Invitrogen’s recommendations with genomic DNA and primers complementary to the 5′ and 3′ regions of the <italic>AOX1</italic> gene.</p></sec>
24670990|Expression and purification of lipases|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Expression and purification of lipases</title><p>The <italic>P. pastoris His</italic><sup>+</sup> transformants were cultured in 25 ml of buffered glycerol-complex medium shaken at 30°C and 250 rpm in 250 ml glass flasks. When cultures reached an optical density at 600 nm (OD<sub>600</sub>) of ∼6.0, the cells were centrifuged and resuspended in 100 ml buffered methanol-complex medium to an OD<sub>600</sub> of 1.0, shaken at 28°C and 250 rpm in 500 ml glass flasks for 120 h. The cultures were supplemented with 5 g/l methanol every 12 h to induce the expression of lipase.</p><p>After induction, the lipases from the culture supernatant were harvested by centrifugation at 8,000 <italic>g</italic> at 4°C for 20 min and then concentrated and interchanged with 10 mM phosphate buffer (pH 8.0) by ultrafiltration through a 10 kDa membrane (Millipore). Then, the concentrated solutions were loaded onto a HiTrap SP FF column (Pharmacia, 5 × 5 ml) equilibrated with 20 mM acetic acid-sodium acetate buffer (pH 5.0), and eluted with 0–0.5 M NaCl in the same buffer. Fractions containing lipase activities were pooled, concentrated, and chromatographed on a HiTrap Phenyl HP (Pharmacia, 5 × 5 ml) equilibrated in 50 mM sodium phosphate buffer (pH 7.5) containing 1.6 M ammonium sulfate. Lipases were then eluted in an ammonium sulfate concentration gradient ranging from 1.6 to 0 M in 50 mM sodium phosphate buffer (pH 7.5). Protein fractions with lipase activities were collected and dialyzed against phosphate buffer (pH 8.0). The purified enzymes were stored at 4°C. Protein fractions collected from the previous steps were analyzed by SDS-PAGE. Protein concentrations were determined using the Bradford assay. Bovine serum albumin was used as a standard.</p></sec>
24670990|Influence of pH and temperature on activity and stability|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Influence of pH and temperature on activity and stability</title><p>The enzymatic activities for hydrolyses of <italic>p</italic>-nitrophenyl esters were measured according to Kordel et al. (<xref rid="bib24" ref-type="bibr">24</xref>). Optimal pH was determined by examining the activity of the enzyme using <italic>p-</italic>nitrophenyl palmitate (<italic>p</italic>NPP) as substrate at 40°C in the following buffers: 50 mM citrate (pH 5.0–5.5), 50 mM phosphate (pH 6.0–8.0), 50 mM Tris-HCl (pH 8.5–9.0), and 50 mM carbonate (pH 9.5–10.0). The pH stability was determined by incubating 0.2 U lipase solution in buffers (50 mM, pH 5.0–10.0) for 1 h at 25°C and analyzing the residual activity. Optimal temperature was determined by measuring the enzyme activity using <italic>p</italic>NPP as substrate at optimal pH under various temperatures (20°C–70°C). Thermostability was determined by preincubating 0.2 U lipase for various intervals up to 1 h at temperatures ranging from 20°C to 70°C in optimal pH buffer and analyzing the residual activity.</p></sec>
24670990|Lipase substrate specificity|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Lipase substrate specificity</title><p>Chain-length specificity of the purified enzyme was analyzed by using various fatty acid esters of triglycerides as substrates. The enzymatic activities for hydrolyses of triglycerides were determined by the spectrophotometric assay at 430 nm using the formation of copper soaps for the detection of free fatty acids (<xref rid="bib25" ref-type="bibr">25</xref>). One unit (1 U) of lipase activity was defined as the amount of enzyme needed to liberate 1 μmol of free fatty acids per minute under defined reaction conditions.</p></sec>
24670990|Interfacial kinetics|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Interfacial kinetics</title><p>The values of interfacial kinetic parameters <italic>K</italic>*<italic><sub>m</sub></italic> and <italic>k*<sub>cat</sub></italic> were determined in a heterogeneous medium reacted under the condition of pH 8.0 and 40°C for S4-3 and S4-3M and of pH 8.0 and 45°C for S4-3N using various concentrations of <italic>p</italic>-nitrophenyl laurate (<italic>p</italic>NPL), <italic>p</italic>-nitrophenyl acetate, or <italic>p</italic>-nitrophenyl propionate as substrate according to the method described by Burdette et al. (<xref rid="bib26" ref-type="bibr">26</xref>).</p></sec>
24670990|3D structure simulation|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>3D structure simulation</title><p>A 3D model of <italic>R. chinensis</italic> lipase in a closed conformation was built by SWISS-MODEL protein automated modeling program (<xref rid="bib27" ref-type="bibr">27</xref>) on the basis of the crystal structure of lLGY (crystal structure of lipase II from <italic>Rhizopus niveus</italic> solved with a resolution of 2.20 Å) (<xref rid="bib28" ref-type="bibr">28</xref>). The structure of <italic>R. chinensis</italic> lipase in an open form was modeled by SWISS-MODEL based on the 3D crystallographic structure of the inhibited <italic>R. miehei</italic> lipase (PDB id: 4TGL) (<xref rid="bib29" ref-type="bibr">29</xref>). The structures were energy minimized by molecular dynamics for 10 ps at 298 K.</p></sec>
24671012|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">METHODS</title>
24671012|Reagents, plasmids, and gene expression|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Reagents, plasmids, and gene expression</title><p>GW3965 and T0901317 were synthesized as described (<xref rid="bib51" ref-type="bibr">51</xref>–<xref rid="bib53" ref-type="bibr">53</xref>). LG268 was a gift of R. Heyman (Ligand Pharmaceuticals). Oxysterols were purchased from Sigma and used as described (<xref rid="bib54" ref-type="bibr">54</xref>). Emetine was a gift from D. Black (Howard Hughes Medical Institute, University of California, Los Angeles). Ligands were dissolved in dimethyl sulfoxide before use in cell culture. pBABE-LBP retrovirus was generated using pBABE-puro (Invitrogen Gateway adapted) as a backbone. For gene expression analysis, RNA was isolated using TRIzol reagent (Invitrogen) and analyzed by real-time PCR using an Applied Biosystems 7900HT. Results are normalized to 36B4. The primer sequences are available upon request.</p></sec>
24671012|Animals and diets|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Animals and diets</title><p>All animals (C57Bl/6, greater than 10 generations backcrossed) were housed in a temperature-controlled room under a 12 h light/12 h dark cycle and under pathogen-free conditions. LXRα<sup>−/−</sup>, LXRβ<sup>−/−</sup>, and LXRαβ<sup>−/−</sup> mice were originally provided by David Mangelsdorf, University of Texas Southwestern Medical Center, Dallas, TX. LBP<sup>−/−</sup> mice (C57Bl/6 background) were obtained from Grace Su University of Michigan. Mice were fed either standard chow or Western diet as indicated (21% fat, 0.21% cholesterol; D12079B; Research Diets Inc.). For bone marrow transplantation studies, recipient LDLR<sup>−/−</sup> mice (11 weeks of age) were lethally irradiated with 900 rads and transplanted with 3 × 10<sup>6</sup> bone marrow cells from 8-week-old or older donors (WT or LBP<sup>−/−</sup>) via tail vein injection as previously described (<xref rid="bib22" ref-type="bibr">22</xref>). Mice were gavaged with either vehicle or 40 mg/kg of GW3965 once a day for 3 days. Livers were harvested 4 h after the last gavage. Cholesterol and triglyceride levels were measured as previously described (<xref rid="bib55" ref-type="bibr">55</xref>). All animal experiments were approved by the Institutional Animal Care and Research Advisory Committee at University of California, Los Angeles.</p></sec>
24671012|Cell culture|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Cell culture</title><p>Primary peritoneal macrophages were isolated 4 days after thioglycollate injection and prepared as described (<xref rid="bib19" ref-type="bibr">19</xref>). Bone marrow cells were harvested as described and cultured in L929 cell-conditioned media for 7 days to induce differentiation into macrophages (<xref rid="bib22" ref-type="bibr">22</xref>). Peritoneal macrophages were incubated in 0.5% FBS in DMEM, with 5 μM simvastatin and 100 μM mevalonic acid. Five to eight hours later, cells were pretreated with DMSO or an appropriate ligand overnight. For inflammation studies, cells were treated with 10 or 100 ng/ml LPS (Axxora, ALX-581-008-L002) for 4 h after ligand stimulation. Mouse primary hepatocytes were isolated as previously described and cultured in William’s E medium with 5% FBS (<xref rid="bib54" ref-type="bibr">54</xref>). Stable cell lines were made using pBABE retroviral vectors as described (<xref rid="bib56" ref-type="bibr">56</xref>).</p></sec>
24671012|Electrophoretic mobility shift assay|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Electrophoretic mobility shift assay</title><p>Electrophoretic mobility shift assay (EMSA) was performed as previously described (<xref rid="bib57" ref-type="bibr">57</xref>). Briefly, Klenow enzyme buffer system (Promega) was used for labeling and annealing oligonucleotides. TNT quick coupled transcription/translation system (Promega) was used for in vitro translation of RXRα and LXRα. The translated protein products were combined and incubated at room temperature for 10 min with labeled DNA and 100 M NaCl, 1 mM EDTA, 20 mM HEPES, 5% glycerol, 0.01% Nonidet P-40, and 2 μg/μl poly(dI:dC). Protein-DNA complexes were electrophoresed on a polyacrylamide gel and visualized by autoradiography.</p></sec>
24671012|Antibodies and immunohistochemistry|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Antibodies and immunohistochemistry</title><p>The following antibodies were used for immunohistochemistry: CD68 (MCA1957GA, AbD) 1:400 with secondary antibody biotin-SP-conjugated AffiniPure goat anti-rat IgG (H+L) (Jackson Laboratories) 1:1,000 and α-smooth actin rabbit monoclonal (E184) 1:100 with secondary antibody biotinylated goat anti-rabbit IgG (Vector Laboratories) 1:200. For immunoblot analysis the following antibodies were used: ABCA1 (Novus) 1:1,000, COX-2 (Santa Cruz) 1:200, LDLR (Cayman Chemicals) 1:1,000, and actin (Sigma) 1:10,000.</p></sec>
24671012|Cholesterol efflux|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Cholesterol efflux</title><p>Assays were performed as previously described (<xref rid="bib55" ref-type="bibr">55</xref>). Briefly, bone marrow-derived macrophages from WT or LBP<sup>−/−</sup> mice were labeled with [3H]cholesterol (1.0 μCi/ml) in the presence of acyl-CoA:cholestrol <italic>O</italic>-acyltransferase inhibitor (2 μg/ml) either with DMSO or with ligand for LXR and RXR (1 μM GW3965, 100 nM LG268). After equilibrating the cholesterol pools, cells were washed with PBS and incubated in DMEM containing 0.2% BSA in the absence or presence of apoA-I (15 μg/ml) or HDL (50 μg/ml) for 6 h. The data are presented as percent apoA-I- or HDL-specific efflux.</p></sec>
24671012|Histological and lesion analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Histological and lesion analysis</title><p>Immunohistochemistry of sections and preparation and staining of frozen and paraffin-embedded sections from aortas were performed as described previously (<xref rid="bib19" ref-type="bibr">19</xref>). Atherosclerosis in the aortic roots and the descending aortas (en face) were quantified by computer-assisted image analysis as described (<xref rid="bib58" ref-type="bibr">58</xref>). Atherosclerotic lesions at the aortic valve were analyzed as described (<xref rid="bib59" ref-type="bibr">59</xref>). The presence of apoptotic cells was assessed by terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay of paraffin-embedded tissue sections as previously described using a Promega DeadEnd fluorometric TUNEL system (<xref rid="bib26" ref-type="bibr">26</xref>). Thirty high power fields from at least seven mice from each genotype were analyzed for apoptotic TUNEL, positive and DAPI-stained cells.</p></sec>
24671012|Statistical analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Statistical analysis</title><p>Non-paired Student’s <italic>t</italic>-test was used to determine statistical significance, defined at <italic>P</italic> &lt; 0.05. Unless otherwise noted, error bars represent standard deviations. For real-time PCR analysis of macrophages, each condition represents averages of two independent samples.</p></sec>
24686158|None|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Specific Trials</title>
24686158|None|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P38">To qualify for the TTrials overall, a man had to meet all of the general enrollment criteria described above and also the specific eligibility criteria for at least one of the three main trials (<xref ref-type="table" rid="T1">Table 1</xref>). A subject who also met the specific enrollment criteria for the Cardiovascular Trial and the Bone Trial could enroll in them. Each specific trial had its own hypotheses and tests of efficacy (<xref ref-type="table" rid="T3">Table 3</xref>). Most also had their own inclusion and exclusion criteria (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
24686158|Physical Function Trial|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S19"><title>Physical Function Trial</title><p id="P39">The primary hypothesis of the Physical Function Trial was that testosterone treatment for one year of elderly men with a low serum testosterone concentration and mobility disability would increase the proportion of men who improved their distance in the 6-minute walk test by ≥50m. The 6-minute walk test was selected as the primary outcome because 1) walking is essential for most activities of daily living and predicts meaningful clinical outcomes<sup><xref rid="R33" ref-type="bibr">33</xref>-<xref rid="R35" ref-type="bibr">35</xref></sup> and 2) data about the minimum clinically important difference (MCID) (50m) were available<sup><xref rid="R36" ref-type="bibr">36</xref>-<xref rid="R38" ref-type="bibr">38</xref></sup>. One investigator (TWS) trained the staff at each site in the administration of this test and visited each site once a year to monitor performance. This test was administered at months 0, 3, 6, 9 and 12. The sample size estimate was based on the MCID of 50m, the assumption that 15% of men in the placebo group and &gt;30% of men in the testosterone group would increase by at least this amount, and the goal of 90% power. The estimated sample size was 175 per treatment arm.</p><p id="P40">The most important secondary hypothesis was that treatment would be associated with greater improvement in self-reported physical function, as assessed by the physical function component (PF10) of the Medical Outcomes Study Short Form-36 (MOS SF36) questionnaire<sup><xref rid="R39" ref-type="bibr">39</xref></sup>.</p><p id="P41">The inclusion criterion for the Physical Function Trial was symptomatic and objective mobility disability, defined by a combination of self-reported difficulty walking one-quarter mile and/or walking up one flight of stairs and a gait speed of &lt;1.2 meters/second on the 6-minute walk test, a value associated with reduced survival <sup><xref rid="R40" ref-type="bibr">40</xref><xref rid="R41" ref-type="bibr">41</xref></sup>. Exclusion criteria are listed in <xref ref-type="table" rid="T2">Table 2</xref>.</p></sec>
24686158|Sexual Function Trial|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S20"><title>Sexual Function Trial</title><p id="P42">The primary hypothesis of the Sexual Function Trial was that testosterone treatment for one year of elderly men with low sexual interest will increase sexual activity, as assessed by question 4 of the Harbor-UCLA 7-day Sexual Function Diary. This questionnaire had been used in two previous testosterone trials to demonstrate increased sexual activity <sup><xref rid="R42" ref-type="bibr">42</xref>, <xref rid="R43" ref-type="bibr">43</xref></sup>. We administered it by interactive voice response (IVR) <sup><xref rid="R44" ref-type="bibr">44</xref></sup>, but because it had not previously been administered by IVR, we first conducted a pilot study to compare the results obtained by IVR with those obtained by pencil and paper; the correlation (r) was 0.99, and Bland Altman analysis indicated excellent agreement (unpublished). The questionnaire was administered daily for seven days at months 0, 3, 6, 9 and 12. The sample size estimate was based on data that testosterone treatment of hypogonadal men increased the score by 0.75 units and a standard deviation of change from baseline to 12 months of 1.86 <sup><xref rid="R43" ref-type="bibr">43</xref></sup>. We calculated that 131 subjects/arm would provide 90% power to detect a change of this magnitude or greater.</p><p id="P43">Secondary end points included erectile function, assessed by the International Index of Erectile Function (IIEF), and libido, assessed by the Derogatis Inventory of Sexual Function - Male (DISF-M-II SR). Based on data showing that a change of 4 points in the IIEF is clinically meaningful <sup><xref rid="R45" ref-type="bibr">45</xref></sup> and that men who are not undergoing treatment do not experience a change, we estimated we would have 90% power to detect if there is a difference in the proportion of men who improve their score by 4 or more points. We expect to have 80% power to detect a difference of 3 units in the DISF-M-II SR <sup><xref rid="R46" ref-type="bibr">46</xref></sup></p><p id="P44">The inclusion criterion was decreased libido, both self-reported and by a score of ≤20 on the DISF-M-II SR questionnaire, as well as a partner willing to have sexual intercourse at least twice a month. Exclusion criteria are listed in <xref ref-type="table" rid="T2">Table 2</xref>.</p></sec>
24686158|Vitality Trial|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S21"><title>Vitality Trial</title><p id="P45">The primary hypothesis of the Vitality Trial was that testosterone treatment for one year of elderly men with low vitality would increase the proportion whose score on the Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue scale increased by ≥4 <sup><xref rid="R47" ref-type="bibr">47</xref></sup>. This test was administered by IVR at months 0, 3, 6, 9 and 12. A pilot study showed a correlation (r) between IVR and paper versions of 0.92, and Bland Altman analysis indicated excellent agreement (unpublished). The sample size estimate was based on the assumptions that 20% of men in the placebo group and 35% of men in the testosterone group would exhibit an increase at least this great. We calculated that a sample size of 200 per treatment arm would provide 90% power to detect this difference.</p><p id="P46">Secondary outcomes included vitality, as measured by the SF-36 Vitality subscale, the two subscales of the Positive and Negative Affect Schedule (PANAS), and the Patient Health Questionnaire-(PHQ)-9 depression, which were also administered by IVR. A pilot study comparing the IVR and paper versions showed correlations (r) of 0.94 for the SF-36 Vitality, 0.96 for the PANAS, and 0.95 for the PHQ-9, and Bland Altman analyses indicated excellent agreement for all (unpublished).</p><p id="P47">The inclusion criterion for the Vitality Trial was low vitality, as defined by both self-reported decreased energy and a score of &lt;40 on the FACIT-Fatigue scale. There were no exclusion criteria.</p></sec>
24686158|Cognitive Function Trial|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S22"><title>Cognitive Function Trial</title><p id="P48">The primary hypothesis was that testosterone treatment for one year of elderly men who have Age-Associated Memory Impairment (AAMI) would result in greater improvement, or less decline, in verbal memory, as assessed by the Delayed Paragraph Recall Subscale (Logical Memory II) of the Wechsler Memory Scale-Revised (WMS-R) <sup><xref rid="R48" ref-type="bibr">48</xref></sup>. Men with AAMI were defined as those who had subjective memory complaints, as determined by their score on the Memory Assessments Clinics-Questionnaire (MAC-Q), and objective memory impairment, as determined either by a score on the Delayed Paragraph Recall Subscale or by Benton Visual Retention Test (BVRT) &gt;1 standard deviation (SD) below the performance for young men. We calculated that a sample size of approximately 235 men/arm would provide 90% power to detect a difference of 3 points in the Wechsler memory scale, the difference between the 50<sup>th</sup> percentile for 70-75 year old men (17) and that of 45-54 year-old men (20). Based on previous studies showing that about 60% of men over 65 years meet the criteria for AAMI, and an estimated total enrollment of 800, we anticipated having this power.</p><p id="P49">Secondary end points were visual memory, as assessed by the BVRT <sup><xref rid="R49" ref-type="bibr">49</xref></sup>; spatial ability, as assessed by the Card Rotation Test <sup><xref rid="R50" ref-type="bibr">50</xref></sup>; and executive function/working memory, as assessed by the Trail Making Test (TMT) <sup><xref rid="R51" ref-type="bibr">51</xref></sup>.</p><p id="P50">The Wake Forest Cognitive Function Coordinating Center trained, certified and recertified semiannually the site personnel who administered the tests.</p></sec>
24686158|Anemia Trial|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S23"><title>Anemia Trial</title><p id="P51">The primary aim, developed in collaboration with investigators of Partnership for Anemia: Clinical and Translational Trials in the Elderly (PACTTE), was to determine if testosterone treatment would improve unexplained mild to moderate anemia of the elderly, defined as a hemoglobin concentration 10.0-12.7 g/dL not due to nutrient deficiency, renal insufficiency, inflammation, or known hematologic disease. Specific exclusion criteria<sup><xref rid="R52" ref-type="bibr">52</xref>, <xref rid="R53" ref-type="bibr">53</xref></sup> are listed in <xref ref-type="table" rid="T2">Table 2</xref>.</p><p id="P52">Based on data from the first 21 months of enrollment, we estimated that approximately 106 enrollees would have unexplained anemia of the elderly, which would provide 95% power to detect a difference of 1.0 g/dL in hemoglobin<sup><xref rid="R54" ref-type="bibr">54</xref></sup> between the two treatment groups at the end of 12 months of treatment.</p></sec>
24686158|Cardiovascular Trial|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S24"><title>Cardiovascular Trial</title><p id="P53">The primary hypothesis was that testosterone treatment would decrease progression of noncalcified coronary artery plaque volume, as assessed by computed tomography (CT) angiography. Data using similar CT angiography techniques to those employed in this trial indicated that scans at baseline and 12 months for 60 men/arm would be sufficient to give 80% power to detect a 13 mm<sup>3</sup> difference between treatment arms after one year of treatment, a value chosen to be more conservative than the 14 mm<sup>3</sup> treatment effect of statins (Dr. Matthew Budoff, unpublished data). Dr. Budoff trained the site CT technicians who performed the CT angiography.</p><p id="P54">There were no inclusion criteria. Exclusion criteria are listed in <xref ref-type="table" rid="T2">Table 2</xref>.</p></sec>
24686158|Bone Trial|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S25"><title>Bone Trial</title><p id="P55">The primary hypothesis was that testosterone treatment for one year would increase trabecular volumetric bone mineral density (vBMD) of the lumbar spine, measured by quantitative computed tomography (QCT). Assuming that testosterone increases vBMD by 9% in one year <sup><xref rid="R55" ref-type="bibr">55</xref></sup> and the standard error of the change is 3%, we estimated that we should have 90% power with 86 subjects per arm.</p><p id="P56">Secondary outcomes included trabecular vBMD of the hip, areal BMD (aBMD) of the spine and hip by dual energy absorptiometry (DXA), and bone strength of the spine and hip as determined by finite element analysis of the QCT data.</p><p id="P57">ON Diagnostics, the QCT Reading Center, trained the site CT technicians who performed the QCT scans and monitored scan quality. The University of California San Francisco DXA Quality Assurance Group trained the trial site DXA technicians and monitored scan quality.</p><p id="P58">There were no inclusion criteria. Exclusion criteria are listed in <xref ref-type="table" rid="T2">Table 2</xref>.</p></sec>
24686158|Lymphoblastoid Cell Lines|('method', 0.9011508602155676)|('other', 0.09884913978443251)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S26"><title>Lymphoblastoid Cell Lines</title><p id="P59">To allow for subsequent pharmacogenetic studies, lymphoblastoid cell lines were established by Epstein-Barr virus transformation<sup><xref rid="R56" ref-type="bibr">56</xref></sup> for all enrollees who consented. For controls, cell lines were also established on a subset of subjects at the first in person screening visit, most of whom had testosterone values &gt;275 ng/dL.</p></sec>
24686158|None|('method', 0.9749067400037836)|('other', 0.025093259996216255)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Recruitment and Screening</title>
24686158|Recruitment|('method', 0.9749067400037836)|('other', 0.025093259996216255)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S28"><title>Recruitment</title><p id="P60">After more than a year of recruiting using several methods, we found that a much greater number of enrollees came from mass mailings based on gender, age and zip codes, so subsequently we employed this method primarily.</p></sec>
24686158|Screening|('method', 0.9749067400037836)|('other', 0.025093259996216255)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S29"><title>Screening</title><p id="P61">Screening was conducted in three successive steps (<xref ref-type="fig" rid="F2">Figure 2</xref>, <xref ref-type="table" rid="T4">Table 4</xref>):</p><p id="P62">Prescreening was conducted by telephone interview. Men who had a qualifying symptom and did not have a disqualifying disease by history were asked to come to the trial site for the first in-person screening visit.</p><p id="P63">At the first in-person screening visit, subjects had a more detailed medical history and had blood drawn for serum testosterone concentration. If the value was &lt;275 ng/dL, a PSA and comprehensive metabolic panel were measured on saved serum. If the risk of prostate cancer, as determined by the Prostate Cancer Risk Calculator, was sufficiently low, the subject was asked to return for a second in-person screening visit.</p><p id="P64">At the second in-person screening visit, a second measurement of testosterone, digital rectal examination, and other tests were performed to determine if the subject qualified for any of the main trials. Subjects who qualified on the basis of these tests were asked to schedule a baseline visit.</p></sec>
24686158|None|('method', 0.9993306301196131)|('other', 0.0006693698803868457)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Statistical Considerations</title>
24686158|Treatment Blinding|('method', 0.9993306301196131)|('other', 0.0006693698803868457)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S31"><title>Treatment Blinding</title><p id="P65">Several methods were used to maintain blinding. Only the Data Coordinating Center and the Central Pharmacy knew treatment assignment. The testosterone and placebo preparations looked, smelled, and felt the same. When a subject in the testosterone arm was asked to change the dose of gel, a subject in the placebo group was asked to change his dose simultaneously. Clinical sites did not have access to laboratory tests, such as testosterone, PSA, and hemoglobin concentrations, that testosterone treatment might increase.</p></sec>
24686158|Sample Size Considerations|('method', 0.9993306301196131)|('other', 0.0006693698803868457)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S32"><title>Sample Size Considerations</title><p id="P66">We collected primary endpoint data in the three main trials at baseline, 3, 6, 9 and 12 months. Therefore, sample size calculations assumed use of repeated outcome measures. To be conservative, we performed sample size calculations based only on comparisons between baseline and 12-month values. We then inflated each sample size by 5% to compensate for subjects with no post-baseline measures.</p></sec>
24686158|Analytic Methods|('method', 0.9993306301196131)|('other', 0.0006693698803868457)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S33"><title>Analytic Methods</title><p id="P67">Each of the trials is considered a separate trial, so we shall analyze the results of each trial separately. The primary and secondary endpoints of each trial will be evaluated for those subjects who qualified for that trial. Subjects will be analyzed in the group to which they were assigned, regardless of compliance with treatment. Each of the seven trials will be analyzed according to a prespecified analytic plan.</p><p id="P68">Primary analyses of outcomes from all time points will be performed with random effects models for longitudinal data. Logistic models will be used for binary variables and linear models for continuous variables. Outcomes with measures at baseline and 12 months only (Cardiovascular and Bone Trials) will be compared using multivariate logistic regression for binary variables and multivariate linear regression for continuous variables, where models adjust for balancing factors. Dichotomous outcomes, rather than continuous, will be used for analysis of MCIDs to determine not only if testosterone had a statistically significant effect compared with placebo, but also if it had an effect that was of clinical significance. We shall perform sensitivity analyses to assess the potential impact of missing data using shared parameter models, pattern mixture models, and inverse probability weighting. All analyses will be adjusted for baseline balancing factors.</p></sec>
24700577|None|('method', 0.991932223656235)|('other', 0.008067776343765074)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Materials and methods</title>
24700577|2.1. Cartilage specimen preparation|('method', 0.991932223656235)|('other', 0.008067776343765074)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1. Cartilage specimen preparation</title><p id="P8">Hog ankles from eight different individuals (<italic>n</italic> = 8), all males from either York or Barron strains, 5–7 months old and weighing 97–195 kg, were obtained from a local slaughterhouse. The ankles were carefully opened within 24 h of the hogs’ death. The joint compartments were opened (<xref rid="F1" ref-type="fig">Figure 1</xref>), wrapped in Kimwipes, soaked in 0.01 M phosphate-buffered saline (PBS) containing 0.138 M sodium chloride and 0.0027 M potassium chloride, and stored at −20°C (<xref rid="R3" ref-type="bibr">Allen and Athanasiou, 2005</xref>) (storage time &lt; 1 month). Cartilage specimens (thickness 0.901–1.185 mm; <xref rid="F2" ref-type="fig">Figure 2</xref>) were sectioned from the central portion of each ankle of the eight different hogs using a precision diamond saw (Isomet 1000, Buehler, Lake Bluff, IL, USA).</p></sec>
24700577|2.2. Hydrogel specimen preparation|('method', 0.991932223656235)|('other', 0.008067776343765074)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.2. Hydrogel specimen preparation</title><p id="P9">An effort was made to make the hydrogel geometries as similar as possible to the articular cartilage specimen, so as to enable apparent fracture toughness comparisons as closely as possible between cartilage and hydrogels. Gels were synthesized following the basic methods of our previous work (<xref rid="R7" ref-type="bibr">DeKosky <italic>et al.</italic>, 2010</xref>; <xref rid="R12" ref-type="bibr">Ingavle <italic>et al.</italic>, 2012</xref>, <xref rid="R13" ref-type="bibr">2013</xref>). Briefly, 2-hydroxyethyl agarose (type VII) was obtained from Sigma-Aldrich (St. Louis, MO, USA). PEG-DA (MW 6000 Da) was obtained from SunBio (Anyang City, South Korea). The photoinitiator Irgacure 2959 (I-2959) was purchased from Ciba (Basel, Switzerland). Agarose powder (0.2 g) was added to 10 ml PBS and autoclaved for 30 min to yield a 2% w/v agarose solution. When the agarose had cooled to 39°C, it was pipetted into rectangular silicon rubber moulds (10 mm wide × 20 mm long × 1 mm high) between glass plates. After 10 min cooling at 4°C, the gels were removed and added to a reservoir of PBS to equilibrate for at least 24 h before synthesizing PEG-DA and IPNs. A solution of 0.1% w/v I-2959 photoinitiator in deionized (DI) water was dissolved in 20% w/v PEG-DA in PBS at room temperature. One rectangular agarose gel (10 mm width, 20 mm length, 1 mm height) was cut evenly into eight pieces and placed into a 2 ml Falcon tube. 1 ml monomer solution was added into the 2 ml Falcon tube to soak those eight pieces under constant agitation using a rocker for 6 h. The eight soaked pieces were then placed four at a time into a rectangular silicon mould between optical glass microscope slides (four pieces/mould) and the surrounding space was filled with monomer solution. The gels were exposed to ultraviolet light for 5 min on each side, using 312 nm light, 3.0 mW/cm<sup>½</sup> (XL-1000; Spectronics Corp., Lincoln, NE, USA). Four pieces of IPNs/mould were cut using a razor blade. The PEG-DA gels were made by the same exposure procedure, except for filling the moulds with only monomer solution. In total, for each outcome measure, five separate batches of hydrogels were prepared.</p><p id="P10">Hydrogel samples were then trimmed to strips using two razor blades evenly bonded together (distance between the two blades was 1 mm). Each hydrogel strip (1×1×20 mm) was then glued to a piece of marked closed-cell polyurethane foam (<xref rid="R24" ref-type="bibr">Thompson <italic>et al.</italic>, 2003</xref>) (Pacific Research Laboratories, Vashon, WA, 10 pcf) 20 mm wide, 40 mm long and 1 mm thick (<xref rid="F3" ref-type="fig">Figure 3</xref>) with a cyanoacrylate adhesive. This foam is commonly used to model the elastic properties of cancellous bone (<xref rid="R24" ref-type="bibr">Thompson <italic>et al.</italic>, 2003</xref>). The crack was made through the closed-cell foam into the gels with the same series of cutting tools (<xref rid="F4" ref-type="fig">Figure 4</xref>). A new razor blade was used for each sample to maintain a consistent sharp crack tip inside the hydrogel. When pressing the blade, the specimen was cut through to create the crack with a certain part of the hydrogel remaining inside the notch that was not cut. In such a way, crack lengths were reproducible.</p><p id="P11">Care was taken to ensure that hydrogel specimen dimensions matched cartilage specimen dimensions as closely as possible, which we emphasize is important for the current study and for future comparisons back to data obtained here for hydrogels and cartilage.</p><p id="P12">The thickness of the hydrogel (<italic>B</italic>′), the width of the hydrogel (<italic>w</italic>′), the width of the whole specimen (<italic>W</italic>′) and the crack length (<italic>a</italic>′) were measured with a micrometer under a stereomicroscope (~ × 10 magnification).</p></sec>
24700577|2.3. Solids content characterization|('method', 0.991932223656235)|('other', 0.008067776343765074)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.3. Solids content characterization</title><p id="P13">Swelling characteristics and solids content of the hydrogels were analysed to verify their suitability as a three-dimensional (3D) scaffold for tissue engineering, as solids content can help to provide a better understanding and context for mechanical properties. Cylindrical hydrogel constructs (3 mm diameter, ~1.9 mm height) were synthesized for solids content characterization, using the methods described above. Five independent batches were made for each type of hydrogel. The swollen gel mass (<italic>m<sub>s</sub></italic>) was measured after soaking in excess deionized water for 24 h, and the dry gel mass (<italic>m<sub>d</sub></italic>) was measured after drying in a desiccation chamber over calcium sulphate for 72 h. Measurements were made in triplicate (three separate samples) for each batch, using a high-precision balance (Shimadzu Corp., Kyoto, Japan). The swelling degree (<italic>Q</italic>) and solids content were calculated by:<disp-formula id="FD1"><mml:math id="M1" display="block" overflow="scroll"><mml:mi>Q</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:msub><mml:mi>m</mml:mi><mml:mi>s</mml:mi></mml:msub><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub></mml:mfrac><mml:mo>;</mml:mo><mml:mspace width="1em"/><mml:mtext mathvariant="italic">Solids content</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>Q</mml:mi></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></disp-formula></p><p id="P14">The conversion efficiency was evaluated in terms of the conversion of the PEG-DA in the PEG-DA and IPN gels. The conversion percentage of PEG-DA in pure PEG-DA gels was calculated by:<disp-formula id="FD2"><mml:math id="M2" display="block" overflow="scroll"><mml:mo>%</mml:mo><mml:mtext>Conversion of</mml:mtext><mml:mspace width="0.2em"/><mml:mo stretchy="false">(</mml:mo><mml:mtext>PEG</mml:mtext><mml:mo>−</mml:mo><mml:mtext>DA</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.2em"/><mml:mtext>in</mml:mtext><mml:mspace width="0.2em"/><mml:mo stretchy="false">(</mml:mo><mml:mtext>PEG</mml:mtext><mml:mo>−</mml:mo><mml:mtext>DA</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.2em"/><mml:mtext>gels</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo>(</mml:mo><mml:mtext mathvariant="italic">PEG</mml:mtext><mml:mo>−</mml:mo><mml:mtext mathvariant="italic">DA</mml:mtext><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>ϕ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>V</mml:mi></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></disp-formula></p><p id="P15">The denominator represents the theoretical amount of PEG-DA in the gel for 100% conversion efficiency, where <italic>φ</italic><sub>0</sub> is the w/v concentration of PEG-DA solution before photopolymerization (0.2) and <italic>V</italic> is the calculated volume of the preswollen sample, based on the biopsy punch diameter and mould thickness. The conversion of PEG-DA in IPNs was calculated by:<disp-formula id="FD3"><mml:math id="M3" display="block" overflow="scroll"><mml:mo>%</mml:mo><mml:mspace width="0.2em"/><mml:mtext mathvariant="italic">Conversion of</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext mathvariant="italic">PEG</mml:mtext><mml:mo>−</mml:mo><mml:mtext mathvariant="italic">DA</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mtext mathvariant="italic">in IPNs</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mtext mathvariant="italic">IPN</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi>d</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mtext mathvariant="italic">agarose</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi mathvariant="italic">κϕ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>V</mml:mi></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></disp-formula>where the numerator is the estimated mass of PEG-DA in the dried IPN, <italic>κ</italic> is the partition coefficient (assumed to be 1) and the overbar denotes the average value for a given batch. Similarly, the percentage of PEG-DA in dried IPNs was also calculated:<disp-formula id="FD4"><mml:math id="M4" display="block" overflow="scroll"><mml:mo>%</mml:mo><mml:mspace width="0.2em"/><mml:mo stretchy="false">(</mml:mo><mml:mtext mathvariant="italic">PEG</mml:mtext><mml:mo>−</mml:mo><mml:mtext mathvariant="italic">DA</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.2em"/><mml:mtext mathvariant="italic">in dry IPN</mml:mtext><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mtext mathvariant="italic">IPN</mml:mtext><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>m</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi>d</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mtext mathvariant="italic">agarose</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>m</mml:mi><mml:mi>d</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mtext mathvariant="italic">IPN</mml:mtext><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>×</mml:mo><mml:mn>100</mml:mn><mml:mo>%</mml:mo></mml:math></disp-formula></p></sec>
24700577|2.4. Toughness test for articular cartilage|('method', 0.991932223656235)|('other', 0.008067776343765074)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.4. Toughness test for articular cartilage</title><p id="P16">A crack was made through the bone to the cartilage with a series of custom-designed cutting tools (there were three cutting tools with three different notch distances, 0.25, 0.36 and 0.48 mm). The thickness of the specimen (<italic>B</italic>), the width of the articular cartilage (<italic>w</italic>), the width of the whole specimen (<italic>W</italic>) and the crack length (<italic>a</italic>) were then measured with a micrometer under a stereomicroscope (~ × 10 magnification). A new razor blade was used for each specimen to maintain a sharp crack tip. As with the hydrogel specimen preparation, part of the specimen was positioned inside the notch and remained uncut, to ensure that crack lengths were reproducible (<xref rid="F4" ref-type="fig">Figure 4</xref>).</p><p id="P17">Each specimen was then marked (<xref rid="F5" ref-type="fig">Figure 5</xref>), placed in a custom-built bath-grip assembly (<xref rid="R20" ref-type="bibr">Singh and Detamore, 2008</xref>) in an Instron Model 5848 (50 N load cell; Canton, MA), and lined up (<xref rid="F5" ref-type="fig">Figure 5</xref>) in a hydrated environment with PBS at 37°C (<xref rid="F6" ref-type="fig">Figure 6</xref>). For each sample, the crack tip was consistently 30 mm away from the centre of the grips, consistent with gel specimens as noted below. Tensile loading was applied with a displacement rate of 1.5 mm/min until the specimen pulled apart. The ratio <italic>a:W</italic> was varied from 0.95 to 0.98, consistent with gel specimens as noted below.</p></sec>
24700577|2.5. Toughness test for hydrogels|('method', 0.991932223656235)|('other', 0.008067776343765074)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>2.5. Toughness test for hydrogels</title><p id="P18">Five independent batches were made for each hydrogel group (PEG-DA and IPN) to provide a sample size of <italic>n</italic> = 5. Eight samples were tested from each batch. Each specimen was marked, placed in the same custom-built bath-grip assembly in the Instron Model 5848, lined up and immersed in fresh PBS. For each sample, the crack tip was consistently 30 mm away from the centre of the grips, consistent with cartilage specimens as noted above (<xref rid="F7" ref-type="fig">Figure 7</xref>). The same tensile loading was applied with the displacement rate of 1.5 mm/min until the specimen pulled apart. Load and displacement were measured. The ratio <italic>a′:W′</italic> was varied from 0.95 to 0.98, consistent with cartilage specimens as noted above.</p></sec>
24700577|2.6. Calculation of apparent fracture toughness|('method', 0.991932223656235)|('other', 0.008067776343765074)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.6. Calculation of apparent fracture toughness</title><p id="P19">The models from the <xref rid="R4" ref-type="bibr">American Society for Testing and Materials (ASTM) method D 5045–99 (2007)</xref> were adopted. Apparent fracture toughness was characterized as <italic>K<sub>Q</sub></italic> in units of MPa/mm<sup>½</sup>. <italic>K<sub>Q</sub></italic> was calculated as follows:<disp-formula id="FD5"><mml:math id="M5" display="block" overflow="scroll"><mml:msub><mml:mi>K</mml:mi><mml:mi>Q</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo>(</mml:mo><mml:mfrac><mml:msub><mml:mi>P</mml:mi><mml:mi>Q</mml:mi></mml:msub><mml:msup><mml:mi mathvariant="italic">BW</mml:mi><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:msup></mml:mfrac><mml:mo>)</mml:mo><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:math></disp-formula>where 0.2 &lt; <italic>x</italic> &lt;0.8, and <italic>f</italic>(<italic>x</italic>) is defined as follows:<disp-formula id="FD6"><mml:math id="M6" display="block" overflow="scroll"><mml:mi>f</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mi>x</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>0.886</mml:mn><mml:mo>+</mml:mo><mml:mn>4.64</mml:mn><mml:mi>x</mml:mi><mml:mo>−</mml:mo><mml:mn>13.32</mml:mn><mml:msup><mml:mi>x</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mn>14.72</mml:mn><mml:msup><mml:mi>x</mml:mi><mml:mn>3</mml:mn></mml:msup><mml:mo>−</mml:mo><mml:mn>5.6</mml:mn><mml:msup><mml:mi>x</mml:mi><mml:mn>4</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>x</mml:mi><mml:mo>)</mml:mo></mml:mrow><mml:mfrac><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:mfrac></mml:msup></mml:mfrac></mml:math></disp-formula>where <italic>P<sub>Q</sub></italic> = load determined in <xref rid="R4" ref-type="bibr">ASTM D 5045–99 (2007)</xref>, <italic>B</italic> = specimen thickness, <italic>W</italic> = specimen width, <italic>a</italic> = crack length and <italic>x</italic> = <italic>a/W</italic>.</p><p id="P20">Note that, due to the inherent geometry of articular cartilage, neither the range of <italic>a:W</italic> nor the specimen thickness would meet the dimension requirements of the ASTM standard. The use of the undersized specimen results in an overestimation of the actual plane strain fracture toughness. This is recognized as a limitation of the method, but is required because of the physical limitations of the biological material. For this reason, identical geometries are used for comparison tests and the term ‘apparent fracture toughness’ is used to describe the fracture toughness properties.</p></sec>
24700577|2.7. Statistical analyses|('method', 0.991932223656235)|('other', 0.008067776343765074)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>2.7. Statistical analyses</title><p id="P21">To compare experimental groups, a single-factor analysis of variance (ANOVA) was performed, followed by a Tukey’s Honestly Significant Difference <italic>post hoc</italic> test when significance was detected. Analysis was performed using the SPSS/PASW 17.0 statistical software package. All quantitative results were expressed as mean ± standard deviation (SD).</p></sec>
24739533|None|('method', 0.9999965152556302)|('other', 3.4847443697446345e-06)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">METHODS</title>
24739533|Data collection|('method', 0.9999965152556302)|('other', 3.4847443697446345e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Data collection</title><p id="P10">The study sample was children enrolled in the Florida Medicaid program. Throughout the manuscript, we use the terms “children” and “child” to refer to the individuals from the time of birth to their 18<sup>th</sup> birthday (<xref rid="R31" ref-type="bibr">31</xref>). In this Medicaid sample, the majority of families are within 100% of the federal poverty level (FPL), with some participants within 155% of the FPL if the child is between the ages of 2 and 5. To be eligible for study participation, families were required to have 12 months of continuous Medicaid enrollment. For the eligible families, 5,879 phone numbers were available for contact for phone interview. However, 2,873 phone numbers were disconnected, non-working, or fax lines. Of the remaining 3,006 eligible numbers, 908 parents agreed to participate and completed the interview. The overall response rate was 30.2% (i.e., 908/3006). Ages of children were stratified by three strata (2–7, 8–12, and 13–17 years). The survey was conducted through the telephone interview and participants spent between 40 to 50 minutes to complete the survey. This study was approved by the University of Florida Institutional Review Board.</p></sec>
24739533|Survey instruments|('method', 0.9999965152556302)|('other', 3.4847443697446345e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Survey instruments</title><p id="P11">Four pediatric HRQOL instruments (the CHIP, the KIDSCREEN-52, the KINDL and the PedsQL) and the Children with Special Health Care Needs (CSHCN) Screener were administered using parent-proxy reports. The instruments were delivered in the following sequence: the CHIP, the CSHCN, the KIDSCREEN-52, the PedsQL, and the KINDL (Kiddy or Kid/Kiddo). Age-appropriate versions of the instruments were administered for each child. Each instrument was scored according to the developers’ guidelines and all items were scored so that higher scores indicate better HRQOL. The domain scores and the total score were transformed to a 0–100 point scale, with 100 representing the best HRQOL. Missing item information was imputed based on each instrument’s respective guidelines. Because missing on all items was less than 5% for each participant, we retained the entire sample in the analyses (n=908).</p><p id="P12"><xref rid="T1" ref-type="table">Table 1</xref> compares the characteristics of the pediatric HRQOL instruments. Briefly, the CHIP was designed to identify risk populations of poor functional status and HRQOL in epidemiology studies, and to assess the effects of health services and public policy on children’s health outcomes (<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R32" ref-type="bibr">32</xref>). The CHIP contains 5 domains (45 items) including satisfaction (5 items), comfort (12 items), resilience (8 items), risk avoidance (8 items), and achievement (8 items).</p><p id="P13">The KIDSCREEN-52 is the most commonly administered pediatric HRQOL instrument in Europe (<xref rid="R33" ref-type="bibr">33</xref>). The instrument contains 10 domains (52 items): physical well-being (5 items), psychological well-being (6 items), moods and emotions (7 items), self-perception (5 items), autonomy (5 items), parent relationship and home life (6 items), social support and peers (6 items), social acceptance and bullying (3 items), school environment (6 items), and financial resources (3 items).</p><p id="P14">The KINDL was developed to assess HRQOL among healthy and chronically or acutely ill children (<xref rid="R11" ref-type="bibr">11</xref>). The instrument has two versions (i.e., Kiddy KINDL (4–7 years of age) and the Kid/Kiddo KINDL (8–16 years of age)) with different wordings for the friends and school functioning domains. Each version has six domains, each with four items: physical well-being, psychological well-being, self-esteem, family functioning, friends (or named social functioning in Kiddy KINDL), and school functioning (or named everyday functioning relevant to nursery school/kindergarten in Kiddy KINDL).</p><p id="P15">The PedsQL 4.0 was developed to assess the World Health Organization’s core concept of health (physical, emotional, and social functioning) plus school functioning for children (<xref rid="R12" ref-type="bibr">12</xref>). This instrument contains 23 items measuring problems of performing daily functioning over the past month. The four domains include physical functioning (8 items), emotional functioning (5 items), social functioning (5 items), and school functioning (3 items for 2–4 years of age, and 5 items for 5–18 years of age).</p><p id="P16">The CSHCN screener (<xref rid="R34" ref-type="bibr">34</xref>) was administered to assess known-groups validity for the HRQOL instruments. Known-groups validity is described in the Statistical Analysis section. A child with special health care needs is defined as having a chronic condition (i.e. allergies, asthma, and/or attention deficit disorder) and requiring health-related services beyond a child’s normal requirements. This screener is comprised of 5 question sequences evaluating the presence and duration of health conditions. It uses a primary health consequence item to determine whether the “sub-items” need to be answered. The screener is comprised of 3 domains: dependency on prescription medications, service use above routine levels, and functional limitations. If the parent responds “yes” to a primary health consequence item, then 2 follow-up items are asked to determine if the consequence is due to a medical or health condition and whether the duration or expected duration is 12 months or longer. Both follow-up items must be answered “yes” to qualify the child as a CSHCN.</p></sec>
24739533|Statistical analyses|('method', 0.9999965152556302)|('other', 3.4847443697446345e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Statistical analyses</title><p id="P17">Comparisons across the four instruments were performed based on standard psychometric methods, including distribution of domain scores, reliability, structural validity, convergent/discriminant validity, and known-groups validity.</p><p id="P18">To examine the distribution of domain scores, summary measures (mean, standard deviation, range, 25 percentile, 50 percentile, and 75 percentile) of each domain in the four instruments were calculated. In addition, floor and ceiling effects were examined to determine whether the domain scores are collapsed at the extreme ends of the domain. Ceiling effect refers to when scores are at the maximum possible value for a domain, and floor effect refers to when scores are at the minimum possible value for a domain. The Shapiro-Wilk method was used to test the normality of domain score distribution. Cronbach’s alpha coefficients were calculated to represent the internal consistency of the domains. If the alpha coefficient of a domain is above 0.7, it is deemed acceptable for the purpose of group comparisons (<xref rid="R35" ref-type="bibr">35</xref>).</p><p id="P19">Structural validity refers to how well operationalized items measure the theoretical domains (i.e., factorial structure) of HRQOL within each instrument. We used confirmatory factor analysis (CFA) to confirm the constructs of individual HRQOL domains in each instrument. We used two fit indices to determine an acceptable goodness-of-fit, including the Comparative Fit Index (CFI &gt;0.95) and Root Mean Square Error of Approximation (RMSEA &lt;0.06) (<xref rid="R36" ref-type="bibr">36</xref>).</p><p id="P20">Convergent/discriminant validity refers to how well the domains of the target instruments are associated with domains of well-established instruments. We evaluated the convergent and discriminant validity based on the multitrait-multimethod (MTMM) that demonstrates the correlation between homogenous and heterogeneous domains of each instrument (<xref rid="R37" ref-type="bibr">37</xref>). For example, homogenous domains between instruments would be physical functioning of the PedsQL and physical well-being of the KIDSCREEN-52. Heterogeneous domains would be the psychological domain of the KIDSCREEN-52 and the achievement of the CHIP. Specifically, we calculated Spearman’s rank coefficients to account for non-normality of the data. In the present study, the PedsQL was chosen as the anchor because this instrument measures the concept of health suggested by the World Health Organization (<xref rid="R38" ref-type="bibr">38</xref>). The domains of the PedsQL (physical, emotional, social and school functioning) capture generic and basic functional status for general children population and are almost all included in other three HRQOL instruments. The PedsQL can be used by the broadest age range of children (2 to 18 years old) compared to other three instruments. Correlations among the domains of the PedsQL (anchor instrument) and the CHIP, the KIDSCREEN-52, and the KINDL (as target instruments) were compared. Moderate (r = 0.50–0.69) to strong (r ≥0.7) correlations among homogenous domains of the target and the anchor instrument indicate good convergent validity. In contrast, small (r = 0.30–0.49) or negligible (r &lt;0.30) correlations among heterogeneous domains of the target and the anchor instrument indicate good discriminant validity (<xref rid="R39" ref-type="bibr">39</xref>).</p><p id="P21">Known-groups validity refers to the extent to which the mean domain scores of each instrument can discriminate between clinically meaningful groups (i.e., CSHCN status) which are known to differ in the underlying HRQOL construct being investigated (<xref rid="R40" ref-type="bibr">40</xref>). Bivariate and multivariate linear regression were used to examine the mean difference in HRQOL scores between groups with and without adjusting for covariates (i.e., parent age, child age, sex, income and education). Huber-White robust standard errors were used to account for non-normality in the distribution of HRQOL scores. Effect sizes (ES) were calculated by using the difference in domain scores between CSHCN and those without needs and dividing by pooled standard deviation. Cohen’s d criteria were used (&lt;0.2 as negligible, 0.2–0.49 as small, 0.5–0.79 as moderate, and &gt;0.8 as large) to determine the magnitude of ES (<xref rid="R41" ref-type="bibr">41</xref>).</p><p id="P22">As part of known-groups validity, we calculated relative validity (RV) to examine the extent to which an instrument is more efficient (i.e., more systematic variation is explained by the items relative to variation due to error) versus the other instruments (<xref rid="R42" ref-type="bibr">42</xref>, <xref rid="R43" ref-type="bibr">43</xref>). Essentially, RV compares two or more instruments’ ability to discriminate between participants’ varying levels of the underlying HRQOL. To determine the RV for a domain of an instrument, the F-statistics (squared t-statistics) of individual domains were contrasted against the domain with the lowest F-statistic (<xref rid="R42" ref-type="bibr">42</xref>, <xref rid="R44" ref-type="bibr">44</xref>). Linear regression with robust standard errors, using domain score as the dependent variable and CSHCN status as the independent variable, was applied to obtain F-statistics (<xref rid="R45" ref-type="bibr">45</xref>). A domain of one instrument demonstrating a higher ratio of F-statistics represents superior RV to the other domains. STATA version 9 (<xref rid="R46" ref-type="bibr">46</xref>) was used for all analyses.</p></sec>
24739533|None|('method', 0.9590535080663006)|('other', 0.04094649193369937)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
24739533|None|('method', 0.9590535080663006)|('other', 0.04094649193369937)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><media xlink:href="NIHMS574450-supplement-supplement_1.pdf" orientation="portrait" xlink:type="simple" id="d37e512" position="anchor"/></supplementary-material>
24748682|None|('method', 0.9747235836503394)|('other', 0.025276416349660644)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I. A Model</title>
24748682|None|('method', 0.9747235836503394)|('other', 0.025276416349660644)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">We begin by presenting a stylized model of individual coverage choice and healthcare utilization. The model allows us to more precisely define the objects that we focus on, “moral hazard” and “selection on moral hazard.” The model will also be the main ingredient in our subsequent econometric specification and counterfactual exercises.</p>
24748682|A. A model of coverage choice and utilization|('method', 0.9747235836503394)|('other', 0.025276416349660644)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S2"><title>A. A model of coverage choice and utilization</title><p id="P17">We consider a two period model, which is designed to allow us to isolate and examine three potential determinants of insurance coverage choice: risk aversion, expected healthcare needs, and the incremental health spending that is driven by insurance coverage. In the first period, a risk-averse expected-utility maximizing individual makes an optimal health insurance coverage choice, using his available information to form his expectation regarding his subsequent health realization. In the second period, the individual observes his realized health and makes an optimal healthcare utilization decision, which depends on realized health as well as his coverage.<xref ref-type="fn" rid="FN2">2</xref></p><p id="P18">We begin with notation. This is a model of individual behavior, so we omit <italic>i</italic> subscripts to simplify notation; in Section IV we describe how individuals may vary. At the time of his utilization choice (period 2), an individual is characterized by two objects: his health realization λ, and his price sensitivity ω. λ captures the uncertain aspect of demand for healthcare, with higher λ representing sicker individuals who demand greater healthcare consumption. The parameter ω determines how responsive healthcare utilization decisions are to insurance coverage. In other words, ω affects the individual’s price elasticity of demand for healthcare with respect to its (out of pocket) price; individuals with higher ω increase their utilization more sharply in response to more generous insurance coverage. The focus of the paper will be on how plan choice varies with ω. That is, ω is the object that we refer to as moral hazard, although we defer a more detailed discussion of its interpretation until after the description of the model.</p><p id="P19">At the time of coverage choice (period 1), an individual is characterized by three objects: <italic>F</italic><sub>λ</sub>(·), ω, and ψ. The first, <italic>F</italic><sub>λ</sub>(·), represents the individual’s expectation about his subsequent health risk λ. It is precisely because individuals do not know λ with certainty at the time of coverage choice that they demand insurance. The second object is ω, which determines the individual’s period 2 price elasticity of demand for healthcare. Because individuals are forward looking, they anticipate that ω will subsequently affect their utilization choices, and this in turn affects their utility from different coverages. It is this channel that creates the potential for selection on moral hazard, which is the main focus of our paper. Finally, the third object is ψ, which captures the individual’s coefficient of absolute risk aversion. Importantly, unlike ω and <italic>F</italic><sub>λ</sub>(·) that enter the coverage choice and also affect utilization decisions, risk preferences affect coverage choice but do not directly affect utilization.</p><sec id="S3"><title>Utilization choice</title><p id="P20">In the second period, insurance coverage, denoted by <italic>j</italic>, is taken as given. We assume that the individual’s healthcare utilization decision is made in order to maximize a tradeoff between health and money. Specifically, we assume that the individual’s second period utility is separable in health and money and can be written as <italic>u</italic>(<italic>m</italic>; λ, ω) = <italic>h</italic>(<italic>m</italic> − λ; ω) + <italic>y</italic>(<italic>m</italic>), where <italic>m</italic> ≥ 0 is the monetized utilization choice, λ is the monetized health realization, and <italic>y</italic>(<italic>m</italic>) is the residual income. Naturally, <italic>y</italic>(<italic>m</italic>) is decreasing in <italic>m</italic> at a rate that depends on coverage. We further assume that <italic>h</italic>(<italic>m</italic> − λ; ω) is concave in its first argument: it is increasing for low levels of utilization (when treatment improves health) and is decreasing eventually (when there is no further health benefit from treatment and time costs dominate). Thus, the marginal benefit from incremental utilization is decreasing. Using this formulation, we think of λ, the underlying health realization, as shifting the level of optimal utilization <italic>m</italic><sup>*</sup>. Finally, we assume that <italic>h</italic>(<italic>m</italic> − λ; ω) is increasing in its second argument, but this is purely a normalization which (as we will see below) allows us to interpret individuals with higher ω as those who are more elastic with respect to the price of medical utilization.</p><p id="P21">We parametrize further so that the second-period utility function is given by<disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>;</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munder><mml:munder><mml:mrow><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn><mml:mi>ω</mml:mi></mml:mrow></mml:mfrac><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">︸</mml:mo></mml:munder><mml:mrow><mml:mi>h</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mo>;</mml:mo><mml:mi>ω</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mo>+</mml:mo><mml:munder><mml:munder><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mi>y</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mo stretchy="true">︸</mml:mo></mml:munder><mml:mrow><mml:mi>y</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:munder><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>That is, we assume that <italic>h</italic>(<italic>m</italic> − λ; ω) is quadratic in its first argument, with ω affecting its curvature. We also explicitly write the residual income as the initial income <italic>y</italic> minus the premium <italic>p<sub>j</sub></italic> associated with coverage <italic>j</italic> and the out-of-pocket expenditure <italic>c<sub>j</sub></italic>(<italic>m</italic>) associated with utilization <italic>m</italic> under coverage <italic>j</italic>. Given this parameterization, the optimal utilization is given by<disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mi>m</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mtext>arg </mml:mtext><mml:munder><mml:mtext>max</mml:mtext><mml:mrow><mml:mi>m</mml:mi><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:munder><mml:mspace width="thinmathspace"/><mml:mi>u</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>;</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>which gives rise to the realized utility <italic>u</italic><sup>*</sup>(λ, ω, <italic>j</italic>) ≡ <italic>u</italic>(<italic>m</italic><sup>*</sup>(λ, ω, <italic>j</italic>); λ, ω, <italic>j</italic>).</p><p id="P22">To facilitate intuition, we consider here optimal utilization for the case of a linear coverage contract, so that <italic>c<sub>j</sub></italic>(<italic>m</italic>) = <italic>c</italic>·<italic>m</italic>, with <italic>c</italic> ∈ [0, 1] (in the empirical application below we explicitly account for the non-linear coverage contracts offered in the data). Full insurance is given by <italic>c</italic> = 0 and no insurance is given by <italic>c</italic> = 1. The first order condition implied by <xref ref-type="disp-formula" rid="FD2">equation (2)</xref> is given by 1 − (<italic>m</italic> − λ)/ω − <italic>c</italic> = 0, or<disp-formula id="FD3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mi>m</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mtext>max </mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mi>λ</mml:mi><mml:mo>+</mml:mo><mml:mi>ω</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>Abstracting from the potential truncation of utilization at zero, the individual will optimally choose <italic>m</italic><sup>*</sup> = λ with no insurance (when <italic>c</italic> = 1) and <italic>m</italic><sup>*</sup> = λ + ω with full insurance (when <italic>c</italic> = 0). Thus, ω can be thought of as the incremental utilization that is attributed to the change in coverage from no insurance to full insurance. One way to think about this model, therefore, is that λ represents non-discretionary healthcare shocks that the individual will pay to treat, regardless of insurance. In addition, there exist discretionary healthcare utilization which without insurance will not be undertaken. With insurance, some amount of this discretionary care will be consumed, and this incremental amount is increasing in ω.<xref ref-type="fn" rid="FN3">3</xref></p></sec><sec id="S4"><title>Coverage choice</title><p id="P23">In the first period, the individual faces a fairly standard insurance coverage choice. As mentioned, we assume that the individual is an expected-utility maximizer, with a coefficient of absolute risk aversion of ψ. We further assume that the individual’s von Neumann Morgenstern (vNM) utility function is of the constant absolute risk aversion (CARA) form, <italic>w</italic>(<italic>x</italic>) = −exp(−ψ<italic>x</italic>). In a typical insurance setting <italic>w</italic>(<italic>x</italic>) is defined solely over financial outcomes. However, because moral hazard is present, <italic>w</italic>(<italic>x</italic>) is defined over the realized second-period utility <italic>u</italic><sup>*</sup>(λ, ω, <italic>j</italic>).</p><p id="P24">Consider now a set of coverage options <italic>J</italic>, with each option <italic>j</italic> ∈ <italic>J</italic> defined by its premium <italic>p<sub>j</sub></italic> and coverage function <italic>c<sub>j</sub></italic>(<italic>m</italic>). Following the above assumptions, the individual will then evaluate his expected utility from each option,<disp-formula id="FD4"><label>(4)</label><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>υ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo>−</mml:mo><mml:mstyle displaystyle="true"><mml:mo stretchy="true">∫</mml:mo></mml:mstyle><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mi>ψ</mml:mi><mml:msup><mml:mi>u</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mtext mathvariant="italic">dF</mml:mtext><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>with his optimal coverage choice given by<disp-formula id="FD5"><label>(5)</label><mml:math id="M5" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mtext>arg </mml:mtext><mml:munder><mml:mtext>max</mml:mtext><mml:mrow><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mi>J</mml:mi></mml:mrow></mml:munder><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>υ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p id="P25">Willingness to pay for more coverage is generally increasing in risk aversion ψ and in risk <italic>F</italic><sub>λ</sub>(·) (in a first order stochastic dominance sense).<xref ref-type="fn" rid="FN4">4</xref> Given our specific parametrization, willingness to pay for more coverage is also increasing in ω, thus possibly generating what we term as selection on moral hazard.<xref ref-type="fn" rid="FN5">5</xref></p></sec></sec>
24748682|B. Interpreting ω as moral hazard|('method', 0.9747235836503394)|('other', 0.025276416349660644)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>B. Interpreting ω as moral hazard</title><p id="P26">As noted, our focus is on the parameter ω and on its importance in driving coverage choice. We think of ω as moral hazard and of its relationship with coverage choice as selection on moral hazard. Given the varying ways by which the term moral hazard has been used (and abused) in economics in general and in the context of health insurance in particular, it seems useful to discuss the interpretation of ω and why we think it may be appropriate to refer to it as moral hazard.</p><p id="P27">Traditional models of adverse selection in health insurance focus on the possibility that sicker individuals will choose greater health insurance coverage. This source of selection is captured in our model by the fact that individuals with greater <italic>F</italic><sub>λ</sub>(·) (in a first-order stochastic dominance sense) purchase greater coverage. The key conceptual distinction we are interested in is the possibility that selection may be driven not only by the level of expected health care spending, but also by its “slope,” or by how healthcare spending changes with insurance coverage. In other words, we are interested in health insurance choices (selection) that are effected by the incremental medical expenditure that is associated with increased coverage. We refer to this incremental spending, captured in the model by ω, as moral hazard and to selection on it as selection on moral hazard. Just like traditional selection, which would lead to adverse selection (sicker individuals are willing to pay more for insurance and at the same time are associated with greater expected cost to the insurance company), in our model selection on moral hazard is also adverse in the sense that higher moral hazard individuals are willing to pay more for the same amount of coverage and will also be more expensive for the insurance company. Thus, we view selection on moral hazard as one possible component of the overall adverse selection.</p><p id="P28">The use of the term moral hazard to refer to the responsiveness of healthcare spending to insurance coverage dates back at least to <xref rid="R2" ref-type="bibr">Arrow (1963)</xref>. Consistent with the notion of hidden action, which is typically associated with the term moral hazard, it has been conjectured that health insurance may induce individuals to exert less (unobserved) effort in maintaining their health (e.g., <xref rid="R21" ref-type="bibr">Ehrlich and Becker 1972</xref>). However, in the context of health insurance the term moral hazard is often used to refer to the price elasticity of demand for healthcare, conditional on underlying health status (<xref rid="R35" ref-type="bibr">Pauly 1968</xref>; <xref rid="R14" ref-type="bibr">Cutler and Zeckhauser 2000</xref>). We thus follow this abuse of terminology and use the term in a similar way. In other words, our model, like most in this literature, does not consider the potential impact of insurance on underlying health λ. As a result, the asymmetric information problem that we associate with moral hazard is arguably more accurately described as one of hidden information (rather than of hidden action). The individual’s actions (utilization) are observed and contractible, but his underlying health λ and his price sensitivity ω are unknown to the insurer. For our purposes, whether the problem is one of hidden information or hidden action is simply an issue of appropriate usage of terminology, and here we simply follow convention.</p><p id="P29">Our model is designed for conceptual clarity and analytical tractability, both of which come at the cost of not explicitly modeling the underlying primitives that give rise to ω. An individual’s incremental utilization response to increased insurance coverage (ω) is presumably driven by a number of “deeper” primitives including his value of time (income) and disutility of doctor visits. It may also relate to the severity and nature of his underlying health conditions – some of which are more likely to be price inelastic than others – as well as to one’s risk aversion regarding future health conditions.<xref ref-type="fn" rid="FN6">6</xref></p><p id="P30">Also for clarity and tractability, we chose to model ω as a level shift in spending that is (except due to the truncation of spending at zero) independent of one’s health (λ) (see, e.g., <xref ref-type="disp-formula" rid="FD3">equation (3)</xref>). Our choice of the utility function in <xref ref-type="disp-formula" rid="FD1">equation (1)</xref> is designed to achieve a simple economic interpretation of the key parameters of interest in the first order condition <xref ref-type="disp-formula" rid="FD3">(3)</xref>, so that λ (health status) is the monetized health spending without insurance (i.e., one’s nondiscretionary spending) and ω captures incremental, discretionary spending as individuals are moved from no insurance to full insurance. This allows us to straightforwardly measure and compare the magnitude of (and heterogeneity in) health risk λ and moral hazard ω.</p><p id="P31">It is not a priori obvious whether or not moral hazard affects individuals in a manner that is additively separable from their health. On the one hand, it seems plausible that seeking care for a minor skin irritation may be unaffected by one’s overall severity of illness. On the other hand, one could also imagine that changes in medical care utilization in response to insurance coverage would depend on one’s underlying health; for example, sicker individuals have more occasions to exercise moral hazard.<xref ref-type="fn" rid="FN7">7</xref> In principle, our setting does not preclude this. Although we do not explicitly model this complementarity “within” an individual, our empirical specification below will allow for this relationship by modeling a cross-sectional distribution with an arbitrary correlation between moral hazard and health risk. Thus, a multiplicative model, for example, can be approximated by simply relabeling a multiplicative moral hazard effect ω′ to be equal to ω/λ. The key modeling assumption is therefore not the additive separable relationship, but rather the fact that all uncertainty at the time of coverage choice is about health (λ), while moral hazard (ω) is assumed to be known at the time of coverage choice.<xref ref-type="fn" rid="FN8">8</xref></p></sec>
24748682|None|('method', 0.930539569788253)|('other', 0.06946043021174687)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IV. Econometric Specification</title>
24748682|A. Parameterization|('method', 0.930539569788253)|('other', 0.06946043021174687)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S14"><title>A. Parameterization</title><p id="P54">We now turn to specify a more complete econometric model that is based on the economic model of individual coverage choice and utilization developed in Section I. This will allow us to jointly estimate coverage choices and utilization, relate the estimated parameters of the model to underlying economic objects of interest, and quantify how spending and welfare may be affected under various counterfactuals. The additional modeling assumptions in this section are of two different natures. First, we will need to specify more parametrically some of the objects introduced earlier (e.g., individuals’ beliefs <italic>F</italic><sub>λ</sub>(·)). Second, we need to specify what form of heterogeneity we allow across individuals, and for a given individual over time.</p><p id="P55">Our unit of observation is an employee <italic>i</italic>, in a given year <italic>t</italic>. We abstract from the specifics of the timing and nature of claims, and, as we have done so far, simply code utilization <italic>m<sub>it</sub></italic> as the total medical spending (in dollars) for the entire year. The individual faces the choice set of either the original plan options or the new plan options (as described in <xref ref-type="table" rid="T2">Table 2</xref>), depending on the year and the employee’s union affiliation, which dictates whether and when he was switched to the new benefits options.</p><p id="P56">Using the model of Section I, recall that individuals are defined by three objects: their beliefs about their subsequent health status <italic>F</italic><sub>λ</sub>(·), their moral hazard parameter ω, and their risk aversion ψ. We assume that ω<sub><italic>i</italic></sub> and ψ<sub><italic>i</italic></sub> may vary across employees, but are constant for a given employee over time. It is the potential heterogeneity in ω<sub><italic>i</italic></sub> which is the focus of the paper. We also assume that <italic>F</italic><sub>λ</sub>(·) is a (shifted) lognormal distribution with parameters μ<sub>λ,<italic>it</italic></sub>, σ<sub>λ,<italic>i</italic></sub>, with support (κ<sub>λ,<italic>i</italic></sub>, ∞), as explained below. That is, beliefs about health also vary across employees, and we allow μ<sub>λ,<italic>it</italic></sub> to be time varying to reflect the possibility that information about one’s health evolves with time.</p><p id="P57">At the time of coverage choice individuals believe that<disp-formula id="FD6"><label>(6)</label><mml:math id="M6" display="block" overflow="scroll"><mml:mrow><mml:mtext>log </mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mtext mathvariant="italic">it</mml:mtext></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:mo>~</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="italic">it</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>and these beliefs are correct. Assuming a lognormal distribution for λ is natural, as the distribution of annual health expenditures is highly skewed (<xref ref-type="fig" rid="F1">Figure 1</xref>). The additional parameter κ<sub>λ,<italic>i</italic></sub> is used in order to capture the significant fraction of individuals who have no spending over an entire year. When κ<sub>λ,<italic>i</italic></sub> is negative, the support of the implied distribution of λ<sub><italic>it</italic></sub> is expanded, allowing for λ<sub><italic>it</italic></sub> to obtain negative values, which in turn implies (when ω<sub><italic>i</italic></sub> is not too large) zero spending. The parameter σ<sub>λ,<italic>i</italic></sub> indicates the precision of the individual’s information about his subsequent health.</p><p id="P58">It is the heterogeneity in μ<sub>λ,<italic>it</italic></sub>, σ<sub>λ,<italic>i</italic></sub>, and κ<sub>λ,<italic>i</italic></sub> that gives rise to the traditional form of adverse selection on the basis of expected health, i.e. on the basis of expected λ (denoted λ̅) which is given by<disp-formula id="FD7"><label>(7)</label><mml:math id="M7" display="block" overflow="scroll"><mml:mrow><mml:mi>λ̅</mml:mi><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>σ</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mtext>exp </mml:mtext><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mn>2</mml:mn></mml:mfrac><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>λ</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>That is, higher μ<sub>λ,<italic>it</italic></sub>, σ<sub>λ,<italic>i</italic></sub>, or κ<sub>λ,<italic>i</italic></sub> are all associated with higher expected λ, which all else equal leads to greater expected medical spending and greater cost by the insurance provider. All else equal, individuals with higher μ<sub>λ,<italic>it</italic></sub>, σ<sub>λ,<italic>i</italic></sub>, or κ<sub>λ,<italic>i</italic></sub> also prefer to choose greater coverage, thus giving rise to adverse selection.</p><p id="P59">Let <italic>x<sub>it</sub></italic> denote a vector of observables which are taken as given, and let <inline-formula><mml:math id="M8" overflow="scroll"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> denote their within-individual average. In order to link the latent variables to observables, we make several parametric assumptions. First, we assume that log ω<sub><italic>i</italic></sub>, log ψ<sub><italic>i</italic></sub>, and <inline-formula><mml:math id="M9" overflow="scroll"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> (which denotes the average (over time) of μ<sub>λ,<italic>it</italic></sub> for individual <italic>i</italic>) are drawn from a jointly normal distribution, such that<xref ref-type="fn" rid="FN23">23</xref><disp-formula id="FD8"><label>(8)</label><mml:math id="M10" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:mtext>log </mml:mtext><mml:msub><mml:mi>ω</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:mtext>log </mml:mtext><mml:msub><mml:mi>ψ</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mspace width="thinmathspace"/><mml:mo>~</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>N</mml:mi><mml:mspace width="thinmathspace"/><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover><mml:msub><mml:mi>β</mml:mi><mml:mi>λ</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover><mml:msub><mml:mi>β</mml:mi><mml:mi>ω</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover><mml:msub><mml:mi>β</mml:mi><mml:mi>ψ</mml:mi></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mrow><mml:mtable><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>μ̄</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ω</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>μ</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="center"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ψ</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow></mml:mrow><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p><p id="P60">We then assume a random effects structure on μ<sub><italic>it</italic></sub>: we let μ<sub><italic>it</italic></sub> vary over time, but assume that it is correlated within an employee, so that<disp-formula id="FD9"><label>(9)</label><mml:math id="M11" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="italic">it</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mtext mathvariant="italic">it</mml:mtext></mml:msub><mml:mo>−</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover><mml:mo stretchy="false">)</mml:mo><mml:mspace width="thinmathspace"/><mml:msub><mml:mi>β</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="italic">it</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where ε<sub>λ,<italic>it</italic></sub> is an i.i.d. normally distributed error term, with variance <inline-formula><mml:math id="M12" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ε</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>. The variance of μ<sub>λ,<italic>it</italic></sub> is then <inline-formula><mml:math id="M13" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>μ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>μ̄</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>ε</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>. Finally, we assume that<disp-formula id="FD10"><label>(10)</label><mml:math id="M14" display="block" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mspace width="thinmathspace"/><mml:mo>~</mml:mo><mml:mspace width="thinmathspace"/><mml:mi mathvariant="normal">Γ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mn mathvariant="bold">1</mml:mn><mml:mo stretchy="false">{</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>≤</mml:mo><mml:msup><mml:mi>σ̄</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:math></disp-formula>and that<disp-formula id="FD11"><label>(11)</label><mml:math id="M15" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mspace width="thinmathspace"/><mml:mo>~</mml:mo><mml:mspace width="thinmathspace"/><mml:mi>N</mml:mi><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover><mml:msub><mml:mi>β</mml:mi><mml:mi>κ</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>κ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>That is, <inline-formula><mml:math id="M16" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> is drawn from a right truncated inverse gamma distribution, and κ<sub>λ,<italic>i</italic></sub> is drawn from a normal distribution, and both are drawn independently from the other latent variables.</p><p id="P61">Thus, overall we estimate four vectors of mean shifters (β<sub>λ</sub>,β<sub>ω</sub>,β<sub>ψ</sub>,β<sub>κ</sub>), eight variance and covariance parameters (σ<sub>μ</sub>, σ<sub>ε</sub>, σ<sub>ω</sub>,σ<sub>ψ</sub>,σ<sub>κ</sub>,σ<sub>μ,ω</sub>, σ<sub>μ,ψ</sub>,σ<sub>ω,ψ</sub>), and two additional parameters (γ<sub>1</sub>, γ<sub>2</sub>) that determine the distribution of <inline-formula><mml:math id="M17" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow><mml:mrow><mml:mo>−</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula>. Of course, an important decision is what observables <inline-formula><mml:math id="M18" overflow="scroll"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> shift which primitive, and whether we would like any observables to be excluded from one or more of the (four) equations. To pay particular attention to the underlying variation emphasized in Section II, in all the specifications we experiment with, we include in <inline-formula><mml:math id="M19" overflow="scroll"><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">¯</mml:mo></mml:mover></mml:mrow></mml:math></inline-formula> treatment group fixed effects for each of the four treatment groups (see <xref ref-type="table" rid="T1">Table 1</xref>), as well as a year fixed effect on μ<sub>λ,<italic>it</italic></sub>, the only time varying latent variable. We also include coverage tier fixed effects since both the choice sets and spending varies substantially by coverage tier (see <xref ref-type="table" rid="T2">Table 2</xref> and <xref ref-type="fig" rid="F1">Figure 1</xref>, respectively), and a rich set of demographics, specifically age, gender, job tenure, income, and health risk scores.</p></sec>
24748682|B. Estimation|('method', 0.930539569788253)|('other', 0.06946043021174687)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S15"><title>B. Estimation</title><p id="P62">We estimate the model using Markov Chain Monte Carlo (MCMC) Gibbs sampling. The multi-dimensional unobserved heterogeneity naturally lends itself to such methods, as the iterative sampling allows us to avoid evaluating multi-dimensional integrals numerically, which is computationally cumbersome. The key observation is that the model we developed is sufficiently flexible so that we can augment the latent variables into the model and formulate a hierarchical statistical model. To see this, let θ<sub>1</sub> = {β<sub>λ</sub>, β<sub>ω</sub>, β<sub>ψ</sub>, β<sub>κ</sub>; σ<sub>μ</sub>, σ<sub>ε</sub>, σ<sub>ω</sub>, σ<sub>ψ</sub>, σ<sub>κ</sub>, σ<sub>μ,ω</sub>, σ<sub>μ,ψ</sub>, σ<sub>ω,ψ</sub>; γ<sub>1</sub>, γ<sub>2</sub>} be the set of parameters we are interested in, and let <inline-formula><mml:math id="M20" overflow="scroll"><mml:mrow><mml:msub><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mtext mathvariant="italic">it</mml:mtext></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mtext mathvariant="italic">it</mml:mtext></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>σ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>κ</mml:mi><mml:mrow><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>ω</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>ψ</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>2003</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>N</mml:mi><mml:mo>,</mml:mo><mml:mi>t</mml:mi><mml:mo>=</mml:mo><mml:mn>2004</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:math></inline-formula> be the set of employee-year latent variables. The model is set up so that, even conditional on θ<sub>1</sub>, we can always rationalize the observed data – namely, plan choice and medical utilization – by appropriately finding a set of latent variables for each individual, θ<sub>2</sub>.</p><p id="P63">Thus, the iterative procedure is straightforward. We can first sample from the distribution of θ<sub>1</sub> conditional on θ<sub>2</sub>. Because, conditional on θ<sub>2</sub>, there is no additional information in the data about θ<sub>1</sub>, this part of the sampling is simple and quite standard. Then, we can sample from the distribution of θ<sub>2</sub> conditional on θ<sub>1</sub> and the information available in the data. This latter step is of course more customized toward our specific model, but does not introduce any conceptual difficulties. The full sampling procedure, the specific prior distributions we impose, and the resultant posteriors are described in detail in Appendix D. We verified using Monte Carlo simulations that the procedure works effectively, and is robust to initial values. For our baseline results, the estimation appears to converge after about 5,000 iterations of the Gibbs sampler, so we drop the first 10,000 draws and use the last 10,000 draws of each parameter to report our results. The results we report are based on the posterior mean and posterior standard deviation from these 10,000 draws.</p><p id="P64">One important difficulty that our model introduces is related to our decision to not allow for an additive separable plan-specific error term. It is extremely common in applications of discrete choice (such as ours) to add such error terms, and often to assume that they are distributed i.i.d. across plans and individuals. Such error terms serve two important roles. First, they allow the researcher to rationalize any choice observed in the data through a large enough error term. Second, their independence makes the objective function of any M-estimator smooth, which is computationally attractive for numerical optimization. In the context of our application, however, we view such error terms as economically unappealing. The options from which individuals in our sample choose are financially rankable and are identical in their non-financial features. This makes one wonder what such error terms would capture that is outside of our model. The clear ranking of the options also makes the i.i.d. nature of the error terms not very appealing. Instead, we introduce a fair amount of heterogeneity along the other dimensions of our model. Some of this heterogeneity (e.g., the heterogeneity in σ<sub>λ,<italic>i</italic></sub> and κ<sub>λ,<italic>i</italic></sub>) is richer than the minimum required to capture the key economic forces we would like to capture, but this richness is what allows us to rationalize all observed choices in the data. This still leads to a model which is not very attractive for numerical optimization, which is one important reason why we use Gibbs sampling.<xref ref-type="fn" rid="FN24">24</xref></p></sec>
24748682|C. Identification|('method', 0.930539569788253)|('other', 0.06946043021174687)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S16"><title>C. Identification</title><p id="P65">We now discuss the identification of the model. Conditional on the individual-behavior model described in Section I, the object of interest that we seek to identify is the joint distribution of <italic>F</italic><sub>λ</sub>(·), ω, and ψ. We have data on individuals’ health insurance options, choices, and medical spending. Throughout the paper we make the strong assumption that individual beliefs about their subsequent health status (<italic>F</italic><sub>λ</sub>(·)) are correct.<xref ref-type="fn" rid="FN25">25</xref></p><p id="P66">The model and its identification share many properties with some of our earlier work on insurance (<xref rid="R13" ref-type="bibr">Cohen and Einav 2007</xref>; <xref rid="R19" ref-type="bibr">Einav, Finkelstein, and Schrimpf 2010</xref>). The key novel element is that we now allow for moral hazard, and heterogeneity in it. The panel structure of the data and the staggered timing of the introduction of the new options are key in allowing us to identify this new element. We start our discussion of identification by considering nonparametric identification of our model with ideal data. We then discuss the ways in which our actual data is different from the ideal, thus requiring us to make additional parametric assumptions that aid in identification.</p><p id="P67">The two features of our data set that are instrumental for identification are the panel structure of the data and the exogenous change in the health insurance options available to employees. In the ideal setting, we consider a case in which we observe individuals for a sufficiently long period before and a sufficiently long period after the change in coverage. Moreover, we assume that the choice set from which employees can choose coverage is continuous (for example, one can imagine a continuous coinsurance rate, and an increasing and differentiable mapping from coinsurance rate to premium).</p><p id="P68">In such a setting, our model is non-parametrically identified. To see this, note that such data provide us with two medical expenditure distributions, <inline-formula><mml:math id="M21" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>G</mml:mi><mml:mi>i</mml:mi><mml:mtext mathvariant="italic">before</mml:mtext></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mtext> and </mml:mtext><mml:msubsup><mml:mi>G</mml:mi><mml:mi>i</mml:mi><mml:mtext mathvariant="italic">after</mml:mtext></mml:msubsup><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, for each individual <italic>i</italic>. Using the realized utility model (during the second period of the model), these two distributions allow us to recover for each individual <italic>F</italic><sub><italic>i</italic>,λ</sub>(·) and ω<sub><italic>i</italic></sub>. To see this, recall that abstracting from the truncation of medical spending at zero, our model implies that medical expenditure <italic>m<sub>it</sub></italic> is equal to λ<sub><italic>it</italic></sub> + ω<sub><italic>i</italic></sub>(1 − <italic>c<sub>t</sub></italic>). If <italic>F</italic><sub><italic>i</italic>,λ</sub>(·) is stable over time,<xref ref-type="fn" rid="FN26">26</xref> one can regress (for each employee <italic>i</italic> separately) <italic>m<sub>it</sub></italic> on a dummy variable that is equal to 1 after the change. The estimated coefficient on the dummy variable would be then an estimate of ω<sub><italic>i</italic></sub> (<italic>c<sub>after</sub></italic> − <italic>c<sub>before</sub></italic>), providing an estimate of ω<sub><italic>i</italic></sub>. The distribution of λ<sub><italic>it</italic></sub> can then be recovered by observing that λ<sub><italic>it</italic></sub> = <italic>m<sub>it</sub></italic> − ω<sub><italic>i</italic></sub>(1 − <italic>c<sub>t</sub></italic>), which is known.</p><p id="P69">Conditional on <italic>F</italic><sub><italic>i</italic>,λ</sub>(·) and ω<sub><italic>i</italic></sub>, individual <italic>i</italic>’s choice from a continuous set of options provides a unique mapping from choices to his coefficient of absolute risk aversion since – conditional on <italic>F</italic><sub><italic>i</italic>,λ</sub>(·) and ω<sub><italic>i</italic></sub> – the coefficient of risk aversion is the only unknown primitive that may shift employees’ choices, and it does so monotonically. Thus, using information about <italic>F</italic><sub><italic>i</italic>,λ</sub>(·) and ω<sub><italic>i</italic></sub> and individual <italic>i</italic>’s choice from the continuous option set,<xref ref-type="fn" rid="FN27">27</xref> we can recover ψ<sub><italic>i</italic></sub>. Since we recovered <italic>F</italic><sub><italic>i</italic>,λ</sub>(·), ω<sub><italic>i</italic></sub>, and ψ<sub><italic>i</italic></sub> for each employee, we can now combine these estimates for our entire sample, and obtain the joint distributions of <italic>F</italic><sub>λ</sub>(·), ω, and ψ.</p><p id="P70">Our actual data depart from the ideal data described above in two main ways. First, although we have a panel structure, we only observe individuals for two periods in the baseline sample (that is limited to 2003 and 2004). Second, the choice set is highly discrete (including three to five options) rather than continuous. We thus make additional parametric assumptions to aid us in identification. This implies that our identification in the actual estimation cannot rely anymore on identifying the individual-specific parameters employee-by-employee. Rather, we observe a distribution of medical expenditures before the change and a distribution for medical expenditure after the change. We then identify the model by comparing the distribution after to the distribution before, using the untreated individuals to account for time-varying effects in medical spending, just like in the difference-in-difference analysis of Section III. Once the distribution of moral hazard, ω<sub><italic>i</italic></sub>, is known, the remaining identification challenge is very similar to our earlier work mentioned above. In the working paper version (<xref rid="R20" ref-type="bibr">Einav et al. 2011</xref>) we provide a more detailed intuition for these last steps.</p></sec>
24748682|None|('method', 0.9556245233974984)|('other', 0.04437547660250164)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">VI. Illustrative Welfare Analysis</title>
24748682|None|('method', 0.9556245233974984)|('other', 0.04437547660250164)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P93">Our findings of selection on moral hazard also have implications for policies aimed at reducing selection. Analysis of how to mitigate selection often focuses on risk adjustment – whereby individual’s insurance premiums are adjusted on the basis of individual covariates (such as age, gender, and prior health conditions) that are predictive of expected medical spending. From this perspective, the potential for selection on moral hazard suggests that investments in better monitoring technologies – such as coinsurance rates that vary across diagnoses (e.g., heart attack vs. headache) or types of healthcare (e.g., doctor visits vs. inpatient services) with different behavioral responsiveness to insurance – may also be effective at ameliorating adverse selection. Our final set of counterfactual analyses considers these issues of contract design by using our model to go further out of sample and analyze the impact of alternative contract designs on social welfare.<xref ref-type="fn" rid="FN30">30</xref></p>
24748682|A. Measuring welfare|('method', 0.9556245233974984)|('other', 0.04437547660250164)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S24"><title>A. Measuring welfare</title><p id="P94">Our standard measure of consumer welfare will be the notion of certainty equivalent. That is, for an individual defined by (<italic>F</italic><sub>λ</sub>(·), ω, ψ), we denote the certainty equivalent to a contract <italic>j</italic> by the scalar <italic>e<sub>j</sub></italic> that solves −exp(−ψ<italic>e<sub>j</sub></italic>) = υ<sub><italic>j</italic></sub>(<italic>F</italic><sub>λ</sub>(·), ω, ψ), or<disp-formula id="FD12"><label>(12)</label><mml:math id="M22" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≡</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>ψ</mml:mi></mml:mfrac><mml:mtext>ln </mml:mtext><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:mo stretchy="true">∫</mml:mo></mml:mstyle><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mi>ψ</mml:mi><mml:msup><mml:mi>u</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mtext mathvariant="italic">dF</mml:mtext><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>Our assumption of CARA utility over (additively separable) income and health implies no income effects. Because <italic>y</italic> and <italic>p<sub>j</sub></italic> are taken as given (at the time of utilization choice), it will be convenient to define<disp-formula id="FD13"><label>(13)</label><mml:math id="M23" display="block" overflow="scroll"><mml:mrow><mml:mi>ũ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>;</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>2</mml:mn><mml:mi>ω</mml:mi></mml:mrow></mml:mfrac><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo>−</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mo>−</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>so that (based on <xref ref-type="disp-formula" rid="FD1">equation 1</xref>) <italic>u</italic>(<italic>m</italic>; λ, ω, <italic>j</italic>) = <italic>ũ</italic>(<italic>m</italic>; λ, ω, <italic>j</italic>)+<italic>y</italic> − <italic>p<sub>j</sub></italic>. It will also be convenient to denote <italic>ũ</italic><sup>*</sup>(λ, ω, <italic>j</italic>) ≡ <italic>ũ</italic>(<italic>m</italic><sup>*</sup>(λ, ω, <italic>j</italic>); λ, ω, <italic>j</italic>).</p><p id="P95">To see the implications of no income effects, we can substitute <italic>u</italic><sup>*</sup>(λ, ω, <italic>j</italic>) = <italic>ũ</italic><sup>*</sup>(λ, ω, <italic>j</italic>) + <italic>y</italic> − <italic>p<sub>j</sub></italic> into <xref ref-type="disp-formula" rid="FD12">equation (12)</xref> and reorganize to obtain<disp-formula id="FD14"><label>(14)</label><mml:math id="M24" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≡</mml:mo><mml:msub><mml:mi>ẽ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>y</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>≡</mml:mo><mml:mo>−</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mi>ψ</mml:mi></mml:mfrac><mml:mtext>ln </mml:mtext><mml:mrow><mml:mo stretchy="true">[</mml:mo><mml:mrow><mml:mstyle displaystyle="true"><mml:mo>∫</mml:mo></mml:mstyle><mml:mtext>exp</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mo>−</mml:mo><mml:mi>ψ</mml:mi><mml:msup><mml:mi>ũ</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mtext mathvariant="italic">dF</mml:mtext><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo stretchy="true">]</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>y</mml:mi><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>so that <italic>ẽ</italic><sub><italic>j</italic></sub>(<italic>F</italic><sub>λ</sub>(·), ω, ψ) captures the welfare from coverage, and residual income enters additively. Using this notation, differences in <italic>ẽ</italic>(·) across contracts with different coverages capture the willingness to pay for coverage. For example, an individual defined by (<italic>F</italic><sub>λ</sub>(·), ω, ψ) is willing to pay at most <italic>ẽ</italic><sub><italic>k</italic></sub>(<italic>F</italic><sub>λ</sub>(·), ω, ψ) − <italic>e<sub>j</sub></italic>(<italic>F</italic><sub>λ</sub>(·), ω, ψ) in order to increase his coverage from <italic>j</italic> to <italic>k</italic>.</p><p id="P96">We assume that insurance providers are risk neutral, so that the provider’s welfare is given by his expected profits, or<disp-formula id="FD15"><label>(15)</label><mml:math id="M25" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>π</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≡</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:mstyle displaystyle="true"><mml:mo stretchy="true">∫</mml:mo></mml:mstyle><mml:mo stretchy="false">[</mml:mo><mml:msup><mml:mi>m</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>m</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mtext mathvariant="italic"> dF</mml:mtext><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where the integrand captures the share of the utilization covered by the provider under contract <italic>j</italic>. Total surplus <italic>s<sub>j</sub></italic> is then given by<disp-formula id="FD16"><label>(16)</label><mml:math id="M26" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>s</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mi>π</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>ẽ</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>F</mml:mi><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>ψ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>y</mml:mi><mml:mo>−</mml:mo><mml:mstyle displaystyle="true"><mml:mo stretchy="true">∫</mml:mo></mml:mstyle><mml:mo stretchy="false">[</mml:mo><mml:msup><mml:mi>m</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>−</mml:mo><mml:msub><mml:mi>c</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mspace width="thinmathspace"/><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>m</mml:mi><mml:mo>*</mml:mo></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo>,</mml:mo><mml:mi>ω</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">]</mml:mo><mml:msub><mml:mtext mathvariant="italic"> dF</mml:mtext><mml:mi>λ</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>λ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>That is, total surplus is simply certainty equivalent minus expected cost.</p><p id="P97">To gain intuition, it may be useful to discuss the nature of the efficient contract in this setting. Because of our CARA assumption, premiums are a transfer which do not affect total surplus. Therefore, the efficient contract can be characterized by the efficient coverage function <italic>c</italic><sup>*</sup>(·) that maximizes total surplus (as given by <xref ref-type="disp-formula" rid="FD16">equation (16)</xref>) over the set of possible coverage functions. Such optimal contracts would trade off two offsetting forces. On one hand, an individual is risk averse while the provider is risk natural, so optimal risk sharing implies full coverage, under which the individual is not exposed to risk. On the other hand, the presence of moral hazard makes an insured individual’s privately optimal utilization choice socially inefficient; any positive insurance coverage makes the individual face a healthcare price which is lower than the social cost of healthcare, leading to excessive utilization. Efficient contracts will therefore resolve this tradeoff by some form of partial coverage (<xref rid="R3" ref-type="bibr">Arrow 1971</xref>; <xref rid="R28" ref-type="bibr">Holmstrom 1979</xref>). For example, it is easy to see that no insurance (<italic>c</italic><sup>*</sup>(<italic>m</italic>) = <italic>m</italic>) is efficient if individuals are risk neutral or face no risk (<italic>F</italic><sub>λ</sub>(·) is degenerate), and that full insurance (<italic>c</italic><sup>*</sup>(<italic>m</italic>) = 0) is efficient when moral hazard is not present (ω = 0). In all other situations, the efficient contract is some form of partial insurance.</p></sec>
24748682|B. Welfare implications|('method', 0.9556245233974984)|('other', 0.04437547660250164)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S25"><title>B. Welfare implications</title><p id="P98"><xref ref-type="table" rid="T10">Table 10</xref> reports our welfare results. Once again we restrict our attention to a choice between the no deductible and high deductible plans under the new options (<xref ref-type="table" rid="T2">Table 2</xref>, options 5 and 1 respectively). Throughout this section we make the simplifying assumption of perfect competition for the incremental coverage among providers of the no deducible plan, so that the incremental price of the no deductible plan breaks even for those who provide it: incremental price is equal to incremental cost.<xref ref-type="fn" rid="FN31">31</xref> We report the implications of various counterfactual contracts for the equilibrium (incremental) premium for the no deductible plan, the share choosing this plan, expected spending per employee, and total welfare (or surplus) per employee. Our primary focus is on the consequence of different contract designs for total welfare (i.e., the sum of consumer welfare and producer welfare) which in our context is the certainty equivalent minus expected costs (see <xref ref-type="disp-formula" rid="FD16">equation (16)</xref>).</p><p id="P99">The first row presents the “status quo” benchmark contract with no (additional) screening or monitoring. As with the observed contracts in our data, individuals are offered a “uniform” price that only varies by coverage tier, and insurance companies reimburse medical spending, regardless of its origin, based on their contract rules. We estimate that the competitive, average incremental price for the no deductible plan (relative to the high deductible plan) is about $1,570, and that at this competitive price 90 percent of the employees would select the no deductible plan. We normalize total welfare per employee in this status quo benchmark to be zero, so that we can more easily compare the welfare gains from alternative contract designs.</p><p id="P100">The second row presents our “perfect screening” counterfactual, which eliminates adverse selection. Specifically, we assume that insurers can observe and price on all the determinants of health care utilization that the individual knows at the time of his insurance choice – i.e., all of the components of <italic>F</italic>(λ) as well as ω. We solve for the incremental price of the no deductible plan that breaks even for each employee individually, thereby eliminating the adverse selection that arises from uniform pricing. The results indicate that, as expected, the elimination of adverse selection leads to a lower (average) incremental premium for the no deductible plan, increased coverage (i.e., greater fraction choosing the no deductible plan), and higher welfare. It also leads to lower expected spending since the risk-based pricing disproportionately shifts higher moral hazard (ω) individuals into lower coverage. We estimate the welfare gain per employee from eliminating adverse selection to be about $52.<xref ref-type="fn" rid="FN32">32</xref></p><p id="P101">Of particular interest is the contribution of eliminating selection on moral hazard – i.e. one component of adverse selection – to the total welfare gain from eliminating adverse selection. Row 3 explores this by reporting the welfare gain from eliminating only selection on moral hazard (ω) but continuing to allow selection on health risk (<italic>F</italic>(λ)). Specifically, we allow insurers to observe ω and price on it, but not on <italic>F</italic>(λ); thus we are eliminating adverse selection on the slope of health spending with respect to the insurance contract (ω) but not on the level of health spending <italic>F</italic>(λ). This is of course not a very sensible scenario, since presumably if insurers could observe ω they could also refuse to reimburse on it, and thus eliminate moral hazard entirely (not just selection on moral hazard). But it is a conceptually useful way to examine the welfare cost of different sources of adverse selection. The results in row 3 suggest that the welfare cost of selection on moral hazard is $34, or about 65 percent of the $52 total welfare cost of selection from row 2.</p><p id="P102">In an analogous fashion, we can investigate the contribution of eliminating selection on moral hazard to the total welfare gain from eliminating moral hazard. In our setting, the welfare gain from eliminating moral hazard stems from two sources: removing the allocative inefficiency that arises from selection on moral hazard and eliminating the traditional moral hazard distortion that comes through socially inefficient over-utilization of health care. We show the results from eliminating moral hazard in the fourth row, which presents our “perfect monitoring” counterfactual. Here we assume that insurance coverage only applies to “λ-related” spending, which in the context of our model means that instead of reimbursing based on actual spending (i.e., reimbursing <italic>m</italic> − <italic>c<sub>j</sub></italic>(<italic>m</italic>)), the contracts reimburse max{λ, 0} − <italic>c<sub>j</sub></italic>(max{λ, 0}) regardless of what the actual spending is. In such situations, optimizing individuals would spend max{λ, 0}, which would be the socially efficient level of spending. Row 4 of <xref ref-type="table" rid="T10">Table 10</xref> indicates that, relative to the status quo (row 1), this elimination of moral hazard reduces spending by more than $1,100 per employee (column 3) and increases welfare by about $490 per employee, which is an order of magnitude greater relative to the welfare gain associated with eliminating adverse selection through perfect screening (row 2).</p><p id="P103">To examine the relative contribution of selection on moral hazard to this welfare cost, in row 5 we again consider an artificial counterfactual. Specifically, we assume that individuals make their contract choices in the first period as if they are faced with the “perfect monitoring” contracts (row 4), but then in the second period make their spending decision faced with the observed contracts that reimburse in the same manner as the actual contracts (i.e., reimburse based on <italic>m</italic> rather than based on λ). This allows us to isolate the welfare gain from eliminating solely selection on moral hazard, while preserving the distortion in second period consumption caused by moral hazard. The results suggest that eliminating selection on moral hazard can achieve welfare gains of $25 per employee, or only about 5 percent of the total welfare cost of moral hazard (row 4).</p><p id="P104">Overall, these results suggest that, in our setting, selection on moral hazard contributes non-trivially to the total welfare cost of selection, but contributes much less relative to the total welfare cost of moral hazard. At a broad level, our findings suggest that in thinking about contract design, traditional approaches to combatting moral hazard may well aid in combatting selection, and possibly vice versa. Of course, our quantitative estimates undoubtedly depend on our specific setting (contracts and population) and on our modeling assumptions. While there is not much we can do about the former (at least in the current paper), we investigate the latter in Appendix F.</p></sec>
24752180|None|('method', 0.7556225527840881)|('other', 0.24437744721591204)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Development Process</title>
24752180|Setting and context|('method', 0.7556225527840881)|('other', 0.24437744721591204)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Setting and context</title><p id="P8">CHA is an urban, integrated safety net health care system that includes two hospitals and 16 community health centers serving 100,000 patients in the greater Boston, MA area. The health care system spans five adjacent towns and has a robust electronic health record (EHR) system that includes a patient portal. As a safety net health care system, CHA cares for a low-income, vulnerable and historically underserved population with a high proportion of patients who are either uninsured or on government-sponsored insurance. Its population is racially and ethnically diverse, comprised of 15% Black non-Hispanic, 44% White non-Hispanic, 19% Hispanic, 5% Asian, and 17% Other individuals. About one-third of CHA's patients speak a language other than English at home, with Portuguese (19%) and Spanish (9%) being the largest subgroups. CHA patients are insured by Medicaid or other government sponsored insurance (43%), Medicare (29%), private insurance (20%), or are uninsured (9%).</p></sec>
24752180|Collaborating organizations and project team|('method', 0.7556225527840881)|('other', 0.24437744721591204)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Collaborating organizations and project team</title><p id="P9">A community-based participatory research and evaluation organization (Institute for Community Health, or ICH) that is closely aligned with a safety net health care system (Cambridge Health Alliance, CHA) partnered with an academic research department (Department of Population Medicine at Harvard Medical School, HMS) to develop a family diabetes and obesity prevention community program guide. The project team aimed to develop a comprehensive list of physical activity, nutrition, and weight management community programs, which would be plotted on an interactive, web-based map for the five towns in CHA's catchment area. The development of this program guide was envisioned as formative work towards a larger effort to improve diabetes prevention for CHA patients and individuals living in the surrounding communities.</p><p id="P10">The project team consisted of faculty and staff from ICH and HMS, including primary care physicians (one of whom practices at CHA), academic health services researchers, project managers working on related diabetes prevention activities, a research associate, and three public health students. The project team held bi-weekly meetings by phone or in person to discuss project goals, progress, and products.</p></sec>
24752180|Overview of development process|('method', 0.7556225527840881)|('other', 0.24437744721591204)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Overview of development process</title><p id="P11">A community based participatory research (CBPR)<sup><xref rid="R22" ref-type="bibr">22</xref></sup> approach was used to develop the program guide. CBPR has been successfully used to develop resource guides relevant to target communities such as minorities. <sup><xref rid="R23" ref-type="bibr">23</xref></sup> Though the current work was not research, community members were invited to join in a cooperative, respectful and engaging process to guide the development of the program guide. Community member input—obtained through informant interviews and focus groups—was sought on all stages of development from conception to dissemination. We combined this input with results from internet searches to develop a comprehensive guide that would be useful to end-users.</p></sec>
24752180|Identifying community resources|('method', 0.7556225527840881)|('other', 0.24437744721591204)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Identifying community resources</title><p id="P12">To generate the information in the program guide database, the team adapted a methodology used in previous efforts to identify community programs for a weight loss intervention targeting children.<sup><xref rid="R24" ref-type="bibr">24</xref></sup> The team searched an existing online compendium of physical activity, nutrition and weight management programs for communities in the CHA catchment area and conducted an internet search to identify new programs and to confirm details for programs listed in the compendium. Test searches on several different online search engines led to the selection of the one (Google.com) that produced the most relevant information most efficiently. After conducting several test searches, it was decided that the first five pages of results ; this threshold struck the optimum balance between search time and the comprehensiveness of the program list.</p><p id="P13">The team developed an initial set of 44 physical activity terms, 10 nutrition terms, and 9 weight management terms to search; because these terms would capture all diabetes prevention programs, the team did not include a specific term for diabetes prevention.. The team used search terms combined with each community name in the catchment area for each program area in the guide. Examples include “basketball” and “community pools” to search for physical activity programs; “farmers’ markets” and “healthy eating” to search for nutrition programs; and “childhood obesity programs” and “weight loss programs” to search for weight management programs. We also searched the websites of hospitals, health centers, community centers, recreation centers, fitness centers, etc. to find venues with a broad range of activities and programs. In addition, key informants suggested additional search terms and provided names of specific nutrition and weight management community programs. The final list of search terms is available in the <xref ref-type="app" rid="APP1">appendix</xref>.</p><p id="P14">The accuracy of the program data was verified by calling a random sample of the identified programs/activities to validate four pieces of information (phone number, physical address, ages served, and program description). If a program was not reached on the first day, one further call was attempted.</p><p id="P15">The team partnered with a local university geographic analysis center to create the online, searchable community resource map. This center provided assistance with geocoding (i.e., conversion of street addresses for the programs into geographical coordinates) and mapping, as well as expertise on customizing the mapping platform to improve user-friendliness and aesthetics. The center provided guidance concerning choice of web interface; ultimately we chose WorldMap© because it has built-in system updating and would therefore require no ongoing maintenance. Additionally, WorldMap has a mobile version so that users could easily navigate the database on mobile devices.</p></sec>
24752180|Key informant interviews|('method', 0.7556225527840881)|('other', 0.24437744721591204)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Key informant interviews</title><p id="P16">In initial meetings, the project team determined the types of formative information needed to refine the tool and adapt it to the clinical context. This information was to be collected from key informants within CHA and community organizations. The team identified the following domains to discuss with key informants: (1) suggestions for making the program guide useful to the target population, including the types of information the guide should contain; (2) suggestions and potential challenges for integrating the program guide into clinical care; and (3) suggestions for naming and promoting the community program guide.</p><p id="P17">Based on her knowledge as a CHA primary care provider, one team member (LZ) identified key informants having a variety of roles within and outside of the organization. The team then conducted one-on-one and group interviews with two diabetes educators, an endocrinologist, a primary care physician with a particular interest in weight management, outpatient nutritionists, representatives of a local city public health department, community affairs department members, two community health workers who work with medically and socially complex patients, the CHA Patient &amp; Family Advisory Council, and CHA patients including a group of patients who were ICH employees.</p></sec>
24752550|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">EXPERIMENTAL PROCEDURES</title>
24752550|Reagents|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Reagents</title><p>C3G was purchased from the National Institute for the Control of Pharmaceutical and Biological Products (Beijing, China). Dexamethasone (DEX) (purity &gt;99.6%) was purchased from Changle Pharmaceutical Co. (Xinxiang, Henan, China). Methyl-β-cyclodextrin (MβCD), DMSO, LPS (<italic>Escherichia coli</italic> 055:B5), and 3-(4,5-dimethylthiazol-2-y1)-2,5-diphenyltetrazolium bromide (MTT) were purchased from Sigma Chemical Co. (St. Louis, MO). DMEM and FBS were obtained from Hyclone. Mouse TNF-α, interleukin (IL)-6, and IL-1β ELISA kits were purchased from BioLegend (San Diego, CA). Mouse RANTES ELISA kits were purchased from R&amp;D Systems (Minneapolis, MN). Mouse monoclonal Ab (mAb) phospho-NF-κB, mouse mAb NF-κB, mouse mAb phospho-IRF3, and rabbit mAb IRF3 were purchased from Cell Signaling Technology Inc. (Beverly, MA). LXRα and ABCG1 antibodies were purchased from Santa Cruz Biotechnology. HRP-conjugated goat anti-rabbit antibodies were provided by GE Healthcare (Buckinghamshire, UK). All other chemicals were of reagent grade.</p></sec>
24752550|Mouse model of LPS-induced mastitis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Mouse model of LPS-induced mastitis</title><p>Seventy-two female mice were purchased from the Center of Experimental Animals of Baiqiuen Medical College of Jilin University (Jilin, China) 5–7 days after parturition. All animals were housed in microisolator cages and fed with standard laboratory chow and water ad libitum; the mice were kept at a temperature of 24 ± 1°C and a relative humidity of 40–80%. All experiments followed the guidelines for the care and use of laboratory animals published by the US National Institutes of Health. Both L4 (on the left) and R4 (on the right) abdominal mammary glands were infused with LPS using a 100 μl syringe with a 30-gauge blunt needle. Lactating mice were anesthetized by ethyl ether and put on their back under a binocular. The teats and the surrounding area were disinfected with 70% ethanol. LPS (10 μg dissolved in 50 μl sterile PBS) was infused into the mammary gland through the duct of the mammary gland (<xref rid="bib18" ref-type="bibr">18</xref>).</p><p>Seventy-two female mice were randomly divided into six groups: the blank control group, the LPS group, the LPS + C3G groups (10, 20, or 40 mg/kg), and the LPS + DEX (5 mg/kg) group. The treatment groups were respectively administered 10, 20, and 40 mg/kg C3G ip at 1 h before and 12 h after LPS infusion based on our preliminary experiment. The DEX group was administered 5 mg/kg DEX ip at 1 h before and 12 h after LPS infusion. The blank control group and LPS group were supplied with an equal volume of distilled water ip. At 24 h after LPS inoculation, the mice were euthanized with CO<sub>2</sub> inhalation and then the four pairs of mammary glands were collected and stored at −80°C until analysis.</p></sec>
24752550|Histopathologic evaluation of the mammary tissue|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Histopathologic evaluation of the mammary tissue</title><p>The mammary tissues were collected and fixed with 10% buffered formalin, imbedded in paraffin, and sliced. After hematoxylin and eosin staining, pathological changes of the mammary tissues were observed under a light microscope.</p></sec>
24752550|Myeloperoxidase activity analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Myeloperoxidase activity analysis</title><p>Myeloperoxidase (MPO) activity represents the parenchymal infiltration of neutrophils and macrophages. MPO activity in homogenates of mammary tissue was determined using test kits purchased from Nanjing Jiancheng Bioengineering Institute (China) according to the instructions.</p></sec>
24752550|Cell culture and treatment|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Cell culture and treatment</title><p>Mouse mammary epithelial cells (MMECs) were prepared as previously described. Briefly, the mammary glands from pregnant female mice were minced and digested at 37°C with a collagenase I/II/trypsin mixture (Invitrogen, Carlsbad, CA). Undissociated tissues and debris were removed after filtration. Then the cells were collected by centrifugation at 250 <italic>g</italic> for 5 min three times. Cell pellets were resuspended in DMEM/F12 containing 10% FCS and incubated for 1 h at 37°C, and then the supernatant was collected. This step was repeated three times to clear away fibroblasts. After the last incubation, cells were resuspended in DMEM/F12 containing 10% FCS, 0.5% transferrin, 0.1% T3, and 0.5% EGF and cultured at 37°C with 5% CO<sub>2</sub>. Medium was changed once every 48 h. In all experiments, MMECs were incubated in the presence or absence of various concentrations of C3G that was always added 12 h prior to LPS (0.1 μg/ml) treatment.</p></sec>
24752550|MTT assay for cell viability|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>MTT assay for cell viability</title><p>Cell viability was determined by MTT assay. In brief, 1 × 10<sup>4</sup> MMECs were isolated and seeded in 96-well plates, then the cells were treated with 50 μl of C3G at different concentrations (0–100 μM) for 1 h, followed by stimulation with 50 μl LPS. After 18 h of LPS stimulation, 20 μl MTT (5 mg/ml) was added to each well, and the cells were further incubated for an additional 4 h. The supernatant was removed and the formation of formazan was resolved with 150 μl/well of DMSO. The optical density (OD) was measured at 570 nm on a microplate reader (TECAN, Austria).</p></sec>
24752550|ELISA assay|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>ELISA assay</title><p>The levels of inflammatory cytokines, TNF-α, IL-1β, IL-6, and RANTES, were measured by ELISA kits according to the manufacturer’s instructions (BioLegend).The OD of the microplate was read at 450 nm.</p></sec>
24752550|Western blot analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Western blot analysis</title><p>Total proteins from cells were extracted by mammalian protein extraction reagent (M-PER, Thermo). Briefly, culture medium was carefully removed from cells. Then, 200 μl M-PER reagent was added to the 6-well plate and shaken gently for 5 min. The lysate was collected and transferred to a microcentrifuge tube and centrifuged at 14,000 <italic>g</italic> for 7 min to pellet the cell debris. Then the supernatant was transferred for analysis.</p><p>Protein concentration was determined through the BCA method. Equal amounts of protein were loaded in each well and separated by 10% SDS-PAGE, which subsequently was transferred onto a polyvinylidene difluoride membrane. The membrane was blocked for 2 h with 5% skim milk in TBST on the shaker at room temperature and then washed three times (10 min each) with Tri-Tween buffered saline [20 mM Tris-HCl buffer (pH 7.6), 137 mM NaCl, and 0.05% Tween 20]. The membrane was placed on primary antibody diluted at a 1:1,000 proportion in diluent buffer [5% (w/v) BSA and 0.1% Tween 20 in TBS] and incubated overnight at 4°C on the shaker. Subsequently, the membrane was washed with PBS-T followed by incubation with the secondary antibody conjugated with HRP at room temperature for 1 h. The membrane was again washed three times (10 min each), as above, and finally the results were generated by using an ECL Western blotting kit.</p></sec>
24752550|Isolation of lipid rafts|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Isolation of lipid rafts</title><p>Lipid rafts were isolated as described previously (<xref rid="bib19" ref-type="bibr">19</xref>). Briefly, MMECs were lysed in ice-cold MBS buffer [25 mM MES (pH 6.5), 150 mM NaCl, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 1% Triton X-100, and protease inhibitors]. Lysates were mixed with 4 ml of 40% sucrose by mixing with 2 ml of 80% sucrose and overlaid with 4 ml of 35% sucrose and 4 ml of 5% sucrose in MBS buffer. Samples were ultracentrifuged at 39,000 rpm for 18 h and fractionated into 12 subfractions. The translocation of TLR4 to lipid rafts was measured by Western blot analysis.</p></sec>
24752550|Quantification of cholesterol levels in lipid rafts of MMECs|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Quantification of cholesterol levels in lipid rafts of MMECs</title><p>Lipid rafts were isolated as described above. The cholesterol level of lipid rafts was assayed by gas-liquid chromatography as previously described (<xref rid="bib20" ref-type="bibr">20</xref>).</p></sec>
24752550|Cholesterol replenishment experiment|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Cholesterol replenishment experiment</title><p>MMECs were treated with culture medium alone or medium containing C3G (10, 20, or 40 μM), or MβCD (10 mM) at 37°C for 60 min. Subsequently, the cells were washed with PBS and incubated with medium alone or medium containing water-soluble cholesterol (84 μg/ml) for 30 min (<xref rid="bib21" ref-type="bibr">21</xref>). The cells were exposed to LPS. The translocation of TLR4 to lipid rafts was analyzed as mentioned above.</p></sec>
24752550|LXR gene assay|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>LXR gene assay</title><p>For LXR activation studies, 0.75 μg of LXRE-driven luciferase reporter vector (LXRE-tk-Luc) and 0.75 μg of β-galactosidase control vector (Promega) were used. The MMECs were transfected with vectors using FuGENE HP transfection reagent (Roche Applied Science, Indianapolis, IN) according to the manufacturer’s instructions. Six hours after transfection, cells were treated with C3G for 12 h. The β-galactosidase enzyme activity was determined using the β-galactosidase enzyme system (Promega) according to the manufacturer’s instructions. Luciferase activity was normalized by β-galactosidase activity.</p></sec>
24752550|Transient transfection of siRNA against LXRα|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Transient transfection of siRNA against LXRα</title><p>The plasmid containing siRNA against LXRα (si-LXRα ON-TARGETplus SMART pool), nontargeting siRNA (si-control), and the DharmaFECT transfection reagent were purchased from Thermo Scientific Dharmacon (USA). si-LXRα and si-control stock solutions (20 μM) were diluted with diethyl pyrocarbonate water to form 5 μM solutions. The DharmaFECT transfection reagent was mixed with 5 μM si-LXRα or si-control, incubated for 20 min, and then added to the culture medium at a final concentration of 25 μM. The MMECs were incubated with si-LXRα and si-control for 48 h.</p></sec>
24752550|Statistical analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Statistical analysis</title><p>All data are expressed as mean ± SEM. The differences among the various experimental groups were analyzed by one-way ANOVA. <italic>P</italic> &lt; 0.05 was considered to be statistically significant.</p></sec>
24770853|None|('method', 0.841449997071521)|('other', 0.15855000292847896)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 Data</title>
24770853|None|('method', 0.841449997071521)|('other', 0.15855000292847896)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Blood pressure measures from four studies were analysed here. These studies are part of the FALCon collaboration and were selected on the basis of being funded by the UK Medical Research Council and covering different but overlapping periods of the life course with at least two measures of blood pressure. Studies included in the analysis are: (1) the Avon Longitudinal Study of Parents And Children (ALSPAC), relating to children born in Avon in the 1990s;<sup><xref rid="bibr9-0962280214532576" ref-type="bibr">9</xref></sup> (2) the Medical Research Council (MRC) National Survey of Health and Development (NSHD)<sup><xref rid="bibr10-0962280214532576" ref-type="bibr">10</xref></sup> of individuals born in England, Scotland or Wales in 1946; (3) the Caerphilly Prospective Study (CAPS),<sup><xref rid="bibr11-0962280214532576" ref-type="bibr">11</xref></sup> which includes only men initially recruited in and (4) the Twenty-07 study (T-07),<sup><xref rid="bibr12-0962280214532576" ref-type="bibr">12</xref></sup> undertaken in the west of Scotland and started in 1986. The T-07 study is formed by three age defined subcohorts of individuals born in 1970s, 1950s and 1930s that were regarded as independent studies.</p>
24770853|None|('method', 0.841449997071521)|('other', 0.15855000292847896)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Blood pressure measures were taken by trained nurses in all studies except for CAPS, where measures were taken by physicians in the first four data collection waves and by a trained field worker in the fifth wave. In most studies at least two measurements were taken at each assessment. Instead, in CAPS one single blood pressure measure was taken in all collection waves except the second when two measures were taken. At the time of taking the measures, participants were seated and allowed at least 2 min rest prior to measurement. Different devices were used over time and in the different studies to take blood pressure reading. In ALSPAC and late waves of CAPS, NSHD and T-07 an automated oscillometric (AO) device was used to take the readings, whilst a manual random zero sphygmomanometer (MRZ) was used in earlier waves of the CAPS, NSHD and T-07 studies. Specifically, in CAPS, an MRZ machine was used in the first four waves and an AO machine in the last wave. In NSHD, an MRZ machine was used in the first two waves and an AO in the third one, whilst T-07 switched from an MRZ to an AO in the third wave, when both machines were used.</p>
24770853|None|('method', 0.841449997071521)|('other', 0.15855000292847896)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="table" rid="table1-0962280214532576">Table 1</xref> presents the range of ages of individuals, the number of waves and total number of individuals for each cohort. Each study collected information specific to their original research aims, but a common core of socio-demographic variables such as participants’ height and weight, occupational social class at study entry and marital status was collected in all studies. In studies of young people (ALSPAC and youngest cohort of the T-07 study), social class was defined by the parents’ main occupation. Adult males’ and non-married women’s social classes were defined based on their own occupations; married women’s social classes were defined according to their husbands’ occupations or, if this information was not available, on their own occupations. Information about medication intake collected by nurses was available in all studies of individuals aged 18 years and older.<table-wrap id="table1-0962280214532576" orientation="portrait" position="float"><label>Table 1.</label><caption><p>Age range of individuals and number of waves within each cohort.</p></caption><alternatives><graphic specific-use="table1-0962280214532576" xlink:href="10.1177_0962280214532576-table1"/><table frame="hsides" rules="groups"><thead align="left" valign="top"><tr><th rowspan="1" colspan="1">Study</th><th rowspan="1" colspan="1">Year initiation</th><th rowspan="1" colspan="1">Age range of participants</th><th rowspan="1" colspan="1">Number of data waves</th><th rowspan="1" colspan="1">Total number of individuals</th></tr></thead><tbody align="left" valign="top"><tr><td rowspan="1" colspan="1">ALSPAC</td><td rowspan="1" colspan="1">1990–1992</td><td rowspan="1" colspan="1">7–18</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">9432</td></tr><tr><td rowspan="1" colspan="1">T-07 (1970s)</td><td rowspan="1" colspan="1">1986</td><td rowspan="1" colspan="1">15–38</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">1481</td></tr><tr><td rowspan="1" colspan="1">T-07 (1950s)</td><td rowspan="1" colspan="1">1986</td><td rowspan="1" colspan="1">30–63</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">1391</td></tr><tr><td rowspan="1" colspan="1">T-07 (1930s)</td><td rowspan="1" colspan="1">1986</td><td rowspan="1" colspan="1">55–79</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">1479</td></tr><tr><td rowspan="1" colspan="1">NSHD</td><td rowspan="1" colspan="1">1946</td><td rowspan="1" colspan="1">36, 43, 53</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">3655</td></tr><tr><td rowspan="1" colspan="1">CAPS</td><td rowspan="1" colspan="1">1990–1992</td><td rowspan="1" colspan="1">43–85</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">2949</td></tr></tbody></table></alternatives></table-wrap></p>
24770853|None|('method', 0.841449997071521)|('other', 0.15855000292847896)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">We derived a set of variables to account for factors known to be associated with hypertension. First, using information about social class, we derived an indicator of manual occupation at study entry. Body mass index (BMI) was calculated as <inline-formula id="ilm1-0962280214532576"><mml:math id="mml-math1-0962280214532576"><mml:mrow><mml:mtext>weight</mml:mtext><mml:mo>/</mml:mo><mml:mrow><mml:mtext>height</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mtext>kg</mml:mtext><mml:mo>/</mml:mo><mml:mrow><mml:mtext>m</mml:mtext></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. Using published cut-off points,<sup><xref rid="bibr13-0962280214532576" ref-type="bibr">13</xref></sup> we defined binary indicators to classify individuals as underweight, normal weight and overweight.<sup><xref rid="bibr14-0962280214532576" ref-type="bibr">14</xref></sup> For children we used a different criterion as BMI classification varies by age and gender. If a child has BMI for age below the 5th percentile then it was considered as in the underweight group while a child with BMI for age above the 95th percentile was considered in the overweight group,<sup><xref rid="bibr14-0962280214532576" ref-type="bibr">14</xref></sup> with all other children classified as in the normal weight group.</p>
24770853|None|('method', 0.841449997071521)|('other', 0.15855000292847896)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Where information about medication intake was available, blood pressure readings were corrected for medication intake using published methods<sup><xref rid="bibr15-0962280214532576" ref-type="bibr">15</xref></sup> that assume that blood pressure from medicated individuals is higher than the observed measure. This correction was conducted by adding 15% of its value to the observed measure.</p>
24770853|None|('method', 0.841449997071521)|('other', 0.15855000292847896)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">To correct for possible differences in the blood pressure measures taken in the first and second reading, we calculated the average of the two readings. Given the differences observed in blood pressure trajectories within the different studies, data from men and women were analysed separately.</p>
24770853|None|('method', 0.6386962884547445)|('other', 0.3613037115452555)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3 Methods</title>
24770853|None|('method', 0.6386962884547445)|('other', 0.3613037115452555)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Suppose we wish to model life course trajectories using splines in some way. As we will invariably have data on many individuals, we might consider fitting a separate spline to each individual and then characterising the population distribution of spline parameters in some way. However, this would require that all individuals share the same set of parameters, albeit with different values, which is impractical when individuals are observed over different stages of life, not least because each individual spline would have to be extrapolated into the unobserved age ranges. As an alternative, we propose using a single spline to define the population mean life course, with individuals’ departures from that mean behaviour accounted for by adding random effects to the spline rather than its parameters. We also add random effects to account for differences between cohorts/studies that are due to unmeasured covariates. A principal advantage of this approach is that the spline may be <italic>adaptive</italic>, with an a priori unknown number of knots. Individual-specific adaptive splines would have different numbers of parameters with different meanings, in general, which would preclude overall inferences.</p>
24770853|3.1 Model description|('method', 0.6386962884547445)|('other', 0.3613037115452555)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="sec4-0962280214532576"><title>3.1 Model description</title><p>Let <inline-formula id="ilm2-0962280214532576"><mml:math id="mml-math2-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denote the <italic>k</italic>th blood pressure measurement <inline-formula id="ilm3-0962280214532576"><mml:math id="mml-math3-0962280214532576"><mml:mrow><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mi>ij</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> taken for the <italic>j</italic>th individual <inline-formula id="ilm4-0962280214532576"><mml:math id="mml-math4-0962280214532576"><mml:mrow><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>J</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula> in study <italic>i</italic><inline-formula id="ilm5-0962280214532576"><mml:math id="mml-math5-0962280214532576"><mml:mrow><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>I</mml:mi><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. We assume <inline-formula id="ilm6-0962280214532576"><mml:math id="mml-math6-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>, with<disp-formula id="disp-formula1-0962280214532576"><alternatives><mml:math id="math1-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>μ</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mtext>mrz</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>ij</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="10.1177_0962280214532576-eq1.jpg" specific-use="disp-formula1-0962280214532576" position="float" orientation="portrait"/></alternatives></disp-formula>where <inline-formula id="ilm7-0962280214532576"><mml:math id="mml-math7-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denotes the spline function to be fitted as described below; <inline-formula id="ilm8-0962280214532576"><mml:math id="mml-math8-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm9-0962280214532576"><mml:math id="mml-math9-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are study-level random effects, representing study-specific deviations from the mean spline and effects of using an MRZ device, respectively (<inline-formula id="ilm10-0962280214532576"><mml:math id="mml-math10-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mtext>mrz</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula> if <inline-formula id="ilm11-0962280214532576"><mml:math id="mml-math11-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>y</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> was measured using an MRZ device and <inline-formula id="ilm12-0962280214532576"><mml:math id="mml-math12-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mtext>mrz</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> if an AO device was used), whilst <inline-formula id="ilm13-0962280214532576"><mml:math id="mml-math13-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>ij</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> represents an individual-level random effect. The term <inline-formula id="ilm14-0962280214532576"><mml:math id="mml-math14-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> represents the combined effects of various individual-level risk factors<disp-formula id="disp-formula2-0962280214532576"><alternatives><mml:math id="math2-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>r</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mtext>manual</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mtext>bmiu</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mtext>bmio</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math><graphic xlink:href="10.1177_0962280214532576-eq2.jpg" specific-use="disp-formula2-0962280214532576" position="float" orientation="portrait"/></alternatives></disp-formula>In this expression parameters <inline-formula id="ilm15-0962280214532576"><mml:math id="mml-math15-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm16-0962280214532576"><mml:math id="mml-math16-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm17-0962280214532576"><mml:math id="mml-math17-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mn>3</mml:mn></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are study-level random effects and <inline-formula id="ilm18-0962280214532576"><mml:math id="mml-math18-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mtext>manual</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm19-0962280214532576"><mml:math id="mml-math19-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mtext>bmiu</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm20-0962280214532576"><mml:math id="mml-math20-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mtext>bmio</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are binary indicators of manual occupation, being underweight and being overweight, respectively.</p><p>The spline <italic>s<sub>ijk</sub></italic> is a piecewise polynomial given by<disp-formula id="disp-formula3-0962280214532576"><alternatives><mml:math id="math3-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>s</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow><mml:mo>+</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>q</mml:mi></mml:mrow></mml:munderover><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>ℓ</mml:mi><mml:mo>=</mml:mo><mml:mi>c</mml:mi></mml:mrow><mml:mrow><mml:mi>d</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>λ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>ℓ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow><mml:mrow><mml:mi>ℓ</mml:mi></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10.1177_0962280214532576-eq3.jpg" specific-use="disp-formula3-0962280214532576" position="float" orientation="portrait"/></alternatives></disp-formula>for <inline-formula id="ilm21-0962280214532576"><mml:math id="mml-math21-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, where <inline-formula id="ilm22-0962280214532576"><mml:math id="mml-math22-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> denotes the age of individual <italic>j</italic> in study <italic>i</italic> at the <italic>k</italic>th observation time, <italic>x</italic><sub>0</sub> is the lowest age for which the function is defined and <inline-formula id="ilm23-0962280214532576"><mml:math id="mml-math23-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>x</mml:mi></mml:mrow></mml:math></inline-formula> if <inline-formula id="ilm24-0962280214532576"><mml:math id="mml-math24-0962280214532576"><mml:mrow><mml:mi>x</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm25-0962280214532576"><mml:math id="mml-math25-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>x</mml:mi></mml:mrow><mml:mrow><mml:mo>+</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> otherwise. Parameters <inline-formula id="ilm26-0962280214532576"><mml:math id="mml-math26-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>η</mml:mi></mml:mrow><mml:mrow><mml:mi>q</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are the ‘knots’ of the spline and the βs are regression coefficients. The constants <inline-formula id="ilm27-0962280214532576"><mml:math id="mml-math27-0962280214532576"><mml:mrow><mml:mi>c</mml:mi><mml:mo>≥</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm28-0962280214532576"><mml:math id="mml-math28-0962280214532576"><mml:mrow><mml:mi>d</mml:mi><mml:mo>≥</mml:mo><mml:mi>c</mml:mi></mml:mrow></mml:math></inline-formula> represent the ‘continuity’ and ‘order’ of the spline, respectively, and <inline-formula id="ilm29-0962280214532576"><mml:math id="mml-math29-0962280214532576"><mml:mrow><mml:mi>λ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>l</mml:mi><mml:mo>,</mml:mo><mml:mi>ℓ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>q</mml:mi><mml:mo>+</mml:mo><mml:mi>l</mml:mi><mml:mo>×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>d</mml:mi><mml:mo>-</mml:mo><mml:mi>c</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>ℓ</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. In this paper we use a <italic>linear</italic> spline by selecting <inline-formula id="ilm30-0962280214532576"><mml:math id="mml-math30-0962280214532576"><mml:mrow><mml:mi>c</mml:mi><mml:mo>=</mml:mo><mml:mi>d</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>. We choose a linear form, as opposed to a quadratic or cubic form, say, because then the knots correspond directly to change points in the fitted trajectory, whereas higher order splines can change direction away from the knots. This aids in interpreting the fitted trajectory and in specifying a prior distribution (see below) for the number of knots <italic>q</italic>, which is estimated as an unknown parameter, so that the smoothness of the fitted curve is estimated as part of the model, and hence the spline adapts itself to the information present in the data. We scale the age range so that the minimum and maximum values are 0 and 1, respectively.</p><p>Possible differences in the variability of measurements by device were accounted for by modelling the residual standard deviation <inline-formula id="ilm31-0962280214532576"><mml:math id="mml-math31-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> as a function of the device used as follows<disp-formula id="disp-formula4-0962280214532576"><alternatives><mml:math id="math4-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mtext>mrz</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mrow><mml:mtext>mrz</mml:mtext></mml:mrow><mml:mrow><mml:mi>ijk</mml:mi></mml:mrow></mml:msub><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10.1177_0962280214532576-eq4.jpg" specific-use="disp-formula4-0962280214532576" position="float" orientation="portrait"/></alternatives></disp-formula>where <inline-formula id="ilm32-0962280214532576"><mml:math id="mml-math32-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula id="ilm33-0962280214532576"><mml:math id="mml-math33-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> are study-level random effects representing the study-specific residual standard deviations associated with the AO and MRZ devices, respectively.</p></sec>
24770853|3.2 Model estimation|('method', 0.6386962884547445)|('other', 0.3613037115452555)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="sec5-0962280214532576"><title>3.2 Model estimation</title><p>The model was estimated within a Bayesian framework. Analyses were performed using WinBUGS<sup><xref rid="bibr16-0962280214532576" ref-type="bibr">16</xref>,<xref rid="bibr17-0962280214532576" ref-type="bibr">17</xref></sup> with ‘Jump’ interface installed.<sup><xref rid="bibr18-0962280214532576" ref-type="bibr">18</xref></sup> As described by Lunn et al.,<sup><xref rid="bibr18-0962280214532576" ref-type="bibr">18</xref></sup> the reversible jump algorithm is implemented in WinBUGS<sup><xref rid="bibr16-0962280214532576" ref-type="bibr">16</xref>,<xref rid="bibr17-0962280214532576" ref-type="bibr">17</xref></sup> to draw samples from the joint full conditional distribution of the coefficients β, knots η and number of knots <italic>q</italic>, whilst standard Gibbs/Metropolis steps are used to update the remaining model parameters. As the value of <italic>q</italic> changes during the Markov chain Monte Carlo (MCMC) simulation, so do the dimensions of β and η. One of the main challenges in such ‘variable dimension’ analyses is choosing sensible values for the spline coefficients when attempting a dimension-changing move. This is because the change of dimension necessitates a change of parameter space, which may have been visited previously (in the MCMC simulation) only rarely, if ever. Hence the MCMC sampler will have had little opportunity to learn about appropriate parameter values in the new space. This problem can be alleviated if we can derive the full conditional distribution for the coefficients in closed form, since appropriate coefficients can then be generated instantly for any set of proposed knots. A multivariate normal prior for the coefficients β combines with the normal likelihood to give a multivariate normal full conditional, which is straightforward to derive. In our analyses the prior mean and variance for each coefficient are 0 and 100<sup>2</sup>, respectively.</p><p>As the age range was scaled to the interval (0,1), we chose a Unif(0,1) distribution as a prior distribution for the location of each knot. The RJMCMC algorithm considered here increased the model flexibility with regard to the number of knots of the model. However, it requires a prior distribution for the number of knots <italic>q</italic>. We chose a Poisson prior with mean 3 as this distribution represents our a priori expectation that, after increasing throughout childhood and adolescence, blood pressure may begin to level off in early adulthood; it may then begin to increase again in middle age, with a possible further change in later life. The shape of the Poisson distribution then penalises large numbers of knots, which encourages parsimony.</p><p>The individual- and study-level random effects (or their logarithms) were assumed to arise from normal population distributions. For <inline-formula id="ilm34-0962280214532576"><mml:math id="mml-math34-0962280214532576"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi> </mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:math></inline-formula><disp-formula id="disp-formula5-0962280214532576"><alternatives><mml:math id="math5-0962280214532576"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mi>ij</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mrow><mml:mi>ζ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>   </mml:mi><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>J</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>φ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>l</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mi>l</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>   </mml:mi><mml:mi>l</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mn>3</mml:mn><mml:mo>,</mml:mo></mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow><mml:mrow><mml:mi>log</mml:mi><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>a</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msubsup><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10.1177_0962280214532576-eq5.jpg" specific-use="disp-formula5-0962280214532576" position="float" orientation="portrait"/></alternatives></disp-formula>where the means and standard deviations are unknown parameters with appropriate, vague prior distributions<disp-formula id="disp-formula6-0962280214532576"><alternatives><mml:math id="math6-0962280214532576"><mml:mrow><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mtext>N</mml:mtext><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>   </mml:mi><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>m</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mtext>N</mml:mtext><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mi>log</mml:mi><mml:mn>10</mml:mn><mml:mo>,</mml:mo><mml:mrow><mml:mn>100</mml:mn></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10.1177_0962280214532576-eq6.jpg" specific-use="disp-formula6-0962280214532576" position="float" orientation="portrait"/></alternatives></disp-formula><disp-formula id="disp-formula7-0962280214532576"><alternatives><mml:math id="math7-0962280214532576"><mml:mrow><mml:mi>ζ</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>φ</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:mi>γ</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>α</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mtext>Unif</mml:mtext><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>60</mml:mn><mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo><mml:mi>   </mml:mi><mml:msub><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>m</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>ω</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:mi>a</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mtext>Unif</mml:mtext><mml:mrow><mml:mo>(</mml:mo></mml:mrow><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>10</mml:mn><mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math><graphic xlink:href="10.1177_0962280214532576-eq7.jpg" specific-use="disp-formula7-0962280214532576" position="float" orientation="portrait"/></alternatives></disp-formula>The upper bound of 60 for standard deviations defined on the natural scale is chosen as systolic pressures outside the range 0–240 mmHg are very unlikely or impossible. For standard deviations defined on the log-scale, an upper bound of 10 is chosen as this represents a vast degree of variability on the natural scale.</p><p>The code can be found in Appendix 1, and a graphical representation of the model is presented in <xref ref-type="fig" rid="fig1-0962280214532576">Figure 1</xref>. For each analysis, two MCMC chains were simulated from different initial states. Convergence was assessed via visual inspection of the trace plots and by the Brooks–Gelman–Rubin method.<sup><xref rid="bibr19-0962280214532576" ref-type="bibr">19</xref>,<xref rid="bibr20-0962280214532576" ref-type="bibr">20</xref></sup> The Monte Carlo standard error (MCSE) for all parameters of interest was examined periodically to ensure accurate inferences. The rule of thumb of requiring an MCSE less than 5%<sup><xref rid="bibr21-0962280214532576" ref-type="bibr">21</xref></sup> (p. 277) was fully satisfied in our analysis, with <inline-formula id="ilm35-0962280214532576"><mml:math id="mml-math35-0962280214532576"><mml:mrow><mml:mo>&lt;</mml:mo><mml:mn>2</mml:mn><mml:mi>%</mml:mi></mml:mrow></mml:math></inline-formula> achieved for the vast majority of parameters.<fig id="fig1-0962280214532576" orientation="portrait" position="float"><label>Figure 1.</label><caption><p>Directed acyclic graph (DAG) corresponding to blood pressure life course model. ‘Nodes’ represent variables in the model and are joined together by arrows to show direct dependence between variables. Solid arrows denote stochastic dependence whereas ‘dashed’ arrows denote logical dependence (deterministic functions). Rectangular nodes represent covariates that have been included in the model. The rectangular ‘containers’ labelled <inline-formula id="ilm36-0962280214532576"><mml:math id="mml-math36-0962280214532576"><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:mi>I</mml:mi></mml:mrow></mml:math></inline-formula>, <inline-formula id="ilm37-0962280214532576"><mml:math id="mml-math37-0962280214532576"><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mo>…</mml:mo><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>J</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, etc. denote repetition, i.e. ‘loops’ over the index used in the label.</p></caption><graphic xlink:href="10.1177_0962280214532576-fig1"/></fig></p></sec>
24771866|None|('method', 0.9999925877027994)|('other', 7.412297200457802e-06)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIAL AND METHODS</title>
24771866|Patients|('method', 0.9999925877027994)|('other', 7.412297200457802e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Patients</title><sec><title>CTX patient 1.</title><p>CTX patient 1 is a 32-year-old woman referred to the lipid clinic in Oslo due to large xanthomas on both Achilles tendons and normal plasma lipid values. The xanthomas developed during her teens. There had been a progressive cognitive decline from the she started school at the age of 7. She also had premature cataracts, which were surgically removed. These features of her medical history triggered the suspicion for CTX, a diagnosis that was verified by markedly reduced plasma levels of 27-hydroxycholesterol (<xref ref-type="table" rid="tbl1"><bold>Table 1</bold></xref>). Cerebral MRI, echocardiography, Doppler of the carotid arteries, and stress ECG showed normal findings. Treatment was initiated with chenodeoxycholic acid (250 mg three times daily) in May 2009. Due to lack of sufficient effect, the dose was doubled after a year.</p><table-wrap id="tbl1" position="float"><label>TABLE 1.</label><caption><p>Levels of oxysterols in three patients with CTX before and after treatment with chenodeoxycholic acid</p></caption><table frame="hsides" rules="groups"><thead><tr><td rowspan="1" colspan="1"/><td colspan="2" align="center" rowspan="1">Patient 1</td><td colspan="2" align="center" rowspan="1">Patient 2</td><td colspan="2" align="center" rowspan="1">Patient 3</td></tr><tr><td rowspan="1" colspan="1">Steroid</td><td align="center" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">After<xref ref-type="table-fn" rid="tblfn1"><italic><sup>a</sup></italic></xref></td><td align="center" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">After<xref ref-type="table-fn" rid="tblfn2"><italic><sup>b</sup></italic></xref></td><td align="center" rowspan="1" colspan="1">Before</td><td align="center" rowspan="1" colspan="1">After<xref ref-type="table-fn" rid="tblfn3"><italic><sup>c</sup></italic></xref></td></tr></thead><tbody><tr><td rowspan="1" colspan="1">27-Hydroxycholesterol (ng/ml)</td><td align="char" char="." rowspan="1" colspan="1">&lt;5</td><td align="char" char="." rowspan="1" colspan="1">&lt;5</td><td align="char" char="." rowspan="1" colspan="1">&lt;5</td><td align="char" char="." rowspan="1" colspan="1">&lt;5</td><td align="char" char="." rowspan="1" colspan="1">8</td><td align="char" char="." rowspan="1" colspan="1">7</td></tr><tr><td rowspan="1" colspan="1">7α-Hydroxycholesterol (μg/ml)</td><td align="char" char="." rowspan="1" colspan="1">3.4</td><td align="char" char="." rowspan="1" colspan="1">0.4</td><td align="char" char="." rowspan="1" colspan="1">2.2</td><td align="char" char="." rowspan="1" colspan="1">0.04</td><td align="char" char="." rowspan="1" colspan="1">0.6</td><td align="char" char="." rowspan="1" colspan="1">0.01</td></tr><tr><td rowspan="1" colspan="1">7β-Hydroxycholesterol (μg/ml)</td><td align="char" char="." rowspan="1" colspan="1">1.0</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">0.05</td><td align="char" char="." rowspan="1" colspan="1">0.05</td><td align="char" char="." rowspan="1" colspan="1">0.01.</td></tr><tr><td rowspan="1" colspan="1">7-Ketocholesterol (μg/ml)</td><td align="char" char="." rowspan="1" colspan="1">2.1</td><td align="char" char="." rowspan="1" colspan="1">0.3</td><td align="char" char="." rowspan="1" colspan="1">0.6</td><td align="char" char="." rowspan="1" colspan="1">0.1</td><td align="char" char="." rowspan="1" colspan="1">0.03</td><td align="char" char="." rowspan="1" colspan="1">0.03</td></tr></tbody></table><table-wrap-foot><fn><p>Values were determined by GC-MS and are for the sum of esterified and nonesterified sterols. Normal levels of 27-hydroxycholesterol, 90–230 ng/ml; 7α-hydroxycholesterol, &lt;0.12 μg/ml; 7β-hydroxycholesterol, &lt;0.02 μg/ml; 7-ketocholesterol, &lt;0.03 μg/ml (<xref rid="bib16" ref-type="bibr">16</xref>).</p></fn><fn id="tblfn1"><label>a</label><p>The patients were treated with 750 mg/day of chenodeoxycholic acid for 9 months.</p></fn><fn id="tblfn2"><label>b</label><p>The patients were treated with 500 mg/day of chenodeoxycholic acid for 6 months.</p></fn><fn id="tblfn3"><label>c</label><p>The patients were treated with 1,000 mg/day of chenodeoxycholic acid for 12 months.</p></fn></table-wrap-foot></table-wrap><p>Plasma samples were obtained from the patient in May 2009, March 2012, and March 2013 (<xref ref-type="table" rid="tbl1">Table 1</xref>).</p></sec><sec><title>CTX patient 2.</title><p>CTX patient 2 is a woman diagnosed with CTX at the age of 38 years. In childhood, she had unspecific chronic diarrhea and in her teens she was operated on for bilateral cataracts. When she was about 15 years old, she developed problems with balance and concentration and had her first seizures. From the age of 30, the neurological problems progressed further with cerebellar ataxia, dysphagia, and decline in cognitive function. At age 37, cerebral MRI showed cerebellar atrophy. Swelling of the Achilles tendons due to xanthoma was noted and the diagnosis of CTX was confirmed by the demonstration of very low levels of 27-hydroxycholesterol in combination with high levels of 7α-hydroxycholesterol. The patient was treated with chenodeoxycholic acid (500 mg/day) (<xref ref-type="table" rid="tbl1">Table 1</xref>).</p></sec><sec><title>CTX patient 3.</title><p>CTX patient 3 is a female who developed Achilles xanthoma when she was 18–20 years of age. Initially, the condition was believed to be due to hypercholesterolemia, but treatment with statins was unsuccessful. At the age of 32, the diagnosis of CTX was established by the demonstration of low levels of 27-hydroxcholesterol and high excretion of 25-hydroxylated bile alcohols. Cerebral MRI showed normal findings. The patient was treated with chenodeoxycholic acid (750 mg/day) (<xref ref-type="table" rid="tbl1">Table 1</xref>). A detailed characterization of this patient with a very mild form of CTX has been published (<xref rid="bib16" ref-type="bibr">16</xref>).</p></sec><sec><title>SLO patient 1.</title><p>SLO patient 1 is a 23-year-old woman in whom the diagnosis was suspected in infancy because of microcephalus, cleft hard palate, and feeding difficulties with pronounced vomiting. It was confirmed at the age of 9, when the cholesterol deficiency was discovered. She was then able to walk with a frame, had no speech, and was fed orally. She had a severe photosensitivity and started treatment with cholesterol and bile acids. Her light tolerance improved, which was verified by UVA-light tests. She now has a stable condition, is wheel-chair dependent, and has some autistic behavior in addition to severe mental retardation.</p></sec><sec><title>SLO patient 2.</title><p>SLO patient 2 is a 6-year-old girl born with typical features, cleft hard palate, and severe feeding difficulties. The SLO diagnosis was verified at the age of 3 months. She has had bilateral cataracts, has a hearing defect, and is fed by a gastrostomy. She has severe mental retardation, cannot sit unsupported, and has no speech. She has an increased susceptibility to infections and a moderate photosensitivity. She has been treated with cholesterol since the diagnosis was confirmed with little effect on her sterol pattern.</p></sec><sec><title>SLO patient 3.</title><p>SLO patient 3 is an 11-year-old girl in whom the diagnosis was obtained early. She has severe mental retardation and feeding difficulties, with frequent vomiting. At present she is fed by a gastrostomy. She was treated with cholesterol during the first years of life, but at present is not using any medications.</p></sec></sec>
24771866|Healthy volunteers|('method', 0.9999925877027994)|('other', 7.412297200457802e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Healthy volunteers</title><p>Blood was collected from six healthy subjects (laboratory staff, four males and two females, age 31–82 years, mean age 64 years).</p></sec>
24771866|Ethical aspects|('method', 0.9999925877027994)|('other', 7.412297200457802e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Ethical aspects</title><p>Informed consent to scientific use of blood analysis and clinical examinations was obtained from the three CTX patients and/or the legal guardian in accordance with ethical regulations for case reports. In the case of the analyses of serum from the three SLO subjects, serum had been collected for diagnostic purposes and ethical permission was obtained from the local ethical committee at Huddinge University Hospital to use the excess of this material for other measurements. Permission was also obtained from this committee to collect blood from healthy subjects for reference purposes.</p></sec>
24771866|Standards|('method', 0.9999925877027994)|('other', 7.412297200457802e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Standards</title><p>Cholesterol-7,8-epoxide was synthesized as described (<xref rid="bib8" ref-type="bibr">8</xref>). The deuterium-labeled 24-hydroxycholesterol used as internal standard was synthesized as described previously (<xref rid="bib17" ref-type="bibr">17</xref>).</p></sec>
24771866|Analysis|('method', 0.9999925877027994)|('other', 7.412297200457802e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Analysis</title><sec><title>GC-MS.</title><p>The oxysterols (7α- and 7β- hydroxycholesterol, 7-ketocholesterol, and cholesterol-7,8-epoxide were analyzed by combined GC-MS after hydrolysis, extraction, and silicic acid chromatography as described (<xref rid="bib17" ref-type="bibr">17</xref>). The epoxide was stable during hydrolysis and appeared in the same chromatographic fraction as other oxysterols. The steroids were converted into trimethylsilyl ether derivatives prior to GC. Deuterium-labeled 24-hydroxycholesterol was added as internal standard, and the quantitation was performed with use of a standard curve obtained by analysis of mixtures of a fixed amount of the standard with increasing amounts of cholesterol-7,8-epoxide. The area of the peak obtained in the tracing of the ion <italic>m/z</italic> 364 (cholesterol-7,8-epoxide) and the peak obtained in the tracing of the ion <italic>m/z</italic> 416 (d3-24-hydroxycholesterol) were used in the quantitations. Cholesterol precursors, including 7-dehydrocholesterol and lathosterol, were assayed as described (<xref rid="bib18" ref-type="bibr">18</xref>).</p></sec><sec><title>LC-MS<sup>n</sup>.</title><p>In contrast to the GC-MS analysis, where total oxysterols were measured (esterified and nonesterified), in the LC-MS<sup>n</sup> analysis, no hydrolysis was performed and nonesterified oxysterols were analyzed as described in (<xref rid="bib19" ref-type="bibr">19</xref>). This experiment is qualitative in nature and was done to confirm the identity of the epoxide with use of a different method and with use of a high resolution instrument. Key aspects of the LC-MS<sup>n</sup> method were: <italic>i</italic>) separation of oxysterols from more hydrophobic sterols, including cholesterol and 7-dehydrocholesterol in an initial step; <italic>ii</italic>) charge-tagging of the oxysterols by exploiting oxidation of the 3β-hydroxy group to a 3-oxo group by cholesterol oxidase, and subsequent derivatization of the oxo group with the cationic Girard P reagent; <italic>iii</italic>) chromatographic separation of oxysterols on a C<sub>18</sub> column; and <italic>iv</italic>) ESI-MS<sup>n</sup> analysis by exploiting high-resolution exact mass measurements and MS<sup>3</sup> fragmentation ([M]<sup>+</sup>→[M-Py]<sup>+</sup>→), where [M-Py]<sup>+</sup> corresponds to loss of pyridine from the molecular ion.</p></sec></sec>
24776714|None|('method', 0.9999992341142077)|('other', 7.658857923895747e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">METHOD</title>
24776714|Participants and Procedure|('method', 0.9999992341142077)|('other', 7.658857923895747e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Participants and Procedure</title><p id="P12">Data for the participants in this study came from a community-based, random sample residing in two upstate New York counties first assessed for drug use in 1983. The sample was taken from an earlier study using maternal interviews in 1975 (T1). The original maternal/youth study assessed problem behavior among youngsters. The sampled families were generally representative of the population of families in Albany and Saratoga counties, with respect to gender, family intactness, family income, and education. Interviews of both mothers and youths were conducted in 1983 (T2, N = 756), 1985–1986 (T3, N = 739), and 1992 (T4, N = 750). Three more interviews of the second generation were conducted in 1997 (T5, N = 749), 2002 (T6, N = 673), and 2005–2006 (T7, N = 607). The mean ages (SDs) of participants at the interviews were 14.1 (2.8) at T2, 16.3 (2.8) at T3, 22.3 (2.8) at T4, 27 (2.8) at T5, 31.9 (2.8) at T6, and 36.6 (2.8) at T7, respectively. In the current analyses, we included the participants (N=551) whose measurements of ADHD and CD at T2 and T3 and of nonprescription stimulant use at T7 were available. Using the T2 sample (N = 756) as the baseline, there was a significantly higher percentage of female participants among those who met the inclusion criteria (N=551) than among those who did not meet the inclusion criteria (N=205) (55.4% and 37.9%, respectively; χ<sup>2</sup>(1) = 18.6, p-value &lt; 0.001). There was a significantly lower percentage of participants with ADHD at T2 in the 551 sample as compared with the 205 sample (10.1% and 17.1%, respectively; χ<sup>2</sup>(1) = 7.0, p-value &lt; 0.01). There was also a significantly lower percentage of participants with CD at T2 in the 551 sample as compared with the 205 sample (9.4% and 17.1%, respectively; χ<sup>2</sup>(1) = 8.9, p-value &lt; 0.01).</p><p id="P13">Extensively trained and supervised lay interviewers administered the interviews in private. Written informed consent was obtained from participants and their mothers in 1983, 1986, and 1992, and from participants only in 1997, 2002, and 2005–2006. The Institutional Review Boards of the Mount Sinai Medical Center, New York Medical College, and New York University School of Medicine authorized the use of human subjects in this research study. Additional information regarding the study methodology is available from prior publications (<italic>name deleted to maintain the integrity of the review process</italic>).</p></sec>
24776714|Measures|('method', 0.9999992341142077)|('other', 7.658857923895747e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Measures</title><sec id="S9"><title>ADHD and CD at T2-T3</title><p id="P14">The parent and youth versions of the Diagnostic Interview Schedule for Children (DISC-I) (<xref rid="R13" ref-type="bibr">Costello, Edelbrock, Dulcan, Kalas, &amp; Klaric, 1984</xref>) were administered in 1983 (T2), and again in 1985–1986 (T3) to assess psychiatric disorders including ADHD and CD (<xref rid="R2" ref-type="bibr">Anderson, Cohen, &amp; Naumova, 2006</xref>). Symptoms of ADHD include an unusually high and chronic level of inattention, hyperactivity, or both. Some items from other parts of the questionnaire were added to the DISC-I to make the diagnosis of ADHD consistent with the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) (<xref rid="R1" ref-type="bibr">American Psychiatric Association, 1994</xref>). Criteria from DSM-IV were used to classify the participants with respect to ADHD. The proportion of participants (N=551) who met the DSM-IV criteria for ADHD at T2 or T3 or both was 13.1%.</p><p id="P15">According to the DSM-IV, conduct disorder is a repetitive and persistent pattern of behavior in which the basic rights of others or major age-appropriate societal norms are violated, as manifested by the presence of three (or more) of several criteria in the past 12 months, with at least one criterion present in the past six months. The proportion of participants who met the DSM-IV criteria for CD at T2 or T3 or both was 14.2%.</p></sec><sec id="S10"><title>Substance Use Disorder at T5-T6</title><p id="P16">At T5 and T6, substance use disorder (dependence or abuse) was assessed by use of the University of Michigan Composite International Diagnostic Interview (UM-CIDI) substance use disorder measure (<xref rid="R24" ref-type="bibr">Kessler, Nelson, McGonagle, Edlund, Frank, &amp; Leaf, 1996</xref>). We adapted this measure to make it consistent with the criteria used in the DSM-IV (<xref rid="R1" ref-type="bibr">American Psychiatric Association, 1994</xref>). We ascertained substance dependence by the presence of three or more of the following criteria for each substance (marijuana or other illicit drug, e.g., cocaine/crack, heroin, LSD, ecstasy, and amphetamines) used during the 12-month period before the interviews at both T5 and T6: (1) use of more of the substance than usual to get the same effect, or the same amount has less of an effect than before; (2) the presence of withdrawal symptoms or the use of the substance to avoid withdrawal symptoms; (3) the use of much larger amounts of the substance than intended, or use for a longer period of time than intended; (4) the presence of such a strong desire or urge to use the substance that the person could not resist using it; (5) a period of a month or more in which the person spent a great deal of time using the substance or getting over its effects; (6) the person gave up activities because of use of the substance; or, (7) emotional or psychological problems resulting from using the substance such as feeling uninterested in things, feeling depressed, suspicious of people, paranoid, or having strange ideas. If a participant did not meet the criteria for substance dependence, substance abuse was ascertained by the presence of at least one of the following four criteria during the 12-month period before the interviews: (1) being under the effects of the substance or suffering its after-effects while at work or school or while taking care of children; (2) being under the effects of the substance or feeling its after-effects in a situation which increased the user’s chances of getting hurt – i.e., when driving a car or boat, using knives or guns or machinery, crossing against traffic, climbing or swimming; (3) having legal problems because of use of the substance; or (4) having problems getting along with other people because of use of the substance. The proportion of participants who met the DSM-IV criteria for SUD at T5 or T6 or both was 12.7%.</p></sec><sec id="S11"><title>Nonprescription Stimulant Use at T7</title><p id="P17">At T7, the scale of nonprescription stimulant use during the past 12 months consisted of three items: A) diet pills (such as Dexatrim and Dietic), B) stay-awake pills (such as No-Doz, Vivarin, and Caffedrine), and C) other nonprescription stimulants and pep pills. Each item was scored on a 7 point scale indicating the frequency of use: 0 (1), 1–2 (2), 3–5 (3), 6–9 (4), 10–19 (5), 20–39 (6), and 40+ (7). The Cronbach’s alpha of the scale was .67. The proportion of participants who ever used nonprescription stimulants in the past 12 months at T7 was 9.6% (6% used nonprescription diet pill; 4.6% used stay-awake pills; and 2% used other nonprescription stimulants and pep pills).</p></sec></sec>
24776714|Data Analysis|('method', 0.9999992341142077)|('other', 7.658857923895747e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Data Analysis</title><p id="P18">We conducted t-test analyses and χ2 test analyses to compare the participants with/without T7 nonprescription stimulant use. We used a structural equation model (SEM) to examine the empirical validity of the hypothesized pathways. To account for the influences of the participants’ age, gender, T2 stimulant use, T2 depressive mood, T2 delinquency, T2 self-esteem, T2 time spent with friends, T2 maternal marijuana use, T2 parental educational level, T2 family income, and T7 neighborhood cohesion (see <xref ref-type="table" rid="T1">Table 1</xref> for the details on these control variables) on these pathways, we created residual variables by statistically partialing out the effects of the above variables from each of the manifest variables. We then used the residual variables in the Mplus software (<xref rid="R28" ref-type="bibr">Muthén &amp; Muthén, 2010</xref>) to estimate the proposed model. We used the full information maximum likelihood (FIML) option in Mplus (<xref rid="R28" ref-type="bibr">Muthén &amp; Muthén, 2010</xref>) to impute any missing data. The advantage of FIML is that the results are less likely to be biased even if the data are not missing completely at random (<xref rid="R27" ref-type="bibr">Muthén, Kaplan, &amp; Hollis, 1987</xref>). The correlation matrix of the resulting data is called the partial correlation matrix and is used for the SEM analysis. We chose three fit indices to assess the fit of the model: (1) the root mean square error of approximation (RMSEA), (2) Bentler’s comparative fit index (CFI) (<xref rid="R9" ref-type="bibr">Bentler, 1990</xref>) and (3) the standardized root mean square residual (SRMR). Values between .90 and 1.0 on Bentler’s CFI indicate that the model provides a good fit to the data (<xref rid="R23" ref-type="bibr">Kelloway, 1998</xref>). Values for the RMSEA and the SRMR below .10 indicate a good fit. To account for the non-normal distribution of the model variables (e.g., smoking and drinking measures), we used Mplus’s maximum likelihood with robust standard errors (MLR) as the estimator. In order to test for mediational effects (<xref rid="R8" ref-type="bibr">Baron &amp; Kenny, 1986</xref>; <xref rid="R25" ref-type="bibr">MacKinnon, Lockwood, Hoffman, West, &amp; Sheets, 2002</xref>), we calculated the standardized total effects and total indirect effects by using the Model Indirect command in Mplus. The standardized total effect equals the sum of the direct and the indirect effects of each earlier latent variable (estimated in the analysis) on nonprescription stimulant use at T7. The total indirect effect of a latent construct on nonprescription stimulant use is the mediated effect via the intermediate variables that are depicted in the model (see <xref ref-type="fig" rid="F1">Figure 1</xref>).</p></sec>
24788912|None|('method', 0.7214202319245897)|('other', 0.27857976807541024)|<italic toggle="yes">n</italic> = 5) in the affluent areas of Mumbai were recruited. Child’s height and weight were measured by the researcher using standard equipment/protocols. Mothers also reported their child’s height and weight.
24792926|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24792926|Materials|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Materials</title><p>The 18-NBD-Sph [omega(7-nitro-2-1,3-benzoxadiazol-4-yl)(2<italic>S</italic>,3<italic>R</italic>,4<italic>E</italic>)-2-aminooctadec-4-ene-1,3-diol] and 18-NBD-S1P were from Avanti Polar Lipids (Alabaster, AL). The (<italic>R</italic>)-[1-(4-{[3-methyl-5-(phenylsulfonylmethyl)phenoxy]methyl} benzyl) pyrrolidin-2-yl]methanol (PF-543), <italic>Escherichia coli</italic> Rossetta-2 cells, and pET16b were from EMD-Millipore (Billerica, MA). The <italic>n</italic>-octyl-β-<sc>d</sc>-glucopyranoside was from Affymetrix (Santa Clara, CA). All other reagents and chemicals were reagent grade and purchased from Sigma-Aldrich.</p></sec>
24792926|Protein expression and purification|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Protein expression and purification</title><p><italic>Homo sapiens</italic> SphK1 (residues 2–384 with an N-terminal MGHHHHHHHHHHSSG tag) and <italic>H. sapiens</italic> SphK2 (residues 2–618 with an N-terminal MGHHHHHHHHHHSSGHIEGRQL tag) were cloned into a modified pET16b bacterial expression vector. For expression, transformed <italic>E. coli</italic> Rossetta-2 cells were grown in Luria broth with appropriate antibiotics at 37°C with shaking until optical density at 600 nm = 0.4, then the temperature was reduced to 18°C. After 3 h at 18°C, expression was induced overnight with 0.1 mM isopropyl β-<sc>d</sc>-1-thiogalactopyranoside. Cells were harvested by centrifugation and resuspended at a ratio of 10 ml buffer per liter of initial culture in ice-cold buffer: SphK1 resuspension buffer contained 30 mM Tris-HCl [pH 7.4], 300 mM NaCl, 10% glycerol, 5 mM imidazole, 5 mM MgCl<sub>2</sub>, 5 mM β-mercaptoethanol, and 2.5 mM octyl β-<sc>d</sc>-glucopyranoside; SphK2 resuspension buffer contained 30 mM Tris-HCl [pH 7.4], 1 M KCl, 10% glycerol, 5 mM imidazole, 5 mM β-mercaptoethanol, and 2.5 mM <italic>n</italic>-octyl-β-<sc>d</sc>-glucopyranoside. Cells were disrupted by sonication and centrifuged for 45 min at 25,000 <italic>g</italic> to remove cell debris, and the supernatants incubated at 4°C with 100 µl Ni-NTA Agarose (Qiagen, Valencia, CA) slurry per liter of initial culture volume (preequilibrated with resuspension buffer described previously) for 2 h with gentle shaking. The resin was extensively washed in batch with resuspension buffer, followed by washing with 2 ml per liter of initial culture volume with resuspension buffer containing 0.5 mM ATP and 5 mM MgCl<sub>2</sub>. SphKs were eluted with a step gradient containing 20, 30, 50, 60, 70, and 200 mM imidazole. Fractions containing SphK1 were pooled, concentrated, and loaded onto a 16/60 Superdex S75 (GE Healthcare, Pittsburgh, PA) column (120 ml) preequilibrated with 30 mM Tris-HCl [pH 7.4], 300 mM NaCl, 10% glycerol, and 2.5 mM <italic>n</italic>-octyl-β-<sc>d</sc>-glucopyranoside, and run at a flow rate of 0.1 ml/min in an AKTA fast protein LC system (GE Healthcare). SphK1 eluted as two peaks, one at a position expected for a monomer and another in the void volume of the column. Fractions corresponding to the monomeric volume were pooled and concentrated to 1 mg/ml (ε = 48,275 M<sup>−1</sup> cm<sup>−1</sup>). SphK2 was similarly purified on 16/60 Superdex S200 column preequilibrated with 30 mM Tris-HCl [7.5], 1 M KCl, 10% glycerol, 3 mM <italic>n</italic>-octyl-β-<sc>d</sc>-glucopyranoside, and 1 mM DTT. SphK2 also eluted as two peaks, one in the void volume and another at a volume consistent with monomeric SphK2. Monomeric SphK2 was concentrated to 0.1 mg/ml (ε = 63,660 M<sup>−1</sup> cm<sup>−1</sup>).</p></sec>
24792926|NBD-Sph substrate preparation|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>NBD-Sph substrate preparation</title><p>A stock solution of NBD-Sph in chloroform-methanol (8:2) was dried under nitrogen in a glass tube, solubilized in 5% Triton X-100, and sonicated extensively in a water bath with alternating vigorous vortexing. Concentrated stocks of 3.5 mM NBD-Sph in 5% Triton X-100 were stored frozen at −20°C until use. However, after thawing and prior to use in assays, NBD-Sph solutions were extensively resonicated with alternating vigorous vortexing.</p></sec>
24792926|Fluorescence Sph kinase assay|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Fluorescence Sph kinase assay</title><p>Fluorescence emission was measured with a TECAN Infi­nite M1000 fluorescence plate reader (Männedorf, Switzerland) at 37°C in 384-well polypropylene plates (Greiner Bio-One, Frickenhausen, Germany). Excitation wavelength was 550 nm, and emission wavelength was set at 584 nm with a 5 nm band-pass. Reactions analyzed using absorption were performed in quartz cuvettes with a Cary 50 Bio UV-visible spectroscopy (UV/Vis) Spectrophotometer (Agilent, Santa Clara, CA), and data were collected either in scanning kinetics mode (400–600 nm) or at 550 nm. Prior to the initiation of reactions, solutions were allowed to equilibrate, as indicated, at either 25°C or 37°C for 10 min. In most cases, assays were initiated with 20× ATP-Mg (20 mM ATP, 200 mM MgCl<sub>2</sub>, 900 mM Tris-HCl, pH 7.4), after which 384-well plates were shaken or cuvettes were mixed for 15 s for complete mixing. All assays were prepared as master mixes immediately before use in either SphK1 or SphK2 reaction buffer containing enzyme, NBD-Sph, and inhibitors where indicated. SphK1 reaction buffer contained 30 mM Tris-HCl, pH 7.4, 0.05% Triton X-100, 150 mM NaCl, 10% glycerol, 1 mM Na<sub>3</sub>VO<sub>4</sub>, 10 mM NaF, and 10 mM β-glycero-phosphate. SphK2 reaction buffer contained 30 mM Tris-HCl, pH 7.4, 0.05% Triton X-100, 200 mM KCl, and 10% glycerol. Due to the poor solubility of NBD-Sph, optimal assay conditions contain 0.05–0.1% Triton X-100. It was important to add NBD-Sph to the master mix last and for the solution to be immediately and extensively vortexed just prior to use. Concentrations of DMSO up to 2% had no appreciable effects on catalytic rates and were used where indicated.</p></sec>
24803576|None|('method', 0.9995558635392235)|('other', 0.00044413646077645657)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and methods</title>
24803576|None|('method', 0.9995558635392235)|('other', 0.00044413646077645657)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P4">Archived serum and placentas collected on St. Paul Island, Alaska, as part of routine live animal, rookery, and postmortem sampling were available for use in this study. Serum from 40 animals had been collected by standard venipuncture technique and stored at −80°C until testing. Twenty-five samples were from subadult males sampled immediately postmortem as part of the St. Paul subsistence harvest in 1994 (<italic>n</italic> = 15) or 2011 (<italic>n</italic> = 10). Fifteen serum samples from female NFSs represented 11 adults and 4 pups handled in 2009 and 2011. Serum samples were tested by <italic>Brucella</italic> microagglutination test (BMAT) with minor modifications.<sup><xref rid="R2" ref-type="bibr">2</xref></sup> A titer of ≥ 160 was considered positive, 20–80 for borderline, and &lt;20 was considered negative. A high, low, and negative reference control was included with each run.<sup><xref ref-type="fn" rid="FN2">a</xref></sup></p>
24803576|None|('method', 0.9995558635392235)|('other', 0.00044413646077645657)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P5">In 2011, 119 placentas were collected from a single NFS rookery on St. Paul Island, Alaska as part of an ongoing health and disease investigation program. Each placenta was subsampled, and both fresh and formalin-fixed tissues were archived. DNA was extracted from each placenta as previously described<sup><xref rid="R10" ref-type="bibr">10</xref></sup> and available for use in the present study. Additionally, DNA was extracted from serum samples using a commercial kit.<sup><xref ref-type="fn" rid="FN3">b</xref></sup><italic>Brucella</italic> spp. DNA was detected by real-time PCR (qPCR) using a fluorescently labeled hydrolysis probe targeting the insertion sequence (IS) 711 gene as previously described.<sup><xref rid="R21" ref-type="bibr">21</xref></sup> The PCR conditions were modified for detection in clinical specimens. The qPCR amplification was performed using 5 μl of DNA extract, 200 nM of each primer and probe, and a commercially available PCR master mix<sup><xref ref-type="fn" rid="FN4">c</xref></sup> in a 25-μl reaction volume. An exogenous internal positive control<sup><xref ref-type="fn" rid="FN4">c</xref></sup> was added to each reaction to test for inhibition. Amplification and fluorescence detection was performed on a commercially available PCR platform<sup><xref ref-type="fn" rid="FN4">c</xref></sup> with an initial denaturation for 10 min at 95°C, 45 cycles of denaturation for 15 sec at 95°C, and annealing for 1 min at 60°C. A sample was considered positive if the fluorescent growth curves crossed the threshold line within 40 cycles.</p>
24803576|None|('method', 0.9995558635392235)|('other', 0.00044413646077645657)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">Multilocus variable number tandem repeat (VNTR) analysis was performed on IS711 PCR–positive placentas. The PCR amplification of the 15 VNTR loci was performed as described previously<sup><xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R35" ref-type="bibr">35</xref></sup> with modifications for amplification in low template samples. Multiplex PCR assays (AI, BI, AII, and BII) were performed to amplify 15 VNTR loci in a final volume of 10 μl containing 1× PCR buffer, 2 mM MgCl<sub>2</sub>, 2 mM deoxynucleoside triphosphate mix, 0.04 U DNA polymerase,<sup><xref ref-type="fn" rid="FN5">d</xref></sup> and 5 μl of DNA template. All reactions were performed on a commercial thermocycler using the primer concentrations reported previously. Thermal cycling amplification cycles were increased from 35 to 45. Multiplex PCR assays (AI + BI and AII + BII) were combined 1:1. Amplicons underwent fragment analysis on an automated fluorescent capillary DNA sequencer.<sup><xref ref-type="fn" rid="FN4">c</xref></sup> Allele designations were assigned by internal binning capabilities in the commercially available software,<sup><xref ref-type="fn" rid="FN4">c</xref></sup> and a distance tree was generated by clustering analysis using the unweighted pair group method with arithmetic averages (UPGMA).</p>
24803576|None|('method', 0.9995558635392235)|('other', 0.00044413646077645657)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">All placentas positive on PCR were examined microscopically. Formalin-fixed tissues were paraffin embedded, sectioned at 5 μm, and stained with hematoxylin and eosin for histologic review. Sections with histologic lesions were further reviewed using immunohistochemical staining (IHC) for <italic>C. burnetii</italic><sup><xref rid="R9" ref-type="bibr">9</xref></sup> and <italic>Brucella</italic><sup><xref rid="R14" ref-type="bibr">14</xref></sup> as previously described.</p>
24844841|None|('method', 0.9730533758032679)|('other', 0.026946624196732105)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 Dose-finding methods</title>
24844841|2.1 Toxicity monitoring|('method', 0.9730533758032679)|('other', 0.026946624196732105)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.1 Toxicity monitoring</title><p id="P14">Compared to conventional cytotoxic agents, toxicity is often of less concern for molecularly targeted agents and the dose finding is mainly driven by efficacy. However, it is still important to monitor toxicity during the dose finding to ensure patients’ safety.</p><p id="P15">Let (<italic>d</italic><sub>1</sub>, …, <italic>d<sub>J</sub></italic>) denote a set of <italic>J</italic> pre-specified increasing doses for the molecularly targeted agent under investigation and and <italic>q<sub>j</sub></italic> denote the toxicity probability of dose level <italic>j</italic>. Assuming that <italic>x<sub>j</sub></italic> out of <italic>n<sub>j</sub></italic> patients experienced toxicity at dose level <italic>j</italic>, we model the toxicity of each dose level independently using a beta-binomial model<disp-formula id="FD1"><mml:math display="block" id="M1" overflow="scroll"><mml:mtable><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>x</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>∼</mml:mo><mml:mi>b</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi><mml:mi>o</mml:mi><mml:mi>m</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mi>q</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>∼</mml:mo><mml:mi>b</mml:mi><mml:mi>e</mml:mi><mml:mi>t</mml:mi><mml:mi>a</mml:mi><mml:mo>(</mml:mo><mml:mi>a</mml:mi><mml:mo>,</mml:mo><mml:mi>b</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>where <italic>binom</italic>(·) and <italic>beta</italic>(·) denote binomial and beta distributions, respectively, and <italic>a</italic> and <italic>b</italic> are hyperparameters.</p><p id="P16">Let <italic>φ</italic> denote the target toxicity upper bound, the safety of dose level <italic>j</italic> can be monitored by the posterior probability Pr(<italic>q<sub>j</sub></italic> &gt; <italic>φ</italic>|<italic>n<sub>j</sub>, x<sub>j</sub></italic>). Specifically, we define the admissible set <inline-formula><mml:math display="inline" id="M2" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula> as a set of doses satisfying the following safety rule:<disp-formula id="FD2"><label>(1)</label><mml:math display="block" id="M3" overflow="scroll"><mml:mrow><mml:mi mathvariant="script">A</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:mi>j</mml:mi><mml:mo>:</mml:mo><mml:mover accent="true"><mml:mi>Pr</mml:mi><mml:mo stretchy="true">~</mml:mo></mml:mover><mml:mo>(</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>∣</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo>}</mml:mo></mml:mrow></mml:math></disp-formula>where <inline-formula><mml:math display="inline" id="M4" overflow="scroll"><mml:mrow><mml:mover accent="true"><mml:mi>Pr</mml:mi><mml:mo stretchy="true">~</mml:mo></mml:mover><mml:mo>(</mml:mo><mml:msub><mml:mi>q</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>&gt;</mml:mo><mml:mi>ϕ</mml:mi><mml:mo>∣</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>x</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> is the isotonically transformed posterior probability Pr(<italic>q<sub>j</sub></italic> &gt; <italic>φ|n<sub>j</sub>, x<sub>j</sub></italic>) based on the pool adjacent violators algorithm (PAVA) [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>], and <italic>C<sub>T</sub></italic> is a pre-specified toxicity threshold. The isotonic transformation is used to impose dose-toxicity monotonicity and borrow information across dose levels. During the dose finding, we restrict dose assignment and selection within the admissible set <inline-formula><mml:math display="inline" id="M5" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula>, thereby protecting patients from overly toxic doses. Before treating any patient in the trial, all investigational doses should be in <inline-formula><mml:math display="inline" id="M6" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula> and open for testing. This can be done by choosing the values of hyperparameters <italic>a</italic> and <italic>b</italic> such that <italic>Beta</italic>(<italic>φ</italic>; <italic>a, b</italic>) = 1 − <italic>C<sub>T</sub></italic> + <italic>δ</italic>, where <italic>δ</italic> is a small positive number, e.g., <italic>δ</italic> = 0.05. That is, <italic>a priori</italic>, all doses just satisfy the safety rule given in (<xref ref-type="disp-formula" rid="FD2">1</xref>).</p></sec>
24844841|2.2 Logistic design|('method', 0.9730533758032679)|('other', 0.026946624196732105)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>2.2 Logistic design</title><p id="P17">We assume that efficacy is recorded as a binary outcome. Let <italic>p<sub>j</sub></italic> denote the probability of efficacy at dose level <italic>j</italic>. Because the dose-efficacy curve for a molecularly targeted agent is often non-monotonic, an intuitive method for fitting this curve is the logistic regression with a quadratic term, which can be written as<disp-formula id="FD3"><mml:math display="block" id="M7" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>∕</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msubsup><mml:mi>d</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>Assume that at dose level <italic>j, y<sub>j</sub></italic> out of <italic>n<sub>j</sub></italic> patients experienced efficacy, the likelihood for the observed data <inline-formula><mml:math display="inline" id="M8" overflow="scroll"><mml:mrow><mml:mi mathvariant="script">D</mml:mi><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>;</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula> is given by<disp-formula id="FD4"><mml:math display="block" id="M9" overflow="scroll"><mml:mrow><mml:mi>L</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="script">D</mml:mi><mml:mo>∣</mml:mo><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>)</mml:mo><mml:mo>∝</mml:mo><mml:munderover><mml:mo>∏</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msubsup><mml:mi>d</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:msup></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msubsup><mml:mi>d</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msup><mml:msup><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>γ</mml:mi><mml:msubsup><mml:mi>d</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:msup></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>−</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:msup><mml:mo>;</mml:mo></mml:mrow></mml:math></disp-formula>and the posterior of unknown regression parameters <italic>α, β</italic> and <italic>γ</italic> is <inline-formula><mml:math display="inline" id="M10" overflow="scroll"><mml:mrow><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>∣</mml:mo><mml:mi mathvariant="script">D</mml:mi><mml:mo>)</mml:mo><mml:mo>∝</mml:mo><mml:mi>f</mml:mi><mml:mo>(</mml:mo><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>)</mml:mo><mml:mi>L</mml:mi><mml:mo>(</mml:mo><mml:mi mathvariant="script">D</mml:mi><mml:mo>∣</mml:mo><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>β</mml:mi><mml:mo>,</mml:mo><mml:mi>γ</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> where <italic>f</italic>(<italic>α, β, γ</italic>) is the prior distribution of <italic>α, β</italic> and <italic>γ</italic>.</p><p id="P18">Similar as Gelman et al [<xref rid="R12" ref-type="bibr">12</xref>], we specify a Cauchy prior distribution with center 0 and scale 10 for <italic>α</italic>, i.e., <italic>Cauchy</italic>(0, 10); and two independent Cauchy priors <italic>Cauchy</italic>(0, 2.5) for <italic>β</italic> and <italic>γ</italic>, respectively. The posterior distribution can be easily sampled based on the Markov chain Monte Carlo (MCMC) method and used for guiding dose escalation and de-escalation.</p><p id="P19">The proposed Bayesian logistic model-based dose-finding method can be summarized as follows:<list list-type="order" id="L1"><list-item><p id="P20">The first cohort of patients is treated at the lowest dose <italic>d</italic><sub>1</sub>, or at the physician-specified dose.</p></list-item><list-item><p id="P21">At the current dose level <italic>j</italic>, based on the toxicity outcomes, applying safety rule (<xref ref-type="disp-formula" rid="FD2">1</xref>) to find the admissible set <inline-formula><mml:math display="inline" id="M11" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula>.</p></list-item><list-item><p id="P22">Identify the dose level <italic>j</italic>* which has the highest posterior estimate of efficacy probability within <inline-formula><mml:math display="inline" id="M12" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula>. If <italic>j</italic>* &gt; <italic>j</italic>, the dose level is escalated to <italic>j</italic> + 1; if <italic>j</italic>* &lt; <italic>j</italic>, the dose level is de-escalated to <italic>j</italic> − 1; otherwise, the dose level remains at <italic>j</italic>.</p></list-item><list-item><p id="P23">Once the maximum sample size is reached, the dose that has the highest estimate of efficacy probability within <inline-formula><mml:math display="inline" id="M13" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula> is selected as the optimal biological dose.</p></list-item></list></p><p id="P24">This parametric design is straightforward and easy to implement, but may be sensitive to model misspecifications. In the subsection that follows, we propose a nonparametric approach based on the isotonic regression.</p></sec>
24844841|2.3 Isotonic design|('method', 0.9730533758032679)|('other', 0.026946624196732105)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>2.3 Isotonic design</title><p id="P25">Within conventional phase I trial designs for cytotoxic agents, various isotonic designs have been proposed to find the MTD without making any parametric assumption beyond the monotonicity on the dose-toxicity curve. However, the existing isotonic designs cannot be directly used to find the optimal biological dose because in order to conduct isotonic regression, these designs require that the dose-response order constraint is known (e.g., monotonicity), which may not be satisfied for molecularly targeted agents.</p><p id="P26">Specifically, for the molecularly targeted agents with unimodal or plateaued dose-efficacy curves, our goal is to find the optimal biological dose, the dose level <italic>j</italic>* such that<disp-formula id="FD5"><label>(2)</label><mml:math display="block" id="M14" overflow="scroll"><mml:mrow><mml:msub><mml:mi>p</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>≤</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>∗</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo>≥</mml:mo><mml:mo>⋯</mml:mo><mml:mo>≥</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>J</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula>In other words, before we identify the optimal biological dose, the order constraint (<xref ref-type="disp-formula" rid="FD5">2</xref>) is actually unknown. To overcome this difficulty, we take the approach of double-sided isotonic regression [<xref rid="R15" ref-type="bibr">15</xref>]. In this approach, we first enumerate all <italic>J</italic> possible locations of <italic>j</italic>*, <italic>j</italic>* = 1, …, <italic>J</italic>. Given each of the locations, say <italic>j</italic>* = <italic>k</italic>, the isotonic estimates <inline-formula><mml:math display="inline" id="M15" overflow="scroll"><mml:mrow><mml:mo>{</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>j</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>k</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>;</mml:mo><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula> can be obtained by fitting two separate standard isotonic regressions: one for <italic>p</italic><sub>1</sub>, …, <italic>p<sub>j</sub></italic>* with the constraint <italic>p</italic><sub>1</sub> ≤ ⋯ ≤ <italic>p<sub>j</sub></italic>* and the other one for <italic>p<sub>j</sub></italic>*+1, … <italic>p<sub>J</sub></italic> with the constraint <italic>p<sub>j</sub></italic>*+1 ≥ ⋯ ≥ <italic>p<sub>J</sub></italic>. Each of these two isotonic regressions can be done using the PAVA algorithm[<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>], which yields isotonic estimates by replacing any adjacent observations violated the monotonicity assumption with their (weighted) average.</p><p id="P27">After applying this procedure to each of <italic>J</italic> possible locations of <italic>j</italic>*, we obtain <italic>J</italic> sets of possible isotonic estimates <inline-formula><mml:math display="inline" id="M16" overflow="scroll"><mml:mrow><mml:mo>{</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>j</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>k</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>}</mml:mo><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>J</mml:mi></mml:mrow></mml:math></inline-formula>. We select as the final isotonic estimates <inline-formula><mml:math display="inline" id="M17" overflow="scroll"><mml:mrow><mml:mo>{</mml:mo><mml:msub><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>j</mml:mi></mml:msub><mml:mo>}</mml:mo><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>j</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mi>k</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula>, the set of isotonic estimates with the smallest sum of the square error, i.e.,<disp-formula id="FD6"><mml:math display="block" id="M18" overflow="scroll"><mml:mrow><mml:msup><mml:mi>k</mml:mi><mml:mo>∗</mml:mo></mml:msup><mml:mo>=</mml:mo><mml:msub><mml:mi>argmin</mml:mi><mml:mrow><mml:mi>k</mml:mi><mml:mo>∈</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msub><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:mrow><mml:msup><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>p</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi>j</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:mi>k</mml:mi><mml:mo>)</mml:mo></mml:mrow></mml:msubsup><mml:mo>−</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>y</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mrow></mml:math></disp-formula></p><p id="P28">Our isotonic design can be described as follows:<list list-type="order" id="L2"><list-item><p id="P29">Treat the first cohort of patients at the lowest dose <italic>d</italic><sub>1</sub>, or at the physician-specified dose.</p></list-item><list-item><p id="P30">At the current dose level <italic>j</italic>, based on the toxicity outcomes, applying safety rule (<xref ref-type="disp-formula" rid="FD2">1</xref>) to find the admissible set <inline-formula><mml:math display="inline" id="M19" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula>.</p></list-item><list-item><p id="P31">Identify the dose level <italic>j</italic>* that has the highest isotonic estimate of efficacy probability among the tried doses within <inline-formula><mml:math display="inline" id="M20" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula>. Where there are ties, we select <italic>j</italic>* as the lowest dose level among the ties. Let <italic>j<sup>t</sup></italic> denote the highest dose level tried thus far. If <italic>j</italic>* &gt; <italic>j</italic>, we escalate the dose level to <italic>j</italic> + 1; if <italic>j</italic>* &lt; <italic>j</italic>, we de-escalate the dose level to <italic>j</italic> − 1; if <italic>j</italic>* = <italic>j</italic> = <italic>j<sup>t</sup></italic>, we escalate the dose level to <italic>j</italic> + 1 given that <italic>j</italic> + 1 is in <inline-formula><mml:math display="inline" id="M21" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula>, otherwise we retain the dose level <italic>j</italic>.</p></list-item><list-item><p id="P32">Once the maximum sample size is reached, we select the lowest dose that has the highest estimate of efficacy probability within <inline-formula><mml:math display="inline" id="M22" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula> as the optimal biological dose.</p></list-item></list></p><p id="P33">One limitation of the isotonic regression is that it cannot estimate the efficacy probabilities for the untried doses at which no patients have been treated. Therefore, during the trial conduct, when the dose with the highest estimate of efficacy is the highest tried dose (i.e., <italic>j</italic>* = <italic>j</italic> = <italic>j<sup>t</sup></italic>), there is no information to determine whether we have achieved the maximum point of the dose-efficacy curve or not. To overcome this limitation, in the above dose-finding algorithm, when <italic>j</italic>* = <italic>j</italic> = <italic>j<sup>t</sup></italic> we automatically escalate the dose level to further explore the dose-efficacy curve and search the maximum point, given that the next higher dose level is safe (i.e., within the admissible set <inline-formula><mml:math display="inline" id="M23" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula>).</p></sec>
24844841|2.4 Local logistic design|('method', 0.9730533758032679)|('other', 0.026946624196732105)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>2.4 Local logistic design</title><p id="P34">We have proposed the L-logistic design. In the L-logistic design, we fit a local Bayesian linear logistic model based on the local data <inline-formula><mml:math display="inline" id="M24" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo>{</mml:mo><mml:msub><mml:mi>y</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>;</mml:mo><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mo>−</mml:mo><mml:mi>l</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>}</mml:mo></mml:mrow></mml:math></inline-formula> collected from the current dose level <italic>j</italic> up to the previous <italic>l</italic> − 1 dose levels as,<disp-formula id="FD7"><mml:math display="block" id="M25" overflow="scroll"><mml:mrow><mml:mi>log</mml:mi><mml:mo>(</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>∕</mml:mo><mml:mo>(</mml:mo><mml:mn>1</mml:mn><mml:mo>−</mml:mo><mml:msub><mml:mi>p</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>)</mml:mo><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mi>d</mml:mi><mml:mi>k</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mi>j</mml:mi><mml:mo>−</mml:mo><mml:mi>l</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>j</mml:mi><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="FD8"><mml:math display="block" id="M26" overflow="scroll"><mml:mrow><mml:mi>α</mml:mi><mml:mo>∼</mml:mo><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>y</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>10</mml:mn><mml:mo>)</mml:mo><mml:mo>,</mml:mo><mml:mspace width="1em"/><mml:mi>β</mml:mi><mml:mo>∼</mml:mo><mml:mi>C</mml:mi><mml:mi>a</mml:mi><mml:mi>u</mml:mi><mml:mi>c</mml:mi><mml:mi>h</mml:mi><mml:mi>y</mml:mi><mml:mo>(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>2.5</mml:mn><mml:mo>)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where 2 ≤ <italic>l</italic> ≤ <italic>J</italic>. We take the weakly informative Cauchy prior distribution for <italic>α</italic> and <italic>β</italic>, as described in Section 2.1. We recommend <italic>l</italic> = 2 because we find that increasing the value of <italic>l</italic> yields similar or even worse operating characteristics in our simulation studies. One may question how reliable the estimation of the parameters for the local logistic model is based on data observed from 2 doses. We note that for the purpose of dose finding, our goal here is not to obtain precise estimates of the model parameters, but to capture the local trend (e.g., increasing or decreasing) of the dose-response curve for directing dose escalation/deescalation. As long as the estimates correctly identify the trend of the curve (i.e., the sign of the slope), they lead to appropriate dose escalation and deescalation. Simulation studies in Section 3 show that the L-logistic design based on two local doses yields good operating characteristics, suggesting that the estimation using local data is adequately stable to identify the local trend of the dose-response curve.</p><p id="P35">To direct the dose escalation/de-escalation in a trial, we calculate the posterior probability <inline-formula><mml:math display="inline" id="M27" overflow="scroll"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> based on the local logistic model. Let <italic>C</italic><sub><italic>E</italic>1</sub> and <italic>C</italic><sub><italic>E</italic>2</sub> be pre-specified efficacy cutoffs and <italic>C</italic><sub><italic>E</italic>1</sub> &gt; <italic>C</italic><sub><italic>E</italic>2</sub>. If <inline-formula><mml:math display="inline" id="M28" overflow="scroll"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> (i.e., the current trend of the dose-efficacy curve is increasing), we escalate the dose because the next higher dose level is expected to have higher efficacy. In contrast, if <inline-formula><mml:math display="inline" id="M29" overflow="scroll"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, which indicates a decreasing dose-efficacy curve, we de-escalate the dose because the lower dose level is expected to have higher efficacy. Otherwise, we stay at the current dose to accumulate more data. The values of <italic>C</italic><sub><italic>E</italic>1</sub> and <italic>C</italic><sub><italic>E</italic>2</sub> can be calibrated by simulation to obtain good operating characteristics. Typically, <italic>C</italic><sub><italic>E</italic>1</sub> should be larger than <italic>C</italic><sub><italic>E</italic>2</sub> by a certain reasonable margin, such as 10% to 20%. By using the posterior probability <inline-formula><mml:math display="inline" id="M30" overflow="scroll"><mml:mrow><mml:mi>Pr</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula> as the criterion of dose escalation, we automatically account for the uncertainty associated with parameter estimation.</p><p id="P36">The dose-finding algorithm for the proposed L-logistic design is described as follows:<list list-type="order" id="L3"><list-item><p id="P37">Starting from the lowest <italic>l</italic> dose levels, treat one cohort of patients at each dose levels.</p></list-item><list-item><p id="P38">At the current dose level <italic>j</italic>, based on the toxicity outcomes, applying safety rule (<xref ref-type="disp-formula" rid="FD2">1</xref>) to find the admissible set <inline-formula><mml:math display="inline" id="M31" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula>.</p></list-item><list-item><p id="P39">Based on the efficacy outcomes from the current and previous <italic>l</italic>−1 dose levels, calculate the posterior probability <inline-formula><mml:math display="inline" id="M32" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo></mml:mrow></mml:math></inline-formula>. If <inline-formula><mml:math display="inline" id="M33" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>&gt;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, the dose level is escalated to <italic>j</italic> + 1 when <italic>j</italic> + 1 is in <inline-formula><mml:math display="inline" id="M34" overflow="scroll"><mml:mi mathvariant="script">A</mml:mi></mml:math></inline-formula> and otherwise retain at <italic>j</italic>; if <inline-formula><mml:math display="inline" id="M35" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, the dose level is de-escalated to <italic>j</italic> − 1; otherwise, i.e., <inline-formula><mml:math display="inline" id="M36" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>)</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, the dose level <italic>j</italic> is retained.</p></list-item><list-item><p id="P40">Once the maximum sample size is reached, based on all the observed data, we carry out a double-sided isotonic regression and select the lowest dose that has the highest estimate of the efficacy probability as the optimal biological dose.</p></list-item></list></p><p id="P41">One potential problem of the above dose-finding algorithm is that the dose movement may bounce back and forth between dose levels <italic>j</italic> and <italic>j</italic> + 1 when the dose level <italic>j</italic> is the maximum point of the dose-efficacy curve. To avoid this problem, before conducting any dose escalation, we will determine whether <inline-formula><mml:math display="inline" id="M37" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> whenever the dose level <italic>j</italic> + 1 has been used to treat any patients. If <inline-formula><mml:math display="inline" id="M38" overflow="scroll"><mml:mrow><mml:mi>P</mml:mi><mml:mi>r</mml:mi><mml:mo>(</mml:mo><mml:mi>β</mml:mi><mml:mo>&gt;</mml:mo><mml:mn>0</mml:mn><mml:mo>∣</mml:mo><mml:msub><mml:mi mathvariant="script">D</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>)</mml:mo><mml:mo>&lt;</mml:mo><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>E</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>, indicating that the dose level <italic>j</italic> is the maximum point of the curve, we will retain the current dose level. The values of <italic>C<sub>E</sub></italic><sub>1</sub> and <italic>C<sub>E</sub></italic><sub>2</sub> are calibrated according to the desirable operating characteristics.</p></sec>
24852168|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">METHODS</title>
24852168|Study participants|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Study participants</title><p>The Study of Women’s Health Across the Nation (SWAN) is an ongoing longitudinal multi-ethnic study of the biological, physical, psychological, and social changes during the menopausal transition. The study design has been previously reported (<xref rid="bib23" ref-type="bibr">23</xref>). In brief, between 1996 and 1997, 3,302 participants aged 42–52 years were recruited from seven designated sites (Boston, MA; Detroit, MI; Oakland, CA; Los Angeles, CA; Pittsburgh, PA; Chicago, IL; and Newark, NJ). The eligibility criteria for the SWAN study were: <italic>1</italic>) an intact uterus and at least one ovary; <italic>2</italic>) not pregnant or breastfeeding; <italic>3</italic>) at least one menstrual period within the past 3 months; and <italic>4</italic>) no HT use within the past 3 months.</p><p>Participants of the current study were part of an ancillary study to SWAN at the Pittsburgh site where enrollment began between 1998 and 2003. Lipoprotein subclasses were available from blood samples (collected at SWAN core visits 1 through 5) of 120 participants who were selected from the larger Pittsburgh sample of participants who were not using HT (43.3% were premenopausal or early perimenopausal and 56.7% were late peri- or postmenopausal). Research protocols were approved by the University of Pittsburgh institutional review board and all the participants provided written informed consent prior to enrollment.</p></sec>
24852168|Study measures|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Study measures</title><sec><title>Blood assays.</title><p>Phlebotomy was performed in the morning after 12 h of fasting. The participants were scheduled for venipuncture on days 2 to 5 of a spontaneous menstrual cycle. Two attempts were made to obtain a sample at days 2 to 5. If a timed sample could not be obtained (because menstrual cycles became less regular, samples tied to the early follicular phase were not feasible), a random fasting sample was taken within 90 days of the annual visit. Blood was maintained up to 1 h at 4°C until separated and then frozen (−80°C) and sent on dry ice to the Medical Research Laboratories. EDTA-treated plasma was used to analyze lipids and lipoprotein subclasses. Triglycerides were determined by enzymatic methods (Hitachi 747 analyzer; Boehringer Mannheim Diagnostics, Indianapolis, IN). HDL-C was isolated with heparin-2M manganese chloride. LDL-C was calculated by the Friedewald equation for all subjects with triglycerides &lt;400 mg/dl (<xref rid="bib24" ref-type="bibr">24</xref>). LDL-C was set to missing for those with triglycerides ≥400 mg/dl (only 1 participant). ApoA-1 and ApoB were measured by immunonephelometry (BN1A-100; Behring Diagnostics, Westwood, MA).</p><p>Lipoprotein subclasses were determined by an automated NMR spectroscopic assay (LipoScience Inc., Raleigh, NC), using the LipoProfile-3 algorithm (<xref rid="bib11" ref-type="bibr">11</xref>, <xref rid="bib25" ref-type="bibr">25</xref>). Total particle concentrations of VLDLs and LDLs in nanomoles per liter units and HDLs in micromoles per liter units were determined by summing the concentrations of their respective subclasses [total VLDL-Ps as the sum of large, medium, and small VLDL-Ps; total LDL-Ps as the sum of large and small LDL-Ps and IDL particles; total HDL-Ps as the sum of large, medium, and small HDL-Ps], which were obtained from the measured amplitudes of the distinct lipid methyl group NMR signals they emit. Weighted-average VLDL-, LDL-, and HDL-P size was calculated by summing the diameter of each subclass multiplied by its relative mass percentage as estimated by the amplitude of its methyl NMR signal. Particle diameters and coefficients of variation (CVs) have been previously published for the NMR measures, with between-run CVs 7.1% or below for all particles except IDLs (13%) (<xref rid="bib25" ref-type="bibr">25</xref>).</p><p>Endogenous sex hormones were measured at the University of Michigan Endocrine Laboratory using the Automated Chemilumisence System 180 automated analyzer (Bayer Diagnostics Corp., Norwood, MA). E2 was measured using a modified off-line Automated Chemilumisence System 180 (E2-6). The lower limit of detection (LLD) was between 1 and 7 pg/ml. The averaged inter- and intra-assay CVs were 10.6 and 6.4%, respectively. Serum testosterone concentration was evaluated with the Automated Chemilumisence System 180 total testosterone assay modified to increase precision in the low ranges. The LLD was between 2 and 2.2 ng/dl. The inter- and intra-assay CVs were 10.5 and 8.5%, respectively. SHBG was measured with a two-site chemiluminescent immunoassay. The LLD was between 1.9 and 3.2 nM. The inter- and intra-assay CVs were 9.9 and 6.1%, respectively. The FAI was used to estimate the amount of the free active (unbounded to SHBG) testosterone. FAI was calculated as (100 × testosterone)/(28.84 × SHBG) (<xref rid="bib26" ref-type="bibr">26</xref>). Only E2 assays were conducted in duplicate. The arithmetic mean for the duplicate measures was calculated and reported (CVs of 3–12%). Hormone values below the LLD were replaced with a random value between zero and the LLD. For the current sample of SWAN women, only one participant had an E2 value that was below the LLD. None of the women had values for the other hormones that were below the LLD, and therefore the LLD was not an issue in the current analyses. Cycle day of blood draw was reported as days 2 to 5 (for regularly menstruating women) or outside of that period (for irregularly and nonmenstruating women).</p></sec><sec><title>Study covariates.</title><p>Weight and height were measured at each clinic visit. BMI was calculated as weight/height<sup>2</sup>. Race/ethnicity was self-reported and age, smoking status (current vs. past/never), physical activity, and alcohol use were derived from interviews administered during clinic visits. Physical activity was assessed via a modified Kaiser Permanente Health Plan Activity Survey (<xref rid="bib27" ref-type="bibr">27</xref>). Alcohol use was reported as average weekly number of servings of beer, wine, liquor, or mixed drinks (none, &lt;2 servings/week, ≥2 servings/week). Menopausal status was determined annually based on reports about frequency, regularity of menstrual bleeding, and use of HT as follow: <italic>1</italic>) premenopause: monthly bleeding with no perceived change in cycle interval; <italic>2</italic>) early perimenopause: monthly bleeding with a perceived change in cycle interval, but at least one menstrual period within the past 3 months; 3) late perimenopause: 3 consecutive months of amenorrhea; and <italic>4</italic>) postmenopause: 12 consecutive months of amenorrhea. Both pre- and early perimenopausal women were combined in one group while late peri- and postmenopausal women were combined in a second group.</p></sec></sec>
24852168|Statistical analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Statistical analysis</title><p>The distribution of each continuous variable was examined and variables were log transformed or categorized if the distribution was not normal. Two-sample <italic>t</italic>-test, two-sample Wilcoxon rank sum test, and chi-square test were utilized to compare participant characteristics between pre-/early perimenopausal and late peri-/postmenopausal.</p><p>Spearman correlations and partial Spearman correlations were used to assess the strength and direction of the associations between endogenous sex hormones and lipoprotein subclasses (separate model for each sex hormone with each lipoprotein subclass). Partial correlation coefficients were adjusted for covariates known to impact lipoprotein levels (physical activity, alcohol use, BMI) (<xref rid="bib18" ref-type="bibr">18</xref>) in addition to age, cycle day of blood draw, and race. Quintiles of E2 were created and evaluated in relation to lipoprotein subclasses that were found to be significantly correlated with E2 level, using linear regression. Adjusted geometric means of lipoprotein subclasses were estimated for E2 quintiles and graphed. These graphs suggested a potential threshold effect of E2 at the third quintile (E2 ≥25.7 pg/ml), which was close to the median value of E2 among late peri-/postmenopausal participants in the current study. This threshold effect was evaluated by testing significant differences in lipoprotein subclasses among women with an E2 level below 25.7 pg/ml and those with an E2 ≥25.7 pg/ml. Effect modifications of menopausal status, BMI, and race on associations between sex hormones and lipoprotein subclasses were also evaluated. Analyses were performed with SAS version 9.2 (SAS Institute, Cary, NC).</p></sec>
24855118|None|('method', 0.9744054745017384)|('other', 0.025594525498261623)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 Notation and Models</title>
24855118|None|('method', 0.9744054745017384)|('other', 0.025594525498261623)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">Let <italic>Y</italic> be the outcome measure. A binary variable <italic>T</italic> ∈ {−1/2, 1/2} indicates the new drug or treatment, with <italic>T</italic> = −1/2 for those who receive the standard treatment. The other covariates in the model are <bold><italic>W</italic></bold> = {<italic>W</italic><sub>1</sub>,<italic>W</italic><sub>2</sub>, . . . , <italic>W<sub>q</sub></italic>}<sup>⊤</sup> ∈ ℝ<italic><sup>q</sup></italic>, assumed to be a length-<italic>q</italic> vector of commonly measured prognostic variables, and <italic>V</italic> ∈ ℝ, which is the biomarker. The biomarker is chosen so that patients with higher values of <italic>V</italic> are expected to be more responsive to the new treatment. In the simplest case of a continuous <italic>Y</italic>, the outcome model may be given by: <disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mi>Y</mml:mi><mml:mo>∣</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mo>~</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where the length-(<italic>q</italic> + 4) vector <bold><italic>X</italic></bold> = {1, <italic>T</italic>,<bold><italic>W</italic></bold><sup>⊤</sup>, <italic>V</italic>, <italic>T</italic> × <italic>V</italic> }<sup>⊤</sup>, <inline-formula><mml:math id="M2" display="inline" overflow="scroll"><mml:mrow><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msubsup><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup><mml:mo>,</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>V</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:math></inline-formula> and <bold><italic>β<sub>W</sub></italic></bold> = {<italic>β<sub>W</sub></italic><sub>1</sub>, <italic>β<sub>W</sub></italic><sub>2</sub>, . . . , <italic>β<sub>Wq</sub></italic>}<sup>⊤</sup>. Our primary goal in this paper is to determine if <italic>V</italic> is predictive, meaning that a patient’s measure of <italic>V</italic> determines in part the extent the treatment <italic>T</italic> affects <italic>Y</italic> . Algebraically, this is true if <italic>θ</italic> ≠ 0. In contrast, our focus is not in determining whether <italic>V</italic> is prognostic, which means that typical values of the outcome <italic>Y</italic> depend on <italic>V</italic> for patients treated under the standard of care, i.e. when <italic>T</italic> = −1/2. The biomarker is prognostic if <italic>β<sub>V</sub></italic> −<italic>θ</italic>/2 ≠ 0. Clearly, <italic>V</italic> may be both prognostic and predictive, but inference on <italic>θ</italic> is of primary interest.</p>
24855118|Group 1: Prospective randomized clinical trial (RCT)|('method', 0.9744054745017384)|('other', 0.025594525498261623)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Group 1: Prospective randomized clinical trial (RCT)</title><p id="P7">We call the primary, small prospective phase II study group 1 and assume it has <italic>n</italic><sub>1</sub> observations. The treatment <italic>T</italic> may take on both values in this group. Because the data in group 1 come from a RCT, <italic>T</italic> is assumed to be independent of both <italic>V</italic> and <bold><italic>W</italic></bold>.</p></sec>
24855118|Group 2: Historical data under standard of care|('method', 0.9744054745017384)|('other', 0.025594525498261623)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4" sec-type="methods"><title>Group 2: Historical data under standard of care</title><p id="P8">In group 2, <italic>T</italic> = −1/2 for all observations, corresponding to a set of patients treated under the standard of care, and the biomarker <italic>V</italic> is measured. We will call these data, containing <italic>n</italic><sub>2</sub> observations, group 2. By itself, group 2 only provides information about the quantity <italic>β<sub>V</sub></italic> − <italic>θ</italic>/2, i.e. whether or not the biomarker is prognostic, and <italic>θ</italic> is not identified because <italic>T</italic> does not vary in this group. However, as we will show, even by helping to inform the quantity <italic>β<sub>V</sub></italic> −<italic>θ</italic>/2, group 2 may still provide a gain in efficiency for estimating <italic>θ</italic>.</p></sec>
24855118|Group 3: Historical data that is missing biomarker information|('method', 0.9744054745017384)|('other', 0.025594525498261623)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5" sec-type="methods"><title>Group 3: Historical data that is missing biomarker information</title><p id="P9">In these data (group 3), <italic>T</italic> varies, as with group 1, but the biomarker <italic>V</italic> is unmeasured. These may be patient data from earlier-phase studies of the treatment of interest, either observational or a randomized study, before the biomarker <italic>V</italic> was identified or in which it was not measured. It is reasonable to assume that the distribution of <italic>T</italic> is conditionally independent of (the unobserved) <italic>V</italic> given <bold><italic>W</italic></bold>. This is trivially satisfied if group 3 arises from an RCT. However, even if group 3 comes from an observational study, so that the distribution of <italic>T</italic> depends on the prognostic variables <bold><italic>W</italic></bold>, conditional independence may be assumed because <italic>V</italic> was not measured or not known. The assumption is critical because it differentiates this scenario from a more problematic retrospective validation of purely observational data, in which <italic>T</italic> and <italic>V</italic> may be highly correlated.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> In practice, conditional independence will not hold exactly; however, if <bold><italic>W</italic></bold> is sufficiently rich, assuming so will be a good approximation. Depending on the underlying model for <italic>V</italic> or <italic>V</italic> |<bold><italic>W</italic></bold>, by itself, group 3 will typically only provide information on expressions containing both <italic>θ</italic> and the remaining elements of <bold><italic>β</italic></bold>, and <italic>θ</italic> alone is not identified. However, as with group 2, group 3 may contribute a gain in efficiency for estimating <italic>θ</italic> when combined with group 1.</p><p id="P10">We will quantify this efficiency gain in estimating <italic>θ</italic> from the inclusion of groups 2 or 3 through a numerical evaluation of Fisher information matrices. The assumed biomarker and treatment models are, respectively,</p><p id="P11"><disp-formula id="FD2"><label>(2)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:mi>V</mml:mi><mml:mo>∣</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>~</mml:mo><mml:mi mathvariant="normal">N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>,</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="FD3"><label>(3)</label><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:mi>T</mml:mi><mml:mo>∣</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:mo>~</mml:mo><mml:mtext>Bin</mml:mtext><mml:mo stretchy="false">(</mml:mo><mml:mtext>expit</mml:mtext><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>α</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">α</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo stretchy="false">}</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where expit{<italic>x</italic>} = [1 + exp(−<italic>x</italic>)]<sup>–1</sup>. Model (<xref rid="FD3" ref-type="disp-formula">3</xref>) does not apply to group 2, because <italic>T</italic> does not vary in that group. We also assume that <bold><italic>α</italic></bold> = <bold>0</bold><italic><sub>q</sub></italic> in group 1, because it is a randomized trial. If group 3 corresponds to data from an observational study, then <bold><italic>α</italic> ≠ 0</bold><italic><sub>q</sub></italic>. When <italic>V</italic> is missing, as in group 3, the marginal outcome model can be determined by mixing over the original outcome model (<xref rid="FD1" ref-type="disp-formula">1</xref>) and the biomarker model (<xref rid="FD2" ref-type="disp-formula">2</xref>), leading to</p><disp-formula id="FD4"><label>(4)</label><mml:math id="M5" display="block" overflow="scroll"><mml:mrow><mml:mi>Y</mml:mi><mml:mo>∣</mml:mo><mml:mi>T</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mspace width="0.16667em"/><mml:mo stretchy="false">(</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msub><mml:mi>β</mml:mi><mml:mi>V</mml:mi></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>θ</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>+</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>V</mml:mi></mml:msub><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mo stretchy="false">[</mml:mo><mml:mi>θ</mml:mi><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mo>,</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>V</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>T</mml:mi><mml:mi>θ</mml:mi><mml:mo stretchy="false">]</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><p id="P12">The variance of <italic>Y</italic> |<italic>T</italic>,<bold><italic>W</italic></bold> depends on the value of the treatment <italic>T</italic>. Under these models, then, four functions of the parameters contain <italic>θ</italic>, through which group 3 contributes its relevant information: <italic>β<sub>T</sub></italic> + <italic>γ</italic><sub>0</sub><italic>θ</italic>, <italic>θ</italic><bold><italic>γ</italic></bold>, <italic>τ</italic><sup>2</sup>[<italic>β<sub>V</sub></italic> −<italic>θ</italic>/2]<sup>2</sup> + <italic>σ</italic><sup>2</sup> (the error variance when <italic>T</italic> = −1/2), <italic>τ</italic><sup>2</sup>[<italic>β<sub>V</sub></italic> + <italic>θ</italic>/2]<sup>2</sup> + <italic>σ</italic><sup>2</sup> (the error variance when <italic>T</italic> = 1/2).</p><sec id="S6"><title>Remark 1</title><p id="P13">Although models (<xref rid="FD1" ref-type="disp-formula">1</xref>) – (<xref rid="FD3" ref-type="disp-formula">3</xref>) are written so that all parameters are shared between the three groups, we will weaken this assumption in our numerical study. The intercepts <italic>β</italic><sub>0</sub> and <italic>γ</italic><sub>0</sub> may vary between groups, which is important because it allows for the populations to differ in ways that may not be explained by <bold><italic>W</italic></bold>.</p></sec><sec id="S7"><title>Remark 2</title><p id="P14">It is not necessary to write an explicit model for <bold><italic>W</italic></bold>, because it is fully observed in all groups. For ease of notation, we denote the first two moments of <bold><italic>W</italic></bold> as E[<bold><italic>W</italic></bold>] and E[<bold><italic>WW</italic></bold><sup>⊤</sup>] but do not require that these be equal between groups.</p></sec></sec>
24855118|None|('method', 0.8174977050137823)|('other', 0.1825022949862177)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3 Numerical study of efficiency gains</title>
24855118|None|('method', 0.8174977050137823)|('other', 0.1825022949862177)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P15">In this section, we assess, through a numerical study, the benefit to the analysis of group 1, assumed to be RCT data, from adding either the group 2 or group 3 data. To do this, we estimate the asymptotic variance of the interaction parameter <italic>θ</italic> by numerically calculating and inverting the expected Fisher information matrices of the parameters from models (<xref rid="FD1" ref-type="disp-formula">1</xref>) and (<xref rid="FD2" ref-type="disp-formula">2</xref>) and recording the resulting entry corresponding to <italic>θ</italic>. The expected Fisher information matrices for one observation from groups 1, 2, or 3 are respectively denoted as <bold><italic>I</italic></bold><sub>1</sub>, <bold><italic>I</italic></bold><sub>2</sub> or <bold><italic>I</italic></bold><sub>3</sub> and are derived in Appendices A1–A3: <disp-formula id="FD5"><label>(5)</label><mml:math id="M6" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>T</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>V</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>V</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:msup><mml:mi>V</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mi>V</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>V</mml:mi><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mi>V</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:msup><mml:mi>V</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>V</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:mrow><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>τ</mml:mi><mml:mn>4</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula><disp-formula id="FD6"><label>(6)</label><mml:math id="M7" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:mo>-</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>V</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:mo>-</mml:mo><mml:mi>V</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>V</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:msup><mml:mi>V</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mo>-</mml:mo><mml:mi>V</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>V</mml:mi><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mo>-</mml:mo><mml:mi>V</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mo>-</mml:mo><mml:msup><mml:mi>V</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>V</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:mrow><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msubsup><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>τ</mml:mi><mml:mn>4</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><disp-formula id="FD7"><label>(7)</label><mml:math id="M8" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>T</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi mathvariant="bold-italic">W</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>τ</mml:mi><mml:mn>4</mml:mn></mml:msup><mml:msup><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:msup><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>T</mml:mi><mml:msup><mml:mi>τ</mml:mi><mml:mn>4</mml:mn></mml:msup><mml:msup><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mn>4</mml:mn><mml:mo>+</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>4</mml:mn></mml:msup><mml:msup><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>D</mml:mi><mml:mo>/</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi>D</mml:mi><mml:mo>/</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi>D</mml:mi></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mi>D</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>D</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>D</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>D</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:msup><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mrow><mml:mi>D</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mi>D</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>D</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>D</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:mover accent="true"><mml:mi>V</mml:mi><mml:mo>∼</mml:mo></mml:mover><mml:mi>D</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:msub><mml:mn mathvariant="bold">0</mml:mn><mml:mi>q</mml:mi></mml:msub></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:msup><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mo>·</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mi>D</mml:mi><mml:mn>3</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:mi>T</mml:mi><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mi>D</mml:mi><mml:mn>3</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>D</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mn>0</mml:mn></mml:mtd><mml:mtd><mml:mrow><mml:msup><mml:mi>D</mml:mi><mml:mn>4</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msup><mml:mi>δ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula> where, in <bold><italic>I</italic></bold><sub>3</sub>, <italic>D</italic> = <italic>β<sub>V</sub></italic> + <italic>Tθ</italic>, <italic>Ṽ</italic> = E[<italic>V</italic> |<bold><italic>W</italic></bold>] = <italic>γ</italic><sub>0</sub> +<bold><italic>W</italic></bold><sup>⊤</sup><bold><italic>γ</italic></bold>, and <italic>δ</italic> = (<italic>τ</italic><sup>2</sup><italic>D</italic><sup>2</sup> + <italic>σ</italic><sup>2</sup>)<sup>1/2</sup>. Reading down the diagonal of each matrix, the elements correspond to <italic>β</italic><sub>0</sub>, <italic>β<sub>T</sub></italic>, <bold><italic>β<sub>W</sub></italic></bold>, <italic>β<sub>V</sub></italic>, <italic>θ</italic>, <italic>σ</italic><sup>2</sup>, <italic>γ</italic><sub>0</sub>, <bold><italic>γ</italic></bold>, and <italic>τ</italic><sup>2</sup>, and so the fifth row/column, corresponding to <italic>θ</italic>, is of primary interest. Compared to <bold><italic>I</italic></bold><sub>1</sub> or <bold><italic>I</italic></bold><sub>2</sub>, <bold><italic>I</italic></bold><sub>3</sub> contains additional non-zero off-diagonal elements, which may depend on the values of <italic>β<sub>V</sub></italic> or <italic>θ</italic>, because it is required to marginalize over the missing biomarker measurements <italic>V</italic>, which are fully observed in groups 1 and 2.</p>
24855118|None|('method', 0.8174977050137823)|('other', 0.1825022949862177)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">For each group, given a set of parameter values, we independently sample 100,000 draws of <bold><italic>W</italic></bold> ~ N(<bold><italic>μ</italic></bold>,<bold>Σ<italic><sub>W</sub></italic></bold>), <italic>T</italic>|<bold><italic>W</italic></bold> (for groups 1 and 3), and <italic>V</italic> |<bold><italic>W</italic></bold> (for groups 1 and 2), and calculate the average values of <bold><italic>I</italic></bold><sub>1</sub>, <bold><italic>I</italic></bold><sub>2</sub>, and <bold><italic>I</italic></bold><sub>3</sub>. Given these estimates of typical information matrices, define the following measures of relative efficiency for estimating <italic>θ</italic>, given some non-negative number <italic>k</italic>: <disp-formula id="FD8"><mml:math id="M9" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>RE</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msubsup><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>RE</mml:mtext><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msubsup><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>RE</mml:mtext><mml:mn>23</mml:mn></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mn>0.5</mml:mn><mml:mi>k</mml:mi><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:mo stretchy="false">]</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msubsup><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="right"><mml:mrow><mml:msub><mml:mtext>RE</mml:mtext><mml:mo>max</mml:mo></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msubsup><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></p>
24855118|None|('method', 0.8174977050137823)|('other', 0.1825022949862177)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P17">For an arbitrary sample size <italic>n</italic><sub>1</sub>, RE<sub>2</sub>(<italic>k</italic>), RE<sub>3</sub>(<italic>k</italic>), RE<sub>23</sub>(<italic>k</italic>), and RE<sub>max</sub>(<italic>k</italic>) are, respectively, the variance of <italic>θ</italic> from analyzing (i) group 1 containing <italic>n</italic><sub>1</sub> observations and group 2 containing <italic>kn</italic><sub>1</sub> observations, (ii) group 1 containing <italic>n</italic><sub>1</sub> observations and group 3 containing <italic>kn</italic><sub>1</sub> observations, (iii) group 1 containing <italic>n</italic><sub>1</sub> observations, group 2 containing 0.5<italic>kn</italic><sub>1</sub> observations, and group 3 containing 0.5<italic>kn</italic><sub>1</sub> observations, and (iv) group 1 containing <italic>n</italic><sub>1</sub>(1 + <italic>k</italic>) observations, relative to the variance of <italic>θ</italic> from analyzing group 1 alone, containing <italic>n</italic><sub>1</sub> observations. The quantity <italic>k</italic> is the sample size ratio of the added data versus the original group 1 data, and the value of <italic>n</italic><sub>1</sub> is arbitrary. The final metric, RE<sub>max</sub>(<italic>k</italic>), may be considered the ideal efficiency gain, in which the additional data are most informative for estimating <italic>θ</italic> because group 1 increases in size. As mentioned, group 1 is supposed to correspond to RCT data, meaning that <bold><italic>α</italic></bold> = <bold>0</bold><italic><sub>q</sub></italic> throughout. We vary <bold><italic>α</italic></bold> in group 3 to represent RCT data (= <bold>0</bold><italic><sub>q</sub></italic>) or observational data (≠ <bold>0</bold><italic><sub>q</sub></italic>).</p>
24855118|None|('method', 0.8174977050137823)|('other', 0.1825022949862177)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P18">We now discuss the parameter values considered, which are summarized in <xref rid="T1" ref-type="table">Table 1</xref>.</p>
24855118|<italic>Y</italic> |<bold><italic>X</italic></bold> [Model (<xref rid="FD1" ref-type="disp-formula">1</xref>)]|('method', 0.8174977050137823)|('other', 0.1825022949862177)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title><italic>Y</italic> |<bold><italic>X</italic></bold> [Model (<xref rid="FD1" ref-type="disp-formula">1</xref>)]</title><p id="P19">Because (<xref rid="FD1" ref-type="disp-formula">1</xref>) is a Gaussian-linear model, the information matrices from groups 1 and 2 do not change with any elements of <bold><italic>β</italic></bold>, and the error variance <italic>σ</italic><sup>2</sup> acts only as a multiplicative scalar. However, the information matrix from group 3, which requires marginalization over <italic>V</italic>, does depend on <italic>β<sub>V</sub></italic>, <italic>θ</italic>, and <italic>σ</italic><sup>2</sup> (Appendix A3). We consider three sets of values for <italic>β<sub>V</sub></italic> and <italic>θ</italic>, <inline-formula><mml:math id="M10" display="inline" overflow="scroll"><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>V</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">}</mml:mo><mml:mo>∈</mml:mo><mml:mspace width="0.16667em"/><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">}</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msqrt><mml:mn>5</mml:mn></mml:msqrt><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>/</mml:mo><mml:msqrt><mml:mn>5</mml:mn></mml:msqrt><mml:mo stretchy="false">}</mml:mo><mml:mo>,</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>2</mml:mn><mml:mo>/</mml:mo><mml:msqrt><mml:mn>5</mml:mn></mml:msqrt><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msqrt><mml:mn>5</mml:mn></mml:msqrt><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:mrow></mml:math></inline-formula>. Graphical depictions of these three choices are given in <xref rid="F1" ref-type="fig">Figure 1</xref>. For a fixed fraction of explained variance <inline-formula><mml:math id="M11" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>∈</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.3</mml:mn><mml:mo>,</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:math></inline-formula>, we determine <italic>σ</italic><sup>2</sup> by solving <inline-formula><mml:math id="M12" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mtext>Var</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mtext>Var</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. Appendix A4 has details on this calculation. The parameters <italic>β<sub>T</sub></italic> and <bold><italic>β<sub>W</sub></italic></bold> are required only for calculating <italic>σ</italic><sup>2</sup>; we use <italic>β<sub>T</sub></italic> = 0 and <bold><italic>β<sub>W</sub></italic></bold> = (<italic>q</italic><sup>–1/2</sup>)<bold>1</bold><italic><sub>q</sub></italic> (so that <inline-formula><mml:math id="M13" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo>⊤</mml:mo></mml:msubsup><mml:msub><mml:mi mathvariant="bold-italic">β</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:math></inline-formula>). Finally, we allow the intercept <italic>β</italic><sub>0</sub> to differ between groups, meaning that each group’s information matrix has a distinct row and column for <italic>β</italic><sub>0</sub>, and no group contributes information regarding another group’s intercept. However, because we are focusing only on efficiency, the information contribution remains the same for an arbitrary set of three intercepts and no actual values need to be chosen.</p></sec>
24855118|<italic>V</italic> |<bold><italic>W</italic></bold> [Model (<xref rid="FD2" ref-type="disp-formula">2</xref>)]|('method', 0.8174977050137823)|('other', 0.1825022949862177)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title><italic>V</italic> |<bold><italic>W</italic></bold> [Model (<xref rid="FD2" ref-type="disp-formula">2</xref>)]</title><p id="P20">For the biomarker model, we use <bold><italic>γ</italic></bold> = (<italic>q</italic><sup>–1/2</sup>)<bold>1</bold><italic><sub>q</sub></italic>, so that <bold><italic>γ</italic></bold><sup>⊤</sup><bold><italic>γ</italic></bold> = 1. We chose <italic>γ</italic><sub>0</sub> so that, for a given E[<bold><italic>W</italic></bold>] (see following paragraph) and <bold><italic>γ</italic></bold>, we have E[<italic>V</italic> ] = <italic>γ</italic><sub>0</sub>+<bold><italic>γ</italic></bold><sup>⊤</sup>E[<bold><italic>W</italic></bold>] = 0. As already noted, we assume that <italic>γ</italic><sub>0</sub>, like <italic>β</italic><sub>0</sub>, varies between groups, so that each group’s information matrix contains a distinct row and column for <italic>γ</italic><sub>0</sub>. To determine <italic>τ</italic><sup>2</sup>, we solved <inline-formula><mml:math id="M14" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mtext>Var</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mo>⊤</mml:mo></mml:msup><mml:mtext>Var</mml:mtext><mml:mo stretchy="false">[</mml:mo><mml:mi mathvariant="bold-italic">W</mml:mi><mml:mo stretchy="false">]</mml:mo><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> using <inline-formula><mml:math id="M15" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>∈</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>0.1</mml:mn><mml:mo>,</mml:mo><mml:mn>0.3</mml:mn><mml:mo>,</mml:mo><mml:mn>0.5</mml:mn><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:math></inline-formula>.</p></sec>
24855118|<italic>T</italic>|<bold><italic>W</italic></bold> [Model (<xref rid="FD3" ref-type="disp-formula">3</xref>)] and model for <bold><italic>W</italic></bold>|('method', 0.8174977050137823)|('other', 0.1825022949862177)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title><italic>T</italic>|<bold><italic>W</italic></bold> [Model (<xref rid="FD3" ref-type="disp-formula">3</xref>)] and model for <bold><italic>W</italic></bold></title><p id="P21">For group 1, we assume that <bold><italic>α</italic></bold> = <bold>0</bold><italic><sub>q</sub></italic> and <italic>α</italic><sub>0</sub> = 0, corresponding to a RCT with equal randomization probabilities. For group 2, no model for <italic>T</italic> is required because <italic>T</italic> is fixed at −1/2. For group 3, we considered <bold><italic>α</italic></bold> ∈ {<bold>0</bold><italic><sub>q</sub></italic>, (2<italic>q</italic><sup>–1/2</sup>)<bold>1</bold><italic><sub>q</sub></italic>} but still chose <italic>α</italic><sub>0</sub> so that <italic>E</italic>[<italic>T</italic>] = E[expit{<italic>α</italic><sub>0</sub>+<bold><italic>α</italic></bold><sup>⊤</sup><bold><italic>W</italic></bold>}]−0.5 = 0. We drew <bold><italic>W</italic></bold> from a multivariate normal distribution with E[<bold><italic>W</italic></bold>] ≡ <bold><italic>μ</italic></bold> = <bold>0</bold><italic><sub>q</sub></italic> and Var[<bold><italic>W</italic></bold>] ≡ <bold>Σ<italic><sub>W</sub></italic></bold> = diag{1, 1, . . . , 1}.</p><p id="P22">Graphical depictions of how each RE measure changes with <italic>k</italic> for <inline-formula><mml:math id="M16" display="inline" overflow="scroll"><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mi>V</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">}</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msqrt><mml:mn>5</mml:mn></mml:msqrt><mml:mo>,</mml:mo><mml:mn>2</mml:mn><mml:mo>/</mml:mo><mml:msqrt><mml:mn>5</mml:mn></mml:msqrt><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:math></inline-formula> are given in <xref rid="F2" ref-type="fig">Figure 2</xref> (<bold><italic>α</italic></bold> = <bold>0</bold><italic><sub>q</sub></italic> in group 3) and <xref rid="F3" ref-type="fig">Figure 3</xref> (<bold><italic>α</italic></bold> = (2<italic>q</italic><sup>–1/2</sup>)<bold>1</bold><italic><sub>q</sub></italic> in group 3). Analogous figures for the other values of {<italic>β<sub>V</sub></italic>, <italic>θ</italic>} are in Figures A1–A4 in the Appendix, for which much of the following interpretation of <xref rid="F2" ref-type="fig">Figures 2</xref> and <xref rid="F3" ref-type="fig">3</xref> remains the same. Within each figure, we show results for all values of <inline-formula><mml:math id="M17" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M18" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>. In the top-right corner of each panel is the partial-<italic>R</italic><sup>2</sup> of <italic>θ</italic>, which is a measure in (0, 1) of how much of <inline-formula><mml:math id="M19" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>R</mml:mi><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> is due to <italic>θ</italic>. As the partial-<italic>R</italic><sup>2</sup> increases, <italic>θ</italic> explains a greater proportion of the variance in model (<xref rid="FD1" ref-type="disp-formula">1</xref>).</p><p id="P23">The typical initial drop in RE<sub>2</sub>(<italic>k</italic>) is steep, suggesting that even a small amount of data from group 2 is helpful. However, there are diminishing gains from increasingly large sample sizes in group 2, and the curves for group 2 eventually plateau at some positive asymptote. Under this model configuration, the asymptote is lim<italic><sub>k</sub></italic><sub>→∞</sub> RE<sub>2</sub>(<italic>k</italic>) = 0.5. Section 4 discusses this in more detail. The efficiency gains from a small amount of group 3 are less noticeable. Empirically, there is also an asymptote for possible efficiency gains from group 3 (not shown). However, the height of the asymptote changes and may be smaller than 0.5, as in the rightmost column of <xref rid="F2" ref-type="fig">Figures 2</xref> and <xref rid="F3" ref-type="fig">3</xref>. When <bold><italic>α</italic></bold> = <bold>0</bold><italic><sub>q</sub></italic> (<xref rid="F2" ref-type="fig">Figure 2</xref>), RE<sub>3</sub>(<italic>k</italic>) is smaller than when <bold><italic>α</italic> ≠ 0</bold><italic><sub>q</sub></italic> (<xref rid="F3" ref-type="fig">Figure 3</xref>), meaning, when the group 3 data are from an observational study, they are generally less informative for estimating <italic>θ</italic> than when they come from an RCT.</p><p id="P24">The figures also contain RE<sub>23</sub>(<italic>k</italic>), which is the relative efficiency from adding 0.5<italic>kn</italic><sub>1</sub> observations from each of groups 2 and 3. In all cases, at around <italic>k</italic> = 1, RE<sub>23</sub>(<italic>k</italic>) is smaller than either RE<sub>2</sub>(<italic>k</italic>) or RE<sub>3</sub> (<italic>k</italic>), suggesting an apparent synergy from the joint addition of data from both groups 2 and 3. Also, in the cases we considered, the asymptote is empirically always nearly zero, meaning that, with enough data, adding equal numbers of observations from both groups can match the ideal scenario of having an equivalently-sized group 1. In other words, adding some data from both groups would seem most preferred.</p><p id="P25">We reiterate that these results are for the case when <italic>β</italic><sub>0</sub> and <italic>γ</italic><sub>0</sub> are assumed to differ between groups. These results are also invariant to the <italic>true</italic> value(s) of <italic>β</italic><sub>0</sub>, because it does not appear in the information matrix, and numerical studies (not shown) suggest that these are invariant to the true values of <bold><italic>μ</italic></bold> and <italic>γ</italic><sub>0</sub>, even when they vary between groups. Intuitively, then, these parameters are not primarily responsible for the efficiency gain in estimating <italic>θ</italic>.</p></sec>
24855118|None|('method', 0.9388443123513422)|('other', 0.06115568764865782)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 Combining groups 1 and 2</title>
24855118|None|('method', 0.9388443123513422)|('other', 0.06115568764865782)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P26">In this section, we analytically assess the potential contribution from group 2 toward inference on <italic>θ</italic>, with the goal of optimally randomizing the group 1 patients. Here, we assume it is known that <italic>γ</italic><sub>0</sub> = 0 and E[<bold><italic>W</italic></bold>] = <bold>0</bold><italic><sub>q</sub></italic> for both groups. The matrix (1/<italic>n</italic><sub>1</sub>)(<bold><italic>I</italic></bold><sub>1</sub> + <italic>k</italic><bold><italic>I</italic></bold><sub>2</sub>)<sup>–1</sup>, with <bold><italic>I</italic></bold><sub>1</sub> and <bold><italic>I</italic></bold><sub>2</sub> as in (<xref rid="FD5" ref-type="disp-formula">5</xref>) and (<xref rid="FD6" ref-type="disp-formula">6</xref>), is the large-sample covariance matrix of the parameters, where <italic>k</italic> = <italic>n</italic><sub>2</sub>/<italic>n</italic><sub>1</sub> is the sample size ratio as in Section 3. Some algebra (Appendix A5) gives that the large-sample variance of <italic>θ̂</italic> is</p>
24855118|None|('method', 0.9388443123513422)|('other', 0.06115568764865782)|<disp-formula xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="FD9"><label>(8)</label><mml:math id="M20" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left" columnspacing="2pt"><mml:mtr><mml:mtd><mml:msub><mml:mi>v</mml:mi><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>≡</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:msub><mml:mi mathvariant="bold-italic">I</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>5</mml:mn><mml:mo>,</mml:mo><mml:mn>5</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:msub></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.16667em"/><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:msup><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mi>T</mml:mi></mml:msup><mml:msub><mml:mi mathvariant="bold-italic">∑</mml:mi><mml:mi mathvariant="bold-italic">W</mml:mi></mml:msub><mml:mi mathvariant="bold-italic">γ</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>τ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mspace width="0.16667em"/><mml:mrow><mml:mo>(</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>4</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>)</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula>
24855118|None|('method', 0.9388443123513422)|('other', 0.06115568764865782)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P27">From this, only the last expression contains <italic>k</italic>, and so the variance reduction from adding group 2 does not depend on the values of any model parameters except <italic>μ<sub>T</sub></italic>. We can use (<xref rid="FD9" ref-type="disp-formula">8</xref>) to calculate the maximum possible efficiency gain from adding group 2: <disp-formula id="FD10"><mml:math id="M21" display="block" overflow="scroll"><mml:mrow><mml:munder><mml:mo>lim</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>→</mml:mo><mml:mo>∞</mml:mo></mml:mrow></mml:munder><mml:mfrac><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mi>v</mml:mi><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:munder><mml:mo>lim</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>→</mml:mo><mml:mo>∞</mml:mo></mml:mrow></mml:munder><mml:mfrac><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn><mml:mo>-</mml:mo><mml:msubsup><mml:mi>μ</mml:mi><mml:mi>T</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>4</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p>
24855118|None|('method', 0.9388443123513422)|('other', 0.06115568764865782)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P28">When <italic>μ<sub>T</sub></italic> = 0, the addition of group 2 can reduce the variance of <italic>θ̂</italic> by no more than 1/2, compared to using group 1 alone; this is the asymptote for RE<sub>2</sub>(<italic>k</italic>) in <xref rid="F2" ref-type="fig">Figures 2</xref> and <xref rid="F3" ref-type="fig">3</xref>. A larger variance reduction may be possible as <italic>μ<sub>T</sub></italic> increases toward 1/2.</p>
24855118|None|('method', 0.9388443123513422)|('other', 0.06115568764865782)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P29">For designing a trial that will generate data corresponding to group 1, we can also use (<xref rid="FD9" ref-type="disp-formula">8</xref>) to choose how to optimally randomize the <italic>n</italic><sub>1</sub> individuals, given <italic>n</italic><sub>2</sub>, so that we have the largest possible efficiency for estimating <italic>θ</italic>. That is, choose <italic>μ<sub>T</sub></italic> to minimize <italic>v<sub>θ̂</sub></italic>(<italic>μ<sub>T</sub></italic>, <italic>n</italic><sub>1</sub>, <italic>k</italic>): <disp-formula id="FD11"><label>(9)</label><mml:math id="M22" display="block" overflow="scroll"><mml:mrow><mml:mfrac><mml:mrow><mml:mo>∂</mml:mo><mml:mtext>log</mml:mtext><mml:mspace width="0.16667em"/><mml:msub><mml:mi>v</mml:mi><mml:mover accent="true"><mml:mi>θ</mml:mi><mml:mo>^</mml:mo></mml:mover></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>,</mml:mo><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo>∂</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub></mml:mrow></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>-</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:mi>k</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mn>4</mml:mn><mml:mo>+</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>k</mml:mi><mml:mo>-</mml:mo><mml:msub><mml:mi>μ</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mover><mml:mo>=</mml:mo><mml:mtext>set</mml:mtext></mml:mover><mml:mn>0</mml:mn><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:mo>⇒</mml:mo><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:msubsup><mml:mi>μ</mml:mi><mml:mi>T</mml:mi><mml:mtext>opt</mml:mtext></mml:msubsup><mml:mo>=</mml:mo><mml:mi>k</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo>=</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>/</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>n</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></p>
24855118|None|('method', 0.9388443123513422)|('other', 0.06115568764865782)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P30">A consequence of this is that, if <italic>k</italic> ≥ 1, equivalently <italic>n</italic><sub>2</sub> ≥ <italic>n</italic><sub>1</sub>, then the asymptotic variance of <italic>θ̂</italic> is minimized by assigning all patients in group 1 to the treatment arm, i.e. <italic>μ<sub>T</sub></italic> = 1/2. In other words, when group 2 is large and precision of <italic>θ̂</italic> is of primary importance, the prospective phase II trial should be a single-arm trial. Although the result assumes that the generating model for the outcome is identical between groups, which is why randomization within group 1 is often recommended,<sup><xref rid="R14" ref-type="bibr">14</xref></sup> this may be relaxed somewhat. Namely, the expression for <italic>v<sub>θ̂</sub></italic>(<italic>μ<sub>T</sub></italic>, <italic>n</italic><sub>1</sub>, <italic>n</italic><sub>2</sub>) in (<xref rid="FD9" ref-type="disp-formula">8</xref>) is free of the intercept and treatment effect, respectively <italic>β</italic><sub>0</sub> and <italic>β<sub>T</sub></italic>. Also, <italic>β̂</italic><sub>0</sub> and <italic>β̂<sub>T</sub></italic> are independent of <italic>θ̂</italic>. Therefore, it is possible to parametrize (<xref rid="FD1" ref-type="disp-formula">1</xref>) so that <italic>β</italic><sub>0</sub> and/or <italic>β<sub>T</sub></italic> differ between groups 1 and 2 (subject to constraints on identifiability) while still being able to show that that <inline-formula><mml:math id="M23" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>μ</mml:mi><mml:mi>T</mml:mi><mml:mtext>opt</mml:mtext></mml:msubsup></mml:mrow></mml:math></inline-formula> in (<xref rid="FD11" ref-type="disp-formula">9</xref>) remains the same.</p>
24855118|None|('method', 0.9388443123513422)|('other', 0.06115568764865782)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P31">An analogous result of finding an optimal <italic>μ<sub>T</sub></italic> when combining groups 1 and 3 would also be desirable, but the integration over the missing measurements of <italic>V</italic> adds complexity to the matrix <bold><italic>I</italic></bold><sub>1</sub> + <italic>k</italic><bold><italic>I</italic></bold><sub>3</sub>, and a closed-form solution to its inverse, while theoretically possible, does not lend itself to the same intuition as above.</p>
24859760|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24859760|Materials|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Materials</title><p>STO-609 was obtained from EMD Millipore (Billerica, MA) and dissolved in 100 mM NaOH. BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N’,N’-tetraacetic acid tetrakis(acetoxymethyl ester)) was obtained from Abcam (Cambridge, MA) and dissolved in DMSO. EDTA was obtained from Mediatech (Manassas, VA). Dorsomorphin dihydrochloride (compound C) and 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) were obtained from Tocris Bioscience (Minneapolis, MN) and dissolved in water. Rabbit monoclonal antibodies for detection of human AMPKα, phospho-AMPKα (T172), acetyl-CoA carboxylase (ACC), and phospho-ACC (S79) were obtained from Cell Signaling Technology (Beverly, MA). Polyclonal goat anti-rabbit secondary antibody was obtained from Abcam. Mouse monoclonal antibody for detection of human β-actin was obtained from Sigma-Aldrich (St. Louis, MO). Polyclonal sheep anti-mouse secondary antibody was obtained from GE Healthcare Life Sciences (Pittsburgh, PA). Radioactively labeled [1-<sup>14</sup>C]18:2n-6 (55 mCi/mmol) was purchased from American Radiolabeled Chemicals (St. Louis, MO). Fatty acid methyl ester standards (18:2n-6, 18:3n-6, 20:2n-6, 20:3n-6, 20:4n-6, 22:4n-6, and 22:5n-6) were purchased from NuChek Prep (Elysian, MN). HPLC grade solvents were purchased from Fisher Scientific (Pittsburgh, PA) and IN-flow 2:1 liquid scintillation cocktail was purchased from IN/US Systems (Tampa, FL).</p></sec>
24859760|Cell culture|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Cell culture</title><p>16HBEo<sup>−</sup> sense and antisense cells were a gift from Dr. Pamela Davis (Case Western Reserve University School of Medicine, Cleveland, OH). IB3 and C38 cells were obtained from ATCC (Manassas, VA). Cells were grown in tissue culture flasks precoated with LHC basal media (Invitrogen, Carlsbad, CA) containing 0.1 mg/ml BSA (Sigma-Aldrich), 10 μg/ml human fibronectin (Sigma-Aldrich), and 3 μg/ml vitrogen (Angiotech Biomaterials, Palo Alto, CA). Complete culture medium consisted of minimum essential medium + glutamax (Invitrogen) supplemented with 100 μg/ml streptomycin, 100 U/ml penicillin, and 10% horse serum (Atlanta Biologicals, Lawrenceville, GA). Cells were grown at 37°C in a 5% CO<sub>2</sub> humidified incubator. Medium was changed three times weekly. Experiments were performed after cells reached 100% confluence.</p></sec>
24859760|SDS-PAGE and immunoblotting|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>SDS-PAGE and immunoblotting</title><p>Total protein was isolated from cells using RIPA buffer (Sigma-Aldrich) and 2× Halt protease and phosphatase inhibitor cocktail (Thermo Scientific, Waltham, MA). Protein concentrations were determined by BCA assay (Thermo Scientific). Protein samples were mixed 1:1 with 2× Laemmli sample buffer (Bio-Rad Laboratories, Hercules, CA) and boiled for 5 min. Then, volumes equivalent to 15–25 μg of protein were loaded into precast 4–20% gradient polyacrylamide gels (Bio-Rad). After electrophoresis, protein was transferred onto Immobilon-P polyvinylidene fluoride membranes (EMD Millipore). Membranes were blocked using 5% (w/v) blotting grade blocker (Bio-Rad) in TBS-Tween (Sigma-Aldrich). After antibody incubations, protein bands were detected using SuperSignal West Pico chemiluminescent substrate (Thermo Scientific). Membranes were exposed to Amersham Hyperfilm ECL film (GE Healthcare). Films were scanned and densitometry was performed using Image J analysis software (National Institutes of Health). β-actin was used as a loading control. For repeat immunoblotting, membranes were stripped using Restore Western blot stripping buffer (Thermo Scientific).</p></sec>
24859760|Quantitative reverse transcription PCR|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Quantitative reverse transcription PCR</title><p>Specific primers for quantification of mRNA from <italic>FADS1</italic> (Δ5D), <italic>FADS2</italic> (Δ6D), <italic>ELOVL5</italic> (ELO5), and <italic>RPLP0</italic> genes were described previously (<xref rid="bib19" ref-type="bibr">19</xref>). Total RNA was isolated from cells using TRIzol (Invitrogen) according to the manufacturer’s instructions. Contam­inating DNA was removed from the RNA samples using DNA-free (Ambion, Austin, TX) according to the manufacturer’s instructions. cDNA was synthesized from 1 μg of total RNA using iScript cDNA synthesis kit (Bio-Rad). Quantitative reverse transcription PCR (qRT-PCR) was performed in 10 μl reactions containing 50 ng cDNA, 156 nM forward and reverse primers, and 1× iTaq Universal SYBR Green (Bio-Rad) in 96-well plates. Each reaction was performed in duplicate. C<sub>t</sub> values were determined using the CFX96 real-time PCR detection system with CFX Manager software (Bio-Rad). Relative mRNA levels were calculated using the comparative C<sub>t</sub> method with <italic>RPLP0</italic> as a reference gene.</p></sec>
24859760|Desaturase activity assay|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Desaturase activity assay</title><p>Confluent cells were incubated in minimum essential medium containing 10% reduced-lipid fetal bovine serum (Hyclone, Logan, UT) and 4.7 μM of [1-<sup>14</sup>C]LA (18:2n-6) for 4 h. Cells were then washed and incubated an additional 20 h in complete medium. Cells were scraped on ice and pelleted by centrifugation, then resuspended in 0.5 ml PBS. Lipids were extracted using a modified method of Folch, Lees, and Sloane Stanley (<xref rid="bib33" ref-type="bibr">33</xref>). Briefly, lipids were extracted by addition of 3 ml chloroform-methanol (2:1, v/v). After centrifugation, the organic phase was separated and dried under nitrogen. Fatty acids were methylated by adding 0.5 ml of 0.5 N methanolic NaOH (Acros Organics, Geel, Belgium) and then heated at 100°C for 3 min, followed by addition of 0.5 ml BF<sub>3</sub> and heating at 100°C for 1 min. The resulting fatty acid methyl esters were extracted into 1 ml of hexane, followed by addition of 6.5 ml of water saturated with NaCl. After centrifugation, the hexane layer was retrieved and dried completely under nitrogen.</p><p>For HPLC analysis, fatty acid methyl esters were dissolved in 50 μl of acetonitrile, and 20 μl was injected into an HPLC instrument (Agilent 1200 series; Agilent Technologies, Santa Clara, CA) equipped with an Agilent Zorbax Eclipse XDB-C18 column, 4.6 × 250 mm, 5 μm. A guard column of 4.6 × 12.5 mm, 5 μm was used in conjunction with the analytical column. The fatty acids were separated using a binary solvent system. Solvent A consisted of HPLC grade water with 0.02% H<sub>2</sub>PO<sub>4</sub>, and solvent B was 100% HPLC grade acetonitrile. The solvent program started with 42% solvent A and 58% solvent B for 25 min, followed by a linear gradient from 58 to 61% solvent B over 2 min, a hold for 8 min, another linear gradient from 61 to 100% solvent B over 15 min, and a hold for 20 min, followed by reconstitution of the original conditions. The flow rate was 1 ml/min. Peaks were detected by UV absorbance at 205 nm and identified by comparison with retention times of unlabeled fatty acid methyl ester standards. Radioactivity from <sup>14</sup>C-labeled fatty acid methyl esters was measured with a scintillation detector (β-RAM model 4, IN/US Systems) coupled to the HPLC. The counting efficiency of this detector is 90% for <sup>14</sup>C with 5 cpm background.</p></sec>
24859760|Statistical analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Statistical analysis</title><p>Statistical differences between groups were evaluated by the Mann-Whitney test using STATA or by two-way ANOVA followed by Tukey’s honestly significant difference (HSD) post hoc test for multiple comparisons using R (R Foundation for Statistical Computing, Vienna, Austria).</p></sec>
24859784|None|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24859784|None|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The Cincinnati Clinic of the National Heart, Lung, and Blood Institute LRC Prevalence Study (1973–78) studied students in grades 1–12 (ages 6 through 19) of the public and parochial schools in the Princeton School District (Cincinnati, OH) and a random sample of their parents and has been described previously (<xref rid="bib25" ref-type="bibr">25</xref>). The student population from which participants came was 73% white and 27% African American, and 52.3% male and 47.7% female (<xref rid="bib26" ref-type="bibr">26</xref>).</p>
24859784|None|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><xref ref-type="fig" rid="fig1"><bold>Figure 1</bold></xref> depicts the flow of subjects for all phases of the study. At the first LRC visit (1973–75), basic demographic information was collected, and TC and TGs were measured after an overnight fast (<xref rid="bib25" ref-type="bibr">25</xref>). Approximately 6 weeks after visit 1, a 15% random subset of subjects, independent of visit 1 lipid results, was recalled to visit 2 (“random” subjects). In addition, hyperlipidemic subjects were recruited to visit 2 if they had TC or TGs in the approximate top 5% (age specific) (<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib28" ref-type="bibr">28</xref>). At visit 2, height, weight, fasting TC, TGs, HDL-C, and LDL-C were measured, as well as blood pressure and questions about lifestyle (e.g., smoking and alcohol use) (<xref rid="bib26" ref-type="bibr">26</xref>). The LRC Family Study (or visit 3) was conducted from 1976 to 1978, involving all first-degree relatives of selected probands seen at visit 2 (either parents or offspring as probands), which again were chosen either randomly (15% of the visit 2 random subset) or as hyperlipidemic cases (top 5% of TC, LDL-C, or TGs) (<xref rid="bib27" ref-type="bibr">27</xref>, <xref rid="bib29" ref-type="bibr">29</xref>). At visit 3, the same variables were measured as at visit 2, with the exception of blood pressure, smoking, and alcohol use. All first-degree relatives of probands at visit 3 were invited to participate regardless of whether they had previously attended any LRC visits.</p>
24859784|None|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<fig xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="fig1" position="float"><label>Fig. 1.</label><caption><p>The flow of subjects for all phases of the study.</p></caption><graphic xlink:href="1515fig1"/></fig>
24859784|None|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">The PFS was conducted between 1998 and 2003, 22–30 years after the last LRC visit. The PFS focused on changes in the familial correlations of LDL-C, so LRC subjects at visit 2 and visit 3 with at least one first-degree relative at one of these visits were targeted. Methods for PFS have been described previously (<xref rid="bib30" ref-type="bibr">30</xref>, <xref rid="bib31" ref-type="bibr">31</xref>), but briefly, participants underwent a physical examination (height, weight, and blood pressure), fasting blood draw for clinical chemistries and DNA extraction, and questionnaires regarding lifestyle (e.g., smoking, alcohol use, and diet) and personal and family medical history. The study protocol was approved by the Children’s Hospital Institutional Review Board, and all participants gave signed, informed consent.</p>
24859784|None|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">All individuals and families that attended the PFS visit were eligible for inclusion in the present analysis (n = 1,454). Potential LRC participants who otherwise would have been eligible for PFS but who died prior to follow-up (n = 184) or otherwise were not seen at PFS (n = 983) were not included in analysis. For this analysis, PFS participants from the LRC study were classified as being in random or hyperlipidemic families according to the classification of the family’s proband at LRC (visit 2 or visit 3). Visit 2 families were classified as random if all family members at visit 2 were random subjects; otherwise, they were classified as hyperlipidemic families because the family group included at least one hyperlipidemic subject. Refer to <xref ref-type="fig" rid="fig1">Fig. 1</xref> for depiction of random and hyperlipidemic family types.</p>
24859784|Clinical measures|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Clinical measures</title><p>In both the LRC and PFS, data were collected using standard protocols (<xref rid="bib32" ref-type="bibr">32</xref>). Height and weight were measured with subjects in light, indoor clothing and shoes removed. In the LRC, one measurement of height and weight was made. In the PFS, two measurements of height and weight were made, with a third measurement made if the first two differed by more than 0.5 cm (height) and/or 0.3 kg (weight). The mean of replicate measurements was used for analyses. The BMI (kg/m<sup>2</sup>) was used to characterize body habitus. Prior to each visit, participants were instructed to fast for 12 h prior to screening. In each study, fasting blood was drawn into vacutainers containing EDTA, kept on wet ice (LRC) or cold packs (PFS), and delivered to the laboratory within 3 h for processing. Lipid profiles were measured in LRC-Centers for Disease Control standardized laboratories (<xref rid="bib33" ref-type="bibr">33</xref>). LDL-C was calculated using the Friedewald formula but was measured by direct determination for all participants with TGs &gt;400 mg/dl (LRC) or &gt;250 mg/dl (PFS).</p><p>For individuals on lipid-lowering therapy at PFS, both the TC and LDL-C values were multiplied by 1.506 to model a 33.6% reduction in TC and LDL-C due to treatment as shown previously (<xref rid="bib34" ref-type="bibr">34</xref>, <xref rid="bib35" ref-type="bibr">35</xref>). This represents the average treatment effect for LDL-C across a broad range of drug classes and doses targeting lipid reduction (<xref rid="bib36" ref-type="bibr">36</xref>). Use of lipid-lowering therapy was rare at LRC, so unaltered lipid values were used.</p></sec>
24859784|Genotyping|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Genotyping</title><p>Genomic DNA was extracted from buffy coats collected at PFS by a simple salting out procedure using the Puregene isolation kit (Gentra Systems, Minneapolis, MN) (<xref rid="bib37" ref-type="bibr">37</xref>). The ApoE gene includes two polymorphisms (rs7412 and rs429358), which, in combination, code for the three major isoforms: E2, E3, and E4. ApoE polymorphisms were assessed by restriction fragment length polymorphism-PCR by the method of Hixson with minor modifications using the following primer sequences: 5′-ACA GAA TTC GCC CCG GCC <underline>TGG TAC AC-</underline>3′ (reverse) and 5′-<underline>TAA GCT T</underline>GG CAC GGC TGT CCA AGG A-3′ (forward) (<xref rid="bib38" ref-type="bibr">38</xref>). Amplified PCR products (244 bp) were digested with <italic>Hha</italic>I restriction enzyme (New England Biolabs, Ipswich, MA) overnight at 37°C, separated by electrophoresis on 12% acrylamide gel, and visualized after ethidium bromide staining. Accuracy of genotypes was assured by incorporating a known sample on each acrylamide gel plate for each of the three possible genotypes. A random sample of 10% was repeated, and results were compared with original values. Mendelian inconsistencies for ApoE genotypes in family pedigrees were identified using pedsys and resolved by removing inconsistent individuals’ genotypes (n = 14). Individuals were classified using indicator variables for ApoE2 and ApoE4 carrier status, with the E3/E3 genotype as reference.</p></sec>
24859784|Statistical methods|('method', 0.9999998026058871)|('other', 1.973941130506443e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Statistical methods</title><p>Women who were pregnant at either LRC or PFS were excluded from analyses of that visit (n = 2 at PFS, n = 0 at LRC). For individuals seen at both visit 2 and visit 3, visit 2 data were used. Continuous variables were examined for normality using the Shapiro-Wilk test, and BMI, TC, HDL-C, and TGs were natural-log transformed for analysis to improve normality at both time points; however, nontransformed values are presented.</p><p>To estimate the proportion of phenotypic variation explained by additive genetic effects (heritability), we used mixed models as implemented in SOLAR (<xref rid="bib39" ref-type="bibr">39</xref>) on lipid traits during the period of shared households (1970s) and after the period of shared households (2000s). Briefly, fixed effects account for covariate effects on the mean while random effects disentangle covariance between relative pairs into genetic and environmental components. This is operationalized in equation 1:<disp-formula id="fd1"><label>(<italic>Eq. 1</italic>)</label><mml:math id="m1"><mml:mtable><mml:mtr><mml:mtd><mml:mi>y</mml:mi><mml:mo>=</mml:mo><mml:mi>μ</mml:mi><mml:mo>+</mml:mo><mml:mi>β</mml:mi><mml:mo>×</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mi mathvariant="italic">covariate</mml:mi></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi>g</mml:mi><mml:mo>+</mml:mo><mml:mi>e</mml:mi></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="bold">Ω</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mi mathvariant="bold">Φ</mml:mi><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>g</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:mi mathvariant="bold">I</mml:mi><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mtd></mml:mtr></mml:mtable></mml:math></disp-formula>where μ is the grand mean, <italic>β</italic> is the vector of measured covariate effects, and <italic>g</italic> and <italic>e</italic> are genetic and environmental deviations. Assuming <italic>g</italic> and <italic>e</italic> are uncorrelated random normal variables with expectation 0, the phenotypic covariance of relative pairs (<bold>Ω</bold>) can be partitioned into additive genetic and environmental components, where <bold>Φ</bold> is the kinship matrix, <bold>I</bold> is the identity matrix, and <italic>σ<sub>g</sub></italic><sup>2</sup> and <italic>σ<sub>e</sub></italic><sup>2</sup> are the variance due to additive genetic (<italic>g</italic>) and residual (<italic>e</italic>) effects. The significance of covariates is determined by comparing the log likelihood from a model where the covariate effect is estimated with one where it is constrained to 0. To test the significance of the additive genetic component, the log likelihood of a model where <italic>σ<sub>g</sub></italic><sup>2</sup> is estimated is compared with the log likelihood of a model where <italic>σ<sub>g</sub></italic><sup>2</sup> is constrained to 0. Twice the difference in log likelihoods of these models yields a test statistic distributed as a 1/2:1/2 mixture of a χ<sup>2</sup> variable with 1 degree of freedom and a point mass at 0 (<xref rid="bib40" ref-type="bibr">40</xref>).</p><p>Covariates considered for inclusion in models included BMI, age, age<sup>2</sup>, sex, race, age by sex interaction, age<sup>2</sup> by sex interaction, ApoE2 carrier, ApoE4 carrier, family ascertainment status, smoking, alcohol use, prescription medication use (for diabetes, hypertension, thyroid, heart, and cholesterol, as well as birth control pills and steroids), insulin use for diabetes, nonprescription weight-reducing medication, special diets (to control cholesterol and diabetes), and dietary intake of the ratio of polyunsaturated to saturated fat (P/S ratio, PFS). Each covariate was evaluated for each lipid trait in univariate analyses, and covariates with <italic>P</italic> ≤ 0.10 were included in the final models. Of note, due to analytic procedures, individuals must have complete covariate data in addition to the outcome variables to enter into the final models. Thus, due to missing data, each outcome had different numbers of individuals entering the analyses.</p><p>To estimate the expected shared contribution of genes and environments to circulating lipid concentrations both in the 1970s and 30 years later, we performed bivariate analysis. In this model, the phenotype covariance is further decomposed to include the genetic correlation between traits due to additive genetic effects, such that the covariation between two individuals for the two time points is given by<disp-formula id="fd2"><label>(<italic>Eq. 2</italic>)</label><mml:math id="m2"><mml:mrow><mml:mi mathvariant="bold">Ω</mml:mi><mml:mo>=</mml:mo><mml:mrow><mml:mo>|</mml:mo><mml:mrow><mml:mtable columnalign="left"><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi mathvariant="bold">Ω</mml:mi><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi mathvariant="bold">Ω</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr><mml:mtr columnalign="left"><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi mathvariant="bold">Ω</mml:mi><mml:mrow><mml:mn>12</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd><mml:mtd columnalign="left"><mml:mrow><mml:msub><mml:mi mathvariant="bold">Ω</mml:mi><mml:mrow><mml:mn>22</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow><mml:mo>|</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>where <bold>Ω</bold> is a covariance matrix of 2 × 2 covariance matrices. The matrix elements are defined by<disp-formula id="fd3"><label>(<italic>Eq. 3</italic>)</label><mml:math id="m3"><mml:mrow><mml:msub><mml:mi mathvariant="bold">Ω</mml:mi><mml:mrow><mml:mi>a</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mi mathvariant="bold">Φ</mml:mi><mml:msub><mml:mi mathvariant="italic">ρ</mml:mi><mml:mi>g</mml:mi></mml:msub><mml:msub><mml:mi mathvariant="italic">σ</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="italic">σ</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi mathvariant="bold">I</mml:mi><mml:msub><mml:mi mathvariant="italic">ρ</mml:mi><mml:mi>e</mml:mi></mml:msub><mml:msub><mml:mi mathvariant="italic">σ</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>a</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi mathvariant="italic">σ</mml:mi><mml:mrow><mml:mi>e</mml:mi><mml:mi>b</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula>where <italic>a</italic> and <italic>b</italic> represent the two time points, and <italic>ρ<sub>g</sub></italic> and <italic>ρ<sub>e</sub></italic> are the additive genetic and environmental correlations between the two time points, respectively. The genetic correlation estimates the proportion of variance that lipid traits at the two time points share due to genetic causes and is independent of trait heritability. If <italic>a</italic> = <italic>b</italic>, then <italic>ρ<sub>g</sub></italic> is 1, and the covariance of a pair of relatives simplifies to equation 1. Likewise, the environmental correlation estimates the proportion of unmeasured environmental effects shared in common between the two time points. For bivariate models, covariates that were significant in the univariate models were included.</p><p>To understand whether differences in heritability estimates were due to differences in the amount of variation explained by genes, formal models tested whether the genetic variance differed by race. This was operationalized by estimating models where the genetic variation was allowed to differ by race and comparing the model fit with a model where the genetic variation by race was constrained to be equal. The difference in the −2 log likelihood between these models was tested for significance. For all analyses, <italic>P</italic> ≤ 0.05 was considered significant.</p></sec>
24875538|None|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Material and Methods</title>
24875538|Animals and diets|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Animals and diets</title><p>We obtained <italic>fat-1</italic> breeders on a C57BL/6 background from Dr. Jing ×. Kang (Harvard Medical School) and raised them in the Laboratory Animal Center, University of Macau. Mice were housed in a temperature-controlled, 12:12 light/dark room and were allowed free access to water and food. The heterozygous <italic>fat-1</italic> mice and WT littermates were obtained by mating male heterozygous <italic>fat-1</italic> mice with female C57BL/6 mice. The <italic>fat-1</italic> phenotypes of each animal were characterized using isolated genomic DNA and fatty acid composition analysis from mouse tails. Both the <italic>fat-1</italic> and WT mice were fed a modified diet containing 10% corn oil (TROPHIC Animal Feed High-tech Co., Ltd, China), with a fatty acid profile high in ω-6 PUFAs (mainly linoleic acid) and low in ω-3 PUFAs (∼0.1% of the total fat supplied).</p></sec>
24875538|Fatty acid analysis|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Fatty acid analysis</title><p>To examine whether the expression of the <italic>fat-1</italic> gene and the dietary regime altered the PUFA composition in the hippocampus, the naïve (non-ischemic) hippocampus of the two experimental groups was isolated and processed for fatty acid analysis by using GC-MS as described previously (<xref rid="bib17" ref-type="bibr">17</xref>). Briefly, tissue samples were ground to powder under liquid nitrogen and subjected to fatty acid methylation by 14% boron trifluoride-methanol reagent at 100°C for 1 h. Fatty acid methyl esters were analyzed by an Agilent GC-MS system (Agilent Technologies, Palo Alto, CA) consisting of an Agilent 6890 gas chromatograph and an Agilent 5973 mass spectrometer. Fatty acids were identified in forms of their methyl esters by three means: <italic>i</italic>) searching potential compounds from NIST MS Search 2.0 database, <italic>ii</italic>) comparing retention time with those of reference compounds (Nu-Chek Prep, Elysian, MN) eluted under the identical chromatographic condition, and <italic>iii</italic>) comparing their mass spectra plots with those of authentic standards. Quantification was performed by normalizing individual peak area as the percentage of total fatty acids.</p></sec>
24875538|Transient global ischemia model|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Transient global ischemia model</title><p>All studies were conducted in accordance with prevailing laws on animal experiments and were approved by the ethical committee of the University of Macau. A total of 60 mice fed a high ω-6 PUFA diet were used in the study. Among them, 48 mice (24 <italic>fat-1</italic> mice and 24 WT mice with a high ω-6 PUFA diet) were subjected to transient cerebral ischemia produced by 20 min bilateral common carotid artery occlusion (2-VO) with small vascular clips and 12 mice (6 <italic>fat-1</italic> mice and 6 WT mice) served as sham-operated controls (sham). In addition, an extra group consisting of 12 WT mice with a normal diet served as baseline controls in the present study. The animals were deeply anesthetized with 0.035ml/10g 10% chloral hydrate and the rectal temperature was maintained at 37 ± 0.5°C with a regulated heating pad (TR-200, FST, CA) throughout the surgery. Mice were excluded if their rectal temperature was out of the range of the criterion (36.5–37.5°C) during ischemic surgery. The animal was placed on its back and an incision was made in the ventral neck skin. The thyroid and associated musculature and connective tissue were carefully dissected away from the trachea, and the common carotid arteries were separated from the vagus nerves and adjacent muscles using blunt forceps. A suture (5-0, silk) was looped around each common carotid artery and then the bilateral common carotid arteries were clamped with small vascular clips. Reperfusion was induced by removing the small vascular clips after 20 min occlusion. Shams were subjected to the same surgical procedure but without actual ligation. We measured regional cerebral blood flow from the start of anesthetic induction to 5 min after reperfusion with a Laser Doppler Blood Flow and Temperature Monitor System (moorVMS-LDF<sup>TM</sup>, Moor Instruments Ltd, UK). Animals with a mean cerebral blood flow successfully reduced to 10% baseline cerebral blood flow within the first minute of occlusion and recovered at least up to 75% after reperfusion were used in subsequent data analysis. Heart rate and blood oxygen saturation were continuously monitored via a pulse oximeter (MouseOx; Starr Life Sciences Corp.., Oakmont, PA) clipped to the hind paw of the mouse. After surgery, all mice were allowed to recover for 24 h in a recovery cage (Harvard) and had free access to drinking water. Thereafter, mice were returned to general housing (22°C to 24°C). Overall, around 18% of all animals were excluded because of insufficient cerebral blood flow reduction and around 12% of animals died during or immediately after surgery. No further losses were observed after recovery from surgical anesthesia.</p></sec>
24875538|Morris Water Maze Test|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Morris Water Maze Test</title><p>Spatial learning and memory abilities were tested using the Morris Water Maze test on days 1, 3, 5, and 7 after the surgical procedures. A circular pool (90 cm diameter, 35 cm height) divided into four quadrants was filled with white opaque water by the addition of water-insoluble and nontoxic titanium dioxide (24 ± 1°C), and an 8 cm diameter × 25 cm platform was positioned 1 cm below the water surface in the center of one of the quadrants. The swimming trials were recorded using a video camera mounted above the center of the pool and analyzed using a video tracking and analysis system (Institute of Medica, Chinese Academy of Medical Sciences). One day prior to testing, animals were habituated to the water by swimming for 1 min, henceforth, the mice received four consecutive training trials during which the hidden platform was kept in a constant location. During the testing days, the mice started each trial facing the edge of the pool and were given 60s to complete a trial. The time to reach the platform was recorded. If a mouse could not find the platform within 60s, it was guided toward the platform and then permitted to stay on for 10s.</p></sec>
24875538|Space probe trial|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Space probe trial</title><p>On the 7th day, memory retention was evaluated during a 60s probe trial carried out 24 h after the last training session in the absence of the escape platform. The total number of crossings to the exact position where the platform was located was measured.</p></sec>
24875538|Tissue preparation|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Tissue preparation</title><p>For histologic evaluation, on day 7 after 2-VO and sham-operation, a total of 36 mice (n = 6 per subgroup) were perfused transcardially with 50ml of ice-cold saline followed by 200 ml of 4% (w/v) formaldehyde in PBS. Brains were then incubated overnight in 20 to 30% sucrose and embedded in Tissue-Tek Optimal Cutting Temperature compound (Sakura Fine Technical, Tokyo, Japan) at −20°C. Brain tissue blocks were consecutively cryosectioned into 10 µm thick sections with a cryostat microtome (Leica Microsystems Inc., Jena, Germany). In order to ascertain that the hippocampus CA1 neurons were counted at the same rostrocaudal level, we first dissected the same regions from each brain using the Bregma as a reference point. Then we collected 10 μm thick coronal slices of the dorsal hippocampus (−3.3 mm to −4.5 mm from the Bregma) at the same levels of sectioned specimens. A total of 30 tissue sections per brain were made and stored at −40°C.</p><p>For protein analysis and QPCR analysis, on days 1, 3 and 7 after 2-VO, a total of 24 mice with a high ω-6 PUFA diet (<italic>fat-1</italic>: n = 4 per time point; WT: n = 4 per time point) were perfused transcardially with 50 ml of ice-cold saline. Brains from the remaining mice were rapidly removed from the skulls. These brains were placed in a brain blocker maintained on ice. The bilateral hippocampi were isolated and then further processed for protein extraction and total RNA isolation.</p></sec>
24875538|Nissl staining|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Nissl staining</title><p>The frozen sections were selected at intervals of 6 in consecutive frozen section (10 μm thickness, 50 μm apart), dried at room temperature, rehydrated, and immersed in 0.1% cresyl violet (5 min) for Nissl staining. The sections were rinsed in distilled water, dehydrated in a graded series of ethanol (70%, 80%, 90%, and 100%), cleared in xylene, and coverslipped with xylene using Permount. The number of cells that presented a well-delimited, spherical form with a distinct nucleus and nucleolus was counted in the hippocampus CA1 (40× magnification; Olympus microscope). Neurons that had shrunken cell bodies or surrounding empty spaces were considered to be destined to die and excluded from Nissl counting. We counted the number of neurons in five random fields in the hippocampus CA1 region per section at 40× magnification and five tissue sections per animal were used to quantify the mean number of intact neurons in the hippocampus CA1 region for each animal (total of six animals in each group).</p></sec>
24875538|TUNEL staining|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>TUNEL staining</title><p>Apoptosis was determined by using the in situ cell death detection, Fluorescein kit (Roche Applied Science), according to the manufacturer’s instructions. Briefly, sections were treated with 0.3% triton and 10% anti-donkey serum for 1 h at room temperature. Subsequently, the sections were incubated with terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) reaction mixture for 1 h at 37°C in the dark. After washing with PBS, the sections were incubated with the polyclonal antibody NeuN (1:500, Millipore) overnight at 4°C in the dark. Then the sections were incubated with the secondary antibody Alexa Fluor® 555 donkey anti-rabbit IgG (1:500, Invitrogen) for 1 h at room temperature in the dark and washed with PBS again. Cells expressing NeuN with red fluorescence were considered to be surviving neurons and cells with green fluorescence in the nucleus were considered to be the apoptotic cells under the microscope. Total TUNEL-positive cells and NeuN-positive cells in the hippocampus (CA1) were calculated in five random fields under the light microscope with 20× magnification. The final average number of TUNEL-positive cells and NeuN-positive cells of three sections from each animal was used for analysis and the severity of brain damage was evaluated by apoptotic index defined as the percentage of TUNEL-positive cells over NeuN-positive cells.</p></sec>
24875538|Immunofluorescence|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Immunofluorescence</title><p>To assess reactive astrocytosis and microgliosis of hippocamus CA1 region after 2-VO, frozen sections were selected at intervals of six in consecutive frozen sections. The frozen sections were treated with 0.3% triton and 10% anti-donkey serum for 1 h at room temperature. Subsequently, the sections were incubated with goat polyclonal antibody Iba-1 (1:400, abCAM) and monoclonal antibody glial fibrillary acidic protein (GFAP) (1:500, abCAM) overnight at 4°C in dark, and then incubated with secondary antibodies at 37°C for 1 h in the dark. The secondary antibodies were Alexa Fluor® 488 donkey anti-mouse IgG (1:500, Invitrogen) and Alexa Fluor® 555 donkey anti-goat IgG (1:500, Invitrogen) respectively.</p><p>The expression of Iba-1 and GFAP was examined using the Olympus fluorescence microscope (20× magnification). Quantification of Iba1 labeled macrophages/microglia and GFAP labeled astrocytes was performed using the image analysis program ImageJ (ImageJ 1.39u, the National Institutes of Health). For evaluating the average density of fluorescence, three measuring frames of 1360 × 1024 pixels in the hippocampus (CA1) region per sample was used for analysis. In the ImageJ program, these images were converted to a binaryimage using a threshold that was set manually at a level to detect most of the finest microglial or astrocytes processes and then counted automatically using the “analyze particles ” program. The level of immunoreactivity was expressed as the percentage of the area of the measuring frame that contained immunoreactivity (field detected area).</p></sec>
24875538|Real-time PCR|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Real-time PCR</title><p>The total hippocampus RNA was isolated using the E.Z.N.A.® Total RNA Kit II (Omega Bio-Teck, Doraville, GA). cDNA was produced using Taqman reverse transcription kits (TaKaRa Biotechnology, Dalian). Real-time PCR was performed on an ABI-Prism 7700 using SYBR Green II as a double stranded DNA specific dye according to the manufacturer’s instructions (TaKaRa Biotechnology, Dalian). Each sample was tested in triplicate and the average values were used for calculations. The primers used were 5′- CTGCC­CCTCTGCATCTTGT -3′ and 5′- AGATTTCTCCTATGCGGTTGG -3′ for GPR120, 5′- CATCCGTA­AAGACCTCTATGCCAAC-3′ and 5′-ATGGAGCCACCGATCCACA-3′ for β-actin.</p></sec>
24875538|Western blot assay|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Western blot assay</title><p>The nuclear and cytoplasmic proteins of the hippocampus were extracted by Nuclear and Cytoplasmic Protein Extraction Kit (Beyotime Institute of Biotechnology, China), respectively, according to the manufacturer’s instructions. SDS-PAGE (7.5% gel) was carried out on each sample (30 μg of protein). Separated proteins were subsequently electrotransferred to 0.2 μm nitrocellulose membranes at 16 V for 30 min. The membranes were blocked with 5% fat-free milk in TBS containing 0.05% Tween 20 (TBST; 2 h at room temperature) and washed in TBST. The blots were probed with primary antibodies: NF-κB P65 (Sigma) diluted 1: 1000, α-tubulin (Sigma) diluted 1: 2000, and histone 3 (Sigma) diluted 1: 2000 at 4°C overnight, washed for 30 min in TBST, incubated with horseradish peroxidase-conjugated goat anti-mouse IgG and goat anti-rabbit IgG (both at 1:5000) for 2 h at room temperature, and visualized using a DAB kit. Densitometric quantification of blots was carried out using Alphapart 11 Ease version 5.0, and a ratio relative to control was calculated.</p></sec>
24875538|ELISA|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>ELISA</title><p>The supernatant of the hippocampus homogenate (10%) was collected after 4,000 × <italic>g</italic> centrifugation for 15 min. ELISA measurements were performed with TNF-α ELISA kit (BD), IL-1β, IL-6, MCP-1 ELISA kits (R and D), and RvD1 EIA kits (Cayman Chemical) following the recommendations of the manufacturers.</p></sec>
24875538|Statistical analysis|('method', 0.9999995759692274)|('other', 4.240307726620858e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Statistical analysis</title><p>All values are expressed as mean ± SEM. ANOVA followed by post hoc Newman-Keuls multiple range tests was used for multiple groups. Significance was defined as <italic>P</italic> &lt; 0.05 in all statistical analyses.</p></sec>
24878348|None|('method', 0.9995928080922938)|('other', 0.00040719190770620306)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24878348|Participants and Study Design|('method', 0.9995928080922938)|('other', 0.00040719190770620306)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Participants and Study Design</title><p id="P11">A total of 1,232 children with OFC, including isolated and nonisolated OFC, were born in North Carolina between 1996 and 2002 and ascertained by the North Carolina Birth Defects Monitoring Program (NCBDMP). From this total, we used the survey select procedure in SAS software version 9.3 (SAS Institute, Cary, NC) to identify a random sample of mothers of school-aged (5–12 years old) children with OFC (n = 504). The NCBDMP is a population-based, statewide birth defects surveillance system that gathers information from all hospitals, except military hospitals, in the state. The NCBDMP ascertains information on all live-born infants, fetal deaths at or after 20 weeks’ gestation, and pregnancy terminations that are associated with one or more major birth defects diagnosed in the first year of life and in which the mother is a North Carolina resident. For infants with major birth defects, the NCBDMP collects information from health services databases, Medicaid-paid claims information, and vital statistics data (<xref rid="R17" ref-type="bibr">National Birth Defects Prevention Network, 2011</xref>). Major birth defects are defined as conditions present at birth that cause structural changes in one or more parts of the body and can have a serious, adverse effect on health, development, or functional ability (<xref rid="R21" ref-type="bibr">Parker et al., 2010</xref>).</p><p id="P12">This study included children with cleft lip only, cleft palate only, and cleft lip with cleft palate. Children with a nonisolated OFC were identified through the NCBDMP by the presence of at least one other major birth defect, using the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and British Pediatric Association Classification of Diseases (BPA) diagnostic codes. Children with a nonisolated OFC were excluded from our analysis because their academic success may have been affected by the additional birth defect(s) instead of the OFC alone. This exclusion also allowed for a more homogenous group and direct comparability with previous studies.</p><p id="P13">The control group was a random sample of mothers of children <italic>without</italic> a major birth defect born during the same time period, between 1996 and 2002, and selected from North Carolina birth certificates (n = 504). Mothers who were unable to speak or read English or Spanish, whose child had died before the survey, or whose child was born out of state were excluded from both groups of children.</p><p id="P14">Between May 2007 and April 2008, questionnaires were mailed to mothers in our study sample. The survey included Likert-scale and closed-ended and open-ended questions from validated quality-of-life instruments, including the Pediatric Quality of Life Inventory 4.0, Youth Quality of Life Instrument-Research Version, and Youth Quality of Life Instrument-Facial Differences Module (<xref rid="R32" ref-type="bibr">Strauss et al., 1995</xref>; <xref rid="R22" ref-type="bibr">Patrick et al., 2002</xref>; <xref rid="R7" ref-type="bibr">Edwards et al., 2005</xref>; <xref rid="R34" ref-type="bibr">Topolski et al., 2005</xref>; <xref rid="R36" ref-type="bibr">Varni et al., 2005</xref>; <xref rid="R35" ref-type="bibr">Varni et al., 2006</xref>;). Survey domains included demographics, outcomes, family life, dental health, diagnostic experiences, and other quality-of-life aspects, but only the results related to academic outcomes are described in this study. If potential participants did not respond to the initial mailing, up to three subsequent mailings were attempted in order to contact the mothers. Most participants responded to the first mailing. For successful completion and return of the survey, respondents were sent a $20 gift card.</p><p id="P15">The academic outcomes measured included overall letter grades, number of school days missed, and grade retention from maternal report in the questionnaire. For overall letter grades, mothers selected the grade (A through F) that their child had received most frequently in the recent grading period. Because of the small numbers, letter-grade categories were collapsed into mostly As and Bs (typically above average) and mostly Cs, Ds, or Fs (below average). Mothers could also answer “not in school” or “other,” followed by an open-ended question to allow for further explanation. Children indicated as “not in school” or “other” whose response could not be reassigned a letter-grade category were excluded from all the letter-grade analyses.</p><p id="P16">Number of school days missed in the past 12 months was a free-response question that also included the option “not in school.” The number of school days missed was collapsed into categories of 5 or fewer days (1 school week or less) missed and 6 or more days (more than 1 school week) missed based on consultation with clinical and public health experts in cleft and craniofacial conditions and developmental disabilities. Children whose mothers responded “not in school” were excluded from the school days missed analyses. Grade retention was measured by asking, “Starting since kindergarten, has your child repeated any grades?” Grade retention was analyzed as a binary variable (yes/no).</p><p id="P17">Maternal and child characteristics thought to be associated with academic outcomes were considered for the multivariable analyses. The child's sex, race/ethnicity, age, and primary health insurance; mother's age at delivery; respondent's relationship to the child; marital status; household income; and maternal education were obtained from the survey. Preterm birth and child's birth weight were obtained from vital statistics data. If information on the child's age or race/ethnicity or the mother's age was missing or illogical from the survey responses, we used demographic data from vital statistics.</p><p id="P18">A socioeconomic status (SES) variable was created from the mother's education level, household income level, and child's primary insurance. Each of these three components was categorized as “low” or “high” for each child. “Low” was equal to mother's education ≤high school degree, household income &lt;$25,000, and public or no insurance for the child. “High” was equal to mother's education &gt;high school degree, household income ≥$25,000, and private insurance for the child. A child was given one point for each characteristic classified as low for an SES score ranging from zero to three with zero representing the highest SES (high SES or no low categories) and three the lowest SES category (all categories were low). This SES method was derived from a similar study involving children with OFC and academic outcomes and another study involving other birth defects (<xref rid="R38" ref-type="bibr">Yang et al., 2008</xref>; <xref rid="R37" ref-type="bibr">Wehby et al., 2012</xref>). These categorizations were evaluated using a correlation matrix.</p><p id="P19">The presence of other medical conditions was obtained from maternal report on the questionnaire. The questions used to ascertain this information were validated, standardized questions used in the 2003 <italic>National Survey of Children's Health</italic> to collect information on the presence of medical conditions. The wording of these questions was as follows: “Has a doctor or medical professional ever told you that your child has_________” (<xref rid="R16" ref-type="bibr">Maternal and Child Health Bureau, 2013</xref>). The 10 conditions included in the survey were mental retardation, attention deficit disorder (ADD) or attention deficit hyperactivity disorder (ADHD), depression or anxiety, behavior or conduct problems, problems with shyness, developmental delay or physical impairment, hearing problems, speech problems, and three or more ear infections in the past 12 months. The term “mental retardation” was used in the survey instrument, but a more acceptable term, “intellectual disability,” will be used throughout the remainder of this article to represent this developmental disability (<xref rid="R29" ref-type="bibr">Schalock et al., 2007</xref>).</p></sec>
24878348|Statistical Analysis|('method', 0.9995928080922938)|('other', 0.00040719190770620306)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Statistical Analysis</title><p id="P20">We compared the selected maternal and child characteristics and the presence of the selected medical conditions between children with OFC and children without a major birth defect using chi-square tests, Fisher exact tests, and <italic>t</italic> tests where appropriate to calculate <italic>P</italic> values. A <italic>P</italic> value &lt; .05 was considered statistically significant.</p><p id="P21">Multivariable regression models were developed for each of the three academic outcomes with presence of OFC as the independent variable of interest. The adjusted model included child's sex, race/ethnicity, and age; whether the birth was preterm; SES; and maternal age and marital status. The selected medical conditions were not included in the multivariable analyses because we could not differentiate if these conditions resulted from the OFC itself or developed along a causal pathway distinct from the OFC. Low birth weight was not included in the adjusted models because it was correlated with preterm birth, and preterm birth is more often associated with cognitive function. Crude odds ratios (cORs), adjusted odds ratios (aORs), and 95% confidence intervals (CIs) were determined for the three academic outcomes.</p><p id="P22">To examine the effects of nonresponse, a sensitivity analysis was conducted for each of the three adjusted models. First, a propensity score was calculated for the probability of each mother responding to the questionnaire using maternal race, education, age, and marital status from the birth certificate. Deciles were created from the propensity scores, and within each group, the responders were weighted to represent the proportion of children from the underlying population in that group (responders and nonresponders). The weights were scaled and used in the adjusted logistic regression models for the three outcomes to estimate adjusted odds ratios.</p><p id="P23">All analyses were conducted using SAS software 9.3. This study was approved by the institutional review boards of the North Carolina Division of Public Health, the University of North Carolina at Chapel Hill, and Emory University.</p></sec>
24879803|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24879803|Materials|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Materials</title><p>Bacterial expression of mouse CGI-58 cDNA as a 12-histidine (His) fusion protein using the pET-28a vector (Novagen) was previously reported (<xref rid="bib11" ref-type="bibr">11</xref>). Expression of mouse CGI-58 and β-galactosidase using adenoviral expression vectors was also previously reported (<xref rid="bib14" ref-type="bibr">14</xref>). The cDNA for mouse ATGL (IMAGE: 30024535) was purchased from the American Type Culture Collection (Manassas, VA). SM2-1 <italic>E. coli</italic> were obtained from the Coli Genetic Stock Center at Yale University. DH10Bac <italic>E. coli</italic> were purchased from Invitrogen. BL21(DE3) <italic>E. coli</italic> were purchased from Novagen. A λDE3 lysogenization kit was purchased from Novagen. Skin fibroblasts from a human with CDS were generously donated by Dr. Rosalind A. Coleman (University of North Carolina-Chapel Hill). WS1 human skin fibroblasts and Sf9 insect cells were purchased from American Type Culture Collection. The yeast strain <italic>ict1</italic>Δ (<italic>MAT</italic><bold>a</bold><italic>his3</italic>Δ<italic>1 leu2</italic>Δ<italic>0 met15</italic>Δ<italic>0 ura3</italic>Δ<italic>0 ict1</italic>Δ<italic>::kanMX</italic>) lacking a soluble LPAAT was purchased from Invitrogen. Yeast nitrogen base, raffinose, and galactose were purchased from Sigma.</p><p>TALON His-Tag Purification Resin was purchased from Clontech Laboratories Inc. Glutathione Sepharose 4B was purchased from GE Healthcare Life Sciences. DMEM and MEM were purchased from Mediatech. BSA, fatty acid-free BSA, and fetal bovine serum were purchased from Sigma. Lipofectamine, Plus Reagent, Cellfectin, and Grace’s Medium were purchased from Invitrogen. Coomassie Plus “The Better Bradford Assay Reagent” and GelCode Blue Stain Reagent were purchased from Pierce.</p><p>Rabbit polyclonal antiserum raised against full-length recombinant mouse CGI-58 was previously described (<xref rid="bib14" ref-type="bibr">14</xref>). Anti-6-His antibody was purchased from Clontech Laboratories Inc. Anti-glutathione-S-transferase (GST) antibody was purchased from GE Healthcare. Anti-human ABHD5 antibody was purchased from Fitzgerald Industries. Anti-β-galactosidase, anti-calnexin, and peroxidase-conjugated anti-mouse, anti-rabbit, and anti-goat antibodies were purchased from Sigma. Enhanced chemiluminescence reagents were purchased from Pierce.</p><p>Phosphatidylinositol phosphate (PIP) strips, PIP Arrays, Membrane Lipid Strips, Sphingo Strips, phosphatidylinositol (PI) diC8, PI(3)P, PI(5)P, and PI(4,5)P were purchased from Echelon Inc.(Salt Lake City, UT). PA and LPA were purchased from Sigma. Egg phosphatidylcholine (PC) and soy PI were purchased from Avanti Polar Lipids. Radiolabeled [9,10(N)<sup>3</sup>H]triolein and [oleoyl-1-<sup>14</sup>C]oleoyl-CoA were purchased from PerkinElmer Life Sciences (Boston, MA). Hydrofluor scintillation cocktail was purchased from National Diagnostics, and ScintiVerse BD Cocktail was purchased from Fisher Scientific. Silica gel hard layer fluorescent TLC plates were obtained from Analtech (Newark, DE). Additional chemicals and organic solvents were purchased from either Fisher Scientific or Sigma.</p></sec>
24879803|Generation of a 3D protein model of CGI-58|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Generation of a 3D protein model of CGI-58</title><p>The primary amino acid sequence for mouse CGI-58 (NP_080455.1) was submitted to the online Protein Homology/analogy Recognition Engine (PHYRE) version 0.2 (<xref rid="bib15" ref-type="bibr">15</xref>). Resulting models were then evaluated using the Structural Analysis and Verification Server (SAVES) (<ext-link ext-link-type="uri" xlink:href="http:nihserver.mbi.ucla.edu/SAVES">http:nihserver.mbi.ucla.edu/SAVES</ext-link>). The SAVES program includes five programs, including PROCHECK (<xref rid="bib16" ref-type="bibr">16</xref>), WHAT_CHECK (<xref rid="bib17" ref-type="bibr">17</xref>), ERRAT (<xref rid="bib18" ref-type="bibr">18</xref>), VERIFY 3D (<xref rid="bib19" ref-type="bibr">19</xref>), and PROVE (<xref rid="bib20" ref-type="bibr">20</xref>), which assess the structural stability of the computer-generated models. The highest-ranked model was based on a putative hydrolase (2632844) from <italic>Bacillus subtilis</italic> (Protein Data Bank ID: 2R11). Images of the model were captured with PyMOL software (The PyMOL Molecular Graphics System, Version 1.5.0.1, Schrödinger LLC).</p></sec>
24879803|Generation of SM2-1(DE3) <italic>E. coli</italic>|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Generation of SM2-1(DE3) <italic>E. coli</italic></title><p>SM2-1(DE3) <italic>E. coli</italic> were produced using a λDE3 lysogenization kit to integrate the λDE3 prophage into the SM2-1 <italic>E. coli</italic> chromosome for isopropyl-β-D-1-thiogalactopyranoside (IPTG)-induced expression of T7 RNA polymerase, needed for expression of 12-His-tagged CGI-58 using the pET-28a vector. T7 polymerase was detected by immunoblotting bacterial lysates (not shown).</p></sec>
24879803|Expression and partial purification of recombinant 12-His-tagged CGI-58|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Expression and partial purification of recombinant 12-His-tagged CGI-58</title><p>CGI-58 cDNA in a pET-28a vector was used to transform BL21(DE3) or SM2-1(DE3) <italic>E. coli</italic>; transformants were grown in Luria Broth with kanamycin at 37°C with shaking at 225 rpm to an optical density at 600 nm of 0.6–0.8 before addition of 1 mM IPTG for 5 or 3 h, respectively. Cells were centrifuged at 4,000 <italic>g</italic> for 10 min at 4°C, the supernatant was removed, and cell pellets were stored at −20°C.</p><p>Thawed cells were suspended in 1 mg/ml lysozyme in lysis buffer containing 50 mM sodium phosphate, pH 7.5, 100 mM potassium chloride, 20 mM imidazole, 1 mM DTT, and protease inhibitors (Roche cOmplete, EDTA free), followed by incubation on ice for 30 min. Cells were disrupted with glass beads in a Bead-Beater<sup>®</sup> (Biospec Products Inc.) chamber surrounded by ice water; cells were disrupted with 10 cycles of 15 s blending with 2 min intermittent cooling. Lysed cells were centrifuged at 21,000 <italic>g</italic> for 20 min at 4°C. Clarified supernatant was incubated with 0.5 ml TALON His-Tag Purification Resin for 1.5 h at 4°C prior to brief centrifugation at 800 <italic>g</italic> at 4°C. The resin pellet was resuspended in lysis buffer with either 20 mM imidazole (early experiments) or 100 mM imidazole (later experiments) and transferred to a column for washing with an excess (at least 50 column volumes) of lysis buffer containing either 20 mM imidazole (early experiments) or 100 mM imidazole (later experiments), followed by elution with 250 mM imidazole, 40% glycerol (v/v) in lysis buffer, pH 8.0. Collected fractions were stored at −20°C.</p></sec>
24879803|Expression and partial purification of GST-tagged CGI-58|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Expression and partial purification of GST-tagged CGI-58</title><p>Mouse CGI-58 cDNA was subcloned into the pGEX-4T-1 expression plasmid (GE Healthcare) to append the nucleotide sequence encoding a GST tag to the 5′ end of the CGI-58 cDNA. Bl21(DE3) <italic>E. coli</italic> expressing GST-CGI-58 were grown in Luria Broth with shaking at 225 rpm at 37°C to an optical density at 600 nm of 0.6–0.8 before addition of 0.01 mM IPTG for 1–2 h. Cells were centrifuged at 4,000 <italic>g</italic> for 10 min at 4°C, the supernatant was removed, and pelleted cells were lysed in PBS with 0.5 mg/ml lysozyme and protease inhibitors. A fraction of lysate was centrifuged at 16,000 <italic>g</italic> to remove membranes. Supernatants and whole cell lysates were assayed for LPAAT activity.</p></sec>
24879803|Expression of 6-His-plsC|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Expression of 6-His-plsC</title><p>6-His-plsC was expressed in SM2-1(DE3) cells using the same conditions as described for the expression of 12-His-CGI-58 in SM2-1(DE3) cells.</p></sec>
24879803|Expression of ATGL in Sf9 insect cells|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Expression of ATGL in Sf9 insect cells</title><p>Mouse ATGL cDNA was amplified by PCR using forward (5′-GCCACCATGTTCCCGAGGG-3′) and reverse (5′-TTAGTGATGGTGATGGTGATGTCCGCAAGGCGGGAG-3′) primers to add DNA encoding a <italic>Spe</italic>I restriction site and a Kozak sequence before the start of the coding sequence of ATGL cDNA and a glycine-linked 6-His tag and <italic>Xho</italic>I restriction site to the 3′ end. The PCR product was ligated into pCR-Blunt (Invitrogen) followed by restriction digestion and ligation into the pFastBac1 vector (Invitrogen). Using the Bac-to-Bac Baculovirus Expression System (Invitrogen), the ATGL-6-His cDNA in pFastBac1 was recombined into a bacmid in DH10Bac <italic>E. coli</italic>. Recombined bacmids were identified by blue/white screening of colonies, isolated by plasmid minipreps, and confirmed by PCR using M13 forward and reverse primers (Invitrogen). TOP10 <italic>E. coli</italic> were transformed with bacmids for plasmid purification using the Wizard Plus Midiprep kit (Promega). Cultured Sf9 insect cells were transfected with bacmid complexed with Cellfectin Reagent (Invitrogen) for assembly and propagation of baculovirus. Sf9 cells were maintained in Sf-900II SFM media (Invitrogen) at 28°C. Media were collected 72 h after transfection and centrifuged at 800 <italic>g</italic> for 10 min at 4°C to remove cells and debris; supernatants containing baculovirus were stored at 4°C.</p><p>For expression of recombinant 6-His-tagged ATGL, Sf9 cells were grown to 70% confluence in 150 mm dishes; growth medium containing 200 µl baculovirus was added for 72 h to induce protein expression. Media were removed, and cell monolayers washed with PBS. Cells were detached from culture dishes by scraping into PBS followed by centrifugation at 800 <italic>g</italic> for 10 min at 4°C. Supernatants were removed by aspiration and pellets were stored at −70°C.</p><p>To prepare cell lysates containing ATGL for TAG hydroly­sis assays, frozen cell samples were thawed and resuspended in Sf9 lysis buffer containing 20 mM potassium phosphate, pH 7.0, 1 mM EDTA, 1 mM DTT, with protease inhibitors for 10 min on ice. The resuspended cells were disrupted by passing them through a 27.5 gauge syringe 10 times. Lysates were centrifuged at 800 <italic>g</italic> for 10 min at 4°C to remove intact cells and heavy membranes.</p></sec>
24879803|Expression of human CGI-58 in yeast|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Expression of human CGI-58 in yeast</title><p>To overexpress human CGI-58 with an N-terminal fusion of Protein A in yeast, its cDNA was amplified by PCR using forward (5′-GCCCATATGGCGGCGGAGGAGGAG-3′) and reverse (5′-CCG­CTCGAGTCAGTCCACAGTGTC-3′) primers and was subcloned into the <italic>Nde</italic>I and <italic>Xho</italic>I restriction sites of the pYES2 vector (Invitrogen) containing the Protein A sequence derived from <italic>PtA-DGK1</italic> (<xref rid="bib21" ref-type="bibr">21</xref>). The internal <italic>Nde</italic>I restriction site of the human CGI-58 (hCGI-58) cDNA was removed by introduction of a silent mutation using the QuikChange<sup>®</sup> Site-Directed Mutagenesis kit (Stratagene).</p><p>Yeast strains BY4741 (<xref rid="bib22" ref-type="bibr">22</xref>) and <italic>ict1</italic>Δ (<italic>MAT</italic><bold>a</bold><italic>his3</italic>Δ<italic>1 leu2</italic>Δ<italic>0 met15</italic>Δ<italic>0 ura3</italic>Δ<italic>0 ict1</italic>Δ<italic>::kanMX</italic>) containing pYES2-PtA-hCGI-58 (or the pYES2 control vector) were grown at 30°C in SC-Ura media containing 2% raffinose as a carbon source. The cultures at the exponential phase were supplemented with 2% galactose (final concentration) and incubated for 7 h to express the Protein A-hCGI-58 fusion protein.</p><p>Yeast cells expressing hCGI-58 were harvested and suspended in cold lysis buffer (20 mM Tris-HCl, pH 8.0, 150 mM potassium chloride, 5 mM magnesium chloride) supplemented with complete EDTA-free protease inhibitors (Roche) and were disrupted using a Mini-Bead-Beater<sup>®</sup>-16 with 15 pulse sequences of 15 s with intermittent cooling. Cell lysates were centrifuged for 10 min at 1,500 <italic>g</italic> at 4°C to remove unbroken cells and cell debris. The cell extracts were incubated for 30 min with 0.1% (final concentration) Tween-20 at 4°C with gentle rotation, and then centrifuged for 1 h at 100,000 <italic>g</italic> at 4°C in a SW60Ti rotor in a Beckman Ultracentrifuge. The supernatants were collected, 20% (final concentration) glycerol was added, and samples were stored at −20°C.</p></sec>
24879803|Assay for LPAAT activity|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Assay for LPAAT activity</title><p>LPAAT activity of recombinant CGI-58 was assessed by mixing partially purified recombinant CGI-58 (from <italic>E. coli</italic>) or yeast cell extracts with 50 µM LPA and 10 µM [1-<sup>14</sup>C-oleoyl]oleoyl-CoA in 50 mM Tris-HCl, pH 7.5 (<xref rid="bib10" ref-type="bibr">10</xref>), followed by incubation of samples for 10 min at 37°C. Reactions were terminated and products extracted by addition of 0.1N HCl in methanol-chloroform-MgCl<sub>2</sub> [1:2:3 (v/v/v)] and centrifugation at 800 <italic>g</italic> for 10 min at room temperature. After phase separation, the top aqueous phase was discarded, and the lower organic phase was dried via speed vacuum centrifugation. The dried organic phase was dissolved in chloroform and spotted onto a silica gel hard layer fluorescent TLC plate. Lipids were separated using developing solvent of chloroform-methanol-acetone-acetic acid-water [50:10:20:15:5 (v/v/v/v/v)], and radiolabeled lipids were visualized using a Storm System Phosphorimager (Molecular Dynamics). Bands corresponding to PA were identified by comigration with a lipid standard and were scraped from the TLC plates, and radioactivity was quantified by liquid scintillation counting (PerkinElmer Life Sciences).</p></sec>
24879803|Assay for TAG lipase activity|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Assay for TAG lipase activity</title><p>To study the effect of recombinant CGI-58 on TAG lipase activity of ATGL, 50 µg Sf9 cell extract containing recombinant ATGL was mixed with up to 1 µg of purified recombinant CGI-58 in a final volume of 100 µl 0.1 M potassium phosphate, pH 7.0, before mixing with 100 µl substrate containing 330 µM [9,10-<sup>3</sup>H]triolein emulsified with 145 µM PC-PI (3:1) (<xref rid="bib23" ref-type="bibr">23</xref>). Reactions were incubated at 37°C for 1 h and terminated by the addition of 3.25 ml methanol-chloroform-heptane [10:9:7 (v/v/v)] and 1.05 ml 0.1 M potassium carbonate, 0.1 M boric acid, pH 10.5. Reactions were centrifuged at 800<italic> g</italic> for 20 min at room temperature, after which 1 ml of each top phase was removed, and radioactivity quantified by liquid scintillation counting.</p></sec>
24879803|Protein-lipid overlay assays|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Protein-lipid overlay assays</title><p>PIP Strips (P-6001), PIP Arrays (P-6100), Membrane Lipid Strips (P-6002), or Sphingo Strips (P-6000) (Echelon Inc.) were incubated in 5% nonfat dry milk in PBS with 0.1% Tween-20 for 1 h at room temperature, followed by 12.8 nM (0.5 µg/ml) partially purified recombinant 12-His-tagged CGI-58 in 5% milk in PBS for 1 h at room temperature. Membranes were rinsed three times in PBS with 0.1% Tween-20, followed by incubation with either rabbit polyclonal anti-CGI-58 antiserum or mouse anti-6-His antibody for 1 h at room temperature. Membranes were again rinsed three times followed by incubation with peroxidase-conjugated anti-rabbit or anti-mouse IgG for 1 h and further rinses. Membranes were developed using enhanced chemiluminescence reagent (Pierce) and then exposed to X-ray film.</p></sec>
24879803|Immunoblotting|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Immunoblotting</title><p>Immunoblotting of recombinant proteins was performed as described previously (<xref rid="bib11" ref-type="bibr">11</xref>).</p></sec>
24879803|Statistical analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Statistical analysis</title><p>Data representing the means of duplicate or triplicate samples ± standard deviation were analyzed using GraphPad Prism 6 software. Variance was measured using either one-way or two-way ANOVA, followed by Tukey’s multiple comparisons post hoc test or Bonferroni’s multiple comparisons post hoc test, respectively.</p></sec>
24904022|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24904022|Subjects and study design|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Subjects and study design</title><p>Study subjects were selected from participants in a clinical nutrition study conducted by the National Leading Research Laboratory of Clinical Nutrigenetics/Nutrigenomics at Yonsei University. Study subjects were recruited from the Health Service Center during routine check-up at National Health Insurance Corporation Ilsan Hospital, Goyang, Korea (January 2012–December 2012). Based on the data screened from the Health Service Center, subjects who had IFG (100 ≤ fasting glucose &lt; 126 mg/dl) or newly diagnosed T2D (fasting glucose ≥126 mg/dl) were referred to the Department of Family Medicine or Internal Medicine. Subjects were excluded if they had any diagnosis of vascular disease, cancer (clinically or by anamnesis), renal disease, liver disease, thyroid disease, chronic alcoholism, and acute or chronic inflammatory diseases; took antioxidants; were pregnant, breast feeding, or intending to become pregnant during the time of study; or were taking glucose-lowering, lipid-lowering, or antihypertensive medications. A total of 100 subjects were enrolled. The macronutrient composition of each subject’s usual diet was that of a typical diet with cooked refined rice, which is consumed by a substantial number of Koreans. All subjects provided written informed consent before participation in this study, which was approved by the Institutional Review Board of Yonsei University and performed in accordance with the Declaration of Helsinki.</p><p>Independently performed computer randomization was used to allocate numbers and divide the patients into two groups. The present study was carried out in two phases; a 2 week run-in phase consisting of the usual diet with refined rice and a 12 week intervention phase consisting of the usual diet of refined rice or consumption of whole grains and legumes as a carbohydrate source. At the beginning, a total 120 subjects were screened for the study. Twenty subjects were excluded; 13 subjects were taking medications or supplements which related to hypertension, and 7 subjects were taking blood glucose and lipid lowering drugs. During the run-in period, one subject, not having maintained energy intake, dropped out. The remaining 99 were randomly subdivided into two groups and were assigned to consume either their usual diet (refined rice) or the whole grains and legumes as a carbohydrate source for three meals a day during the 12 week intervention.</p></sec>
24904022|Dietary education and assessment of dietary intake/physical activity level|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Dietary education and assessment of dietary intake/physical activity level</title><p>All subjects were given written and verbal instructions by a registered dietitian on completion of a 3 day (2 week days and 1 weekend day) dietary record every 2 weeks throughout the whole study. On the sheet, subjects were instructed to record the amount of foods before ingestion and any remaining after ingestion by weighing the foods. During the 2 week run-in period, all participants were advised to continue their usual diet of refined rice. Baseline measurements were also performed at the start of the run-in phase. After the run-in period, the subjects in the control group maintained their usual diet of refined rice, and the subjects in the whole grain group replaced refined rice intake with 1/3 of legumes (black soybeans), 1/3 of barley, and 1/3 of brown rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30–70 g/unit) per day for sufficient dietary fiber intake. To check participants’ compliance during the whole study period, the dietitian interviewed them during biweekly visits or by telephone. They were interviewed to discern whether they were following the program well, including dietary intake and weight changes. During the study period, all participants were also encouraged to maintain their usual lifestyle and were reminded not to make any changes to their usual dietary habits, except for the whole grain substitution in whole grain group.</p><p>Dietary energy values and nutrient content from the 3 day food records were calculated using a computer aided nutritional analysis program (CAN-pro 3.0; Korean Nutrition Society, Seoul, Korea). Total energy expenditure (kcal/day) was calculated from activity patterns including basal metabolic rate, physical activity for 24 h (<xref rid="bib10" ref-type="bibr">10</xref>), and specific dynamic action of food. Basal metabolic rate for each subject was calculated with the Harris-Benedict equation (<xref rid="bib11" ref-type="bibr">11</xref>).</p></sec>
24904022|Anthropometric parameters, blood pressure, and blood collection|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Anthropometric parameters, blood pressure, and blood collection</title><p>Body weight and height were measured in the morning in unclothed subjects without shoes to calculate BMI (kg/m<sup>2</sup>). Waist circumference was measured at the umbilical level with the subjects standing after normal expiration and the hip girth was measured at the widest part of the hip, and the waist and hip ratio (WHR) was calculated. Blood pressure (BP) was measured in the left arm of seated patients with an automatic BP monitor (TM-2654; A and D, Tokyo, Japan) after a 20 min rest. Study subjects were interviewed for smoking and drinking behavior during their visit. After a 12 h fasting period, venous blood specimens were collected in EDTA-treated and plain tubes, centrifuged to produce plasma or serum, and stored at −70°C until analysis.</p></sec>
24904022|Oral glucose tolerance test, hemoglobin A<sub>1c</sub>, and homeostasis model assessment-insulin resistance|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Oral glucose tolerance test, hemoglobin A<sub>1c</sub>, and homeostasis model assessment-insulin resistance</title><p>All subjects drank a 75 g glucose solution after a 12 h overnight fast. At 0 and 12 weeks, venous specimens were subsequently collected at, before, and 30, 60, and 120 min after loading to determine the serum levels and response areas of glucose, insulin, and C-peptide according to dietary intervention. Glucose was measured by a glucose oxidase method using the Beckman glucose analyzer (Beckman Instruments, Irvine, CA). Insulin and C-peptide were measured by radioimmunoassay with commercial kits from Immuno Nucleo Corp. (Stillwater, MN). Each response of glucose, insulin, C-peptide, and FFA was calculated with the area under each response curve using a trapezoidal method. Hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) was measured by immunoturbidimetric analyzer using a turbidimeter. Insulin resistance was calculated from the homeostasis model assessment-insulin resistance (HOMA-IR) (<xref rid="bib12" ref-type="bibr">12</xref>) using the following equation: HOMA-IR = [fasting insulin (μIU/ml) × fasting glucose (mmol/l)]/22.5.</p></sec>
24904022|Serum lipid profile, FFAs, and serum high-sensitivity C reactive protein|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Serum lipid profile, FFAs, and serum high-sensitivity C reactive protein</title><p>Fasting serum concentrations of total-cholesterol and triglycerides were measured using commercially available kits on a Hitachi 7150 autoanalyzer (Hitachi Ltd., Tokyo, Japan). After precipitation of apoB-containing lipoproteins with dextran sulfate-magnesium, HDL-cholesterol concentrations in the supernatants were measured enzymatically. LDL-cholesterol was indirectly estimated in participants with serum triglyceride concentrations less than 400 mg/dl using the Friedewald formula: LDL-cholesterol = total-cholesterol − [HDL-cholesterol + (triglycerides/5)]. FFAs were analyzed with a Hitachi 7150 autoanalyzer (Hitachi Ltd.). Serum high-sensitivity C reactive protein (hs-CRP) concentrations were measured with an Express Plus<sup>TM</sup> autoanalyzer (Chiron Diagnostics Co., Walpole, MA) using a commercially available high-sensitivity CRP-Latex(II) X2 kit (Seiken Laboratories Ltd., Tokyo, Japan).</p></sec>
24904022|Cytokine secretion in nonstimulated PBMCs|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Cytokine secretion in nonstimulated PBMCs</title><p>Whole blood was mixed with the same volume of RPMI 1640 (Gibco, Invitrogen, Carlsbad, CA). The sample was then centrifuged at 2,000 rpm for 20 min at 10°C. After the separation, a thin layer of PBMCs was isolated and washed twice with RPMI 1640. The pellet was resuspended in RPMI 1640 supplemented with 10% fetal bovine serum (Gibco, Invitrogen) and seeded in 12-well plates (1 × 106 cells/ml; Nunc, Roskilde, Denmark) and incubated at 37°C with 5% CO<sub>2</sub> for 24 h. After 24 h incubation, supernatants were collected and stored at 80°C until interleukin (IL)-1β, IL-6, TNF-α, and Lp-PLA<sub>2</sub> activity levels were assayed (<xref rid="bib13" ref-type="bibr">13</xref>, <xref rid="bib14" ref-type="bibr">14</xref>).</p></sec>
24904022|Cytokine assay for IL-1β, IL-6, and TNF-α levels in serum and PBMC supernatants|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Cytokine assay for IL-1β, IL-6, and TNF-α levels in serum and PBMC supernatants</title><p>Levels of IL-1β, IL-6, and TNF-α in serum and PBMC supernatants were measured using the Bio-PlexTM reagent kit on the Bio-PlexTM (Bio-Rad Laboratories, Hercules, CA) according to the manufacturer’s instuctions.</p></sec>
24904022|Urinary 8-epi-prostaglandin F<sub>2α</sub> and plasma malondialdehyde|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Urinary 8-epi-prostaglandin F<sub>2α</sub> and plasma malondialdehyde</title><p>Urine was collected in polyethylene bottles containing 1% butylated hydroxytoluene after a 12 h fast. The bottles were immediately covered with aluminum foil and stored at −70°C until further analysis. The compound 8-epi-prostaglandin F<sub>2α</sub> (8-epi-PGF<sub>2α</sub>) was measured using an enzyme immunoassay (BIOXYTECH urinary 8-epi-PGF<sub>2α</sub> TM assay kit; OXIS International Inc., Portland, OR). Urinary creatinine levels were determined using the alkaline picrate (Jaffe) reaction. Plasma malondialdehyde (MDA) was measured from thiobarbituric acid-reactive substances (TBARS assay kit; Zepto-Metrix Co., Buffalo, NY).</p></sec>
24904022|Plasma oxidized LDL, LDL particle size, and Lp-PLA<sub>2</sub> activity|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Plasma oxidized LDL, LDL particle size, and Lp-PLA<sub>2</sub> activity</title><p>Plasma oxidized LDL (ox-LDL) was measured using an enzyme immunoassay (Mercodia, Uppsala, Sweden). The resulting color reaction was read at 450 nm on a Wallac Victor2 multilabel counter (Perkin Elmer Life Sciences, Turku, Finland). Particle size distribution of LDL (1.019–1.063 g/ml) isolated by sequential flotation ultracentrifugation was examined by a pore gradient lipoprotein system (CBS Scientific, San Diego, CA) on commercially available nondenaturing polyacrylamide slab gels containing a linear gradient of 2–16% acrylamide (Alamo Gels Inc., San Antonio, TX). Standards of latex beads (34 nm), thyroglobulin (17 nm), apoferritin (12.2 nm), and catalase (10.4 nm) were used to estimate the relative migration rates of each band. Gels were scanned using a GS-800 calibrated imaging densitometer (Bio-Rad, Graz, Austria). The activity of Lp-PLA<sub>2</sub> in plasma and PBMC supernatants was measured by using a modification of a previously described high-throughput radiometric activity assay (<xref rid="bib15" ref-type="bibr">15</xref>).</p></sec>
24904022|Statistical analyses|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML"><title>Statistical analyses</title><p>Statistical analyses were performed using the SPSS version 12.0 for Windows (Statistical Package for the Social Sciences; SPSS Inc., Chicago, IL). A paired <italic>t</italic>-test was used to evaluate the effects of the dietary intervention. The primary endpoint was to assess changes of Lp-PLA<sub>2</sub> activities in plasma and PBMC between groups. One-way ANOVA with the Bonferroni correction or independent <italic>t</italic>-test was used to test the inter-group comparison. Pearson and partial correlation coefficients were used to determine the relationship between changes in Lp-PLA<sub>2</sub> activities in plasma and PBMC supernatants, and metabolic parameters. General linear model analysis was also used for the comparison with adjustment for confounding factors. Multiple linear regression analyses were performed to identify major factors associated with initial and changed variables, according to changes in Lp-PLA<sub>2</sub> activities in plasma and PBMC supernatants. For descriptive purposes, mean values are presented using untransformed values. Results are expressed as the mean ± standard error. A two-tailed <italic>P</italic> value of less than 0.05 was considered statistically significant.</p></sec>
24905737|None|('method', 0.9925643431101567)|('other', 0.007435656889843118)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24905737|Study design and setting|('method', 0.9925643431101567)|('other', 0.007435656889843118)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Study design and setting</title><sec id="S8"><title>Design</title><p id="P9">CSP #569 is an observational study of PTSD among Veterans who are members of the VET-R (<xref rid="R16" ref-type="bibr">Henderson <italic>et al.</italic> 1990</xref>). The study collected data by mail and telephone between January 2010 and September 2012. A mail questionnaire obtained general health information and PTSD symptoms with the PCL and VET-R PTSD scale. A telephone interview used the CIDI to diagnose PTSD.</p></sec><sec id="S9"><title>Setting</title><p id="P10">The VET-R is the source of Vietnam-Era Veterans for this study. It was constructed from computerised military discharge records and is a national sample of male twins from all branches who served on active duty during the Vietnam Era (1964–1975) (<xref rid="R11" ref-type="bibr">Eisen <italic>et al.</italic> 1987</xref>; <xref rid="R16" ref-type="bibr">Henderson <italic>et al.</italic> 1990</xref>; <xref rid="R15" ref-type="bibr">Goldberg <italic>et al.</italic> 2002</xref>). Members of the Registry were born between 1939 and 1957 representing a cross-section of Veterans of the era who were assembled on the basis of being members of a twin pair. The VET-R is a non-clinical sample and was not compiled based on post-discharge medical or psychiatric disorders or health seeking behaviours. A complete description of the VET-R has been published (<xref rid="R11" ref-type="bibr">Eisen <italic>et al.</italic> 1987</xref>; <xref rid="R16" ref-type="bibr">Henderson <italic>et al.</italic> 1990</xref>; <xref rid="R15" ref-type="bibr">Goldberg <italic>et al.</italic> 2002</xref>).</p></sec></sec>
24905737|Subjects and methods|('method', 0.9925643431101567)|('other', 0.007435656889843118)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Subjects and methods</title><sec id="S11" sec-type="subjects"><title>Subjects</title><p id="P11">All members of the VET-R who were known to be alive and had not withdrawn were recruited to participate in this study. Informed consent was obtained from all participating VET-R members, and the VA Central Institutional Review Board approved the study’s protocol.</p></sec><sec id="S12"><title>Field work</title><p id="P12">We mailed all twins an initial letter with a 20-page health survey and invited them to participate. Twins were instructed to complete and return the survey by mail. For twins who did not send back a survey, we attempted to call them directly. Because of the size and scope of the study, all mail and telephone fieldwork was done under contract by Abt-SRBI, Inc.</p></sec></sec>
24905737|Measures|('method', 0.9925643431101567)|('other', 0.007435656889843118)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>Measures</title><sec id="S14"><title>PTSD diagnosis</title><p id="P13">PTSD was assessed by a telephone administration of the CIDI according to the 4th edition of the DSM-IV (<xref rid="R2" ref-type="bibr">American Psychiatric Association, 1994</xref>). The CIDI is a structured instrument administered by trained lay interviewers (<xref rid="R26" ref-type="bibr">Robins <italic>et al.</italic> 1988</xref>). Interview training was done by CIDI certified trainers at the start of the study and continuously monitored during the course of the fieldwork. We assessed each respondent for current PTSD (an episode within the 12 months prior to the interview).</p></sec><sec id="S15"><title>Dimensional assessment of PTSD</title><p id="P14">The mailed survey included the PCL (<xref rid="R33" ref-type="bibr">Weathers <italic>et al.</italic> 1993</xref>). As VET-R members were discharged from the military decades ago, we used the civilian, rather than the military, version of the PCL (<xref rid="R34" ref-type="bibr">Weathers &amp; Ford, 1996</xref>). For each item the respondent was asked to rate how bothered he has been in the past month by that symptom on a 5-point scale from ‘not at all’ (a value of 1) to ‘extremely’ (a value of 5). Responses to the 17 items were summed to generate the PCL score which can range from 17 to 85. Developed in 1993 by researchers at the National Center of PTSD, initial psychometric data showed that the PCL correlates highly (<italic>r</italic> = 0.93) with the CAPS (<xref rid="R4" ref-type="bibr">Blake <italic>et al.</italic> 1990</xref>), has good diagnostic efficiency (&gt;0.70) and robust psychometric properties with a variety of traumatically exposed populations (<xref rid="R6" ref-type="bibr">Blanchard <italic>et al.</italic> 1996</xref>; <xref rid="R3" ref-type="bibr">Andrykowski <italic>et al.</italic> 1998</xref>; <xref rid="R23" ref-type="bibr">Manne <italic>et al.</italic> 1998</xref>). A score of 50 was originally recommended for a presumptive diagnosis of PTSD; however, in recent years analyses support the use of lower cutoff scores (<xref rid="R36" ref-type="bibr">Yeager <italic>et al.</italic> 2007</xref>; <xref rid="R35" ref-type="bibr">Yeager &amp; Magruder, 2013</xref>).</p><p id="P15">The mailed survey also included the VET-R PTSD a 15 item-scale that assesses the frequency of symptoms in the previous 6 months. The items were derived based on the DSM-III-R (<xref rid="R1" ref-type="bibr">American Psychiatric Association, 1987</xref>) criteria and asked in the context of ‘military service experiences’ (see <xref ref-type="supplementary-material" rid="SD1">online Supplemental Material</xref> for the question items). Response options range from 1 ‘never’ to 5 ‘very often’ along a 5-point ordinal scale. The total VET-R PTSD score ranges from 15 to 75. The total scale demonstrated excellent internal consistency (Chronbach’s <italic>α</italic> = 0.9) and the test–retest reliability was 0.6 (<xref rid="R27" ref-type="bibr">Roy-Byrne <italic>et al.</italic> 2004</xref>). The rationale for read-ministering the VET-R PTSD scale was that it permits a direct comparison of the course of PTSD symptoms across a 25-year interval.</p><p id="P16">The two PTSD self-report measures were contained in separate (non-contiguous) sections of the mailed survey material. We considered randomly assigning the order of the scales within the survey, but because PCL uses the more contemporary DSM-IV criteria and was more relevant to the primary study question, we made that scale appear first in all questionnaires.</p></sec><sec id="S16"><title>Demographic and military service factors</title><p id="P17">Data on key demographic and military service characteristics were available from archival information in the VET-R. Variables used descriptively in the present study include age, race, branch of service, military rank and military service in the Southeast Asia theatre of operations.</p></sec></sec>
24905737|Statistical analysis|('method', 0.9925643431101567)|('other', 0.007435656889843118)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S17"><title>Statistical analysis</title><p id="P18">Descriptive statistics examined the mean or percent distribution for demographic and military service characteristics. For both scales, we calculated Cronbach’s <italic>α</italic> as an estimate of internal reliability; we also used the Pearson <italic>r</italic> to examine the correlation between the two scales. Using the CIDI PTSD diagnosis as the criterion, we calculated sensitivity and specificity at each point, as well as positive and negative predictive values and the percent correctly classified. Optimal cutoff points were identified that maximised the percent correctly classified.</p><p id="P19">We plotted the receiver operator characteristic (ROC) curve at every value of the PCL and VET-R PTSD scale. The ROC curve is a graphical plot of sensitivity <italic>v</italic>. one-specificity across all possible values on the PCL and the VET-R PTSD scale. ROC plots provide a visual way to examine the tradeoffs between sensitivity and specificity at any scale value. We also estimated the area under the curve (AUC) values for both PCL and the VET-R PTSD scale, which provides an index of the predictive accuracy of a measure. Typically an AUC value ≥80% is considered to be indicative of a scale with good diagnostic accuracy (<xref rid="R19" ref-type="bibr">Kraemer, 1987</xref>). We adjusted the AUC confidence intervals for clustering due to the sample of twin pairs.</p><p id="P20">We also calculated positive and negative likelihood ratios (LR+ and LR−), which are based on the ratio of sensitivity and specificity and are unaffected by prevalence. Larger values for these ratios indicate a higher probability of having PTSD and conversely, smaller values correspond to a lower probability of having PTSD. LR+ values that exceed 5 and LR− values that are below 0.2 are considered informative for the likelihood of the presence or absence of the disorder. Last, we calculated quality estimates for <italic>k</italic>(0.0), <italic>k</italic>(1.0), and <italic>k</italic>(0.5). Kappa (<italic>k</italic>) is a measure of diagnostic efficiency which is often evaluated at weights of 0.0 (optimising sensitivity), 1.0 (optimising specificity) and 0.5 (optimising efficiency) (<xref rid="R19" ref-type="bibr">Kraemer, 1987</xref>). The target range for <italic>k</italic> (0.5) is between 0.4 and 0.6; however, 0.2–0.4 is considered acceptable, and 0.6–0.8 ‘a cause for celebration’ (<xref rid="R20" ref-type="bibr">Kraemer <italic>et al.</italic> 2012</xref>).</p><p id="P21">All analyses were done in Stata 11.2 (<xref rid="R31" ref-type="bibr">StataCorp, 2009</xref>).</p></sec>
24905737|None|('method', 0.9499491373848796)|('other', 0.05005086261512035)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
24905737|None|('method', 0.9499491373848796)|('other', 0.05005086261512035)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Supplemental material</label><media xlink:href="NIHMS951993-supplement-Supplemental_material.doc" orientation="portrait" xlink:type="simple" id="d36e714" position="anchor"/></supplementary-material>
24906823|Materials and Methods|('method', 0.9903649865479731)|('other', 0.009635013452026803)|<title>Materials and Methods</title>
24906823|Mice|('method', 0.9903649865479731)|('other', 0.009635013452026803)|<sec id="Sec3"><title>Mice</title><p>All animal studies were carried out under an approved IACUC animal protocol according to the institutional guidelines at Albert Einstein College of Medicine (Bronx, NY) and at Baylor College of Medicine (Houston, TX). Female and male <italic toggle="yes">neuropeptide Y</italic> (<italic toggle="yes">Npy</italic>-<italic toggle="yes">Gfp</italic>) transgenic mice [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR13">13</xref>] were obtained from The Jackson Laboratory (Bar Harbor, ME) and maintained in our colony on a C57BL/6J background. The <italic toggle="yes">Npy</italic>-<italic toggle="yes">Gfp</italic> mice were generated using bacterial artificial chromosome technology (BAC) to insert a <italic toggle="yes">Tau</italic>-<italic toggle="yes">Sapphire</italic> fusion reporter cassette downstream of the <italic toggle="yes">Npy</italic> gene’s regulatory elements [<xref ref-type="bibr" rid="CR4">4</xref>]. The modified and purified BAC DNA was injected by standard pronuclear injection [<xref ref-type="bibr" rid="CR4">4</xref>]. Homozygous <italic toggle="yes">Npy</italic><sup><italic toggle="yes">LacZ</italic></sup> knock-in mice were purchased as homozygote breeder pairs from the Jackson Laboratory and thereafter maintained in our colony [<xref ref-type="bibr" rid="CR14">14</xref>]. We performed homozygous to homozygous crosses to generate mutants (<italic toggle="yes">Npy</italic><sup><italic toggle="yes">LacZ</italic>/<italic toggle="yes">LacZ</italic></sup>), and we analyzed heterozygotes (<italic toggle="yes">Npy</italic><sup><italic toggle="yes">LacZ</italic>/+</sup>) from backcrosses to C57BL/6J. All matings were timed and based on the presence of a vaginal plug. Noon on the day a vaginal plug was detected was considered embryonic day (E) 0.5. The day of birth was designated as postnatal day (P) 0, and mice that were P28 or older were considered mature. Male and female <italic toggle="yes">Npy</italic>-<italic toggle="yes">Gfp</italic> mice were analyzed at postnatal day (P) 0 (<italic toggle="yes">n</italic> = 5), P2/3 (<italic toggle="yes">n</italic> = 5), P5 (<italic toggle="yes">n</italic> = 4), P10 (<italic toggle="yes">n</italic> = 6), and as mature adults (<italic toggle="yes">n</italic> = 16). Mice carrying the <italic toggle="yes">Npy</italic>-<italic toggle="yes">Gfp</italic> allele were identified by genotyping using a standard PCR protocol with primers designed to detect the <italic toggle="yes">Gfp</italic> cassette (GFP 5′ sense: CTGGTCGAGCTGGACGGCGACG, GFP 3′ antisense: CACGAACTCCAGCAGGACCATG). The expected band size is ~600 bp when run and visualized on a 2 % agarose gel made with ethidium bromide. The <italic toggle="yes">Npy</italic><sup><italic toggle="yes">LacZ</italic></sup> mice were genotyped by incubating a 2 mm piece of tail clip in X-gal reaction buffer for 4–8 h at 37° (see below). We analyzed male and female <italic toggle="yes">Npy</italic><sup><italic toggle="yes">LacZ</italic></sup> mice at P28 or older (<italic toggle="yes">n</italic> = 9 mutants and <italic toggle="yes">n</italic> = 6 controls).</p></sec>
24906823|Immunohistochemistry|('method', 0.9903649865479731)|('other', 0.009635013452026803)|<sec id="Sec4"><title>Immunohistochemistry</title><p>Mice were anesthetized with avertin. Once all reflexes were abolished (e.g., lack of blink and toe pinch reflexes) the blood was flushed through the heart by perfusing with 0.1 M phosphate buffered saline (PBS; pH7.2). The tissue was then fixed by perfusing with 4 % paraformaldehyde (4 % PFA) diluted in PBS. The brains were then postfixed for 24–48 h in 4 % PFA and then cryoprotected in buffered sucrose solutions (15 % and then 30 % diluted in PBS). Serial 40 μm thick coronal sections were cut on a cryostat and collected as free-floating sections in PBS. Immunohistochemistry was carried out as described previously [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Briefly, the tissue sections were washed thoroughly, blocked with 10 % normal goat serum (NGS; Sigma, St. Louis MO, USA) for 1 h at room temperature, and then incubated in 0.1 M PBS containing 10 % NGS, 0.1 % Tween-20, and the primary antibodies (see below) for 16–18 h at room temperature. The tissue sections were then washed three times in PBS and incubated in secondary antibodies (see below) for 2 h at room temperature. Then the tissue was rinsed again and immunoreactivity revealed as described below.</p><p>Rabbit polyclonal anti-HSP25 (1:500; Catalogue # SPA-801) was purchased from StressGen (Victoria, BC, Canada), and its expression in tissue revealed a pattern identical to what has previously been reported in the mouse cerebellum [<xref ref-type="bibr" rid="CR17">17</xref>]. Rabbit anti-GFP (1:1,000) was purchased from Molecular Probes (Invitrogen; Carlsbad, CA). Chicken anti-GFP (1:2,000) was purchased from Abcam (Cambridge, MA). Glial Fibrillary Acidic Protein (GFAP; 1:500; Cat. # AB5804) and tenascin (1:500; Cat. # AB19011) were purchased from Chemicon (Millipore, Temecula, CA, USA), and we used them to mark Bergmann glia in the adult cerebellum [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>].</p><p>We visualized immunoreactive complexes either using diaminobenzidine (DAB; 0.5 mg/ml; Sigma, St. Louis, MO, USA) or fluorescence. For the DAB reaction, we used horseradish peroxidase (HRP) conjugated goat anti-rabbit (diluted 1:200 in PBS; DAKO, Carpinteria, CA, USA) antibodies to bind the primary antibodies. Staining for fluorescent immunohistochemistry was carried out using Alexa 488- and 555-conjugated immunoglobulins (Molecular Probes Inc., Eugene, OR, USA), both diluted 1:1,500. Tissues sections were cover slipped using FLUORO-GEL with Tris buffer (Electron Microscopy Sciences, Hatfield, PA). We tested the specificity of the secondary antibodies by processing the tissue sections in the absence of primary antibodies. No signal was detected in such control experiments indicating that the staining we observed was not due to non-specific signals from the Alexa or HRP conjugated antibodies (data not shown).</p></sec>
24906823|X-gal Staining to Detect ß-Galactosidase|('method', 0.9903649865479731)|('other', 0.009635013452026803)|<sec id="Sec5"><title>X-gal Staining to Detect ß-Galactosidase</title><p>We performed the X-gal staining as previously described [<xref ref-type="bibr" rid="CR20">20</xref>]. The whole brain was immersed in the reaction buffer until the intense blue reaction product was visible.</p></sec>
24906823|Golgi-Cox Staining|('method', 0.9903649865479731)|('other', 0.009635013452026803)|<sec id="Sec6"><title>Golgi-Cox Staining</title><p>We performed the Golgi-Cox staining [<xref ref-type="bibr" rid="CR21">21</xref>] with a modified procedure using the FD Rapid GolgiStain Kit (FD Neurotechnologies, Inc). The main difference is that before staining, we flushed the blood from the brain by perfusing the mice with PBS for 2 min before quickly removing the brain from the skull. The tissue sections were cut at 80 μm on a cryostat and processed as described by the manufacturer using a free-floating approach (<italic toggle="yes">n</italic> = 6). The stained neurons were imaged as described below.</p></sec>
24906823|Microscopy and Data Analysis|('method', 0.9903649865479731)|('other', 0.009635013452026803)|<sec id="Sec7"><title>Microscopy and Data Analysis</title><p>Photomicrographs of tissue sections were captured using Leica DFC 360 FX (fluorescence) and DFC 490 (DAB reacted tissue and Golgi-Cox staining) cameras mounted on a Leica DM5500 microscope. Images of the tissue sections were acquired and analyzed using Leica Application Suite and Leica Application Suite FX software supplemented with a deconvolution module. For deconvolution, stacks of 10–20 sections in the <italic toggle="yes">z</italic>-axis were collected every 0.2–0.5 μm. The z stack images were deconvolved (~10 iterations) and then analyzed as compressed projections or as individual slices. Photomicrographs of wholemount X-gal stained brains were captured with a Leica MZ16 FA stereomicroscope mounted with a Leica DFC3000 FX camera running Leica LAS software supplemented with the Leica Montage module. After wholemount staining, some cerebella were cryoprotected and then cut frozen at 40 μm. The tissue sections were mounted and then imaged using a Zeiss AxioCam MRc5 camera mounted on a Zeiss Axio Imager.M2 microscope. High-resolution z stacks were acquired with a constant inter-stack interval, and select “slices” were segmented out and analyzed using the Zeiss ZEN software (2012 edition). The raw data was imported into Adobe Photoshop version CS5 and corrected for brightness and contrast only. The schematics were drawn in Adobe Illustrator version CS5.</p></sec>
24906823|Statistical Analysis|('method', 0.9903649865479731)|('other', 0.009635013452026803)|<sec id="Sec8"><title>Statistical Analysis</title><p>The cerebellar vermis is comprised of ten anatomically distinct lobules [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Gene expression and functional connectivity can be used to organize the lobules into four broad transverse domains [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] referred to from anterior to posterior as follows: the anterior (lobules I–V), central (lobules VI and VII), posterior (lobules VIII and anterior IX), and nodular domain (lobules posterior IX and X). The number of labeled Bergmann glia in lobules I–V, VI–VII, VIII–IX, and IX–X of <italic toggle="yes">Npy</italic>-<italic toggle="yes">Gfp</italic> mice was computed based on equally spaced 40 μm sections (sampled from within ~200–300 μm of the midline) with the limits chosen to ensure that counts of Bergmann glia that were positive for GFP were restricted to the vermis and not the paravermis or hemispheres. Six tissue sections per animal were used for the analysis (<italic toggle="yes">n</italic> = 4 animals analyzed). The number of GFP positive profiles, which we could clearly identify as Bergmann glia based on their distinct palisade morphology (their processes extend to the pial surface) and the location of their cell bodies within the Purkinje cell layer, was counted for each lobule and computed per transverse domain. The sum of the number of Bergmann glia for each domain was calculated, and the mean for each domain was used to calculate the SEM. The <italic toggle="yes">P</italic> value (considered significant only if &lt;0.05) was acquired using a one-way ANOVA test (GraphPad Prism) to compare the differences in the number of <italic toggle="yes">Npy</italic>-<italic toggle="yes">Gfp</italic> expressing Bergmann glia that reside in each of the four transverse domains.</p></sec>
24936025|None|('method', 0.5870573477730607)|('other', 0.4129426522269393)|<title xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">How the Illness Started</title>
24936025|None|('method', 0.5870573477730607)|('other', 0.4129426522269393)|<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">I was a student in Chemical Engineering at a reputed university in Kolkata, India. The academic pressures were immense and the expectations from seniors were high. Competition, intense competitive pressure, and the strive for excellence in studies were running high in my mind in the years 1988–1992. I was introvert and in the similar manner vulnerable. The vision of life was crumbling as I was approaching the final stages of my graduation year. History of schizophrenic illness was taking a vicious turn. I started hearing voices and delusion was creeping in. Doubt, suspicion, and immense brooding were occupying in my mind.<sup><xref rid="CIT0001" ref-type="bibr">1</xref></sup> Along with the negative thoughts, the pressure to excel in studies was prevalent. Illness was slowly and briskly bringing me closer to devastation and intense agony. I graduated in Chemical Engineering with not so brilliant academic record. This was due to the fierce competition in classroom.</p>
24936025|None|('method', 0.5870573477730607)|('other', 0.4129426522269393)|<p xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="indent">The year was 1993. I just finished my coursework in postgraduation in chemical engineering and about to enter third semester project work.<sup><xref rid="CIT0001" ref-type="bibr">1</xref></sup> My delusions and sound hearing was slowly simmering and leading to intense proportions. I was taking drugs also spuriously. I was not drug-addicted, but the competitive atmosphere and uncertainties in life and career made me to rely on drugs. In November, 1993, a vicious event happened in my life. My mental agony and immense mental agony took its final toll. I went to my teacher’s house in November 14, 1993 at 2.00 AM at night totally bedraggled, bewildered, and belittled with agony and delusion. History took a disastrous and vicious turn on that day. I was thinking someone is plotting against me and a black magic was playing my mind’s thoughts.<sup><xref rid="CIT0001" ref-type="bibr">1</xref>,<xref rid="CIT0002" ref-type="bibr">2</xref></sup></p>
24936546|None|('method', 0.9999995212124845)|('other', 4.787875156100102e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CASE REPORT</title>
24936546|None|('method', 0.9999995212124845)|('other', 4.787875156100102e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">A 42-year-old man with homozygous SCD (Hb SS, defined as homozygosity for the mutation that carries hemoglobin S) diagnosed at 2 years of age presented after allogeneic peripheral blood SCT from a sibling donor for fertility evaluation. He had normal onset of puberty at age 13 years, unintentionally impregnated his partner at age 20, experienced decreased testicular size and some decrease in libido at age 22 and transfusion-related hemosiderosis by age 25 (due to an estimated 250 units of erythrocyte transfusions up to that time), prompting start of iron chelation with desferoxamine (and subsequently deferasirox) and regular phlebotomies. At 26 years of age, he began exhibiting hydroxyurea. At age 28, he noted a further decrease in libido. At 30 years of age, he was diagnosed with hepatitis C (genotype 2A), with biopsy-confirmed hepatic hemosiderosis, moderate inflammation, and fibrosis. At age 33, he developed gynecomastia, which was corrected with bilateral reduction mammoplasties. By 39 years of age, he had lost all sexual drive.</p>
24936546|None|('method', 0.9999995212124845)|('other', 4.787875156100102e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">At 40 years of age, the patient presented for consideration of HSCT. He first received a 9-month course of interferon and ribavirin and became seronegative for hepatitis C. At 41 years of age, he underwent uncomplicated HSCT following nonmyeloablative conditioning comprised of alemtuzumab followed by 1 dose of total-body irradiation (TBI) with 300 centigrays (cGy) using testicular shielding (<xref rid="R10" ref-type="bibr">10</xref>). Immunosuppression was achieved with sirolimus (<xref rid="R11" ref-type="bibr">11</xref>). One year after HSCT, despite continued lack of libido and persistent fatigue, the patient desired to father a child with his 39-year-old partner, who had neither SCD nor carried the sickle cell trait. On physical examination, he had normal virilization and no residual gynecomastia. Both testes were soft and atrophic, with decreased orchidometric volumes (5 mL bilaterally [normal adult, 17 to 32 mL]). The prostate gland was not palpable. Laboratory investigations confirmed low serum testosterone along with inappropriately low gonadotropin levels (fasting 9 am total testosterone, 262 [range, 300 to 1,000 ng/dL]; sex hormone–binding globulin [SHBG] markedly elevated at 128 nmol/L [normal, 13 to 71 nmol/L]; calculated free testosterone [cFT], 1.9 [normal, 7.4 to 22.6 ng/dL]; luteinizing hormone [LH], 5.4 [normal, 1 to 9 U/L]; follicle-stimulating hormone [FSH] 4.2 [normal, 1 to 9 U/L]). A thyroid panel and a 250-µg short synacthen (adrenocorticotropic hormone) adrenal stimulation test were normal. The insulin-like growth factor 1 level was low, at 82 ng/mL (normal, 101 to 267 ng/mL).</p>
24936546|None|('method', 0.9999995212124845)|('other', 4.787875156100102e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">The hypogonadotropic hypogonadism and likely growth hormone deficiency were attributed to hemochromatosis secondary to numerous blood transfusions; the patient’s serum ferritin level before HSCT had been 5,121 µg/L (normal, 18 to 370 µg/L), and although considerably decreased with intermittent iron chelation and regular phlebotomies, his serum ferritin level was still elevated, at 1,452 µg/L 1 year after HSCT. A T2-weighted pituitary magnetic resonance imaging scan was unremarkable, with a homogenous bright signal and no evidence of iron deposition, although this does not rule out pituitary hemosiderosis (<xref rid="R12" ref-type="bibr">12</xref>). The exceptionally high SHBG level was attributed to hepatic hemosiderosis and hepatitis C, contributing to the very low cFT level.</p>
24936546|None|('method', 0.9999995212124845)|('other', 4.787875156100102e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P10">Although the laboratory tests were consistent with central hypogonadism, the examination findings of such small testes suggested possible additional concomitant primary hypogonadism. Semen analysis revealed azoospermia; the patient’s ejaculate volume was 0.9 mL (normal, ≥1.5 mL per World Health Organization 2010 criteria). The patient’s karyotype was 46,XY, excluding Klinefelter syndrome.</p>
24936546|None|('method', 0.9999995212124845)|('other', 4.787875156100102e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">To restore fertility, the patient was begun on human chorionic gonadotropin (hCG) (2,000 IU) plus human menopausal gonadotropin (hMG; 75 IU FSH), self-administered subcutaneously 3 times weekly. Within 4 months of treatment, his libido improved and he became sexually active. His cFT level rose to 9.3 ng/dL and his SHBG level decreased to 94 nmol/L (<xref ref-type="table" rid="T1">Table 1</xref>). The patient’s testicular volume increased to 7 mL and his semen volume to 1.9 mL, with the appearance of motile sperm (51%) at 0.76 × 10<sup>6</sup> in a single ejaculate (<xref ref-type="table" rid="T2">Table 2</xref>).</p>
24936546|None|('method', 0.9999995212124845)|('other', 4.787875156100102e-07)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P12">After 10 months of gonadotropin therapy, the patient’s partner, who did not carry the sickle cell gene, conceived naturally. The pregnancy was uncomplicated, and a healthy daughter was delivered at term. Hemoglobin electrophoresis revealed that the newborn carried the sickle cell trait.</p>
24967609|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">MATERIALS AND METHODS</title>
24967609|Mice|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Mice</title><p id="P11">Four-week old C57BL/6J (The Jackson Laboratories, Bar Harbor, ME) male mice were utilized in this study adhering to the approved protocol and guidelines of the Chancellor’s Animal Research Committee at the University of California, Los Angeles. Mice were fed a soft diet (BioServe ®, Frenchtown, New Jersey) <italic>ad libitum</italic> for the duration of the experiments.</p></sec>
24967609|Tooth extraction and implant placement|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Tooth extraction and implant placement</title><p id="P12">Under inhalation anesthesia with 3% isoflurane, maxillary left 1<sup>st</sup>, 2<sup>nd</sup>, and 3<sup>rd</sup> molars were extracted and sockets were allowed to heal for eight weeks. Animals were given antibiotics (sulfamethoxazole and trimethoprim oral suspension, USP; 850μg/170μg/mL) orally by incorporating the medications into the drinking water for four weeks after extractions.</p><p id="P13">Custom-designed screw-shaped implants 0.5 mm in diameter by 1 mm in length were fabricated from 6AL4V titanium rods (DP Machining Inc., La Verne, CA) (<xref ref-type="fig" rid="F1">Figure 1</xref>). Eight weeks after extractions and under general anesthesia, a mesial-distal incision was made with a 12D blade in the edentulous left alveolar ridge. Buccal and palatal full thickness flaps were elevated with a #5 dental explorer as to exposed the healed alveolar ridge. Implant fixture osteotomy was performed with a 0.03 mm carbide micro hand drill (BIG Kaiser Precision Tooling Inc., Hoffman Estates, Illinois) in the first/second molar area, using the teeth in the opposite side as spatial reference. One implant was placed in each mouse. Implant fixtures were inserted to the point that the implant head was leveled with the bone using a clock-wise screwing motion. Antibiotics as described above were given to the animals for four weeks after implant placement.</p></sec>
24967609|Induction of peri-implant mucositis and peri-implantitis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Induction of peri-implant mucositis and peri-implantitis</title><p id="P14">The induction of peri-implant mucositis and peri-implantitis was initiated four weeks after implant placement via lipopolysaccharide (LPS) injection into the peri-implant mucosa. Mice were divided into three groups: (1) no-injected control (2) vehicle-injected control (2μl injection of phosphate-buffer saline - PBS) and (3) LPS-injected, experimental group (2 μl of 10 mg/ml ultrapure LPS from <italic>Porphyromonas gingivalis</italic> [InvivoGen, San Diego, CA]), as described in a previous study (<xref rid="R31" ref-type="bibr">Sartori et al, 2009</xref>).</p><p id="P15">Injections were administered in the disto-palatal aspect of the peri-implant mucosa twice a week for a period of six weeks with the use of a hamilton syringe and a 33 gauge needle. At the end of the treatment period, mice were sacrificed, their maxillae harvested and fixed in 4% paraformaldehyde for 48 hours. Maxillae were then stored in 70% ethyl alcohol.</p></sec>
24967609|Clinical assessment of peri-implant mucositis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Clinical assessment of peri-implant mucositis</title><p id="P16">Macroscopic images of the specimens were obtained using a Keyence ® VHX-1000 (Osaka, Japan) digital optical microscope. Clinical images were analyzed with Aperio Image Scope software V11.1.2.752 (Vista, CA) to determine the amount of soft tissue coverage over the implant head. Soft tissue coverage was assessed by the evaluation of the exposed implant head surface area (μm<sup>2</sup>). If the head of the implant had complete soft tissue coverage the exposed surface area was considered to be 0 μm<sup>2</sup>.</p></sec>
24967609|Micro-CT analysis of peri-implantitis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Micro-CT analysis of peri-implantitis</title><p id="P17">Mouse maxillae were imaged by micro-computed tomography (micro-CT) scanning (SkyScan 1172; SkyScan, Kontich, Belgium) at 10μm resolution and x-ray energy of 55 KVp and 181 μA. Volumetric data were converted into Digital Imaging and Communications in Medicine (DICOM) format and imported into Dolphin Imaging software (Chatsworth, CA) to generate three-dimensional/multi-planar reconstructed images. Bone levels were assessed using the Dolphin software by measuring from the outermost edge of the head of the implant to the alveolar bone in the palatal aspect of the implant through the use of sagittal and coronal images.</p></sec>
24967609|Histology|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Histology</title><p id="P18">For histological evaluation of implant osseointegration and peri-implant bone levels, undecalcified maxillae were embedded in methylmethacrylate (<xref rid="R26" ref-type="bibr">Pereira, Stadmeyer et al. 2007</xref>) and ground to 20 μm-thick sections in the sagittal plane, parallel to the to the long axis of the implant (EXAKT Cutting &amp; Grinding System, Exakt Apparatebau, Norderstedt, Germany). Toluidine blue staining of the sections was performed according to standard protocols.</p><p id="P19">Additional samples were decalcified in 15% EDTA. At the end of the decalcification period, implant were removed via unscrewing motion and the specimens embedded in paraffin. Five μm-thick paraffin sections were generated. Sections were cut sagittally and stained with hematoxylin and eosin (H&amp;E) using standard protocols.</p></sec>
24967609|Statistics|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>Statistics</title><p id="P20">Data were represented as group means plus/minus the standard error of the mean (SEM). Comparisons between groups were conducted by Student’s t-tests utilizing GraphPad Instat software (La Jolla, CA).</p></sec>
24997169|None|('method', 0.9969089565721836)|('other', 0.0030910434278164267)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
24997169|None|('method', 0.9969089565721836)|('other', 0.0030910434278164267)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P17">Adolescents and adults who received healthcare from two comprehensive SCD centers in the Baltimore/Washington metropolitan area completed the <italic>MoSCS</italic> as part of the baseline assessment for Improving Patient Outcomes through Respect and Trust (<italic>IMPORT</italic>), a longitudinal, observational study of SCD patient experiences with healthcare funded by the National Institutes of Health. Participants were eligible for the <italic>IMPORT</italic> study if they were aged over 15 years, diagnosed with one of the major types of sickle cell hemoglobinopathy, and able to speak English. Informed consent was obtained according to protocols approved by the institutional review boards at the two participating medical institutions. Participants were paid US$50 for completing an audio computer-assisted survey instrument that included the measures described below.</p>
24997169|SCD stigma|('method', 0.9969089565721836)|('other', 0.0030910434278164267)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>SCD stigma</title><p id="P18">The 11-item <italic>MoSCS</italic> was used to assess SCD-specific stigma. As noted above, higher scores indicated greater levels of stigma.</p></sec>
24997169|Acute care service utilization|('method', 0.9969089565721836)|('other', 0.0030910434278164267)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Acute care service utilization</title><p id="P19">Participants responded to a single item that asked them to indicate the number of times they went to the emergency room or infusion clinic for SCD-related pain over the past year. Rather than assess these visits separately, we created a unitary measure of utilization because we were interested in participants’ overall utilization of acute care services. At our particular site, the infusion clinic is an urgent care center specifically designed to treat acute SCD pain. It was implemented in 2008 through a collaborative relationship with emergency department staff and hospital administrators to reduce patient wait times and provide quality care specific to the needs of adults with SCD.</p></sec>
24997169|Hospital admissions|('method', 0.9969089565721836)|('other', 0.0030910434278164267)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Hospital admissions</title><p id="P20">Participants responded to a single item that asked them to report how many hospital admissions for SCD-related pain they had over the past year.</p></sec>
24997169|Perceived disease severity|('method', 0.9969089565721836)|('other', 0.0030910434278164267)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Perceived disease severity</title><p id="P21">Participants responded to a statement that read, “Compared to other people with sickle cell disease, the severity of my disease is —.” Responses ranged on a 5-point scale from 5 (“much worse”) to 1 (“much better”). Higher scores indicated greater perceived disease severity.</p></sec>
24997169|None|('method', 0.6845580037302024)|('other', 0.3154419962697974)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Participants</title>
24997169|None|('method', 0.6845580037302024)|('other', 0.3154419962697974)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P22">A total of 279 adults were enrolled in the <italic>IMPORT</italic> study, and complete data on the variables of interest to this particular study were collected from 262 respondents (138 women and 124 men) between the ages of 15 and 70 years (mean age = 34.5 years; SD = 11.97 years). In all, 97 percent of participants were African American. Approximately 23.7 percent of participants were currently enrolled in school, and 18.7 percent were college graduates who had achieved at least a 4-year college degree (of these, about 8% had a graduate or professional degree). With regard to employment status, about one-third of participants were working full time or part time during their participation in the study, and roughly 10 percent were unemployed and looking for work. In all, 43 percent of participants reported that they were disabled and not working.</p>
25005039|None|('method', 0.9897091260792028)|('other', 0.010290873920797174)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Method</title>
25005039|Participants|('method', 0.9897091260792028)|('other', 0.010290873920797174)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6" sec-type="subjects"><title>Participants</title><p id="P12">The study sample was drawn from a clinical outpatient population seeking psychological evaluation for behavioral concerns at the BLINDED FOR REVIEW. Families being seen for an ADHD evaluation were approached about allowing ratings collected during the evaluation to be used for research purposes. The Institutional Review Board approved the above described procedures and the analyses presented in this study.</p><p id="P13">A total of 168 children between the ages of 6 and 12 (<italic>M</italic> = 8.43, <italic>SD</italic> = 1.86) were included in this study with approximately two-thirds (<italic>n</italic> = 110) of the participants being male. Eighty-one percent of the sample was Caucasian, 13% were African American, and 6% were of other race/ethnicity. Of the 168 children, 144 (86%) had both parent and teacher ratings of the variables used in this study, an additional 17 (10%) had complete data for parent ratings only, and 2 (1%) had complete data for teacher ratings only. Thus, 146 children were included in the analyses examining teacher-reported variables and 161 children were included in the analyses examining parent-reported variables.</p><p id="P14">Diagnosis of ADHD was established by clinicians at the BLIND FOR REVIEW using the Vanderbilt ADHD Diagnostic Rating Scale completed separately by parents and teachers (Wolraich et al., 1998), the Child Behavior Checklist and Teacher Report Form (Achenbach, 1991), a clinic-developed developmental questionnaire that inquires about early developmental history, and parent responses to a clinic-developed semi-structured interview assessing ADHD symptoms and additional DSM-IV criteria for ADHD (e.g., age of onset, functional impairment), as well as possible comorbid disorders including anxiety and depression. Of the 168 participants in this study, 155 (92%) were diagnosed with ADHD. Of those, 62 (40%) were diagnosed with ADHD-Combined type, 83 (53.5%) were diagnosed with ADHD-Predominantly Inattentive Type, and 10 (6.5%) were diagnosed with ADHD Not Otherwise Specified (NOS). Finally, of the 155 children diagnosed with ADHD, 103 (66.5%) were diagnosed with ADHD alone, while 28 (18.1%) were diagnosed with a comorbid behavioral disorder (Oppositional Defiant Disorder [ODD] or Conduct Disorder [CD]), and 17 (10%) with a comorbid Anxiety Disorder. No children were diagnosed with a comorbid mood disorder.</p></sec>
25005039|None|('method', 0.561149396263606)|('other', 0.43885060373639406)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Measures</title>
25005039|ADHD symptoms|('method', 0.561149396263606)|('other', 0.43885060373639406)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>ADHD symptoms</title><p id="P15">Parents and teachers completed the Vanderbilt ADHD Diagnostic Parent Rating Scale (VADPRS) and Vanderbilt ADHD Diagnostic Teacher Rating Scale (VADTRS) respectively (Wolraich et al., 1998). The VADPRS and VADTRS include items assessing the 18 DSM-IV symptoms of ADHD, and these items were used in the present study to measure inattentive (Parent α = .87, Teacher α = .94) and hyperactive-impulsive symptoms (Parent α = .92, Teacher α = .94). Children's behavior is rated on a 4-point scale ranging from ‘never’ (0) to ‘very often’ (3). For all variables, mean scale scores range from 0-3 with higher scores indicative of greater symptomatology.</p></sec>
25005039|SCT symptoms|('method', 0.561149396263606)|('other', 0.43885060373639406)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>SCT symptoms</title><p id="P16">Three items from the parent-completed Child Behavior Checklist (CBCL; Achenbach, 2001) and four items from the teacher-completed Teacher Report Form (TRF; Achenbach, 2001) were used to measure SCT. These items which appear on both the CBCL and TRF have been frequently used in previous studies to measure SCT: confused or seems to be in a fog, daydreams, and stares blankly (<xref rid="R11" ref-type="bibr">Becker &amp; Langberg, 2014</xref>; Carlson &amp; Mann, 2002; <xref rid="R20" ref-type="bibr">Garner et al., 2010</xref>; Hartman et al., 2004; McBurnett et al., 2001). The teacher measure of SCT includes an additional item, apathetic or unmotivated, that is not present on the CBCL. Parents and teachers rated each item on a 3-point scale ranging from ‘not true’ (0) to ‘very true or often true’ (2). Reliability on these SCT items was adequate to good in the present sample (Parent α = .76, Teacher α = .81). Of note, <xref rid="R40" ref-type="bibr">Skirbekk and colleagues (2011)</xref> found the CBCL/TRF measure of SCT to be strongly correlated (<italic>r</italic> = .77) with a longer measure of SCT.</p><sec id="S10" sec-type="methods"><title>Statistical Analysis</title><p id="P17">Mplus Version 7.11 (<xref rid="R37" ref-type="bibr">Muthén &amp; Muthén, 1998-2012</xref>) was used for all statistical analyses. ADHD and SCT ratings were treated as continuous data in all analyses. Missing item data varied from 0.5% to 4.2% and 0.6% to 3.2% across the parent and teacher data sets, respectively. Consistent with current best-practice, maximum likelihood estimation was used for handling missing item-level data (e.g., Enders, 2010; <xref rid="R23" ref-type="bibr">Graham, 2012</xref>).</p><p id="P18">Statistical modeling was conducted separately for parent and teacher ratings and followed three steps. First, three orthogonal bi-factor models were estimated and compared (<xref rid="F1" ref-type="fig">Figure 1</xref>, Models 1-3). In the first two models, all symptoms loaded on a single general factor called ADHD. In Model 1, symptoms of inattention and SCT loaded on a single factor (Inattention), while symptoms of hyperactivity and impulsivity loaded onto a separate factor (Hyperactivity/Impulsivity). This model would indicate that SCT symptoms are not independent from Inattention or ADHD as a psychopathology. In Model 2, all ADHD and SCT symptoms loaded on a single general factor called ADHD. However, the three symptom dimensions loaded on separate specific factors. This model would support the notion that although symptoms of SCT represent a separate construct from Inattention these symptoms still fall under the umbrella of ADHD. In Model 3, SCT symptoms formed a separate factor and do not load on the ADHD general factor, whereas symptoms of inattention and hyperactivity/impulsivity loaded directly onto the ADHD ‘g’ factor as well as onto separate specific factors. This final model would suggest that SCT is a construct clearly separate from ADHD. As recommended (<xref rid="R37" ref-type="bibr">Muthén &amp; Muthén, 1998-2012</xref>), all factors (general and specific) were orthogonal (i.e., correlations are fixed to zero). The three models were compared sequentially. Specifically, Model 1 was compared to Model 2 and the resulting superior model served as the model against which Model 3 was compared. Models were compared using various fit indices including chi-square fit statistics, root mean square error of approximation (RMSEA), and comparative fit index (CFI). Good fit is typically indicated by non-significant chi-square model fit values, low (&lt; .06) RMSEA and (.08) SRMR values, and high (&gt; .95) CFI values (<xref rid="R27" ref-type="bibr">Kline, 2011</xref>).</p></sec></sec>
25005039|Supplemental analyses|('method', 0.561149396263606)|('other', 0.43885060373639406)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Supplemental analyses</title><p id="P19">Theoretically driven supplemental models (<xref rid="F1" ref-type="fig">Figure 1</xref>, Supplemental Models 4 and 5) were tested in the event that model fit was poor in the original three orthogonal models. Traditionally, because the shared variance between the specific factors is thought to be “conditional” upon the g-factor, bi-factor modeling specifies that latent factors are orthogonal (Reise, 2012). However, as discussed by Jennrich and Bentler (2011), it is permissible in some cases to specify correlations between specific factors. Furthermore, Reise (2012) acknowledges that forcing orthogonality between specific factors does not reflect the true nature of psychopathology since psychiatric diagnoses are not orthogonal in the real world given the high rates of comorbidity observed across various psychiatric diagnoses.</p><p id="P20">Hence, in the first supplemental model (Model 4) we planned to test whether allowing the two ADHD symptom factors to correlate with each other would improve model fit. Allowing specific factors to correlate with one another would suggest that there is “left-over” shared variance between Inattention and Hyperactivity/Impulsivity even with ADHD ‘g’ is modeled. This shared variance could be due to a third related factor (e.g., comorbidity).</p><p id="P21">In addition, given the strong association between SCT and inattention (<xref rid="R47" ref-type="bibr">Wilcutt et al., 2012</xref>) we tested a final model (Model 5) in which we estimated the correlation between SCT and specific ADHD factors. We also modeled the correlation between SCT and hyperactivity/impulsivity since studies are mixed in regard to the nature of the relationship between these dimensions (<xref rid="R15" ref-type="bibr">Burns et al., 2013</xref>; <xref rid="R31" ref-type="bibr">Lee et al., 2014</xref>; <xref rid="R39" ref-type="bibr">Penny et al., 2009</xref>). Support for Model 5 would suggest that although SCT is a construct independent from ADHD as a diagnostic entity, it is highly comorbid among individuals with high levels of inattention and possibly hyperactivity/impulsivity (depending on the nature of the relationship between the two factors).</p></sec>
25025472|None|('method', 0.9999370345530955)|('other', 6.296544690454373e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">METHODS</title>
25025472|Study Setting and Population|('method', 0.9999370345530955)|('other', 6.296544690454373e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Study Setting and Population</title><p id="P9">The UNC Health Care System includes NC Memorial Hospital, a Neuroscience Hospital, the UNC Women’s Hospital, the UNC Children’s Hospital and an Ambulatory Care Center in which 154,224 unique patients were seen at UNC Ambulatory Centers for 973,122 visits. Overall, 10% of patients are Latino, 58% female, and 97,851 were between 19 and 59 years of age, while 34,862 were aged 60 or older.</p></sec>
25025472|Natural Language Processing (NLP) of Free-Text Clinical Documents|('method', 0.9999370345530955)|('other', 6.296544690454373e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Natural Language Processing (NLP) of Free-Text Clinical Documents</title><p id="P10">The NLP software used for the study employs dictionary-based named entity recognition<sup><xref rid="R18" ref-type="bibr">18</xref></sup> to identify the standard terminologies used to document mammography and Pap smear results in the free-text reports. All NLP models were developed using the IBM Content Analytics software package residing on a computer server at the Information Services Division of the University of North Carolina Hospital. The study was conducted at the University of North Carolina Healthcare System and was approved by the institutional review board (IRB number 11-1197). The project was funded by a National Institutes of Health grant 1UL1TR001111 through the North Carolina Translational and Clinical Sciences Institute.</p><p id="P11">Our goal is to attain NLP performance characteristics (precision, recall and accuracy) greater than 95%, with 95% confidence intervals of +/− 1.5% (range of 3%). For these performance specifications, we calculated that a minimum sample size of 400 reports, each for mammograms and Pap smears, was required.</p></sec>
25025472|Mammography Reports|('method', 0.9999370345530955)|('other', 6.296544690454373e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Mammography Reports</title><p id="P12">Mammography results are reported as Breast Imaging Reporting and Data System (BIRADS) assessment categories ranging from 0 to 6, each with a specific recommendation for follow-up (<xref rid="T1" ref-type="table">table 1</xref>).<sup><xref rid="R19" ref-type="bibr">19</xref></sup><xref rid="F1" ref-type="fig">Figure 1</xref> shows an example of a mammography report with the BIRADS result and follow-up recommendations highlighted in yellow. In the semi-structured mammography reports, results are always located after the word “IMPRESSION:” and the follow-up recommendations appear after a detailed description of the mammography findings. NLP algorithms were developed to detect the term “IMRESSION:” in the free-text mammography documents and to extract the BIRADS results that appear afterwards. In the corpus of mammography reports, there was some variability in how results were documented; for example, BIRADS 1 might appear as “BI-RADS 1”, “BIRADS I”, “BIRADS-1” or “BIRADS #1”. Therefore algorithms were developed to correctly map all possible iterations of BIRADS 1 using conditional logic (if …, then … rules) in the NLP soft software.</p><p id="P13">We selected a random sample of 421 free-text mammography reports completed between January 2003 and January 2012 from the Carolina Data Warehouse for Health (CDW-H). The reports were manually reviewed by a general internist (CM) and the BIRADS result determined for each. We developed and tested the performance of an NLP model to extract the BIRADS results from the same set of reports. The two assessments (‘gold’ standard vs. NLP) were compared to determine the precision, recall and accuracy of NLP for extracting mammography results. Precision, recall and accuracy were calculated as follows:</p><p id="P14">Precision = TP/(TP+FP), Recall = TP/(TP+FN), and Accuracy = (TP+TN)/Total; where TP=true-positive, FP=false-positive, TN=true-negative, and FN=false-negative.</p></sec>
25025472|Papanicolaou (Pap) Smear Reports|('method', 0.9999370345530955)|('other', 6.296544690454373e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Papanicolaou (Pap) Smear Reports</title><p id="P15"><xref rid="F2" ref-type="fig">Figure 2</xref> shows a portion of a Pap smear report with results highlighted in yellow. Pap smear results are always located in free-text after the expression “RESULTS/INTERPRETATION” and are reported using the Bethesda Classification<sup><xref rid="R20" ref-type="bibr">20</xref></sup> of cervical cytology (<xref rid="T2" ref-type="table">table 2</xref>). For example, results of the Pap report in <xref rid="F2" ref-type="fig">figure 2</xref> would map to “ASC-H” in <xref rid="T2" ref-type="table">table 2</xref>. NLP algorithms were developed that map the results identified in the free-text documents with the corresponding Bethesda Classification shown in <xref rid="T2" ref-type="table">table 2</xref>.</p><p id="P16">We used a random sample of 500 free-text Pap smear reports completed between January 2003 and January 2012 and stored in the CDW-H. Pap smear reports were manually reviewed by a general internist (CM) and the results (Bethesda Classification<sup><xref rid="R21" ref-type="bibr">21</xref></sup>) were determined for each report; this was used as the “gold” standard to compare with NLP results. The performance of NLP was assessed using Precision, Recall and Accuracy as described previously.</p><p id="P17">Finally, we determined inter-rater reliability for manual review of mammogram and Pap smear results by having a second reviewer (EA) independently abstract results from a 20% random sample of mammogram and Pap smear reports. We compared the results to those obtained by the 1<sup>st</sup> reviewer (CM). Inter-rater agreement was calculated using the kappa coefficient.</p></sec>
25025472|Follow-up of Abnormal Pap Spear and Mammogram Results|('method', 0.9999370345530955)|('other', 6.296544690454373e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Follow-up of Abnormal Pap Spear and Mammogram Results</title><p id="P18">For each abnormal Pap smear and mammogram (BIRADS 4, 5, and 6) result identified using NLP, we reviewed the electronic medical record (EMR) to assess the amount of time to repeat testing or follow-up procedure (example; colposcopy or core biopsy). If none was found, we reviewed clinical notes to determine if the abnormal result was acknowledged and that medical management other than repeat testing was chosen or that follow-up was to be completed at an outside institution. All calculations were performed using Stata for Windows (Stata Corporation, College Station, Tx).</p></sec>
25043704|None|('method', 0.7553574458661367)|('other', 0.24464255413386307)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
25043704|Participants|('method', 0.7553574458661367)|('other', 0.24464255413386307)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6" sec-type="subjects"><title>Participants</title><p id="P9">The participants in the study were 132 fathers recruited for the Comparative Study on Fathering (<xref rid="R53" ref-type="bibr">Stover, Easton, &amp; McMahon, 2013</xref>). This study was designed to examine the parenting of men with IPV and substance use histories and those without these problems. A number of participants (36.80%) had co-occurring IPV and substance abuse histories. Some participants (8.33%) reported IPV only, 21.21% reported substance abuse only, and the remaining 33.67% of the fathers had neither problem. The participants reported using many different drugs, including alcohol (63.9%), marijuana (28.5%), opiates (4.6%), sedatives (4.6%), hallucinogens (3.0%), cocaine (2.4%), inhalants (2.3%), and amphetamines (.8%). The fathers mean age was 34.56, and ages ranged from 20 to 52. They reported their racial/ethnic backgrounds as African American (55.7%), White/Caucasian (17.7%), Hispanic (15.2%), Mixed (8.0%), and other (1.3%). A large portion of the sample was unemployed (46.8%). Finally, 46.8% of the sample lived with their child, and fathers saw their children 20.30 (<italic>SD</italic> = 9.63) days a month on average. Their children ranged in age from 2 to 6 years. Fathers with children of this age were targeted for recruitment given that families impacted by IPV often have younger children (DOJ, 2006; Fantuzzo &amp; Mohr, 1999), fathers are more likely to be involved when children are younger, young children are most affected by IPV and negative parenting (Shonkoff &amp; Phillips, 2000) and the broader study included a measure of child behavioral functioning which was designed for early childhood (aged 2 to 6 years).</p></sec>
25043704|Measures|('method', 0.7553574458661367)|('other', 0.24464255413386307)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Measures</title><p id="P10">Fathers completed a series of demographic and family history questions and standardized measures of IPV and parenting.</p><p id="P11"><italic>The Revised Conflict Tactics Scale</italic> (CTS2; <xref rid="R56" ref-type="bibr">Straus, Hamby, Boney-McCoy, &amp; Sugarman, 1996</xref>) is a self-report measure of participants’ use of violence in the last year and over the course of the relationship with their partner. In this study, fathers were asked to report violence in their relationship with the mother of the target child. The CTS2 was used to assess the presence of both physical and psychological IPV in the last 12 months on the part of the mother and father. Because we only collected data on fathers’ hostility and substance use and the focus of our study is on father-initiated IPV and aggressive parenting, only male initiated violence scores are used in the analyses. It is important to note, however, that fathers did report much mother initiated violence (physical violence [<italic>M</italic> = 6.69, <italic>SD</italic> = 9.24]; psychological aggression [<italic>M</italic> = 15.60, <italic>SD</italic> = 10.06]). The CTS2 is the most commonly used self-report measure for assessing IPV in the research literature. In this sample, internal consistencies of the physical and psychological IPV scales were .92 and .89, respectively.</p><p id="P12"><italic>The Parental Acceptance Rejection Questionnaire</italic> (PARQ; <xref rid="R50" ref-type="bibr">Rohner, Khaleque, &amp; Cournoyer, 2005</xref>) documents the frequency of rejecting and hostile-aggressive parenting. Respondents rate how frequently they engage in rejecting (not showing love, affection, or care to the child) or aggressive (violent or harsh actions directed toward the child) behavior toward their child from 0 (“Almost never true of me”) to 3 (“Almost always true of me”). Examples of items that index rejecting parenting include, “I see my child as a big nuisance” and “When my child misbehaves, I make him/her feel unloved”. Examples of items that index aggressive parenting include, “I yell at my child when I am angry” and “I hit my child even when (s)he may not deserve it”. Each subscale consists of 15-items and each has demonstrated good convergent, discriminant, and construct validity, as well as internal consistency (Rohner &amp; Khaleque, 2005). The PARQ has shown utility in multiple studies of fathers with IPV and substance abuse histories (<xref rid="R38" ref-type="bibr">McMahon et al., 2008</xref>; <xref rid="R53" ref-type="bibr">Stover et al., 2013</xref>; <xref rid="R55" ref-type="bibr">Stover et al., 2012</xref>). For this study, fathers were asked to rate the frequency of specific acts of parenting behavior occurring in their relationship with their oldest biological child between the ages of two and six years. In this sample, internal consistencies of the aggressive and rejecting parenting scales were .77 and .60, respectively.</p><p id="P13"><italic>The Addiction Severity Index 5<sup>th</sup> Edition</italic> (ASI; <xref rid="R37" ref-type="bibr">McLellan et al., 1992</xref>) is an interview assessing drug use and problems. From the ASI, we gathered frequency of alcohol and drug use in the past month, measured by number of days on which a substance was used. We summed across drug categories to obtain a measure of total substance use. The ASI has been validated in many different populations (<xref rid="R34" ref-type="bibr">Makela, 2004</xref>). Furthermore, reports of drug use on the ASI are correlated with drug use detection via urinalysis (<xref rid="R13" ref-type="bibr">Denis et al., 2012</xref>).</p><p id="P14"><italic>Brief Symptom Inventory</italic> (BSI; <xref rid="R14" ref-type="bibr">Derogatis &amp; Melisaratos, 1983</xref>) is a 53-item self-report measure assessing multiple domains of symptoms. Items are rated on 5-point scale that ranges from 0 (never) to 4 (always). We used the hostility subscale of the BSI (example items include: “Feeling easily annoyed or irritated,” and “Having urges to beat, injure, or harm someone”). The BSI has high internal consistency and convergent validity with other measures of psychological distress (<xref rid="R6" ref-type="bibr">Boulet &amp; Boss, 1991</xref>). Internal consistency was .62 in the current sample.</p></sec>
25043704|Procedure|('method', 0.7553574458661367)|('other', 0.24464255413386307)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Procedure</title><p id="P15">Fathers were recruited into the study by flyers posted in substance abuse treatment programs, health clinics, pediatric offices, the court house, domestic violence programs, unemployment offices, preschools, pediatric clinics, bus stops, libraries and community agencies in New Haven, CT. Men were screened by phone for eligibility (biological father of a child between 2 and 6 years of age with at least monthly visitation) and then met in person for a single two-hour session with trained research assistants to complete informed consent and study measures. Recruitment was focused on collecting a sample of fathers of young children with at least half struggling with substance use and/or IPV. Data were collected regarding fathers’ relationships and parenting behavior toward their oldest biological children aged two through six years. Participants were paid $50 for their time and the study was approved by the Yale University School of Medicine Human Investigations Committee.</p></sec>
25043704|Data Analysis|('method', 0.7553574458661367)|('other', 0.24464255413386307)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Data Analysis</title><p id="P16">We proposed that hostility would lead to increased IPV and poorer parenting via substance use. We tested for the significance of indirect effects of hostility on outcomes through substance use by using bootstrapping methodology (<xref rid="R32" ref-type="bibr">MacKinnon, Lockwood, Hoffman, West, &amp; Sheets, 2002</xref>). This procedure produces an empirical sampling distribution, consisting of 5000 bootstrap samples, of the estimated indirect effect of the independent variable on the dependent variable through the proposed mediator. This sampling distribution is then used to provide an estimate of the indirect effects and a 95% confidence interval. Simulation studies have found that the bias-corrected bootstrap yields the most accurate confidence intervals (<xref rid="R12" ref-type="bibr">Cheung &amp; Lau, 2008</xref>; <xref rid="R33" ref-type="bibr">MacKinnon, Lockwood, &amp; Williams, 2004</xref>). Thus, we report bootstrap estimates and bias-corrected confidence intervals for each mediational relationship (<xref rid="R46" ref-type="bibr">Preacher &amp; Hayes, 2008</xref>). For these analyses, confidence intervals for the estimate of the indirect effect that do not contain zero are considered significantly different from zero, indicating a meaningful effect. When testing study hypotheses, we used two outcomes for IPV—physical and psychological IPV—and two outcomes for parenting—aggressive and rejecting parenting.</p><p id="P17">Because research suggested that being high in hostility and substance use could have an interactive effect on IPV and parenting, we added an interaction term (hostility X substance use) to these models, using the Process macro for SPSS (<xref rid="R46" ref-type="bibr">Preacher &amp; Hayes, 2008</xref>) to examine potential moderated-mediation relationships. Moderated-mediation occurs when a mediated relationship is qualified by an interaction (<xref rid="R47" ref-type="bibr">Preacher, Rucker, &amp; Hayes, 2007</xref>)—in other words, the strength of the indirect effect depends on a moderator variable (note that in this case, the moderator variable is also the mediator variable).</p></sec>
25047654|Materials and methods|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<title>Materials and methods</title>
25047654|None|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<p>This is a prospective cohort study using clinical records, operation notes and patients outcome assessment. Approval for the study was obtained from the Research Ethics Board of Peking University Third Hospital. All subjects were unrelated individuals. The patients or guardians provided written informed consent for surgical operation and medical photography as well as inclusion in the prospective cohort clinical study.</p>
25047654|Patients|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<sec id="Sec3"><title>Patients</title><p>From June 2009 to December 2012, a consecutive series of 27 patients diagnosed with SESMCs and without SNRFs underwent microsurgical treatment. Basic demographics, clinical and radiological data were evaluated. Preoperative neuroimaging including MRI was performed in all cases. Symptomatic period prior to presentation was defined as the time from the onset of symptoms to the time of presentation, and was recorded in months.</p></sec>
25047654|Inclusion and exclusion criteria|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<sec id="Sec4"><title>Inclusion and exclusion criteria</title><p>Patients were included in the study if they met the following inclusion criteria: (1) radiological findings consistent with SESMCs and (2) neurological symptoms attributable to SESMCs as well as (3) SNRFs absence in SESMCs as seen under microscope. Patients were excluded from the study if their symptoms could not be differentiated from lumbar spinal stenosis or lumbar intervertebral disc herniation.</p><p>The patients with SESMCs and without SNRFs were divided into two different groups based on the origin of cysts: armpit of SNRFs or extremity of terminal pool. Clinicians blinded to the SNRF status of the patients collected the clinical data prospectively. These data were then analyzed using the appropriate statistical methods.</p></sec>
25047654|Clinical presentation|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<sec id="Sec5"><title>Clinical presentation</title><p>The initial presenting symptoms, location of presenting symptoms, and symptomatic period prior to initial presentation were recorded. The presenting symptoms were categorized into (1) bowel/bladder and sexual drive dysfunction, (2) lower extremity weakness, (3) lower extremity numbness, (4) pain, (5) tenesmus, (6) more than one symptom. The location of the presenting symptoms was categorized as (1) sacrococcygeal, (2) perineum and external genitalia, (3) low waist, (4) buttocks, (5) legs, or (6) more than one region.</p><p>Abnormalities on neurological examination were classified as sensory dysfunction, lower extremity weakness, and bowel/bladder dysfunction. The Improved Japanese Orthopedic Association (IJOA) grading system was used to evaluate preoperative and postoperative neurological function. The IJOA is based on the Japanese Orthopedic Association (JOA) grading system, with the addition of a score for bowel function as normal, slight dysfunction, severe dysfunction, or incontinent [<xref ref-type="bibr" rid="CR10">10</xref>].</p></sec>
25047654|Surgical techniques|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<sec id="Sec6"><title>Surgical techniques</title><p>When bone erosion was found in the neuroimaging of patients with SESMCs displaying neural irritation symptoms, surgical intervention was highly recommended for these patients. When sacral extradural spinal meningeal cyst was discovered incidentally, the patient would be kept under yearly surveillance. Surgical intervention would only be carried out if the cyst progressively enlarged, or patient became symptomatic.</p><p>Our operative technique followed the standard procedures for SESMCs surgery. An incision was made from L5 to S3, and the sacral laminae were completely exposed according to the location of SESMCs. Laminectomy was performed with a rongeur, while carefully preserving the integrity of the underlying cyst. The surgical microscope was then brought into the field. The terminal thecal sac was identified and dissected free from the overlying cysts. Each cyst was dissected from surrounding structures to reveal its origin and relationship with SNRFs by the senior authors (ZY Wang, JJ Sun). If the SESMCs were identified as those without SNRFs, which originated in the armpit of SNRFs (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) or extremity of terminal pool (Fig. <xref rid="Fig2" ref-type="fig">2</xref>), the neck of cyst was transfixed, ligated and the remaining cyst wall resected distal to the ligation. If the cysts were associated with a tethered cord, then untethering would be performed during the same procedure (Fig. <xref rid="Fig3" ref-type="fig">3</xref>). Intraoperative neurophysiological monitoring was used to differentiate SNRFs from other tissues. Electrical stimulation was used to verify that no motor nerve fibers were involved. The closure was reinforced with a local muscle flap. <fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Sacral extradural spinal meningeal cysts origin in the armpit of spinal nerve root fibers</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="586_2014_3471_Fig1_HTML.gif" id="MO1" position="float" orientation="portrait"/></fig><fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Sacral extradural spinal meningeal cysts origin directly from extremity of terminal pool without spinal nerve root fibers</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="586_2014_3471_Fig2_HTML.gif" id="MO2" position="float" orientation="portrait"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>A special case with sacral extradural spinal meningeal cysts without spinal nerve root fibers. A 30-year-old previously healthy male patient presented with a 1-year history of numbness from left leg to buttock, and complaint of sexual drive dysfunction. Preoperative IJOA score was 18. A magnetic resonance imaging (MRI) scan showed single great cyst in sacral canal. The single cyst combined with tethered cord was showed on T1-weighted images (<bold>a</bold>, an <italic toggle="yes">arrow</italic> showed thickened inner terminal filament), and T2-weighted images (<bold>b</bold>, an <italic toggle="yes">arrow</italic> showed the high signal cyst). The <italic toggle="yes">inner terminal filament</italic> showed slight low signal intensity on T1-weighted fat-suppression phase view (<bold>c</bold>). The <italic toggle="yes">thickened inner terminal</italic><italic toggle="yes">filament</italic> showed high signal intensity on T2-weighted axial view (<bold>d</bold>, <italic toggle="yes">yellow arrow</italic>). Extending cyst without sacral nerve root fibers was shown on T2-weighted axial view (<bold>e</bold>). Two weeks after surgical intervention, no single small cyst remained in the sacral canal, and conus medullaris was untethered and ascended on T1-weighted images (<bold>f</bold>), and T2-weighted images (<bold>g</bold>). No small cyst and effusion were shown on axial view (<bold>h</bold>). Three months later, no recurrent cysts were showed on T1-weighted images (<bold>i</bold>), and T2-weighted images (<bold>j</bold>), as well as on axial view (<bold>k</bold>). One year later, no recurrent cyst was found on T1-weighted images (<bold>l</bold>), and T2-weighted images (<bold>m</bold>). Preoperative numbness and sexual dysfunction slowly improved</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="586_2014_3471_Fig3_HTML.jpg" id="MO3" position="float" orientation="portrait"/></fig></p></sec>
25047654|Characteristics of SESMCs|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<sec id="Sec7"><title>Characteristics of SESMCs</title><p>Under the surgical microscope, the number, maximum diameter, and types of cyst were identified. If there were multiple cysts in the sacral canal of one patient, the maximum diameter, types of cyst and surgical technique were recorded for the largest one.</p></sec>
25047654|Postoperative management and evaluation|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<sec id="Sec8"><title>Postoperative management and evaluation</title><p>Postoperatively, all patients were kept in the prone position for several days. Wound healing was classified into well healed, delayed healing, or requiring debridement/suturing. MRI scans were performed 2 weeks following surgery. Postoperative radiological evaluation of the sacral canal was performed by a neuroradiologist blinded to the patient’s intraoperative diagnosis, and was classified as complete cyst resolution, residual cyst, or disappearance of the cyst, but with effusion into the canal cavity. Postoperative IJOA scores were evaluated three months after surgery.</p></sec>
25047654|Follow-up|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<sec id="Sec9"><title>Follow-up</title><p>All patients were followed up until July 2013 by outpatient clinical visits or by telephone questionnaires. The outcome of each patient was assessed using the IJOA score, and subjective assessment of whether preoperative symptoms remained the same or improved as good outcome, or worsening symptoms as poor outcome.</p></sec>
25047654|Statistical analysis|('method', 0.99876187163471)|('other', 0.0012381283652900487)|<sec id="Sec10"><title>Statistical analysis</title><p>Data analysis was performed using SPSS 17.0 (SPSS, Chicago, USA). Data were compared using two-sample <italic toggle="yes">t</italic> test or one-way ANOVA test for the parametric data, and the Mann–Whitney or Wilcoxon tests for non-parametric data. Data are expressed as the mean ± standard error. <italic toggle="yes">P</italic> values of less than 0.05 were considered statistically significant.</p></sec>
25050821|None|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2.0 Materials and Methods</title>
25050821|2.1 Subjects|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" sec-type="subjects" id="S2"><title>2.1 Subjects</title><p id="P4">Male Sprague-Dawley rats (Harlan, Indianapolis) weighing 225-250g upon arrival were individually housed in a humidity- and temperature-controlled (21-22° C) vivarium on a reversed light-dark cycle (lights off 07:00 hours, on 19:00 hours) with unlimited access to water. Rats received 20g of food daily between the hours of 14:00-16:00. Training and experimental sessions were conducted during the dark phase at the same time each day (09:00-15:00) and perfusions were performed between 11:00-14:00. All experimental procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals and under local IACUC approval.</p></sec>
25050821|2.2 Surgery|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.2 Surgery</title><p id="P5">A control group of rats (n=14) was handled daily for 5 days before acute cocaine or vehicle injection. A second group (n=29) was anesthetized with isoflurane and implanted with jugular catheters as described previously (<xref rid="R23" ref-type="bibr">23</xref>). These rats were allowed at least 7 days to recover from surgery. For the first 2 weeks after surgery, catheters were flushed daily with 0.1 ml of sterile saline containing heparin (30units/ml), timentin (66.67mg/ml), and streptokinase (9333 U/ml) to maintain catheter patency and prevent infection. Thereafter, catheters were flushed with heparinized saline before and after each experimental session throughout the cocaine self-administration experiments.</p></sec>
25050821|2.3 Self-administration training|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.3 Self-administration training</title><p id="P6">Self-administration and extinction training was conducted in operant conditioning chambers within sound-attenuating, ventilated cubicles (Med Associates, St. Albans, VT, USA). The chambers were equipped with two retractable response levers on one side panel, with a 28-V white light above each lever, and a red house light near the chamber ceiling. Intravenous cocaine infusions were delivered via syringe pump controlled by a drug delivery system (Med Associates). Experimental events and data collection were automatically controlled by interfaced computer software (Med Associates).</p><p id="P7">After recovery from surgery, rats were trained to intravenously self-administer cocaine on a fixed-ratio 1 (FR1) schedule in operant chambers. Daily self-administration sessions were initiated by the extension of two levers into the chamber and illumination of the red house light. During each 2 hr session, each active lever press resulted in an infusion of cocaine (0.2 mg/kg/50ul infusion) along with presentation of a 5-sec light-tone stimulus complex, followed by a 20-sec timeout period during which active lever responses were recorded but resulted in no programmed consequences. Inactive lever presses were always recorded but had no programmed consequences. Rats received 12 2-hr cocaine self-administration sessions (one session per day), during which all rats achieved a criterion of receiving least 10 infusions of cocaine.</p></sec>
25050821|2.4 Extinction training|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.4 Extinction training</title><p id="P8">After completing the self-administration phase, a subset of rats (n=13) was subjected to daily extinction sessions. Extinction sessions were initiated by extension of the two levers into the chamber and illumination of the red house light. Sessions lasted 2 hr, during which active and inactive lever presses were recorded but resulted in no programmed consequences. All rats received 8 days of extinction training, during which responding decreased to &lt;20% of responding recorded during the final 3 days of cocaine self-administration.</p></sec>
25050821|2.5 Treatment-induced cFos induction|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.5 Treatment-induced cFos induction</title><p id="P9">After 5 days of daily handling (controls, n=14), 12 days of cocaine self-administration without extinction (n=16), or 12 days of self-administration followed by 8 days of extinction (n=13), rats were injected with either cocaine (20 mg/kg, i.p.) or saline, then returned to their home cage for 90-120 minutes before perfusion. This post-treatment survival time is similar to that used in previous studies examining the effects of acute cocaine on cFos induction (<xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>). Perfusion and tissue collection have been previously described (<xref rid="R26" ref-type="bibr">26</xref>). Briefly, rats were deeply anesthetized with sodium pentobarbital (Nembutal, 10 mg/kg BW i.p.) and transcardially perfused using aqueous 0.15M NaCl for 1 min followed by 4% paraformaldehyde in 0.1M phosphate buffer (pH 7.4) for 10 min. Fixed brains were removed from the skull, blocked, frozen, and sectioned coronally (35 μm) on a freezing-stage microtome. Sections from the upper cervical spinal cord through the rostral corpus callosum were collected in six adjacent sets and stored in cryopreservant solution (<xref rid="R27" ref-type="bibr">27</xref>) at −20°C prior to processing for immunohistochemistry.</p></sec>
25050821|2.6 Immunohistochemistry|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>2.6 Immunohistochemistry</title><p id="P10">One set of tissue sections from each rat (i.e., representing brain regions sampled at 210 μM intervals) was processed for dual immunoperoxidase localization of nuclear cFos and cytoplasmic DbH, as previously described (<xref rid="R26" ref-type="bibr">26</xref>), the latter to identify NA neurons and fibers. DbH immunolabeling also was used as a guide to standardize selection of anatomical regions and subnuclei for quantitative analyses. A second set of sections was processed for immunoperoxidase localization of cFos followed by immunofluorescent localization of cytoplasmic tyrosine hydroxylase (TH) to identify both NA neurons within the LC. This procedure was used to obviate the problem of overly dark DbH peroxidase staining within the LC, that can impede visualization of nuclear cFos immunoperoxidase labeling (see Results). cFos protein was localized using a rabbit antiserum provided by Dr. Phillip Larsen, Denmark (1:50K). The specificity of this antibody has been reported (<xref rid="R28" ref-type="bibr">28</xref>). Tissue sections were processed as previously described (<xref rid="R21" ref-type="bibr">21</xref>) and reacted with nickel-intensified diaminobenzidine (DAB) to produce a blue-black nuclear peroxidase label for cFos protein. DbH was subsequently localized in cFos-reacted tissue sections using a mouse monoclonal antibody (1:30K; Millipore, AB1585) as previously described (<xref rid="R21" ref-type="bibr">21</xref>). Sections were reacted using plain DAB to produce a brown cytoplasmic peroxidase label. An alternate set of cFos-reacted tissue sections was labeled using a monoclonal antibody raised against TH (1:5K, Sigma-Aldrich, T2928), followed by donkey anti-mouse IgG conjugated to Dylight-488; Jackson ImmunoResearch, 1:300). Double-labeled tissue sections were then rinsed and mounted, dehydrated in a graded series of ethanols, defatted in xylene, and placed under coverslips using Cytoseal (Richard Allan Scientific).</p></sec>
25050821|2.7 Quantification|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.7 Quantification</title><p id="P11">Cell counting in double-labeled tissue sections was performed as previously described to document the extent of treatment-induced cFos immunoreactivity in the NTS, caudal ventrolateral medulla (VLM), LC, PVN, and anterior vlBNST (<xref rid="R26" ref-type="bibr">26</xref>). Anatomical landmarks were defined with reference to the atlas of Paxinos and Watson (<xref rid="R29" ref-type="bibr">29</xref>), with sampling regions further standardized across animals based on the subregional distribution of DbH immunolabeling. DbH-positive neurons exhibited a brown cytoplasm with a clearly defined nucleus, and were classified as cFos-positive if the nucleus contained visible blue-black labeling, independent of intensity. Alternate sections labeled for TH immunofluorescence were analyzed to identify any NA neurons within the LC that displayed cFos-positive nuclei.</p><p id="P12">Each area of interest was sampled bilaterally in sections spaced by 210 μM. The NTS and VLM were partitioned along their rostral-caudal extent, based on previous evidence for rostrocaudal differences in NA activation within the NTS and VLM in rats after stressful or rewarding stimuli (<xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R31" ref-type="bibr">31</xref>). For this purpose, data were collected and averaged for the caudal NTS/VLM (i.e., 5-6 tissue sections per rat located caudal to the area postrema, AP), mid NTS/VLM (i.e., 3-4 sections per rat through the level of AP), and rostral NTS/VLM (i.e., approximately 3 sections per rat located rostral to the AP but caudal to the level at which the NTS pulls away from the walls of the 4<sup>th</sup> ventricle). cFos-positive cells within the PVN and anterior vlBNST were counted bilaterally in 2-3 sections per region, with counts standardized to include only the subregions that are most densely innerved by DbH-positive NA fibers (i.e., see <xref ref-type="fig" rid="F2">Fig. 2A, C</xref>). For each brain region, the total number of neurons counted was divided by the number of sections in which counts were made in order to derive the average number of immunopositive cells per section for each rat.</p></sec>
25050821|2.8 Statistical analysis|('method', 0.9965286558011991)|('other', 0.0034713441988010363)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>2.8 Statistical analysis</title><p id="P13">The number of infusions, active lever responses during extinction, and cell count data are presented as group means ± SEM. The number of cocaine infusions received by rats during the last 2 days of self-administration was analyzed using two-way ANOVA to ensure equivalent drug exposure in rats subsequently divided into different extinction groups. Terminal responding during the last 2 days of extinction was compared using a t-test to ensure equivalent levels of responding in rats that received a final injection of cocaine vs. vehicle before perfusion fixation. Cell count data from the NTS and VLM were initially analyzed using three-way ANOVAs to determine effects of drug history, acute injection, and rostral-caudal level on NA activation. Since the NTS and VLM caudal to the AP displayed minimal cFos and DbH double-labeling (see Results), a subsequent analysis eliminated the most caudal NTS and VLM counts (i.e., caudal to the AP) and collapsed the data for sections through and rostral to the AP. Two-way ANOVAs were then performed to further examine main effects of (and interactions between) drug injection and history on cFos activation within the NTS and VLM. Cell counts in the PVN and anterior vlBNST were similarly analyzed using two-way ANOVA. Significant main effects and interactions were further investigated using Bonferroni post-hoc tests. Correlational analyses were performed to evaluate potential within-subjects relationships between cocaine-induced cFos activation in the NTS, VLM, PVN, and BNST, and whether these relationships were altered by cocaine history. Differences were considered statistically significant when p&lt;0.05. Tissue sections from one rat were excluded from analysis because count data from this rat were &gt;3 standard deviations from the group mean.</p></sec>
25058502|None|('method', 0.9958252906991389)|('other', 0.004174709300861196)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
25058502|None|('method', 0.9958252906991389)|('other', 0.004174709300861196)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P5">Two rhesus monkeys (<italic>Macaca mulatta</italic>), R (male, 10 y/o, 11 kg) and Z (male, 6 y/o, 7 kg), were used as subjects in this study. All animal care and experimental procedures were approved by the National Eye Institute and Institutional Animal Care and Use Committee and complied with the Public Health Service Policy on the humane care and use of laboratory animals.</p>
25058502|Behavioral tests|('method', 0.9958252906991389)|('other', 0.004174709300861196)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Behavioral tests</title><p id="P6">A major goal of our study was to understand what kinds of information are transmitted from PPTg neurons to DA neurons. In order to achieve this goal, we used a variety of behavioral tasks in which the monkey’s behavior was examined in different contexts. The tasks included: (1) Reward-biased saccade task, (2) Reward-unbiased saccade task, (3) Passive auditory task. In addition, we used a variety of ‘clinical’ tests. Below, we described details of these tasks.</p><sec id="S4"><title>Reward-biased saccade task (<xref rid="F1" ref-type="fig">Fig. 1A</xref>)</title><p id="P7">The goal of this task was to examine reward-related properties of PPTg neurons. Specifically, saccades to one direction were followed by a juice reward, but saccades to the other direction were followed by no reward. Details of this “one direction rewarded (1DR)” task were described previously (<xref rid="R33" ref-type="bibr">Lauwereyns et al., 2002</xref>; <xref rid="R22" ref-type="bibr">Hong et al., 2011</xref>). Visual stimuli were rear-projected by a projector onto a frontoparallel screen 33 cm from the monkey’s eyes. Eye movements were monitored using a scleral search coil system (<xref rid="R55" ref-type="bibr">Robinson, 1963</xref>). A trial started when a small spot of light appeared on the screen, on which the monkey had to fixate. After the monkey maintained fixation on the spot for 750~1250ms, the fixation spot disappeared and another spot of light (target) appeared on either the right or left side, 10° from the fixation spot. The monkey was required to make a saccade to the target within 750 ms. Correct and incorrect saccades were signaled by a tone and a beep 200 ms after the saccade, respectively. Within a block of 24 trials, saccades to one fixed direction were rewarded with 0.3 ml of apple juice while saccades to the other direction were not rewarded. The position-reward contingency was reversed in the next block with no external instruction. Even in the unrewarded trials, the monkey had to make a correct saccade; otherwise, the same trial was repeated. In rewarded trials a liquid reward was delivered which started simultaneously with a tone stimulus.</p></sec><sec id="S5"><title>Reward-unbiased saccade task (<xref rid="F1" ref-type="fig">Fig. 1B</xref>)</title><p id="P8">The goal of this task was to examine the visual and saccade-related properties of PPTg neurons, while excluding reward-related properties. The procedure was the same as 1DR task, except that the target appeared at one of the 8 positions with the same eccentricity and that the successful trial was always followed by a reward (0.3 ml of apple juice). We changed the target eccentricity depending on the neuron’s response.</p></sec><sec id="S6"><title>Passive auditory task (<xref rid="F1" ref-type="fig">Fig. 1C</xref>)</title><p id="P9">The goal of this task was to examine complex auditory responses of PPTg neurons. Sound stimuli consisted of regular tics (interval: 0.5 s) and unexpected sounds. There were three kinds of unexpected sounds: (1) Odd tics – a tic sound was inserted between two regular tics with a probability of 10%, (2) A beep (duration: 400 ms) delivered at the end of a trial with a probability of 25%, (3) A tone (duration: 400ms) with juice delivery at the end of a trial with a probability of 25%. One trial consisted of 20–35 regular tics with or without the unexpected sounds. The inter-trial interval varied between 3~6 sec.</p></sec><sec id="S7"><title>Clinical tests</title><p id="P10">PPTg neurons showed a variety of activity that was not elucidated by the computer-controlled behavioral tasks. To obtain some evidence for their functions, we tested each neuron’s activity in the following manners. To examine general visual properties, we presented various visual images on the screen, including stationary pictures of various objects and moving light spots. We also presented real objects in front of the monkey. To examine general auditory properties, we presented various click and tapping sounds at various positions (e.g., behind and in front of the monkey). To examine somatosensory and motor properties, we lightly touched and moved various body parts of the monkey, and examined the relationship between neuronal firing and the monkey’s spontaneous body movements.</p></sec></sec>
25058502|Recording and stimulation procedures|('method', 0.9958252906991389)|('other', 0.004174709300861196)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Recording and stimulation procedures</title><p id="P11">To study whether and how signals are transmitted from PPTg neurons to DA neurons, we placed a single electrode in the PPTg and a set of three electrodes in the SNc. This required careful placement of recording/stimulation chambers, chamber-based MR imaging, and exploration of single neuronal activity in the PPTg and SNc, as described below.</p><sec id="S9"><title>Electrode access to PPTg and SNc</title><p id="P12">To minimize artifactual interactions between the PPTg and SNc electrodes, we placed two recording/stimulation chambers along the midline, the posterior chamber aiming at the PPTg and the anterior chamber aiming at the SNc. For monkey R, the PPTg chamber was placed vertically in the stereotaxic coordinates while the SNc chamber was tilted anteriorly by 20°. For monkey Z, the PPTg chamber was tilted posteriorly by 15 ° while the SNc chamber was tilted anteriorly by 15°. These recording/stimulation chambers together with a head holder were held in place with dental acrylic and secured to the skull with ceramic screws. The placement of the chambers was guided by a brain atlas (<xref rid="R59" ref-type="bibr">Saleem and Logothetis, 2006</xref>). After the chambers were implanted surgically, MR images were acquired along the 3D coordinates of each chamber using a 4.7T vertical scanner (Bruker BioSpec 4.7T). We used a T1 weighted modified driven-equilibrium Fourier transform (MDEFT) (<xref rid="R36" ref-type="bibr">Lee et al., 1995</xref>). To visualize the chamber coordinates, we filled chamber-attached grid holes with saline-gadolinium solution. The MDEFT images had a field of view 96 × 96 × 64 mm, and 0.5 mm isotropic voxel size. The MRI procedure was performed for both monkey R and Z. Based on the MR images, we performed craniotomy and, after the monkey’s recovery, performed single unit recording (see below).</p></sec><sec id="S10"><title>Single-unit recording</title><p id="P13">We used monopolar tungsten electrodes (Frederick Haer, diameter: 0.25 mm, 0.5–2 M Ohm) for single unit recording. To position the electrode we used a grid system, which allowed recordings at every 1 mm between penetrations. The electrode was introduced into the brain through a stainless steel guide tube, which was inserted into one of the grid holes and then to the brain via the dura. We advanced the electrode using an oil-driven micromanipulator (MO-97A, Narishige). The neuronal electrical signal was amplified with a band-pass filter (200 Hz–10 kHz; BAK, Mount Airy, MD) and was collected at 40 kHz. Activity of a single neuron was isolated on-line using a custom voltage-time window discrimination software (Blip; available at <ext-link ext-link-type="uri" xlink:href="www.simonhong.org">www.simonhong.org</ext-link>). The software allowed us to set multiple inclusion and exclusion windows so that only such activity was isolated that goes through all inclusion windows but does not go through any of the exclusion windows.</p></sec><sec id="S11"><title>Antidromic activation</title><p id="P14">Electrical stimulation at the axon terminal of a PPTg neuron would evoke an action potential (spike) that conducts antidromically to the cell soma of the PPTg neuron. We used this method to test if a PPTg neuron projects its axon to the SNc where DA neurons were located. For this purpose, we chromically implanted three bipolar platinum electrodes (Frederick Haer, diameter: 250μm, 10 kOhm) in the medial, central, and lateral portions of the SNc (<xref rid="F2" ref-type="fig">Fig. 2</xref>, also see below for further comments). To detect antidromic spikes, we lowered the recording electrode toward and inside the PPTg, while electrical stimulation was applied via the three SNc electrodes one at a time at every 0.5 s. We used a biphasic square pulse (0.2ms negative followed by 0.2 ms positive, &lt;300 μA) for the stimulation. If spikes with a fixed latency were detected, we performed a collision test by triggering the electrical stimulation by spontaneous spikes of the same neuron: if the stimulation is applied before (or immediately after) a spontaneous spike reaches the stimulation site, the antidromic spike would collide with the spontaneous spike and therefore would not conduct to the cell soma. The procedure for the antidromic activation was controlled by Blip. To minimize the stimulation-induced electrical artifact, we used an artifact remover (Artifact Zapper-1, Riverband Instrument) by which the averaged post-stimulation potential was subtracted from the current post-stimulation potential. After the identification of antidromic activation, we examined the activity of the SNc-projecting PPTg neuron using various tasks (<xref rid="F1" ref-type="fig">Fig. 1</xref>). If the PPTg neuron remained stable, we simultaneously recoded its activity and the multiunit SNc activity.</p></sec><sec id="S12"><title>Chronic implantation of stimulating electrodes</title><p id="P15">It has been noted (but not published) that the effectiveness of electrical stimulation declines if the electrode is implanted at the same position for a long time. It may be because neural tissue around the electrode tip is damaged and/or replaced with glial tissue (<xref rid="R18" ref-type="bibr">Griffith &amp; Humphrey, 2006</xref>; <xref rid="R51" ref-type="bibr">Polikov et al., 2005</xref>). To minimize this effect, we positioned the electrodes about 3 mm above the DA neuron areas and, only during experiment, moved them down to the DA neuron areas. This method appeared to work well because DA neuron activity remained detectable even after repeated experiments in most of the electrodes. Also, the antidromic activation of PPTg neurons remained effective during repeated experiments spanning more than 2 months.</p></sec><sec id="S13"><title>Orthodromic activation</title><p id="P16">To determine the nature of PPTg connection to DA neurons, we examined the responses of presumed DA neurons to electrical stimulation of the PPTg. After examining the activity of a PPTg neuron, we repeatedly stimulated the location of the PPTg neuron (inter-stimulus interval: 1.2–1.7 s) and recorded the multiunit activity of presumed DA neurons via the three implanted electrodes in the SNc. For stimulation we used a biphasic square pulse: a 0.2ms 100 μA negative pulse followed by a 0.2ms 20 μA positive pulse.</p></sec></sec>
25058502|Data Analysis|('method', 0.9958252906991389)|('other', 0.004174709300861196)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S14"><title>Data Analysis</title><p id="P17">To analyze reward-related activity, we primarily focused on the neuron’s response to the saccade target which indicated the presence or absence of the upcoming reward. The post-target response was defined as the discharge rate during 150–350 ms period after the target onset minus the background discharge rate during the 1000 ms period before the fixation point appeared. The post-reward response was defined as the average discharge rate during 150–350 ms after the onset of the tone stimulus (which was synchronized with reward onset if reward was present) minus the background discharge rate. We set the time windows such that they included major parts of the excitatory and inhibitory responses of both PPTg and DA neurons.</p><p id="P18">Using one-way ANOVA and ROC (receiver operating characteristic) we classified neurons into three groups: 1) reward-positive type, if their firing rate increased in response to an expected reward (p&lt;0.01, ANOVA &amp; ROC&gt;0.5); 2) negative type, if their firing rate decreased in response to an expected reward (p&lt;0.01, ANOVA &amp; ROC&lt;0.5); 3) reward unmodulated type (p&gt;0.01, ANOVA). We further classified these reward modulated neurons into “value state” type (i.e., sustained modulation) and “value change” type (i.e., phasic modulation). A neuron was classified as value state type if it showed sustained modulation (p&lt;0.05, Wilcoxon signed rank test) during the period from 350 ms to 750 ms after the appearance of the fixation point. A neuron was classified as value change type if it showed no sustained modulation.</p></sec>
25058502|Histological examination|('method', 0.9958252906991389)|('other', 0.004174709300861196)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S15"><title>Histological examination</title><p id="P19">To verify the locations of neurons in the PPTg that projected to the SNc, we made electrolytic marking lesions (12 μA, 30 sec, electrode being anode) at recording sites of some of the antidromically activated neurons in monkey Z. At the conclusion of the experiment, the animal was deeply anesthetized with pentobarbital sodium and perfused with 4% paraformaldehyde. Frozen sections were cut every 50 μm in the coronal plane. The sections were stained with cresyl violet (Nissl staining) in which the marking lesions were identified. The locations of the three stimulating electrodes were identified as three linear lesions in the SNc which were aligned in parallel (<xref rid="F2" ref-type="fig">Fig. 2</xref>). The locations of the recorded neurons were reconstructed by the 3D coordinates of the recording sites relative to the marking lesions.</p></sec>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II. Data</title>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">We use two primary sources of data. First, we use a database of health insurance claims for privately insured individuals in the United States. These data are provided by a leading healthcare information company which provides cost management and benefit consulting services to employers, health plans, pharmaceutical manufacturers, and others. The database contains complete medical claims including inpatient care, outpatient care, and pharmaceutical use for individuals insured by approximately 40 large employers in the United States.</p>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P12">The pharmaceutical claims data contain a record for each outpatient prescription filled for each individual covered by each drug plan in the data. Each record contains a scrambled individual identifier, information on the type of drug, the drug name, the National Drug Code<sup><xref ref-type="fn" rid="FN1">1</xref></sup> (NDC) identifying the drug, dosage, days supplied, place of purchase, and payments by enrollees and by health plans for the drug.</p>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P13">In addition to claims data, the database also provides basic demographic information and summary descriptions of the benefit designs of the private insurance plans.</p>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P14">Each employer in the database has a number of different health plans. These different plans may reflect a menu of different choices available to enrollees, different plans available to employees in different geographical areas, different plans available to union and non-union employees, and different plans available to active employees and retirees. Many employers offered health benefits to their retirees (and their dependents), and these plans and enrollees are reflected in the database.</p>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P15">From this database we draw a sample of individuals aged 65 and older. We draw only individuals who filled at least one prescription in 2007. In order to ensure that our sample represents a wide variety of health plans and benefit designs, we draw five enrollees randomly from each of the 342 plans covering people aged 65 and older in our data. For each of the 1,710 sampled individuals, we draw all of their pharmaceutical claims for 2007. The individuals in our sample are not enrolled in Medicare Part D: they are enrolled in their employer’s retiree prescription drug plan.</p>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">Our second source of data is the Medicare Prescription Drug Plan Formulary and Pharmacy Network Files (PDPFPNF). The PDPFPNF provides a detailed description of each Medicare Part D plan’s FBD. These files are available monthly starting in 2006, and we use the January 2007 files.</p>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P17">These files contain identifiers for each Medicare Part D plan. These identifiers link to formulary files which list the NDC code of each drug covered on each plan’s formulary. The formulary files also identify to which cost-sharing tier each drug is assigned. A separate file describes the coinsurance or copayment rate associated with each tier of coverage in each coverage segment (deductible, initial coverage segment, doughnut hole, catastrophic coverage). Thus, using the PDPFPNF, it is possible to identify the cost sharing associated with any covered drug in any Part D plan on any coverage segment.</p>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P18">We choose to focus only on PDP plans of which there are 1,909 in the data for 2007. Firms may offer many plans, so there are many fewer than 1,909 firms in the data. There are 39 PDP markets defined by the Centers for Medicare and Medicaid Services (CMS), and a firm which offers the same plan in each of these contributes 39 plans to the overall count. In addition, the same firm may offer multiple plans in the same market.</p>
25067840|None|('method', 0.6614565185851147)|('other', 0.3385434814148853)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P19">In addition to these primary sources of data, we also link plans to their enrollment and premium data, available from the CMS Web site.</p>
25067844|None|('method', 0.7857472990557645)|('other', 0.2142527009442354)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II. Results</title>
25067844|None|('method', 0.7857472990557645)|('other', 0.2142527009442354)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">To estimate the effects of community HIV testing on individual beliefs and behavior we estimate the following regression:<disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>M</mml:mi><mml:mover accent="true"><mml:mrow><mml:mi>e</mml:mi><mml:mi>a</mml:mi><mml:mi>n</mml:mi><mml:mi>G</mml:mi></mml:mrow><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mi>o</mml:mi><mml:msub><mml:mi>t</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mo>′</mml:mo></mml:msubsup><mml:mi>γ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo></mml:math></disp-formula>where “<italic>MeanGot</italic>” is the percent of those in individual <italic>i</italic>’s village, <italic>j</italic>, who learned their HIV results and <italic>Y<sub>ij</sub></italic> are answers to questions about beliefs and sexual behavior. Across villages, the average proportion of individuals learning their HIV results is 0.72 (standard deviation 0.19; <xref ref-type="table" rid="T1">Table 1</xref>, panel A, columns 3 and 4). <italic>X<sub>ij</sub></italic> is a vector of controls from 2004 that include age, age squared, years of schooling, marital status, an indicator for gender, and village size (number of respondents). In each regression we also include a control for the 2004 baseline level of <italic>Y</italic>, for each different outcome. Missing covariates are imputed with the mean of the covariate, and a missing dummy indicator is included in the set of controls. Our main coefficient of interest is β<sub>1</sub> indicating the impact of village-level HIV knowledge on beliefs and sexual behavior.</p>
25067844|None|('method', 0.7857472990557645)|('other', 0.2142527009442354)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P17">The decision to learn HIV results is likely correlated with individual characteristics. Similarly, the village-level rate of learning results is likely to be correlated to both individual and village-level characteristics. Because of this we use the randomly assigned incentives and distance to results center to instrument for the village-level rate of results-seeking. Our first stage estimate of the rate of the village learning results is<disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:msub><mml:mtext mathvariant="italic">MeanGot</mml:mtext><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>α</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mtext mathvariant="italic">MeanAny</mml:mtext><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mtext mathvariant="italic">MeanAmt</mml:mtext><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>γ</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mtext mathvariant="italic">MeanDist</mml:mtext><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>X</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mo>′</mml:mo></mml:msubsup><mml:mi>γ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>.</mml:mo></mml:math></disp-formula><italic>MeanAny</italic>, <italic>MeanAmt</italic>, and <italic>MeanDist</italic> are village-averages of being offered any incentive, the amount of the incentive, and the distance to the HIV results center, respectively. The first stage estimate without controls yields an <italic>F</italic>-statistic of 23.98 (not shown). We cluster our standard errors by village and run linear OLS regressions, including village weights in each specification.</p>
25067844|None|('method', 0.7857472990557645)|('other', 0.2142527009442354)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P18"><xref ref-type="table" rid="T2">Table 2</xref> presents the effects of increased community members learning HIV-negative results on beliefs about sickness and death attributed to AIDS.</p>
25067844|None|('method', 0.7857472990557645)|('other', 0.2142527009442354)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P19">As more people in the village learn their HIV results, individuals revise their beliefs about friends, family, and acquaintances who they suspect to have died from AIDS. A 10 percentage point increase in the proportion of the village learning their HIV results leads to respondents attributing 1.27 fewer deaths to AIDS, (<xref ref-type="table" rid="T2">Table 2</xref>, column 1). While there is no statistically significant effect on the reported number of people who have died from AIDS in the past year (coefficient −0.863, standard error 0.699; column 2), there is a significant effect on the number of relatives suspected to be sick from or have died from AIDS. With each 10 percentage point increase in the proportion of the village learning their HIV results, 0.14 fewer relatives are suspected to have died from AIDS (column 3).</p>
25067844|None|('method', 0.7857472990557645)|('other', 0.2142527009442354)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P20">As beliefs about HIV infections among friends and acquaintances decreases, the perceived external HIV risk decreases and therefore individuals may re-optimize their own sexual behavior. <xref ref-type="table" rid="T2">Table 2</xref>, columns 4–6 presents the impact of others’ testing on multiple partnerships and condom use.</p>
25067844|None|('method', 0.7857472990557645)|('other', 0.2142527009442354)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P21">As more people in the village learned their HIV results and beliefs about overall AIDS risk decreases, behavior responds with a significant decrease in the likelihood of using condoms and no change in multiple partnerships (column 4). The coefficient on condom use is −0.382 (standard error 0.132) on the use of condoms with a current partner and −0.385 (standard error 0.132) on condom use for any of the past three partners (columns 5 and 6). In other words, if 10 percent more community members learn their HIV results (approximately four people), individuals are 38 percentage points less likely to use a condom.</p>
25070967|None|('method', 0.9999699397800645)|('other', 3.0060219935341857e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
25070967|None|('method', 0.9999699397800645)|('other', 3.0060219935341857e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">Participants were recruited from a large health maintenance organization in the Midwest and a large insurance plan in North Carolina. Mammography cost was covered with no out-of-pocket costs to members. IRB approval was obtained at both sites. First, eligible women were sent a letter explaining the study and provided an opportunity to call a toll-free number within two weeks if they did not want to be contacted. If a woman did not opt out, they were called by research assistants (RAs) using standard protocol and a computerized tracking system. RA’s explained the study and determined their interest in participating. If participants were willing to enter the study, a verbal consent was obtained and T1 data collected either immediately or during another scheduled phone call. All data were collected by trained interviewers on the phone. Consented women were mailed the written HIPPA form, which was signed and returned so that their 6 month data could be accessed from medical records. After consent, women were randomized to one of the three groups: 1) telephone, 2) mailed tailored interactive DVD, or 3) usual care. Data were collected at baseline (T1), 4 weeks (T2), and six months (T3). The T2 data included belief variables, and knowledge to determine if the intervention changed these mediators. Additionally, at T2, women in the intervention group were asked questions about satisfaction with method of intervention delivery (<xref rid="R28" ref-type="bibr">Skinner et al., 2011a</xref>). Although only the intervention groups were asked about satisfaction with the intervention, these questions were embedded in T2 which was completed by women in all groups. Data were collected by phone using trained interviewers at an established survey center. The usual care group completed surveys but did not receive a tailored intervention. Usual care varied depending on location but ranged from nothing to a post-card reminder when it was time to schedule a mammogram.</p>
25070967|None|('method', 0.9999699397800645)|('other', 3.0060219935341857e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P12">Demographic, beliefs, and self-reported screening activities were collected at T1. Beliefs and self-reported screening were collected at T3. A twenty dollar incentive was given for each of the three surveys to all three groups. Medical record claims data were used to identify mammography adherence post-intervention. Disposition of sample participants is illustrated in the Consort Diagram (<xref rid="F1" ref-type="fig">Figure 1</xref>).</p>
25070967|Statistical Strategy|('method', 0.9999699397800645)|('other', 3.0060219935341857e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Statistical Strategy</title><p id="P13">The three groups were compared for distributional properties on baseline characteristics using the Kruskal-Wallis test for continuous and ordinal variables and the two-sided Fisher’s exact test for nominal categorical variables. Binary logistic regression was used to analyze the intervention effect. Demographic and other theoretically justified variables were entered as potential confounders of the relationship between the interventions and mammography adherence (<xref rid="R25" ref-type="bibr">Senn, 1994</xref>). Wald chi-square tests, adjusted odds ratios, and 95% confidence intervals were used to test independent variables in the logistic regression models. Interactions between the intervention and baseline covariates were tested for potential moderating effects. The study was designed to achieve a sample size of at least 534 in each of the three groups at six months, considering attrition, in order to insure at least 80% power to detect 10% differences (phone 40%, DVD 30%, usual care 20%) in six months screening between any pair of randomized groups (the omnibus test between all three groups exceeded 80% power) and 80% power to detect intervention moderation (i.e., interaction) effects that were two times stronger (i.e., 2.0 odds ratio) for one demographic category versus another category. An intent-to-treat analysis was used.</p></sec>
25070967|Measurement|('method', 0.9999699397800645)|('other', 3.0060219935341857e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Measurement</title><p id="P14">Demographics and family history were assessed using standard questions. Belief scales included perceived risk, perceived benefits, perceived barriers, self-efficacy, breast cancer fear, and fatalism. All scales had been previously tested and found to be both reliable and valid (<xref rid="R8" ref-type="bibr">Champion et al., 2008</xref>)</p><p id="P15"><italic>Mammography adherence</italic> was computed with both six-month self-report interview data and medical records claim data. If either self-report or medical records indicated that women had a mammogram between baseline and six months, the mammography adherence outcome variable was scored “yes”. Of the 1,681 women with baseline interviews, 25.8% were missing the six-month interview, 9.6% were missing medical record data, and only 2.6% were missing both pieces of information. Use of both self-report and medical record data served to decrease potential bias due to missing data in either interview or medical record information. The Kappa coefficient of agreement for adherence between self-report and medical records was .82 in our sample among women with both sources of data.</p></sec>
25070967|None|('method', 0.5598533035363028)|('other', 0.4401466964636972)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Theoretical Development of Intervention</title>
25070967|None|('method', 0.5598533035363028)|('other', 0.4401466964636972)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">The theoretical frameworks supporting the development of tailored interventions included the Health Belief and Transtheoretical Model previously associated with mammography use (<xref rid="R8" ref-type="bibr">Champion et al., 2008</xref>; <xref rid="R19" ref-type="bibr">Prochaska et al., 2008</xref>; <xref rid="R7" ref-type="bibr">Champion and Huster, 1995</xref>; <xref rid="R9" ref-type="bibr">Champion et al., 2000</xref>; <xref rid="R10" ref-type="bibr">Champion and Skinner, 2003</xref>; <xref rid="R16" ref-type="bibr">King et al., 1994</xref>; <xref rid="R27" ref-type="bibr">Skinner et al., 1998</xref>; <xref rid="R6" ref-type="bibr">Champion, 1991</xref>; <xref rid="R35" ref-type="bibr">Vernon et al., 1990</xref>; <xref rid="R24" ref-type="bibr">Schechter et al., 1990</xref>; <xref rid="R17" ref-type="bibr">Lierman et al., 1991</xref>; <xref rid="R21" ref-type="bibr">Rimer et al., 1988</xref>; <xref rid="R33" ref-type="bibr">Taplin and Montano, 1993</xref>; <xref rid="R22" ref-type="bibr">Rimer et al., 2002</xref>; <xref rid="R12" ref-type="bibr">Champion et al., 2006</xref>; <xref rid="R1" ref-type="bibr">Avis et al., 2004</xref>). Perceived and actual risk, perceived benefits, barriers, self-efficacy, and knowledge constructs were used for tailoring both the DVD and telephone interventions. Although intervention content has been explained in detail elsewhere, we provide the basic methodology below (<xref rid="R28" ref-type="bibr">Skinner et al., 2011a</xref>).</p>
25070967|None|('method', 0.5598533035363028)|('other', 0.4401466964636972)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P17">First tailored messages were developed for the theoretical constructs of perceived and actual risk, benefits, self-efficacy, and barriers as well as age and race. Tailoring was done by first asking participants to respond to a question about each belief. Participants responded to the belief questions using the arrows on the DVD remote. Message responses were selected based on algorithms built into the DVD program. Fatalism, which was assessed with its own scale for the baseline and follow-up assessments, was considered to be a barrier for the purpose of tailoring. By answering simple questions with the remote control throughout the program, messages specific to the individual woman’s beliefs were delivered. For instance, if a woman did not perceive herself to be at risk for breast cancer and had a family history, the message delivered included information that 3 out of 4 women who get breast cancer have no family history. There were 36 or more combinations of messaging. The number of message possibilities varied depending on the woman’s responses to queries. A woman could select none or up to seven barriers and for each barrier selected, a message was delivered. If a barrier was not selected, no message was delivered. The DVD allowed us to use video and other visual representations when delivering the message. The programmed DVD began with a narrator introducing the program. Four women representing different demographic profiles were selected to deliver intervention messages. An animation of breast cancer developing and metastasizing was shown. Women who had not had a previous mammogram viewed a video of the mammography process. Finally, women were queried about barriers that would prevent them from receiving a mammogram and messages to address these barriers provided through tailored programming. Fatalism and fear were measured with separate scales during interview assessments, but were considered as part of the barriers construct for the purpose of tailoring. For instance, one barrier was “<italic>I am afraid of finding out that I might have breast cancer</italic>”. The DVD program ended with the narrator encouraging viewers to make a mammography appointment.</p>
25070967|None|('method', 0.5598533035363028)|('other', 0.4401466964636972)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P18">The telephone intervention was developed using the same tailoring variables and messages used in the interactive DVD, keeping the message content consistent so that intervention arms varied only by media delivery. Telephone counselors were graduate students trained to deliver a standardized message that reflected each woman’s responses to questions, and sessions were recorded for quality control. Evaluation of phone interventions reflected a high degree of consistency. Interveners were trained to politely terminate attempts at extra dialogue to keep both content and time consistent for each participant. The average length of time spent using the interactive DVD was 10 minutes and the telephone intervention took, on average, 11.3 minutes.</p>
25079483|None|('method', 0.9634527625122066)|('other', 0.03654723748779349)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Case Presentation</title>
25079483|None|('method', 0.9634527625122066)|('other', 0.03654723748779349)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P5">A 10-year-old girl presented to our emergency department with intermittent abdominal pain and bilious emesis for 2 weeks and a preceding diarrheal illness the month prior. Significant findings included weight of 23.7kg (&lt;3<sup>rd</sup>% weight-for-age), height of 122.5cm (&lt;3<sup>rd</sup>% height-for-age), and body mass index (BMI) of 15.2 (16.7% for age). Weight loss of 3.4kg occurred in the preceding 9 days (13% of total body weight). Abdomen was diffusely tender with voluntary guarding.</p>
25079483|None|('method', 0.9634527625122066)|('other', 0.03654723748779349)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">Initial laboratory data was unremarkable with normal complete blood count, comprehensive metabolic panel, fecal calprotectin, amylase/lipase, and inflammatory markers. Abdominal ultrasound and radiograph were normal. UGI showed proximal duodenal dilation with the third duodenal portion curving superiorly to the pylorus before crossing the midline. Duodenojejunal junction was in normal position. These findings were suggestive of duodenum inversum. Interestingly, there was an abrupt cutoff of the dilated proximal duodenum with limited passage of contrast past midline leading to the differential diagnosis of SMA syndrome vs. psoas compression in the setting of duodenum inversum (<xref ref-type="fig" rid="F2">Fig. 2</xref>). The duodenum was decompressed distally suggesting partial duodenal obstruction (<xref ref-type="fig" rid="F3">Fig. 3</xref>).</p>
25079483|None|('method', 0.9634527625122066)|('other', 0.03654723748779349)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">Upon admission, the patient was started on acid suppression given the emesis and known association with peptic ulceration and duodenal inversum (<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R6" ref-type="bibr">6</xref>). Esophagogastroduodenoscopy (EGD) was performed on hospital day 5 with placement of a transpyloric nasojejunal (NJ) tube under fluoroscopy facilitating feedings distal to the partial obstruction. Visually, the duodenum followed an atypical course with the third portion tracking superiorly and then posteriorly. Histology was normal. Continuous enteral nutrition was initiated after NJ placement with polymeric formula over 24hrs and altered to be over 18hrs gradually. No further pain or emesis occurred.</p>
25079483|None|('method', 0.9634527625122066)|('other', 0.03654723748779349)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">The patient was discharged 6 days after NJ tube placement on hospital day 11. As an outpatient, overnight enteral feedings were shortened and an oral liquid diet was advanced. Discharge weight increased to 24.4kg (3<sup>rd</sup>% weight-for-age); representing a 0.7kg (64g/day) weight gain throughout inpatient hospitalization.</p>
25079483|None|('method', 0.9634527625122066)|('other', 0.03654723748779349)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">Two months post-procedure weight increased to 28.1kg (10<sup>th</sup>% weight-for-age) and she had no symptoms. At this time NJ tube was converted to a nasogastric (NG) tube. We continued enteral feeds but decreased to over 8hrs and diet was advanced to a soft diet. Three months from initial hospitalization, the NG tube was removed. Nine months post-discharge she is tolerating an unrestricted regular diet and continues to make excellent weight gain at 24g/day since the initial admission (weight 30.1kg (11<sup>th</sup>% weight-for-age), height 132.7cm (5<sup>th</sup>% height-for-age), and BMI 17 (43<sup>rd</sup>% for age)).</p>
25085653|None|('method', 0.9924575388968327)|('other', 0.0075424611031671435)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Method</title>
25085653|Source of Study Populations|('method', 0.9924575388968327)|('other', 0.0075424611031671435)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Source of Study Populations</title><p id="P10">ASD participants were 107 children and adolescents 6 to 17 years old derived from consecutive referrals to a specialized ambulatory program for ASD at a major academic medical center. ADHD participants (<italic>n</italic> = 74) were children and adolescents 6 to 17 years old derived from consecutive referrals to a general child psychiatry ambulatory clinic at the same institution. Investigators received institutional review board approval to review, analyze, and report anonymously on these participants.</p><sec id="S8"><title>Assessment Procedures</title><p id="P11">All study participants were assessed with the Kiddie Schedule for Affective Disorders and Schizophrenia-Epidemiologic Version (K-SADS-E; <xref rid="R26" ref-type="bibr">Orvaschel, 1994</xref>; <xref rid="R27" ref-type="bibr">Orvaschel &amp; Puig-Antich, 1987</xref>), supplemented with a module to evaluate for ASD. Administered to the parent/guardian (usually the mother), the K-SADS-E provided Axis I psychiatric diagnoses based on <italic>DSM-III-R</italic> (3rd ed., rev.; <xref rid="R1" ref-type="bibr">American Psychiatric Association [APA], 1987</xref>) or <italic>DSM-IV</italic> (4th ed.; <xref rid="R2" ref-type="bibr">APA, 1994</xref>) criteria depending on the time of their interview. We have previously documented the concordance between <italic>DSM-III-R</italic> and <italic>DSM-IV</italic> definitions of ADHD, supporting diagnostic continuity between the two revisions of the <italic>DSM</italic> (<xref rid="R3" ref-type="bibr">Biederman et al., 1997</xref>).</p><p id="P12">Diagnostic interviews were administered by highly trained and closely supervised psychometricians with bachelor’s or master’s degrees in psychology or a related field. To establish rater reliability, board-certified child and adult psychiatrists and licensed clinical psychologists independently diagnosed participants based on audiotaped interviews completed by raters. Kappa coefficients of agreement were computed between rater and senior clinician diagnoses. The median kappa coefficient was .98, calculated using 500 assessments from interviews of adults and children.</p><p id="P13">Diagnoses were considered positive by interviewers if full <italic>DSM-III-R/DSM-IV</italic> criteria (including clinical impairment) were met unequivocally. To resolve diagnostic uncertainties, all interviews were reviewed by a committee of board-certified child and adult psychiatrists and experienced clinical psychologists who were blind to the participant’s referral source, diagnostic status, and all other non-diagnostic data (e.g., socio-economic status [SES], family and social functioning). Diagnoses presented for review were considered positive only if diagnostic criteria were met to a degree that would be considered clinically meaningful based on the nature of the symptoms, the associated impairment, and the coherence of the clinical picture as collected during the interview. The reliability of the diagnostic review process was estimated by computing kappa coefficients of agreement for clinician reviewers. The median reliability between individual clinicians and review committee diagnoses was .87.</p><p id="P14">A diagnosis of ADHD-Inattentive or ADHD-Hyperactive was defined as six or more symptoms of either inattention or hyperactivity, respectively, with an onset at or before age 7 and cross-sectionality, defined as impairment in two or more settings. A diagnosis of ADHD-Combined type required meeting a full diagnosis of both ADHD-Inattentive and ADHD-Hyperactive.</p><p id="P15">For every diagnosis, information regarding the age of symptom onset and offset was obtained. Treatment histories included rates of disorder-specific counseling, pharmacotherapy, and hospitalization.</p><p id="P16">As the K-SADS-E lacks a module to evaluate ASD, we adopted <italic>DSM-III-R</italic> pervasive developmental disorder (PDD) diagnostic criteria into interview format to evaluate for this disorder. ASD was defined as meeting <italic>DSM-III-R</italic> diagnostic criteria for autistic disorder or pervasive developmental disorder–not otherwise specified (PDD-NOS). A diagnosis of autistic disorder required the full presence of 8 out of 16 symptoms with at least 2 symptoms from each of the three domains of ASD; in the absence of autistic disorder, a diagnosis of PDD-NOS required the presence of more than 2 of the required symptoms with symptom(s) present from each of the three ASD domains. To establish rater reliability for the PDD module, an independent clinician with expertise in the diagnosis of ASD (first author) independently diagnosed participants based on audiotaped interviews completed by raters. Based on 20 interviews, the median kappa coefficient of agreement between raters and clinician was .90. The kappa for reliability between independent raters and the final diagnostic decision made by a clinician-reviewer was .88. In addition, concurrent and discriminant validity of the PDD module for diagnosing ASD has been established (<xref rid="R19" ref-type="bibr">Joshi et al., 2011</xref>). Excellent sensitivity for the PDD module is observed with clinical diagnosis of ASD (94%) and with the Social Responsiveness Scale (<italic>T</italic>-score ≥ 60; 96%; <xref rid="R8" ref-type="bibr">Constantino et al., 2003</xref>).</p><p id="P17">Although ADHD could not be diagnosed in the presence of PDD per <italic>DSM-III-R</italic> and <italic>DSM-IV</italic> criteria, the present study employed a non-hierarchical approach to diagnostic endorsements, which required meeting full <italic>DSM</italic> symptom and impairment criteria for diagnosis. This approach allowed for empirical examination of all present disorders in an effort to fully characterize the clinical picture of each participant.</p><p id="P18">ASD participants also completed a clinical diagnostic interview with a board-certified psychiatrist experienced in evaluating ASD and comorbid psychiatric conditions. The psychiatric diagnostic interview was conducted with the participant and parent/guardian(s), and information was incorporated from multiple sources when available (e.g., psychiatric records, schools, social services).</p><p id="P19">All diagnoses of ADHD were determined by the K-SADS-E, regardless of referral source. Diagnoses of ASD in participants referred to the general psychiatry clinic were made based on the K-SADS-E PDD module; in participants referred to the specialized ambulatory clinic, ASD diagnoses were made based on clinical diagnostic interview.</p><p id="P20">The <italic>DSM</italic> Global Assessment of Functioning (GAF) Scale (<xref rid="R10" ref-type="bibr">Endicott, Spitzer, Fleiss, &amp; Cohen, 1976</xref>) was used to assess overall adaptive functioning. To evaluate school functioning, three indices of difficulties were used: placement in special classes, extra tutoring, and repeated grades. SES was established by using categories delineated by <xref rid="R17" ref-type="bibr">Hollingshead (1975)</xref>. Full-scale IQ of ASD participants was assessed with the Vocabulary and Matrix subsets of Wechsler Abbreviated Scale of Intelligence; that of ADHD participants was assessed with the Wechsler Intelligence Scale for Children (<xref rid="R34" ref-type="bibr">Wechsler, 1991</xref>, <xref rid="R35" ref-type="bibr">1999</xref>). Participants with IQ &lt; 70 were excluded.</p></sec></sec>
25085653|Data Analysis|('method', 0.9924575388968327)|('other', 0.0075424611031671435)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Data Analysis</title><p id="P21">Data for this study are expressed as mean ± standard deviation unless otherwise specified. Continuous data were analyzed using <italic>t</italic> tests and categorical data were analyzed via Pearson chi-square analyses. Logistic regression was used to adjust for potential confounders. All analyses were two-tailed; statistical significance was set at the 5% level (<italic>p</italic> &lt; .05).</p></sec>
25091262|Methods|('method', 0.9483591869037865)|('other', 0.05164081309621334)|<title>Methods</title>
25091262|Specimen preparation and loading protocol|('method', 0.9483591869037865)|('other', 0.05164081309621334)|<sec id="Sec3"><title>Specimen preparation and loading protocol</title><p>Ten fresh-frozen human cadaveric thoracic spines (T1–T12) were obtained (IIAM, Jessup, PA, USA). Specimens were dissected, leaving vertebrae, discs, stabilizing ligaments, and the posterior 5 cm of the ribs, with the costovertebral joints intact, as done previously [<xref ref-type="bibr" rid="CR14">14</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR17">17</xref>]. High-resolution radiographs and DEXA scans (Hologic, Inc., Bedford, MA, USA) were taken to assess initial specimen conditions and to exclude those with gross abnormalities or poor bone health.</p><p>Specimens were loaded in an 8-<italic toggle="yes">df</italic> MTS 858 mini-bionix servohydraulic load frame equipped with the Flextest System (MTS Systems Corporation, Eden Prairie, MN, USA) in an inverted position (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). The lower gimbals were mounted on an <italic toggle="yes">x</italic>–<italic toggle="yes">z</italic> table, equipped with two perpendicular linear bearings allowing translation in the transverse plane, while the upper gimbals were fixed to the actuator. All components of the loads and moments (<italic toggle="yes">F</italic><sub><italic toggle="yes">x</italic></sub>, <italic toggle="yes">F</italic><sub><italic toggle="yes">y</italic></sub>, <italic toggle="yes">F</italic><sub><italic toggle="yes">z</italic></sub>, <italic toggle="yes">M</italic><sub><italic toggle="yes">x</italic></sub>, <italic toggle="yes">M</italic><sub><italic toggle="yes">y</italic></sub>, <italic toggle="yes">M</italic><sub><italic toggle="yes">z</italic></sub>) were monitored to ensure that no load or moment was placed on the spine specimens (ATI Industrial Automation, Apex, NC, USA).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>Representative photo of the experimental setup and the 8-<italic toggle="yes">dof</italic> spine simulator. The degrees of freedom are denoted by the superscripts 1–8</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="586_2014_3499_Fig1_HTML.jpg" id="MO1" position="float" orientation="portrait"/></fig></p><p>Pure cyclic moments were applied using a combination of position and torque control to produce bending at a rate of 0.5 °/s to ± 4 Nm. The applied moments are within the range of magnitudes applied throughout the literature in the thoracic spine [<xref ref-type="bibr" rid="CR18">18</xref>–<xref ref-type="bibr" rid="CR21">21</xref>]. For each test, five cycles of bending were applied, with data from the third cycle used for analysis [<xref ref-type="bibr" rid="CR21">21</xref>]. The specimens were first tested in the following single-plane loading directions: flexion–extension, bilateral lateral bending, and bidirectional axial rotation. As the present study aimed to analyze the flexibility of the spine following surgical releases that would be performed intraoperatively with a patient lying prone, no axial preload was applied. Single-plane loading results were used to determine the flexibility in each plane (coronal, sagittal, and transverse).</p><p>Following single-plane loading, specimens were tested in two multi-planar loading conditions: (1) combined axial rotation and flexion–extension, and (2) combined axial rotation and lateral bending (Electronic Supplementary Material).</p><p>Range of motion (ROM) was recorded throughout testing using an Optotrak 3020 motion tracking system (Northern Digital, Inc., Waterloo, ON, Canada). The motion capture system has an accuracy of 0.1 mm and 0.1°, and a resolution of 0.01 mm. The accuracy and precision of this machine has been independently validated [<xref ref-type="bibr" rid="CR22">22</xref>]. Motion flags, equipped with four non-collinear light-emitting diode (LED) markers, were attached via bone screws to the T2, T6, T10, and T11 vertebral bodies, alternately on the left and right, to characterize motion of the spine (T2–T11). Additionally, one flag was mounted on the load frame to establish a fixed coordinate axis and to minimize the effects of any vibrations of the machine. Planes of motion for each of the instrumented vertebra were aligned using tri-planar lasers and a digitizing probe. Total ROM across the segment (T2–T11) was recorded as the motion of T2 with respect to T11. Segmental ROM from T6 to T10 (T6–T10 ROM) was recorded as the motion of T6 with respect to T10. All ROM measurements were calculated as the relative motions of the superior vertebra with respect to the inferior vertebra, and were based solely on the motion tracker markers/flags [<xref ref-type="bibr" rid="CR21">21</xref>]. These relative motions were reported as Euler angles [<xref ref-type="bibr" rid="CR21">21</xref>]. Due to differences in initial specimen flexibility, the data were normalized by calculating the percent increase in total ROM following each destabilization, as compared to the intact condition. Both raw total ROM and normalized total ROM are reported. In addition, as the majority of previous thoracic spine studies did not measure T2–T11 motion or T6–T10 motion, in the present study intact T10–T11 ROM was calculated to provide a direct comparison with previous studies (Electronic Supplementary Material). These measurements pertain to the intact spine prior to any surgical releases.</p><p>The loading protocol and measurements were repeated for each specimen under the following six conditions: (1) intact; (2) following bilateral total facetectomies between T2 and T11; and following Ponte osteotomy at (3) T7–T8; (4) T8–T9; (5) T6–T7; and (6) T9–T10.</p></sec>
25091262|Destabilization procedures|('method', 0.9483591869037865)|('other', 0.05164081309621334)|<sec id="Sec4"><title>Destabilization procedures</title><p>Following intact testing, sequential posterior-only surgical releases were performed to destabilize the spines. Nine en bloc bilateral total facetectomies were first performed from T2 to T11 (Fig. <xref rid="Fig2" ref-type="fig">2</xref>a). Each facetectomy included the bilateral removal of the inferior facet of the superior vertebra (Fig. <xref rid="Fig2" ref-type="fig">2</xref>c) [<xref ref-type="bibr" rid="CR4">4</xref>]. After bilateral total facetectomies and testing, sequential Ponte osteotomies were performed to further destabilize the spine (Fig. <xref rid="Fig2" ref-type="fig">2</xref>b). For each Ponte osteotomy, in addition to the bilateral total facetectomy, resection of the following was performed: the inferior half of the spinous process of the vertebra superior to the osteotomy site, the interspinous ligament, and the ligamentum flavum (Fig. <xref rid="Fig2" ref-type="fig">2</xref>d) [<xref ref-type="bibr" rid="CR2">2</xref>].<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p><bold>a</bold> Full thoracic spine following nine en bloc bilateral total facetectomies from T2 to T11; <bold>b</bold> full thoracic spine following four sequential Ponte osteotomies from T6 to T10; <bold>c</bold> close-up of two example bilateral total facetectomies; <bold>d</bold> close-up of two example Ponte osteotomies</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="586_2014_3499_Fig2_HTML.jpg" id="MO2" position="float" orientation="portrait"/></fig></p></sec>
25091262|Statistical analysis|('method', 0.9483591869037865)|('other', 0.05164081309621334)|<sec id="Sec5"><title>Statistical analysis</title><p>Normal distribution of the data was assured using the Shapiro–Wilk tests, followed by normal Q–Q plots. A multivariate general linear model was constructed to determine the relative effect of each input variable on the outcome variables, using SPSS 15.0 statistical analysis software (SPSS, Inc., Chicago, IL, USA). The input variables were specimen condition, destabilization, and loading direction. The primary outcome variables were (1) total ROM between T2 and T11 in all three planes during single-plane loading, (2) T6–T10 ROM in all three planes during single-plane loading, and (3) total ROM between T2 and T11 in all three planes during multi-planar loading.</p></sec>
25091809|None|('method', 0.9593981450436647)|('other', 0.040601854956335316)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 Methods</title>
25091809|2.1 Setup|('method', 0.9593981450436647)|('other', 0.040601854956335316)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1 Setup</title><p id="P5">Participants in a prevalent cohort are recruited according to the cross-sectional sampling method, in which one ascertains risk factors (e.g., smoking or a genetic variant) and disease status at the time of enrollment, and then prospectively follows the individuals with the disease to observe the events of interest (e.g. death). Subjects with the initiating event prior to time 0 (time of enrollment to the study) who are still at risk for the failure event (e.g. alive) at time 0 are sampled to the <italic>prevalent cohort</italic>, and are followed up to time τ.</p><p id="P6">The difference in sampling scheme between a prevalent cohort study and an incident cohort study is illustrated graphically in <xref rid="F2" ref-type="fig">Figure 2</xref>. Let <italic>T̃</italic> be the population duration time from an initiating event to a failure event. In the <italic>incident cohort</italic>, the event time <italic>T̃</italic> can be observed unbiasedly. Let <italic>Ã</italic> be the duration time measured from the time of the initiating event to study enrollment. In the <italic>prevalent cohort</italic>, the observed time (<italic>T</italic>, <italic>A</italic>) are length biased sampled; they are (<italic>T̃</italic>, <italic>Ã</italic>) observed among those with <italic>T̃</italic> &gt; <italic>Ã</italic> (see for example, cases 1 to 3 depicted in <xref rid="F1" ref-type="fig">Figure 1</xref>). Cases with an initiating event prior to time 0 (time of enrollment to the study) who are still at risk for the failure event (e.g. alive) at time 0 are sampled to the <italic>prevalent cohort</italic>, and we record the truncation time <italic>A</italic>, and residual survival time <italic>V</italic> or residual right-censoring time <italic>C</italic> if it is less than the maximum follow-up time, τ. Here, <italic>T</italic> = <italic>A</italic> + <italic>V</italic> is the failure time measured from the initiating event.</p><p id="P7">Suppose that the goal of a study is to test the association between unbiased failure time <italic>T̃</italic> and a risk (exposure) factor, <italic>X</italic>. Without loss of generality, we compare the hazard rates for the unbiased failure time <italic>T̃</italic> between the exposed and unexposed groups. Let <italic>λ</italic><sub>0</sub> and <italic>λ</italic><sub>0</sub> be the constant hazard rates of the unexposed (<italic>X</italic>=0) and exposed (<italic>X</italic>=1) groups, respectively. Comparing hazards rates is equivalent to testing whether the log-hazard ratio between the two groups <italic>θ</italic> = log(<italic>λ</italic><sub>1</sub>/<italic>λ</italic><sub>0</sub>), where the null hypothesis of no association is</p><disp-formula id="FD1"><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>H</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:mi>θ</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mspace width="0.16667em"/><mml:mtext>vs</mml:mtext><mml:mo>.</mml:mo><mml:mspace width="0.16667em"/><mml:msub><mml:mi>H</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>:</mml:mo><mml:mi>θ</mml:mi><mml:mo>≠</mml:mo><mml:mn>0.</mml:mn></mml:mrow></mml:math></disp-formula></sec>
25091809|2.2 Sample size calculations: <italic>Incident cohort</italic>|('method', 0.9593981450436647)|('other', 0.040601854956335316)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4" sec-type="results"><title>2.2 Sample size calculations: <italic>Incident cohort</italic></title><p id="P8">Various methods for estimating sample size have been proposed for time-to-event outcomes in standard incident cohort designs with different censoring distributions. <sup><xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R20" ref-type="bibr">20</xref>–<xref rid="R21" ref-type="bibr">21</xref></sup> Most of these calculations are based on the exponential distribution assumption for <italic>T̃</italic>. For illustration, we present the sample size calculation equation, assuming that <italic>T̃</italic> follows an exponential distribution with parameter <italic>λ</italic><sub>0</sub> for the unexposed group, and <italic>λ</italic><sub>1</sub> for the exposed group. Using the maximum likelihood estimation method as approximated by Lachin, <sup><xref rid="R22" ref-type="bibr">22</xref></sup> the sample size estimation is derived from the score test statistic and Fisher’s information. Assume that all participants are followed for a fixed study duration τ. Let <italic>n</italic><sub>0</sub> and <italic>n</italic><sub>1</sub> be the respective sample sizes for the unexposed and exposed groups, and <italic>z<sub>α</sub></italic><sub>/2</sub> and <italic>z<sub>β</sub></italic> be the upper <italic>α</italic>/2- and upper <italic>β</italic>-th quantile of the standard normal distribution. The total sample size <italic>n</italic> = <italic>n</italic><sub>0</sub> + <italic>n</italic><sub>1</sub> required to achieve (1 − β) power at the significance level α for a two-sided test can be obtained from the following equation: <disp-formula id="FD2"><label>(1)</label><mml:math id="M2" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>β</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:msup><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>γ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>γ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.16667em"/><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>exp</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where <italic>γ</italic> = <italic>n</italic><sub>0</sub>/<italic>n</italic>. In practice, it is common that participants are recruited uniformly over (0, <italic>τ</italic>). Then a similar formula for sample size calculation can be found, but with different variance estimators,</p><disp-formula id="FD3"><label>(2)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>β</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>τ</mml:mi></mml:mrow><mml:msup><mml:mi>θ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mfrac><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>γ</mml:mi><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>τ</mml:mi><mml:mo>-</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:mo>exp</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>γ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:msup><mml:mi mathvariant="normal">e</mml:mi><mml:mi>θ</mml:mi></mml:msup><mml:mi>τ</mml:mi><mml:mo>-</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>exp</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:mfrac></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula></sec>
25091809|2.3 Sample size calculations: <italic>Prevalent cohort</italic>|('method', 0.9593981450436647)|('other', 0.040601854956335316)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5" sec-type="results"><title>2.3 Sample size calculations: <italic>Prevalent cohort</italic></title><p id="P9">We derive the formulas for power and sample size calculations for a prevalent cohort study based on the maximum likelihood approach. The derivations can be found in the <xref rid="APP1" ref-type="app">appendix</xref>. Under the exponential distribution assumption, the equation that derives the total sample size and power for testing the equality of hazards is based on the asymptotic score test statistic. If all participants can be potentially followed for a fixed time τ, then the total sample size has the following explicit form</p><disp-formula id="FD4"><label>(3)</label><mml:math id="M4" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>β</mml:mi></mml:msub></mml:mrow><mml:mi>θ</mml:mi></mml:mfrac><mml:mo>}</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>γ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>γ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>exp</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>θ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><p id="P10">If the losses to follow-up are uniformly distributed over (0, <italic>τ</italic>), then the above formula needs to be modified. The corresponding sample size formula can be found in <xref rid="APP1" ref-type="app">Appendix I</xref>. We also derive the sample size formula when the population duration time follows a Weilbull distribution assumption. The detail of the formula for testing the hazard rates at a fixed time <italic>t</italic> between two independent groups can be found in a <xref rid="SD1" ref-type="supplementary-material">supplementary material</xref> from the authors.</p></sec>
25091809|2.4 Comparison between prevelent cohort design and incidence cohort design|('method', 0.9593981450436647)|('other', 0.040601854956335316)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.4 Comparison between prevelent cohort design and incidence cohort design</title><p id="P11">Comparing formula (<xref rid="FD2" ref-type="disp-formula">1</xref>) and formula (<xref rid="FD3" ref-type="disp-formula">3</xref>), it is evident that the sample size requirement for prevalent cohort design is smaller than the sample size requirement for incidence cohort design, i.e. <italic>n<sub>P</sub></italic> &lt; <italic>n<sub>I</sub></italic>, under the same design consideration including the same type I/II errors, the same follow-up duration τ and the same null hazard rate <italic>λ</italic><sub>0</sub>. In fact, the sample size difference is</p><disp-formula id="FD5"><mml:math id="M5" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>n</mml:mi><mml:mi>I</mml:mi></mml:msub><mml:mo>-</mml:mo><mml:msub><mml:mi>n</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>z</mml:mi><mml:mi>β</mml:mi></mml:msub></mml:mrow><mml:mi>θ</mml:mi></mml:mfrac><mml:mo>}</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mi>γ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>γ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msup><mml:mi>e</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:msub><mml:mi>λ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mi>τ</mml:mi></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:mrow><mml:mo>}</mml:mo></mml:mrow><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><p id="P12">Intuitively, prevalent cohort design can use the extra information on the backward time <italic>A</italic>, compared to the incident cohort design. When failure time <italic>T̃</italic> follows an exponential distribution, the observed truncation time <italic>A</italic> and residual survival time <italic>V</italic> follow the same exponential distribution and independently contribute information to the likelihood. Moreover, the truncation time <italic>A</italic> is not subject to right censoring, but <italic>V</italic> may be. Hence, it is not surprising that the gain in power for the prevalent cohort study can be more than double that of its counterpart incident cohort study.</p><p id="P13">To further illustrate the difference, we compare the sample sizes and powers of the two types of design, as shown in <xref rid="F3" ref-type="fig">Figure 3</xref>. We consider two sampling methods for the incident cohort study. The first method assumes that all participants are recruited at the beginning of the study -- this is parallel to the cross-sectional sampling of the prevalent cohort design presented in <xref rid="F1" ref-type="fig">Figure 1</xref>. The second method assumes that participants are recruited on a staggered fashion during the interval (0, τ). We consider a range of values for the log hazard ratio <italic>θ</italic>, while assuming α = 0.05, total follow-up duration τ = 4 years, and γ = 0.5.</p><p id="P14">Using sample size estimation <xref rid="FD2" ref-type="disp-formula">equations (1)</xref> and <xref rid="FD3" ref-type="disp-formula">(2)</xref> for the incident designs and <xref rid="FD4" ref-type="disp-formula">equation (3)</xref> for the prevalent design, we can estimate the total sample sizes required to achieve 80% power for the designs, keeping all other design parameters the same. For example, when <italic>θ</italic>=0.5, and <italic>λ</italic><sub>0</sub>=0.6, the total sample size required to achieve 80% power at a significance level of 0.05 is 82 for the prevalent cohort design, and 240 for the incident cohort design, with 1 year follow up. The required sample size for the incident cohort study is almost 3 times as high as the required sample size for the prevalent cohort study (when all participants are recruited at time 0). The difference in sample size requirements is especially large when the hazard ratio is small. The difference becomes small when the hazard ratio increases. With the same total sample size (<italic>n</italic> = 70) and follow-up duration, the power (<xref rid="F3" ref-type="fig">Figure 3b</xref>) for the prevalent cohort design can be up to 2.4 times higher than the power for the corresponding incident design. The difference in power is even larger when the comparison is made between the prevalent cohort design and the incident design with staggered entry. The advantage of the prevalent design is more evident when the hazard ratio is small to moderate.</p></sec>
25091809|None|('method', 0.9893853069326783)|('other', 0.010614693067321539)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3 Numerical studies</title>
25091809|3.1 Simulations|('method', 0.9893853069326783)|('other', 0.010614693067321539)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>3.1 Simulations</title><p id="P15">The power and sample size considerations are based on the most efficient test statistics under parametric models, while assuming every patient can be followed for a fixed time. We conduct simulation studies to compare the powers of incidence cohort deign and prevalent cohort deign, when the data are analyzed instead by nonparametric test statistics, when the sample size is small, and when more general censoring mechanisms are considered. For incident cohort studies, the standard log-rank (LR) test is the asymptotically most efficient test under proportional hazards alternatives. For prevalent cohort studies, Ning et al. proposed an asymptotically most efficient permutation (PM) test under proportional hazards alternatives. <sup><xref rid="R18" ref-type="bibr">18</xref></sup> As shown in Ning et al., the naïve log-rank test is also a valid test statistic, but only when censoring distributions are the same across different groups for analyzing length-biased data. <sup><xref rid="R18" ref-type="bibr">18</xref></sup> We consider two underlying distributions of <italic>T̃</italic>: exponential and Weibull, and two types of censoring mechanisms, as shown in <xref rid="T1" ref-type="table">Table 1</xref>. The total sample size used is 80, with equal numbers in each risk group. For each scenario, we present the statistical power for testing the effect of exposure using the PM test, log-rank (LR) test, and the conditional test for general left- truncated data (denoted as LT) observed from a prevalent cohort. <sup><xref rid="R23" ref-type="bibr">23</xref></sup> We compare the power against that of the log-rank test for traditional survival data observed from an incident cohort with the same sample size and follow-up duration. Under the null hypothesis (<italic>θ</italic> = 0), all test statistics in both designs lead to a type I error rate of around 0.05 (not presented in <xref rid="T1" ref-type="table">Table 1</xref>).</p><p id="P16">With the specified alternatives, the power of the PM test (similar to the LR test) for the prevalent cohort is about 1.3 to 1.9 times higher than that of the LR test for the incident cohort when all participants are recruited at the beginning of a study. With staggered entry during (0, <italic>τ</italic><sub>1</sub>) years for the incident design, it is not surprising that the power is even lower for each scenario. When participants in both cohorts are subject to right censoring, which follows a uniform distribution, the gain in power for the prevalent design compared to the incident design is more substantial than that with type I censoring. Under the Weibull distributions, we observe a similar trend of efficiency advantage for the prevalent design over the incident design. In summary, the asymptotically most efficient permutation test achieves the highest power (similar to the LR test) for the prevalent cohort; whereas the power of the conditional LT test from the prevalent cohort can be as low as (or lower than) that from the parallel incident cohort.</p></sec>
25091809|3.2 An example: CSHA prevelent cohort study|('method', 0.9893853069326783)|('other', 0.010614693067321539)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9" sec-type="methods"><title>3.2 An example: CSHA prevelent cohort study</title><p id="P17">In the CSHA study as mentioned in Introduction, it is of interest to investigate how different types of dementia may impact long-term survival measured from the disease diagnosis, after adjusting for length-biased data obtained from the prevalent cohort. Specifically, one focus is to evaluate whether patients with possible Alzheimer’s disease have similar survival as those with vascular dementia or probable Alzheimer’s diseases. The conventional survival analysis methods in the standard statistical software may result in false interpretation on the association between the type of dementia and time to death.</p><p id="P18">The observed data from CSHA consist of 818 individuals with a diagnosis of possible Alzheimer’s disease (252 subjects), probable Alzheimer’s disease (392 subjects), or vascular dementia (173 subjects). We first show how the prevalent cohort data can be analyzed by valid statistical methods under the most popular Cox model with length-bias assumption, and then illustrate the sample size calculations based on the estimated hazard ratios.</p><p id="P19">To compare the survival distribution of possible Alzheimer’s disease with that of vascular dementia or probable Alzheimer’s disease, we consider statistical methods that are valid for length-biased data including the conditional test, <sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> which is an efficient inverse weighted estimating equation method with easily modified existing statistical software, <sup><xref rid="R19" ref-type="bibr">19</xref></sup> and asymptotically most efficient permutation test. <sup><xref rid="R18" ref-type="bibr">18</xref></sup> Denote the data by {(A<sub>i</sub>, T<sub>i</sub>, δ<sub>i</sub>, X<sub>i</sub>)}, where A<sub>i</sub> is the time measured from dementia diagnosis to the study enrollment, T<sub>i</sub> is the time measured from dementia diagnosis to death or right-censoring, X<sub>i</sub> =1 for possible Alzheimer’s disease and 0 otherwise, and δ<sub>i</sub>= I(T<sub>i</sub>−A<sub>i</sub>&lt;C<sub>i</sub>) is a censoring indicator. The conditional test (LT) for general left-truncated data can be used to model the observed data using SPlus or R, <sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup> where the function and its data input are provided in <xref rid="BX1" ref-type="boxed-text">Box 1</xref>. The corresponding output gives the estimated hazard ratio (HR) of 0.94 (95% CI 0.79–1.12; P=0.47) between possible Alzheimer’s disease and other dementia types, which does not show a statistically significant difference in survival distributions by diagnosis type.</p><boxed-text id="BX1" position="float" orientation="portrait"><label>Box 1</label><caption><title>Use R/SPlus to estimate HR from the prevalent cohort study</title></caption><sec id="S20"><title>Conditional Test</title><preformat>&gt; coxph(Surv(A, T, Δ) ~ X, data=data.name)</preformat><p id="P20">where</p><p id="P21">A= the time measured from dementia diagnosis to the study enrollment</p><p id="P22">T= the time measured from demential diagnosis to death or right-censoring</p><p id="P23">Δ= censoring indicator</p><p id="P24">X= disease type indicator</p></sec><sec id="S21"><title>Inverse weighted estimation</title><preformat>&gt; coxph(Surv(Y<sub>m</sub>, rep(1, m)) ~ X<sub>m</sub> + offset(log(W)), data=data.name)</preformat><p id="P25">where</p><p id="P26">m= the total number of the observed failure times</p><p id="P27">Y<sub>m</sub>= sorted failure times</p><p id="P28">X<sub>m</sub>= the corresponding group indicator associated with Y<sub>m</sub></p><p id="P29">W= (W<sub>1</sub>, …, W<sub>m</sub>), where <inline-formula><mml:math id="M6" overflow="scroll"><mml:mrow><mml:msub><mml:mi>W</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mrow><mml:msubsup><mml:mo>∫</mml:mo><mml:mn>0</mml:mn><mml:msub><mml:mi>Y</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msubsup><mml:mrow><mml:mover accent="true"><mml:msub><mml:mi>S</mml:mi><mml:mi>C</mml:mi></mml:msub><mml:mo stretchy="true">^</mml:mo></mml:mover><mml:mo stretchy="false">(</mml:mo><mml:mi>u</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>d</mml:mi><mml:mi>u</mml:mi></mml:mrow></mml:mrow></mml:mrow></mml:math></inline-formula> is the integral of the Kaplan-Meier estimator of residual censoring time C.</p></sec></boxed-text><p id="P30">The inverse weighted estimation algorithm developed in Qin and Shen can be directly linked to existing S-PLUS or R function for the Cox model by adding appropriate weights using “offset” option, <sup><xref rid="R19" ref-type="bibr">19</xref></sup> see <xref rid="BX1" ref-type="boxed-text">Box 1</xref>. Similarly, one can use “PROC PHREG” in SAS with “offset” to include the weight function W. The estimated HR of 0.84 between possible Alzheimer’s disease and other dementia types has the same interpretation as LT model. However, the standard error of HR should be obtained from the bootstrap method, which shows a statistically significant difference between the groups (95% CI 0.73 to 0.95; P=0.03). Given the censoring distributions across two groups are the same in the CSHA study, both the permutation test of Ning et al <sup><xref rid="R18" ref-type="bibr">18</xref></sup> and the traditional logrank test are valid, while both show that patients with possible Alzheimer’s disease had significantly longer survival than the other types of dementia with a p-value of .010 and .018, respectively.</p><p id="P31">Suppose now that we design a prevalent cohort study on Alzheimer’s disease, and the sample size calculation is based on the hazard ratio <italic>θ</italic>=0.84 of overall survival between possible Alzheimer’s disease (POA) and vascular dementia or probable Alzheimer’s disease (VD+PRA). Assume that the sample size ratio between POA and total study sample is similar to that of the CSHA study, i.e., <italic>γ</italic> = 252/818 ≈ 0.31. Consider a follow up <italic>τ</italic> = 6 years, which is the maximum follow up in the CSHA study. Using the prevalent cohort design, a sample size of 818 subjects would have 80% power to detect a hazard ratio of <italic>θ</italic>=0.84 with a significance level of 0.05, assuming that the hazard rate of death is <italic>λ</italic><sub>0</sub> = 0.114 among the subjects with vascular dementia or probable Alzheimer’s disease. In contrast, under the same design considerations, the incidence cohort design would require 2,538 subjects, three times higher than the sample size requirement using the prevalent cohort design.</p></sec>
25091809|None|('method', 0.8773426181680302)|('other', 0.12265738183196981)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">4 Discussion</title>
25091809|None|('method', 0.8773426181680302)|('other', 0.12265738183196981)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P32">Most sample size calculations in clinical trials and incident cohort studies are approximations based on simple parametric distribution assumptions. Similarly, we propose sample size calculation tools for a cross-sectional prevalent cohort design assuming that the failure times follow exponential or Weibull distribution. We also compare the empirical power of the two types of designs with the same total sample sizes and design parameters under commonly used parametric forms such as exponential and Weibull distributions. The prevalent cohort design achieves higher efficiency/power than the incident cohort design with the same total sample size and study duration. The power advantage for the prevalent design is more evident when the hazard ratio of the two groups is small.</p>
25091809|None|('method', 0.8773426181680302)|('other', 0.12265738183196981)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P33">The likelihood for length-biased data is calculated under the assumption that the onset of the initiating event follows a stationary Poisson process <sup><xref rid="R6" ref-type="bibr">6</xref></sup>, which has a connection to queuing theory that may lead to future works. For length-biased data obtained from a prevalent cohort study, the naïve log-rank test is a valid test statistic if the censoring distributions are the same in the exposed and unexposed groups. Otherwise, the naïve log-rank test could inflate the type I error rate. A related cautionary note is that estimating hazard ratio using standard software for the Cox model will be severely biased for length-biased data from a prevalent cohort. Instead, proper estimation methods for length-biased data should be used. <sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R19" ref-type="bibr">19</xref>,<xref rid="R24" ref-type="bibr">24</xref></sup> We demonstrated some existing methodologies using the example of CSHA cohort study.</p>
25091809|None|('method', 0.8773426181680302)|('other', 0.12265738183196981)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P34">Another interesting observation is that a prevalent cohort design will not lead to any improved power if one uses an inefficient test statistic. The conditional test, which is a valid test statistic that has been widely used for analyzing data observed from prevalent cohort studies over the past decades <sup><xref rid="R8" ref-type="bibr">8</xref>,<xref rid="R23" ref-type="bibr">23</xref>,<xref rid="R25" ref-type="bibr">25</xref></sup> leads to substantial loss of power because the information of the backward recurrence time <italic>A</italic> (in <xref rid="F2" ref-type="fig">Figure 2</xref>) is not properly utilized. For the conditional test, the risk set at each failure time is defined to include participants with survival times that extend beyond that time point and truncation times that are shorter than that time point, which results in few summands compared to that for the logrank test. Gains and losses of power are two sides of the same coin in prevalent cohort designs. When using the asymptotically most efficient test statistic for both cohort studies, it is evident that the prevalent cohort design is more efficient than the incident cohort design because the extra “free” information on <italic>A</italic> is properly utilized. Again, the gain in power for the prevalent cohort design depends on the design as well as the use of efficient test statistics.</p>
25091809|None|('method', 0.8773426181680302)|('other', 0.12265738183196981)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P35">Sample size estimations are ubiquitously approximated using methods under simplified parametric assumptions. For a cross-sectional prevalent cohort study, more precise sample size and power estimations may be proposed as a two-stage design. Using the observed truncation times <italic>A</italic>, we may estimate the distribution parameters and the corresponding distribution in the first stage. At the second stage, given the estimated parameters, we can determine the length of the prospective follow-up for a fixed total sample size to achieve the desired power. Alternatively, we may increase the sample size during the prospective follow-up. Moreover, the sample size calculation for parametric distributions other than exponential can be obtained similarly.</p>
25091809|None|('method', 0.8773426181680302)|('other', 0.12265738183196981)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P36">In summary, while efficient statistical analysis methods have been developed to obtain unbiased estimator of hazard ratio and to test the equality of survival distributions using biased data observed from a prevalent cohort study, it is critical to provide practical design tools by estimating the sample size/power for the prospective prevalent cohort study.</p>
25091809|None|('method', 0.9430029392527567)|('other', 0.05699706074724331)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
25091809|None|('method', 0.9430029392527567)|('other', 0.05699706074724331)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Suppl Material</label><media xlink:href="NIHMS626392-supplement-Suppl_Material.docx" orientation="portrait" xlink:type="simple" id="d36e1442" position="anchor"/></supplementary-material>
25092171|None|('method', 0.999991932670482)|('other', 8.067329518015217e-06)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Materials and methods</title>
25092171|2.1. Human atherosclerotic lesion immunohistology and immunoblot analysis|('method', 0.999991932670482)|('other', 8.067329518015217e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1. Human atherosclerotic lesion immunohistology and immunoblot analysis</title><p id="P6">Human atherosclerotic plaques were obtained at endarterectomy (n=12), and non-atherosclerotic carotid arteries from heart transplant donors (n=10), according to protocols pre-approved by the Human Investigative Review Committee of Brigham and Women’s Hospital. Human atherosclerosis serial cryostat sections (6 µm) were stained for CatG (1:200, Calbiochem, San Diego, CA), CD68 (macrophages, 1:700, Dako, Carpinteria, CA). For localization of CatG to cell types rabbit anti-CatG (1:50) antibody mixed with mouse anti-CD68 (1:50, Dako), or anti-CD31 (endothelial cells [ECs], 1:30, Dako), or -α-actin (SMCs, 1:30, Enzo Diagnostics Inc., Farmingdale, NY), or -CD4 (T cells, 1:20, BD Biosciences, San Jose, CA) antibodies. Consequently, sections incubated with mixture of anti-rabbit Alexa 533 (red, 1:500) and anti-mouse Alexa 488 (green, 1:300, both from Invitrogen, Grand Island, NY). Nuclei stained with Dapi (NucBlue® Fixed Cell ReadyProbes® Reagent, Molecular Probes, Eugene, OR) and slides were coverslip with fluorescent mounting medium (Dako). Human carotid atherosclerotic lesions (n=7) and non-atherosclerotic carotid arteries (n=6) were also lysed in a protein lysis buffer containing 10 mM Tris.HCl, (pH 8.0), 1 mM EDTA, 0.5 mM EGTA, 1% Triton, 0.1% Sodium deoxycholate, 0.1% SDS, and 140 mM NaCl. Equal protein from each sample was separated on a 12% SDS-PAGE for immunoblot analysis with rabbit anti-human CatG polyclonal antibody (1:1000, Calbiochem). Mouse anti-actin monoclonal antibody (1:2000, Santa Cruz Biotechnology, Inc., Dallas, TX) was used to ensure equal protein loading.</p></sec>
25092171|2.2. Mouse experimental atherosclerosis|('method', 0.999991932670482)|('other', 8.067329518015217e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.2. Mouse experimental atherosclerosis</title><p id="P7">We crossbred <italic>Ctsg</italic><sup>−/−</sup> mice (C57BL/6/129/SvJ) [<xref rid="R22" ref-type="bibr">22</xref>] with atherosclerosis-prone <italic>Ldlr</italic><sup>−/−</sup> mice (C57BL/6, N11, The Jackson Laboratory, Bar Harbor, ME) to generate <italic>Ldlr</italic><sup>+/−</sup><italic>Ctsg<sup>+/−</sup></italic> breeding pairs to produce <italic>Ldlr</italic><sup>−/−</sup><italic>Ctsg<sup>+/−</sup></italic> mice and their littermate <italic>Ldlr</italic><sup>−/−</sup><italic>Ctsg</italic><sup>+/+</sup> control mice. All mice used in this study were male. To induce atherosclerosis, 6-week-old mice from each group consumed a Western diet (C12108, Research Diets Inc.) for 3 months or 6 months. At each time point, blood pressures were measured and plasma collected. Lesion characterizations for mouse atherosclerosis, including thoracic and abdominal aorta oil-red O staining, aortic arch lesion intima and media areas, lesion macrophages (Mac-3, 1:900, BD Biosciences), T cells (CD4, 1:90, BD Biosciences), MHC class II-positive cells (MHC class-II, 1:250, BD Biosciences), SMCs (α-actin, 1:750, Sigma), collagen (picrosirius red birefringence), elastin (Verhoeff-van Gieson), arch lipid deposition (0.5% oil-red O), and apoptosis (TUNEL, EMD Millipore, Billerica, MA) were performed as described previously [<xref rid="R23" ref-type="bibr">23</xref>]. The 3-mm long aortic arch from the brachiocephalic artery to the ascending artery perpendicular line toward the descending artery was used for atherosclerotic lesion analysis, as previously described [<xref rid="R24" ref-type="bibr">24</xref>]. We captured images digitally; and measured the stained area using computer-assisted image quantification (Image-Pro Plus software, Media Cybernetics), and immunopositive cells were counted manually. All mouse experiments were performed, and data were analyzed in a blinded fashion, by at least three observers. All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals published by the U.S. National Institutes of Health, and were approved by the Harvard Medical School Standing Committee on Animals (protocol # 03759).</p></sec>
25092171|2.3. Mouse plasma ELISA|('method', 0.999991932670482)|('other', 8.067329518015217e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.3. Mouse plasma ELISA</title><p id="P8">Blood samples were collected from <italic>Ldlr</italic><sup>−/−</sup><italic>Ctsg</italic><sup>−/−</sup> mice and their littermate <italic>Ldlr</italic><sup>−/−</sup><italic>Ctsg</italic><sup>+/+</sup> control mice at harvest by retro-orbital venous plexus puncture. Plasma total cholesterol, triglyceride, and HDL were determined using ELISA kits according to the manufacturer’s instructions (Pointe Scientific, Inc., Canton, MI). LDL cholesterol was calculated as follows: serum LDL cholesterol concentration (mg/dl) = total cholesterol – HDL cholesterol – (triglycerides/5). Mouse plasma Ang-II and angiotensin-converting enzyme (ACE) levels were determined using the Ang-II (USCN Life Science Inc., Houston, TX) and ACE (R&amp;D Systems, Minneapolis, MN) ELISA kits, respectively, according to the manufacturers’ instructions. Both albumin and alanine aminotransferase (ALT) levels were determined from plasma samples from mice that consumed a Western diet for 3 or 6 months to assess whether CatG deficiency affected mouse liver functions (Mouse Metabolic Phenotyping Center, Yale University School of Medicine, New Haven, CT).</p></sec>
25092171|2.4. Blood pressure measurement|('method', 0.999991932670482)|('other', 8.067329518015217e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.4. Blood pressure measurement</title><p id="P9">Mouse blood pressures were measured at different time points while consuming a Western diet. To measure blood pressures from live mice, we used the CODA standard non-invasive blood pressure system — the tail-cuff method, according to the manufacturer’s instructions (Kent Scientific Corporation, Torrington, CT). Briefly, mice were trained for 3–5 times before the experiments to confirm that they became accustomed to the tail-cuff procedure. A single investigator recorded blood pressures in a quiet environment without disturbance. At least 30 measurements were obtained from each mouse to determine the mean values of systolic and diastolic blood pressures and heart rate.</p></sec>
25092171|2.5. Human patient population and plasma CatG ELISA|('method', 0.999991932670482)|('other', 8.067329518015217e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>2.5. Human patient population and plasma CatG ELISA</title><p id="P10">A total of 232 patients from Wuhan Union Hospital, Wuhan, China, were enrolled in the study due to symptoms of chest pain or electrocardiogram abnormalities including ST-T abnormalities, and were scheduled to undergo coronary angiography. The local Hospital Review Committee approved the human study protocol, and all patients gave informed consent. 171 of the 232 subjects were diagnosed with coronary heart disease (CHD) with one or more major coronary arteries having ≥50% stenosis; 61 subjects had &lt;50% or no luminal narrowing of the coronary artery, and were selected as non-CHD controls. Among the 171 patients with CHD, 59 were diagnosed with acute myocardial infarction (AMI) due to increased levels of creatinine kinase-MB (twofold higher than the upper reference limit) or troponin-I (fivefold higher than the upper reference limit), ischemic symptoms, or ST-T abnormalities by electrocardiography indicative of ischemia and/or infarction; 67 were diagnosed with unstable angina pectoris (UAP) due to the progression of ischemic symptoms less than 3 months before admission to the hospital; and 45 were diagnosed with stable angina pectoris (SAP) based on predictable exertional chest discomfort more than 3 months before enrollment. Patients who were treated with anti-inflammatory drugs; who had connective tissue disease, thromboembolism, disseminated intravascular coagulation, advanced liver disease, renal failure, malignant disease, or other inflammatory diseases (such as septicemia or pneumonia); who had other heart diseases such as rheumatic heart disease, valvular heart disease, congenital heart disease; who had atrial fibrillation or had a pacemaker, were excluded. Among all (232) selected patients, 6/61 (9.8%) non-CHD, 22/45 (49%) SAP, 37/67 (55%) UAP, and 37/59 (63%) AMI patients received lipid-lowering treatment with statins. Human plasma CatG levels were determined using commercial ELISA kits according to manufacturer’s recommendation (Alpco, Salem, NH).</p></sec>
25092171|2.6. Isolation and modification of LDL and HDL<sub>3</sub>|('method', 0.999991932670482)|('other', 8.067329518015217e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.6. Isolation and modification of LDL and HDL<sub>3</sub></title><p id="P11">Human LDL (d=1.019–1.050 g/ml) and human HDL<sub>3</sub> (d=1.125–1.210 g/mL) were isolated from plasma of healthy volunteers (from the Finnish Red Cross Bloos Service, Helsinki, Finland) by sequential ultracentrifugation in the presence of 3 mM EDTA [<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref>]. Lipoprotein amounts are expressed in terms of their protein concentrations. Lipoproteins (1 mg/ml) were incubated for 18 hours at 37 °C in phosphate-buffered saline with or without 2 mU/ml of human neutrophil CatG (Calbiochem), after which they underwent FPLC analysis using a Superose™ 6 column in an Äkta chromatography system (GE Healthcare) and by monitoring absorbance at 280 nm.</p></sec>
25092171|2.7. Statistical analysis|('method', 0.999991932670482)|('other', 8.067329518015217e-06)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>2.7. Statistical analysis</title><p id="P12">Human plasma results are expressed as percentages or median (minimum, maximum). Differences in frequencies were compared using the chi-square test. Normal Gaussian distribution of the data was verified by the Kolmogorov-Smirnov goodness-of-fit test. Whenever the data were not normally distributed, the Kruskal-Wallis <italic>H</italic> test was used, followed by post hoc analysis (Mann-Whitney <italic>U</italic> test). To analyze the correlation of serum CatG and blood lipids, we used Pearson’s correlation test. To adjust for the impact of statin treatment on the association between plasma CatG and lipid profiles, we performed partial correlation test with the statin treatment as the controlling variable. All mouse data were expressed as mean ± SEM. Due to our small sample sizes and often skewed data distributions, we performed a pairwise non-parametric Mann-Whitney test followed by Bonferroni corrections to examine the statistical significances. SPSS 16.0 was used for analysis.</p></sec>
25092652|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Materials and ethods</title>
25092652|2.1 Materials|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.1 Materials</title><p id="P11">Chemicals used in the mitochondrial isolation procedure were supplied by Sigma-Aldrich (Saint Louis, MO). Unless otherwise stated, all other chemicals were purchased from Fisher Scientific (Pittsburgh, PA).</p></sec>
25092652|2.2 Langendorff mouse heart perfusion|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>2.2 Langendorff mouse heart perfusion</title><p id="P12">All animal experiments were conducted under the Guidelines on Humane Use and Care of Laboratory Animals for Biomedical Research published by the National Institutes of Health (revised 2011). The Institutional Animal Care and Use Committees of Virginia Commonwealth University and the McGuire Veterans Affairs Medical Center approved the study. Male 8-10 week old C57BL/6 mice (24.6 ± 0.9 g) were anesthetized with pentobarbital sodium (0.1 mg/g i.p.) and anti-coagulated with heparin (1000 U/g i.p.). Hearts were excised and retrograde perfused via the aorta in the Langendorff mode with modified Krebs-Henseleit buffer (115 mM NaCl, 4 mM KCl, 2 mM CaCl<sub>2</sub>, 25 mM NaHCO<sub>3</sub>, 1.1 mM MgSO<sub>4</sub>•H<sub>2</sub>O, 0.9 mM KH<sub>2</sub>PO<sub>4</sub>, and 5.5 mM glucose; pH 7.4) oxygenated with 95% O<sub>2</sub>/5% CO<sub>2</sub> [<xref rid="R30" ref-type="bibr">30</xref>]. Cardiac function was monitored with a balloon inserted into the left ventricle and data were recorded digitally using the Powerlab recording system (AD Instruments, Colorado Springs, CO). After 15 min of stabilization by buffer perfusion, experimental hearts were either subjected to 45 min control perfusion (TC), or 25 min global stop-flow ISC followed by 30 min REP. Hearts were harvested for mitochondrial isolation [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R31" ref-type="bibr">31</xref>] at the end of experiment.</p></sec>
25092652|2.3 Isolation of mitochondria, cytosol, and heart tissue homogenates|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>2.3 Isolation of mitochondria, cytosol, and heart tissue homogenates</title><p id="P13">The heart was washed and placed in pre-chilled modified Chappell-Perry 1 (CP1) buffer (pH 7.4) with the following composition: 100 mM KCl, 50 mM 3-(N-morpholino) propanesulfonic acid (MOPS), 1 mM ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid (EGTA), 5 mM MgSO<sub>4</sub>·7H<sub>2</sub>O, and 1 mM adenosine 5′-triphosphate disodium (ATP). Next, the heart tissue was dried with Whatman filter paper, weighed, and then thoroughly minced in a chilled glass beaker. The minced heart tissue was transferred to a chilled glass tube for homogenization. The tissue was homogenized in 3 mL of CP1 buffer using a polytron tissue blender (Kinematica, Bohemia, NY) for 2.5 s at a rheostat setting of 10,000 rpm. 50 μL of the homogenate was saved as the heart tissue extract. The remaining polytron homogenate was centrifuged at 6,000 × g for 10 min at 4°C and supernatant was saved as a crude cytosol for further purification. The homogenate pellet was re-suspended in 3 ml of CP1 buffer and incubated with 5 mg/g (wet weight) trypsin (Sigma-Aldrich, Saint Louis, MO) for 15 min at 4 °C. Next, 3 mL of CP2 buffer [CP1 buffer containing 0.2% bovine serum albumin (BSA) (Sigma-Aldrich, Saint Louis, MO)] was added to block the trypsin digestion. Digested tissue was then homogenized (two strokes) with a tight Teflon pestle/glass tube homogenizer set at steady stirring speed of 600 rpm. The remaining homogenate was centrifuged at low speed 500 × g for 10 min and the supernatant was again centrifuged at 3000 × g for 10 min at 4 °C. The pellet containing the mitochondria was washed with 2 mL of KME buffer [100 mM KCl, 50 mM MOPS, and 0.5 mM EGTA] and centrifuged at 3000 × g for 10 min. Lastly, the mitochondrial pellet was re-suspended in 80-100 μL of KME and the protein concentration was measured using the Lowry method [<xref rid="R31" ref-type="bibr">31</xref>].</p></sec>
25092652|2.4 Measurement of oxidative phosphorylation in intact mitochondria|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>2.4 Measurement of oxidative phosphorylation in intact mitochondria</title><p id="P14">Oxidative phosphorylation in freshly isolated mitochondria was measured using an oxygen electrode at 30°C (Strathkelvin Instruments, Glasgow, Scotland) as previously described [<xref rid="R32" ref-type="bibr">32</xref>] with minor modifications [<xref rid="R5" ref-type="bibr">5</xref>, <xref rid="R30" ref-type="bibr">30</xref>, <xref rid="R31" ref-type="bibr">31</xref>]. Glutamate (20 mM) + malate (5 mM) (complex I substrate) or succinate (20 mM) plus 7.5 uM rotenone (complex II substrate) stimulated respiration was performed using 150 ug mitochondrial protein. TMPD (N,N,N’,N’ tetramethyl p-phenylenediamine, 1 mM)-ascorbate (10 mM, complex IV substrate via cytochrome <italic>c</italic>) + 7.5 uM rotenone was used to measure respiration selectively through cyt <italic>c</italic> and cytochrome oxidase using 50 μg of mitochondrial protein. State 3 respiration was measured by the rate of oxygen consumption following the addition of 0.2 mM ADP (final concentration) followed by state 4 respiration. Finally, the maximal rate of ADP-stimulated respiration was measured in the presence of 2 mM ADP. Uncoupled respiration was measured using 0.3 mM dinitrophenol (DNP).</p></sec>
25092652|2.5 In-vitro modulation of electron transport chain|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>2.5 In-vitro modulation of electron transport chain</title><p id="P15">One mg of isolated mitochondria was incubated with 20 mM succinate + 7.5 μM rotenone with or without 10 mM TTFA, 10 mM antimycin A or 2 mM azide. Incubation studies of mitochondria were carried out in MSM/EDTA buffer, pH 7.4 (220 mM mannitol, 70 mM sucrose, 5 mM MOPS, 2 mM EDTA) for 50 min at 37 °C with gentle rotation. Then, the mitochondrial protein was spun down and the pellet was re-suspended in immunoprecipitation buffer provided with the kit (Invitrogen, Carlsbad, CA). The production and release of H<sub>2</sub>O<sub>2</sub> from mitochondria was measured using Amplex Red as previously described [<xref rid="R33" ref-type="bibr">33</xref>]. Oxidative stress in the mitochondrial matrix was assessed by measurement of the oxidatively sensitive enzyme aconitase [<xref rid="R34" ref-type="bibr">34</xref>, <xref rid="R35" ref-type="bibr">35</xref>].</p></sec>
25092652|2.6 Immunoprecipitation of cytochrome <italic>c</italic>|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>2.6 Immunoprecipitation of cytochrome <italic>c</italic></title><p id="P16">Cyt <italic>c</italic> was immunoprecipitated from isolated mitochondria using Dynabeads® Protein G immunoprecipitation (IP) kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol. Briefly, 50 μL (1.5 mg) of Dynabeads® and 8 μg of anti-mouse cyt <italic>c</italic> antibody (BD Biosciences San Jose, CA), diluted in antibody binding and washing buffer [PBS buffer + 0.02% Tween-20], were mixed and incubated at RT for 120 min. 0.5 mg of mitochondrial protein suspended in IP buffer (Invitrogen, Carlsbad, CA) was added to the Dynabeads®-antibody complex and incubated with rotation for 120 min. at RT. The elution buffer [50 mM glycine, pH 2.8] was then added to resuspend the Dynabeads®-antibody-antigen complex and incubated with rotation for 5 min at RT. Finally, the supernatant containing eluted antibody and antigen was transferred to a clean tube. For the eluted protein to be used for Western blotting, the pH of the eluate was adjusted by adding 1 μL of 2.8 M Tris pH 8.5 for 45 μL of eluate.</p></sec>
25092652|2.7 Western blot analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S14" sec-type="methods"><title>2.7 Western blot analysis</title><p id="P17">Equal amounts of protein were loaded and separated using 4-20% gradient Tris-glycine pre-cast gels (Invitrogen, Carlsbad, CA) and transferred to Immobilon-P PVDF (polyvinyldifluoridine) membranes (Millipore, Billerica, MA). The blots were then incubated for 1 h at RT with 5% (w/v) non-fat dry milk (Bio-Rad, Hercules, CA) in TBS-Tween buffer (10 mM Tris, pH 7.5, 150 mM NaCl, and 0.1% Tween-20). Next, the membranes were incubated overnight at 4 °C with a 1:2500 dilution of mouse anti-cytochrome c (BD biosciences, San Jose, CA; Cat. #556433) or 1:1000 of polyclonal anti-methionine sulfoxide antibody (Cayman chemicals, Ann Arbor, MI; Cat. # 600161) prepared either in 5% BSA/TBS-T or 0.5% (w/v) non-fat dried milk/TBS. Next day, the blots were incubated with a 1:50,000 dilution of anti-mouse or 1: 10000 anti-rabbit IgG F(ab)<sub>2</sub> fragments conjugated with Horse Radish Peroxidase (HRP) in 5% BSA/TBS-Tween buffer for 1 h. The immunoreactive proteins were visualized using Amersham ECL Plus western blotting detection reagents (GE Healthcare Lifesciences, Piscataway, NJ) or SuperSignal Femto maximum sensitivity substrate kit (Thermo Fisher Scientific Inc., Rockford, IL). Protein bands on western blot were quantified by densitometric analysis using ImageJ software (NIH, Bethesda, MD).</p></sec>
25092652|2.8 In-solution digestion and mass spectrometry analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S15" sec-type="methods"><title>2.8 In-solution digestion and mass spectrometry analysis</title><p id="P18">In-solution digestion of immunoprecipitated cyt <italic>c</italic> was initiated by incubating 40 μL of the isolated protein solution with 5 μl of 0.5 M tris (2-carboxyethyl) phosphine (TCEP) for 1 h at 37 °C, followed by incubation with 15 μL of 55 mM iodoacetamide for 1 h at 37 °C. 100 μl of digestion buffer [Chymotrypsin: 500mM Tris HCl (pH 8.0), 10mM calcium chloride] was added and the reaction was allowed to proceed at 37 °C for 1 day with gentle shaking. 200 μL of 10% TFA and 50 μL of acetonitrile were added to stop the reaction and the solution was subjected to reversed-phase chromatography for solid-phase extraction of peptides. The resulting peptide mixture was evaporated to dryness and re-suspended in 30 μL of 95/5 0.1% TFA (aq)/acetonitrile before being subjected to LC-MS/MS analysis on a system centered around a Thermo LTQ XL linear ion trap instrument.</p><p id="P19">Peptide separation was performed on a CTICAP5150100 reversed-phase C18 column (5 μm particles, 150 μm × 100 mm, 300 Å pores) (Column Technology, Fremont, CA) at a flow rate of ~0.5 μL min<sup>−1</sup>. The injection volume was 20 μL, with a CapTrap (Michrom, Auburn, CA) trapping column being used to reduce sample-loading time. Mobile phase A was 0.1% formic acid in water while B was 0.1% formic acid in methanol. The gradient program was initiated with a rapid increase from the equilibration composition of 5% B to 15% B over 5 min followed by slower increases to 80% B over 70 min and then to 95% B over 15 min. Electrospray ionization was used for mass spectrometry interfacing. The instrument was programmed to cycle between determining the ten most intense incoming ions and recording tandem mass spectra for each of these ions, ions picked for fragmentation twice in a 30 s window were excluded for the next 180 s. Peptides were identified from fragmentation patterns using the version of X! Tandem (2011.12.01) integrated into version 4.6.3 of the Trans-Proteomic Pipeline software package (Institute for Systems Biology, Seattle, WA). The protein sequence database used in the search consisted of the NCBI Reference Sequence version of the complete mouse proteome (29958 proteins; downloaded from <ext-link ext-link-type="ftp" xlink:href="ftp://ftp.ncbi.nlm.nih.gov/refseq/M_musculus/mRNA_Prot">ftp://ftp.ncbi.nlm.nih.gov/refseq/M_musculus/mRNA_Prot</ext-link> on October 16, 2013) and 115 common contaminant proteins (Global Proteome Machine, common Repository of Adventitious Proteins; downloaded from <ext-link ext-link-type="ftp" xlink:href="ftp://ftp.thegpm.org/fasta/cRAP">ftp://ftp.thegpm.org/fasta/cRAP</ext-link> on October 16, 2013).</p></sec>
25092652|2.9 LC-MS/MS analysis of cardiolipin|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S16" sec-type="methods"><title>2.9 LC-MS/MS analysis of cardiolipin</title><p id="P20">Isolated mitochondria (1 mg) in 50 μL of 100 mM potassium phosphate buffer were mixed with 1,2-dipalmitoyl-sn-glycero-3-phospho-N-methylethanolamine (internal standard) and extracted with 1 mL of chloroform:methanol, 2:1 containing 2 mM butylated hydroxytoluene as an antioxidant according to the procedure [<xref rid="R36" ref-type="bibr">36</xref>]. The lipids were separated by reversed-phase LC using a Supelco 2.1 (i.d.) x 150 mm Ascentis C18 column (Sigma, St. Louis, MO) and a binary solvent system at a flow rate of 0.3 mL/min with a column temperature of 60 °C. Prior to injection of the sample, the column was equilibrated for 0.5 min with a solvent mixture of 30% mobile phase A (CH<sub>3</sub>OH/H<sub>2</sub>O, 50/50, v/v, with 0.25% of triethylamine and glacial acetic acid) and 70% mobile phase B (IPA/ H<sub>2</sub>O), 90/10, v/v, with 0.25% of triethylamine and glacial acetic acid). After sample injection (typically 40 μL), the A/B ratio was maintained at 30/70 for 2 min, followed by a linear gradient to 100% B over 7 min, which was held at 100% B for 4.3 min, followed by a 0.6 min gradient return to 30/70 A/B. Cardiolipin peaks were quantified during each run by multiple reaction monitoring (MRM) analysis, and the structure was confirmed via a MS2 scan within the linear ion trap during the elution of each peak [<xref rid="R36" ref-type="bibr">36</xref>]. Cardiolipin peaks were summed to yield the total cardiolipin measurement.</p></sec>
25092652|2.10 Statistical analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S17" sec-type="methods"><title>2.10 Statistical analysis</title><p id="P21">Parameters were expressed as mean±standard error of the mean (SEM). The data consisting of two groups were analyzed by two-tailed Student’s t-test. Differences among multiple groups were compared by one-way ANOVA analysis with post hoc comparisons performed using the Student-Newman-Keuls test. All analyses were executed using SigmaPlot ver.11 software (Systat Software Inc., Chicago, IL). p&lt;0.05 was considered statistically significant.</p></sec>
25092652|None|('method', 0.9389497941436695)|('other', 0.06105020585633042)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
25092652|None|('method', 0.9389497941436695)|('other', 0.06105020585633042)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD2"><label>1</label><media xlink:href="NIHMS624724-supplement-1.doc" orientation="portrait" xlink:type="simple" id="d36e1319" position="anchor"/></supplementary-material>
25092800|None|('method', 0.9999096394603565)|('other', 9.036053964357136e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
25092800|None|('method', 0.9999096394603565)|('other', 9.036053964357136e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">The structure of SAFMO was solved by X-ray crystallography using the JCSG high-throughput structural biology pipeline. Crystals were grown in 1.6M (NH<sub>4</sub>)<sub>2</sub>SO<sub>4</sub>, 0.1M MES, pH 6.0, using sitting drop vapor diffusion method at 4 degree Celsius. Equal volume (200 nL) of protein (16.8 mg/ml) and well solution were mixed and equilibrated against 50 uL of reservoir solutions. Diffraction data were collected at beamline 11-1 at SSRL (Stanford Synchrotron Radiation Lightsource), processed with mosflm, integrated with scala. A total of 8 Se sites were initially identified in SHELX and then refined in SHARP. Density modification was performed with Solomon in SHARP. A total of 290 out of 368 amino acids were traced and docked using ARP/wARP. Structure was refined with REFMAC5. Data collection and refinement statistics are listed in <xref rid="T1" ref-type="table">Table I</xref>. Conservation of SAFMO residues was assessed by ConSurf[<xref rid="R5" ref-type="bibr">5</xref>]. The electrostatics potential surfaces were calculated with PDB2PQR and APBS. Molecular dockings were performed with GOLD.</p>
25092800|None|('method', 0.9620857880562437)|('other', 0.037914211943756285)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
25092800|None|('method', 0.9620857880562437)|('other', 0.037914211943756285)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Supp Material</label><media xlink:href="NIHMS619984-supplement-Supp_Material.pdf" orientation="portrait" xlink:type="simple" id="d36e328" position="anchor"/></supplementary-material>
25100359|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PATIENTS AND METHODS</title>
25100359|Subjects|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" sec-type="subjects" id="S8"><title>Subjects</title><p id="P11">As described elsewhere, healthy men over 65 years of age were recruited by direct mailings to alumni of the University of Pennsylvania and Temple University and by newspaper and television advertisements (<xref rid="R22" ref-type="bibr">22</xref>–<xref rid="R23" ref-type="bibr">23</xref>). The study included men who had a serum T concentration at least one SD below the mean for healthy young men (&lt;475 ng/dL; 16.5 nmol/L) (<xref rid="R22" ref-type="bibr">22</xref>). A total of 108 men met these criteria and were randomized to receive a T or placebo patch in a double blind fashion for 36 months. Ninety-six subjects completed 36 months of treatment. Other inclusion and exclusion criteria are described elsewhere (<xref rid="R22" ref-type="bibr">22</xref>).</p><p id="P12">The study reported here was performed 10 years later using banked serum specimens from 70 of these men, 42 in the T treatment group and 28 in placebo group, who had sufficient sera remaining for assays. Time points for assays were baseline, 3, 6, 9, 12, 18, 24, 30 and 36 months. The flow diagrams for the original RCT and the post hoc data used in the current analysis of the RCT are reported elsewhere (<xref rid="R22" ref-type="bibr">22</xref>). The study protocol was approved by local ethic committee. All participants received a detailed description of the purpose and design of the study and signed informed participation consent.</p></sec>
25100359|Study design|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Study design</title><p id="P13">Testosterone was administered by scrotal patch (Testoderm; Alza Corp., Palo Alto, CA, USA); placebo patches were identical in appearance to testosterone patches. Each subject was asked to wear a patch at all times except when bathing, change the patch once a day, and shaved the scrotum twice a week. Each subject began by wearing a 60-cm<sup>2</sup> testosterone patch, which delivers approximately 6 mg testosterone/24 h, or a 60-cm<sup>2</sup> placebo patch. The data manager reviewed serum T concentrations every 3 months and directed a decrease in patch size to 40 cm<sup>2</sup> if a man's serum T was above 1000 ng/dL (34.7 nmol/L) or re-education in patch technique if a man in the T-treated group had a value less than 250 ng/dL above baseline. To maintain the blinding in both the above manipulations, the data manager directed that a man in the placebo-treated group be treated similarly.</p></sec>
25100359|Storage of the samples|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Storage of the samples</title><p id="P14">The samples were kept frozen at all times at −80°C. The freeze-thaw cycles that affect some analytes, but not others were very limited.</p></sec>
25100359|Hormonal and Cytokine Measurements|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Hormonal and Cytokine Measurements</title><p id="P15">Testosterone was measured together with the inflammatory markers in 2008. Total T was assessed by electrochemiluminescence immunoassay with minimum detectable concentration (MDC) of 2 ng/dL and interassay coefficient of variation (CV) &lt;10%. C-Reactive protein (CRP) was assessed by Siemens BNII Nephelometry with MDC of 0.146 mg/L and interassay CV less than 5%. Interleukin 6 (IL-6), soluble IL-6 receptor, (sIL6r), soluble gp130 (sgp130) and tumor necrosis factor receptor-1 (TNFR1) were assessed by ELISA kits provided by R&amp;D systems. The MDC of IL-6 was 0.156 pg/ml and the interassay CV was less than 12 %. The MDC of sIL6r was 3120 pg/ml and interassay CV less than 14%. The MDC of sgp130 was 25 ng/ml and interassay CV less than 9%. The MDC of TNFR1 was 78 pg /ml and interassay CV less than 6%. TNF-alpha was assayed by Bio-Rad Luminex Flow Cytometry provided by Millipore Panel B. The MDC was 0.64 pg/ml and interassay CV less than 10%.</p></sec>
25100359|Body composition|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Body composition</title><p id="P16">Body composition was determined by Dual energy X-ray Absorptiometry (DXA) using a DPX scanner (Lunar Corp., Madison, WI) with acquisition software versions 3.1–3.61 and body composition software version 1.3.</p></sec>
25100359|Statistical Analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>Statistical Analysis</title><p id="P17">Variables were reported as means ± SD or medians and interquartile range, as appropriate. For measures not normally distributed, log-transformed values were used in the analyses. Differences in baseline characteristics across experimental groups were analyzed using independent sample t tests. Changes within groups from baseline to treatment end were evaluated with paired <italic>t</italic> tests.</p><p id="P18">The association between treatment and change in inflammatory markers over time was examined using random-effect regression analyses, modeling an unstructured covariance matrix with intercept and slope as random effects.</p><p id="P19">Random-effects models were valuable in this context allowing the detection of variation between subjects and autocorrelation between repeated measurements of the same participants over time, giving greater flexibility to model time effects, and handling missing data. The different inflammatory marker measures were entered as dependent variables in separate analyses.</p><p id="P20">The effect of the interaction between treatment and time has been evaluated by introducing a treatment time interaction term in the mixed models (already including the main terms of treatment and time) in order to test the change over time in inflammatory markers according to treatment. Finally, in order to adjust the results for multiple testing, the significance of the treatment*time interaction terms was additionally evaluated using False Discovery Rate (FDR) q (<xref rid="R24" ref-type="bibr">24</xref>).</p><p id="P21">All analyses were performed using SAS (v. 9.1; SAS Institute, Inc., Cary, NC, USA). Significance level was set at p &lt; 0.05.</p></sec>
25100400|None|('method', 0.999981292236821)|('other', 1.8707763178961283e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CASE REPORT</title>
25100400|None|('method', 0.999981292236821)|('other', 1.8707763178961283e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P5">A 61-year-old Chinese woman underwent a liver transplant in November 2012 for cirrhosis secondary to hepatitis C. Her past medical history was notable for portopulmonary hypertension, leukocytoclastic vasculitis, hyperlipidemia, and type 2 diabetes mellitus (T2DM). She was diagnosed with T2DM several years prior to transplant and was managed with glyburide alone. Her diabetic control varied due to her liver disease, and her hemoglobin A<sub>1c</sub> (HbA<sub>1c</sub>) level was generally between 6.5 and 8.0%. In patients with cirrhosis, glycemic control is frequently unsatisfactory for several reasons, including impaired glucose homeostasis and impaired glucagon catabolism, which is accompanied by an increased risk of hypoglycemia due to decreased hepatic insulin extraction and decreased hepatic glycogen stores (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>). In addition, treatment of diabetes in patients with cirrhosis is complex for several reasons, including malnutrition, impaired ability to metabolize certain oral antidiabetic drugs, hepatotoxicity of certain oral antidiabetic drugs, and the risk of hypoglycemia (<xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R2" ref-type="bibr">2</xref>).</p>
25100400|None|('method', 0.999981292236821)|('other', 1.8707763178961283e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P6">Following her transplant, the patient required insulin for several months to achieve glycemic control. Her fingerstick glucose levels were closely monitored to assist with insulin titration, as her immunosuppressant regimen (including prednisone) was often changed. Once her prednisone was tapered to a maintenance dose of 5 mg, she was able to transition off insulin to metformin and glyburide. On this regimen, the patient reported fasting glucose levels of 120 to 160 mg/dL, yet her HbA<sub>1c</sub> decreased from 7.1 to 4.9%. Her metformin and glyburide doses were being reduced based on HbA<sub>1c</sub> results approximately every 6 weeks. Glyburide was stopped based on an HbA<sub>1c</sub> of 4.3%; however, the patient was reporting fasting glucose levels of 160 to 184 mg/dL and pre-dinner glucose levels of 270 to 285 mg/dL. It became increasingly apparent that there was a discordance between her fingerstick glucoses and HbA<sub>1c</sub> levels. Repeat testing showed a fructosamine level of 470 <italic>μ</italic>mol/L (range, 190 to 270 <italic>μ</italic>mol/L), fasting glucose level of 140 mg/dL, and HbA<sub>1c</sub> of 4.2% (<xref rid="T1" ref-type="table">Table 1</xref>).</p>
25100400|None|('method', 0.999981292236821)|('other', 1.8707763178961283e-05)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">An endocrinology eConsult was ordered. Review of the medical records revealed that the patient was started on dapsone 6 months earlier. Prior to dapsone, the patient’s HbA<sub>1c</sub> on insulin alone was 7.1%. One month after initiation of dapsone, her HbA<sub>1c</sub> was 4.9% on metformin and glyburide. It was felt that the falsely low HbA<sub>1c</sub> was due to hemolysis induced by dapsone therapy. Dapsone was stopped.</p>
25100400|Literature Search|('method', 0.999981292236821)|('other', 1.8707763178961283e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6" sec-type="background"><title>Literature Search</title><p id="P8">A systematic review of the literature was performed. The terms “dapsone and hemoglobin A<sub>1c</sub>” were entered into PubMed to search for relevant articles. Twelve articles were returned in the search results. All 12 articles and their references were reviewed.</p></sec>
25101972|None|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
25101972|Materials|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5" sec-type="materials"><title>Materials</title><p id="P9">CD11a (LFA-1) peptide was purchased from Abcam, Inc. (Cambridge, MA). Monoclonal antibody against human ICAM-1 was purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Polyclonal ICAM-1-neutralizing antibody was purchased from EMD Chemicals, Inc. (San Diego, CA). PE-conjugated human ICAM-1 antibody was purchased from eBioscience, Inc. (San Diego, CA). Antibodies against Notch1, NICD1, β-actin, phosphorylated NF-κB p65 and total NF-κB p65 were purchased from Cell Signaling, Inc. (Beverly, MA). The antibody against phosphorylated NF-κB p65 identifies the phosphorylation of Ser536. Antibody against BMP-2 was purchased from Prosci, Inc. (Poway, CA). Medium 199 was purchased from Lonza (Walkersville, MD). Recombinant Jagged1 and BMP-2 ELISA kit were purchased from R&amp;D System (Minneapolis, MN). Jagged1 ELISA kit was purchased from Uscn Life Science Inc. (Germany). Kit for NF-κB DNA-binding assay was purchased from Active Motif (Carlsbad, CA ). Cell lysis buffer was purchased from Thermo Fisher Scientific (Rockford, IL). LPS (E. coli 0111:B4) and all other chemicals and reagents were purchased from Sigma-Aldrich Chemical Co (St Louis, MO).</p></sec>
25101972|Cell Isolation and Treatment|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Cell Isolation and Treatment</title><p id="P10">Normal aortic valve leaflets were collected from the explanted hearts of 6 patients undergoing heart transplantation (4 males and 2 females, mean age 61±7.2 years). All patients gave written consent for the use of their heart valves for this study. This study was approved by the Institutional Review Board of the University of Colorado Denver.</p><p id="P11">AVICs were isolated from each of the aortic valve leaflets, and individual isolate was cultured using a previously described method [<xref rid="R7" ref-type="bibr">7</xref>]. Briefly, valve leaflets were subjected to sequential digestions with collagenase to eliminate endothelial cells and release interstitial cells, and then interstitial cells were collected by centrifugation. Interstitial cells were cultured in M199 growth medium containing penicillin G, streptomycin, amphotericin B and 10% fetal bovine serum. When cell culture reached 80 to 90% confluence, cells were subcultured on plates and chamber slides for the experiments. Cells from passages 4 to 6 were used for this study.</p><p id="P12">Cells were stimulated with LPS (0.05 µg/ml) for 1 to 8 h to up-regulate the levels of ICAM-1 on cell surfaces. Cells were treated with LFA-1 for 24 h, with or without prior to stimulation with LPS, to assess the effect of this ICAM-1 ligand on BMP-2 expression. To determine the role of ICAM-1 in the effect of LFA-1, cells were treated with ICAM-1-neutralizing antibody (10 µg/ml) prior to LFA-1 treatment.</p><p id="P13">Ligation of ICAM-1 by antibody cross-linking was performed to confirm the role of ICAM-1 in the induction of BMP-2 expression, using the method described previously [<xref rid="R24" ref-type="bibr">24</xref>–<xref rid="R27" ref-type="bibr">27</xref>]. Briefly, cells were incubated with 15 µg/ml of mouse monoclonal antibody against human ICAM-1 at 37°C for 60 minutes, and control cells were incubated with 15 µg/ml of isotype-matching mouse IgG. Following incubation, cells were washed three times with medium and subsequently incubated with 50 µg/ml of anti-mouse IgG for 24 h.</p><p id="P14">Cells were treated with LFA-1 for 2 to 8 h to assess the effect of ICAM-1 ligation on Notch1 activation, Jagged1 release and NF-κB activation. Specific NF-κB inhibitor (SN50; 100 µmol/L) was added to culture medium 30 minutes before the addition of LFA-1 to determine the role of NF-κB in the induction of BMP-2 expression. To determine the role of Notch1 in NF-κB phosphorylation and BMP-2 expression, γ-secretase inhibitor DAPT (50 µmol/L) was added 30 minutes prior to addition of LFA-1.</p></sec>
25101972|Immunofluorescent Staining|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Immunofluorescent Staining</title><p id="P15">Immunofluorescent staining was applied to character cell surface ICAM-1 expression as described previously [<xref rid="R28" ref-type="bibr">28</xref>]. After permeabilization with a methanol/acetone mixture, cells on chamber slides were fixed in 4% paraformaldehyde, incubated with a rabbit polyclonal antibody against human ICAM-1 overnight at 4°C. After washing with PBS, cells were incubated with Cy3-tagged secondary antibody against the primary antibody (imaged on the red channel). Nuclei were stained with bis-benzimide (4′,6- diamidino-2- phenylindole, imaged on the blue channel). Microscopy was performed with a Leica DMRXA digital microscope (Leica Mikroskopie und Systeme GmbH, Wetzlar, Germany) equipped with Slidebook software (I. I. I. Inc, Denver, CO).</p></sec>
25101972|Flow cytometry|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Flow cytometry</title><p id="P16">For direct immunofluorescence staining, untreated or LPS-treated cells (2×10<sup>6</sup> cells/ml) were pre-incubated in 5% BSA to block non-specific binding. The cells were washed twice with PBS containing 1% BSA and 0.02% sodium azide, and then incubated with 10 µl of PE-conjugated monoclonal antibody against ICAM-1 or PE- conjugated non-immune IgG at 4 °C for 30 minutes, and analyzed by a flow cytometer (Beckman Coulter FC500, Becton Dickinson, Franklin Lakes, NJ, USA).</p></sec>
25101972|Immunoblotting|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Immunoblotting</title><p id="P17">Immunoblotting was applied to analyze ICAM-1, BMP-2, NICD1, β-actin, phosphorylated NF-κB p65 and total NF-κB p65. Cells were lysed in a sample buffer (100 mM Tris-HCl, pH 6.8, 2% SDS, 0.02% bromophenol blue and 10% glycerol). Protein samples were separated on gradient (4–20%) minigels and transferred onto nitrocellulose membranes (Bio-Rad Laboratories, Hercules, California). The membranes were blocked with 5% non-fat dry milk solution for 1 h at room temperature. The blocked membranes were incubated with a primary antibody against the protein of interest. After washing with TPBS (PBS containing 0.05% Twen 20), the membranes were incubated with a peroxidase-linked secondary antibody specific to the primary antibody. Following further washes, membranes were treated with enhanced chemiluminescence reagents. Then the membrane was exposed on X-ray film. Image J was used to assess band density.</p></sec>
25101972|NF-κB DNA-binding assay|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>NF-κB DNA-binding assay</title><p id="P18">NF-κB p65 DNA-binding activity in cell lysate was measured by an assay kit according to the manufacturer’s instructions. The kit contains 96-well plates to which oligonucleotides containing the NF-κB binding site are immobilized. Activated NF-κB binds to the oligonucleotides and is detected with a specific antibody. The amount of active NF-κB was determined using a microplate reader.</p></sec>
25101972|ELISA for BMP-2 and Jagged1|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>ELISA for BMP-2 and Jagged1</title><p id="P19">Cell culture supernatants were collected. Levels of BMP-2 and Jagged1 were determined using ELISA kits as described previously [<xref rid="R28" ref-type="bibr">28</xref>].</p></sec>
25101972|ALP activity staining|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>ALP activity staining</title><p id="P20">Histochemical staining for alkaline phosphatase activity was performed as previously described [<xref rid="R29" ref-type="bibr">29</xref>]. Briefly, cell monolayers were washed with PBS and fixed for 10 minutes in 4% paraformaldehyde, followed by incubation at room temperature for 30 minutes with a mixture of 0.1 mg/ml of naphthol AS-MX phosphate, 0.5% N,N-dimethylformamide, 2 mM MgCl<sub>2</sub>, and 0.6 mg/ml of fast blue BB salt in 0.1 M Tris-HCl, pH8.5. Excessive dye was removed by washing with PBS. ALP activity staining was examined and photographed with a Nikon Eclipse TS100 microscope (Tokyo, Japan).</p></sec>
25101972|Alizarin red S staining|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>Alizarin red S staining</title><p id="P21">Alizarin red S staining for calcium deposits was performed as described previously [<xref rid="R8" ref-type="bibr">8</xref>, <xref rid="R29" ref-type="bibr">29</xref>, <xref rid="R30" ref-type="bibr">30</xref>]. Briefly, cell monolayers were washed three times with PBS and fixed for 10 min with 4% paraformaldehyde. Fixed cells were incubated with 0.2% alizarin red S solution (pH 4.2) for 30 min. Excessive dye was removed by washing with distilled water. Alizarin red S staining was examined and photographed with a Nikon Eclipse TS100 microscope (Tokyo, Japan). To quantitatively analyze Alizarin red stain, Alizarin red S stains were bleached with 10% acetic acid at 85 °C and assessed spectrophotometrically at 450 nm [<xref rid="R31" ref-type="bibr">31</xref>].</p></sec>
25101972|Statistical analysis|('method', 0.9999870403228307)|('other', 1.295967716936666e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S14"><title>Statistical analysis</title><p id="P22">Data are presented as mean ± standard error (SE). Comparisons between groups were performed using StatView software (Abacus Concepts, Calabasas, CA) with one-way analysis of variance (ANOVA) with the post hoc Fisher test. A difference was considered significant at <italic>P</italic>≤0.05. Significant differences were confirmed with Mann-Whitney non-parametric test.</p></sec>
25102470|None|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Materials and Methods</title>
25102470|Chemicals|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>Chemicals</title><p id="P6">Dulbecco’s Modification of Eagle’s Medium (DMEM, with 4.5 g/L glucose, L-glutamine, and sodium pyruvate), Dulbecco’s Phosphate-Buffered Saline (DPBS), Fetal Bovine Serum (FBS), Trypsin, and Penicillin-Streptomycin were all purchased from Mediatech, Inc. (Manassas, VA). Plasmocin™ was obtained from InvivoGen (San Diego, CA). FBS was ultra-centrifuged for 10 hours at 120,000 × g to remove contaminating exosomes. All media was filtered with 0.22 μm low protein binding cellulose acetate filter from Thermo Fisher Scientific, Inc. (Rockford, IL) before use. MCF-7 cells and PC3 cells were purchased from ATCC. H460 and ARPE-19 cell lines were a gift from Dr. Uday Kompella. 16HBE cells were a generous gift from Dr. Brian Day. SK-Mel-5 and MDA-MB-231 cells were a gift from Dr. David Ross. WPMY cells were a gift from Dr. Isabel Schlaepfer. Uryanl Acetate was ordered from Electron Microscopy Sciences (Hatfield, PA). Formvar/carbon-coated EM grids were made at the University of Colorado, Denver Electron Microscopy Core. Sodium phosphate monobasic monohydrate, sodium phosphate dibasic and bis-tris (Bis(2-hydroxyethyl)-amino-tris(hydroxymethyl)-methane) were purchased from Sigma-Aldrich (St. Louis, MO). Complete Mini EDTA-Free Protease inhibitor cocktail tablets were purchased from Roche (Indianapolis, IN). Anti-calnexin was purchased from Enzo Life Sciences (Farmingdale, NY). Anti-cytochrome C was purchased from Bio Legend (San Diego, CA). Anti-HSP70 was purchased from Cell Signalling Technology (Danvers, MA). Anti-HSP90 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-CD63 and Anti-CD9 were purchased from Abcam (Cambridge, MA). The chemiluminescent kit, ECL™ Plus Western Blot Detection System and both secondary antibodies, ECL™ Anti-mouse IgG horseradish peroxidase linked F(ab′)<sub>2</sub>, and ECL™ Anti-rabbit IgG horseradish peroxidase linked F(ab′)<sub>2</sub> were obtained from GE Healthcare (UK Little Chalfont Buckinghamshire). Carnation powdered milk was purchased from Nestle (Solon, OH). Millipore Immobilon Polyvinylidene Fluoride (PVDF) Transfer Membranes were purchased from Thermo Fisher Scientific, Inc. (Rockford, IL). D(+)-Sucrose, 99.7%, for biochemistry, was purchased from Acros Organics (Fairlawn, New Jersey). L-α-phosphatidylcholine (Chicken Egg) (PC), L-α-phosphatidylserine (Porcine Brain) (PS), Sphingomyelin (Porcine Brain) (SM), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), and cholesterol were purchased from Avanti Polar Lipids (Alabaster, AL). Proteinase K was obtained from Qiagen (Valencia, CA) and NEB2 buffer was purchased from New England BioLabs (Ipswich, MA). BCA Protein Assay Reagent, HPLC grade methanol and chloroform were purchased from Thermo Fisher Scientific, Inc. (Rockford, IL). DID (1,1′-dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate) and rhodamine DHPE (Rhodamine B 1,2-Dihexadecanoyl-<italic>sn</italic>-Glycero-3-Phosphoethanolamine, Triethylammonium Salt) were obtained from Invitrogen (Carlsbad, CA). Fluorescein was purchased from J.T Baker (Center Valley, PA). Hydrochloric acid was obtained from RICCA Chemical Company (Arlington, TX). Sequencing grade trypsin was purchased from Promega Corporation (Madison, WI).</p></sec>
25102470|Cell Culture|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>Cell Culture</title><p id="P7">All cancer (PC3, MCF-7, MDA-MB-231, SK-Mel-5, H460) and non-cancer immortalized (16HBE, WPMY-1, ARPE-19) cell lines were grown in DMEM, 10% FBS, supplemented with Pen-Strep and Plasmocin™ at 5 μg/ml. Media conditions were identical across all cell lines to prevent any media related effects on the extent of exosome association with the various cell lines. All cells appeared healthy and maintained consistent doubling times under these conditions. Identical media conditions were used for experiments in which the pH of the media was shifted from pH 7.4 to pH 6.8 and 6.3, with the addition of 30 mM Bis-Tris. After the addition of Bis-Tris to the media, HCl was used to lower the pH to 6.8 and 6.3, while no HCl was added to the media of cells cultured at pH 7.4.</p></sec>
25102470|Exosome Isolation|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>Exosome Isolation</title><p id="P8">Exosomes were isolated from the supernatant of PC3, MCF-7 and MDA, MB-231 cells lines. All cell lines were grown to 50% confluency in 225 cm<sup>2</sup> BD cell culture flasks, before the media was replaced by exosome-free DMEM 10% FBS media. After 48 hours, the supernatant was collected and purified by a series of centrifugation steps: 10 min 300 × g, 20 min 15,000 × g, and 10 hours 100,000 × g. Concentrated exosomes were then washed in PBS and centrifuged at 200,000 × g for 10 hours on a sucrose density cushion. The sucrose cushion consisted of three distinct layers, 12 % sucrose, 30 % sucrose and 50% sucrose. Exosomes have been previously reported to have a density between 1.1 and 1.2 g/cm<sup>3</sup> [<xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R20" ref-type="bibr">20</xref>, <xref rid="R21" ref-type="bibr">21</xref>]. Subsequently, the 30% sucrose fraction and the top of the 50% sucrose fraction were collected, washed with PBS, and centrifuged at 100,000 × g for 10 hours. The pelleted exosomes were re-suspended in 500 μl PBS. Exosome protein content was quantified using the BCA protein assay. It is well known that proteins account for 25–75% of the weight of various biological membranes, with most membranes possessing approximately 50% protein [<xref rid="R22" ref-type="bibr">22</xref>]. However, the exact protein-to-lipid weight ratio of exosome has not been quantified. For our experiments we assumed exosomes to be equal parts protein and lipid by weight, thus the total weight of exosomes was estimated by doubling BCA protein assay results. While assuming a 50/50 weight ratio of proteins to lipid in exosomes may result in slightly erroneous values when comparing to the equivalent amount of liposomes, the &gt; 10-fold differences reported in <xref rid="F3" ref-type="fig">figure 3</xref> are significantly greater than could be accounted for by more extreme protein-to-lipid ratios in exosomes. Exosomes were then labeled with specific concentrations of DID based on the weight of each sample. Unincorporated DID was removed through density gradient centrifugation as described above.</p></sec>
25102470|Electron Microscopy|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>Electron Microscopy</title><p id="P9">Electron Microscopy was performed on a Technai G2 Bio-twin made by FEI. Isolated exosomes, re-suspended in phosphate buffer, were deposited on formvar/carbon-coated EM grids and left to dry in ambient air. Phosphate buffer containing 2.0% uranyl acetate was added to the exosome-coated grids and left for 10 minutes before washing with phosphate buffer containing 0.4% uranyl acetate.</p></sec>
25102470|Confocal Microscopy|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Confocal Microscopy</title><p id="P10">Confocal microscopy was performed on a Nikon Eclipse TE2000-E microscope. Images were analyzed using Nikon EZ-C1 FreeViewer Version 390 software. Exosomes were labeled with the fluorescent molecule DID. Long-chain dialkylcarbocyanines, such as DID, are used extensively to label biological membranes [<xref rid="R23" ref-type="bibr">23</xref>, <xref rid="R24" ref-type="bibr">24</xref>]. Five microliters of DID labeled exosomes, in PBS, were placed on a cover slip and imaged.</p></sec>
25102470|Fluorescent Imaging of Exosome Uptake|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Fluorescent Imaging of Exosome Uptake</title><p id="P11">Fluorescent images were taken using an OperettaTM High Content Imaging System instrument (Perkin Elmer; Waltham, MA). MCF-7 cells were grown on a 96-well black walled plate made by Greiner Bio-One (Monroe, NC). Five micrograms MCF-7 exosomes in 100 μl DMEM supplemented with 10% FBS, labeled with DID, were incubated with cells for 4 hours. Cell media was subsequently removed and cells were rinsed with PBS twice. Cells were stained with Hoechst 33342 nucleic acid stain at a concentration of 10 μg/ml in PBS for 15 minutes. Cells were rinsed with PBS to remove free Hoeschst 33342 stain. Cells were then fixed for 10 minutes with 3.7% formalin. Formalin was removed by washing with PBS. Images were analyzed using Harmony 3.5.1 software manufactured by Perkin Elmer.</p></sec>
25102470|Western Blotting|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Western Blotting</title><p id="P12">Cells and exosomes were lysed with lysis buffer containing protease inhibitors and subsequently centrifuged for 10 min at 500 × g to remove debris. Twenty micrograms of protein from cells or exosomes were separated by SDS-PAGE. Gels were blotted onto polyvinylidene fluoride (PVDF) membranes and incubated with Tris-buffered saline (TBS) containing 5% powdered milk for one hour, followed by overnight incubation with 5% powdered milk and primary antibody. The PDVF membrane was then washed twice with TBS containing 0.05% Tween 20 before the addition of TBS with 5% powdered milk and the corresponding secondary antibody for 1 hour. Chemiluminescence was used to identify the presence of the protein of interest. Chemiluminescence was imaged using a Molecular Dynamics Storm 860.</p></sec>
25102470|Mass Spectrometry Analysis|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Mass Spectrometry Analysis</title><p id="P13">One hundred μg of isolated exosomes from MCF-7 and PC3 cells were subjected to in solution digestions using performic acic. Performic acid solution was prepared in a 1:19 ratio of 30% hydrogen peroxide:formic acid. Perfromic acid solution was warmed to 55 °C for 3 minutes immediately prior to use. Three volumes of performic acid were added to the exosome sample and incubated on ice for 3 hours. The reaction was quenched using 5 volumes of ice cold double distilled water. Samples were dried to completion using a speed vacuum and resuspended in 50 μl of 50 mM ammonium bicarbonate. Sequencing grade trypsin was added to the sample in a 1:50 trypsin: protein ratio and incubated overnight at 37 °C. The next morning the samples were dried to completion using a speed vacuum and the pellet resuspended in 30 μl of 0.1% formic acid in water. Tryptic digests were separated using a 5–50% ACN gradient over 120 minutes on a C18 column (Michrocom, Agilent). MS/MS spectra were collected using the Amazon Speed ion ETD trap equipped with CaptiveSpray nanoBooster ionization source (Bruker Daltonics) at the University of Colorado School of Pharmacy Mass Spectrometry Core. Acetonitrile enriched nitrogen gas was used as a sheath gas to increase the charge state of peptide ions and enhance identifications. Data processing was performed using ProteinScape 3.1. Database searches were performed against all of the human entries in the Swiss Prot database using the Mascot Server using 0.6 Da peptide mass tolerance and 0.5 Da MS/MS tolerance allowing for 1 missed cleavage and modifications for dioxidation of methionine and trioxidation of cysteine. Protein identification was considered significant if at least 2 unique peptides were used for identification.</p></sec>
25102470|Sucrose Density Gradients|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>Sucrose Density Gradients</title><p id="P14">To identify the density of isolated exosomes, exosomes were placed on top of a discontinuous sucrose density gradient and centrifuged at 200k × g for 10 hrs. The sucrose gradient was composed of 6 distinct sucrose density layers ranging from 1.05 g/cm<sup>3</sup> to 1.23 g/cm<sup>3</sup>.</p></sec>
25102470|Lipid Extraction|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>Lipid Extraction</title><p id="P15">Lipids from PC3 cells and PC3-derived exosomes were extracted using the Bligh and Dyer method [<xref rid="R25" ref-type="bibr">25</xref>]. Briefly, approximately 300 μg exosomes or cells (based on BCA protein content) in 200 μl PBS were added to 1.9 ml CHCl<sub>3</sub>:MeOH 1:2 and vortexed. Subsequently, 0.625 ml CHCl<sub>3</sub> was added and vortexed, followed by addition of 0.625 ml dH<sub>2</sub>O. Samples were then centrifuged to separate the organic and aqueous phases. The organic phase was recovered and dried in pre-weighed HPLC vials. The HPLC vials were re-weighed on a Mettler Toledo MX5 Micro Balance. The difference in weight allowed for an accurate weight of total lipids extracted from PC3 cells and PC3 derived exosomes.</p></sec>
25102470|Liposome Formulations|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>Liposome Formulations</title><p id="P16">All liposome formulations were prepared by mixing lipids at specific ratios with DID in chloroform in pre-weighed 300 ul glass HPLC vials. Lipid mixtures in HPLC vials were dried under nitrogen gas and placed under vacuum to remove residual chloroform. As with exosome and cell lipid extracts, each liposome formulation in HPLC vials was re-weighed on a Mettler Toledo MX5 Micro Balance to obtain an accurate weight of total lipids. To the HPLC vials containing the dried lipids, 500 μl PBS was added, and subsequently sonicated to remove lipids from the HPLC vial walls. The lipid/PBS mixture was removed and extruded through 100 nm pore size polycarbonate membranes (Avestin, Ottawa, ON). All liposome formulations had a mean diameter of 105 ± 10 nm (data not shown).</p></sec>
25102470|Protein Cleavage on Exosomes|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S14"><title>Protein Cleavage on Exosomes</title><p id="P17">To cleave membrane bound proteins from the surface of PC3-derived exosomes labeled with DID, 200 μg exosomes (based on BCA protein content) were incubated with proteinase K at 50 μg/ml and 1× NEB2 buffer at 37°C for one hour, via a protocol modified from Escrevente et al. [<xref rid="R9" ref-type="bibr">9</xref>]. One microgram of control exosomes and proteinase K-treated exosomes were then immediately incubated with PC3 and MCF-7 cell lines for four hours; control experiments indicated that the low level of proteinase K had no detectable effect on cell detachment/viability. Cells were then analyzed with flow cytometry to determine the extent of exosome association.</p></sec>
25102470|Sizing|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S15"><title>Sizing</title><p id="P18">Exosomes and liposomes were sized using a NanoSight LM20. Exosomes were diluted 1/1000 from stock before analysis. Measurements were done in triplicate, using the same stock of exosomes. The size and standard deviation from each of the three individual measurements was then averaged.</p></sec>
25102470|Flow Cytometry|('method', 0.9999585343567549)|('other', 4.1465643245147086e-05)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S16"><title>Flow Cytometry</title><p id="P19">All flow cytometry experiments were performed on a Becton Dikinson FACScan. Briefly, between 1 and 10 ug of DID or rhodamine DHPE-labeled exosomes or liposomes were added to cells cultured in Costar<sup>®</sup> 96 well cell culture flat bottom tissue culture flasks. After four hours incubation with either exosomes or liposomes, cells were rinsed with PBS, removed by trypsinization, suspended in PBS, and put on ice. A minimum of ≥5,000 events were acquired per sample. The small amount of exosomes harvested in any individual preparation require that experiments be replicated a minimum of three times with exosomes from different preparations. While the absolute numbers for association did vary among different exosome preparations, consistent trends were observed. Results from an individual experiment are reported, and the differences were statistically analyzed with FlowJo software as detailed below. The y-axis of flow cytometry data is presented as a count of cells, where each data set is fit to have equivalent maximum peak heights in order to facilitate visual comparison between samples. Using this type of analysis, the area under the curve does not indicate the absolute number of cells analyzed. The extent of exosomes association with recipient cells was quantified by monitoring the percentage of cells that had increased fluorescence when compared to control cells (“positive”). Probability binning, built into Flowjo software, was use to statistically analyze samples of the same cell line, while t-tests were used to statistically analyze the differences among samples across multiple cell lines.</p></sec>
25102470|None|('method', 0.9017368663039729)|('other', 0.09826313369602713)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
25102470|None|('method', 0.9017368663039729)|('other', 0.09826313369602713)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>1</label><media xlink:href="NIHMS696908-supplement-1.pdf" orientation="portrait" xlink:type="simple" id="d36e791" position="anchor"/></supplementary-material>
25102470|None|('method', 0.9017368663039729)|('other', 0.09826313369602713)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD2"><label>2</label><media xlink:href="NIHMS696908-supplement-2.pdf" orientation="portrait" xlink:type="simple" id="d36e795" position="anchor"/></supplementary-material>
25103952|Methods|('method', 0.9993845370766679)|('other', 0.000615462923332239)|<title>Methods</title>
25103952|Inclusion criteria|('method', 0.9993845370766679)|('other', 0.000615462923332239)|<sec id="Sec3"><title>Inclusion criteria</title><p>The study was carried out using the framework of the Eurospine Spine Tango Registry together with our own in-house spine surgery outcomes database. It comprised a retrospective analysis of prospectively collected data of consecutive patients who had undergone surgery by qualified, specialized spine surgeons in our own Spine Center (part of an orthopedic hospital) from Feb 2005 to Feb 2011. To be included, patients had to: have a good understanding of written German or English or (after 2006) French, Spanish, Italian or Portuguese; be at least 2 years’ postoperative; and fulfill the study’s surgical admission criteria. The latter made use of the options ticked in relation to the given fields on the Spine Tango surgery form and were as follows: no previous surgery of the lumbar spine; surgery in the lumbar or lumbosacral region of the spine; degenerative deformity as the main pathology. The diagnosis of ADS (registered on the Tango form) had originally been made based on the normal clinical workup, as per everyday practice. Plain films of the lumbar spine in a–p and lateral standing positions were taken in all patients. Where available, whole spine films were used instead. ADS was defined as a coronal Cobb angle ≥10° [<xref ref-type="bibr" rid="CR12">12</xref>], limited to the lumbar spine, with no known history of adolescent scoliosis. Review of patient charts and X-rays together with the Spine Tango surgery data allowed for categorization of the treatment undertaken into decompression (D) or fusion (F) with or without decompression as the operative procedure. Fusion was further sub-divided into short fusion of 1–2 levels without curve correction (SF), and longer fusion (≥3 levels) with attempted curve correction (LF). All comprised posterior fusion with pedicle instrumentation, with the majority also including interbody fusion [TLIF (mostly) or PLIF (occasionally)]. In the long fusion constructs, a 360° fusion at the lower levels was typically combined with posterior only in the upper levels. In short fusion constructs, a 360° fusion was usually performed.</p><p>The individual surgeon’s decision whether to perform D or F reflected his/her routine decision-making process used in daily clinical practice, and typically considered factors such as the patient’s leg pain, back pain, neurological symptoms and radiological findings, as well as their age, general health status, activity level, and willingness to undergo additional fusion.</p></sec>
25103952|Questionnaires|('method', 0.9993845370766679)|('other', 0.000615462923332239)|<sec id="Sec4"><title>Questionnaires</title><p>Before and 12 and 24 months after surgery, patients were requested to complete the Core Outcome Measures Index (COMI) questionnaire [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. On each occasion, the questionnaires were sent to the patients to complete at home, to ensure that the information given was free of care-provider influence. The COMI is a multidimensional index consisting of validated questions covering the domains of pain (leg/buttock and back pain intensity, each measured separately on a 0–10 graphic rating scale), function, symptom specific well-being, general quality of life, and social and work disability. Patients also indicated by means of a multiple-choice question what they considered their “main/greatest problem” to be: back pain, leg/buttock pain, neurological disturbances. In addition to the above questions, at the 12- and 24-month follow-ups there was a further question inquiring about the global outcome of surgery “how much did the operation help your back problem?”, with five response categories: (1) helped a lot, (2) helped, (3) helped only little, (4) didn’t help, and (5) made things worse. The global outcome was dichotomised into “good” (1 and 2) and “poor” (3, 4 and 5) for the purposes of some of the subsequent analyses. A second item at follow-up inquired about the patient’s overall satisfaction with the treatment of their back problem in our hospital, also with five response categories: (1) very satisfied, (2) satisfied, (3) neither satisfied nor dissatisfied, (4) dissatisfied, and (5) very dissatisfied. These were similarly dichotomised into “satisfied” (1 and 2) and “dissatisfied” (3, 4 and 5) for some subsequent analyses. Patient-rated complications were enquired about with an open-field question, and then categorized as described by Grob et al. [<xref ref-type="bibr" rid="CR15">15</xref>]. Reoperations since the index surgery were also enquired about, including whether they were at the same or a different level of the spine. Reoperations declared by the patients themselves were cross-checked against our in-house outcomes database, and further enquired about if there were discrepancies.</p><p>Comorbidity was assessed using the American Society of Anesthesiologists Physical Status Score (ASA Score), and was recorded on the Spine Tango Surgery documentation form, as were surgical and general complications occurring during the hospital stay.</p></sec>
25103952|Statistical analyses|('method', 0.9993845370766679)|('other', 0.000615462923332239)|<sec id="Sec5"><title>Statistical analyses</title><p>Descriptive data are presented as mean ± standard deviations (SD). The significance of any differences between treatment groups (D, SF, LF) in their baseline variables was analyzed using analysis of variance (ANOVA) (with post hoc Fisher’s PLSD tests) for continuous data and contingency analyses with Chi-squared/Fisher’s exact P test for categorical variables.</p><p>Repeated measures analysis of variance [one “between-measures” (treatment group) and one “within-measures” factor (time of assessment)] was used to compare the reduction in COMI score from preoperatively to the 12-month follow-up and preoperatively to the 24-month follow-up in the three treatment groups (D, SF, LF).</p><p>Multivariable linear regression analyses were used to determine the significant statistical predictors of the 12- and 24-month postoperative COMI scores. The baseline COMI score, age, gender, and comorbidity were entered as control variables (since they are recognized potential confounders in analyses of outcome in such patients), followed by treatment group (D, SF, LF) as potential predictors of outcome.</p><p>Multivariable logistic regression analysis was used to predict the 12- and 24-month outcome category (good or poor, based on dichotomisation of the “global treatment outcome” item, as described above), using the same control variables and predictor variables as described above.</p><p>Logistic regression analysis was also used to identify the factors most likely associated with a patient having undergone decompression only as opposed to fusion (either SF or LF).</p><p>Statistical significance was accepted at the <italic toggle="yes">p</italic> &lt; 0.05 level.</p></sec>
25106474|Experimental|('method', 0.9985115724650444)|('other', 0.0014884275349557217)|<title>Experimental</title>
25106474|Reactants and Solvents|('method', 0.9985115724650444)|('other', 0.0014884275349557217)|<sec id="Sec3"><title>Reactants and Solvents</title><p>Reactants were either commercially available or freshly prepared as detailed in the <italic toggle="yes">Synthesis</italic> section. Commercially available organic solvents, namely cyclohexane (Sigma-Aldrich ACS spectrophotometric grade, ≥99 %), dimethyl sulfoxide (Sigma-Aldrich ACS spectrophotometric grade, ≥99 %) and acetonitrile (Sigma-Aldrich ACS spectrophotometric grade, ≥99 %), used for spectroscopy did not require any additional purification.</p></sec>
25106474|Apparatus and Methods|('method', 0.9985115724650444)|('other', 0.0014884275349557217)|<sec id="Sec4"><title>Apparatus and Methods</title><p>Semi-preparative flash chromatography used for purification of the compounds was performed with the Büchi Sepacore® flash chromatography system using 25 g silica gel cartridges (particle size 40–63 μm) and dichloromethane as an eluting solvent. <sup>1</sup>H NMR spectra were run on 10 % (w/v) sample solutions in CDCl<sub>3</sub> with (CH<sub>3</sub>) <sub>4</sub>Si as an internal standard at room temperature using a 400 MHz Bruker Fourier transform spectrometer, equipped with a DMX AVANCE I system. UV absorption spectra were measured using an Agilent Cary 300 spectrophotometer, and the steady-state fluorescence spectra were recorded with Horiba Jobin Yvon FluoroLog®-3 modular spectrofluorometer and Agilent Cary Eclipse fluorescence spectrophotometer. The fluorescence excitation and emission spectra were corrected for instrumental sensitivity at different excitation and emission slits using the instrument internal excitation-emission matrix (EEM) correction [<xref ref-type="bibr" rid="CR7">7</xref>]. A solution of quinine bisulphate in 0.1 N H<sub>2</sub>SO<sub>4</sub> (Ф<sub>f</sub> = 0.52) was taken as fluorescence standard for the determination of fluorescence quantum yields [<xref ref-type="bibr" rid="CR8">8</xref>]. Constant-illumination fluorescence intensity decay curves at the photostationary steady-state equilibrium between the <italic toggle="yes">trans</italic>- and <italic toggle="yes">cis</italic>-isomers of DMPSDA were recorded with Shimadzu RF-5,301 spectrofluorometer equipped with the 150 W Xenon lamp as a radiation light source. The fluorescence decay at the photostationary steady-state equilibrium was monitored at the emission maximum of DMPSDA after excitation at the excitation maximum using typically 5-nm slit width for excitation and 5-nm slit width for emission. Analysis of the experimental data was performed using Origin® Pro 9.0 for Windows.</p><p>Fluorescence intensity decay curves were analysed with a polynomial fit for calculation of the <italic toggle="yes">trans-cis</italic> isomerization rate constants using a self-written routine within the Origin® Pro 9.0 for analysis of the first-order photochemical reaction rates.</p></sec>
25106474|Synthesis of N,N-Dimethyl-N′-Picryl-4,4′-Stilbenediamine|('method', 0.9985115724650444)|('other', 0.0014884275349557217)|<sec id="Sec5"><title>Synthesis of N,N-Dimethyl-N′-Picryl-4,4′-Stilbenediamine</title><p>The following reactants were prepared by slight modification of our procedure that we published in [<xref ref-type="bibr" rid="CR9">9</xref>]: <italic toggle="yes">trans</italic>-4-dimethylamino-4′-nitrostilbene and <italic toggle="yes">trans</italic>-4-dimethylamino-4′-aminostilbene.<list list-type="order"><list-item><p>Trans-4-Dimethylamino-4′-nitrostilbene</p></list-item></list></p><p>An equimolar mixture of 4-nitrophenylacetic acid (Sigma-Aldrich N20204) (9.1 g) and 4-(dimethylamino) benzaldehyde (Sigma-Aldrich 156,477) (7.5 g) in 3 ml of piperidine was heated for 24 h under reflux in an oil bath maintained at 140°. The resulting dark-red crude solid was recrystallized from 100 ml of chlorobenzene. Upon cooling, the product precipitated as lustrous red flakes, then was collected by vacuum filtration on a Buchner funnel, thoroughly washed with petroleum ether (60–80°) to remove the adherent piperidine and dried in a vacuum oven at 60° for about 2 h. Yield of the lustrous red flakes – 7.4 g (53 %). Chemical purity and structural identity of the product was confirmed by <sup>1</sup>H NMR.<list list-type="order"><list-item><p>Trans-4-Dimethylamino-4′-aminostilbene</p></list-item></list></p><p>Solution of 120 g of potassium hydroxide pellets dissolved in 200 ml of ultrapure water was prepared in 500 ml Erlenmeyer flask and placed in a fridge for storing. This solution is used for decomposition of the prepared stannous complex salt of the product. 15 g of stannous chloride dihydrate was dissolved in 150 ml of concentrated hydrochloric acid at room temperature with stirring. 4 g of fresh <italic toggle="yes">trans</italic>-4-dimethylamino-4′-nitrostilbene prepared in the previous step was introduced into the stirred solution of SnCl<sub>2</sub>. The resulted suspension was refluxed with strong stirring for about 4–5 h until all red flakes and orange viscous particles of the intermediate stannous complex salt formed during the reaction have been completely dissolved, and the yellow reaction mixture has become transparent. The reaction mixture was stirred for additional half an hour and allowed to cool to the point of turbidity. Then it was poured carefully into a cold stirred solution of potassium hydroxide taken from the fridge and placed into an ice bath, in order to decompose the complex stannous salt and to release the product. Caution: the neutralization reaction is highly exothermic and vigour! Well-protective glasses, gloves and clothes should be worn during this step, and all precautions for minimising the reaction mixture splashing should be taken. The crude yellow product was collected by vacuum filtration, thoroughly washed with 10 % sodium bicarbonate solution, ultrapure water and then with petroleum ether (60–80°). The crude yellow product was dissolved in 10 ml of dichloromethane, and subjected to the flash chromatography on the regular silica gel (particle size 40–63 μm). The fractions containing <italic toggle="yes">trans</italic>-isomer (′<sub>abs</sub> = 360 nm) were collected and evaporated to yield the yellow amorphous powder (2.82 g, 77 % reaction yield). Chemical purity and structural identity of the product was confirmed by <sup>1</sup>H NMR.<list list-type="order"><list-item><p>N,N-dimethyl-N′-picryl-4,4′-stilbenediamine</p></list-item></list></p><p>An equimolar mixture of 0.48 g (2 mmol) of <italic toggle="yes">trans</italic>-4-dimethylamino-4′-aminostilbene, prepared in a previous step, and 0.50 g (2 mmol) of 2-chloro-1,3,5-trinitrobenzene (Sigma-Aldrich 79,874) in 5 ml absolute ethanol, which yielded initially a clear solution, was left overnight with stirring The resulted black crystalline precipitate was collected by vacuum filtration on a Buchner funnel, washed with 10 % sodium bicarbonate solution, ultrapure water and then with petroleum ether (60–80°). The crude product was recrystallized from chlorobenzene, and then dried in a vacuum oven at 60° for about 2 h. Yield of the black crystalline product – 0.76 g (85 %). <sup>1</sup>H NMR: δ 3.00 (Me<sub>2</sub>N, s, 6H); δ 6.88, δ 6.93 (CH = CH AB, d, vinyl 2H); δ 6.72, δ 7.89 (4-Me<sub>2</sub>N-Ar AA′XX′, dd, 4H); δ 7.33, δ 7.83 (4′-picrylamine-Ar AA′XX′, dd, 4H); δ 9.24 (picryl ring protons, s, 2H); δ 3.71 (NH).</p></sec>
25108062|None|('method', 0.9997236399099895)|('other', 0.0002763600900105844)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Materials And Methods</title>
25108062|2.1 Purification of proteins|('method', 0.9997236399099895)|('other', 0.0002763600900105844)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.1 Purification of proteins</title><p id="P10">CaD was purified from pig whole stomach [<xref rid="R10" ref-type="bibr">10</xref>] and myosin from pig stomach fundus [<xref rid="R30" ref-type="bibr">30</xref>]. Tropomyosin was purified from chicken gizzard [<xref rid="R31" ref-type="bibr">31</xref>] and actin from chicken pectoralis acetone powder [<xref rid="R32" ref-type="bibr">32</xref>]. Actin was fluorescently labeled by incubation with tetramethylrhodamine isothiocyanate (TRITC)-phalloidin (P1951, Sigma-Aldrich Canada) [<xref rid="R6" ref-type="bibr">6</xref>]. <italic><underline>Phosphorylation of proteins:</underline></italic> For the protocols requiring myosin activation, myosin was thiophosphorylated [<xref rid="R33" ref-type="bibr">33</xref>]. For the protocols requiring CaD activation, CaD was phosphorylated according to Hedges and coworkers [<xref rid="R24" ref-type="bibr">24</xref>] with slight modifications. Briefly, CaD (0.1 mg/ml) was phosphorylated by active ERK (32.6 μg/ml; MAP kinase 2, active, phosphorylated by MEK1; Millipore Billerica, MA) in a buffer containing 25mM Tris, 10 mM magnesium acetate, 0.1 mM EGTA, 1mM DTT, pH 7.5, followed by a 60 min incubation at 30°C.</p></sec>
25108062|2.2.Western blot analysis of CaD phosphorylation|('method', 0.9997236399099895)|('other', 0.0002763600900105844)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>2.2.Western blot analysis of CaD phosphorylation</title><p id="P11">The phosphorylation of CaD was assessed by Western blot analysis. Proteins were run on a 4-15% ready gradient SDS-PAGE gel (Bio-Rad, Hercules, CA). 0.7 μg of CaD and phosphorylated CaD were loaded in each well. Proteins were transferred electrophoretically onto PVDF membranes (Bio-Rad, Hercules, CA). Membranes were blocked with 1% BSA and probed with an anti-phos CaD/serine 789 antibody (SC12931, Santa Cruz, CA), followed by an anti-goat-HRP antibody (Ab6741, AbCam,Cambridge, MA). Antibody detection was done with Clarity substrate (Bio-Rad, Hercules, CA). Image acquisition was performed with ChemiDoc software (Bio-Rad, Hercules, CA). Total CaD was assessed by Coomassie blue staining of the same membranes which was possible because it is a purified protein.</p></sec>
25108062|2.3 Buffers|('method', 0.9997236399099895)|('other', 0.0002763600900105844)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>2.3 Buffers</title><p id="P12"><underline>Myosin buffer</underline> (300 mM KCl, 25 mM imidazole, 1 mM EGTA, 4 mM MgCl<sub>2</sub>, and 30 mM DTT; pH adjusted to 7.4); <underline>Actin buffer</underline> (25 mM KCl, 25 mM imidazole, 1 mM EGTA, 4 mM MgCl2, and 30 mM DTT, with an oxygen scavenger system consisting of 0.25 mg/ml glucose oxidase, 0.045 mg/ml catalase, and 5.75 mg/ml glucose; pH adjusted to 7.4); <underline>Assay buffers:</underline> The in vitro motility assay buffer consisted of actin buffer to which was added methylcellulose (0.5%), to favor binding of myosin to actin, and MgATP (2 mM). The laser trap assay buffer consisted of actin buffer to which methylcellulose (0.3%) and MgATP (200 μM) were added.</p></sec>
25108062|2.4 In vitro motility assay|('method', 0.9997236399099895)|('other', 0.0002763600900105844)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>2.4 In vitro motility assay</title><p id="P13">Our in vitro motility assay to measure the actin filament propulsion velocity (<italic>ν<sub>max</sub></italic>) has been described before [<xref rid="R5" ref-type="bibr">5</xref>]. Ultracentrifugation (Optima ultracentrifuge L-90K and 42.2 Ti rotor, Beckman Coulter, Fullerton, CA) of myosin (500 μg/ml) with equimolar filamentous actin and 1 mM MgATP in myosin buffer was used to eliminate the non-functional myosin molecules. The functional myosin was then perfused in a flow through chamber [<xref rid="R6" ref-type="bibr">6</xref>] kept at 30°C, at a concentration of 125 μg/ml for all velocity measurements and let to randomly attach to the nitrocellulose for 2 min. Next, the following solutions were perfused sequentially in the flow through chamber (all in actin buffer): BSA (0.5 mg/ml), unlabeled G-actin (1.33 μM) to bind to any remaining non-functional myosin, followed by MgATP (1 mM) to remove the unlabeled actin from the functional heads. Then two washes of actin buffer were followed by TRITC labeled actin (30 nM), with or without CaD (300 nM) or phosphorylated CaD (300 nM), or tropomyosin (300 nM) or both CaD and tropomyosin each at 300 nM, incubated for 1 min, and finally, motility assay buffer. The actin filament movement was then observed with an inverted microscope (IX70, Olympus, Melville, NY) with a high numerical aperture objective (X100 magnification Ach 1.25 numerical aperture, Olympus, Melville, NY) and equipped for rhodamine epifluorescence. The images were captured with an intensified video camera (KP-E500 CCD Camera, Hitachi Kokusai Electric, Woodbury, NY, 720 × 480 resolution, 68.6 μm × 45.7 μm real frame size, 29.94 frame/s, 8 bit grayscale) and recorded on computer (custom built by Norbec Communication, Montreal, QC) using a frame grabber (Pinnacle Studio AV/DV V.9 PCI Card) and image acquisition software (AMCap software V9.20) at 29.94 Hz. <italic>ν<sub>max</sub></italic> was obtained by dividing the total path followed by the filaments by the elapsed time using our automated version of the National Institutes of Health tracking software (NIH macro in Scion Image 4.02, Scion) coded in Matlab (R2009b) [<xref rid="R34" ref-type="bibr">34</xref>]. Only filaments present for at least 20% of the recorded video time (50 s) and following a path of at least 3μm were considered.</p></sec>
25108062|2.5 Laser trap assay|('method', 0.9997236399099895)|('other', 0.0002763600900105844)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>2.5 Laser trap assay</title><p id="P14">The force measurements were performed using our single beam laser trap assay [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>] comprised of a Laser Tweezers Workstation (Cell Robotics, Albuquerque, NM) and the motility assay described above. Pedestals were made with 4.5 μm polystyrene microspheres (Polybead, Polysciences, Warrington, PA) as previously described [<xref rid="R5" ref-type="bibr">5</xref>]. The trapping microspheres (3 μm polystyrene, Polybead, Polysciences, Warrington, PA) were prepared by incubation for 30 min at room temperature with N-ethylmaleimide-modified (NEM) skeletal myosin [<xref rid="R6" ref-type="bibr">6</xref>]. Unphosphorylated myosin was perfused in the flow through chamber at a concentration of 16.7μg/ml for all force measurements and let to randomly attach to the nitrocellulose for 2 min. Next, BSA (0.5 mg/ml) was perfused followed by two washes of actin buffer. Then, equal volumes of microspheres (13×10<sup>3</sup> microspheres/μl) and TRITC-labeled actin or regulated actin were mixed in laser trap assay buffer to yield the following final concentrations: actin (1 nM), CaD (10-500 nM), tropomyosin (5-50 nM), phosphorylated CaD (10 nM), or CaD and tropomyosin each at 10 nM. Note that the regulatory proteins were used at saturating concentrations to ensure regulation even at this low concentration of actin. The laser trap was created with a diode pumped Nd:YAG solid-state laser (TEM<sub>00</sub>, 1.5 W, 1064nm). This trap was used to capture a microsphere which was visualized in bright field by a charge coupled device (CCD) camera (XC-75, Sony Corporation of America, New York, NY). An actin filament (with or without the actin regulatory proteins), visualized by fluorescence imaging as described above, was bound to the trapped microsphere (<xref rid="F1" ref-type="fig">Fig.1A</xref>) and then brought in contact with unphosphorylated myosin molecules randomly adhered to a pedestal. Contact between myosin and actin was allowed (∼10s) during which the microsphere baseline position in the trap was recorded (<xref rid="F1" ref-type="fig">Fig.1 B</xref>). The microscope stage, and thus the pedestal, was then moved away from the trap at a slow and constant velocity (∼0.5 μm/s; <xref rid="F1" ref-type="fig">Fig. 1B-C</xref>). Once the filament was taut (<xref rid="F1" ref-type="fig">Fig.1C</xref>), the trapped microsphere moved with the pedestal (<xref rid="F1" ref-type="fig">Fig.1D</xref>) until the force exerted on it by the trap became greater than the binding force of myosin to actin. At that point, the microsphere sprang back to its unloaded baseline position (trap center, <xref rid="F1" ref-type="fig">Fig.1 E</xref>).</p><p id="P15">The total unbinding force (<italic>Total F<sub>unb</sub></italic>) of the myosin molecules was:</p><disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mtext mathvariant="bold-italic">Total</mml:mtext><mml:mspace width="0.2em"/><mml:msub><mml:mi mathvariant="bold-italic">F</mml:mi><mml:mtext mathvariant="bold-italic">unb</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:mi mathvariant="bold">k</mml:mi><mml:mo mathvariant="bold">∗</mml:mo><mml:mo mathvariant="bold">Δ</mml:mo><mml:mi mathvariant="bold-italic">d</mml:mi></mml:math></disp-formula><p id="P16">where k is the trap stiffness and Δ<italic>d</italic> is the maximal displacement of the trapped microsphere from baseline. k was calibrated using the Stokes force (<italic>F<sub>f</sub></italic>) approach [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R5" ref-type="bibr">5</xref>], i.e. a viscous drag was applied to a trapped microsphere by moving it at a constant velocity (<italic>ν</italic>) in 0.3% methylcellulose while measuring Δ<italic>d</italic>. Stokes' law states that the frictional force exerted on spherical objects with very small Reynolds numbers is calculated as:</p><disp-formula id="FD2"><label>(2)</label><mml:math id="M2" display="block" overflow="scroll"><mml:msub><mml:mi mathvariant="bold-italic">F</mml:mi><mml:mi mathvariant="bold-italic">f</mml:mi></mml:msub><mml:mo mathvariant="bold">=</mml:mo><mml:mn mathvariant="bold">6</mml:mn><mml:mspace width="0.2em"/><mml:mi mathvariant="bold-italic">π</mml:mi><mml:mspace width="0.2em"/><mml:mi mathvariant="bold-italic">η</mml:mi><mml:mspace width="0.2em"/><mml:mi mathvariant="bold-italic">r</mml:mi><mml:mspace width="0.2em"/><mml:mi mathvariant="bold-italic">ν</mml:mi></mml:math></disp-formula><p id="P17">where <italic>η</italic> is the dynamic viscosity and <italic>r</italic> is the microsphere radius. The viscosity of 0.3% methylcellulose was measured with a viscometer (DV-I at 60 rpm, Brookfield, Middleboro, MA), using a UL (ultra-low viscosity) adapter and was equal to 10.4 cP, at 30°C. Thus,</p><disp-formula id="FD3"><label>(3)</label><mml:math id="M3" display="block" overflow="scroll"><mml:mi mathvariant="bold-italic">k</mml:mi><mml:mo mathvariant="bold">=</mml:mo><mml:msub><mml:mi mathvariant="bold-italic">F</mml:mi><mml:mi mathvariant="bold-italic">f</mml:mi></mml:msub><mml:mo mathvariant="bold">/</mml:mo><mml:mi mathvariant="bold-italic">Δ</mml:mi><mml:mi mathvariant="bold-italic">d</mml:mi></mml:math></disp-formula><p id="P18">k (0.013 pN/nm, R<sup>2</sup>=0.95) was averaged from several measurements done at different <italic>ν</italic> and then used to obtain the force values.</p><p id="P19">The average binding force per myosin head (<italic>F<sub>unb</sub></italic>) was calculated as we previously reported [<xref rid="R5" ref-type="bibr">5</xref>]. First, the length of actin filament in contact with the pedestal (ℓ) was measured by fluorescence imaging. That is, the actin filament was brought in focus and the bound portion (ℓ) was measured using NIH macro in Scion Image 4.02, (Scion Corp. Frederick, MD). Unbound actin moved in and out of focus due to Brownian motion so was discarded from the length measurements. We then used estimates of the number of active myosin heads on the motility surface, for a given concentration, previously reported by several groups [<xref rid="R35" ref-type="bibr">35</xref>-<xref rid="R38" ref-type="bibr">38</xref>]. The density of active myosin heads was calculated by dividing this number by the surface area and the number of active myosin head per actin filament length was calculated by assuming that all myosins could interact with actin within a 26 nm wide band [<xref rid="R35" ref-type="bibr">35</xref>-<xref rid="R37" ref-type="bibr">37</xref>].</p></sec>
25108062|2.6 Microsphere displacement analysis software|('method', 0.9997236399099895)|('other', 0.0002763600900105844)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S13"><title>2.6 Microsphere displacement analysis software</title><p id="P20">The movement of the trapped microsphere was tracked using Matlab customized software for optimal fitting of a reference image, as previously described in detail [<xref rid="R5" ref-type="bibr">5</xref>]. Briefly, a section of the first frame of the video (720×480 resolution, 68.6×40.3 μm real frame size, 29.94 frame/s, 8 bit grayscale) containing the microsphere image was compared to a section of the same size of each subsequent frame. This microsphere reference image is centered on the center of mass of the largest area of connected pixels above a threshold gray value and was visually confirmed to always contain the microsphere. The microsphere location in the analyzed frame is the location at which the summed absolute difference in pixel grey values between the current frame and the reference image was minimized. Sub-pixel resolution of this position was achieved by interpolation of the absolute difference values for the surrounding 8 pixels using a cubic interpolation algorithm. The microsphere baseline location, i.e. the trap center, was computed as the average microsphere position in the frames where no pedestal movement occurred and displacements were computed relative to this baseline. The local displacement maxima, which denote the detachment of myosin from actin, were found by searching in user defined regions. These maxima, corresponding to the maximal force exerted by the laser trap, were used to calculate the associated total <italic>F<sub>unb</sub></italic>.</p></sec>
25108062|2.7 Statistical analysis|('method', 0.9997236399099895)|('other', 0.0002763600900105844)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S14"><title>2.7 Statistical analysis</title><p id="P21">Differences in <italic>ν<sub>max</sub></italic> and <italic>F<sub>unb</sub></italic> between multiple conditions were tested using one way ANOVAs. When the within group variances differed between the groups, a Satterthwaite T-test, accounting for unequal variances, was performed [<xref rid="R39" ref-type="bibr">39</xref>]. Post-hoc comparisons between conditions were adjusted with a Bonferroni correction. Differences in ν<sub>max</sub> and <italic>F<sub>unb</sub></italic> with only two conditions were tested using the Student's t-test, with t-tests for unequal variance when it applied. A value of p &lt; 0.05 was considered significant. The Systat Software Inc., (San Jose, CA) was used to compute the exact p values of ANOVAs or Student's t-tests. For the motility assay, N represents the number of flow-through chambers studied. A minimum of three locations in each flow through chambers were analyzed; each location contained at least 10 filaments. Thus, a minimum of 30 filaments were analyzed per chamber to make up an N of 1. For the laser trap assay, N represents the number of actin filaments analyzed, with 1 to 3 events per filament. All data are presented as mean±SE.</p></sec>
25108195|None|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. MATERIALS AND METHODS</title>
25108195|2.1 Reagents|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1 Reagents</title><p id="P6">Triple negative HCC38 human breast cancer cells, which we previously showed to also be negative for the ERα splice variants, ERα66 and ERα46, but positive for ERα36 [<xref rid="R18" ref-type="bibr">18</xref>], and human embryonic kidney HEK293 cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA). Roswell Park Memorial Institute 1640 medium (RPMI 1640) was purchased from Invitrogen (Grand Island, NY). Charcoal/dextran-filtered fetal bovine serum (FBS) was purchased from Gemini Bioproducts (Sacramento, CA). E<sub>2</sub> enantiomer (Ent- E<sub>2</sub>) was kindly provided as a gift from Dr. Douglas Covey (Washington University, St. Louis, MO) and has been described previously [<xref rid="R24" ref-type="bibr">24</xref>]. E<sub>2</sub>, E<sub>2</sub>-BSA, taxol, 2-hydroxymyristic acid (HMA), 2-bromohexadecanoic acid (2-bromopalmitate, 2-BP), and tunicamycin (Tm) were purchased from Sigma (St. Louis, MO). Cycloheximide (CHM), Wortmannin, D609, U73122, LY294002, thapsigargin, pertussis toxin (PTX), and cholera toxin (CTX) were purchased from EMD Chemicals (Gibbstown, NJ). VPC32183S and lysophosphatidic acid (LPA) were purchased from Avanti Polar Lipids (Alabaster, AL). Protein content of samples was measured using the Macro BCA reagent kit from Pierce/Thermo Scientific (Rockford, IL). Polyclonal ERα36 antibodies against the unique C-terminal 27 amino acids were generated by Cell Applications Inc. (San Diego, CA). A monoclonal anti-ERα antibody that recognizes the three ERα splice variants ERα66, ERα46, and ERα36 was purchased from Abcam (San Francisco, CA). 740 Y-P and the Titertacs TUNEL assay were purchased from R&amp;D Systems (Minneapolis, MN). Goat antirabbit horseradish peroxidase (HRP) and goat anti-mouse HRP-conjugated secondary antibodies were obtained from Bio-Rad (Hercules, CA). Bax and Bcl2 primers were purchased from Eurofins MWG Operon (Huntsville, AL). The cytochrome C apoptosis assay kit was purchased from MBL International (Woburn, MA). The Amplex Red Phospholipase D (PLD) Assay kit was purchased from Life Technologies (Grand Island, NY). Caspase-3 activity was measured using the CaspAce Assay system from Promega (Madison, WI). ERα36 overexpression plasmids were purchased from Chi Scientific (Maynard, MA). Polyfect transfection reagent was obtained from Qiagen (Germantown, MD).</p></sec>
25108195|2.2 Cell Culture|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.2 Cell Culture</title><p id="P7">HCC38 cells and HEK293 cells were cultured in RPMI 1640-based media or DMEM, respectively, as specified by the ATCC containing 10% charcoal/dextran-filtered FBS and lacking phenol red, which can mimic the effects of E<sub>2</sub> at low levels [<xref rid="R25" ref-type="bibr">25</xref>, <xref rid="R26" ref-type="bibr">26</xref>]. Specific modifications for each experimental question are described below. For all experimental treatments, the solvent used according to preparation instructions by the manufacturer of each reagent was used in equivalent amounts as a treatment vehicle in all controls.</p></sec>
25108195|2.3 Apoptotic Effect of Taxol in HCC38 Cells|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5"><title>2.3 Apoptotic Effect of Taxol in HCC38 Cells</title><p id="P8">The experimental design for this study was based on the ability of E<sub>2</sub> to block the apoptotic effects of taxol. Initial experiments were performed to establish the effect of taxol on HCC38 cells. 24 hours after plating, HCC38 cells were treated with increasing concentrations of taxol (5, 10, 20μM) for 4 hours, after which caspase-3 activity was measured using an assay kit according to the manufacturer’s directions. To confirm that the effects of taxol were apoptotic, as caspase-3 activity is implicated in the terminal differentiation of some cell types [<xref rid="R27" ref-type="bibr">27</xref>–<xref rid="R30" ref-type="bibr">30</xref>], HCC38 cells were treated with 20μM taxol for 12 hours and BAX/BCL2 mRNA levels were determined and cytochrome C translocation from the mitochondria to the cytosol was examined by the cytochrome C apoptosis assay kit from MBL International according to the manufacturer’s instructions. In addition, 24 hours after treatment with taxol, apoptosis-associated DNA-fragmentation was determined using a TUNEL assay kit as per the manufacturer’s directions.</p></sec>
25108195|2.4 Requirement for a Receptor-mediated Membrane-associated Mechanism|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.4 Requirement for a Receptor-mediated Membrane-associated Mechanism</title><p id="P9">E<sub>2</sub> conjugated to bovine serum albumin (E<sub>2</sub>-BSA), which cannot cross the plasma membrane (PM) [<xref rid="R31" ref-type="bibr">31</xref>–<xref rid="R33" ref-type="bibr">33</xref>] was used to verify that the anti-apoptotic effect of E<sub>2</sub> was via a membrane-mediated mechanism. E<sub>2</sub>-BSA has previously been shown to have similar effects to E<sub>2</sub> and can interact with ERs. BSA conjugation prevents E<sub>2</sub> from crossing the PM, and therefore, E<sub>2</sub>-BSA effects can be attributed to either membrane receptor effects or alterations in membrane fluidity due to the hydrophobic nature of E<sub>2</sub>-BSA [<xref rid="R17" ref-type="bibr">17</xref>, <xref rid="R31" ref-type="bibr">31</xref>, <xref rid="R32" ref-type="bibr">32</xref>, <xref rid="R34" ref-type="bibr">34</xref>]. To address the possibility that E<sub>2</sub>’s effect is due to a nonspecific interaction with the PM, cells were also treated with the E<sub>2</sub> enantiomer, Ent-E<sub>2</sub> [<xref rid="R24" ref-type="bibr">24</xref>]. While Ent-E<sub>2</sub> has the same chemical structure as E<sub>2</sub> as its enantiomer, it cannot directly interact with ERs, and therefore, any effects caused by Ent-E<sub>2</sub> could be attributed to its direct effect on membrane fluidity, as it possesses the same hydrophobic properties of E<sub>2</sub>.</p><p id="P10">PLD activity was determined as an outcome measure, based on our previous observation that the anti-apoptotic effect of the vitamin D3 metabolite 24R,25-dihydroxyvitamin-D3 (24,25(OH)2D3) occurs through activation of PLD [<xref rid="R35" ref-type="bibr">35</xref>]. Subconfluent cultures of HCC38 cells in 24-well tissue culture polystyrene (TCPS) plates were treated with E<sub>2</sub> or Ent-E<sub>2</sub>. Also, prior to E<sub>2</sub> treatment, a 15 minute pretreatment of cells with polyclonal ERα36 specific antibodies (1:500 dilution) was performed to block the membrane receptor in order to determine if the effect of E<sub>2</sub> was through membrane-associated ERα36. While antibodies cannot enter the cells, any inhibition of E<sub>2</sub>’s effect in the presence of antibody could be attributed with E<sub>2</sub>’s direct interaction with membrane-associated ERα36. Following the 15 minute antibody pre-treatment, and a 30 minute E<sub>2</sub> treatment, samples were harvested and assayed for PLD activity using the Amplex Red PLD assay from Life Technologies according to manufacturer’s instructions.</p></sec>
25108195|2.5 ERα36 Silencing, Overexpression, and Mutation|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>2.5 ERα36 Silencing, Overexpression, and Mutation</title><p id="P11">In order to confirm the role of ERα36 in the anti-apoptotic effect of E<sub>2</sub>, HCC38 cells were transiently transfected with an ERα36 shRNA expression plasmid in order to transiently knockdown ERα36. The shRNA expression plasmid was produced by cloning a microRNA specific anti-sense target sequence for the 3’UTR of ERα36 cDNA using the DNA oligonucleotides, 5’-GGATCCCATGCCAATAGGTACTGAATTGATATCCGTTCAGTACCTATTGGCATTTTTTTCCAAAAGCTT-3’, and was prepared by Sigma-Aldrich using their Mission shRNA purified plasmid expression system. HCC38 cells were seeded at a density of 1.25×10<sup>5</sup> cells/cm<sup>2</sup> in tissue culture treated polystyrene (TCPS) and cultured in media containing no antibiotics. One day after plating, when cells were approximately 75% confluent, transient transfection was performed using Polyfect transfection reagent from Qiagen according to the manufacturer’s instructions. Media were changed after 24 hours to full growth media, and 48 hours after transfection, cells were treated according to experimental procedures. The PLD and caspase-3 activity assays were performed with HCC38 silenced for ERα36 (denoted as shERα36), wildtype HCC38 cells (denoted as WT), and nontarget transfected HCC38 cells (denoted as shControl). Whole cell lysates were harvested in RIPA and western blot was performed on WT and shERα36 HCC38 cells using ERα36 antibodies (1:500 dilution). Densitometry analysis using Quantity One software was performed to determine percentage of knockdown in shERα36 cells.</p><p id="P12">In order to determine the importance of ERα36 on a more generalized platform, the human embryonic kidney cell line, HEK293, which has been previously cited to not express functional levels of endogenous ERα36 [<xref rid="R21" ref-type="bibr">21</xref>], was used as a model for analysis of wildtype exogenous ERα36 overexpression (denoted as 293ovrx36). Use of HEK293 cells thus allowed us to examine the role of wildtype exogenous ERα36 and mutated ERα36 independent of the presence of functional endogenous ERα36.</p><p id="P13">Because exon 9 is unique to ERα36, and ERα66 has not been shown to mediate the membrane-associated effect of E<sub>2</sub> in ER-positive MCF7 cells [<xref rid="R17" ref-type="bibr">17</xref>], we hypothesized that exon 9 was required for these responses. An exon 9 deletion mutant (denoted as 293ex9d36) was created using overlap extension PCR cloning as previously described by Bryksin and Matsumura [<xref rid="R36" ref-type="bibr">36</xref>]. Exon 9 deleted HEK293 cells were then created according to the methods described below, allowing us to examine the requirement of this exon in the anti-apoptotic pathway of E<sub>2</sub>.</p><p id="P14">HEK293 cells were transiently transfected with ERα36 full-length wildtype cDNA and ERα36 exon 9-deletion cDNA plasmids using Polyfect transfection reagent according to manufacturer’s instructions. HEK293 cells were seeded at a density of 1.25×10<sup>5</sup> cells/cm<sup>2</sup> in TCPS plates and cultured in medium containing no antibiotics. One day after plating, when cells were approximately 75% confluent, transient transfection was performed using Polyfect transfection reagent according to the manufacturer’s protocol. Media were changed after 24 hours to full growth media, and 48 hours after transfection, cells were treated as previously described for measurement of PLD and caspase-3 activity. PLD and caspase-3 activity assays were performed in HEK293 overexpressed with wildtype ERα36 (293ovrx36) and exon 9- deleted ERα36 (293ex9d26). Wildtype HEK293 cells mock transfected with a non-targeting vector and plated at the same time as the mutant cells were used as positive controls. Whole cell lysates were harvested in RIPA and western blot was performed on 293wt, 293ovrx36, and 293ex9d36 HEK293 cells using ERα antibodies (1:500 dilution) that can also detect ERα36. These antibodies were used rather than ERα36 antibodies because the ERα36 antibodies detect the C-terminal domain of ERα36, and the exon 9 deletion mutants (293ex9d36) do not contain this region. Bands shown in western blots were detected at ~36kDa. Densitometry analysis using Quantity One software was performed to determine percentage of knockdown in shERα36 cells.</p></sec>
25108195|2.6 Examination of E<sub>2</sub>’s Anti-apoptotic Pathway|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.6 Examination of E<sub>2</sub>’s Anti-apoptotic Pathway</title><p id="P15">In order to determine the signaling pathway involved in the anti-apoptotic effect of E<sub>2</sub>, we took advantage of the observation that E<sub>2</sub> inhibits taxol-induced apoptosis via membrane-associated signaling by attenuating the effect of taxol on caspase-3 activity [<xref rid="R3" ref-type="bibr">3</xref>, <xref rid="R18" ref-type="bibr">18</xref>]. For the experiments described below, subconfluent cultures of HCC38 cells were pretreated with 10<sup>−8</sup>M E<sub>2</sub> for 90 minutes followed by 20μM taxol treatment, after which time, E<sub>2</sub> was removed from the cultures. After 24 hours of taxol treatment, the number of viable cells was determined by the MTT assay, which measures the reduction of 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to purple formazan by mitochondrial reductase in living cells [<xref rid="R37" ref-type="bibr">37</xref>]. After 4 hours of taxol treatment, caspase-3 activity was determined as described above. Requirement for ERα36 was determined by pretreating the HCC38 cells with antibodies generated against the unique C-terminus of ERα36. Phosphatidylcholine-specific PLD (PC-PLD) was inhibited using 10-5M wortmannin [<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref>]. Phosphatidylcholine-specific phospholipase C (PC-PLC) was inhibited using 5x10<sup>−5</sup>M D609 [<xref rid="R39" ref-type="bibr">39</xref>, <xref rid="R40" ref-type="bibr">40</xref>]. Phosphatidylinositolspecific phospholipase C (PI-PLC) was inhibited using 10<sup>−5</sup>M U73122 [<xref rid="R38" ref-type="bibr">38</xref>, <xref rid="R39" ref-type="bibr">39</xref>]. 10<sup>−6</sup>M VPC32183S was used to block lysophosphatidic acid (LPA) signaling through LPA1 and LPA3 receptors, while LPA was used to activate LPA signaling [<xref rid="R35" ref-type="bibr">35</xref>]. 10<sup>−5</sup>M LY294002 was used to block phosphoinositide-3-kinase (PI3K) [<xref rid="R35" ref-type="bibr">35</xref>]. 10<sup>−6</sup>M 740 Y-P was used to activate PI3K signaling [<xref rid="R41" ref-type="bibr">41</xref>]. 3μM thapsigargin was used to inhibit calcium translocation from the rough endoplasmic reticulum to the cytosol. Pertussis toxin (25ng/mL) was used to inhibit Gαi signaling, while cholera toxin (100ng/mL) was used to inhibit Gαs signaling [<xref rid="R35" ref-type="bibr">35</xref>]. E<sub>2</sub>-BSA was also used in several of these experiments to further determine if these effects were membraneassociated. As previously described, E<sub>2</sub>-BSA cannot cross the PM, but still has many similar effects to E<sub>2</sub>. For all caspase-3 experiments using E<sub>2</sub>-BSA, subconfluent cultures of HCC38 cells were pretreated as with the inhibitors stated above followed with 10<sup>−8</sup>M E<sub>2</sub>-BSA for 90 minutes. 20μM taxol was then added, and after 4 hours of taxol treatment, caspase-3 activity was measured as described above.</p></sec>
25108195|2.7 Requirement for Dynamic Palmitoylation|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>2.7 Requirement for Dynamic Palmitoylation</title><p id="P16">Previous work has shown that ERs, particularly the ERα variants ERα66 and ERα46, can be targeted to the PM by palmitoylation [<xref rid="R42" ref-type="bibr">42</xref>, <xref rid="R43" ref-type="bibr">43</xref>]. ERα66 and ERα46 have been identified as translocating to the PM due to palmitoylation. In order to examine this, tunicamycin and 2-bromohexadecanoic acid (2-bromopalmitate, 2-BP) were used to inhibit palmitoylacetyl-transferase and thus prevent palmitoylation of ERα36 [<xref rid="R42" ref-type="bibr">42</xref>]. Cycloheximide (8μM), an inhibitor of protein synthesis, was used to disrupt N-glycosylation and HMA (0.5mM) was used to block myristoylation [<xref rid="R42" ref-type="bibr">42</xref>]. HCC38 cells were pre-treated with 30μM tunicamycin (Tm) and 10μM 2-BP to inhibit the activity of palmitoylacetyltransferase, which is responsible for post-translational palmitoylation of proteins that are targeted to the PM [<xref rid="R42" ref-type="bibr">42</xref>, <xref rid="R44" ref-type="bibr">44</xref>]. Tunicamycin, however, also inhibits N-linked glycosylation [<xref rid="R42" ref-type="bibr">42</xref>], and because of this, we also pre-treated cells with 8μM cycloheximide (CHM) as a control for N-glycosylation inhibition [<xref rid="R42" ref-type="bibr">42</xref>]. In order to invalidate the possibility that the membrane effects of E<sub>2</sub> through ERα36 do not occur due to myristoylation, we also pre-treated cells with 0.5mM 2- hydroxymyristic acid (HMA), which blocks post-translational myristoylation [<xref rid="R42" ref-type="bibr">42</xref>]. In order to determine if palmitoylation of ERα36 is necessary for the anti-apoptotic effect of E<sub>2</sub>, HCC38 cells were pre-treated with 30μM Tm and 10μM 2-BP for 2 hours prior to E<sub>2</sub> and taxol treatment for 4 hours, after which, caspase-3 activity was measured.</p></sec>
25108195|2.8 Statistical Analyses|('method', 0.9985927004340196)|('other', 0.0014072995659803465)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>2.8 Statistical Analyses</title><p id="P17">For all experiments, statistical analyses were performed by analysis of variance with Bonferroni's correction for multiple comparisons. All experiments were performed with n=6 individual cultures per variable, enabling statistical analysis for individual experiments. Experiments were performed multiple times to ensure validity of the data. Results of individual experiments are presented. For all graphs, error bars represent standard error of the mean of 6 individual cultures per variable in one representative experiment.</p></sec>
25108195|None|('method', 0.9116117660324782)|('other', 0.0883882339675218)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
25108195|None|('method', 0.9116117660324782)|('other', 0.0883882339675218)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>Supplement</label><media xlink:href="NIHMS625077-supplement-Supplement.docx" orientation="portrait" xlink:type="simple" id="d36e1210" position="anchor"/></supplementary-material>
25109469|Materials and methods|('method', 0.9984415013647464)|('other', 0.0015584986352536144)|<title>Materials and methods</title>
25109469|Chemicals|('method', 0.9984415013647464)|('other', 0.0015584986352536144)|<sec id="Sec3"><title>Chemicals</title><p>Benzo[a]pyrene (96 %), cysteamine (98 %), 2-mercaptoethanol (99 %), <italic toggle="yes">N</italic>-methylformanilide (99 %), phosphorus oxychloride (99 %), sodium carbonate (99 %), sodium cyanoborohydride (95 %), methanol (99.8 %), 5,5′-dithiobis(2-nitrobenzoic acid) (DNBA) (99 %), 1,3-dicyclohexylcarbodiimide (99 %), albumin from bovine serum (BSA) (98 %), and <italic toggle="yes">N</italic>-hydroxysuccinimide (NHS) (98 %) were obtained from Sigma-Aldrich. <italic toggle="yes">N</italic>,<italic toggle="yes">N</italic>-dimethylformamide (99.8 %), sulfuric acid (95–98 %), tetrahydrofuran (p.a.), and boric acid (p.a.) were from Merck. Dimethyl ether (99.9 %) and sodium hydroxide solution at 10 N (9.8–10–2 N) were from Fluka. Hydrogen peroxide solution (30 wt% in H<sub>2</sub>O), dimethyl sulfoxyde (99.99 %), and PBS were from Fisher. Acetonitrile (HPLC grade) and sodium tricitrate (reagent grade) were purchased from Prolabo. Antibody anti-benzo[a]pyrene (BaP13) was purchased from Exbio Antibodies. The relative sensitivity of the immunoassay using BaP13 towards 21 parents PAHs was determined by competition ELISA. Highest affinity was found for four- to six-ring PAHs. The greatest specificity among the tested compounds was that toward benzo[a]pyrene (Scharnweber et al. <xref ref-type="bibr" rid="CR27">2001</xref>). This compound is considered as a marker for PAHs by European Commission (Donata <xref ref-type="bibr" rid="CR6">2010</xref>).</p><p>Gold III chloride trihydrate (HAuCl<sub>4</sub> · 3H<sub>2</sub>O) (&gt;49 % Au basis) was obtained from Acros organics. Water used in all experiments was purified using a Milli-Q ultrapure water purification system (Merck Millipore) with resistivity of 18 MΩ/cm. One micrometer-filtered seawater was collected from experimental mollusks hatchery of Ifremer in Argenton (France).</p></sec>
25109469|Instruments|('method', 0.9984415013647464)|('other', 0.0015584986352536144)|<sec id="Sec4"><title>Instruments</title><p>A homemade surface plasmon resonance system was used. It is based on wavelength modulation in a configuration similar to the one designed by Cahill et al. (<xref ref-type="bibr" rid="CR3">1997</xref>). The system was developed for laboratory and underwater experiments (Colas et al. <xref ref-type="bibr" rid="CR4">2010</xref>).</p><p>A NanoDrop 2000 Spectrophotometer (Thermo Scientific) was used to record UV-Vis spectra of colloidal solutions in the spectral region between 350 and 800 nm (resolution <underline>&lt;</underline>1.8 nm). Analyzed solutions were diluted in distilled water (10 %, <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>). Water spectrum was used as the baseline. The light source is a xenon flash lamp.</p><p>A Horiba Jobin Yvon Labram HR800 spectrometer was used for recording the Raman and SERS spectra. Spectra were acquired with a 785 nm laser diode using a 300-groove per millimeter grating and a × 100-long working distance immersion microscope objective from Olympus (NA = 1). Using a 800-mm spectrograph, the resolution was 2 cm<sup>−1</sup>. The laser power was estimated at 0.1 mW focused on an area of 1 μm<sup>2</sup>.</p></sec>
25109469|Synthesis procedures of organometallic nanoprobes|('method', 0.9984415013647464)|('other', 0.0015584986352536144)|<sec id="Sec5"><title>Synthesis procedures of organometallic nanoprobes</title><p>To quantify benzo[a]pyrene contamination in seawater, we chose the method of detection by competitiveness. An organometallic complex assembling gold nanoparticles and antibodies BaP13 is used as a nanoprobe (Scheme <xref rid="Sch1" ref-type="fig">1</xref>a). This assembly is performed chemically using a bifunctional coupling agent called DSNB (5,5′-dithiobis (succinimidyl-2-nitrobenzoate). This molecule also plays the role of the reporter due to its particularly intense Raman signal around 1,330 cm<sup>−1</sup> (Grubisha et al. <xref ref-type="bibr" rid="CR10">2003</xref>). This nanoprobe reacts with the BaP antigen of water sample (Scheme <xref rid="Sch1" ref-type="fig">1</xref>b). The free antibody binding sites of the nanoprobes are then available to react with grafted BaP on a gold-coated quartz substrate (Scheme <xref rid="Sch1" ref-type="fig">1</xref>c). In this configuration, the grafted BaP competes with sample free antigen for nanoprobe antibody binding sites. The more antigens there are in the sample the less organometallic nanoprobes are retained in the surface sensing resulting in a weaker signal.<fig id="Sch1" position="float" orientation="portrait"><label>Scheme 1</label><caption><p>Description of the procedure undertaken for the SERS detection of benzo[a]pyrene</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11356_2014_3384_Sch1_HTML.gif" id="MO1" position="float" orientation="portrait"/></fig></p><sec id="Sec6"><title>Synthesis of 6-benzo[a]pyrenecarboxaldehyde</title><p>Direct synthesis of 6-benzo[a]pyrenecarboxaldehyde from BaP was accomplished via Vilsmeier-Haack reaction using <italic toggle="yes">N</italic>-methylformanilide and POCl<sub>3</sub>. POCl<sub>3</sub> (1.2 g) and <italic toggle="yes">N</italic>-methylformanilide (1.2 g) were added to a solution of benzo[a]pyrene (1 g) in DMF (10 mL) in a 90-mL Pyrex bottle. The screw cap was then sealed, and the reaction bottle was heated at 90 °C overnight. The reaction mixture was cooled and washed with 40 mL of diethyl ether. The red slurry was recovered and mixed with Na<sub>2</sub>CO<sub>3</sub> (2.5 g/50 mL in water) in a 150-mL beaker. The green precipitate was then filtered, washed copiously with water, and then dried off at room temperature (Dai et al. <xref ref-type="bibr" rid="CR5">2007</xref>).</p></sec><sec id="Sec7"><title>Functionalization of the sensor surface with a SAM presenting BaP head groups</title><p>Grafting of BaP on the gold surface begins with a self-assembled mixed monolayer formation of cysteamine on it. This step was assured through the gold-alkanethiolate self-assembly process using cysteamine and 2-mercaptoethanol. The substrate was cleaned in a piranha solution (H<sub>2</sub>SO<sub>4</sub>/H<sub>2</sub>O<sub>2</sub> 30 %–3:1 <italic toggle="yes">v</italic>/<italic toggle="yes">v</italic>) at 80 °C for 4 h to remove organic contaminants. Next, the gold surface of the sensor chip was immersed in methanol solution of 5 mM cysteamine and 5 mM 2-mercaptoethanol for 4 h. The sensor chip is then washed with methanol to remove any adhered/loosely bound alkanethiol molecules from the sensor chip. Afterwards, the substrate was rinsed in DMSO and treated in DMSO solution of 6-benzo[a]pyrenecarboxaldehyde (0.68 mg/mL) for 2 h. This forms a Schiff base which was then reduced by reaction of 14 μL/mL of DMSO of a sodium cyanoborohydride solution 5 M in NaOH 1 M for 1 h. Finally, grafted gold substrate was rinsed in distilled water and dried under a stream of nitrogen gas.</p></sec><sec id="Sec8"><title>Synthesis of 5,5′-dithiobis(succinimidyl-2-nitrobenzoate)</title><p>DSNB is one of derivatives of dithiobis(benzoic acid), which could easily be converted to the corresponding succinimide ester with NHS. The formula of DSNB is shown on Scheme <xref rid="Sch1" ref-type="fig">1</xref>. DSNB is a particularly attractive example because of the strong scattering cross-section of its symmetric NO<sub>2</sub> stretch. To obtain this compound, we activated carboxylic functions of DNBA using a reagent mixture carbodiimide/succinimide. So, 50 mL of dried tetrahydrofuran were added to 0.50 g of DNBA, 0.52 g of DCCD, and 0.29 g of NHS in a 100-mL round-bottom flask equipped with a drying tube. The mixture was magnetically stirred at 25 °C for 12 h, filtered, and then rotaevaporated to remove solvent. The crude product was dissolved in 100 mL of acetonitrile and filtered yielding a yellow solution. We denote by C<sub>0</sub>, the DSNB concentration of this solution. This concentration is equal to 2.5 mM if the yield of the DNBA activation was equal to 100 %.</p></sec><sec id="Sec9"><title>Preparation of Raman reporter-labeled immunogold colloids</title><p>Suspensions of gold nanoparticles were prepared according to the method described by Frens (<xref ref-type="bibr" rid="CR9">1973</xref>). Our preparation technique has been used in different studies and consists in the reduction of HAuCl<sub>4</sub> by sodium tricitrate (Péron et al. <xref ref-type="bibr" rid="CR23">2009b</xref>, <xref ref-type="bibr" rid="CR24">2010</xref>). Here, 10 mL of sodium tricitrate at 8 × 10<sup>−3</sup> M was slowly added to 10 mL of boiling tetrachloroauric acid at 2 × 10<sup>−3</sup> M while stirring. The reactor was placed on a hot plate and magnetically stirred. The mixture of both solutions was refluxed for 1 h. After 1 h of boiling, the mixture was cooled at room temperature while stirring.</p><p>The gold colloidal nanoparticles are coated by the DSNB derivative thanks to its thiolate. The primary amines of an antibody can be then linked by the formation of an amide linkage. The particle synthesis is conducted in two steps. First, 100 μL of a 2.5 mM DSNB solution in acetonitrile was added to 1 mL of the unconjugated colloidal gold suspension and the mixture reacted during 3–5 h. The reporter-labeled colloids were then separated from the solution by centrifugation at 10,000 <italic toggle="yes">g</italic> during 7 min. The clear supernatant was discarded, and the loose red sediment was resuspended in 1 mL of borate buffer (2 mM, pH 9). In step two, BaP13 was coupled to the gold particles via the succinimidyl terminal of the DSNB-derived coating. As such, 35 μg of detection antibody (35 μL of 1 mg/mL BaP13 solution) was added to the 1 mL suspension of the reporter-labeled colloid. The mixture was then incubated at room temperature for 1 h. After centrifugation at 10,000 <italic toggle="yes">g</italic> for 7 min and the supernatant removed, the red sediment was resuspended in 1 mL of PBS (pH 7.0, 1 % BSA) (Grubisha et al. <xref ref-type="bibr" rid="CR10">2003</xref>).</p></sec></sec>
25109469|SERS immunoassay procedure|('method', 0.9984415013647464)|('other', 0.0015584986352536144)|<sec id="Sec10"><title>SERS immunoassay procedure</title><p>Raman analysis is performed using the following steps: firstly, we diluted the probe suspension obtained according to the protocol described above with six volumes of PBS. After that, we mixed one volume of the suspension with one volume of seawater containing benzo[a]pyrene at a predefined concentration and incubate it for 30 min. Therefore, the molecules of BaP present in the sample to analyze will block the antigenic sites of antibodies in the organometallic probes. Then we placed a microdrop (60 μL) of this mixture on the surface of a substrate previously covered with benzo[a]pyrene. We rinsed the substrate with water 30 min after the deposit, and finally, we analyzed it with the Raman spectrometer using × 100 water immersion objective (Scheme <xref rid="Sch2" ref-type="fig">2</xref>).<fig id="Sch2" position="float" orientation="portrait"><label>Scheme 2</label><caption><p>Description of the measurement protocol</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11356_2014_3384_Sch2_HTML.gif" id="MO2" position="float" orientation="portrait"/></fig></p></sec>
25109469|Results and discussion|('method', 0.8337544989118548)|('other', 0.1662455010881451)|<title>Results and discussion</title>
25109469|Surface grafting control of BaP-coated substrate|('method', 0.8337544989118548)|('other', 0.1662455010881451)|<sec id="Sec12"><title>Surface grafting control of BaP-coated substrate</title><p>In order to control the surface grafting of benzo[a]pyrene, we have measured the binding ability of anti-BaP antibodies to the BaP-functionalized substrate. So, we used surface plasmon resonance (SPR) spectroscopy. Thus, we have studied two types of surface, functionalized and nonfunctionalized as controlled surface. The analysis started with the injection of phosphate buffer at pH 7. The BaP13 antibodies at 50 ppm in PBS was then injected. With the two surfaces, we observed an increase in the SPR signal just after injection of antibodies in the measuring cell (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). However, we have noted that the increase obtained with the functionalized surface is considerably higher. Indeed, after PBS rinsing, the SPR profile obtained with the functionalized surface is characteristic for specific ligand-receptor interaction. Moreover, the measured offset is much higher with the functionalized surface (Δ<italic toggle="yes">λ</italic> = 7.8 nm) compared with the uncoated surface (Δ<italic toggle="yes">λ</italic> = 0.4 nm) (Fig. <xref rid="Fig1" ref-type="fig">1</xref>). Thus, we can maintain the presence of BaP molecules on the surface of functionalized substrate and therefore the effectiveness of our protocol.<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>SPR responses of the BaP13 antibodies adsorption onto the uncoated and functionalized surfaces</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11356_2014_3384_Fig1_HTML.gif" id="MO3" position="float" orientation="portrait"/></fig></p></sec>
25109469|Determination of size and concentration of gold nanoparticles from UV-Vis spectra|('method', 0.8337544989118548)|('other', 0.1662455010881451)|<sec id="Sec13"><title>Determination of size and concentration of gold nanoparticles from UV-Vis spectra</title><sec id="Sec14"><title>Size</title><p>We have determined the size of nanoparticles by measuring the wavelength of plasmon resonance. Indeed, a relationship was demonstrated between the optical absorption spectrum (in particular, the plasmon resonance) and the size of the spherical gold nanoparticles (Link and El-Sayed <xref ref-type="bibr" rid="CR18">2000</xref>). Thus, we have analyzed with the spectrophotometer the solution of gold nanoparticles obtained using the protocol described above. The resonance wavelength of this solution is equal to 525 nm (Fig. <xref rid="Fig2" ref-type="fig">2</xref>). The displaying of spectra of nanoparticles solutions with sizes ranging from 9 to 99 nm allows us to determine that the diameter of our nanoparticles is between 22 and 48 nm.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Correlation between size and surface plasmon absorption of spherical gold nanoparticules. Thin lines: literature data (Link and El-Sayed, 2000). Thick line: our experiment</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11356_2014_3384_Fig2_HTML.gif" id="MO4" position="float" orientation="portrait"/></fig></p><p>The dependence of the optical properties of spherical gold nanoparticles on particle size were analyzed by Haiss et al.(Haiss et al. <xref ref-type="bibr" rid="CR13">2007</xref>). They have succeeded in establishing a mathematical relationship between the diameter (<italic toggle="yes">d</italic>) of gold nanoparticles and the absorption values of the corresponding solution at defined wavelengths.</p><p><italic toggle="yes">d</italic> = exp(<italic toggle="yes">B</italic><sub>1</sub> × <italic toggle="yes">A</italic><sub>SPR</sub> /<italic toggle="yes">A</italic><sub>450</sub> − <italic toggle="yes">B</italic><sub>2</sub> ) (Haiss et al. <xref ref-type="bibr" rid="CR13">2007</xref>)</p><p>with <italic toggle="yes">A</italic><sub>SPR</sub> the absorbance at the surface plasmon resonance peak and <italic toggle="yes">A</italic><sub>450</sub> the absorbance at 450 nm. <italic toggle="yes">B</italic><sub>1</sub> and <italic toggle="yes">B</italic><sub>2</sub> values are 3 and 2.2 ,respectively (Haiss et al. <xref ref-type="bibr" rid="CR13">2007</xref>).</p><p>With the absorbance of 0.734 and 0.386 at respective wavelengths of 525 and 450 nm (thick line in Fig. <xref rid="Fig2" ref-type="fig">2</xref>), the average diameter of our nanoparticles calculated is equal to 33 nm.</p></sec><sec id="Sec15"><title>Number density of the GNPs</title><p>To estimate the concentration of nanoparticles of our nanoparticles solution, we have established a relationship between the number density of the GNPs and their average size. Indeed, if we consider that the whole quantity of gold used for the preparation of nanoparticles has been consumed Pluchery and Carriere (<xref ref-type="bibr" rid="CR26">2011</xref>), we can express the number density <italic toggle="yes">n</italic> of nanoparticles in solution using the following equation:<disp-formula id="Equa"><alternatives><mml:math xmlns:mml="http://www.w3.org/1998/Math/MathML" id="M1"><mml:mi>n</mml:mi><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mi>V</mml:mi><mml:mi>T</mml:mi></mml:msub><mml:mo stretchy="true">/</mml:mo><mml:msub><mml:mi>V</mml:mi><mml:mi>P</mml:mi></mml:msub><mml:mspace width="0.25em"/><mml:mo>=</mml:mo><mml:mspace width="0.25em"/><mml:mn>3</mml:mn><mml:mspace width="0.25em"/><mml:mo>×</mml:mo><mml:mspace width="0.25em"/><mml:mi>m</mml:mi><mml:mo stretchy="true">/</mml:mo><mml:mfenced close=")" open="("><mml:mrow><mml:mn>4</mml:mn><mml:mspace width="0.25em"/><mml:mo>×</mml:mo><mml:mspace width="0.25em"/><mml:mi>r</mml:mi><mml:mspace width="0.25em"/><mml:mo>×</mml:mo><mml:mspace width="0.25em"/><mml:mi>p</mml:mi><mml:mspace width="0.25em"/><mml:mo>×</mml:mo><mml:mspace width="0.25em"/><mml:msup><mml:mi>r</mml:mi><mml:mn>3</mml:mn></mml:msup><mml:mspace width="0.25em"/><mml:mo>×</mml:mo><mml:mspace width="0.25em"/><mml:msub><mml:mi>V</mml:mi><mml:mi>S</mml:mi></mml:msub></mml:mrow></mml:mfenced></mml:math><tex-math id="M2">\documentclass[12pt]{minimal}				\usepackage{amsmath}				\usepackage{wasysym} 				\usepackage{amsfonts} 				\usepackage{amssymb} 				\usepackage{amsbsy}				\usepackage{mathrsfs}				\usepackage{upgreek}				\setlength{\oddsidemargin}{-69pt}				\begin{document}$$ n = {V}_T/{V}_P = 3 \times m/\left(4 \times r \times p \times {r}^3 \times {V}_S\right) $$\end{document}</tex-math><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11356_2014_3384_Article_Equa.gif" position="anchor" orientation="portrait"/></alternatives></disp-formula>with <italic toggle="yes">V</italic><sub><italic toggle="yes">T</italic></sub> the volume of all gold nanoparticles, <italic toggle="yes">V</italic><sub><italic toggle="yes">P</italic></sub> the average volume of one nanoparticle, <italic toggle="yes">m</italic> the total mass of used gold, <italic toggle="yes">ρ</italic> the density of gold (19.28 g cm<sup>−3</sup>), and <italic toggle="yes">V</italic><sub><italic toggle="yes">S</italic></sub> the solution volume.</p><p>Thus, with an average diameter of about 33 nm, the nanoparticles prepared are dispersed with a number density of about 5.4 × 10<sup>11</sup> particles/mL.</p></sec></sec>
25109469|SERS assay of nanoprobes|('method', 0.8337544989118548)|('other', 0.1662455010881451)|<sec id="Sec16"><title>SERS assay of nanoprobes</title><p>Prepared DSNB and the nanoprobe made of DNSB and antibodies were analyzed by Raman spectroscopy. The spectra of the range 600 and 1,800 cm<sup>−1</sup> are presented in Fig. <xref rid="Fig3" ref-type="fig">3</xref>. The free DSNB spectrum reported in Fig. <xref rid="Fig3" ref-type="fig">3a</xref> is obtained by subtracting the spectrum of the pure solvent from the acetonitrile solution. This spectrum is dominated by the symmetric nitro stretch at 1,346 cm<sup>−1</sup>. The band at 1,572 cm<sup>−1</sup> is assigned to an aromatic ring mode, and the band at 1,081 cm<sup>−1</sup> is a succinimidyl N–C–O stretch overlapping with aromatic ring modes (Grubisha et al. <xref ref-type="bibr" rid="CR10">2003</xref>). The same bands in the solution spectrum are also observable in the spectrum of the DSNB nanoprobes (Fig. <xref rid="Fig3" ref-type="fig">3b</xref>), although NO<sub>2</sub> signal has shift which is probably assigned to the solvant effect due to the C≡N group of acetoniltrile. We were especially interested in the higher intensity bands to estimate the enhancement factor obtained with the Raman probes that we have prepared. Taking into account the areas of the symmetric nitro stretch bands and the concentration ratio of DSNB for each sample, an enhancement factor equal to about 36,000 is calculated. In order to stick to this calculation, the experimental conditions were proceed the same way for each (exposition time, laser power, …).This estimation assumes that the recovery rate of gold nanoparticles by reporter molecules is equal to 1 molecule/nm<sup>2</sup>.<fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p> Raman spectra of DSNB: (a) Spectrum of DSNB in acetonitrile solution at C<sub>0</sub> concentration (10s); (b) SERS spectrum of gold nanoprobe solution with DSNB at C<sub>0</sub>/10 concentration (10s)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11356_2014_3384_Fig3_HTML.gif" id="MO5" position="float" orientation="portrait"/></fig></p></sec>
25109469|Nanoprobe activity by surface plasmon resonance sensor|('method', 0.8337544989118548)|('other', 0.1662455010881451)|<sec id="Sec17"><title>Nanoprobe activity by surface plasmon resonance sensor</title><p>We have studied the nanoprobe activity by surface plasmon resonance (SPR) spectroscopy using a gold surface covered with BaP. We observed that the coupling of BaP13 antibodies to gold nanoparticles did not affect their affinity for the molecules of benzo[a]pyrene.</p></sec>
25109469|BaP detection|('method', 0.8337544989118548)|('other', 0.1662455010881451)|<sec id="Sec18"><title>BaP detection</title><p>Figure <xref rid="Fig4" ref-type="fig">4</xref> presents the results obtained with concentrations of BaP 0 and 2 nmol/L in natural 1 μm-filtered seawater from Argenton, France. When there is no BaP in the sample, the grafted antibodies onto the nanoparticles recognize and adsorb the BaP molecules immobilized at the surface of the sensor. Hence, the signal of reporter on spectrum (a.) in Fig. <xref rid="Fig4" ref-type="fig">4</xref> is important. On this spectrum, we observe the Raman bands related to C–H (from 700 to 1,000 cm<sup>−1</sup>), C–N (from 1,000 to 1,200 cm<sup>−1</sup>), N–O (from 1,300 to 1,400 cm<sup>−1</sup>), and C═C (from 1,500 to 1,600 cm<sup>−1</sup>) bonds of DSNB. These bands are nearly extinct in the spectrum (b.) in Fig. <xref rid="Fig4" ref-type="fig">4</xref> obtained in the presence of BaP at the concentration of 2 nmol/L. This is perfectly in accordance with the sensing method. Indeed the BaP molecules in the analyzed sample inhibit Raman probes to adsorb on the sensor surface by blocking the antigenic sites free of antibodies at the surface of these probes. Hence, a significant attenuation of the SERS effect was observed. However, it is important to note that this result suffers of a lack of reproducibility. Indeed, a more advanced work on the effectiveness of the analysis is underway to solve this problem.<fig id="Fig4" position="float" orientation="portrait"><label>Fig. 4</label><caption><p>Results of SERS immunoassay for BaP at 0 nmol/L (a) and 2 nmol/L (b)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="11356_2014_3384_Fig4_HTML.gif" id="MO6" position="float" orientation="portrait"/></fig></p></sec>
25109880|None|('method', 0.998773908549683)|('other', 0.001226091450316998)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
25109880|None|('method', 0.998773908549683)|('other', 0.001226091450316998)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">AHOD has been described elsewhere in detail (<xref rid="R26" ref-type="bibr">26</xref>-<xref rid="R28" ref-type="bibr">28</xref>). Briefly, AHOD data collection commenced in 1999 and currently 27 hospitals, sexual health clinics, and general medical practices throughout Australia contribute data every 6 months. At March 2011, over 3000 patients had been recruited to AHOD, and over 2000 were under active follow-up. Data are collected on a core set of variables including sex, age, HIV exposure category, hepatitis B virus surface antigen (HBV), hepatitis C antibody status (HCV), CD4 and CD8 cell counts, viral load, ARV history, AIDS illnesses, date and cause of death. Additional ethics approval was sought for the current sub-study and approved by all local Human Research Ethics Committees.</p>
25109880|None|('method', 0.998773908549683)|('other', 0.001226091450316998)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">Sexual health clinics within AHOD were invited to provide retrospective data for 2005-2010 , and prospective data thereafter. Besides the core AHOD data above, extra STI-specific data variables were extracted from each clinic database and sent electronically to the Kirby Institute twice annually. They included confirmed diagnoses of STI, (infectious syphilis, chlamydia, gonorrhoea, and genital warts), site of infection, STI treatment, and injecting drug use. Specifically, specimens were taken according to symptoms, and/or adherence to guidelines for routine screening in MSM (<xref rid="R29" ref-type="bibr">29</xref>), that included blood, urine, and swabs from ano-genital and pharyngeal sites. They were tested using nucleic acid amplification tests for chlamydia and gonorrhoea, and in the latter case, included supplemental testing, and/or culture, as per current guidelines (<xref rid="R30" ref-type="bibr">30</xref>,<xref rid="R31" ref-type="bibr">31</xref>).</p>
25109880|None|('method', 0.998773908549683)|('other', 0.001226091450316998)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P10">For syphilis, a positive screening enzyme immunoassay (EIA) was confirmed with the <italic>Treponema pallidum</italic> particle agglutination assay and/or the fluorescent treponemal antibody absorption test. The rapid plasma reagin (RPR) test was used to assist clinical staging and to detect re-infection. Infectious syphilis was defined using conventional criteria (<xref rid="R32" ref-type="bibr">32</xref>).</p>
25109880|None|('method', 0.998773908549683)|('other', 0.001226091450316998)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">We tabulated patient characteristics and evaluated differences between AHOD-STI participants and the remaining AHOD population. The extra variables had been collected by some clinics from 1999, and from others since that time. Inspection of eight of the ten databases that used the same data capture mechanism showed that all were consistently recording these STI data by 2005. Therefore, it was possible to calculate diagnosis rates for all STIs and selected STIs, from 2005-2011. We calculated temporal STI diagnosis rates 2005-2011 by summing the total number of patients diagnosed with an STI in a given calendar year divided by the total number of patient years observed in the same period . We used Poisson confidence intervals to evaluate the uncertainty of the calculated rate. Rates are expressed per 100 person-years, and approximate very closely true incidence rates, which by convention are usually restricted in cohort studies to prospective data from baseline, (in this case, 2010), to reflect potentially more uniformly collected data of better quality. We used the Cochran-Armitage statistic to test for a p-trend over the same period.</p>
25110346|None|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2. Material and methods</title>
25110346|2.1. Animal models|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1. Animal models</title><sec id="S4"><title>2.1.1. Model of heart failure</title><p id="P15">Eight weeks old C57BL/6 male mice were purchased from Janvier (CERJ, Saint Berthevin, France). Animals were housed at 5 per cage under controlled environmental conditions, with 12 h light: dark cycle at 22°C of controlled temperature, food and water ad libitum. Animal experiments were conducted in agreement with our institutional guidelines for the use of animals in research.</p><p id="P16">Mice were anesthetized by intraperitoneal injection of pentobarbital sodium (50 mg/kg), intubated, and mechanically ventilated with 100% oxygen <italic>via</italic> a positive pressure Respirator (Minivent type 845, Hugo Sachs, Elektronik-Harvard Apparatus, Germany). The ventilation rate was 170 strokes per minute, and the tidal volume was 200 μl. Body temperature was maintained at 37°C. A left thoracotomy was performed in the fourth intercostal space to induce left ventricular infarction (myocardial infarction, MI) by ligation of the left anterior descending coronary with an 8-0 Prolene, or for a sham operation (Sham). The chest was closed in layers. Myocardial ischemia was confirmed by the occurrence of regional blanching. Echocardiographic examination was performed under isoflurane sedation, using the echocardiography-Doppler (General Electric Medical systems Co, Vivid 7 Dimension/Vivid 7 PRO) with a probe emitting ultrasounds with 9–14 MHz frequency. Two-dimensional images and M-mode measurements were used to quantify left ventricular dimension and function. At least three sets of measures were obtained from three different cardiac cycles. Echocardiography was performed at 1 month and 6 months after MI. At 6 months, the animals were sacrificed and the heart removed for morphometric analysis and tissue sampling.</p></sec><sec id="S5"><title>2.1.2. Model of atherosclerosis</title><p id="P17">ApoE−/− mice were purchased from Charles River. Mice were housed under a 12-hour light/12-hour dark cycle (relative humidity: 55–60%; temperature: 22°C) and were given standard chow and water ad libitum. At 48 weeks of age, male mice were sacrificed by a lethal dose of pentobarbital (intra-peritoneal injection) and heart tissues with attached aortic roots and aortas were collected. Aortas were immediately dissected, snap frozen in RNA later (Ambion) and stored at −80°C for subsequent RNA extraction. Heart tissues were fixed in 4% formalin for 1h then soaked in 20% glucose overnight. Tissues were frozen and stored at −80°C.</p></sec></sec>
25110346|2.2 Ultrasound biomicroscopy of atherosclerosis lesions in the brachiocephalic arteries|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S6"><title>2.2 Ultrasound biomicroscopy of atherosclerosis lesions in the brachiocephalic arteries</title><p id="P18">Images were acquired of the brachiocephalic artery every 3 weeks in mice starting from 30 weeks of age up to 48 weeks. Prior to ultrasound examination, all mice were anesthetized with 3% isoflurane gas and maintained lightly anaesthetized with an isoflurane dose of 1.5% during analysis (Minerve Veterinary Equipment, France). The hair of the anterior chest wall was removed and ultrasound transmission gel was applied liberally before scanning. Ultrasound examinations were performed using the Ultrasound Biomicroscope (VEVO 2100, Visualsonics, Toronto) with a 40 MHz probe (MS550D). The Ultrasound Biomicroscope allows real time <italic>in vivo</italic> observations at high resolution (90 and 40 μM lateral and axial resolution, respectively) using a high frequency transducer (40 MHz). Real time visualization was assessed at 60 images/sec. Images were taken in B-mode, or 2 dimensional mode. The probe was positioned in a right parasternal and longitudinal long- and short-axis view at the level of the ascending aorta. More specifically, the location transducer was at the lower 1/3<sup>rd</sup> of the chest; the direction of the transducer was posterior and leftward, 70° with the coronal plane; the orientation of the imaging plane was parallel to the central axis of the mouse’s body. Proximal and distal plaque areas were defined respectively as the plaque close to the aortic root and the plaque close to the bifurcation of the left subclavian artery. The long axis view in B-mode was used to the bifurcation of the left subclavian artery. The long axis view in B-mode was used to measure the total atherosclerotic plaque surface (mm<sup>2</sup>); lesions visualized in the superior and inferior portion of the brachiocephalic artery were outlined and measured by the VEVO2100 software. The image chosen from each ultrasonographic sequence corresponds to the one representing the largest detected atherosclerotic plaque for all mice.</p></sec>
25110346|2.3 RNA extraction of aortas|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>2.3 RNA extraction of aortas</title><p id="P19">Tissues were thawed and homogenized in an Ultrathurax mechanical homogenizer. mRNA was extracted using the standard Trizol protocol (Life technologies) until phase separation. RNA precipitation was performed using the RNeasy Midi Kit (Qiagen) according to the manufacturer’s instructions, in order to optimize RNA collection and reduce the risk of contamination by organic solvents. RNA quality was determined by agarose gel electrophoresis with ethidium bromide; the 18S and 28S RNA bands were visualized under UV light.</p></sec>
25110346|2.4 Histological analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>2.4 Histological analysis</title><p id="P20">Cardiac fibrosis was determined by Sirius Red staining by using a Picrosirius Red Stain Kit (Polysciences Inc.). Cryosections were fixed in Bouin’s solution (1h, 56°C), then stained with Sirius red. Collagen fibers in the heart stained a red color and cardiac fibrotic area was evaluated using ImageJ software. Cardiac fibrosis was quantified including the infarct scar. Size of cardiomyocytes was evaluated on cross sections using Wheat germ agglutinin (WGA) Alexa Fluor® 488 conjugate (Invitrogen).</p></sec>
25110346|2.5 Real-time quantitative reverse transcription–polymerase chain reaction (RT-PCR) assays|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>2.5 Real-time quantitative reverse transcription–polymerase chain reaction (RT-PCR) assays</title><p id="P21">Relative gene expression was determined using two-step quantitative real-time PCR. Total RNA was isolated with TRIzol reagent (Invitrogen) followed by a cleanup step as described in the RNeasy Isolation kit (Qiagen) with on-column DNase I treatment to eliminate contaminating genomic DNA with RNase-free DNase Set (Qiagen). After annealing oligodT (1 μM) to template RNAs (0.5 μg) at 70°C for 5 minutes, primer extension was initiated by adding the RT-MMLV enzyme plus 0.5 mM dNTP, 1U RNAsin and 10 mM dithiothreitol (DTT), and carried out for 45 minutes at 37°C. Quantitative PCR was performed using the Light Cycler LC480 (Roche Diagnostics). The PCR mix included 5 μl of each reverse transcriptase (diluted 1:25) and 300 nM of each primer in 1 × Light Cycler DNA SYBR Green 1 Master Mix. The forward and reverse primer sequences for complementary DNA (cDNA) of mouse genes (<xref rid="T1" ref-type="table">Table 1</xref>) were designed with the Primer Express software according to European Molecular Biology Laboratory accession numbers.</p><p id="P22">PCRs were performed using the following thermal settings: denaturation and enzyme activation at 95°C for 5 minutes, followed by 40 cycles of 95°C (10 s), 60°C (15 s), and 72°C (15 s). Post-amplification dissociation curves were performed to verify the presence of a single amplification product and the absence of primer dimers. Controls and water blanks were included in each run; they were negative in all cases. Relative expression of a target gene (SERCA) was standardized by a non-regulated reference gene (GAPDH or calsequestrin). Real-time quantitative PCR data represent the amount of each target messenger RNA (mRNA) relative to the amount of GAPDH gene mRNA or cardiac calsequestrin gene mRNA, estimated in the logarithmic phase of the PCR. Each specific cDNA amplicon was purified and serial dilutions of determined concentration were used to determine the fit coefficients of the relative standard curve. Absolute quantification of SERCA mRNA was performed by interpolation of its PCR signal (Cq) into this standard curve using the Livak-Schmittgen equation: <inline-formula><mml:math id="M1" overflow="scroll"><mml:mtext>Quantity</mml:mtext><mml:mo>=</mml:mo><mml:msup><mml:mn>10</mml:mn><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mrow><mml:mtext>Cq</mml:mtext><mml:mo>-</mml:mo><mml:mi mathvariant="normal">b</mml:mi></mml:mrow><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:mi mathvariant="normal">m</mml:mi></mml:mrow></mml:msup></mml:math></inline-formula>, where b is the y-intercept and m is the slope of the linear regression [<xref rid="R23" ref-type="bibr">23</xref>].</p></sec>
25110346|2.6 Protein analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>2.6 Protein analysis</title><p id="P23">Immunoblots were performed according to a standard protocol. Immunolabeling were performed on acetone-fixed sections according to a standard protocol. The following SERCA primary antibodies were used: anti-SERCA2a and anti-SERCA2b were from affinity Bioreagent, the anti-SERCA2c was directed against the corresponding human peptide (YLEPVLSSEL) that is mostly preserved in the potential mice SERCA2c terminal part (YLEQPVLSLEP) and was produce by Eurogentec. The anti-SERCA3a (C90) was raise against the human sequence and was already used to recognize SERCA3a in mice (), anti-SERCA3b was specifically raised against the mice peptide TGKKGPEVNPNPGSRGES, and the anti-SERCA3c was directed against the human C-Terminal peptide of SERCA3c; HTGLASLKK that is also very close to the C-terminal part of the mice SERCA3c: HTGLASWKKRT. [<xref rid="R1" ref-type="bibr">1</xref>, <xref rid="R7" ref-type="bibr">7</xref>]. The others primary antibodies used were purchased from Santa Cruz Biotechnology: anti-<underline>g</underline>lycer<underline>a</underline>ldehyde 3-<underline>p</underline>hosphate <underline>d</underline>e<underline>h</underline>ydrogenase (GAPDH) (sc-47424), anti-calsequestrine (sc-28274) and anti-desmin (sc-271677) and anti-PECAM (sc-1506).</p></sec>
25110346|2.7 Confocal Immunofluorescence Microscopy|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S11"><title>2.7 Confocal Immunofluorescence Microscopy</title><p id="P24">Immunostaining was performed using the described upper primary antibodies and secondary antibodies conjugated to Alexa-546 or Alexa-488. Slides were examined with a Leica TCS4D confocal scanning laser microscope equipped with a 25 mW argon laser and a 1 mW helium-neon laser, using a Plan Apochromat 63X objective (NA 1.40, oil immersion). Green fluorescence was observed with a 505–550 nm band-pass emission filter under 488 nm laser illumination. Red fluorescence was observed with a 560 nm long-pass emission filter under 543 nm laser illumination. Pinholes were set at 1.0 airy units. Stacks of images were collected every 0.4 μm along the z-axis. All settings were kept constant to allow comparison. For double immunofluorescence, dual excitation using the multitrack mode (images taken sequentially) was achieved using the argon and He/Ne lasers.</p></sec>
25110346|2.8 Statistical analysis|('method', 0.9999998999999902)|('other', 1.0000000994736041e-07)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S12"><title>2.8 Statistical analysis</title><p id="P25">All quantitative data are presented as mean of at least 3 independent experiments ± SEM. One-way ANOVA tests were performed for comparisons between multiple groups. Statistical comparisons of 2 groups were done by an unpaired Student’s t-test. Differences were considered significant for P&lt;0.05.</p></sec>
25110346|None|('method', 0.8962654107243089)|('other', 0.10373458927569126)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
25110346|None|('method', 0.8962654107243089)|('other', 0.10373458927569126)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>01</label><media xlink:href="NIHMS620013-supplement-01.pdf" orientation="portrait" xlink:type="simple" id="d36e1065" position="anchor"/></supplementary-material>
25110354|None|('method', 0.5923769094763185)|('other', 0.4076230905236815)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II. Identification of the Impact of the Wage Gap on Domestic Violence</title>
25110354|None|('method', 0.5923769094763185)|('other', 0.4076230905236815)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P13">There are two main threats to identification of the impact of the gender wage gap on domestic violence. The first is the lack of objective measures of domestic violence collected consistently over time. Previous work has found that self-reported measures of domestic violence are under-estimates, and that the degree of misreporting is non-random (<xref rid="R13" ref-type="bibr">Mary Ellsberg et al, 2001</xref>). Even if one could accurately model the degree of under-reporting, there exists no panel of self-reported domestic violence that would enable one to estimate the impact of changes in labor market conditions. Utilizing a cross-section of data is problematic because of the difficulty controlling for multiple differences (in addition to labor market conditions), across geographic regions that might bias estimates.</p>
25110354|None|('method', 0.5923769094763185)|('other', 0.4076230905236815)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P14">The second threat to identification is the difficulty constructing measures of relative labor market conditions that do not reflect the underlying characteristics of male and female workers which could be a function of underlying violence (abused women are less productive) or unobservables that might be correlated with violence (eg education). Thus, for purposes of identification, one ought to construct a measure of prevailing female (male) wages that reflects only the exogenous demand for female (male) labor.</p>
25110354|None|('method', 0.5923769094763185)|('other', 0.4076230905236815)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P15">To address these two threats to identification I construct new measures of both violence against women and relative wages. The measure of violence against women is derived from administrative data on female hospitalizations for assault for the state of California. This measure is collected consistently over a long period of time (1990–2003) and contains detailed geographic identifiers that enable one to characterize the local labor market and include local market (county) fixed effects. In addition, this measure does not rely on self-reports of domestic violence. I include all hospitalizations for assault based on physician classification of injury. As such, the measure is not a function of self-reported battery. However, this measure will also reflect non-intimate violence. To the extent that three quarters of violence against women is intimate and I can control for trends in non-intimate violent crime in the regressions, any potential bias from this measurement error is limited.<sup><xref ref-type="fn" rid="FN4">4</xref></sup></p>
25110354|None|('method', 0.5923769094763185)|('other', 0.4076230905236815)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P16">The measure of relative wages is constructed so as to reflect exogenous demand for female and male labor and is based on the index of labor demand originally proposed by <xref rid="R3" ref-type="bibr">Bartik (1991)</xref> and subsequently used by <xref rid="R5" ref-type="bibr">Blanchard and Katz (1992)</xref>, <xref rid="R7" ref-type="bibr">John Bound and Harry J. Holzer (2000)</xref>, <xref rid="R17" ref-type="bibr">Hilary W. Hoynes (2000)</xref>, and <xref rid="R2" ref-type="bibr">David Autor and Mark Duggan (2003)</xref>. This strategy takes advantage of a history of sex and race segregation by industry that is well established (<xref rid="R4" ref-type="bibr">Kimberly Bayard, et al, 1999</xref>) to construct measures of local labor market wages of women (men) that are based on wage changes in industries dominated by women (men). For example, data for California reveal that 72 percent of service industry employees are women while 90 percent of those employed in the construction industry are men.</p>
25110354|None|('method', 0.5923769094763185)|('other', 0.4076230905236815)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P17">Average annual wages are calculated by gender and race in each county as follows:<disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:msub><mml:mover accent="true"><mml:mi>w</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mrow><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>c</mml:mi><mml:mi>y</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:munder><mml:mo>∑</mml:mo><mml:mi>j</mml:mi></mml:munder><mml:msub><mml:mi>γ</mml:mi><mml:mrow><mml:mi>g</mml:mi><mml:mi>r</mml:mi><mml:mi>c</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>w</mml:mi><mml:mrow><mml:mo>−</mml:mo><mml:mi>c</mml:mi><mml:mi>y</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula>where <italic>g</italic> indexes gender, <italic>r</italic> race, <italic>c</italic> county, <italic>y</italic> year and <italic>j</italic> industry. γ<sub><italic>grjc</italic></sub> is the proportion of female (or male) workers with no more than a high school degree of a given race working in industry <italic>j</italic> in county <italic>c</italic> (from the 1990 census). I focus on low-skilled workers because violence is much more prevalent among this group (see <xref ref-type="table" rid="T1">Table 1</xref>). This proportion (γ) is fixed over this period so that changes in the wage do not reflect selective sorting across industries over this period. <italic>W<sub>−cyj</sub></italic> is the annual wage in industry <italic>j</italic> in the state except for county <italic>c</italic> in year <italic>y</italic> from the Bureau of Economic Analysis annual survey of employers. By measuring prices over all counties in the state except the focal county, I remove from the measure any changes in industry wages that might be caused by changes in the underlying characteristics of workers in the county. With the wage constructed in this way, identification comes from the fact that counties with many workers in industries characterized by large, state-wide wage growth will experience larger increases in average wages than counties with many workers in low wage-growth industries.<sup><xref ref-type="fn" rid="FN5">5</xref></sup></p>
25110354|None|('method', 0.5923769094763185)|('other', 0.4076230905236815)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P18">This inflation-adjusted measure of the female/male wage ratio increases 3.6 percentage points between 1990 and 2003 from 0.945 to 0.981. Over this period, the true wage ratio increased from 70 to 75.5 percent (5.5 percentage points) among low skilled workers in California. We can think of the true wage gap as composed of a between-industry and a within-industry component, with the wage gap measured according to (1) representing the between-industry wage gap. It is interesting to note that even though within-industry differences in wages (between men and women) explain more of the total wage gap than between-industry differences <italic>in levels</italic>, between-industry differences explain more of the <italic>change</italic> in the wage gap over the period 1990–2003.</p>
25110354|None|('method', 0.783520037107824)|('other', 0.2164799628921761)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Supplementary Material</title>
25110354|None|('method', 0.783520037107824)|('other', 0.2164799628921761)|<supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="local-data" id="SD1"><label>01</label><media xlink:href="NIHMS515426-supplement-01.pdf" mimetype="application" mime-subtype="pdf" orientation="portrait" xlink:type="simple" id="d36e665" position="anchor"/></supplementary-material>
25125453|None|('method', 0.9453581529169085)|('other', 0.054641847083091506)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2 Two-level model</title>
25125453|2.1 Statistical model|('method', 0.9453581529169085)|('other', 0.054641847083091506)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S3"><title>2.1 Statistical model</title><p id="P5">When the group-based experimental arm assumes a two level data structure, and the control arm assumes a one level data structure, a pertinent mixed-effects linear model can be formulated as follows</p><disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></disp-formula><p id="P6">The two sets, E and C, are defined as: E = {<italic>j</italic>, <italic>k</italic> | <italic>X<sub>jk</sub></italic> = 1} and C = {<italic>j</italic>, <italic>k</italic> | <italic>X<sub>jk</sub></italic> = 0}. Groups in the experimental arm are indexed by <italic>j</italic> = 1, 2, …, <italic>J</italic> for <italic>j</italic> ∈ E so that #{<italic>j</italic> | <italic>j</italic> ∈ E} = <italic>J</italic>, where #{.} denotes the number of elements in the set {.}. Although there are no groups in the control arm, we assign “pseudo” group indices for observations from the control arm subjects as follows: <italic>j</italic> = <italic>J</italic> + 1, <italic>J</italic> + 2, …, <italic>J</italic> + <italic>J</italic>′ for <italic>j</italic> ∈ C so that #{<italic>j</italic> | <italic>j</italic> ∈ C} = <italic>J</italic>′. Subjects are indexed by <italic>k</italic> = 1, 2, …, <italic>K<sub>j</sub></italic> and <italic>K<sub>j</sub></italic> &gt; 1 for <italic>j</italic> ∈ E and <italic>K<sub>j</sub></italic> = 1 for <italic>j</italic> ∈ C so that each subject serves as his/her own group in the control arm. The total number of subjects in the experimental arm is denoted by <inline-formula><mml:math id="M2" overflow="scroll"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:msubsup><mml:msub><mml:mi>K</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>, whereas that in the control arm is denoted by <inline-formula><mml:math id="M3" overflow="scroll"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>J</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msubsup><mml:msub><mml:mi>K</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi>J</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:math></inline-formula>.</p><p id="P7">The fixed-effect parameters <italic>β</italic><sub>0</sub> and <italic>δ</italic><sup>(2)</sup> represent the intercept and the main effect of the experimental intervention on the outcome <italic>Y</italic><sup>(2)</sup>, respectively. Group-specific random effects in the experimental arm are denoted by <inline-formula><mml:math id="M4" overflow="scroll"><mml:mrow><mml:msub><mml:mi>u</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> for <italic>j</italic> ∈ E. The random noise is denoted by <italic>e<sub>jk</sub></italic> which is assumed to be <inline-formula><mml:math id="M5" overflow="scroll"><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. Furthermore, although <italic>u<sub>j</sub></italic> and <italic>e<sub>jk</sub></italic> are assumed to be mutually independent (mutual independence assumption), the elements of <italic>e<sub>jk</sub></italic> are assumed to be independent over <italic>k</italic> for given <italic>u<sub>j</sub></italic> (conditional independence assumption). We assume that the magnitudes of all variance components in model (<xref rid="FD1" ref-type="disp-formula">1</xref>) are known.</p><p id="P8">Under these assumptions, it can be shown that <inline-formula><mml:math id="M6" overflow="scroll"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M7" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></inline-formula>. Let <inline-formula><mml:math id="M8" overflow="scroll"><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>≡</mml:mo><mml:mi mathvariant="italic">Var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∣</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> denote the variance of <italic>Y</italic><sup>(2)</sup> in the experimental arm, then the intra-class correlation coefficient (ICC) of outcome <italic>Y</italic> within groups in the experimental arm can be expressed as</p><p id="P9"><disp-formula id="FD2"><label>(2)</label><mml:math id="M9" display="block" overflow="scroll"><mml:mrow><mml:mi>ρ</mml:mi><mml:mo>≡</mml:mo><mml:mi mathvariant="italic">Corr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></disp-formula> for <italic>k</italic> ≠ <italic>k</italic>′ and <italic>j</italic> ∈ E. The variance of <italic>Y</italic><sup>(2)</sup> in the control arm is simply equal to <inline-formula><mml:math id="M10" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>, i.e. <inline-formula><mml:math id="M11" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∣</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>≤</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> for <italic>j</italic> ∈ C. The null hypothesis for testing the significance of the main effect of experimental intervention is H<sub>0</sub>: <italic>δ</italic><sup>(2)</sup> = 0.</p></sec>
25125453|2.2 Parameter estimates and variances|('method', 0.9453581529169085)|('other', 0.054641847083091506)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S4"><title>2.2 Parameter estimates and variances</title><p id="P10">An estimate of <italic>δ</italic><sup>(2)</sup> under model (<xref rid="FD1" ref-type="disp-formula">1</xref>) can be obtained as</p><p id="P11"><disp-formula id="FD3"><mml:math id="M12" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></disp-formula> where</p><p id="P12"><disp-formula id="FD4"><mml:math id="M13" display="block" overflow="scroll"><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:munderover><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo stretchy="true">/</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:msub><mml:mi>K</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:mtext>and</mml:mtext><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>J</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="true">/</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>J</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:msub><mml:mi>K</mml:mi><mml:mi>j</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>J</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:math></disp-formula> are the sample means of <italic>Y</italic><sup>(2)</sup> in the experimental and control arms, respectively. The variances of these means can be expressed as</p><p id="P13"><disp-formula id="FD5"><mml:math id="M14" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula> and</p><disp-formula id="FD6"><mml:math id="M15" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><p id="P14">It follows that</p><disp-formula id="FD7"><label>(3)</label><mml:math id="M16" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula></sec>
25125453|2.3 Test statistics, power functions and sample size formulae|('method', 0.9453581529169085)|('other', 0.054641847083091506)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S5" sec-type="results"><title>2.3 Test statistics, power functions and sample size formulae</title><p id="P15">The following test statistic <italic>D</italic><sup>(2)</sup> can be used to test the null hypothesis H<sub>0</sub>: <italic>δ</italic><sup>(2)</sup> = 0</p><disp-formula id="FD8"><mml:math id="M17" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msqrt><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msqrt></mml:mfrac><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:msqrt><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:mstyle displaystyle="true"><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover></mml:mstyle><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><p id="P16">The power function <italic>D</italic><sup>(2)</sup> at a two-sided significance level of <italic>α</italic> can be expressed as follow</p><p id="P17"><disp-formula id="FD9"><label>(4)</label><mml:math id="M18" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mi>φ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>≡</mml:mo><mml:mi>φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="true">/</mml:mo><mml:msqrt><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>J</mml:mi></mml:munderover><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>j</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:msqrt><mml:mo>-</mml:mo><mml:msup><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula> where Δ<sub>(2)</sub> = |<italic>δ</italic><sup>(2)</sup>/<italic>σ</italic>| is a standardized effect size or Cohen’s d<sup><xref rid="R17" ref-type="bibr">17</xref></sup> and Φ is the cumulative distribution function (CDF) of a standard normal distribution. Determination of varying group sizes <italic>K<sub>j</sub></italic>’s, or <italic>N</italic><sub>E</sub>, for fixed <italic>N</italic><sub>C</sub> can be made by solving <xref rid="FD9" ref-type="disp-formula">equation (4)</xref> iteratively for <italic>K<sub>j</sub></italic>’s. On the other hand, determination of sample size <italic>N</italic><sub>C</sub> for fixed group sizes <italic>K<sub>j</sub></italic>’s, or <italic>N</italic><sub>E</sub> should be straightforward by solving <xref rid="FD9" ref-type="disp-formula">equation (4)</xref> for <italic>N</italic><sub>C</sub>.</p><p id="P18">For special cases of equal number of units, sample size determinations are much more tractable. Suppose that group sizes are equal in the experimental arm, i.e. <italic>K<sub>j</sub></italic> = <italic>K</italic> for all <italic>j</italic> ∈ E so that <italic>N</italic><sub>E</sub> = <italic>JK</italic>, and that total numbers of subjects are the same between the two arms, i.e. <italic>N</italic><sub>E</sub> = <italic>JK</italic> = <italic>N</italic><sub>C</sub>, then the variance (<xref rid="FD7" ref-type="disp-formula">3</xref>) can be reduced to</p><p id="P19"><disp-formula id="FD10"><mml:math id="M19" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mi>J</mml:mi><mml:mi>K</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="false">{</mml:mo><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>K</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:math></disp-formula> which simplifies the power function (<xref rid="FD9" ref-type="disp-formula">4</xref>) to</p><disp-formula id="FD11"><label>(5)</label><mml:math id="M20" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mi>φ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:msqrt><mml:mfrac><mml:mrow><mml:mi>J</mml:mi><mml:mi>K</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>K</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac></mml:msqrt><mml:mo>-</mml:mo><mml:msup><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><p id="P20">It follows that the number of groups for fixed group sizes in E can be expressed as</p><p id="P21"><disp-formula id="FD12"><label>(6)</label><mml:math id="M21" display="block" overflow="scroll"><mml:mrow><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>{</mml:mo><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>K</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>K</mml:mi><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula> and the group sizes for fixed number of groups in E can be expressed as</p><p id="P22"><disp-formula id="FD13"><label>(7)</label><mml:math id="M22" display="block" overflow="scroll"><mml:mrow><mml:mi>K</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>-</mml:mo><mml:mi>ρ</mml:mi><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula> for <inline-formula><mml:math id="M23" overflow="scroll"><mml:mrow><mml:mi>ρ</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>J</mml:mi><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>, where</p><p id="P23"><disp-formula id="FD14"><label>(8)</label><mml:math id="M24" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msup><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msup><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mi>φ</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></disp-formula> and Φ<sup>−1</sup> is the inverse CDF of a standard normal distribution. We note that when <italic>K</italic> needs to be determined for a desired level of power for a given <italic>J</italic>, it is possible that <italic>K</italic> cannot be determined, especially when <italic>J</italic> is small and <italic>ρ</italic> (<xref rid="FD2" ref-type="disp-formula">2</xref>) is large, resulting in a combination which can make the denominator of <xref rid="FD13" ref-type="disp-formula">equation (7)</xref> negative. Therefore, when only a limited number of groups <italic>J</italic> are feasible to form, the correlation <italic>ρ</italic> in particular must be small enough for <inline-formula><mml:math id="M25" overflow="scroll"><mml:mrow><mml:mi>ρ</mml:mi><mml:mo>&lt;</mml:mo><mml:mi>J</mml:mi><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> to be true in <xref rid="FD13" ref-type="disp-formula">equation (7)</xref>.</p></sec>
25125453|None|('method', 0.9322484077100647)|('other', 0.06775159228993514)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">3 Three-level model</title>
25125453|3.1 Statistical model|('method', 0.9322484077100647)|('other', 0.06775159228993514)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>3.1 Statistical model</title><p id="P24">When the group-based intervention arm assumes a three level data structure while the control arm assumes a two level data structure, model (<xref rid="FD1" ref-type="disp-formula">1</xref>) can be extended as follow</p><disp-formula id="FD15"><label>(9)</label><mml:math id="M26" display="block" overflow="scroll"><mml:mrow><mml:msubsup><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mi>X</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:msub><mml:mi>X</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>e</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub></mml:mrow></mml:math></disp-formula><p id="P25">The two sets are defined as E = {<italic>i</italic>, <italic>j</italic>, <italic>k</italic> | <italic>X<sub>ijk</sub></italic> = 1} and C = {<italic>i</italic>, <italic>j</italic>, <italic>k</italic> | <italic>X<sub>ijk</sub></italic> = 0}. Centers are indexed by <italic>i</italic> = 1, 2, …, <italic>I</italic> for <italic>i</italic> ∈ E so that #{<italic>i</italic> | <italic>i</italic> ∈ E} = <italic>I</italic> and <italic>i</italic> = <italic>I</italic> + 1, <italic>I</italic> + 2, …, <italic>I</italic> + <italic>I</italic>′ for <italic>i</italic> ∈ C so that #{<italic>i</italic> | <italic>i</italic> ∈ C} = <italic>I</italic>′. Groups are indexed by <italic>j</italic> = 1, 2, …, <italic>J<sub>i</sub></italic> and subjects by <italic>k</italic> = 1, 2, …, <italic>K<sub>ij</sub></italic>. Concerning the number of groups within centers, <italic>J<sub>i</sub></italic> &gt; 1 for <italic>i</italic> ∈ E, and <italic>J<sub>i</sub></italic> = 1 for <italic>i</italic> ∈ C, we assign pseudo group indices so that each center serves as its own single nesting pseudo group in the control arm. Similarly, concerning group sizes (or the number of subjects within groups), <italic>K<sub>ij</sub></italic> = <italic>K<sub>i</sub></italic> for <italic>i</italic> ∈ C. The total number of subjects in E is denoted by <inline-formula><mml:math id="M27" overflow="scroll"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>I</mml:mi><mml:mi>j</mml:mi></mml:msub></mml:msubsup><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math></inline-formula> whereas that in C is denoted by <inline-formula><mml:math id="M28" overflow="scroll"><mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msubsup><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msubsup><mml:msub><mml:mi>K</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula>.</p><p id="P26">The fixed-effect parameters <italic>β</italic><sub>0</sub> and <italic>δ</italic><sup>(3)</sup> represent the intercept and the main effect of the experimental intervention on the outcome <italic>Y</italic><sup>(3)</sup>, respectively, whereas the center-specific random intercepts are denoted by <inline-formula><mml:math id="M29" overflow="scroll"><mml:mrow><mml:msub><mml:mi>u</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. The group-specific random intercepts within the experimental arm centers are denoted by <inline-formula><mml:math id="M30" overflow="scroll"><mml:mrow><mml:msub><mml:mi>u</mml:mi><mml:mrow><mml:mi>j</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula> for <italic>j</italic> ∈ E. The random noise is denoted by <italic>e<sub>ijk</sub></italic> which is assumed to be <inline-formula><mml:math id="M31" overflow="scroll"><mml:mrow><mml:msub><mml:mi>e</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>~</mml:mo><mml:mi>N</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mspace width="0.16667em"/><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:math></inline-formula>. These three random components are assumed to be mutually independent (mutual independence assumption). However, the elements of <italic>e<sub>ijk</sub></italic> are assumed to be independent over <italic>k</italic> for given <italic>u<sub>i</sub></italic> and <italic>u<sub>j</sub></italic>, and those of <italic>u<sub>j</sub></italic> are independent over <italic>j</italic> for given <italic>u<sub>i</sub></italic> (conditional independence assumption). Again, we assume that the magnitudes of all variance components in model (<xref rid="FD15" ref-type="disp-formula">9</xref>) are known.</p><p id="P27">It follows that <inline-formula><mml:math id="M32" overflow="scroll"><mml:mrow><mml:mi>E</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mi>β</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msup><mml:mi>δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mi>X</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub></mml:mrow></mml:math></inline-formula> and <inline-formula><mml:math id="M33" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:msub><mml:mi>X</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>. Let <inline-formula><mml:math id="M34" overflow="scroll"><mml:mrow><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>≡</mml:mo><mml:mi mathvariant="italic">Var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∣</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula> denote the variance of <italic>Y</italic><sup>(3)</sup> in the experimental arm. Then, the correlations among the group-level observations can be obtained as</p><p id="P28"><disp-formula id="FD16"><label>(10)</label><mml:math id="M35" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>≡</mml:mo><mml:mi mathvariant="italic">Corr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></disp-formula> for <italic>j</italic> ≠ <italic>j</italic>′ and <italic>i</italic> ∈ E. The correlations among the subject-level observations can be obtained as</p><p id="P29"><disp-formula id="FD17"><label>(11)</label><mml:math id="M36" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>≡</mml:mo><mml:mi mathvariant="italic">Corr</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mi>Y</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi><mml:msup><mml:mi>k</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></disp-formula> for <italic>k</italic> ≠ <italic>k</italic>′ and <italic>i</italic> ∈ E. On the other hand, the variance of <italic>Y</italic><sup>(3)</sup> in the control arm is denoted by <inline-formula><mml:math id="M37" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msubsup><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>∣</mml:mo><mml:msub><mml:mi>X</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mi>e</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>+</mml:mo><mml:msubsup><mml:mi>σ</mml:mi><mml:mn>3</mml:mn><mml:mn>2</mml:mn></mml:msubsup><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mo>≤</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup></mml:mrow></mml:math></inline-formula> since <italic>ρ</italic><sub>2</sub> ≤ <italic>ρ</italic><sub>1</sub>. The null hypothesis for testing the significance of the main effect of experimental intervention is H<sub>0</sub>: <italic>δ</italic><sup>(3)</sup> = 0.</p></sec>
25125453|3.2 Parameter estimates and variances|('method', 0.9322484077100647)|('other', 0.06775159228993514)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>3.2 Parameter estimates and variances</title><p id="P30">An estimate of <italic>δ</italic><sup>(3)</sup> under model (<xref rid="FD15" ref-type="disp-formula">9</xref>) can be obtained as</p><p id="P31"><disp-formula id="FD18"><mml:math id="M38" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:math></disp-formula> where</p><p id="P32"><disp-formula id="FD19"><mml:math id="M39" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:munderover><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub></mml:mrow></mml:mrow><mml:mo stretchy="true">/</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:munderover><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:mspace width="0.38889em"/><mml:mtext>and</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:munderover><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub></mml:mrow><mml:mo stretchy="true">/</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:msub><mml:mi>K</mml:mi><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:munderover><mml:mrow><mml:msub><mml:mi>Y</mml:mi><mml:mi mathvariant="italic">ijk</mml:mi></mml:msub><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:mrow></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula> are the sample means of <italic>Y</italic><sup>(3)</sup> in the experimental and control arms, respectively. The variances of these means can be expressed as</p><p id="P33"><disp-formula id="FD20"><label>(12)</label><mml:math id="M40" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub></mml:mrow><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mo>+</mml:mo><mml:mn>2</mml:mn><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>&gt;</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow></mml:mrow><mml:mo>)</mml:mo></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula> and</p><disp-formula id="FD21"><label>(13)</label><mml:math id="M41" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>/</mml:mo><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:mrow><mml:msubsup><mml:mi>K</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><p id="P34">It follows that</p><disp-formula id="FD22"><label>(14)</label><mml:math id="M42" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left" columnspacing="2pt"><mml:mtr><mml:mtd><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>2</mml:mn><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>&gt;</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:msubsup><mml:mi>K</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula></sec>
25125453|3.3 Test statistics, power functions and sample size formulae|('method', 0.9322484077100647)|('other', 0.06775159228993514)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9" sec-type="results"><title>3.3 Test statistics, power functions and sample size formulae</title><p id="P35">The following test statistic <italic>D</italic><sup>(3)</sup> can be used to test the null hypothesis H<sub>0</sub>: <italic>δ</italic><sup>(3)</sup> = 0</p><disp-formula id="FD23"><mml:math id="M43" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left" columnspacing="2pt"><mml:mtr><mml:mtd><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msqrt><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>)</mml:mo></mml:mrow></mml:mrow></mml:msqrt></mml:mfrac></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>-</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup></mml:mrow><mml:mrow><mml:mi>σ</mml:mi><mml:msqrt><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>2</mml:mn><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msubsup><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>&gt;</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msubsup><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msubsup><mml:msubsup><mml:mi>K</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:msubsup><mml:mrow><mml:msubsup><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:msubsup><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:msqrt></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula><p id="P36">The power function of <italic>D</italic><sup>(3)</sup> at a two-sided significance level of <italic>α</italic> can be expressed as follow</p><p id="P37"><disp-formula id="FD24"><label>(15)</label><mml:math id="M44" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left" columnspacing="2pt"><mml:mtr><mml:mtd><mml:msup><mml:mi>φ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>≡</mml:mo><mml:mi>φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mo>{</mml:mo><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:mo stretchy="true">/</mml:mo><mml:msqrt><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi></mml:msub></mml:mfrac><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msub><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi></mml:msub></mml:mfrac></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mrow><mml:mo>(</mml:mo><mml:mrow><mml:mfrac><mml:mn>2</mml:mn><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup><mml:mo>&gt;</mml:mo><mml:mi>j</mml:mi></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:mrow><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:msup><mml:mi>j</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:mn>1</mml:mn><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">C</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo>+</mml:mo><mml:msup><mml:mi>I</mml:mi><mml:mo>′</mml:mo></mml:msup></mml:mrow></mml:munderover><mml:msubsup><mml:mi>K</mml:mi><mml:mi>i</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mo>)</mml:mo></mml:mrow><mml:mo>+</mml:mo><mml:mfrac><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msubsup><mml:mi>N</mml:mi><mml:mi mathvariant="normal">E</mml:mi><mml:mn>2</mml:mn></mml:msubsup></mml:mfrac><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mi>I</mml:mi></mml:munderover><mml:mrow><mml:munderover><mml:mo>∑</mml:mo><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:msub><mml:mi>J</mml:mi><mml:mi>i</mml:mi></mml:msub></mml:munderover><mml:msubsup><mml:mi>K</mml:mi><mml:mrow><mml:mi>i</mml:mi><mml:mi>j</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mrow></mml:msqrt><mml:mo>-</mml:mo><mml:msup><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:mo>}</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula> where Δ<sub>(3)</sub> = |<italic>δ</italic><sup>(3)</sup>/<italic>σ</italic>| is again a standardized effect size. The determinations of varying group sizes in the experimental arm and cluster sizes in both arms should be made in an iterative manner.</p><p id="P38">For special cases where there are equal number of units, sample size determinations are much more tractable. If the sizes of units are equal for both arms, i.e. <italic>J<sub>i</sub></italic>=<italic>J</italic> for all <italic>i</italic> ∈ E and <italic>K<sub>j</sub></italic>=<italic>K</italic> for all <italic>j</italic> ∈ E so that <italic>N</italic><sub>E</sub>=<italic>IJK</italic> in the experimental arm and <italic>K<sub>i</sub></italic>=<italic>JK</italic> for all <italic>i</italic> ∈ C and <italic>I</italic>′ = <italic>I</italic> so that <italic>N</italic><sub>E</sub>=<italic>N</italic><sub>C</sub>=<italic>IJK</italic> in the control arm (total numbers of subjects are the same between the two arms), then the variances (<xref rid="FD20" ref-type="disp-formula">12</xref>), (<xref rid="FD21" ref-type="disp-formula">13</xref>) and (<xref rid="FD22" ref-type="disp-formula">14</xref>) can be, respectively, reduced to</p><p id="P39"><disp-formula id="FD25"><mml:math id="M45" display="block" overflow="scroll"><mml:mrow><mml:mtable columnalign="left"><mml:mtr><mml:mtd><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="italic">IJK</mml:mi></mml:mfrac><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>K</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>K</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>J</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>,</mml:mo></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>Y</mml:mi><mml:mo>¯</mml:mo></mml:mover><mml:mi mathvariant="normal">C</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="italic">IJK</mml:mi></mml:mfrac><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>J</mml:mi><mml:mi>K</mml:mi><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></disp-formula> and</p><disp-formula id="FD26"><mml:math id="M46" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Var</mml:mi><mml:mrow><mml:mo>(</mml:mo><mml:msubsup><mml:mover accent="true"><mml:mi>δ</mml:mi><mml:mo>^</mml:mo></mml:mover><mml:mi mathvariant="normal">E</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msubsup><mml:mo>)</mml:mo></mml:mrow><mml:mo>=</mml:mo><mml:mfrac><mml:msup><mml:mi>σ</mml:mi><mml:mn>2</mml:mn></mml:msup><mml:mi mathvariant="italic">IJK</mml:mi></mml:mfrac><mml:mo stretchy="false">{</mml:mo><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>K</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>K</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mi>J</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:math></disp-formula><p id="P40">It follows that the power function (<xref rid="FD24" ref-type="disp-formula">15</xref>) can be simplified to</p><disp-formula id="FD27"><label>(16)</label><mml:math id="M47" display="block" overflow="scroll"><mml:mrow><mml:msup><mml:mi>φ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo>≡</mml:mo><mml:mi>φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mi>D</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>{</mml:mo><mml:mrow><mml:msub><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msub><mml:msqrt><mml:mrow><mml:mi mathvariant="italic">IJK</mml:mi><mml:mo>/</mml:mo><mml:mo>{</mml:mo><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>K</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>K</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mi>J</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>}</mml:mo></mml:mrow></mml:msqrt><mml:mo>-</mml:mo><mml:msup><mml:mi mathvariant="normal">Φ</mml:mi><mml:mrow><mml:mo>-</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msup><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:mi>α</mml:mi><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mo>}</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula><p id="P41">Subsequently, the sample size of each level can be determined as follow</p><p id="P42"><disp-formula id="FD28"><label>(17)</label><mml:math id="M48" display="block" overflow="scroll"><mml:mrow><mml:mi>I</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>{</mml:mo><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>K</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mi>K</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mi>J</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>}</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:mi>K</mml:mi><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula><disp-formula id="FD29"><label>(18)</label><mml:math id="M49" display="block" overflow="scroll"><mml:mrow><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mo>{</mml:mo><mml:mn>2</mml:mn><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mi>K</mml:mi><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>-</mml:mo><mml:mi>K</mml:mi><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>}</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>K</mml:mi><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>-</mml:mo><mml:mn>2</mml:mn><mml:mi>K</mml:mi><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula> for <inline-formula><mml:math id="M50" overflow="scroll"><mml:mrow><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>&lt;</mml:mo><mml:mi>I</mml:mi><mml:mi>K</mml:mi><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>/</mml:mo><mml:mn>2</mml:mn><mml:mi>K</mml:mi><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:math></inline-formula>, and</p><p id="P43"><disp-formula id="FD30"><label>(19)</label><mml:math id="M51" display="block" overflow="scroll"><mml:mrow><mml:mi>K</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>2</mml:mn><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo>-</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mi>J</mml:mi><mml:msubsup><mml:mi mathvariant="normal">Δ</mml:mi><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mn>3</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mn>2</mml:mn></mml:msubsup><mml:mo>-</mml:mo><mml:mo>{</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>2</mml:mn><mml:mi>J</mml:mi><mml:mo>-</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo><mml:msub><mml:mi>ρ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mo>}</mml:mo><mml:msubsup><mml:mi>z</mml:mi><mml:mrow><mml:mi>α</mml:mi><mml:mo>,</mml:mo><mml:mi>φ</mml:mi></mml:mrow><mml:mn>2</mml:mn></mml:msubsup></mml:mrow></mml:mfrac></mml:mrow></mml:math></disp-formula> for combinations <italic>ρ</italic><sub>1</sub> (<xref rid="FD17" ref-type="disp-formula">11</xref>) and <italic>ρ</italic><sub>2</sub> (<xref rid="FD16" ref-type="disp-formula">10</xref>) that makes the denominator of <xref rid="FD30" ref-type="disp-formula">equation (19)</xref> positive, where <italic>z<sub>α</sub></italic><sub>,</sub><italic><sub>φ</sub></italic> is defined as in (<xref rid="FD14" ref-type="disp-formula">8</xref>). Again, we note that determinations of <italic>J</italic> (<xref rid="FD29" ref-type="disp-formula">18</xref>) with given <italic>I</italic> and <italic>K</italic> or determinations of <italic>K</italic> (<xref rid="FD30" ref-type="disp-formula">19</xref>) with given <italic>I</italic> and <italic>J</italic> may not be possible for desired power with certain combinations of Δ<sub>(3)</sub>, <italic>ρ</italic><sub>1</sub>, <italic>ρ</italic><sub>2</sub>, and <italic>IK</italic> or <italic>IJ</italic>, respectively. For example, <italic>ρ</italic><sub>2</sub> in particular must be very small for small Δ<sub>(3)</sub>, <italic>I</italic> and <italic>J</italic> in <xref rid="FD30" ref-type="disp-formula">equation (19)</xref>.</p></sec>
25125699|None|('method', 0.9563689832105823)|('other', 0.043631016789417575)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II. Empirical Specification</title>
25125699|None|('method', 0.9563689832105823)|('other', 0.043631016789417575)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P11">Since the primary goal is to estimate the relationship between the current migration status of children and parental health, I estimate the following regression equation:<disp-formula id="FD1"><label>(1)</label><mml:math display="block" id="M1" overflow="scroll"><mml:mrow><mml:msub><mml:mstyle mathvariant="italic"><mml:mtext>Health</mml:mtext></mml:mstyle><mml:mi>i</mml:mi></mml:msub><mml:mo>=</mml:mo><mml:mi>β</mml:mi><mml:msub><mml:mstyle mathvariant="italic"><mml:mtext>MigrantChild</mml:mtext></mml:mstyle><mml:mi>i</mml:mi></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold">X</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:mi>γ</mml:mi><mml:mo>+</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mi mathvariant="normal">i</mml:mi></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula>where the dependent variable, <italic>Health<sub>i</sub></italic>, denotes a health outcome for the parent remaining in Mexico. As described above, the health outcomes include binary variables for “Poor Health Quality,” “Poor Physical Health,” and “Poor Mental Health.” The effect of interest is captured by the coefficient on <italic>MigrantChild<sub>i</sub></italic>, a variable which is an indicator equal to one if the respondent has at least one child currently in the U.S. and zero otherwise. The vector of covariates, <bold>X</bold><sub>i</sub>, includes the following characteristics of the elderly parent: age, age squared, education categorical variables (corresponding to educational attainment of 1-6, 7-9, 10-12, and 13 or more years, with no education being the omitted group), a married dummy variable, assets, monthly income from all sources, a dummy indicating whether the respondent reports having a right to access medical services, the number of children, number of grandchildren, and a dummy variable indicating the respondent lives in a more urban area (population of 100,000 or more).</p>
25146972|None|('method', 0.999878330640519)|('other', 0.00012166935948098083)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Methods</title>
25146972|Study Site and Population|('method', 0.999878330640519)|('other', 0.00012166935948098083)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S7"><title>Study Site and Population</title><p id="P9">This cross-sectional study uses data on HIV-infected patients who enrolled in HIV/AIDS CTCs in Dar es Salaam, Tanzania, between November 2004 and December 2011. These CTCs were supported by Management and Development for Health (MDH), one of the recipients of the US President’s Emergency Plan for AIDS Relief. All nonpregnant patients aged 15 years and older whose weight and height were recorded at program enrollment were included.</p><p id="P10">Standard practice dictates that all patients attending MDH-supported HIV CTCs receive comprehensive care and support per Tanzanian national guidelines.<sup><xref rid="R31" ref-type="bibr">31</xref></sup></p></sec>
25146972|Data Collection|('method', 0.999878330640519)|('other', 0.00012166935948098083)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S8"><title>Data Collection</title><p id="P11">Physicians and nurses at the CTCs complete standard forms to record demographic, clinical, laboratory, and medication information. Weight and height are measured using standardized protocols, which include measuring height to the nearest 0.1 cm using a stadiometer and weight to the nearest 0.1 kg on a calibrated scale.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> Clinical data collected include history of tuberculosis (TB) and medication data collected include previous use of ART. Laboratory data collected include CD4 count and hemoglobin. All patients are referred for general nutrition education provided by a trained nurse counselor and nutrition counseling provided by the nutritionist. Additional sessions of nutrition counseling and therapeutic food are provided to those undernourished until they graduate from malnutrition. Clinical and laboratory data are entered into a national standard case report form, reviewed at site level for accuracy and completeness, and then entered into a protected computerized database which is updated daily and undergoes weekly quality assurance audits.</p><p id="P12">The study protocol was approved by the Institutional Review Boards of the National Institute of Medical Research, Muhimbili University of Health and Allied Sciences, and the Harvard School of Public Health.</p></sec>
25146972|Outcomes and Risk Factors|('method', 0.999878330640519)|('other', 0.00012166935948098083)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S9"><title>Outcomes and Risk Factors</title><p id="P13">The primary outcome in this cross-sectional study was the prevalence of overweight or obesity at enrollment. Normal weight was defined as 18.5 to &lt;25 kg/m<sup>2</sup>, overweight as 25 to &lt;30 kg/m<sup>2</sup>, and obese as ≥30 kg/m<sup>2</sup>. For each risk factor studied, two comparisons were made: overweight versus normal weight and obese versus normal weight.<sup><xref rid="R32" ref-type="bibr">32</xref></sup></p><p id="P14">We examined the following potential baseline risk factors for overweight and obesity: age, sex, marital status, parity, functional status (categorized as confined to bed, limited ambulation, or able to work), CD4 count, World Health Organization (WHO) HIV staging, hemoglobin concentration, previous ART use, and history of TB at enrollment. We also assessed the relationships between overweight or obesity and opportunistic infections (diarrhea, oral candidiasis, and other AIDS-defining illnesses).</p></sec>
25146972|Statistical Analyses|('method', 0.999878330640519)|('other', 0.00012166935948098083)|<sec xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="S10"><title>Statistical Analyses</title><p id="P15">A total of 90 118 patients aged 15 years and older were enrolled in the MDH program between 2004 and 2011. We excluded 36 293 patients, because of pregnancy (11 674), missing height or weight (3998), or being underweight (20 621; BMI &lt; 18.5 kg/m<sup>2</sup>).</p><p id="P16">Chi-square tests were used to test for differences in the prevalence of obesity and overweight by potential risk factors. Univariate and multivariate relative risk models were used to assess the associations between overweight and obesity compared to normal weight (18.5 kg/m<sup>2</sup> ≤ BMI &lt; 25.0 kg/m<sup>2</sup>) and baseline risk factors.<sup><xref rid="R33" ref-type="bibr">33</xref></sup> Log-binomial regression was used for all univariate regressions. Poisson regression was used for the multivariate regressions because the multivariate log-binomial regressions did not converge. All variables in the univariate analyses were included in the multivariate models. We used the missing indicator method and set continuous variables to the mean value for missing covariates. Wald tests were calculated for median scores of categorical variables and for binary variables. Based on known differences in the proportion of and risk factors for overweight and obesity between men and women, we tested for an interaction between sex and each risk factor associated with overweight and obesity.</p><p id="P17">We examined the possibly nonlinear relation between age and CD4 count with the relative risks of obesity and overweight nonparametrically with restricted cubic splines.<sup><xref rid="R34" ref-type="bibr">34</xref></sup> All analyses were performed using SAS software version 9.3 (SAS Institute, Inc, Cary, North Carolina). <italic>P</italic> values less than .05 were considered statistically significant.</p></sec>
25147383|None|('method', 0.9089903851001389)|('other', 0.09100961489986108)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">II. Data</title>
25147383|None|('method', 0.9089903851001389)|('other', 0.09100961489986108)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">Our data on cognitive function at older ages come from the HRS. Since its inception in 1992, the HRS has been documenting the physical and mental health and life circumstances of a cohort of men and women in the United States over the age of 50. The measures of cognitive function that we use began to be collected in wave 3 of the study (1996), and for this reason we restrict our analysis to waves 3 to 7, which were collected in even years between 1996 and 2004. To reduce heterogeneity, we further restrict our analysis to non-Hispanic black and white men and women between the ages of 50 and 90 for whom no proxy respondent was used.</p>
25147383|None|('method', 0.9089903851001389)|('other', 0.09100961489986108)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">We use two markers of cognitive function. “Delayed word recall” records the number of words that the respondent remembers approximately five minutes after having heard a list of ten nouns read aloud. This measure has a sample mean of 4.60 and a standard deviation of 2.10. “Counting backward” is an indicator the respondent can count backward by one from 86 to 77. This assessment, which was conducted in waves 3 to 6, has a “pass rate” of 87.5 percent.</p>
25147383|None|('method', 0.9089903851001389)|('other', 0.09100961489986108)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P9">We examine the association between cognitive function and infant mortality, and mortality rates by-cause within census region of birth for typhoid, malaria, measles, influenza, and diarrhea. (Diarrhea deaths are for those under the age of two.) Mortality data from 1900 to 1936 are from Grant Miller’s data archive on the National Bureau of Economic Research Web site (available at <ext-link ext-link-type="uri" xlink:href="http://www.nber.org/data/vital-statistics-deaths-historical">http://www.nber.org/data/vital-statistics-deaths-historical</ext-link>). Data from 1937 to 1950 are from the Vital Statistics of the United States documents (downloaded from the Centers for Disease Control Web site). Mortality rates are expressed as the number of deaths per 100,000 population, and infant mortality rates are the number of infants deaths (under one year, exclusive of stillbirths) per 1,000 live births. We aggregated mortality rates to the level of the nine Census regions (New England, Mid-Atlantic, East-North Central, West-North Central, South Atlantic, East-South Central, West-South Central, Mountain, and Pacific).</p>
25147383|None|('method', 0.9089903851001389)|('other', 0.09100961489986108)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P10">Infant mortality and by-cause mortality rates vary substantially across regions and over time. To illustrate, <xref rid="F1" ref-type="fig">Figures 1</xref> and <xref rid="F2" ref-type="fig">2</xref> show typhoid and measles mortality in three regions (Mid-Atlantic, West-North Central, and East-South Central). Although all of the diseases we examine decline over this period, their initial levels and patterns of decline differ across regions. Typhoid shows relatively small year-to-year fluctuations, whereas measles mortality has the sawtooth pattern that is characteristic of this disease. (For a complete set of figures, see: <ext-link ext-link-type="uri" xlink:href="http://www.princeton.edu/rpds/papers/pdfs/earlylifehealth_additions.pdf">http://www.princeton.edu/rpds/papers/pdfs/earlylifehealth_additions.pdf</ext-link>.)</p>
25152535|None|('method', 0.825667382411643)|('other', 0.17433261758835697)|<title xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">III. Econometric Approach</title>
25152535|None|('method', 0.825667382411643)|('other', 0.17433261758835697)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P7">We estimate the following model: <disp-formula id="FD1"><label>(1)</label><mml:math id="M1" display="block" overflow="scroll"><mml:mrow><mml:mi mathvariant="italic">Health</mml:mi><mml:mspace width="0.16667em"/><mml:msub><mml:mi mathvariant="italic">Outcome</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>=</mml:mo><mml:msub><mml:mi mathvariant="normal">ϒ</mml:mi><mml:mn>0</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">ϒ</mml:mi><mml:mn>1</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">Close</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">ϒ</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">During</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">ϒ</mml:mi><mml:mn>3</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">After</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">ϒ</mml:mi><mml:mn>4</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">Close</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="italic">During</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">ϒ</mml:mi><mml:mn>5</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="italic">Close</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>∗</mml:mo><mml:msub><mml:mi mathvariant="italic">After</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">ϒ</mml:mi><mml:mn>6</mml:mn></mml:msub><mml:msub><mml:mi mathvariant="bold-italic">X</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold">α</mml:mi><mml:mtext>j</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="bold">δ</mml:mi><mml:mtext>t</mml:mtext></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi>ε</mml:mi><mml:mtext>ijt</mml:mtext></mml:msub><mml:mo>,</mml:mo></mml:mrow></mml:math></disp-formula> where i indicates a birth, j is the mother’s street address, and t denotes the year of birth. There are three key indicator variables in this specification. <italic>Close</italic><sub>ijt</sub> equals one if the mother resided within 2000 meters of a site where a clean-up was finished during the sample. <italic>During</italic><sub>ijt</sub> equals one if the birth occurred during the site clean-up. <italic>After</italic><sub>ijt</sub> indicates that it occurred after the site clean-up was completed. The vector <italic>X</italic><sub>ijt</sub> of maternal and child controls includes: indicators for the mother’s age (&lt;20, 20–34, 35 plus, age missing); maternal education (less than high school, high school, some college, college, education missing); maternal race and ethnicity (African-American, non-Hispanic white, Hispanic, other, race and ethnicity missing); birth order (first, second, third, fourth, fifth or higher order births, and birth order missing); and maternal smoking (smokes, does not smoke, smoking status missing).</p>
25152535|None|('method', 0.825667382411643)|('other', 0.17433261758835697)|<p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" id="P8">We present results that adjust for all time invariant or fixed neighborhood characteristics in two different ways. In the first, <bold>α</bold><sub>j</sub> is implemented with a full set of indicators for each site. We also report on specifications that replace the site fixed effects with zip code fixed effects that are based on the zip code of the mother’s residence. On the one hand, there are ten times as many zip codes as sites so that zip code fixed effects may control more fully for the characteristics of local areas. On the other hand, the differences in exposure to Superfund site hazards between births within 2,000 meters and those 2,000 to 5,000 meters from a site are likely to be smaller within a zip code. Additionally, we include a vector of indicators for the year, δ<sub>t</sub>, which allow us to control for time trends non-parametrically. The estimates are qualitatively similar if year indicators are replaced with state by year ones.</p>
